01290000000000469000450099100020000070000020000270600020000470100020000609100090
00081300061000171510026000782300040001040350010001444800041001540300027001959300
00500222117000800227085000500235935001000240031000300250032000200253036000600255
04200020026120000020026306500090026512200030027404800140027704800140029104800240
03050490025003290490023003540490023003770490031004000490032004310490033004630490
03000496049003200526049003700558043007500595043007500670043007500745#1#0#i#1#201
10411#ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)#ABCD, arq. br
as. cir. dig#Brazilian Archives of Digestive Surgery#0102-6720#Colégio Brasileir
o de Cirurgia Digestiva#ABCD, arq. bras. cir. dig.#ABCD#vancouv#decs#0102-6720#2
4#1#20111#1#1#20110300#21#^les^hSumario#^lpt^hSumário#^len^hTable of Contents#^l
pt^cABCD010^tEditorial#^lpt^cABCD050^tTécnica#^len^cABCD050^tTechnic#^lpt^cABCD0
60^tArtigo Original#^len^cABCD060^tOriginal Article#^lpt^cABCD070^tArtigo de Rev
isão#^len^cABCD070^tReview Article#^lpt^cABCD100^tCartas ao Editor#^len^cABCD100
^tLetters to the Editor#^les^tABCD, arq. bras. cir. dig.^vvol.24^nno.1^cSão Paul
o^mene./mar.^a2011#^lpt^tABCD, arq. bras. cir. dig.^vvol.24^nno.1^cSão Paulo^mja
n./mar.^a2011#^len^tABCD, arq. bras. cir. dig.^vvol.24^nno.1^cSão Paulo^mJan./Ma
r.^a2011##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a01.htm#S#o#1#1#text#1#20
110411#103833#v24n1a01.htm#35##
00983000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002700104
03100030013103200020013406500090013601400070014503500100015212300020016201200990
01640120099002630100033003620100035003950100042004300100031004720700057005030020
01300560#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a01.htm#S#h#2#1#text#1#ed
#pt#br1.1#1#4.0#ND#01#ABCD010#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f1^l2
#0102-6720#1#Cirurgia auxiliada por robô: avanço tecnológico à serviço do pacien
te ou pressão da indústria?^lpt#Robot-assisted surgery: technological advance in
 the service of patients or industry pressure?^len#^rND^1A01^nCarlos Eduardo^sJa
cob#^rND^1A01^nJoaquim^sGama-Rodrigues#^rND^1A01^nCláudio José Caldas^sBresciani
#^rND^1A01^nAngelita^sHabr-gama#Hospital Alemão Oswaldo Cruz^iA01^cSão Paulo^sSP
^pBrasil#v24n1a01.htm##
01011000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002700104
03100030013103200020013406500090013601400070014503500100015212300020016201201130
01640120113002770100033003900100035004230100042004580100031005000700057005310020
01300588#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a01.htm#S#f#3#1#text#1#ed
#pt#br1.1#1#4.0#ND#01#ABCD010#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f1^l2
#0102-6720#1#<b>Cirurgia auxiliada por robô</b>: <b>avanço tecnológico à serviço
 do paciente ou pressão da indústria?</b>^lpt#<b>Robot-assisted surgery</b>: <b>
technological advance in the service of patients or industry pressure?</b>^len#^
rND^1A01^nCarlos Eduardo^sJacob#^rND^1A01^nJoaquim^sGama-Rodrigues#^rND^1A01^nCl
áudio José Caldas^sBresciani#^rND^1A01^nAngelita^sHabr-gama#Hospital Alemão Oswa
ldo Cruz^iA01^cSão Paulo^sSP^pBrasil#v24n1a01.htm##
01100000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030002600119
03100030014503200020014806500090015001400070015903500100016612300020017601200990
01780120099002770100033003760100035004090100042004440100031004860700059005170020
01300576008008900589#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a01.htm#S#l#4
#1#text#1#^mjan./mar.^a2011#ed#pt#br1.1#1#4.0#01#ABCD010#nd#ABCD, arq. bras. cir
. dig#24#1#20110300#^f1^l2#0102-6720#1#Cirurgia auxiliada por robô: avanço tecno
lógico à serviço do paciente ou pressão da indústria?^lpt#Robot-assisted surgery
: technological advance in the service of patients or industry pressure?^len#^rN
D^1A01^nCarlos Eduardo^sJacob#^rND^1A01^nJoaquim^sGama-Rodrigues#^rND^1A01^nCláu
dio José Caldas^sBresciani#^rND^1A01^nAngelita^sHabr-gama#^iA01^1Hospital Alemão
 Oswaldo Cruz^cSão Paulo^sSP^pBrasil#v24n1a01.htm#Internet^ihttp://www.scielo.br
/scielo.php?script=sci_arttext&pid=S0102-67202011000100001##
00344000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704011500070002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#5#1#text#31#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL </b> </font></p
>     ^cY#v24n1a01.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#6#2#text#31#<p>&nbsp;</p>     ^cY#v24
n1a01.htm##
00462000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704023300070002001300303#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#7#3#text#31#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Cirurgia auxiliada por rob&ocirc;: avan
&ccedil;o tecnol&oacute;gico &agrave; servi&ccedil;o do paciente ou press&atilde
;o da ind&uacute;stria?</b> </font></p>     ^cY#v24n1a01.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#8#4#text#31#<p>&nbsp;</p>     ^cY#v24
n1a01.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#9#5#text#31#<p>&nbsp;</p>     ^cY#v24
n1a01.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704019900071002001300270#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#10#6#text#31#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Carlos Eduardo Jacob; Joaquim Gama-Rod
rigues; Cl&aacute;udio Jos&eacute; Caldas Bresciani; Angelita Habr-gama</b></fon
t></p>     ^cY#v24n1a01.htm##
00379000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704014900071002001300220#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#11#7#text#31#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Hospital Alem&atilde;o Oswaldo Cruz, S&at
ilde;o Paulo, SP, Brasil </font></p>     ^cY#v24n1a01.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#12#8#text#31#<p>&nbsp;</p>     ^cY#v2
4n1a01.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#13#9#text#31#<p>&nbsp;</p>     ^cY#v2
4n1a01.htm##
00838000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704060700072002001300679#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#14#10#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Os avan&ccedil;os tecnol&oacute;gicos ob
servados nas &uacute;ltimas d&eacute;cadas trouxeram evidentes benef&iacute;cios
 aos pacientes com afec&ccedil;&otilde;es do aparelho digestivo. O desenvolvimen
to do exame endosc&oacute;pico alto e baixo a partir da d&eacute;cada de 50 perm
itiu o diagn&oacute;stico precoce de les&otilde;es neopl&aacute;sicas, melhorand
o o resultado do tratamento cir&uacute;rgico e criando oportunidade para o nasci
mento das ressec&ccedil;&otilde;es endosc&oacute;picas com car&aacute;ter curati
vo. </font></p>     ^cY#v24n1a01.htm##
00572000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704034100072002001300413#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#15#11#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O desenvolvimento dos aparelhos de manom
etria anorretal e esof&aacute;gica ajudaram a definir doen&ccedil;as e balizar o
 tratamento cl&iacute;nico e cir&uacute;rgico das doen&ccedil;as funcionais do a
parelho digestivo &agrave; partir da d&eacute;cada de 60. </font></p>     ^cY#v2
4n1a01.htm##
00901000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704067000072002001300742#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#16#12#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Os grampeadores cir&uacute;rgicos criado
s nas primeiras d&eacute;cadas do s&eacute;culo 20 na Hungria e aperfei&ccedil;o
ados na d&eacute;cada de 50 na antiga Uni&atilde;o Sovi&eacute;tica, foram popul
arizados pelos cirurgi&otilde;es americanos no intuito de padronizar v&aacute;ri
as t&eacute;cnicas operat&oacute;rias. Permitiram os grampeadores o aperfei&cced
il;oamento das suturas mec&acirc;nicas e a realiza&ccedil;&atilde;o de anastomos
es colorretais baixas e esofagojejunais que passaram a ser realizadas com segura
n&ccedil;a por muitos cirurgi&otilde;es  com treinamento adequado. </font></p>  
   ^cY#v24n1a01.htm##
01098000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704086700072002001300939#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#17#13#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A d&eacute;cada de 80 assistiu ao nascim
ento e desenvolvimento de uma das maiores revolu&ccedil;&otilde;es na cirurgia n
o &uacute;ltimo s&eacute;culo: as opera&ccedil;&otilde;es minimamente invasivas,
 tamb&eacute;m conhecidas como opera&ccedil;&otilde;es laparosc&oacute;picas. Es
ta metodologia que est&aacute; associada a menores &iacute;ndices de dor e infec
&ccedil;&atilde;o de parede, tempo de interna&ccedil;&atilde;o reduzido, retorno
 precoce ao trabalho e forte apelo est&eacute;tico foi rapidamente aceita pelo m
eio m&eacute;dico e pelos pacientes. Atualmente a cirurgia laparosc&oacute;pica 
&eacute; utilizada com sucesso no tratamento da maioria das afec&ccedil;&otilde;
es do aparelho digestivo, desde que respeitadas as no&ccedil;&otilde;es de bom s
enso e de &eacute;tica. </font></p>     ^cY#v24n1a01.htm##
00578000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704034700072002001300419#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#18#14#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Todos estes progressos est&atilde;o sedi
mentados no conhecimento m&eacute;dico. Entretanto ao se relembrar de como foi a
 postura de expressiva parcela da comunidade acad&ecirc;mica diante destas novas
 t&eacute;cnicas, surpreendentes lembran&ccedil;as nos afligem. </font></p>     
^cY#v24n1a01.htm##
00489000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704025800072002001300330#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#19#15#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Quantos de n&oacute;s ouvimos de eminent
es professores ou mesmo &agrave;s vezes fomos porta-vozes de frases como:</font>
 </p> <font size="2" face="Verdana, Arial, Helvetica, sans-serif">     ^cY#v24n1
a01.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#20#16#text#31#<blockquote>     ^cY#v2
4n1a01.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021500072002001300287#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#21#17#text#31#<p>&#149; "A ressec&cce
dil;&atilde;o endosc&oacute;pica mesmo que restrita a certos subtipos morfol&oac
ute;gicos e histopatol&oacute;gicos de um c&acirc;ncer g&aacute;strico precoce &
eacute; um crime" </p>      ^cY#v24n1a01.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010900072002001300181#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#22#18#text#31#<p>&#149; "A anastomose
 colorretal manual &eacute; muito mais segura que o duplo grampeamento" </p>    
  ^cY#v24n1a01.htm##
00406000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704017500072002001300247#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#23#19#text#31#<p>&#149; "A colecistec
tomia laparosc&oacute;pica est&aacute; associada a maiores complicac&otilde;es. 
A laparotomia ainda &eacute; a via de acesso preferencial"</p>      ^cY#v24n1a01
.htm##
00451000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022000072002001300292#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#24#20#text#31#<p>&#149; "Operar c&aci
rc;ncer por laparoscopia &eacute; loucura por v&aacute;rias raz&otilde;es, entre
 elas o fato de que o &iacute;ndice de implantes nos portais &eacute; proibitivo
". </p></blockquote></font>      ^cY#v24n1a01.htm##
01002000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704077100072002001300843#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#25#21#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Estas observa&ccedil;&otilde;es expressa
s por muitos como verdades &agrave; &eacute;poca, n&atilde;o resistiram &agrave;
 luz da experi&ecirc;ncia cl&iacute;nica e hoje est&atilde;o ultrapassadas. A re
ssec&ccedil;&atilde;o endosc&oacute;pica de neoplasias precoces do aparelho dige
stivo, desde que obedecidas as regras internacionalmente aceitas mantendo-se res
trita aos objetivos e crit&eacute;rios de indica&ccedil;&atilde;o e &agrave;s re
comenda&ccedil;&otilde;es de contraindica&ccedil;&atilde;o, est&aacute; , associ
ada a &iacute;ndices de sobreviv&ecirc;ncia e curabilidade semelhantes aos obtid
os com procedimentos mais alargados e com qualidade de vida expressivamente supe
riores. </font></p>     ^cY#v24n1a01.htm##
00583000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704035200072002001300424#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#26#22#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A difus&atilde;o do grampeadores cir&uac
ute;rgicos permitiu sedimentar que a anastomose mec&acirc;nica &eacute; t&atilde
;o boa ou melhor que a anastomose manual, desde que realizada por cirurgi&atilde
;o com treinamento apropriado e com indica&ccedil;&atilde;o correta. </font></p>
     ^cY#v24n1a01.htm##
00628000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704039700072002001300469#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#27#23#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O acesso laparosc&oacute;pico &eacute; o
 preferencial n&atilde;o s&oacute; no tratamento da colelit&iacute;ase como tamb
&eacute;m em todas as afec&ccedil;&otilde;es benignas do aparelho digestivo, pri
ncipalmente na doen&ccedil;a do refluxo gastroesof&aacute;gico e na doen&ccedil;
a diverticular dos c&oacute;lons. </font></p>     ^cY#v24n1a01.htm##
00853000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704062200072002001300694#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#28#24#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Por fim o tratamento do c&acirc;ncer do 
aparelho digestivo pela laparoscopia tem deixado de ser encarado como heresia. O
s resultados de trabalhos prospectivos randomizados nos EUA e Espanha demonstram
 a possibilidade e seguran&ccedil;a desta metodologia no tratamento do c&acirc;n
cer colorretal. Al&eacute;m disso, observa&ccedil;&otilde;es preliminares querem
 sugerir que a laparoscopia esteja relacionada com melhores &iacute;ndices de so
breviv&ecirc;ncia devido &agrave; melhor resposta imunol&oacute;gica p&oacute;s-
operat&oacute;ria. </font></p>     ^cY#v24n1a01.htm##
00511000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704028000072002001300352#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#29#25#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Recentemente a experi&ecirc;ncia com c&a
circ;ncer de es&ocirc;fago e est&ocirc;mago no Jap&atilde;o e Cor&eacute;ia pare
cem apontar no mesmo sentido quanto ao  benef&iacute;cio desta metodologia. </fo
nt></p>      ^cY#v24n1a01.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704027500072002001300347#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#30#26#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">No momento atual, a proposta de cirurgia
 laparosc&oacute;pica  auxiliada por rob&ocirc; nos colocou diante de dilemas pa
recidos com os que cercaram o advento da cirurgia laparosc&oacute;pica. </font><
/p>     ^cY#v24n1a01.htm##
00614000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704038300072002001300455#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#31#27#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A confiabilidade, acur&aacute;cia, segur
an&ccedil;a e reprodutividade que o emprego de rob&ocirc;s desenvolveu na presen
te d&eacute;cada em outras &aacute;reas como, por exemplo, na ind&uacute;stria a
utomobil&iacute;stica, permitem vislumbrar que a cirurgia auxiliada por rob&ocir
c; veio para ficar. </font></p>     ^cY#v24n1a01.htm##
00909000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704067800072002001300750#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#32#28#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A rob&oacute;tica traz benef&iacute;cios
 &agrave; pr&aacute;tica da cirurgia do aparelho digestivo. Talvez o mais eviden
te tenha sido a melhoria quanto &agrave;s  limita&ccedil;&otilde;es com as quais
 as opera&ccedil;&otilde;es laparosc&oacute;picas se deparam. O emprego da rob&o
acute;tica em cirurgia determinou incremento da destreza, retorno &agrave; vis&a
tilde;o tridimensional, magnifica&ccedil;&atilde;o e miniaturiza&ccedil;&atilde;
o dos movimentos, possibilidade de opera&ccedil;&otilde;es &agrave; dist&acirc;n
cia, supress&atilde;o do tremor do cirurgi&atilde;o e ganhos na ergonomia. </fon
t></p>     ^cY#v24n1a01.htm##
00691000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704046000072002001300532#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#33#29#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Recentemente foram publicadas as primeir
as metan&aacute;lises sobre cirurgia rob&oacute;tica, demonstrando que a utiliza
&ccedil;&atilde;o desta metodologia est&aacute; associada a resultados pelo meno
s semelhantes aos obtidos com o acesso laparosc&oacute;pico, com promissoras exp
ectativas quanto &agrave; melhoria t&eacute;cnica das opera&ccedil;&otilde;es on
col&oacute;gicas.</font></p>     ^cY#v24n1a01.htm##
01236000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704100500072002001301077#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#34#30#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Entretanto algumas quest&otilde;es se l
evantam e n&atilde;o podem de forma alguma  serem esquecidas. O altocusto &eacut
e; a mais saliente dentre todas. Como justificar a compra e a utiliza&ccedil;&at
ilde;o desta tecnologia em um pa&iacute;s com enormes dificuldades econ&ocirc;mi
cas como o nosso? Como garantir o acesso universal da popula&ccedil;&atilde;o &a
grave;s novas op&ccedil;&otilde;es de tratamento? A experi&ecirc;ncia pregressa 
nos mostra que o pre&ccedil;o da tecnologia est&aacute; ligado &agrave; escala d
e produ&ccedil;&atilde;o dos equipamentos. Muito provavelmente este custo cair&a
acute; com o passar dos anos. Outras indaga&ccedil;&otilde;es s&atilde;o os aspe
ctos legais e &eacute;ticos do procedimento e o treinamento necess&aacute;rio pa
ra a pr&aacute;tica da cirurgia rob&oacute;tica, t&atilde;o expressivos quanto o
 s&atilde;o para a pr&oacute;pria interven&ccedil;&atilde;o laparosc&oacute;pica
. </font></p>     ^cY#v24n1a01.htm##
01173000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704094200072002001301014#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a01.htm#S#p#35#31#text#31#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Todos estes aspectos devem ser debatidos
 pelas sociedades m&eacute;dicas e universidades, visando desenvolver recomenda&
ccedil;&otilde;es obtidas em  consensos que possam orientar os colegas cirurgi&o
tilde;es brasileiros. O Col&eacute;gio Brasileiro de Cirurgia Digestiva particip
a de f&oacute;runs como os da Associa&ccedil;&atilde;o Paulista de Medicina, ond
e este tema &eacute; debatido exaustivamente. O ac&uacute;mulo de literatura esp
ecializada torna evidente que esta tecnologia traz benef&iacute;cios que n&atild
e;o podem ser descartados simplesmente pelo maior custo envolvido. Torna-se nece
ss&aacute;ria a participa&ccedil;&atilde;o da comunidade acad&ecirc;mica e das s
ociedades m&eacute;dicas neste debate visando legitimar esta metodologia emergen
te na pr&aacute;tica cl&iacute;nica na depend&ecirc;ncia dos resultados que se v
ierem a observar. </font></p>      ^cY#v24n1a01.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#o#1#1#article#1
#20110411#103836#v24n1a02.htm#209##
03571000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002700109
03100030013603200020013906500090014101400070015003500100015701200920016701200900
02590100026003490100030003750831171004050850010015760850030015860850031016160850
02801647083117701675085001002852085003202862085003202894085002702926117000802953
072000302961112000902964111001102973114000902984113001102993002001303004#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4
.0#ILUS#02#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f3^l8#0102-6720#
Gastroplastia a Collis associada à fundoplicatura parcial ou total: estudo exper
imental^lpt#Collis gastroplasty associated to parcial or total fundoplication: e
xperimental study^len#^rND^nLuiz Roberto^sLopes#^rND^nNelson Adami^sAndreollo#^l
pt^aRACIONAL: A esofagite de refluxo complicada com estenose e encurtamento do ó
rgão é doença de difícil tratamento cirúrgico com frequente insucesso. A gastrop
lastia a Collis associada à fundoplicatura parcial ou total pode ser empregada n
esta situação. OBJETIVOS: Avaliar a técnica da gastroplastia a Collis com fundop
licatura parcial ou total em cães. MÉTODOS: Sete cães foram submetidos a Collis-
Lind (Grupo A) e quatro a Collis-Nissen (Grupo B) após miotomia da junção esofag
ogástrica. O refluxo foi avaliado com medidas de pH e as pressões na transição e
sofagogástrica com microtransdutores. RESULTADOS: Após a miotomia ocorreu reflux
o livremente em todos os animais. Entretanto, após a operação de Collis-Lind ou 
Collis-Nissen o refluxo espontâneo não ocorreu. A aplicação de pressão manual so
bre o estômago, promoveu refluxo em 28,5 % dos animais do Grupo A. A avaliação d
as pressões na peça cirúrgica mostrou que não houve diferença na zona de alta pr
essão, nos dois grupos. CONCLUSÃO: A operação de Collis-Lind ou Collis-Nissen im
pediu o refluxo gastroesofágico. As medidas das pressões e a extensão da zona de
 alta pressão foram semelhantes nos dois grupos.#^ddecs^i1#^tm^lpt^kEsofagite pé
ptica^i1#^tm^lpt^kEstenose esofágica^i1#^tm^lpt^kModelos animais^i1#^len^aBACKGR
OUND: Reflux esophagitis complicated by stenosis and shortening of the organ is 
a difficult disease to surgical treatment with frequent failure. The Collis gast
roplasty associated with a partial or total fundoplication can be employed in th
is situation. OBJECTIVE: To evaluate the technique of fundoplication with partia
l or total Collis gastroplasty in dogs. METHODS: Seven dogs underwent a Collis-L
ind (Group A) and four to Collis-Nissen (Group B) after myotomy of the gastroeso
phageal junction; reflux was evaluated with measurements of pH and pressures in 
the esophagogastric transition with microtransducer. RESULTS: After myotomy refl
ux occurred freely in all animals. However, after Collis-Lind or Collis-Nissen p
rocedures, it not ocurred spontaneously. The application of manual pressure on t
he stomach caused reflux in 28.5% of animals in Group A. The assessment of press
ures in the surgical specimen showed no difference in the area of high pressure 
in both groups. CONCLUSION: The Collis-Lind and Collis-Nissen procedures prevent
 gastroesophageal reflux. The pressure measurements and the extension of the hig
h pressure zone were similar in both groups.#^ddecs^i2#^tm^len^kEsophagitis, pep
tic^i2#^tm^len^kEsophageal stenosis^i2#^tm^len^kModels, animal^i2#vancouv#34#201
01115#15/11/2010#20101221#21/12/2010#v24n1a02.htm##
03669000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002700109
03100030013603200020013906500090014101400070015003500100015701201060016701201040
02730100026003770100030004030831206004330850010016390850030016490850031016790850
02801710083121201738085001002950085003202960085003202992085002703024117000803051
072000303059112000903062111001103071114000903082113001103091002001303102#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4
.0#ILUS#02#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f3^l8#0102-6720#
<b>Gastroplastia a Collis associada à fundoplicatura parcial ou total</b>: <b>es
tudo experimental</b>^lpt#<b>Collis gastroplasty associated to parcial or total 
fundoplication</b>: <b>experimental study</b>^len#^rND^nLuiz Roberto^sLopes#^rND
^nNelson Adami^sAndreollo#^lpt^a<b>RACIONAL: </b>A esofagite de refluxo complica
da com estenose e encurtamento do órgão é doença de difícil tratamento cirúrgico
 com frequente insucesso. A gastroplastia a Collis associada à fundoplicatura pa
rcial ou total pode ser empregada nesta situação. <b>OBJETIVOS:</b> Avaliar a té
cnica da gastroplastia a Collis com fundoplicatura parcial ou total em cães. <b>
MÉTODOS: </b>Sete cães foram submetidos a Collis-Lind (Grupo A) e quatro a Colli
s-Nissen (Grupo B) após miotomia da junção esofagogástrica. O refluxo foi avalia
do com medidas de pH e as pressões na transição esofagogástrica com microtransdu
tores. <b>RESULTADOS:</b> Após a miotomia ocorreu refluxo livremente em todos os
 animais. Entretanto, após a operação de Collis-Lind ou Collis-Nissen o refluxo 
espontâneo não ocorreu. A aplicação de pressão manual sobre o estômago, promoveu
 refluxo em 28,5 % dos animais do Grupo A. A avaliação das pressões na peça cirú
rgica mostrou que não houve diferença na zona de alta pressão, nos dois grupos. 
<b>CONCLUSÃO: </b>A operação de Collis-Lind ou Collis-Nissen impediu o refluxo g
astroesofágico. As medidas das pressões e a extensão da zona de alta pressão for
am semelhantes nos dois grupos.#^ddecs^i1#^tm^lpt^kEsofagite péptica^i1#^tm^lpt^
kEstenose esofágica^i1#^tm^lpt^kModelos animais^i1#^len^a<b>BACKGROUND: </b>Refl
ux esophagitis complicated by stenosis and shortening of the organ is a difficul
t disease to surgical treatment with frequent failure. The Collis gastroplasty a
ssociated with a partial or total fundoplication can be employed in this situati
on. <b>OBJECTIVE:</b> To evaluate the technique of fundoplication with partial o
r total Collis gastroplasty in dogs. <b>METHODS:</b> Seven dogs underwent a Coll
is-Lind (Group A) and four to Collis-Nissen (Group B) after myotomy of the gastr
oesophageal junction; reflux was evaluated with measurements of pH and pressures
 in the esophagogastric transition with microtransducer. <b>RESULTS: </b>After m
yotomy reflux occurred freely in all animals. However, after Collis-Lind or Coll
is-Nissen procedures, it not ocurred spontaneously. The application of manual pr
essure on the stomach caused reflux in 28.5% of animals in Group A. The assessme
nt of pressures in the surgical specimen showed no difference in the area of hig
h pressure in both groups. <b>CONCLUSION:</b> The Collis-Lind and Collis-Nissen 
procedures prevent gastroesophageal reflux. The pressure measurements and the ex
tension of the high pressure zone were similar in both groups.#^ddecs^i2#^tm^len
^kEsophagitis, peptic^i2#^tm^len^kEsophageal stenosis^i2#^tm^len^kModels, animal
^i2#vancouv#34#20101115#15/11/2010#20101221#21/12/2010#v24n1a02.htm##
03717000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000260012703100030015303200020015606500090015801400070016703500100017401200920
01840120090002760100026003660100030003920831180004220850010016020850030016120850
03101642085002801673083118401701085001002885085003202895085003202927085002702959
11700080298607200030299411200090299711100110300611400090301711300110302600200130
3037008008903050#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#l#4#1#a
rticle#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#02#ABCD060#nd#ABCD, arq. bras.
 cir. dig#24#1#20110300#^f3^l8#0102-6720#Gastroplastia a Collis associada à fund
oplicatura parcial ou total: estudo experimental^lpt#Collis gastroplasty associa
ted to parcial or total fundoplication: experimental study^len#^rND^nLuiz Robert
o^sLopes#^rND^nNelson Adami^sAndreollo#^lpt^aRACIONAL: A esofagite de refluxo co
mplicada com estenose e encurtamento do órgão é doença de difícil tratamento cir
úrgico com frequente insucesso. A gastroplastia a Collis associada à fundoplicat
ura parcial ou total pode ser empregada nesta situação. OBJETIVOS: Avaliar a téc
nica da gastroplastia a Collis com fundoplicatura parcial ou total em cães. MÉTO
DOS: Sete cães foram submetidos a Collis-Lind (Grupo A) e quatro a Collis-Nissen
 (Grupo B) após miotomia da junção esofagogástrica. O refluxo foi avaliado com m
edidas de pH e as pressões na transição esofagogástrica com microtransdutores. R
ESULTADOS: Após a miotomia ocorreu refluxo livremente em todos os animais. Entre
tanto, após a operação de Collis-Lind ou Collis-Nissen o refluxo espontâneo não 
ocorreu. A aplicação de pressão manual sobre o estômago, promoveu refluxo em 28,
5  por cento dos animais do Grupo A. A avaliação das pressões na peça cirúrgica 
mostrou que não houve diferença na zona de alta pressão, nos dois grupos. CONCLU
SÃO: A operação de Collis-Lind ou Collis-Nissen impediu o refluxo gastroesofágic
o. As medidas das pressões e a extensão da zona de alta pressão foram semelhante
s nos dois grupos.#^ddecs^i1#^tm^lpt^kEsofagite péptica^i1#^tm^lpt^kEstenose eso
fágica^i1#^tm^lpt^kModelos animais^i1#^len^aBACKGROUND: Reflux esophagitis compl
icated by stenosis and shortening of the organ is a difficult disease to surgica
l treatment with frequent failure. The Collis gastroplasty associated with a par
tial or total fundoplication can be employed in this situation. OBJECTIVE: To ev
aluate the technique of fundoplication with partial or total Collis gastroplasty
 in dogs. METHODS: Seven dogs underwent a Collis-Lind (Group A) and four to Coll
is-Nissen (Group B) after myotomy of the gastroesophageal junction; reflux was e
valuated with measurements of pH and pressures in the esophagogastric transition
 with microtransducer. RESULTS: After myotomy reflux occurred freely in all anim
als. However, after Collis-Lind or Collis-Nissen procedures, it not ocurred spon
taneously. The application of manual pressure on the stomach caused reflux in 28
.5 percent of animals in Group A. The assessment of pressures in the surgical sp
ecimen showed no difference in the area of high pressure in both groups. CONCLUS
ION: The Collis-Lind and Collis-Nissen procedures prevent gastroesophageal reflu
x. The pressure measurements and the extension of the high pressure zone were si
milar in both groups.#^ddecs^i2#^tm^len^kEsophagitis, peptic^i2#^tm^len^kEsophag
eal stenosis^i2#^tm^len^kModels, animal^i2#vancouv#34#20101115#15/11/2010#201012
21#21/12/2010#v24n1a02.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_
arttext&pid=S0102-67202011000100002##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011900074002001300193#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#5#1#article#171#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b></
font></p>     ^cY#v24n1a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#6#2#article#171#<p>&nbsp;</p>     ^cY
#v24n1a02.htm##
00437000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704020400074002001300278#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#7#3#article#171#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Gastroplastia a
 Collis associada &agrave; fundoplicatura parcial ou total: estudo experimental<
/b></font></p>     ^cY#v24n1a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#8#4#article#171#<p>&nbsp;</p>     ^cY
#v24n1a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#9#5#article#171#<p>&nbsp;</p>     ^cY
#v24n1a02.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013200075002001300207#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#10#6#article#171#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Luiz Roberto Lopes; Nelson Adami A
ndreollo</b></font></p>     ^cY#v24n1a02.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#11#7#article#171#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a02.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#12#8#article#171#<p>&nbsp;</p>     ^c
Y#v24n1a02.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004500075002001300120#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#13#9#article#171#<p>&nbsp;</p> <hr si
ze="1" noshade >     ^cY#v24n1a02.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#14#10#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a02.htm##
00628000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039300076002001300469#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#15#11#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL: </b> A esofagite de ref
luxo complicada com estenose e encurtamento do &oacute;rg&atilde;o &eacute; doen
&ccedil;a de dif&iacute;cil tratamento cir&uacute;rgico com frequente insucesso.
 A gastroplastia a Collis associada &agrave; fundoplicatura parcial ou total pod
e ser empregada nesta situa&ccedil;&atilde;o.     ^cY#v24n1a02.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013700076002001300213#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#16#12#article#171#<br>   <b>OBJETIVOS
:</b>  Avaliar a t&eacute;cnica da gastroplastia a Collis com fundoplicatura par
cial ou total em c&atilde;es.     ^cY#v24n1a02.htm##
00569000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033400076002001300410#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#17#13#article#171#<br>   <b>M&Eacute;
TODOS: </b>Sete c&atilde;es foram submetidos a Collis-Lind (Grupo A) e quatro a 
Collis-Nissen (Grupo B) ap&oacute;s miotomia da jun&ccedil;&atilde;o esofagog&aa
cute;strica. O refluxo foi avaliado com medidas de pH e as press&otilde;es na tr
ansi&ccedil;&atilde;o esofagog&aacute;strica com microtransdutores.    ^cY#v24n1
a02.htm##
00767000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053200076002001300608#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#18#14#article#171#<br>   <b>RESULTADO
S:</b> Ap&oacute;s a miotomia ocorreu refluxo livremente em todos os animais. En
tretanto, ap&oacute;s a opera&ccedil;&atilde;o de Collis-Lind ou Collis-Nissen o
 refluxo espont&acirc;neo n&atilde;o ocorreu. A aplica&ccedil;&atilde;o de press
&atilde;o manual sobre o est&ocirc;mago, promoveu refluxo em 28,5 % dos animais 
do Grupo A. A avalia&ccedil;&atilde;o das press&otilde;es na pe&ccedil;a cir&uac
ute;rgica mostrou que n&atilde;o houve diferen&ccedil;a na zona de alta press&at
ilde;o, nos dois grupos.     ^cY#v24n1a02.htm##
00502000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026700076002001300343#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#19#15#article#171#<br> <b>CONCLUS&Ati
lde;O: </b> A opera&ccedil;&atilde;o de Collis-Lind ou Collis-Nissen impediu o r
efluxo gastroesof&aacute;gico. As medidas das press&otilde;es e a extens&atilde;
o da zona de alta press&atilde;o foram semelhantes nos dois grupos. </font></p> 
    ^cY#v24n1a02.htm##
00432000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019700076002001300273#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#20#16#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b> Esofagite p&eac
ute;ptica. Estenose esof&aacute;gica. Modelos animais. </font></p> <hr size="1" 
noshade >     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#21#17#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#22#18#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#23#19#article#171#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></fon
t></p>     ^cY#v24n1a02.htm##
01360000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112500076002001301201#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#24#20#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A esofagite de refluxo &eacute; doen
&ccedil;a caracterizada por inflama&ccedil;&atilde;o da mucosa esofagiana causad
a por repetidos e prolongados contatos do conte&uacute;do gastroduodenal reflu&i
acute;do para o es&ocirc;fago<sup>3</sup>. Al&eacute;m do problema do estreitame
nto da luz do &oacute;rg&atilde;o, outra situa&ccedil;&atilde;o que pode acompan
har as altera&ccedil;&otilde;es inflamat&oacute;rias transmurais, &eacute; o es&
ocirc;fago curto adquirido e motivo de controv&eacute;rsia no seu diagn&oacute;s
tico<sup>10,26</sup>. Mercer e Hill (1986)<sup>19</sup>, acreditavam que sempre 
&eacute; poss&iacute;vel obter segmento abdominal de es&ocirc;fago para um repar
o cir&uacute;rgico adequado, enquanto que outros autores reconhecem essa situa&c
cedil;&atilde;o e enfatizam a influ&ecirc;ncia negativa nos resultados cir&uacut
e;rgicos<sup>10,30</sup>. Em avalia&ccedil;&atilde;o intraoperat&oacute;ria em o
ito diferentes centros de estudos, chegou-se a cerca de 20% a incid&ecirc;ncia d
e es&ocirc;fago curto adquirido<sup>17</sup>. </font></p>     ^cY#v24n1a02.htm##
01034000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079900076002001300875#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#25#21#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tratamento cir&uacute;rgico ideal 
visa restaurar o tr&acirc;nsito alimentar normal e prevenir o refluxo subsequent
e<sup>30</sup>. Com a aplica&ccedil;&atilde;o das t&eacute;cnicas antirefluxo da
s fundoplicaturas na vig&ecirc;ncia de es&ocirc;fago encurtado, a ocorr&ecirc;nc
ia de falha no tratamento &eacute; maior, pois a jun&ccedil;&atilde;o esofagog&a
acute;strica  (JEG) fica no abdome sob tens&atilde;o, prejudicando a a&ccedil;&a
tilde;o  do esf&iacute;ncter inferior do es&ocirc;fago (EIE), al&eacute;m de pod
er ocorrer o escorregamento da JEG para o t&oacute;rax, ficando o envolvimento d
a v&aacute;lvula na parte proximal g&aacute;strica, n&atilde;o sendo efetivo no 
controle do refluxo<sup>1,7,26,34</sup>.</font></p>     ^cY#v24n1a02.htm##
01076000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084100076002001300917#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#26#22#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Collis em 1957<sup>5</sup> descreveu
 a opera&ccedil;&atilde;o da gastroplastia, na qual um alongamento do es&ocirc;f
ago com a pequena curvatura g&aacute;strica era obtido e que tinha o mesmo calib
re do es&ocirc;fago sendo sua continuidade, alcan&ccedil;ando um dos princ&iacut
e;pios da cirurgia antirefluxo que &eacute; obter segmento abdominal de es&ocirc
;fago mantendo o &acirc;ngulo de entrada do es&ocirc;fago no est&ocirc;mago, mas
 que se mostrou insuficiente, pois encontrou recorr&ecirc;ncia de sintomas<sup>6
</sup>. Pearson, et al.<sup>23</sup>, associaram &agrave; gastroplastia uma fund
oplicatura parcial tipo Belsey e Henderson<sup>12</sup> preferiu associar a fund
oplicatura total tipo Nissen, obtendo melhores resultados no controle do refluxo
. </font></p>     ^cY#v24n1a02.htm##
01182000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094700076002001301023#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#27#23#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A t&eacute;cnica descrita por Collis
 associada &agrave; fundoplicatura total para tratamento dos pacientes portadore
s de esofagites e estenoses que levam a encurtamento do es&ocirc;fago alcan&cced
il;ava os principais objetivos propostos hoje: h&aacute; preserva&ccedil;&atilde
;o do es&ocirc;fago, o esf&iacute;ncter inferior n&atilde;o &eacute; excisado, o
s nervos vagos permanecem &iacute;ntegros<sup>24</sup>, obt&eacute;m-se um segme
nto de neoes&ocirc;fago subdiafragm&aacute;tico para adequado reparo<sup>2,11</s
up>, elimina-se a tens&atilde;o no reparo<sup>2,23</sup>, utiliza se tecido n&at
ilde;o inflamado para a fundoplicatura<sup>2,21,22</sup>, e mant&eacute;m-se a a
ngula&ccedil;&atilde;o da JEG<sup>18</sup>. Est&aacute; associada &agrave; baixa
 morbidade e mortalidade e baixa recorr&ecirc;ncia anat&ocirc;mica de h&eacute;r
nia e refluxo<sup>27</sup>. </font></p>     ^cY#v24n1a02.htm##
01096000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086100076002001300937#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#28#24#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A opera&ccedil;&atilde;o, a princ&ia
cute;pio, foi usada para doentes com estenose p&eacute;ptica do es&ocirc;fago di
stal e consequente es&ocirc;fago encurtado, por&eacute;m atualmente, tem a sua i
ndica&ccedil;&atilde;o ampliada para reopera&ccedil;&otilde;es de doentes com re
cidiva de refluxo, ou com outros fatores predisponentes ao refluxo<sup>25</sup>,
 tais como esofagite de refluxo grave com ou sem estenose, doen&ccedil;a pulmona
r obstrutiva cr&ocirc;nica, obesidade, necessidade de esofagomiotomia, esclerode
rmia e grandes h&eacute;rnias encarceradas<sup>21</sup>. Todos estes fatores cit
ados interferem nas suturas usadas nas opera&ccedil;&otilde;es comuns e resultam
 em aumento de tens&atilde;o no reparo, prejudicando a corre&ccedil;&atilde;o do
 refluxo<sup>2</sup>. </font></p>     ^cY#v24n1a02.htm##
00566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033100076002001300407#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#29#25#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A partir do advento da cirurgia por 
v&iacute;deo passou a ser empregada tamb&eacute;m por esta via sendo considerada
 a primeira escolha para os casos de es&ocirc;fago encurtado grave e com grande 
dificuldade para solucionar o refluxo<sup>31</sup>. </font></p>     ^cY#v24n1a02
.htm##
00775000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054000076002001300616#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#30#26#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Considerando-se dif&iacute;cil o tra
tamento das esofagites complicadas com estenose e encurtamento do es&ocirc;fago 
e a pouca experi&ecirc;ncia com a t&eacute;cnica do alongamento tubular do es&oc
irc;fago com a pequena curvatura g&aacute;strica (t&eacute;cnica de Collis) asso
ciada &agrave; fundoplicatura parcial ou total, planejou-se um estudo experiment
al em c&atilde;es com a finalidade de testar a t&eacute;cnica na preven&ccedil;&
atilde;o do refluxo. </font></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#31#27#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#32#28#article#171#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font></p>    
 ^cY#v24n1a02.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022200076002001300298#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#33#29#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O trabalho foi aprovado pelo Comit&e
circ; de &Eacute;tica e Pesquisa Animal do Instituto de Biologia da Unicamp com 
o Protocolo nº 1867-1. </font></p>     ^cY#v24n1a02.htm##
00566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033100076002001300407#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#34#30#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foram utilizados 11 c&atilde;es com 
peso m&eacute;dio de 10,6 kg operados sob anestesia geral com pentobarbital s&oa
cute;dico e mantidos em respira&ccedil;&atilde;o positiva intermitente por tuba&
ccedil;&atilde;o oro-traqueal com aparelho Takaoka. </font></p>     ^cY#v24n1a02
.htm##
01284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104900076002001301125#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#35#31#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A opera&ccedil;&atilde;o iniciou-se 
por laparotomia mediana, dissec&ccedil;&atilde;o da JEG e isolamento do es&ocirc
;fago com dreno laminar fino. Para a ocorr&ecirc;ncia de refluxo, uma miotomia d
a JEG foi realizada em extens&atilde;o de 4 cm na parede anterior do es&ocirc;fa
go (3 cm) e do est&ocirc;mago (1 cm) (<a href="#fig1">Figura 1</a>). Foi realiza
da a amarradura do duodeno para impedir o escape da solu&ccedil;&atilde;o de sor
o fisiol&oacute;gico 0,9% (500 ml) e 1,2 ml de &aacute;cido clor&iacute;drico 12
N, solu&ccedil;&atilde;o ajustada para atingir pH 3,0, confirmado por pHmetro Be
ckman, injetada no est&ocirc;mago atrav&eacute;s de uma gastrostomia com sonda u
retral nº 8. Ap&oacute;s isso, uma sonda Foley nº 12 era colocada pela boca do a
nimal at&eacute; o ter&ccedil;o distal do es&ocirc;fago para a coleta de l&iacut
e;quido reflu&iacute;do para an&aacute;lise do seu pH atrav&eacute;s da leitura 
em fita do indicador universal de pH -0-14 Merck. </font></p>     ^cY#v24n1a02.h
tm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#36#32#article#171#<p><a name="fig1"><
/a></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#37#33#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#38#34#article#171#<p align="center"><
img src="/img/revistas/abcd/v24n1/a02fig1.jpg" ></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#39#35#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00763000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052800076002001300604#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#40#36#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Com a comprova&ccedil;&atilde;o da e
xist&ecirc;ncia do refluxo ap&oacute;s a miotomia longitudinal, a opera&ccedil;&
atilde;o prosseguia com a realiza&ccedil;&atilde;o do alongamento do es&ocirc;fa
go em uma extens&atilde;o de 4 cm a partir do fundo g&aacute;strico paralelo ao 
es&ocirc;fago, com uma sonda Portex nº 8,5 french colocada no es&ocirc;fago para
 evitar o estreitamento do neoes&ocirc;fago a ser criado (<a href="#fig2">Figura
 2</a>). </font></p>     ^cY#v24n1a02.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#41#37#article#171#<p><a name="fig2"><
/a></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#42#38#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#43#39#article#171#<p align="center"><
img src="/img/revistas/abcd/v24n1/a02fig2.jpg"></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#44#40#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00622000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038700076002001300463#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#45#41#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os animais foram divididos em dois g
rupos: Grupo A - em que a fundoplicatura realizada foi de 270º &agrave; maneira 
de Lind (sete animais - <a href="#fig3">Figura 3</a>) e Grupo B - em que a fundo
plicatura realizada foi de 360º &agrave; maneira de Nissen (quatro animais - <a 
href="#fig4">Figura 4</a>). </font></p>     ^cY#v24n1a02.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#46#42#article#171#<p><a name="fig3"><
/a></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#47#43#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#48#44#article#171#<p align="center"><
img src="/img/revistas/abcd/v24n1/a02fig3.jpg"></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#49#45#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#50#46#article#171#<p><a name="fig4"><
/a></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#51#47#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#52#48#article#171#<p align="center"><
img src="/img/revistas/abcd/v24n1/a02fig4.jpg" ></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#53#49#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00910000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067500076002001300751#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#54#50#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s a realiza&ccedil;&atilde
;o da gastroplastia e da fundoplicatura, novamente era colocada a solu&ccedil;&a
tilde;o de pH &aacute;cido no est&ocirc;mago e observada a ocorr&ecirc;ncia de r
efluxo espont&acirc;neo e for&ccedil;ado aplicando-se compress&atilde;o manual n
o est&ocirc;mago e coletando-se poss&iacute;vel l&iacute;quido  reflu&iacute;do 
no es&ocirc;fago. Previamente, o es&ocirc;fago era lavado com soro fisiol&oacute
;gico para n&atilde;o incorrer em erro de leitura do pH anteriormente &aacute;ci
do documentado, confirmado em leitura de fita do indicador universal de pH. </fo
nt></p>     ^cY#v24n1a02.htm##
00855000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062000076002001300696#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#55#51#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Enquanto era infundida a solu&ccedil
;&atilde;o &aacute;cida no est&ocirc;mago, media-se o volume injetado e anotava-
se o valor m&aacute;ximo. Ocorrendo ou n&atilde;o o refluxo espont&acirc;neo, em
pregava-se posteriormente press&atilde;o manual na parede g&aacute;strica medind
o-se a press&atilde;o intrag&aacute;strica em cm de &aacute;gua atrav&eacute;s d
a sonda de gastrostomia conectada &agrave; uma coluna de &aacute;gua, observando
 a ocorr&ecirc;ncia do refluxo pela sonda Foley colocada no es&ocirc;fago distal
 e medindo o seu pH. </font></p>     ^cY#v24n1a02.htm##
00580000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034500076002001300421#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#56#52#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s os testes de refluxo &aa
cute;cido terem sido feitos e anotados os resultados, a pe&ccedil;a cir&uacute;r
gica era retirada constando do es&ocirc;fago distal, o neo-es&ocirc;fago confecc
ionado, o est&ocirc;mago e o duodeno abaixo da ligadura do mesmo. </font></p>   
  ^cY#v24n1a02.htm##
00516000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028100076002001300357#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#57#53#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A perveabilidade do neoes&ocirc;fago
 era testada atrav&eacute;s da passagem do indicador do examinador e da sonda po
rtex 8,5 french para comprovar a exist&ecirc;ncia de estreitamento ou n&atilde;o
. </font></p>     ^cY#v24n1a02.htm##
01264000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102900076002001301105#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#58#54#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O conjunto retirado era levado ao la
borat&oacute;rio para estudo das press&otilde;es nesse neoes&ocirc;fago criado c
irurgicamente, por meio da coloca&ccedil;&atilde;o de cateter com microtransduto
res de press&atilde;o sendo um deles intrag&aacute;strico e o outro na &aacute;r
ea do alongamento e da fundoplicatura. Para este teste de press&atilde;o foi inj
etado soro fisiol&oacute;gico no est&ocirc;mago atrav&eacute;s da sonda de gastr
ostomia e medida as altera&ccedil;&otilde;es de press&atilde;o nos dois pontos a
pontados. Tamb&eacute;m a aplica&ccedil;&atilde;o de press&atilde;o manual sobre
 a parede anterior do est&ocirc;mago foi realizada e as altera&ccedil;&otilde;es
 de press&atilde;o foram registradas em papel milimetrado pr&oacute;prio para es
se exame. A retirada lenta e progressiva do cateter de microtransdutor foi reali
zada medindo-se a extens&atilde;o da zona de alta press&atilde;o obtida com o al
ongamento e a fundoplicatura. </font></p>     ^cY#v24n1a02.htm##
00501000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026600076002001300342#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#59#55#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise estat&iacute;stica 
foi realizada dos par&acirc;metros estudados com o teste T-Student e o teste de 
Wilcoxon considerando-se diferen&ccedil;a significativa p&lt;0,05. </font></p>  
   ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#60#56#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009900076002001300175#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#61#57#article#171#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUTADOS</b></font></p>     ^cY#
v24n1a02.htm##
00525000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029000076002001300366#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#62#58#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ocorreu refluxo espont&acirc;neo em 
todos os c&atilde;es ap&oacute;s a miotomia longitudinal da JEG com m&eacute;dia
 de 171,42 ml no grupo A e de 187,5 ml no grupo B de l&iacute;quido infundido (p
&gt;0,05). </font></p>     ^cY#v24n1a02.htm##
00674000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043900076002001300515#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#63#59#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s a realiza&ccedil;&atilde
;o do alongamento do es&ocirc;fago e da confec&ccedil;&atilde;o da fundoplicatur
a parcial ou total e infus&atilde;o de l&iacute;quido no est&ocirc;mago, n&atild
e;o ocorreu refluxo espont&acirc;neo para o es&ocirc;fago, com uma m&eacute;dia 
de 371,42 ml no grupo A e de 425 ml no grupo B de volume infundido (p&gt;0,05). 
</font></p>     ^cY#v24n1a02.htm##
00676000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044100076002001300517#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#64#60#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A diferen&ccedil;a entre o volume in
fundido para os grupos com a miotomia e ap&oacute;s a realiza&ccedil;&atilde;o d
a opera&ccedil;&atilde;o apresentou diferen&ccedil;a significativa entre eles (p
&lt;0,05), mostrando que a miotomia &eacute; suficiente para provocar refluxo ga
stroesof&aacute;gico (grupo A - 171,42 ml/371,42 ml e grupo B - 187,5 ml/425 ml)
. </font></p>     ^cY#v24n1a02.htm##
00717000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048200076002001300558#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#65#61#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Com a aplica&ccedil;&atilde;o de pre
ss&atilde;o manual sobre a parede g&aacute;strica, ocorreu refluxo em dois c&ati
lde;es do grupo A (28,5%) e em nenhum do grupo B com p&gt;0,05. As m&eacute;dias
 das press&otilde;es intrag&aacute;stricas obtidas nos dois grupos n&atilde;o mo
straram diferen&ccedil;as significativas - p&gt;0,05 -(grupo A - 27,14 cmH<sub>2
</sub>O e grupo B - 30 cm H<sub>2</sub>O). </font></p>     ^cY#v24n1a02.htm##
00924000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068900076002001300765#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#66#62#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O estudo das press&otilde;es com mic
rotransdutores da pe&ccedil;a cir&uacute;rgica que foi ressecada no grupo A most
rou a m&eacute;dia de press&atilde;o com infus&atilde;o de soro fisiol&oacute;gi
co no est&ocirc;mago de 20 mmHg e na gastroplastia de 15 mmHg, enquanto que no g
rupo B a m&eacute;dia no est&ocirc;mago foi de 15,66 mmHg e na gastroplastia de 
14,66 mmHg com p&gt;0,05 em ambos os grupos. Na compara&ccedil;&atilde;o das m&e
acute;dias das press&otilde;es tanto no est&ocirc;mago como na gastroplastia ent
re os dois grupos n&atilde;o houve diferen&ccedil;a significativa entre eles (p&
gt;0,05). </font></p>     ^cY#v24n1a02.htm##
00750000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051500076002001300591#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#67#63#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Quando se aplicou press&atilde;o man
ual na parede g&aacute;strica e avaliaram-se as altera&ccedil;&otilde;es de pres
s&atilde;o no est&ocirc;mago e na gastroplastia de ambos os grupos, encontrou-se
 os seguintes valores: grupo A - 23,75 mmHg e 15,75 mmHg e grupo B - 9,33 mmHg e
 12,66 mmHg, havendo diferen&ccedil;a significativa apenas na compara&ccedil;&at
ilde;o entre a press&atilde;o obtida intrag&aacute;strica no grupo A e o B. </fo
nt></p>     ^cY#v24n1a02.htm##
00517000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028200076002001300358#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#68#64#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A medida da extens&atilde;o da zona 
de alta press&atilde;o obtida com a fundoplicatura no grupo A foi de 3,25 cm e n
o grupo B de 3,66 cm, n&atilde;o sendo diferen&ccedil;a significativa (p&gt;0,05
). </font></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#69#65#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#70#66#article#171#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>  
   ^cY#v24n1a02.htm##
00592000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035700076002001300433#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#71#67#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O trabalho experimental conforme del
ineado, proporcionou atrav&eacute;s da realiza&ccedil;&atilde;o da miotomia de 4
 cm na parede anterior da JEG, o refluxo esperado em todos os animais para ent&a
tilde;o avaliar a efic&aacute;cia da t&eacute;cnica cir&uacute;rgica proposta.</
font></p>     ^cY#v24n1a02.htm##
01042000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080700076002001300883#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#72#68#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> As opera&ccedil;&otilde;es empregad
as para a conten&ccedil;&atilde;o do refluxo tentam restaurar a compet&ecirc;nci
a do EIE colocando-o em por&ccedil;&atilde;o intra-abdominal, al&eacute;m de cor
rigir os poss&iacute;veis defeitos da regi&atilde;o do hiato<sup>3,20</sup>. Qua
ndo da exist&ecirc;ncia de processo inflamat&oacute;rio intenso e es&ocirc;fago 
encurtado, se a opera&ccedil;&atilde;o &eacute; realizada com a confec&ccedil;&a
tilde;o de uma v&aacute;lvula anti-refluxo em um segmento curto ou inexistente d
e es&ocirc;fago abdominal, essa fundoplicatura fica sob tens&atilde;o e a tend&e
circ;ncia &eacute; a recorr&ecirc;ncia anat&ocirc;mica da h&eacute;rnia hiatal e
 da persist&ecirc;ncia do refluxo<sup>26</sup>. </font></p>     ^cY#v24n1a02.htm
##
00801000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056600076002001300642#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#73#69#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A realiza&ccedil;&atilde;o de um tub
o com a pequena curvatura g&aacute;strica como o alongamento do es&ocirc;fago pr
oposto por Collis em 1957 foi bem aceito<sup>6</sup>. O tubo tinha cerca de 7 a 
9 cm de extens&atilde;o com a aproxima&ccedil;&atilde;o do est&ocirc;mago ao tub
o sem uma fundoplicatura significativa. Com isso conseguia-se alongamento funcio
nal do es&ocirc;fago distal, mantendo um &acirc;ngulo agudo de entrada entre o e
s&ocirc;fago e o est&ocirc;mago<sup>4,6</sup>. </font></p>     ^cY#v24n1a02.htm#
#
00857000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062200076002001300698#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#74#70#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Pearson, et al.<sup>23</sup>, associ
aram ao alongamento do es&ocirc;fago uma fundoplicatura de 240º. Consideravam qu
e n&atilde;o apenas o &acirc;ngulo de entrada do es&ocirc;fago ao est&ocirc;mago
 e o segmento de es&ocirc;fago abdominal eram importantes, mas que, ao agregar u
ma fundoplicatura ao redor do neoes&ocirc;fago, criava-se um mecanismo valvular.
 Com isso utilizava-se uma regi&atilde;o livre de processo inflamat&oacute;rio, 
mais f&aacute;cil manipula&ccedil;&atilde;o, menor risco de les&atilde;o e de in
sucesso a longo prazo. </font></p>     ^cY#v24n1a02.htm##
00654000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041900076002001300495#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#75#71#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os benef&iacute;cios desta t&eacute;
cnica empregada alcan&ccedil;avam um segmento de zona de alta press&atilde;o int
ra-abdominal, o EIE era preservado e n&atilde;o excisado ou destru&iacute;do, os
 nervos vagos mantidos &iacute;ntegros com a&ccedil;&atilde;o da press&atilde;o 
positiva abdominal sobre essa regi&atilde;o<sup>7,24</sup>. </font></p>     ^cY#
v24n1a02.htm##
00651000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041600076002001300492#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#76#72#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Henderson<sup>12 </sup>associou &agr
ave; gastroplastia uma fundoplicatura total &agrave; maneira de Nissen, pois em 
trabalho do seu grupo com a opera&ccedil;&atilde;o de Collis-Belsey encontrou 44
,6% de refluxo radiol&oacute;gico e de 25,7% de sintomas importantes, apesar de 
apenas 1,5% de recorr&ecirc;ncia de h&eacute;rnia hiatal.</font></p>     ^cY#v24
n1a02.htm##
00541000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030600076002001300382#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#77#73#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Steichen<sup>29</sup> descreveu a o
pera&ccedil;&atilde;o de Collis-Nissen em 77 pacientes onde encontrou 1,2% de re
corr&ecirc;ncia de h&eacute;rnia hiatal e nenhum caso de refluxo radiol&oacute;g
ico ou sintom&aacute;tico. </font></p>     ^cY#v24n1a02.htm##
00841000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060600076002001300682#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#78#74#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Thomas-Ridocci, et al.<sup>33</sup>,
 comparando a opera&ccedil;&atilde;o de Nissen com a de Collis-Nissen, encontrar
am melhor resultado com a segunda com 6,6% e 0% de sintomas de recorr&ecirc;ncia
 e h&eacute;rnia hiatal recidivada em 18% e 0% respectivamente. J&aacute; a mano
metria foi semelhante nos dois grupos e a pHmetria mostrou refluxo em 10% e 5% r
espectivamente, concluindo que a opera&ccedil;&atilde;o da gastroplastia com fun
doplicatura foi melhor, apesar destes doentes serem mais graves que os do outro 
grupo. </font></p>     ^cY#v24n1a02.htm##
00542000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030700076002001300383#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#79#75#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No presente trabalho optou-se por re
alizar o estudo do alongamento do es&ocirc;fago em uma extens&atilde;o de 4 cm e
 de associar fundoplicatura em uma extens&atilde;o igual recobrindo praticamente
 todo o tubo confeccionado. </font></p>     ^cY#v24n1a02.htm##
00737000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050200076002001300578#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#80#76#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A compara&ccedil;&atilde;o dos dois 
tipos de fundoplicatura (parcial ou total) foi realizada, pois, em determinadas 
situa&ccedil;&otilde;es &eacute; necess&aacute;rio empregar a fundoplicatura par
cial. Em trabalho experimental em gatos comparando a opera&ccedil;&atilde;o de C
ollis-Belsey e Collis-Nissen, ficou mostrado ser claramente superior a fundoplic
atura total na conten&ccedil;&atilde;o do refluxo<sup>9</sup>. </font></p>     ^
cY#v24n1a02.htm##
01192000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095700076002001301033#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#81#77#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Neste trabalho o refluxo ocorreu em 
28,5% dos animais no grupo da opera&ccedil;&atilde;o de Collis-Lind, mas apenas 
no teste com press&atilde;o sobre a parede g&aacute;strica, o que proporciona fa
tor facilitador para a ocorr&ecirc;ncia do refluxo. Em situa&ccedil;&atilde;o no
rmal o refluxo n&atilde;o ocorreu em nenhum dos animais. Portanto as t&eacute;cn
icas se equivalem quanto &agrave; prote&ccedil;&atilde;o contra o refluxo espont
&acirc;neo. Os dados encontrados na literatura mostram a mesma observa&ccedil;&a
tilde;o seja em trabalhos experimentais ou cl&iacute;nicos<sup>9,26,30</sup>. Ol
iveira, et al.<sup>20</sup>, realizaram fundoplicatura parcial (Lind) e total (N
issen) em coelhos e conclu&iacute;ram que ambos promovem aumento da press&atilde
;o e comprimento da zona de alta press&atilde;o e seu aumento n&atilde;o depende
 do tipo de fundoplicatura realizada. </font></p>     ^cY#v24n1a02.htm##
00636000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040100076002001300477#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#82#78#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o da ocorr&e
circ;ncia do refluxo por aplicar press&atilde;o sobre o est&ocirc;mago foi muito
 utilizado nos trabalhos experimentais e todos mostraram o aumento da press&atil
de;o intrag&aacute;strica e no segmento de alongamento do es&ocirc;fago envolvid
o pela v&aacute;lvula<sup>16,24,28</sup>. </font></p>     ^cY#v24n1a02.htm##
00563000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032800076002001300404#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#83#79#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No intraoperat&oacute;rio era observ
ado a ocorr&ecirc;ncia do refluxo espont&acirc;neo ou com compress&atilde;o do e
st&ocirc;mago atrav&eacute;s da coleta do l&iacute;quido reflu&iacute;do no es&o
circ;fago e an&aacute;lise com fita de pHmetria. </font></p>     ^cY#v24n1a02.ht
m##
01064000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082900076002001300905#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#84#80#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Por&eacute;m, o estudo das press&oti
lde;es no tubo com a fundoplicatura era feito na pe&ccedil;a cir&uacute;rgica re
ssecada. Isso foi usado por Butterfield<sup>4</sup> em pe&ccedil;as anat&ocirc;m
icas retiradas de cad&aacute;ver constituindo do es&ocirc;fago distal, o est&oci
rc;mago e o duodeno. Em seguida era colocado &aacute;gua no est&ocirc;mago com o
 duodeno fechado e observado refluxo no es&ocirc;fago. Foram realizadas as opera
&ccedil;&otilde;es de Nissen, Belsey, Hill e Thal-Hatafuku e mais uma vez observ
ado a ocorr&ecirc;ncia do refluxo. N&atilde;o ocorrendo refluxo espont&acirc;neo
 era aplicado press&atilde;o arbitr&aacute;ria de 250 mmHg no est&ocirc;mago. Ne
sse trabalho as melhores t&eacute;cnicas foram a de Nissen e de Hill. </font></p
>     ^cY#v24n1a02.htm##
00735000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050000076002001300576#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#85#81#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O fator mais importante considerado 
no controle do refluxo &eacute; a obten&ccedil;&atilde;o de zona de alta press&a
tilde;o junto do EIE e a sua extens&atilde;o. Khan, et al.<sup>15</sup>, estudan
do c&atilde;es, mostraram que os m&eacute;todos cir&uacute;rgicos que colocam o 
EIE no abdome associado ao envolvimento pelo fundo g&aacute;strico, levam a aume
nto da zona de alta press&atilde;o e da sua extens&atilde;o. </font></p>     ^cY
#v24n1a02.htm##
00753000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051800076002001300594#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#86#82#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As varia&ccedil;&otilde;es de press&
atilde;o no est&ocirc;mago e no neoes&ocirc;fago com ou sem press&atilde;o sobre
 a parede g&aacute;strica n&atilde;o mostrou diferen&ccedil;a significativa entr
e os dois grupos estudados aqui, mostrando respostas semelhantes. Nos trabalhos 
da literatura os que compararam as press&otilde;es entre as fundolicaturas parci
al ou total, mostraram melhor resposta na fundoplicatura total<sup>9,22</sup>. <
/font></p>     ^cY#v24n1a02.htm##
00840000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060500076002001300681#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#87#83#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Quanto &agrave; extens&atilde;o da z
ona de alta press&atilde;o tamb&eacute;m n&atilde;o houve diferen&ccedil;a estat
&iacute;stica entre os dois grupos estudados. Portanto, qualquer tipo de fundopl
icatura &eacute; capaz de obter segmento suficiente para a contens&atilde;o do r
efluxo. Ellis, et al.<sup>9</sup>, em trabalho experimental encontraram resultad
os tamb&eacute;m semelhantes na avalia&ccedil;&atilde;o da extens&atilde;o da zo
na de alta press&atilde;o na opera&ccedil;&atilde;o de Collis-Nissen e Collis-Be
lsey. </font></p>     ^cY#v24n1a02.htm##
00986000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075100076002001300827#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#88#84#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Como &uacute;ltima informa&ccedil;&a
tilde;o, a opera&ccedil;&atilde;o de Collis associada &agrave; fundoplicatura pa
rcial ou total, pode ser realizada por videocirurgia atraindo o benef&iacute;cio
 da cirurgia minimamente invasiva, obtendo em s&eacute;ries cl&iacute;nicas, res
ultados satisfat&oacute;rios no controle refluxo<sup>13,14,17,31,32</sup>. &Eacu
te;, portanto, adequada para a contens&atilde;o do refluxo gastroesof&aacute;gic
o, podendo ser indicada para os casos graves de es&ocirc;fago encurtado. Os trab
alhos cl&iacute;nicos mostram que a t&eacute;cnica tem baixa incid&ecirc;ncia de
 recorr&ecirc;ncia dos sintomas e poucas falhas no controle do refluxo. </font><
/p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#89#85#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#90#86#article#171#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>  
   ^cY#v24n1a02.htm##
00544000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030900076002001300385#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#91#87#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A opera&ccedil;&atilde;o de Collis-L
ind ou Collis-Nissen impediu o refluxo gastroesof&aacute;gico. As medidas das pr
ess&otilde;es e a extens&atilde;o da zona de alta press&atilde;o foram semelhant
es nos dois grupos estudados. </font></p>     ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#92#88#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#93#89#article#171#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>AGRADECIMENTO</b></font></p>     
^cY#v24n1a02.htm##
00494000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025900076002001300335#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#94#90#article#171#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ao Prof Dr. Nelson Ary Brandalise qu
e foi o orientador deste trabalho e continua a ensinar gera&ccedil;&otilde;es de
 cirurgi&otilde;es com sua capacidade, nos quais me incluo. </font></p>     ^cY#
v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#95#91#article#171#<p>&nbsp;</p>     ^
cY#v24n1a02.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#96#92#article#171#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIA</b></font></p>  
   ^cY#v24n1a02.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021100078002001300289#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#97#93#article#171#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. 	Andriani AC, Neves
 TT. A gastroplastia em manga (sleeve gastrectomy) e o diabetes mellitus. ABCD A
rq Bras Cir Dig . 2008; 21(3):133-135.    ^cY#v24n1a02.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#98#94#article#171# </font></p>     ^c
Y#v24n1a02.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024400078002001300322#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#99#95#article#171#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Agha FP, Trenhner S
W, Orringer MB, Vinh PN. The combined Collis gastroplasty-Nissen fundoplication:
 surgical procedure and radiographic evaluation. AJR. 1985; 145:729-34.    ^cY#v
24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#100#96#article#171# </font></p>     ^
cY#v24n1a02.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704026400079002001300343#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#101#97#article#171#3#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Andreollo NA, 	Lop
es LR, Coelho-Neto JS. Doen&ccedil;a do refluxo gastroesof&aacute;gico: qual a e
fic&aacute;cia dos exames no diagn&oacute;stico?. ABCD Arq  Bras Cir Dig. 2010; 
23(1): 6-10.    ^cY#v24n1a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#102#98#article#171# </font></p>     ^
cY#v24n1a02.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704021300079002001300292#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#103#99#article#171#4#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Butterfield WC. Cu
rrent hiatal hernia repairs: similarities, mechanism and extended indications - 
an autopsy study. Surgery. 1971;69:910-6.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#104#100#article#171# </font></p>     
^cY#v24n1a02.htm##
00422000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704017100080002001300251#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#105#101#article#171#5#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Collis JL. An ope
ration for hiatus hernia with short esophagus. J. Thorac. Surg. 1957; 34:768-78.
    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#106#102#article#171# </font></p>     
^cY#v24n1a02.htm##
00411000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704016000080002001300240#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#107#103#article#171#6#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Collis JL. Surgic
al control of reflux in hiatus hernia. Am. J. Surg. 1968; 115:465-71.    ^cY#v24
n1a02.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704001700078002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#108#104#article#171# </font>     ^cY#
v24n1a02.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704019900080002001300279#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#109#105#article#171#7#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Deitel M, Khanna 
RK, Hagen J, Ilves R. Vertical banded gastroplasty as an antireflux procedure. A
m. J. Surg. 1988; 155:512-6.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#110#106#article#171# </font></p>     
^cY#v24n1a02.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704020700080002001300287#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#111#107#article#171#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Demos NJ. A simpl
ified, improved technique for the Collis gastroplasty for dilatable strictures. 
Surg. Gynecol. Obst. 1976; 42:591-2.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#112#108#article#171# </font></p>     
^cY#v24n1a02.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704024100080002001300321#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#113#109#article#171#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Ellis FH, Leonard
i HK, Dabuznsky L, Crozier RE. Surgery for short esophagus with stricture: an ex
perimental and clinical manometric study. Ann. Surg. 1978; 188:341-50.    ^cY#v2
4n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#114#110#article#171# </font></p>     
^cY#v24n1a02.htm##
00425000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017300081002001300254#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#115#111#article#171#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Gatzinsky P, Be
rgh NP. Hiatal hernia and shortened oesophagus. Acta Chir. Scand. 1979; 145:159-
66.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#116#112#article#171# </font></p>     
^cY#v24n1a02.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026500081002001300346#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#117#113#article#171#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Henderson RD, B
oszko A, Mugashi F, Szcepanski MM, Marryatt G. Oesophageal replacement by a gast
ric tube: an experimental study of the properties of gastric tube. Br. J. Surg. 
1974; 61:533-7.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#118#114#article#171# </font></p>     
^cY#v24n1a02.htm##
00415000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016300081002001300244#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#119#115#article#171#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Henderson RD. R
eflux control following gastroplasty. Ann. Thorac. Surg. 1977; 24:206-14.    ^cY
#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#120#116#article#171# </font></p>     
^cY#v24n1a02.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023100081002001300312#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#121#117#article#171#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Jobe BA, Horvat
h KD, Swanstrom LL. Postoperative function following laparoscopic Collis gastrop
lasty for shortened esophagus. Arch. Surg., 133:867-74, 1998.    ^cY#v24n1a02.ht
m##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#122#118#article#171# </font></p>     
^cY#v24n1a02.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026800081002001300349#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#123#119#article#171#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Johnson AB, Odd
sdottir M, Hunter JG. Laparoscopic Collis gastroplasty and Nissen fundoplication
: A new technique for the management of esophageal foreshortening. Surg. Endosc.
 1998; 12:1055-60.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#124#120#article#171# </font></p>     
^cY#v24n1a02.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#125#121#article#171#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 15. Khan TA, Crisp
in JS, Lind JF. Effect change of position on the function of the canine lower es
ophageal sphincter. Gastroenterol. 1974; 67:957-64.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#126#122#article#171# </font></p>     
^cY#v24n1a02.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022900081002001300310#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#127#123#article#171#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Leonardi HK, Le
e ME, El-Kurd MF, Ellis FH. An experimental study of the effectiveness of variou
s antireflux operations. Ann. Thorac.Surg. 1977; 24:215-22.    ^cY#v24n1a02.htm#
#
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#128#124#article#171# </font></p>     
^cY#v24n1a02.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027200081002001300353#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#129#125#article#171#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Luketich JD, Gr
ondin SC, Pearson FG. Minimally invasive approaches to acquired shortening of th
e esophagus: laparoscopic Collis-Nissen gastroplasty. Semin. Thorac. Cardiovasc.
 Surg. 2000; 12:173-8.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#130#126#article#171# </font></p>     
^cY#v24n1a02.htm##
00625000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037300081002001300454#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#131#127#article#171#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Mattioli S, Lug
aresi ML, Costantini M, Del Genio A, Di Martino N, Fei L, Fumagalli U, Maffetton
e V, Monaco L, Morino M, Rebecchi F, Rosati R, Rossi M, Santi S, Trapani V, Zani
notto G. The short esophagus: intraoperative assesment of esophageal length. J. 
Thorac. Cardiovasc. Surg, 2008; 136:834-41.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#132#128#article#171# </font></p>     
^cY#v24n1a02.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#133#129#article#171#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Mercer CD, Hill
 LD. Surgical management of peptic esophageal stricture. Twenty-year experience.
 J. Thorac. Cardiovasc. Surg. 1986; 91:371-8.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#134#130#article#171# </font></p>     
^cY#v24n1a02.htm##
00507000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025500081002001300336#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#135#131#article#171#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Oliveira WK, He
nry MACA, Lerco MM. Manometric evaluation of lower esophageal sphincter in rabbi
ts submitted to total and partial fundoplication. Acta Cir Bras. 2004;19(5): 555
-564.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#136#132#article#171# </font></p>     
^cY#v24n1a02.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020500081002001300286#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#137#133#article#171#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Orringer MB, Sl
oan H. Collis-Belsey reconstruction of the esophagogastric junction. J. Thorac. 
Cardiovasc. Surg. 1976; 71:295-303.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#138#134#article#171# </font></p>     
^cY#v24n1a02.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020900081002001300290#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#139#135#article#171#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Orringer MB, Sl
oan H. Complcations and failings of the combined Collis-Belsey operation. J. Tho
rac. Cardiovasc. Surg. 1977; 74:726-35.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#140#136#article#171# </font></p>     
^cY#v24n1a02.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#141#137#article#171#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Pearson FG, Lan
ger B, Henderson RD. Gastroplasty and Belsey hiatus repair - An operation for th
e management of peptic stricture with acquired short esophagus. J. Thorac. Cardi
ovasc. Surg. 1971; 61:50-63.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#142#138#article#171# </font></p>     
^cY#v24n1a02.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#143#139#article#171#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Pearson FG, Hen
derson RD. Experimental and clinical studies of gastroplasty in the management o
f acquired short esophagus. Surg. Gynecol. Obstet. 1973; 136:737-44.    ^cY#v24n
1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#144#140#article#171# </font></p>     
^cY#v24n1a02.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#145#141#article#171#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Pearson FG, Hen
derson RD. Long-term follow-up of strictures managed by dilatation, modified Col
lis gastroplasty and Belsey hiatus hernia repair. Surgery. 1976; 80:396-404.    
^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#146#142#article#171# </font></p>     
^cY#v24n1a02.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019900081002001300280#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#147#143#article#171#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 26. Pearson FG. Su
rgical management of acquired short esophagus with dilatable peptic stricture. W
orld J. Surg. 1977; 1:463-73.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#148#144#article#171# </font></p>     
^cY#v24n1a02.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#149#145#article#171#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Pearson FG, Coo
per JD, Patterson GA, Ramires J, Todd TR. Gastroplasty and fundoplication for co
mplex problems - Long term results. Ann. Surg. 1987; 206:473-81.    ^cY#v24n1a02
.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#150#146#article#171# </font></p>     
^cY#v24n1a02.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#151#147#article#171#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Sicular A, Cohe
n B, Zimmerman A, Kark AE. The significance of onintra-abdominal segment of cani
ne esophagus as a competent anti-reflux mechanism. Surgery. 1967; 61:784-90.    
^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#152#148#article#171# </font></p>     
^cY#v24n1a02.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020000081002001300281#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#153#149#article#171#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Steichen FM. Ab
dominal approach to the Collis gastroplasty and Nissen fundoplication. Surg. Gyn
ecol. Obstet. 1986; 162:273-5.    ^cY#v24n1a02.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021700081002001300298#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#154#150#article#171#30# <
/font></p> <font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Stirl
ing MC, Orringer MB. The combined Collis-Nissen operation for esophageal reflux 
strictures. Ann. Thorac. Surg. 1988; 45:148-57.    ^cY#v24n1a02.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#155#151#article#171# </font> </p>    
 ^cY#v24n1a02.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023200081002001300313#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#156#152#article#171#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Swanstrom LL, M
arcus DR, Galloway GQ. Laparoscopic Collis gastroplasty is the treatment of choi
ce for the shortened esophagus. Am. J. Surg. 1996; 171:477-81.    ^cY#v24n1a02.h
tm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#157#153#article#171# </font></p>     
^cY#v24n1a02.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019800081002001300279#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#158#154#article#171#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Terry ML, Verno
n A, Hunter JG. Stapled-wedge Collis gastroplasty for the shortened esophagus. A
m. J. Surg. 2004; 188:195-9.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#159#155#article#171# </font></p>     
^cY#v24n1a02.htm##
00593000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034100081002001300422#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#160#156#article#171#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Thomas-Ridocci 
M, Paris F, Carbonell-Antoli C, Mora F, Molina R, Padilha J, Carbonell-Canti C, 
Moreno-Osset E, Guijarro R, Benages A. Total fundoplication with or without gast
roplasty for gastroesphageal reflux: comparative study. Ann. Thorac. Surg. 1985;
 39:508-11.    ^cY#v24n1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#161#157#article#171# </font></p>     
^cY#v24n1a02.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#162#158#article#171#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Valezi AC, Mali
-Junior J, Brito EM, Marson AC. Gastroplastia vertical com bandagem em y-de-roux
: an&aacute;lise de resultados. Rev Col Bras Cir. 2004; 31(1):49-56.    ^cY#v24n
1a02.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#163#159#article#171# </font></p>     
^cY#v24n1a02.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#164#160#article#171#<p>&nbsp;</p>    
 ^cY#v24n1a02.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#165#161#article#171#<p>&nbsp;</p>    
 ^cY#v24n1a02.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019800078002001300276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#166#162#article#171#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ec
irc;ncia:</b>    ^cY#v24n1a02.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#167#163#article#171#<br>   Luiz Rober
to Lopes    ^cY#v24n1a02.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010100078002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#168#164#article#171#<br> e-mail: <a h
ref="mailto:lopeslr@fcm.unicamp.br ">lopeslr@fcm.unicamp.br </a></font></p>     
^cY#v24n1a02.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012100078002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#169#165#article#171#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 15/11/2010    ^cY#v24n1a02.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006400078002001300142#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#170#166#article#171#<br>   Aceito par
a publica&ccedil;&atilde;o: 21/12/2010     ^cY#v24n1a02.htm##
00296000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005900078002001300137#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#171#167#article#171#<br>   Fonte de f
inanciamento: n&atilde;o h&aacute;    ^cY#v24n1a02.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007200078002001300150#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#172#168#article#171#<br>   Conflito d
e interesses: n&atilde;o h&aacute; </font></p>     ^cY#v24n1a02.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#173#169#article#171#<p>&nbsp;</p>    
 ^cY#v24n1a02.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#174#170#article#171#<p>&nbsp;</p>    
 ^cY#v24n1a02.htm##
00527000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704029000078002001300368#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a02.htm#S#p#175#171#article#171#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado na Disciplina d
e Mol&eacute;stias do Aparelho Digestivo - Departamento de Cirurgia - Faculdade 
de Ci&ecirc;ncias M&eacute;dicas -  Universidade Estadual de Campinas. Campinas,
 SP, Brasil. </font></p>     ^cY#v24n1a02.htm##
00535000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100016000960120
07200112030002200184710000200206065000900208064000500217031000300222032000200225
014000800227865000900235002001300244#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a02.htm#S#c#176#1#article#34#1#^rND^sAndriani^nAC#^rND^sNeves^nTT#A gastropla
stia em manga (sleeve gastrectomy) e o diabetes mellitus^lpt#ABCD Arq Bras Cir D
ig#2#20080000#2008#21#3#133-135#20110300#v24n1a02.htm##
00619000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100019000920100
01900111010001500130012010700145030000400252065000900256064000500265031000400270
014000700274865000900281002001300290035001000303801000400313#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a02.htm#S#c#177#2#article#34#2#^rND^sAgha^nFP#^rND^sT
renhner^nSW#^rND^sOrringer^nMB#^rND^sVinh^nPN#The combined Collis gastroplasty-N
issen fundoplication: surgical procedure and radiographic evaluation^len#AJR#198
50000#1985#145#729-34#20110300#v24n1a02.htm#0361-803X#AJR##
00577000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100016000970100
02200113012008200135030002200217710000200239065000900241064000500250031000300255
032000200258014000500260865000900265002001300274#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a02.htm#S#c#178#3#article#34#3#^rND^sAndreollo^nNA#^rND^sLopes^nL
R#^rND^sCoelho-Neto^nJS#Doença do refluxo gastroesofágico: qual a eficácia dos e
xames no diagnóstico?^lpt#ABCD Arq Bras Cir Dig#2#20100000#2010#23#1#6-10#201103
00#v24n1a02.htm##
00539000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770120103000990300
00800202065000900210064000500219031000300224014000600227865000900233002001300242
035001000255801000800265#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S
#c#179#4#article#34#4#^rND^sButterfield^nWC#Current hiatal hernia repairs: simil
arities, mechanism and extended indications - an autopsy study^len#Surgery#19710
000#1971#69#910-6#20110300#v24n1a02.htm#0039-6060#Surgery##
00468000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120056000940300
01600150710000200166065000900168064000500177031000300182014000700185865000900192
002001300201#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#c#180#5#art
icle#34#5#^rND^sCollis^nJL#An operation for hiatus hernia with short esophagus^l
en#J. Thorac. Surg#2#19570000#1957#34#768-78#20110300#v24n1a02.htm##
00489000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120048000940300
01200142065000900154064000500163031000400168014000700172865000900179002001300188
035001000201801001200211#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S
#c#181#6#article#34#6#^rND^sCollis^nJL#Surgical control of reflux in hiatus hern
ia^len#Am. J. Surg#19680000#1968#115#465-71#20110300#v24n1a02.htm#0002-9610#Am. 
j. surg##
00582000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01500110010001500125012006000140030001200200065000900212064000500221031000400226
014000600230865000900236002001300245035001000258801001200268#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a02.htm#S#c#182#7#article#34#7#^rND^sDeitel^nM#^rND^s
Khanna^nRK#^rND^sHagen^nJ#^rND^sIlves^nR#Vertical banded gastroplasty as an anti
reflux procedure^len#Am. J. Surg#19880000#1988#155#512-6#20110300#v24n1a02.htm#0
002-9610#Am. j. surg##
00504000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120090000930300
02000183710000200203065000900205064000500214031000300219014000600222865000900228
002001300237#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#c#183#8#art
icle#34#8#^rND^sDemos^nNJ#A simplified, improved technique for the Collis gastro
plasty for dilatable strictures^len#Surg. Gynecol. Obst#2#19760000#1976#42#591-2
#20110300#v24n1a02.htm##
00622000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01900112010001800131012009400149030001000243065000900253064000500262031000400267
014000700271865000900278002001300287035001000300801001000310#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a02.htm#S#c#184#9#article#34#9#^rND^sEllis^nFH#^rND^s
Leonardi^nHK#^rND^sDabuznsky^nL#^rND^sCrozier^nRE#Surgery for short esophagus wi
th stricture: an experimental and clinical manometric study^len#Ann. Surg#197800
00#1978#188#341-50#20110300#v24n1a02.htm#0003-4932#Ann. surg##
00526000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980120
04300114030001700157065000900174064000500183031000400188014000700192865000900199
002001300208035001000221801001700231#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a02.htm#S#c#185#10#article#34#10#^rND^sGatzinsky^nP#^rND^sBergh^nNP#Hiatal he
rnia and shortened oesophagus^len#Acta Chir. Scand#19790000#1979#145#159-66#2011
0300#v24n1a02.htm#0001-5482#Acta chir. scand##
00667000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
01700115010002100132010001800153012010300171030001200274065000900286064000500295
031000300300014000600303865000900309002001300318035001000331801001200341#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#c#186#11#article#34#11#^rND^sHe
nderson^nRD#^rND^sBoszko^nA#^rND^sMugashi^nF#^rND^sSzcepanski^nMM#^rND^sMarryatt
^nG#Oesophageal replacement by a gastric tube: an experimental study of the prop
erties of gastric tube^len#Br. J. Surg#19740000#1974#61#533-7#20110300#v24n1a02.
htm#0007-1323#Br. j. surg##
00499000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790120042000990300
01800141065000900159064000500168031000300173014000700176865000900183002001300192
035001000205801001800215#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S
#c#187#12#article#34#12#^rND^sHenderson^nRD#Reflux control following gastroplast
y^len#Ann. Thorac. Surg#19770000#1977#24#206-14#20110300#v24n1a02.htm#0003-4975#
Ann. thorac. surg##
00595000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
02000112012009400132030001100226031000400237014000700241065000900248064000500257
865000900262002001300271035001000284801001100294#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a02.htm#S#c#188#13#article#34#13#^rND^sJobe^nBA#^rND^sHorvath^nKD
#^rND^sSwanstrom^nLL#Postoperative function following laparoscopic Collis gastro
plasty for shortened esophagus^len#Arch. Surg#133#867-74#19980000#1998#20110300#
v24n1a02.htm#0004-0010#Arch. surg##
00602000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970100
01700117012012800134030001300262710000200275065000900277064000500286031000300291
014000800294865000900302002001300311#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a02.htm#S#c#189#14#article#34#14#^rND^sJohnson^nAB#^rND^sOddsdottir^nM#^rND^s
Hunter^nJG#Laparoscopic Collis gastroplasty and Nissen fundoplication: A new tec
hnique for the management of esophageal foreshortening^len#Surg. Endosc#2#199800
00#1998#12#1055-60#20110300#v24n1a02.htm##
00588000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01500112012008700127030001400214065000900228064000500237031000300242014000700245
865000900252002001300261035001000274801001400284#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a02.htm#S#c#190#15#article#34#15#^rND^sKhan^nTA#^rND^sCrispin^nJS
#^rND^sLind^nJF#Effect change of position on the function of the canine lower es
ophageal sphincter^len#Gastroenterol#19740000#1974#67#957-64#20110300#v24n1a02.h
tm#0892-9386#Gastroenterol##
00581000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100014000980100
01800112010001600130012008000146030001700226710000200243065000900245064000500254
031000300259014000700262865000900269002001300278#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a02.htm#S#c#191#16#article#34#16#^rND^sLeonardi^nHK#^rND^sLee^nME
#^rND^sEl-Kurd^nMF#^rND^sEllis^nFH#An experimental study of the effectiveness of
 various antireflux operations^len#Ann. Thorac.Surg#2#19770000#1977#24#215-22#20
110300#v24n1a02.htm##
00658000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01800116012011500134030003200249065000900281064000500290031000300295014000600298
865000900304002001300313035001000326801003200336#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a02.htm#S#c#192#17#article#34#17#^rND^sLuketich^nJD#^rND^sGrondin
^nSC#^rND^sPearson^nFG#Minimally invasive approaches to acquired shortening of t
he esophagus: laparoscopic Collis-Nissen gastroplasty^len#Semin. Thorac. Cardiov
asc. Surg#20000000#2000#12#173-8#20110300#v24n1a02.htm#1043-0679#Semin. thorac. 
cardiovasc. surg##
00941000000000433000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
02000116010001900136010002000155010001300175010001900188010002000207010001600227
01000160024301000180025901000160027701000150029301000150030801000170032301000190
03400120071003590300028004307100002004580650009004600640005004690310004004740140
00700478865000900485002001300494#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a
02.htm#S#c#193#18#article#34#18#^rND^sMattioli^nS#^rND^sLugaresi^nML#^rND^sCosta
ntini^nM#^rND^sDel Genio^nA#^rND^sDi Martino^nN#^rND^sFei^nL#^rND^sFumagalli^nU#
^rND^sMaffettone^nV#^rND^sMonaco^nL#^rND^sMorino^nM#^rND^sRebecchi^nF#^rND^sRosa
ti^nR#^rND^sRossi^nM#^rND^sSanti^nS#^rND^sTrapani^nV#^rND^sZaninotto^nG#The shor
t esophagus: intraoperative assesment of esophageal length^len#J. Thorac. Cardio
vasc. Surg#2#20080000#2008#136#834-41#20110300#v24n1a02.htm##
00527000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100015000920120
07900107030002800186710000200214065000900216064000500225031000300230014000600233
865000900239002001300248#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S
#c#194#19#article#34#19#^rND^sMercer#^rND^sHill^nLD#Surgical management of pepti
c esophageal stricture: Twenty-year experience^len#J. Thorac. Cardiovasc. Surg#2
#19860000#1986#91#371-8#20110300#v24n1a02.htm##
00600000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01600116012011300132030001400245710000200259065000900261064000500270031000300275
032000200278014000800280865000900288002001300297#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a02.htm#S#c#195#20#article#34#20#^rND^sOliveira^nWK#^rND^sHenry^n
MACA#^rND^sLerco^nMM#Manometric evaluation of lower esophageal sphincter in rabb
its submitted to total and partial fundoplication^len#Acta Cir Bras#2#20040000#2
004#19#5#555-564#20110300#v24n1a02.htm##
00521000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980120
06500113030002800178710000200206065000900208064000500217031000300222014000800225
865000900233002001300242#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S
#c#196#21#article#34#21#^rND^sOrringer^nMB#^rND^sSloan^nH#Collis-Belsey reconstr
uction of the esophagogastric junction^len#J. Thorac. Cardiovasc. Surg#2#1976000
0#1976#71#295-303#20110300#v24n1a02.htm##
00525000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980120
07000113030002800183710000200211065000900213064000500222031000300227014000700230
865000900237002001300246#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S
#c#197#22#article#34#22#^rND^sOrringer^nMB#^rND^sSloan^nH#Complcations and faili
ngs of the combined Collis-Belsey operation^len#J. Thorac. Cardiovasc. Surg#2#19
770000#1977#74#726-35#20110300#v24n1a02.htm##
00611000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
02000113012012500133030002800258710000200286065000900288064000500297031000300302
014000600305865000900311002001300320#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a02.htm#S#c#198#23#article#34#23#^rND^sPearson^nFG#^rND^sLanger^nB#^rND^sHend
erson^nRD#Gastroplasty and Belsey hiatus repair: An operation for the management
 of peptic stricture with acquired short esophagus^len#J. Thorac. Cardiovasc. Su
rg#2#19710000#1971#61#50-63#20110300#v24n1a02.htm##
00554000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970120
10000117030002200217710000200239065000900241064000500250031000400255014000700259
865000900266002001300275#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S
#c#199#24#article#34#24#^rND^sPearson^nFG#^rND^sHenderson^nRD#Experimental and c
linical studies of gastroplasty in the management of acquired short esophagus^le
n#Surg. Gynecol. Obstet#2#19730000#1973#136#737-44#20110300#v24n1a02.htm##
00590000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970120
12200117030000800239065000900247064000500256031000300261014000800264865000900272
002001300281035001000294801000800304#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a02.htm#S#c#200#25#article#34#25#^rND^sPearson^nFG#^rND^sHenderson^nRD#Long-t
erm follow-up of strictures managed by dilatation, modified Collis gastroplasty 
and Belsey hiatus hernia repair^len#Surgery#19760000#1976#80#396-404#20110300#v2
4n1a02.htm#0039-6060#Surgery##
00496000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120084000970300
01400181710000200195065000900197064000500206031000200211014000700213865000900220
002001300229#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#c#201#26#ar
ticle#34#26#^rND^sPearson^nFG#Surgical management of acquired short esophagus wi
th dilatable peptic stricture^len#World J. Surg#2#19770000#1977#1#463-73#2011030
0#v24n1a02.htm##
00633000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
02000114010001700134010001500151012007600166030001000242065000900252064000500261
031000400266014000700270865000900277002001300286035001000299801001000309#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#c#202#27#article#34#27#^rND^sPe
arson^nFG#^rND^sCooper^nJD#^rND^sPatterson^nGA#^rND^sRamires^nJ#^rND^sTodd^nTR#G
astroplasty and fundoplication for complex problems: Long term results^len#Ann. 
Surg#19870000#1987#206#473-81#20110300#v24n1a02.htm#0003-4932#Ann. surg##
00626000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01900111010001500130012010700145030000800252065000900260064000500269031000300274
014000700277865000900284002001300293035001000306801000800316#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a02.htm#S#c#203#28#article#34#28#^rND^sSicular^nA#^rN
D^sCohen^nB#^rND^sZimmerman^nA#^rND^sKark^nAE#The significance of onintra-abdomi
nal segment of canine esophagus as a competent anti-reflux mechanism^len#Surgery
#19670000#1967#61#784-90#20110300#v24n1a02.htm#0039-6060#Surgery##
00498000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120076000980300
02200174710000200196065000900198064000500207031000400212014000600216865000900222
002001300231#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#c#204#29#ar
ticle#34#29#^rND^sSteichen^nFM#Abdominal approach to the Collis gastroplasty and
 Nissen fundoplication^len#Surg. Gynecol. Obstet#2#19860000#1986#162#273-5#20110
300#v24n1a02.htm##
00561000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980120
07400117030001800191065000900209064000500218031000300223014000700226865000900233
002001300242035001000255801001800265#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a02.htm#S#c#205#30#article#34#30#^rND^sStirling^nMC#^rND^sOrringer^nMB#The co
mbined Collis-Nissen operation for esophageal reflux strictures^len#Ann. Thorac.
 Surg#19880000#1988#45#148-57#20110300#v24n1a02.htm#0003-4975#Ann. thorac. surg#
#
00598000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01900116012009200135030001200227065000900239064000500248031000400253014000700257
865000900264002001300273035001000286801001200296#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a02.htm#S#c#206#31#article#34#31#^rND^sSwanstrom^nLL#^rND^sMarcus
^nDR#^rND^sGalloway^nGQ#Laparoscopic Collis gastroplasty is the treatment of cho
ice for the shortened esophagus^len#Am. J. Surg#19960000#1996#171#477-81#2011030
0#v24n1a02.htm#0002-9610#Am. j. surg##
00564000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01700111012006600128030001200194065000900206064000500215031000400220014000600224
865000900230002001300239035001000252801001200262#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a02.htm#S#c#207#32#article#34#32#^rND^sTerry^nML#^rND^sVernon^nA#
^rND^sHunter^nJG#Stapled-wedge Collis gastroplasty for the shortened esophagus^l
en#Am. J. Surg#20040000#2004#188#195-9#20110300#v24n1a02.htm#0002-9610#Am. j. su
rg##
00839000000000373000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100015001030100
02600118010001400144010001600158010001700174010002500191010002200216010001800238
01000170025601201000027303000180037306500090039106400050040003100030040501400070
0408865000900415002001300424035001000437801001800447#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a02.htm#S#c#208#33#article#34#33#^rND^sThomas-Ridocci^nM#^rND
^sParis^nF#^rND^sCarbonell-Antoli^nC#^rND^sMora^nF#^rND^sMolina^nR#^rND^sPadilha
^nJ#^rND^sCarbonell-Canti^nC#^rND^sMoreno-Osset^nE#^rND^sGuijarro^nR#^rND^sBenag
es^nA#Total fundoplication with or without gastroplasty for gastroesphageal refl
ux: comparative study^len#Ann. Thorac. Surg#19850000#1985#39#508-11#20110300#v24
n1a02.htm#0003-4975#Ann. thorac. surg##
00631000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960100
01600117010001700133012007600150030001700226065000900243064000500252031000300257
032000200260014000600262865000900268002001300277035001000290801001700300#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a02.htm#S#c#209#34#article#34#34#^rND^sVa
lezi^nAC#^rND^sMali-Junior^nJ#^rND^sBrito^nEM#^rND^sMarson^nAC#Gastroplastia ver
tical com bandagem em y-de-roux: análise de resultados^lpt#Rev Col Bras Cir#2004
0000#2004#31#1#49-56#20110300#v24n1a02.htm#0100-6991#Rev Col Bras Cir##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#o#1#1#article#1
#20110411#103839#v24n1a03.htm#192##
05060000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000270011303100030014003200020014306500090014501400080015403500100016201201290
01720120117003010100036004180100028004540100028004820100030005100100026005400100
03000566010002800596083180000624085001002424085002402434085002502458085001802483
08500190250108500170252008316890253708500100422608500230423608500240425908500170
4283085001904300085001704319058006204336117000804398072000304406002001304409#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#h#2#1#article#1#oa#pt#br1.1
#1#4.0#ILUS#TAB#03#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f9^l14#0
102-6720#A ingestão de prébioticos previne a malabsorção de ferro e anemia induz
idas pela gastrectomia?: Estudo experimental em ratos^lpt#Ingestion of prebiotic
s prevents gastrectomy-induced iron malabsorption and anemia ?: Experimental stu
dy in rats^len#^rND^nElisvânia Freitas dos^sSantos#^rND^nKathia Hitomi^sTsuboi#^
rND^nMarina Rachel^sAraújo#^rND^nMônica Almeida^sFalconi#^rND^nArthur C.^sOuweha
nd#^rND^nNelson Adami^sAndreollo#^rND^nCelio Kenji^sMiyasaka#^lpt^aRACIONAL: Rat
os gastrectomizados desenvolvem anemia, e a ingestão de galactooligossacarídeo (
GOS) e a polidextrose (PDX) aumenta a absorção de ferro e promove a recuperação 
da anemia em ratos com deficiência de ferro. OBJETIVO: Avaliar se GOS e PDX esti
mulam a absorção de ferro em ratos gastrectomizados e normais. MÉTODOS: Os ratos
 foram laparotomizadas (controle falso-operado) e parcialmente gastrectomizados 
(Billroth II) em grupos de 20 animais. Os animais de ambos os tratamentos foram 
posteriormente submetidos à dieta controle (AIN-93M) ou a mesma dieta suplementa
da com GOS e PDX (25 g/kg de dieta cada) durante oito semanas e divididos em qua
tro subgrupos: sham-operados e gastrectomizados sem GOS e PDX, sham-operados e g
astrectomizados com GOS e PDX. Dois animais morreram durante o experimento. Todo
s os ratos gastrectomizados receberam uma injeção intramuscular de vitamina B-12
 a cada duas semanas. Hematócrito (HCT) e concentração de hemoglobina (HGB) fora
m dosados no início e nos dias 30 e 56 dias após o início da alimentação. No últ
imo dia do estudo, o sangue total foi coletado para determinação da concentração
 de ferro sérico. RESULTADOS: Na dieta com GOS e PDX a excreção de ferro nas fez
es foi significativamente menor do que no grupo sem prebióticos. Absorção aparen
te de ferro e ferro sérico foram maiores nos grupos alimentados com GOS e PDX (a
mbos grupos: sham operados e gastrectomizados) do que nos grupos não alimentados
 com GOS e PDX. O HCT e HGB foram significativamente menores nos ratos gastrecto
mizados que no grupo controle, entretanto, a suplementação com GOS e PDX melhoro
u os níveis de HGB neste grupo. CONCLUSÃO: A associação de GOS e PDX aumenta a a
bsorção de ferro em ratos shamoperados e gastrectomizados e ainda previne a anem
ia pós-gastrectomia.#^ddecs^i1#^tm^lpt^kPrebióticos^i1#^tm^lpt^kGastrectomia^i1#
^tm^lpt^kFerro^i1#^tm^lpt^kAnemia^i1#^tm^lpt^kRato^i1#^len^aBACKGROUND: The inge
stion of two prebiotics, galactooligosaccharide (GOS) and polydextrose (PDX), le
ads to an increase in iron absorption and promotes recovery from anemia in gastr
ectomized rats. AIM: To study whether GOS + PDX stimulate iron absorption in gas
trectomized and normals rats. METHODS: Rats were laparotomized (sham-operated co
ntrol) and partially gastrectomized (Billroth II) in groups of 20 each. Animals 
from both treatments were subsequently fed a control diet (AIN-93M) or the same 
diet supplemented with GOS and PDX (25 g/Kg of diet each) for eight weeks. They 
were divided into four subgroups, i.e., sham-operated and gastrectomized without
 GOS + PDX, sham-operated and gastrectomized with GOS + PDX. Two rats died durin
g the experiment. All gastrectomized rats received an intramuscular injection of
 vitamin B-12 every two weeks. Hematocrit (HCT) and hemoglobin concentration (HG
B) were measured at the start and on day 30 and 56 days after the start of feedi
ng. On the final day of the study, total blood was collected for determination o
f serum iron concentration. RESULTS: In the diet with GOS + PDX, iron excretion 
in feces was significantly lower than without the prebiotics. Apparent iron abso
rption and serum iron was higher in the GOS + PDX fed groups (both sham operated
 and gastrectomized) than in the non-GOS + PDX fed groups. The HCT and HGB conce
ntrations were significantly lower in gastrectomized rats than in the control gr
oup, however, GOS + PDX feeding improved HGB levels in this group. CONCLUSION: T
he association of the GOS + PDX increase absorption of iron in sham-operated and
 gastrectomized rats and still prevent postgastrectomy anemia.#^ddecs^i2#^tm^len
^kPrebiotics^i2#^tm^len^kGastrectomy^i2#^tm^len^kIron^i2#^tm^len^kAnemia^i2#^tm^
len^kRats^i2#Conselho Nacional de Desenvolvimento Científico e Tecnológico#vanco
uv#25#v24n1a03.htm##
05158000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000270011303100030014003200020014306500090014501400080015403500100016201201430
01720120131003150100036004460100028004820100028005100100030005380100026005680100
03000594010002800624083183500652085001002487085002402497085002502521085001802546
08500190256408500170258308317240260008500100432408500230433408500240435708500170
4381085001904398085001704417058006204434117000804496072000304504002001304507#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#f#3#1#article#1#oa#pt#br1.1
#1#4.0#ILUS#TAB#03#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f9^l14#0
102-6720#<b>A ingestão de prébioticos previne a malabsorção de ferro e anemia in
duzidas pela gastrectomia?</b>: <b>Estudo experimental em ratos</b>^lpt#<b>Inges
tion of prebiotics prevents gastrectomy-induced iron malabsorption and anemia ?<
/b>: <b>Experimental study in rats</b>^len#^rND^nElisvânia Freitas dos^sSantos#^
rND^nKathia Hitomi^sTsuboi#^rND^nMarina Rachel^sAraújo#^rND^nMônica Almeida^sFal
coni#^rND^nArthur C.^sOuwehand#^rND^nNelson Adami^sAndreollo#^rND^nCelio Kenji^s
Miyasaka#^lpt^a<b>RACIONAL:</b> Ratos gastrectomizados desenvolvem anemia, e a i
ngestão de galactooligossacarídeo (GOS) e a polidextrose (PDX) aumenta a absorçã
o de ferro e promove a recuperação da anemia em ratos com deficiência de ferro. 
<b>OBJETIVO:</b> Avaliar se GOS e PDX estimulam a absorção de ferro em ratos gas
trectomizados e normais. <b>MÉTODOS: </b>Os ratos foram laparotomizadas (control
e falso-operado) e parcialmente gastrectomizados (Billroth II) em grupos de 20 a
nimais. Os animais de ambos os tratamentos foram posteriormente submetidos à die
ta controle (AIN-93M) ou a mesma dieta suplementada com GOS e PDX (25 g/kg de di
eta cada) durante oito semanas e divididos em quatro subgrupos: sham-operados e 
gastrectomizados sem GOS e PDX, sham-operados e gastrectomizados com GOS e PDX. 
Dois animais morreram durante o experimento. Todos os ratos gastrectomizados rec
eberam uma injeção intramuscular de vitamina B-12 a cada duas semanas. Hematócri
to (HCT) e concentração de hemoglobina (HGB) foram dosados no início e nos dias 
30 e 56 dias após o início da alimentação. No último dia do estudo, o sangue tot
al foi coletado para determinação da concentração de ferro sérico. <b>RESULTADOS
:</b> Na dieta com GOS e PDX a excreção de ferro nas fezes foi significativament
e menor do que no grupo sem prebióticos. Absorção aparente de ferro e ferro séri
co foram maiores nos grupos alimentados com GOS e PDX (ambos grupos: sham operad
os e gastrectomizados) do que nos grupos não alimentados com GOS e PDX. O HCT e 
HGB foram significativamente menores nos ratos gastrectomizados que no grupo con
trole, entretanto, a suplementação com GOS e PDX melhorou os níveis de HGB neste
 grupo. <b>CONCLUSÃO:</b> A associação de GOS e PDX aumenta a absorção de ferro 
em ratos shamoperados e gastrectomizados e ainda previne a anemia pós-gastrectom
ia.#^ddecs^i1#^tm^lpt^kPrebióticos^i1#^tm^lpt^kGastrectomia^i1#^tm^lpt^kFerro^i1
#^tm^lpt^kAnemia^i1#^tm^lpt^kRato^i1#^len^a<b>BACKGROUND:</b> The ingestion of t
wo prebiotics, galactooligosaccharide (GOS) and polydextrose (PDX), leads to an 
increase in iron absorption and promotes recovery from anemia in gastrectomized 
rats. <b>AIM: </b>To study whether GOS + PDX stimulate iron absorption in gastre
ctomized and normals rats. <b>METHODS: </b>Rats were laparotomized (sham-operate
d control) and partially gastrectomized (Billroth II) in groups of 20 each. Anim
als from both treatments were subsequently fed a control diet (AIN-93M) or the s
ame diet supplemented with GOS and PDX (25 g/Kg of diet each) for eight weeks. T
hey were divided into four subgroups, i.e., sham-operated and gastrectomized wit
hout GOS + PDX, sham-operated and gastrectomized with GOS + PDX. Two rats died d
uring the experiment. All gastrectomized rats received an intramuscular injectio
n of vitamin B-12 every two weeks. Hematocrit (HCT) and hemoglobin concentration
 (HGB) were measured at the start and on day 30 and 56 days after the start of f
eeding. On the final day of the study, total blood was collected for determinati
on of serum iron concentration. <b>RESULTS: </b>In the diet with GOS + PDX, iron
 excretion in feces was significantly lower than without the prebiotics. Apparen
t iron absorption and serum iron was higher in the GOS + PDX fed groups (both sh
am operated and gastrectomized) than in the non-GOS + PDX fed groups. The HCT an
d HGB concentrations were significantly lower in gastrectomized rats than in the
 control group, however, GOS + PDX feeding improved HGB levels in this group. <b
>CONCLUSION:</b> The association of the GOS + PDX increase absorption of iron in
 sham-operated and gastrectomized rats and still prevent postgastrectomy anemia.
#^ddecs^i2#^tm^len^kPrebiotics^i2#^tm^len^kGastrectomy^i2#^tm^len^kIron^i2#^tm^l
en^kAnemia^i2#^tm^len^kRats^i2#Conselho Nacional de Desenvolvimento Científico e
 Tecnológico#vancouv#25#v24n1a03.htm##
05189000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000260013103100030015703200020016006500090016201400080017103500100
01790120129001890120117003180100036004350100028004710100028004990100030005270100
02500557010003000582010002800612083180000640085001002440085002402450085002502474
08500180249908500190251708500170253608316890255308500100424208500230425208500240
42750850017042990850019043160850017043350580062043521170008044140720003044220020
01304425008008904438#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#l#4
#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab#03#ABCD060#nd#ABCD, ar
q. bras. cir. dig#24#1#20110300#^f9^l14#0102-6720#A ingestão de prébioticos prev
ine a malabsorção de ferro e anemia induzidas pela gastrectomia?: Estudo experim
ental em ratos^lpt#Ingestion of prebiotics prevents gastrectomy-induced iron mal
absorption and anemia ?: Experimental study in rats^len#^rND^nElisvânia Freitas 
dos^sSantos#^rND^nKathia Hitomi^sTsuboi#^rND^nMarina Rachel^sAraújo#^rND^nMônica
 Almeida^sFalconi#^rND^nArthur C^sOuwehand#^rND^nNelson Adami^sAndreollo#^rND^nC
elio Kenji^sMiyasaka#^lpt^aRACIONAL: Ratos gastrectomizados desenvolvem anemia, 
e a ingestão de galactooligossacarídeo (GOS) e a polidextrose (PDX) aumenta a ab
sorção de ferro e promove a recuperação da anemia em ratos com deficiência de fe
rro. OBJETIVO: Avaliar se GOS e PDX estimulam a absorção de ferro em ratos gastr
ectomizados e normais. MÉTODOS: Os ratos foram laparotomizadas (controle falso-o
perado) e parcialmente gastrectomizados (Billroth II) em grupos de 20 animais. O
s animais de ambos os tratamentos foram posteriormente submetidos à dieta contro
le (AIN-93M) ou a mesma dieta suplementada com GOS e PDX (25 g/kg de dieta cada)
 durante oito semanas e divididos em quatro subgrupos: sham-operados e gastrecto
mizados sem GOS e PDX, sham-operados e gastrectomizados com GOS e PDX. Dois anim
ais morreram durante o experimento. Todos os ratos gastrectomizados receberam um
a injeção intramuscular de vitamina B-12 a cada duas semanas. Hematócrito (HCT) 
e concentração de hemoglobina (HGB) foram dosados no início e nos dias 30 e 56 d
ias após o início da alimentação. No último dia do estudo, o sangue total foi co
letado para determinação da concentração de ferro sérico. RESULTADOS: Na dieta c
om GOS e PDX a excreção de ferro nas fezes foi significativamente menor do que n
o grupo sem prebióticos. Absorção aparente de ferro e ferro sérico foram maiores
 nos grupos alimentados com GOS e PDX (ambos grupos: sham operados e gastrectomi
zados) do que nos grupos não alimentados com GOS e PDX. O HCT e HGB foram signif
icativamente menores nos ratos gastrectomizados que no grupo controle, entretant
o, a suplementação com GOS e PDX melhorou os níveis de HGB neste grupo. CONCLUSÃ
O: A associação de GOS e PDX aumenta a absorção de ferro em ratos shamoperados e
 gastrectomizados e ainda previne a anemia pós-gastrectomia.#^ddecs^i1#^tm^lpt^k
Prebióticos^i1#^tm^lpt^kGastrectomia^i1#^tm^lpt^kFerro^i1#^tm^lpt^kAnemia^i1#^tm
^lpt^kRato^i1#^len^aBACKGROUND: The ingestion of two prebiotics, galactooligosac
charide (GOS) and polydextrose (PDX), leads to an increase in iron absorption an
d promotes recovery from anemia in gastrectomized rats. AIM: To study whether GO
S + PDX stimulate iron absorption in gastrectomized and normals rats. METHODS: R
ats were laparotomized (sham-operated control) and partially gastrectomized (Bil
lroth II) in groups of 20 each. Animals from both treatments were subsequently f
ed a control diet (AIN-93M) or the same diet supplemented with GOS and PDX (25 g
/Kg of diet each) for eight weeks. They were divided into four subgroups, i.e., 
sham-operated and gastrectomized without GOS + PDX, sham-operated and gastrectom
ized with GOS + PDX. Two rats died during the experiment. All gastrectomized rat
s received an intramuscular injection of vitamin B-12 every two weeks. Hematocri
t (HCT) and hemoglobin concentration (HGB) were measured at the start and on day
 30 and 56 days after the start of feeding. On the final day of the study, total
 blood was collected for determination of serum iron concentration. RESULTS: In 
the diet with GOS + PDX, iron excretion in feces was significantly lower than wi
thout the prebiotics. Apparent iron absorption and serum iron was higher in the 
GOS + PDX fed groups (both sham operated and gastrectomized) than in the non-GOS
 + PDX fed groups. The HCT and HGB concentrations were significantly lower in ga
strectomized rats than in the control group, however, GOS + PDX feeding improved
 HGB levels in this group. CONCLUSION: The association of the GOS + PDX increase
 absorption of iron in sham-operated and gastrectomized rats and still prevent p
ostgastrectomy anemia.#^ddecs^i2#^tm^len^kPrebiotics^i2#^tm^len^kGastrectomy^i2#
^tm^len^kIron^i2#^tm^len^kAnemia^i2#^tm^len^kRats^i2#Conselho Nacional de Desenv
olvimento Científico e Tecnológico#vancouv#25#v24n1a03.htm#Internet^ihttp://www.
scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202011000100003##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#5#1#article#163#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL </b><
/font></p>     ^cY#v24n1a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#6#2#article#163#<p>&nbsp;</p>     ^cY
#v24n1a03.htm##
00495000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704026200074002001300336#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#7#3#article#163#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>A ingest&atilde
;o de pr&eacute;bioticos previne a malabsor&ccedil;&atilde;o de ferro e anemia i
nduzidas pela gastrectomia? Estudo experimental em ratos </b></font></p>     ^cY
#v24n1a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#8#4#article#163#<p>&nbsp;</p>     ^cY
#v24n1a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#9#5#article#163#<p>&nbsp;</p>     ^cY
#v24n1a03.htm##
00507000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704027300075002001300348#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#10#6#article#163#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><B>Elisv&acirc;nia Freitas dos Santos
; Kathia Hitomi Tsuboi; Marina Rachel Ara&uacute;jo; M&ocirc;nica Almeida Falcon
i;  Arthur C. Ouwehand; Nelson Adami Andreollo; Celio Kenji Miyasaka </b></font>
</p>     ^cY#v24n1a03.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#11#7#article#163#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a03.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#12#8#article#163#<p>&nbsp;</p>     ^c
Y#v24n1a03.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#13#9#article#163#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a03.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#14#10#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a03.htm##
00578000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034300076002001300419#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#15#11#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL:</b> Ratos gastrectomiza
dos desenvolvem anemia, e a ingest&atilde;o de galactooligossacar&iacute;deo (GO
S) e a polidextrose (PDX) aumenta a absor&ccedil;&atilde;o de ferro e promove a 
recupera&ccedil;&atilde;o da anemia em ratos com defici&ecirc;ncia de ferro.    
^cY#v24n1a03.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#16#12#article#163#<br>   <b>OBJETIVO:
</b> Avaliar se GOS e PDX estimulam a absor&ccedil;&atilde;o de ferro em ratos g
astrectomizados e normais.    ^cY#v24n1a03.htm##
01218000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704098300076002001301059#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#17#13#article#163#<br>   <b>M&Eacute;
TODOS: </b> Os ratos foram laparotomizadas (controle falso-operado) e parcialmen
te gastrectomizados (Billroth II) em grupos de 20 animais. Os animais de ambos o
s tratamentos foram posteriormente submetidos &agrave; dieta controle (AIN-93M) 
ou a mesma dieta suplementada com GOS e PDX (25 g/kg de dieta cada) durante oito
 semanas e divididos em quatro subgrupos: sham-operados e gastrectomizados sem G
OS e PDX, sham-operados e gastrectomizados com GOS e PDX. Dois animais morreram 
durante o experimento. Todos os ratos gastrectomizados receberam uma inje&ccedil
;&atilde;o intramuscular de vitamina B-12 a cada duas semanas. Hemat&oacute;crit
o (HCT) e concentra&ccedil;&atilde;o de hemoglobina (HGB) foram dosados no in&ia
cute;cio e nos dias 30 e 56 dias ap&oacute;s o in&iacute;cio da alimenta&ccedil;
&atilde;o. No &uacute;ltimo dia do estudo, o sangue total foi coletado para dete
rmina&ccedil;&atilde;o da concentra&ccedil;&atilde;o de ferro s&eacute;rico.    
^cY#v24n1a03.htm##
00821000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058600076002001300662#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#18#14#article#163#<br>   <b>RESULTADO
S:</b> Na dieta com GOS e PDX a excre&ccedil;&atilde;o de ferro nas fezes foi si
gnificativamente menor do que no grupo sem prebi&oacute;ticos. Absor&ccedil;&ati
lde;o aparente de ferro e ferro s&eacute;rico foram maiores nos grupos alimentad
os com GOS e PDX (ambos grupos: sham operados e gastrectomizados) do que nos gru
pos n&atilde;o alimentados com GOS e PDX. O HCT e  HGB foram significativamente 
menores nos ratos gastrectomizados que no grupo controle, entretanto, a suplemen
ta&ccedil;&atilde;o com GOS e PDX melhorou os n&iacute;veis de HGB neste grupo. 
   ^cY#v24n1a03.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022600076002001300302#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#19#15#article#163#<br>   <b>CONCLUS&A
tilde;O:</b> A associa&ccedil;&atilde;o de GOS e PDX aumenta a absor&ccedil;&ati
lde;o de ferro em ratos shamoperados e gastrectomizados e  ainda previne a anemi
a p&oacute;s-gastrectomia. </font></p>     ^cY#v24n1a03.htm##
00416000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018100076002001300257#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#20#16#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b> Prebi&oacute;ti
cos. Gastrectomia. Ferro. Anemia. Rato. </font></p> <hr size="1" noshade>     ^c
Y#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#21#17#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#22#18#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#23#19#article#163#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>INTRODU&Ccedil;&Atilde;O</b> </f
ont></p>     ^cY#v24n1a03.htm##
00774000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053900076002001300615#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#24#20#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A anemia &eacute; complica&ccedil;&a
tilde;o comum em pacientes ap&oacute;s ressec&ccedil;&atilde;o g&aacute;strica <
sup>11,12,24,25</sup>. Nas fases iniciais ap&oacute;s a gastrectomia, a anemia p
or defici&ecirc;ncia de ferro ocorre porque o &aacute;cido g&aacute;strico desem
penha papel importante na absor&ccedil;&atilde;o do ferro no intestino delgado a
trav&eacute;s da solubiliza&ccedil;&atilde;o de sais de ferro insol&uacute;veis<
sup>14,17,23</sup>. </font></p>     ^cY#v24n1a03.htm##
01594000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704135900076002001301435#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#25#21#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Alguns autores t&ecirc;m sugerido qu
e a absor&ccedil;&atilde;o de ferro parece n&atilde;o ser somente no intestino d
elgado, o intestino grosso parece contribuir tamb&eacute;m, mas at&eacute; que p
onto ainda n&atilde;o est&aacute; totalmente claro<sup>12</sup>. Assim, a absor&
ccedil;&atilde;o de ferro pelo intestino grosso pode contribuir para a recupera&
ccedil;&atilde;o da anemia em ratos deficientes de ferro<sup>8,9</sup>. De fato,
 tem sido demonstrado que o trato digestivo, especialmente o de c&oacute;lon pro
ximal, tamb&eacute;m pode ser um importante local de absor&ccedil;&atilde;o de f
erro quando a absor&ccedil;&atilde;o no intestino delgado &eacute; insuficiente<
sup>2,3,8 </sup>como talvez no caso ap&oacute;s a gastrectomia<sup>7</sup>. Al&e
acute;m disso, estudo com ratos demonstrou que os &aacute;cidos graxos de cadeia
 curta e, em particular, propionato, parece desempenhar papel no aumento da abso
r&ccedil;&atilde;o de ferro no c&oacute;lon proximal<sup>2</sup>. Essa observa&c
cedil;&atilde;o sugere que a ingest&atilde;o de prebi&oacute;ticos pode aumentar
 a biodisponibilidade do ferro da dieta. Recentemente, tem havido muitos relatos
 indicando que os carboidratos indiger&iacute;veis estimulam a absor&ccedil;&ati
lde;o de minerais<sup>1,10,13,18</sup>. </font></p>     ^cY#v24n1a03.htm##
00593000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035800076002001300434#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#26#22#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O objetivo do presente trabalho foi 
verificar o efeito da suplementa&ccedil;&atilde;o alimentar com uma combina&cced
il;&atilde;o de dois prebi&oacute;ticos (galactooligossacar&iacute;deo e polidex
trose) na absor&ccedil;&atilde;o de ferro em ratos gastrectomizados e normais. <
/font></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#27#23#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#28#24#article#163#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>M&Eacute;TODOS</b> </font></p>  
   ^cY#v24n1a03.htm##
00365000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013000076002001300206#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#29#25#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Animais e procedimento cir&uacute
;rgico </b></font></p>     ^cY#v24n1a03.htm##
01322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704108700076002001301163#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#30#26#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Quarenta ratos machos Wistar com 250
,0 &plusmn; 5 g de peso corporal foram mantidos em gaiolas coletivas, em sala co
m temperatura controlada (22 &plusmn; 1ºC), umidade (60-70%), 12 horas ciclo dia
-noite (luzes acesas &agrave;s 07:00), com dieta (veja abaixo) e &aacute;gua dei
onizada ad libitum. Os animais foram divididos aleatoriamente em dois grupos de 
20 animais cada. Um grupo foi submetido a vagotomia troncular anterior e gastrec
tomia parcial (Billroth II). O outro era falso operado a fim de serem submetidos
 ao mesmo estresse cir&uacute;rgico, onde a cavidade abdominal foi mantida abert
a por aproximadamente 45 minutos, que &eacute; a dura&ccedil;&atilde;o de uma ga
strectomia. Os ratos foram anestesiados com tiopental s&oacute;dico (25 mg/Kg de
 peso corporal/por via intravenosa). O protocolo experimental foi previamente ap
rovado pelo Comit&ecirc; de &Eacute;tica em Experimenta&ccedil;&atilde;o Animal 
(CEEA) da Universidade Estadual de Campinas - UNICAMP (n º 839-1 registro, 08/06
/2005). </font></p>     ^cY#v24n1a03.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012000076002001300196#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#31#27#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Grupos experimentais e dietas </b
></font></p>     ^cY#v24n1a03.htm##
00744000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050900076002001300585#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#32#28#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Quinze dias ap&oacute;s o procedimen
to cir&uacute;rgico, os ratos foram divididos aleatoriamente em quatro subgrupos
 experimentais: sham vs gastrectomia, que foram divididas em dieta controle vs d
ieta com galactooligossacar&iacute;deo polidextrose. Dois ratos gastrectomizados
 alimentados com a dieta do grupo controle morreram durante o experimento. Os an
imais foram alimentados com as dietas experimentais por oito semanas. </font></p
>     ^cY#v24n1a03.htm##
00758000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052300076002001300599#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#33#29#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As dietas controle e experimentais f
oram preparadas segundo a formula&ccedil;&atilde;o AIN-93M, durante oito semanas
<sup>16</sup>. Galactooligossacar&iacute;deo (GOS, 50-55% de oligossacar&iacute;
deos (Yakult SA Ind&uacute;stria e Com&eacute;rcio, S&atilde;o Paulo, SP, Brasil
) e polidextrose (PDX, Litesse Ultra, Danisco Brasil Ltda, Cotia, SP, Brasil); c
ada uma foi adicionada em 25 g/kg dieta, substituindo a sacarose da dieta contro
le. </font></p>     ^cY#v24n1a03.htm##
00623000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038800076002001300464#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#34#30#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A <a href="#tab1">Tabela 1</a> mostr
a a composi&ccedil;&atilde;o das duas dietas experimentais (controle e GOS + PDX
). Metade dos gastrectomizados e metade dos ratos sham-operados foram alimentado
s com a dieta controle, e os ratos remanescentes em ambos os grupos foram alimen
tados com a dieta GOS + PDX. </font></p>     ^cY#v24n1a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#35#31#article#163#<p><a name="tab1"><
/a></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#36#32#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#37#33#article#163#<p align="center"><
img src="/img/revistas/abcd/v24n1/a03tab01.jpg"></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#38#34#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00867000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063200076002001300708#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#39#35#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os animais tinham livre acesso &agra
ve; &aacute;gua deionizada durante todo o per&iacute;odo experimental. Para a pr
even&ccedil;&atilde;o da anemia megalobl&aacute;stica, os ratos gastrectomizados
 receberam suplementos de vitamina B12 (Cianocobalamina 0,5 mg/kg/intramuscular 
-Cianotrat 5000 -Instituto Terap&ecirc;utico Delta Ltda, Indaiatuba, SP, Brasil)
 a cada duas semanas, come&ccedil;ando uma semana depois da opera&ccedil;&atilde
;o. Os animais do grupo sham receberam cloreto de s&oacute;dio a 0,9% (Sanobiol 
Ltda, Pouso Alegre, MG, Brasil). </font></p>     ^cY#v24n1a03.htm##
00499000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026400076002001300340#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#40#36#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Para a coleta de fezes, os animais f
oram colocados em gaiolas metab&oacute;licas individuais, durante tr&ecirc;s dia
s nos per&iacute;odos de 15, 35 e 55 do experimento<sup>5</sup>. </font></p>    
 ^cY#v24n1a03.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020100076002001300277#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#41#37#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O ganho de peso e o consumo da dieta
 dos animais foram monitorados tr&ecirc;s vezes por semana, durante oito semanas
. </font></p>     ^cY#v24n1a03.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012300076002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#42#38#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos anal&iacute;ticos 
</b></font></p>     ^cY#v24n1a03.htm##
00766000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053100076002001300607#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#43#39#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sangue de animais anestesiados foi c
oletado por pun&ccedil;&atilde;o da veia retro-ocular a cada quatro semanas dura
nte o per&iacute;odo experimental. No in&iacute;cio do experimento, o sangue foi
 coletado de animais aleatoriamente antes do procedimento cir&uacute;rgico. Amos
tras de sangue foram analisadas para determinar o hemat&oacute;crito e hemoglobi
na, usando o analisador hematol&oacute;gico (Advia TM 120, Bayer<sup>&reg;</sup>
, Irlanda). </font></p>     ^cY#v24n1a03.htm##
00492000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025700076002001300333#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#44#40#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A concentra&ccedil;&atilde;o de ferr
o s&eacute;rico foi determinada por m&eacute;todo colorim&eacute;trico comercial
mente dispon&iacute;vel (Laborlab, Guarulhos,SP, Brasil). </font></p>     ^cY#v2
4n1a03.htm##
01364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112900076002001301205#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#45#41#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As fezes obtidas foram secas, pesada
s e mo&iacute;das. As dietas e as fezes em p&oacute; secas foram calcinadas em t
emperaturas aumentadas de forma linear at&eacute; 550ªC por 6 h, e depois a 550ª
C por 18 h na mufla (Ind&uacute;stria Fornitec e Com&eacute;rcio Ltda, S&atilde;
o Paulo, SP, Brasil). As amostras foram digeridas com 0,5 ml concentrado de HNO<
sub>3 </sub>(65%) e 0,15 ml (30%) H<sub>2</sub>O<sub>2</sub> (Merck do Brasil, S
&atilde;o Paulo, SP, Brasil), em tubos fechados sob press&atilde;o Hostaflon aqu
ecidas no micro-ondas (DGT-100 Plus Provecto, Jundia&iacute;, SP, Brasil). As de
termina&ccedil;&otilde;es de ferro nas fezes e na dieta foram realizadas por emi
ss&atilde;o &oacute;ptica IRIS-AP (Thermo Jarrell Ash, Franklin - Massachusetts 
- EUA) no laborat&oacute;rio especializado Biominerais An&aacute;lises Qu&iacute
;micas, Campinas, SP, Brasil e os c&aacute;lculos realizados foram: absor&ccedil
;&atilde;o aparente de ferro (mg/dia)=consumo de ferro (mg/dia) - excre&ccedil;&
atilde;o de ferro nas fezes (mg/dia)<sup>5</sup>. </font></p>     ^cY#v24n1a03.h
tm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012400076002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#46#42#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>An&aacute;lise estat&iacute;stica
 </b></font></p>     ^cY#v24n1a03.htm##
00837000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060200076002001300678#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#47#43#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os resultados foram submetidos &agra
ve; an&aacute;lise de vari&acirc;ncia (ANOVA), com o uso do teste de Duncan para
 a compara&ccedil;&atilde;o das m&eacute;dias. Os dados foram analisados por dua
s vias (tratamento e dieta) ou tr&ecirc;s vias (tratamento, dieta e tempo). As d
iferen&ccedil;as foram consideradas significativas quando p&lt;0,05. Os dados fo
ram expressos como m&eacute;dia e erro-padr&atilde;o da m&eacute;dia (EPM) (Stat
istica 6.0<sup>&reg;</sup>, Statsoft, Inc. Tulsa, USA,) para Windows<sup>25</sup
>. </font></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#48#44#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#49#45#article#163#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS </b></font></p>     ^c
Y#v24n1a03.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016300076002001300239#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#50#46#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Ganho de peso e ingest&atilde;o a
limentar (<a href="#tab2">Tabela 2</a>)</b> </font></p>     ^cY#v24n1a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#51#47#article#163#<p><a name="tab2"><
/a></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#52#48#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#53#49#article#163#<p align="center"><
img src="/img/revistas/abcd/v24n1/a03tab02.jpg"></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#54#50#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00912000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067700076002001300753#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#55#51#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Peso corporal inicial em ambos os gr
upos shamoperados foi significativamente maior do que nos ratos gastrectomizados
 correspondentes (p&lt;0,05). Tamb&eacute;m no final do estudo, o peso corporal 
final em ambos os grupos sham-operados foi significativamente maior do que os ra
tos gastrectomizados (p&lt;0,05). No entanto, o ganho de peso corporal total n&a
tilde;o foi significativamente diferente entre os grupos sham e gastrectomizados
 (p&gt;0,05). O consumo alimentar em ratos gastrectomizados foi significativamen
te menor que nos ratos sham-operados, independentemente da dieta (p&lt;0,05). </
font></p>     ^cY#v24n1a03.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015600076002001300232#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#56#52#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Peso &uacute;mido e seco das feze
s (<a href="#tab3">Tabela 3</a>)</b> </font></p>     ^cY#v24n1a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#57#53#article#163#<p><a name="tab3"><
/a></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#58#54#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#59#55#article#163#<p align="center"><
img src="/img/revistas/abcd/v24n1/a03tab03.jpg"></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#60#56#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044700076002001300523#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#61#57#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em ratos sham-operados e gastrectomi
zados, a m&eacute;dia de peso seco e &uacute;mido das fezes foi significativamen
te maior nos ratos que receberam dieta com GOS + PDX do que nos que receberam di
eta controle (sem GOS + PDX) (p&lt;0,05). No entanto, n&atilde;o houve diferen&c
cedil;a entre os ratos sham-operados e gastrectomizados para a mesma dieta (p&gt
;0,05). </font></p>     ^cY#v24n1a03.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021000076002001300286#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#62#58#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Concentra&ccedil;&atilde;o de hem
at&oacute;crito e hemoglobina (<a href="#fig1">Figuras  1</a> e <a href="#fig2">
2</a>)</b> </font></p>     ^cY#v24n1a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#63#59#article#163#<p><a name="fig1"><
/a></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#64#60#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#65#61#article#163#<p align="center"><
img src="/img/revistas/abcd/v24n1/a03fig01.jpg"></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#66#62#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#67#63#article#163#<p><a name="fig2"><
/a></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#68#64#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#69#65#article#163#<p align="center"><
img src="/img/revistas/abcd/v24n1/a03fig02.jpg"></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#70#66#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00766000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053100076002001300607#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#71#67#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os n&iacute;veis de hemat&oacute;cri
to iniciais foram semelhantes em ambos os animais sham-operados e gastrectomizad
os (<a href="#fig1">Figura 1</a>). Ap&oacute;s a quarta e oitava semanas do expe
rimento, os n&iacute;veis de hemat&oacute;crito dos ratos sham-operados permanec
eram a um n&iacute;vel semelhante como no in&iacute;cio do experimento e foram s
uperiores aos n&iacute;veis de hemat&oacute;crito dos animais gastrectomizados (
p&lt;0,05). </font></p>     ^cY#v24n1a03.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#72#68#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os n&iacute;veis de hemoglobina inic
iais foram semelhante para os ratos gastrectomizados e sham-operados (<a href="#
fig2">Figura 2</a>). Na quarta e oitava semana do experimento, a hemoglobina foi
 maior nos ratos sham-operado com dieta controle e dieta com GOS + PDX quando co
mparados aos animais gastrectomizados (p&lt;0,05). No entanto, os n&iacute;veis 
de hemoglobina em ratos gastrectomizados recebendo dieta GOS + PDX foram signifi
cativamente maiores do que em ratos gastrectomizados que receberam dieta control
e (p&lt;0,05), apesar de n&atilde;o chegarem ao mesmon&iacute;vel que os ratos s
ham-operado. </font></p>     ^cY#v24n1a03.htm##
00406000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017100076002001300247#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#73#69#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Concentra&ccedil;&atilde;o de fer
ro s&eacute;rico (<a href="#fig3">Figura 3</a>) </b></font></p>     ^cY#v24n1a03
.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#74#70#article#163#<p><a name="fig3"><
/a></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#75#71#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#76#72#article#163#<p align="center"><
img src="/img/revistas/abcd/v24n1/a03fig03.jpg"></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#77#73#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00532000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029700076002001300373#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#78#74#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em ratos sham-operado, ap&oacute;s o
ito semanas, o ferro s&eacute;rico foi significativamente maior nos ratos que re
ceberam dieta com GOS + PDX do que nos que receberam dieta  controle (sem GOS + 
PDX) (p&lt;0,05). </font></p>     ^cY#v24n1a03.htm##
00740000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050500076002001300581#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#79#75#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em ratos gastrectomizados o ferro s&
eacute;rico foi significativamente menor ap&oacute;s oito semanas em rela&ccedil
;&atilde;o ao sham-operado, independentemente da dieta (p&gt;0,05). Contudo, os 
ratos que receberam a suplementa&ccedil;&atilde;o de GOS + PDX tiveram concentra
&ccedil;&otilde;es de ferro s&eacute;rico significativamente mais elevadas, do q
ue os que receberam a dieta controle (sem GOS + PDX) (p&lt;0,05). </font></p>   
  ^cY#v24n1a03.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020100076002001300277#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#80#76#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Ferro fecal e absor&ccedil;&atild
e;o aparente de ferro (<a href="#fig4">Figuras 4</a> e <a href="#fig5">5</a>)</b
> </font></p>     ^cY#v24n1a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#81#77#article#163#<p><a name="fig4"><
/a></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#82#78#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#83#79#article#163#<p align="center"><
img src="/img/revistas/abcd/v24n1/a03fig04.jpg"></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#84#80#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#85#81#article#163#<p><a name="fig5"><
/a></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#86#82#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#87#83#article#163#<p align="center"><
img src="/img/revistas/abcd/v24n1/a03fig05.jpg"></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#88#84#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00625000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039000076002001300466#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#89#85#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A concentra&ccedil;&atilde;o de ferr
o nas fezes dos ratos shamoperados e gastrectomizados que receberam GOS + PDX na
 dieta foi menor (p&lt;0,05) em compara&ccedil;&atilde;o &agrave; dieta controle
, mas n&atilde;o foi diferente entre os ratos sham-operados e gastrectomizados (
<a href="#fig4">Figura 4</a>). </font></p>     ^cY#v24n1a03.htm##
01040000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080500076002001300881#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#90#86#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A absor&ccedil;&atilde;o aparente de
 ferro em  sham-operados foi significativamente maior (p&lt;0,05) no grupo que r
ecebeu o GOS + PDX na dieta, em compara&ccedil;&atilde;o com os ratos que recebe
ram a dieta controle (<a href="#fig5">Figura 5</a>). A absor&ccedil;&atilde;o ap
arente de ferro de ratos gastrectomizados foi significativamente menor em compar
a&ccedil;&atilde;o com os sham operados recebendo a mesma dieta (p&lt;0,05). No 
entanto, os que receberam o GOS + PDX na dieta, apresentaram absor&ccedil;&atild
e;o aparente de ferro significativamente maior do que nos alimentados com dieta 
controle do mesmo grupo (p&lt;0,05) e foi elevado a um n&iacute;vel semelhante a
o dos ratos sham-operados com dieta controle. </font></p>     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#91#87#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#92#88#article#163#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b> </font></p> 
    ^cY#v24n1a03.htm##
01462000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122700076002001301303#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#93#89#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Como observado anteriormente<sup>23<
/sup>, a absor&ccedil;&atilde;o de ferro foi severamente diminu&iacute;da pelo g
astrectomia parcial (<a href="#fig5">Figura 5</a>). Estudos anteriores mostraram
 que a gastrectomia parcial e vagotomia troncular anterior foram um bom modelo e
xperimental para estudar metabolismo do ferro<sup>21</sup> e metabolismo do c&aa
cute;lcio<sup>22</sup>. No entanto, a etiologia da m&aacute; absor&ccedil;&atild
e;o de ferro ap&oacute;s gastrectomia n&atilde;o foi totalmente esclarecida. Muc
ina g&aacute;strica tem sido relatada a ser envolvida na via integrina-mobilferr
ina, que &eacute; um dos caminhos proposto de transporte de ferro no intestino d
elgado, sugerindo que a falta de mucina g&aacute;strica &eacute; respons&aacute;
vel pela m&aacute; absor&ccedil;&atilde;o de ferro induzida pela gastrectomia<su
p>23</sup>. A m&aacute; absor&ccedil;&atilde;o de ferro (<a href="#fig5">Figura 
5</a>) leva &agrave; anemia, como indicado pela redu&ccedil;&atilde;o da hemoglo
bina, hemat&oacute;crito e os n&iacute;veis s&eacute;ricos de ferro (<a href="#f
ig1">Figuras 1</a>, <a href="#fig2">2</a> e <a href="#fig3">3</a>). </font></p> 
    ^cY#v24n1a03.htm##
01113000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087800076002001300954#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#94#90#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A defici&ecirc;ncia de ferro &eacute
; um problema mundial de sa&uacute;de: ela prejudica o crescimento, desenvolvime
nto cognitivo e imunidade. A baixa taxa de absor&ccedil;&atilde;o de ferro na di
eta &eacute; principalmente devido a sua baixa solubilidade em pH alcalino e ao 
pequeno segmento do intestino proximal dispon&iacute;veis para a absor&ccedil;&a
tilde;o de ferro espec&iacute;ficos. Os efeitos positivos da fermenta&ccedil;&at
ilde;o bacteriana na absor&ccedil;&atilde;o de minerais, como o ferro, sugere qu
e o c&oacute;lon pode contribuir significativamente para a sua disponibilidade. 
Mecanismos de absor&ccedil;&atilde;o de ferro pelo c&oacute;lon n&atilde;o s&ati
lde;o bem compreendidos e os &aacute;cidos graxos de cadeia curta parecem desemp
enhar um papel importante<sup>2</sup>. </font></p>     ^cY#v24n1a03.htm##
01064000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082900076002001300905#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#95#91#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No colo proximal de ratos com defici
&ecirc;ncia de ferro, a absor&ccedil;&atilde;o de seis minerais foi maior que no
 duodeno, jejuno e &iacute;leo e tamb&eacute;m foi maior que nos ratos do grupo 
controle (dieta com ferro). Para todos os minerais, o aumento foi o resultado da
 absor&ccedil;&atilde;o passiva aumentada. Sugerindo que a anemia ferropriva aum
enta a permeabilidade da membrana do c&oacute;lon. Os resultados ap&oacute;iam a
 hip&oacute;tese de que em estados diferentes, incluindo a anemia ferropriva em 
que a capacidade do intestino de absorver nutrientes fica comprometida, a mucosa
 do c&oacute;lon aparentemente compensa a funcionalidade prejudicada do intestin
o delgado<sup>3</sup>, como ap&oacute;s a gastrectomia (Billroth II). </font></p
>     ^cY#v24n1a03.htm##
00891000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065600076002001300732#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#96#92#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m disso, estudos em animai
s revelaram que os &aacute;cidos graxos de cadeia curta, em especial propionato 
parece aumentar a absor&ccedil;&atilde;o de ferro no c&oacute;lon proximal<sup>2
</sup>. Isso pode indicar um potencial mecanismo pelo qual a ingest&atilde;o de 
prebi&oacute;ticos aumentam a biodisponibilidade do ferro diet&eacute;tico. Saka
i, et al.<sup>18</sup> mostraram que a fermenta&ccedil;&atilde;o cecal de fruto-
oligossacar&iacute;deos est&aacute; envolvido na preven&ccedil;&atilde;o da anem
ia induzida por ressec&ccedil;&atilde;o g&aacute;strica. </font></p>     ^cY#v24
n1a03.htm##
01504000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704126900076002001301345#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#97#93#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Estudos nossos anteriores mostraram 
que a administra&ccedil;&atilde;o de polidextrose aumentam a absor&ccedil;&atild
e;o do ferro<sup>19</sup> e c&aacute;lcio<sup>20</sup> em ratos gastrectomizados
. Um estudo in vitro de modelagem de fermenta&ccedil;&atilde;o col&ocirc;nica, m
ostraram que a administra&ccedil;&atilde;o polidextrose aumenta o n&iacute;vel d
e bifidobact&eacute;rias e os n&iacute;veis de &aacute;cidos org&acirc;nicos de 
cadeia curta, &aacute;cido ac&eacute;tico em particular. Al&eacute;m disso, a po
lidextrose reduziu os n&iacute;veis de bact&eacute;rias potencialmente patog&eci
rc;nicas no c&oacute;lon proximal<sup>15</sup>. Consequentemente, especula-se qu
e neste estudo o efeito da polidextrose em aumentar a absor&ccedil;&atilde;o de 
ferro em ratos gastrectomizados aconteceu no intestino grosso. Al&eacute;m disso
, alimenta&ccedil;&atilde;o com GOS aumentou a absor&ccedil;&atilde;o de minerai
s<sup>4,5,6</sup>. Chonan e Watanuki<sup>4,5,6</sup> demonstraram os efeitos est
imulantes do GOS na absor&ccedil;&atilde;o de c&aacute;lcio pode ser parcialment
e associado a solubilidade aumentada do c&aacute;lcio e do conte&uacute;do fluid
o no l&uacute;men intestinal. </font></p>     ^cY#v24n1a03.htm##
01063000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082800076002001300904#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#98#94#article#163#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No presente estudo, a gastrectomia p
arcial causou anemia devido absor&ccedil;&atilde;o de ferro reduzido; este fato 
poderia ser parcialmente evitado atrav&eacute;s da inclus&atilde;o de GOS + PDX 
na dieta <a href="#fig2">(Figuras 2</a>, <a href="#fig3">3</a> e <a href="#fig5"
>5</a>). Ratos gastrectomizados receberam vitamina B12 por via subcut&acirc;nea,
 para evitar a anemia perniciosa. Os resultados aqui apresentados indicam que a 
anemia p&oacute;s-gastrectomia observada neste estudo foi de anemia ferropriva. 
Estes resultados podem ser ben&eacute;ficos para pacientes com anemia p&oacute;s
-gastrectomia. Entretanto, evid&ecirc;ncias adicionais s&atilde;o necess&aacute;
rias para se adaptar ao tratamento cl&iacute;nico dos seres humanos. </font></p>
     ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#99#95#article#163#<p>&nbsp;</p>     ^
cY#v24n1a03.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704010800077002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#100#96#article#163#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"> <b>CONCLUS&Atilde;O</b> </font></p
>     ^cY#v24n1a03.htm##
00575000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704033900077002001300416#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#101#97#article#163#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A suplementa&ccedil;&atilde;o com G
OS + PDX preveniu m&aacute; absor&ccedil;&atilde;o de ferro e anemia em ratos p&
oacute;s-gastrectomia, e o intestino grosso parece estar envolvido no processo d
e absor&ccedil;&atilde;o de ferro em ratos gastrectomizados. </font></p>     ^cY
#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#102#98#article#163#<p>&nbsp;</p>     
^cY#v24n1a03.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704010500077002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#103#99#article#163#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>AGRADECIMENTOS</b> </font></p>  
   ^cY#v24n1a03.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704030800078002001300386#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#104#100#article#163#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Ao Conselho Nacional de Desenvolvi
mento Cient&iacute;fico e Tecnol&oacute;gico (CNPq), Laborat&oacute;rio Biominer
ais An&aacute;lises Qu&iacute;micas Ltda  e Johnson &amp; Johnson<sup>&reg;</sup
>, pelosfios cir&uacute;rgicos.</font></p>     ^cY#v24n1a03.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#105#101#article#163#<p>&nbsp;</p>    
 ^cY#v24n1a03.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010800078002001300186#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#106#102#article#163#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS </b></font></
p>     ^cY#v24n1a03.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704029000080002001300370#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#107#103#article#163#1#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Afsana K, Shiga K
, Ishizuka S, Hara H. Ingestion of an indigestible saccharide, difructose anhydr
ide III, partially prevents the tannic acid-induced suppression of iron absorpti
on in rats. J. Nutr. 2003;133: 3553-60.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#108#104#article#163# </font></p>     
^cY#v24n1a03.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704030700080002001300387#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#109#105#article#163#2#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bougl&eacute; D, 
Vaghefi-Vaezzadeh N, Roland N, Roland N, Bouvard G, Arhan P, Bureau F, Neuville 
D, Maubois JL. Influence of shortchain fatty acids on iron absorption by proxima
l colon. Scand. J.Gastroenterol. 2002; 37(9): 1008-1011.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#110#106#article#163# </font></p>     
^cY#v24n1a03.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704030300080002001300383#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#111#107#article#163#3#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Campos MS, Gomez-
Ayala AE, Lopez-Aliaga I, Pallares I, Hartiti S,Pharm B, Alferez MJ M, Barronuev
o M. Role of the proximal colon in mineral absorption in rats with and without f
erropenic anemia. Nutr. Res. 1996; 16(9): 1529-1543.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#112#108#article#163# </font></p>     
^cY#v24n1a03.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704026000080002001300340#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#113#109#article#163#4#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 4. Chonan O, Matsum
oto K, Watanuki M. Effect of galactooligosaccharides on calcium absorption and p
reventing bone loss in ovariectomized rats. Biosci. Biotech. Biochem. 1995;59(2)
:236-239.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#114#110#article#163# </font></p>     
^cY#v24n1a03.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704020600080002001300286#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#115#111#article#163#5#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 5. Chonan O, Watanu
ki M. Effect of galactooligasaccharides on calcium absorption in rats. J. Nutr. 
Sci. Vitaminol. 1995;41(1): 95-104.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#116#112#article#163# </font></p>     
^cY#v24n1a03.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704025700080002001300337#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#117#113#article#163#6#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 6. Chonan O, Watanu
ki M. The effect of 6'-Galactooligosaccharides onbone mineralization of rats ada
pted to different leves of dietarycalcium. Int J Vitam. Nutr Res. 1996; 66(3): 2
44-49.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#118#114#article#163# </font></p>     
^cY#v24n1a03.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704027100080002001300351#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#119#115#article#163#7#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Diniz MFHS, Diniz
 MTC. Obesidade m&oacute;rbida. In: Fonseca JGM. Obesidade e outros dist&uacute;
rbios alimentares. Rio de Janeiro: M&eacute;dica e Cient&iacute;fica. Parte C, v
.2, 2001, p.290-293.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#120#116#article#163# </font></p>     
^cY#v24n1a03.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704021900080002001300299#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#121#117#article#163#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Ebihara K, Okano 
J, Miyata T. Comparison of ferrous and ferric iron bioavailability following rat
 cecal infusion. Nutr. Res. 1994;14(2): 221-228.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#122#118#article#163# </font></p>     
^cY#v24n1a03.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704024300080002001300323#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#123#119#article#163#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Ebihara K, Okano 
J. Comparison of bioavailability and hemoglobin repletion of ferric and ferrous 
iron infused into the cecum in anemic rats. Nutr. Res. 1995;15: 889-897.    ^cY#
v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#124#120#article#163# </font></p>     
^cY#v24n1a03.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#125#121#article#163#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Hara H, Suzuki 
T, Aoyama Y. Ingesti&oacute;n of the soluble dietary fibre, polydextrose, increa
ses calcium absorption and bone mineralization in normal and total-gastrectomize
d rats. Br. J. Nutr. 2000; 84: 655-661.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#126#122#article#163# </font></p>     
^cY#v24n1a03.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023700081002001300318#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#127#123#article#163#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Ohta A, Ohtsuki
 M, Hosono A, Adachi T, Hara H, Sakata T. Dietary fructooligosaccharides prevent
 osteopenia after gastrectomy in rats. J Nut. 1998;128(1): 106-110.    ^cY#v24n1
a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#128#124#article#163# </font></p>     
^cY#v24n1a03.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025800081002001300339#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#129#125#article#163#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Ohta A, Ohtsuki
 M, Uehara M, Hosono A, Hirayama M, Adachi T, Hara H. Dietary fructooligosacchar
ides prevent postgastrectomy anemia and osteopenia in rats. J Nut. 1998; 128(3):
 485-90.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#130#126#article#163# </font></p>     
^cY#v24n1a03.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#131#127#article#163#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Ohta A, Sakai K
, Takasaki M, Uehara M, Tokunaga T, Adachi T. Dietary heme iron does not prevent
 postgastrectomy anemia but fructooligosaccharides improve bioavailability of he
me iron in rats. Int. J. Vitam. Nutr. Res. 1999; 69(5): 348-355.    ^cY#v24n1a03
.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#132#128#article#163# </font></p>     
^cY#v24n1a03.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020200081002001300283#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#133#129#article#163#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. 	Papini-Berto S
J, Burini RC. Causas da desnutri&ccedil;&atilde;o p&oacute;sgastrectomia. Arq Ga
stroenterol. 2001;38(4): 272-75.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#134#130#article#163# </font></p>     
^cY#v24n1a03.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#135#131#article#163#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Probert HM, Apa
jalahti JHA, Rautonen N, Stowell J, Gibson GR. Polydextrose, lactitol, and fruct
o-oligosaccharide fermentation by colonic bacteria in a three-stage continuous c
ulture system. Appl. Environ. Microbiol. 2004;70(8): 4505-4511.    ^cY#v24n1a03.
htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#136#132#article#163# </font></p>     
^cY#v24n1a03.htm##
00563000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031100081002001300392#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#137#133#article#163#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Reeves PG, Niel
son FH, Fahey GCJR. AIN-93 purified diets for laboratory rodents: final report o
f the American Institute of Nutrition ad hoc writing committee on the reformulat
ion of the AIN-76A rodent diet. J Nut. 1993;123(11): 1939-51.    ^cY#v24n1a03.ht
m##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#138#134#article#163# </font></p>     
^cY#v24n1a03.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026100081002001300342#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#139#135#article#163#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Roviello F, Fot
ia G, Marrelli D, Stefano A, Macchiarelli R, PintoE. Iron deficiency anemia afte
r subtotal gastrectomy for gastric cancer. Hepatogastroenterology.  2004;51(59):
 1510-1514.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#140#136#article#163# </font></p>     
^cY#v24n1a03.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#141#137#article#163#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Sakai K, Ohta A
, Shiga K, Takasaki M, Tokunaga T, Hara H. The cecum and dietary short-chain fru
ctooligosaccharides are involved in preventing postgastrectomy anemia in rats. J
 Nut. 2000; 130(6): 1608-12.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#142#138#article#163# </font></p>     
^cY#v24n1a03.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029700081002001300378#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#143#139#article#163#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Santos EF, Tsub
oi KH, Ara&uacute;jo MR, Falconi MA, Ouwehand AC, Andreollo NA, Miyasaka CK. Ing
estion of polydextrose increase the iron absorption in rats submitted to partial
 gastrectomy. Acta Cir Bras. 2010:25(6)518-524.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#144#140#article#163# </font></p>     
^cY#v24n1a03.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025800081002001300339#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#145#141#article#163#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Santos EF, Tsub
oi KH, Ara&uacute;jo MR, Ouwehand AC, Andreollo NA,Miyasaka CK. Dietary polydext
rose increase calcium absorption in normal rats. ABCD Arq Bras Cir Dig 2009;22(4
):201-5.    ^cY#v24n1a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#146#142#article#163#</font></p>     ^
cY#v24n1a03.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029700081002001300378#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#147#143#article#163#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Santos EF, Tsub
oi KH, Palu BF, Ara&uacute;jo MR, Andreollo NA, Miyasaka CK. Effects of the part
ial gastrectomy associated to anterior truncal vagotomy in the metabolism of the
 iron in rats. Acta Cir Bras. 2008;23(5):401-4.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#148#144#article#163# </font></p>     
^cY#v24n1a03.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031200081002001300393#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#149#145#article#163#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Santos EF, Tsub
oi KH, Palu BF, Ara&uacute;jo MR, Andreollo NA, Miyasaka CK. Partial gastrectomy
 associated to anterior truncal vagotomy: alterations in metabolism of calcium. 
Experimental study in rats. Arq Bras Cir Dig. 2009;22(2)105-9.    ^cY#v24n1a03.h
tm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#150#146#article#163# </font></p>     
^cY#v24n1a03.htm##
00538000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028600081002001300367#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#151#147#article#163#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Shiga K, Nishim
ukai M, Tomita F, Hara H. Ingestion of difructose anhydride III, a non-digestibl
e disaccharide, prevents gastrectomyinduced iron malabsorption and anemia in rat
s. Nutrition. 2006; 22(7-8): 786-93.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#152#148#article#163# </font></p>     
^cY#v24n1a03.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027300081002001300354#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#153#149#article#163#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 24. Statsoft, Inc.
 Statistica for Windows &#91;Computer program manual&#93;. Tulsa, USA, (2000) Av
ailable from <a href="http://www.statsoft.com" target="_blank">http://www.statso
ft.com</a> </font></p>     ^cY#v24n1a03.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019900081002001300280#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#154#150#article#163#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Tovey FI, Hobsl
ey M. Post-gastrectomy patients need to 	be followed up for 20-30 years. World J
 Gastroenterol. 2000; 6:45-8.    ^cY#v24n1a03.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#155#151#article#163# </font></p>     
^cY#v24n1a03.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#156#152#article#163#<p>&nbsp;</p>    
 ^cY#v24n1a03.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#157#153#article#163#<p>&nbsp;</p>    
 ^cY#v24n1a03.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019800078002001300276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#158#154#article#163#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ec
irc;ncia:</b>    ^cY#v24n1a03.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004700078002001300125#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#159#155#article#163#<br> Elisv&acirc;
nia Freitas dos Santos    ^cY#v24n1a03.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009400078002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#160#156#article#163#<br> e-mail: <a h
ref="mailto:elisvania@gmail.com">elisvania@gmail.com</a> </font></p>     ^cY#v24
n1a03.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012100078002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#161#157#article#163#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 10/12/2010    ^cY#v24n1a03.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006400078002001300142#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#162#158#article#163#<br>   Aceito par
a publica&ccedil;&atilde;o: 25/01/2011     ^cY#v24n1a03.htm##
00296000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005900078002001300137#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#163#159#article#163#<br>   Fonte de f
inanciamento: n&atilde;o h&aacute;    ^cY#v24n1a03.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007100078002001300149#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#164#160#article#163#<br>   Conflito d
e interesses: n&atilde;o h&aacute;</font></p>     ^cY#v24n1a03.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#165#161#article#163#<p>&nbsp;</p>    
 ^cY#v24n1a03.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#166#162#article#163#<p>&nbsp;</p>    
 ^cY#v24n1a03.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704044500078002001300523#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a03.htm#S#p#167#163#article#163#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Programa de 
P&oacute;s-Gradua&ccedil;&atilde;o, Departamento de Alimentos e Nutri&ccedil;&at
ilde;o (DEPAN), Faculdade de Engenharia de Alimentos (FEA) e Laborat&oacute;rio 
de Enzimologia e Carcinog&ecirc;nese Experimental, Faculdade de Ci&ecirc;ncias M
&eacute;dicas (FCM), Universidade Estadual de Campinas  UNICAMP, Campinas. SP, 
Brasil. </font></p>     ^cY#v24n1a03.htm##
00669000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01800108010001400126012015300140030000800293065000900301064000500310031000400315
014000800319865000900327002001300336035001000349801000800359#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a03.htm#S#c#168#1#article#25#1#^rND^sAfsana^nK#^rND^s
Shiga^nK#^rND^sIshizuka^nS#^rND^sHara^nH#Ingestion of an indigestible saccharide
, difructose anhydride III, partially prevents the tannic acid-induced suppressi
on of iron absorption in rats^len#J. Nutr#20030000#2003#133#3553-60#20110300#v24
n1a03.htm#0022-3166#J. nutr##
00751000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100027000930100
01600120010001600136010001700152010001500169010001600184010001800200010001800218
01200770023603000230031371000020033606500090033806400050034703100030035203200020
0355014001000357865000900367002001300376#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a03.htm#S#c#169#2#article#25#2#^rND^sBouglé^nD#^rND^sVaghefi-Vaezzadeh^nN
#^rND^sRoland^nN#^rND^sRoland^nN#^rND^sBouvard^nG#^rND^sArhan^nP#^rND^sBureau^nF
#^rND^sNeuville^nD#^rND^sMaubois^nJL#Influence of shortchain fatty acids on iron
 absorption by proximal colon^len#Scand. J.Gastroenterol#2#20020000#2002#37#9#10
08-1011#20110300#v24n1a03.htm##
00737000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100022000940100
02200116010001800138010001700156010001500173010002000188010002000208012009600228
03000100032471000020033406500090033606400050034503100030035003200020035301400100
0355865000900365002001300374#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.h
tm#S#c#170#3#article#25#3#^rND^sCampos^nMS#^rND^sGomez-Ayala^nAE#^rND^sLopez-Ali
aga^nI#^rND^sPallares^nI#^rND^sHartiti^nS#^rND^sPharm^nB#^rND^sAlferez^nMJ M#^rN
D^sBarronuevo^nM#Role of the proximal colon in mineral absorption in rats with a
nd without ferropenic anemia^len#Nutr. Res#2#19960000#1996#16#9#1529-1543#201103
00#v24n1a03.htm##
00604000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01800112012010800130030002500238710000200263065000900265064000500274031000300279
032000200282014000800284865000900292002001300301#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a03.htm#S#c#171#4#article#25#4#^rND^sChonan^nO#^rND^sMatsumoto^nK
#^rND^sWatanuki^nM#Effect of galactooligosaccharides on calcium absorption and p
reventing bone loss in ovariectomized rats^len#Biosci. Biotech. Biochem#2#199500
00#1995#59#2#236-239#20110300#v24n1a03.htm##
00575000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930120
06800111030002400179065000900203064000500212031000300217032000200220014000700222
865000900229002001300238035001000251801002400261#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a03.htm#S#c#172#5#article#25#5#^rND^sChonan^nO#^rND^sWatanuki^nM#
Effect of galactooligasaccharides on calcium absorption in rats^len#J. Nutr. Sci
. Vitaminol#19950000#1995#41#1#95-104#20110300#v24n1a03.htm#0301-4800#J. nutr. s
ci. vitaminol##
00581000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930120
12000111030002200231710000200253065000900255064000500264031000300269032000200272
014000700274865000900281002001300290#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a03.htm#S#c#173#6#article#25#6#^rND^sChonan^nO#^rND^sWatanuki^nM#The effect o
f 6'-Galactooligosaccharides onbone mineralization of rats adapted to different 
leves of dietarycalcium^len#Int J Vitam. Nutr Res#2#19960000#1996#66#3#244-49#20
110300#v24n1a03.htm##
00556000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950120
02200112016001900134018004600153066001500199062002000214065000900234064000500243
014000800248865000900256002001300265#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a03.htm#S#c#174#7#article#25#7#^rND^sDiniz^nMFHS#^rND^sDiniz^nMTC#Obesidade m
órbida^lpt#^rND^sFonseca^nJGM#Obesidade e outros distúrbios alimentares^lpt#Rio 
de Janeiro#Médica e Científica#20010000#2001#290-293#20110300#v24n1a03.htm##
00563000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940100
01600109012008700125030001000212710000200222065000900224064000500233031000300238
032000200241014000800243865000900251002001300260#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a03.htm#S#c#175#8#article#25#8#^rND^sEbihara^nK#^rND^sOkano^nJ#^r
ND^sMiyata^nT#Comparison of ferrous and ferric iron bioavailability following ra
t cecal infusion^len#Nutr. Res#2#19940000#1994#14#2#221-228#20110300#v24n1a03.ht
m##
00558000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940120
12400109030001000233710000200243065000900245064000500254031000300259014000800262
865000900270002001300279#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S
#c#176#9#article#25#9#^rND^sEbihara^nK#^rND^sOkano^nJ#Comparison of bioavailabil
ity and hemoglobin repletion of ferric and ferrous iron infused into the cecum i
n anemic rats^len#Nutr. Res#2#19950000#1995#15#889-897#20110300#v24n1a03.htm##
00647000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01600109012015100125030001200276065000900288064000500297031000300302014000800305
865000900313002001300322035001000335801001200345#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a03.htm#S#c#177#10#article#25#10#^rND^sHara^nH#^rND^sSuzuki^nT#^r
ND^sAoyama^nY#Ingestión of the soluble dietary fibre, polydextrose, increases ca
lcium absorption and bone mineralization in normal and total-gastrectomized rats
^len#Br. J. Nutr#20000000#2000#84#655-661#20110300#v24n1a03.htm#0007-1145#Br. j.
 nutr##
00636000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01600110010001600126010001400142010001600156012008000172030000600252710000200258
06500090026006400050026903100040027403200020027801400080028086500090028800200130
0297#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#178#11#article#25
#11#^rND^sOhta^nA#^rND^sOhtsuki^nM#^rND^sHosono^nA#^rND^sAdachi^nT#^rND^sHara^nH
#^rND^sSakata^nT#Dietary fructooligosaccharides prevent osteopenia after gastrec
tomy in rats^len#J Nut#2#19980000#1998#128#1#106-110#20110300#v24n1a03.htm##
00674000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01600110010001600126010001800142010001600160010001400176012008900190030000600279
71000020028506500090028706400050029603100040030103200020030501400070030786500090
0314002001300323#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#179#1
2#article#25#12#^rND^sOhta^nA#^rND^sOhtsuki^nM#^rND^sUehara^nM#^rND^sHosono^nA#^
rND^sHirayama^nM#^rND^sAdachi^nT#^rND^sHara^nH#Dietary fructooligosaccharides pr
event postgastrectomy anemia and osteopenia in rats^len#J Nut#2#19980000#1998#12
8#3#485-90#20110300#v24n1a03.htm##
00757000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930100
01800108010001600126010001800142010001600160012013400176030002500310065000900335
06400050034403100030034903200020035201400080035486500090036200200130037103500100
0384801002500394#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#180#1
3#article#25#13#^rND^sOhta^nA#^rND^sSakai^nK#^rND^sTakasaki^nM#^rND^sUehara^nM#^
rND^sTokunaga^nT#^rND^sAdachi^nT#Dietary heme iron does not prevent postgastrect
omy anemia but fructooligosaccharides improve bioavailability of heme iron in ra
ts^len#Int. J. Vitam. Nutr. Res#19990000#1999#69#5#348-355#20110300#v24n1a03.htm
#0300-9831#Int. j. vitam. nutr. res##
00545000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100017001020120
04200119030001800161065000900179064000500188031000300193032000200196014000700198
865000900205002001300214035001000227801001800237#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a03.htm#S#c#181#14#article#25#14#^rND^sPapini-Berto^nSJ#^rND^sBur
ini^nRC#Causas da desnutrição pósgastrectomia^lpt#Arq Gastroenterol#20010000#200
1#38#4#272-75#20110300#v24n1a03.htm#0004-2803#Arq Gastroenterol##
00739000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100022000970100
01800119010001700137010001700154012013100171030002500302065000900327064000500336
03100030034103200020034401400100034686500090035600200130036503500100037880100250
0388#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#182#15#article#25
#15#^rND^sProbert^nHM#^rND^sApajalahti^nJHA#^rND^sRautonen^nN#^rND^sStowell^nJ#^
rND^sGibson^nGR#Polydextrose, lactitol, and fructo-oligosaccharide fermentation 
by colonic bacteria in a three-stage continuous culture system^len#Appl. Environ
. Microbiol#20040000#2004#70#8#4505-4511#20110300#v24n1a03.htm#0099-2240#Appl. e
nviron. microbiol##
00656000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01800114012017500132030000600307710000200313065000900315064000500324031000400329
032000300333014000800336865000900344002001300353#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a03.htm#S#c#183#16#article#25#16#^rND^sReeves^nPG#^rND^sNielson^n
FH#^rND^sFahey^nGCJR#AIN-93 purified diets for laboratory rodents: final report 
of the American Institute of Nutrition ad hoc writing committee on the reformula
tion of the AIN-76A rodent diet^len#J Nut#2#19930000#1993#123#11#1939-51#2011030
0#v24n1a03.htm##
00703000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01800112010001700130010002200147010001500169012007300184030002300257065000900280
06400050028903100030029403200030029701400100030086500090031000200130031903500100
0332801002300342#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#184#1
7#article#25#17#^rND^sRoviello^nF#^rND^sFotia^nG#^rND^sMarrelli^nD#^rND^sStefano
^nA#^rND^sMacchiarelli^nR#^rND^sPinto^nE#Iron deficiency anemia after subtotal g
astrectomy for gastric cancer^len#Hepatogastroenterology#20040000#2004#51#59#151
0-1514#20110300#v24n1a03.htm#0172-6390#Hepatogastroenterology##
00676000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01500108010001800123010001800141010001400159012011900173030000600292710000200298
06500090030006400050030903100040031403200020031801400080032086500090032800200130
0337#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#185#18#article#25
#18#^rND^sSakai^nK#^rND^sOhta^nA#^rND^sShiga^nK#^rND^sTakasaki^nM#^rND^sTokunaga
^nT#^rND^sHara^nH#The cecum and dietary short-chain fructooligosaccharides are i
nvolved in preventing postgastrectomy anemia in rats^len#J Nut#2#20000000#2000#1
30#6#1608-12#20110300#v24n1a03.htm##
00709000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01700113010001800130010001900148010002000167010001900187012010000206030001400306
71000020032006500090032206400050033103100030033603200020033901400080034186500090
0349002001300358#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#186#1
9#article#25#19#^rND^sSantos^nEF#^rND^sTsuboi^nKH#^rND^sAraújo^nMR#^rND^sFalconi
^nMA#^rND^sOuwehand^nAC#^rND^sAndreollo^nNA#^rND^sMiyasaka^nCK#Ingestion of poly
dextrose increase the iron absorption in rats submitted to partial gastrectomy^l
en#Acta Cir Bras#2#20100000#2010#25#6#518-524#20110300#v24n1a03.htm##
00653000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01700113010001900130010002000149010001900169012006800188030002200256710000200278
06500090028006400050028903100030029403200020029701400060029986500090030500200130
0314#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#187#20#article#25
#20#^rND^sSantos^nEF#^rND^sTsuboi^nKH#^rND^sAraújo^nMR#^rND^sOuwehand^nAC#^rND^s
Andreollo^nNA#^rND^sMiyasaka^nCK#Dietary polydextrose increase calcium absorptio
n in normal rats^len#ABCD Arq Bras Cir Dig#2#20090000#2009#22#4#201-5#20110300#v
24n1a03.htm##
00690000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01500113010001700128010002000145010001900165012011700184030001400301710000200315
06500090031706400050032603100030033103200020033401400060033686500090034200200130
0351#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#188#21#article#25
#21#^rND^sSantos^nEF#^rND^sTsuboi^nKH#^rND^sPalu^nBF#^rND^sAraújo^nMR#^rND^sAndr
eollo^nNA#^rND^sMiyasaka^nCK#Effects of the partial gastrectomy associated to an
terior truncal vagotomy in the metabolism of the iron in rats^len#Acta Cir Bras#
2#20080000#2008#23#5#401-4#20110300#v24n1a03.htm##
00706000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01500113010001700128010002000145010001900165012013000184030001700314710000200331
06500090033306400050034203100030034703200020035001400060035286500090035800200130
0367#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#189#22#article#25
#22#^rND^sSantos^nEF#^rND^sTsuboi^nKH#^rND^sPalu^nBF#^rND^sAraújo^nMR#^rND^sAndr
eollo^nNA#^rND^sMiyasaka^nCK#Partial gastrectomy associated to anterior truncal 
vagotomy: alterations in metabolism of calcium. Experimental study in rats^len#A
rq Bras Cir Dig#2#20090000#2009#22#2#105-9#20110300#v24n1a03.htm##
00678000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
01600114010001400130012014000144030001000284065000900294064000500303031000300308
032000400311014000700315865000900322002001300331035001000344801001000354#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#190#23#article#25#23#^rND^sSh
iga^nK#^rND^sNishimukai^nM#^rND^sTomita^nF#^rND^sHara^nH#Ingestion of difructose
 anhydride III, a non-digestible disaccharide, prevents gastrectomyinduced iron 
malabsorption and anemia in rats^len#Nutrition#20060000#2006#22#7-8#786-93#20110
300#v24n1a03.htm#0029-6600#Nutrition##
00442000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170014000790180053000930660
00600146065000900152064000500161037002400166865000900190002001300199#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a03.htm#S#c#191#24#article#25#24#Statsoft, In
c#Statistica for Windows [Computer program manual]^len#Tulsa#20000000#2000#http:
//www.statsoft.com#20110300#v24n1a03.htm##
00515000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950120
06900113030002200182710000200204065000900206064000500215031000200220014000500222
865000900227002001300236#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a03.htm#S
#c#192#25#article#25#25#^rND^sTovey^nFI#^rND^sHobsley^nM.#Post-gastrectomy patie
nts need to be followed up for 20-30 years^len#World J Gastroenterol#2#20000000#
2000#6#45-8#20110300#v24n1a03.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#o#1#1#article#1
#20110411#103842#v24n1a04.htm#164##
04325000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000200094049000800096158000300104030002700107
03100030013403200020013706500090013901400090014803500100015701201500016701201380
03170100039004550100038004940100029005320100036005610100033005970100034006300831
34100664085001002005085002702015085002302042085004902065085004802114083133002162
08500100349208500250350208500250352708500430355208500400359511700080363507200030
3643112000903646111001103655114000903666113001103675002001303686#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#4
#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f15^l19#0102-6720#Ligadura
 simples ou ligadura com confecção de bolsa e sepultamento para tratamento do co
to apendicular: estudo comparativo prospecivo randomizado^lpt#Simple ligation or
 ligation and purse string invagination for the treatment of the appendiceal stu
mp: a prospective, randomized trial^len#^rND^nLauro José Victor Avellán^sNeves#^
rND^nAlberto Julius Alves^sWainstein#^rND^nWallace Ceoto^sMathias#^rND^nFabrizio
 Parreira Dias^sCosta#^rND^nJudson Henrique de^sCastro#^rND^nPaulo Roberto^sAvas
si-Rocha#^lpt^aRACIONAL: Apesar da apendicite aguda ser uma das afecções cirúrgi
cas mais comuns, o melhor tratamento do coto apendicular ainda não foi definido.
 Na apendicectomia laparotômica há preferência pela ligadura e sepultamento do c
oto enquanto, na laparoscópica, pela ligadura simples ou clampeamento. OBJETIVOS
: Comparar duas técnicas de tratamento do coto apendicular na apendicectomia lap
arotômica (ligadura simples vs ligadura com confecção de bolsa e sepultamento) p
or meio de análise prospectiva e randomizada. MÉTODOS: Entre os anos de 2003 e 2
005, 113 pacientes foram submetidos à apendicectomia laparotômica por apendicite
 aguda. O coto apendicular foi tratado por ligadura simples em 49 casos e por li
gadura e sepultamento em 64 casos. Os dois grupos foram semelhantes em relação à
s médias de idade, gênero, sinais e sintomas pré-operatórios, tempo de evolução 
da doença e fase da apendicite aguda diagnosticada pelo exame anatomopatológico.
 RESULTADOS: Não houve diferença estatística significativa entre os dois grupos 
em relação ao tempo de duração da operação, presença de complicações (infecção d
e ferida operatória, deiscência de ferida, formação de abscessos, obstrução inte
stinal, seroma e formação de fístula) ou tempo de internação. CONCLUSÃO: As duas
 técnicas são igualmente seguras para tratamento do coto apendicular.#^ddecs^i1#
^tm^lpt^kApendicectomia^i1#^tm^lpt^kApendicite^i1#^tm^lpt^kProcedimentos cirúrgi
cos operatórios^i1#^tm^lpt^kEnsaio clínico controlado aleatório^i1#^len^aBACKGRO
UND: Although acute appendicitis is one of the most common surgical diseases, th
e best treatment of the appendicular stump has not been defined. At laparotomy f
or appendectomy the stump is treated preferably by ligation and burial of the st
ump and, in laparoscopic surgery, by simple ligation or clamping. AIM: To compar
e two techniques for the treatment of appendicular stump in appendectomy (simple
 ligation vs ligation with purse making and burial) by a prospective and randomi
zed study. METHODS: Between the years 2003 and 2005, 113 patients underwent lapa
rotomy appendectomy for acute appendicitis. The appendiceal stump was treated by
 simple ligation in 49 cases and by ligation and burial in 64 cases. The two gro
ups were similar in terms of average age, gender, preoperative signs and symptom
s, time of disease progression and stage of appendicitis diagnosed histopatholog
ical examination. RESULTS: There was no statistically significant difference bet
ween the two groups regarding the duration of operation, complications (wound in
fection, wound dehiscence, abscess formation, intestinal obstruction, fistula an
d seroma ) or hospital stay. CONCLUSIONS: Both techniques are equally safe for t
reatment of appendicular stump, and so, it is possible to recommend simple ligat
ion because it is easier to be done.#^ddecs^i2#^tm^len^kAppendectomy^i2#^tm^len^
kAppendicitis^i2#^tm^len^kSurgical procedures, operative^i2#^tm^len^kRandomized 
controlled trial^i2#vancouv#23#20100929#29/09/2010#20101221#21/12/2010#v24n1a04.
htm##
04423000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000200094049000800096158000300104030002700107
03100030013403200020013706500090013901400090014803500100015701201640016701201520
03310100039004830100038005220100029005600100036005890100033006250100034006580831
37600692085001002068085002702078085002302105085004902128085004802177083136502225
08500100359008500250360008500250362508500430365008500400369311700080373307200030
3741112000903744111001103753114000903764113001103773002001303784#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#4
#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f15^l19#0102-6720#<b>Ligad
ura simples ou ligadura com confecção de bolsa e sepultamento para tratamento do
 coto apendicular</b>: <b>estudo comparativo prospecivo randomizado</b>^lpt#<b>S
imple ligation or ligation and purse string invagination for the treatment of th
e appendiceal stump</b>: <b>a prospective, randomized trial</b>^len#^rND^nLauro 
José Victor Avellán^sNeves#^rND^nAlberto Julius Alves^sWainstein#^rND^nWallace C
eoto^sMathias#^rND^nFabrizio Parreira Dias^sCosta#^rND^nJudson Henrique de^sCast
ro#^rND^nPaulo Roberto^sAvassi-Rocha#^lpt^a<b>RACIONAL:</b> Apesar da apendicite
 aguda ser uma das afecções cirúrgicas mais comuns, o melhor tratamento do coto 
apendicular ainda não foi definido. Na apendicectomia laparotômica há preferênci
a pela ligadura e sepultamento do coto enquanto, na laparoscópica, pela ligadura
 simples ou clampeamento. <b>OBJETIVOS:</b> Comparar duas técnicas de tratamento
 do coto apendicular na apendicectomia laparotômica (ligadura simples vs ligadur
a com confecção de bolsa e sepultamento) por meio de análise prospectiva e rando
mizada. <b>MÉTODOS: </b>Entre os anos de 2003 e 2005, 113 pacientes foram submet
idos à apendicectomia laparotômica por apendicite aguda. O coto apendicular foi 
tratado por ligadura simples em 49 casos e por ligadura e sepultamento em 64 cas
os. Os dois grupos foram semelhantes em relação às médias de idade, gênero, sina
is e sintomas pré-operatórios, tempo de evolução da doença e fase da apendicite 
aguda diagnosticada pelo exame anatomopatológico. <b>RESULTADOS: </b>Não houve d
iferença estatística significativa entre os dois grupos em relação ao tempo de d
uração da operação, presença de complicações (infecção de ferida operatória, dei
scência de ferida, formação de abscessos, obstrução intestinal, seroma e formaçã
o de fístula) ou tempo de internação. <b>CONCLUSÃO:</b> As duas técnicas são igu
almente seguras para tratamento do coto apendicular.#^ddecs^i1#^tm^lpt^kApendice
ctomia^i1#^tm^lpt^kApendicite^i1#^tm^lpt^kProcedimentos cirúrgicos operatórios^i
1#^tm^lpt^kEnsaio clínico controlado aleatório^i1#^len^a<b>BACKGROUND:</b> Altho
ugh acute appendicitis is one of the most common surgical diseases, the best tre
atment of the appendicular stump has not been defined. At laparotomy for appende
ctomy the stump is treated preferably by ligation and burial of the stump and, i
n laparoscopic surgery, by simple ligation or clamping. <b>AIM: </b>To compare t
wo techniques for the treatment of appendicular stump in appendectomy (simple li
gation vs ligation with purse making and burial) by a prospective and randomized
 study. <b>METHODS: </b>Between the years 2003 and 2005, 113 patients underwent 
laparotomy appendectomy for acute appendicitis. The appendiceal stump was treate
d by simple ligation in 49 cases and by ligation and burial in 64 cases. The two
 groups were similar in terms of average age, gender, preoperative signs and sym
ptoms, time of disease progression and stage of appendicitis diagnosed histopath
ological examination. <b>RESULTS:</b> There was no statistically significant dif
ference between the two groups regarding the duration of operation, complication
s (wound infection, wound dehiscence, abscess formation, intestinal obstruction,
 fistula and seroma ) or hospital stay. <b>CONCLUSIONS: </b>Both techniques are 
equally safe for treatment of appendicular stump, and so, it is possible to reco
mmend simple ligation because it is easier to be done.#^ddecs^i2#^tm^len^kAppend
ectomy^i2#^tm^len^kAppendicitis^i2#^tm^len^kSurgical procedures, operative^i2#^t
m^len^kRandomized controlled trial^i2#vancouv#23#20100929#29/09/2010#20101221#21
/12/2010#v24n1a04.htm##
04455000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000200112049000800114158000300122
03000260012503100030015103200020015406500090015601400090016503500100017401201500
01840120138003340100039004720100038005110100029005490100036005780100033006140100
03400647083134100681085001002022085002702032085002302059085004902082085004802131
08313300217908500100350908500250351908500250354408500430356908500400361211700080
36520720003036601120009036631110011036721140009036831130011036920020013037030080
08903716#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#l#4#1#article#1
#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#tab#4#ABCD060#nd#ABCD, arq. bras. cir. dig#
24#1#20110300#^f15^l19#0102-6720#Ligadura simples ou ligadura com confecção de b
olsa e sepultamento para tratamento do coto apendicular: estudo comparativo pros
pecivo randomizado^lpt#Simple ligation or ligation and purse string invagination
 for the treatment of the appendiceal stump: a prospective, randomized trial^len
#^rND^nLauro José Victor Avellán^sNeves#^rND^nAlberto Julius Alves^sWainstein#^r
ND^nWallace Ceoto^sMathias#^rND^nFabrizio Parreira Dias^sCosta#^rND^nJudson Henr
ique de^sCastro#^rND^nPaulo Roberto^sAvassi-Rocha#^lpt^aRACIONAL: Apesar da apen
dicite aguda ser uma das afecções cirúrgicas mais comuns, o melhor tratamento do
 coto apendicular ainda não foi definido. Na apendicectomia laparotômica há pref
erência pela ligadura e sepultamento do coto enquanto, na laparoscópica, pela li
gadura simples ou clampeamento. OBJETIVOS: Comparar duas técnicas de tratamento 
do coto apendicular na apendicectomia laparotômica (ligadura simples vs ligadura
 com confecção de bolsa e sepultamento) por meio de análise prospectiva e random
izada. MÉTODOS: Entre os anos de 2003 e 2005, 113 pacientes foram submetidos à a
pendicectomia laparotômica por apendicite aguda. O coto apendicular foi tratado 
por ligadura simples em 49 casos e por ligadura e sepultamento em 64 casos. Os d
ois grupos foram semelhantes em relação às médias de idade, gênero, sinais e sin
tomas pré-operatórios, tempo de evolução da doença e fase da apendicite aguda di
agnosticada pelo exame anatomopatológico. RESULTADOS: Não houve diferença estatí
stica significativa entre os dois grupos em relação ao tempo de duração da opera
ção, presença de complicações (infecção de ferida operatória, deiscência de feri
da, formação de abscessos, obstrução intestinal, seroma e formação de fístula) o
u tempo de internação. CONCLUSÃO: As duas técnicas são igualmente seguras para t
ratamento do coto apendicular.#^ddecs^i1#^tm^lpt^kApendicectomia^i1#^tm^lpt^kApe
ndicite^i1#^tm^lpt^kProcedimentos cirúrgicos operatórios^i1#^tm^lpt^kEnsaio clín
ico controlado aleatório^i1#^len^aBACKGROUND: Although acute appendicitis is one
 of the most common surgical diseases, the best treatment of the appendicular st
ump has not been defined. At laparotomy for appendectomy the stump is treated pr
eferably by ligation and burial of the stump and, in laparoscopic surgery, by si
mple ligation or clamping. AIM: To compare two techniques for the treatment of a
ppendicular stump in appendectomy (simple ligation vs ligation with purse making
 and burial) by a prospective and randomized study. METHODS: Between the years 2
003 and 2005, 113 patients underwent laparotomy appendectomy for acute appendici
tis. The appendiceal stump was treated by simple ligation in 49 cases and by lig
ation and burial in 64 cases. The two groups were similar in terms of average ag
e, gender, preoperative signs and symptoms, time of disease progression and stag
e of appendicitis diagnosed histopathological examination. RESULTS: There was no
 statistically significant difference between the two groups regarding the durat
ion of operation, complications (wound infection, wound dehiscence, abscess form
ation, intestinal obstruction, fistula and seroma ) or hospital stay. CONCLUSION
S: Both techniques are equally safe for treatment of appendicular stump, and so,
 it is possible to recommend simple ligation because it is easier to be done.#^d
decs^i2#^tm^len^kAppendectomy^i2#^tm^len^kAppendicitis^i2#^tm^len^kSurgical proc
edures, operative^i2#^tm^len^kRandomized controlled trial^i2#vancouv#23#20100929
#29/09/2010#20101221#21/12/2010#v24n1a04.htm#Internet^ihttp://www.scielo.br/scie
lo.php?script=sci_arttext&pid=S0102-67202011000100004##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#5#1#article#137#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL </b><
/font></p>     ^cY#v24n1a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#6#2#article#137#<p>&nbsp;</p>     ^cY
#v24n1a04.htm##
00503000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704027000074002001300344#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#7#3#article#137#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Ligadura simple
s ou ligadura com confec&ccedil;&atilde;o de bolsa e sepultamento para tratament
o do coto apendicular: estudo comparativo prospecivo randomizado </b></font></p>
     ^cY#v24n1a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#8#4#article#137#<p>&nbsp;</p>     ^cY
#v24n1a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#9#5#article#137#<p>&nbsp;</p>     ^cY
#v24n1a04.htm##
00510000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704027600075002001300351#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#10#6#article#137#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Lauro Jos&eacute; Victor Avell&aac
ute;n Neves; Alberto Julius Alves Wainstein; Wallace Ceoto Mathias; Fabrizio Par
reira Dias Costa; Judson Henrique de Castro; Paulo Roberto Avassi-Rocha </b></fo
nt></p>     ^cY#v24n1a04.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#11#7#article#137#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a04.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#12#8#article#137#<p>&nbsp;</p>     ^c
Y#v24n1a04.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#13#9#article#137#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a04.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#14#10#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a04.htm##
00664000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042900076002001300505#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#15#11#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL:</b>  Apesar da apendici
te aguda ser uma das afec&ccedil;&otilde;es cir&uacute;rgicas mais comuns, o mel
hor tratamento do coto apendicular ainda n&atilde;o foi definido. Na apendicecto
mia laparot&ocirc;mica h&aacute; prefer&ecirc;ncia pela ligadura e sepultamento 
do coto enquanto, na laparosc&oacute;pica, pela ligadura simples ou clampeamento
.     ^cY#v24n1a04.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027100076002001300347#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#16#12#article#137#<br>   <b>OBJETIVOS
:</b> Comparar duas t&eacute;cnicas de tratamento do coto apendicular na apendic
ectomia laparot&ocirc;mica (ligadura simples vs ligadura com confec&ccedil;&atil
de;o de bolsa e sepultamento) por meio de an&aacute;lise prospectiva e randomiza
da.     ^cY#v24n1a04.htm##
00786000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055100076002001300627#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#17#13#article#137#<br> <b>M&Eacute;TO
DOS: </b> Entre os anos de 2003 e 2005, 113 pacientes foram submetidos &agrave; 
apendicectomia laparot&ocirc;mica por apendicite aguda. O coto apendicular foi t
ratado por ligadura simples em 49 casos e por ligadura e sepultamento em 64 caso
s. Os dois grupos foram semelhantes em rela&ccedil;&atilde;o &agrave;s m&eacute;
dias de idade, g&ecirc;nero, sinais e sintomas pr&eacute;-operat&oacute;rios, te
mpo de evolu&ccedil;&atilde;o da doen&ccedil;a e fase da apendicite aguda diagno
sticada pelo exame anatomopatol&oacute;gico.    ^cY#v24n1a04.htm##
00731000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049600076002001300572#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#18#14#article#137#<br> <b>RESULTADOS:
 </b>  N&atilde;o houve diferen&ccedil;a estat&iacute;stica significativa entre 
os dois grupos em rela&ccedil;&atilde;o ao tempo de dura&ccedil;&atilde;o da ope
ra&ccedil;&atilde;o, presen&ccedil;a de complica&ccedil;&otilde;es (infec&ccedil
;&atilde;o de ferida operat&oacute;ria, deisc&ecirc;ncia de ferida, forma&ccedil
;&atilde;o de abscessos, obstru&ccedil;&atilde;o intestinal, seroma e forma&cced
il;&atilde;o de f&iacute;stula) ou tempo de interna&ccedil;&atilde;o.    ^cY#v24
n1a04.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014100076002001300217#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#19#15#article#137#<br> <b>CONCLUS&Ati
lde;O:</b>  As duas t&eacute;cnicas s&atilde;o igualmente seguras para tratament
o do coto apendicular.</font></p>     ^cY#v24n1a04.htm##
00491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025600076002001300332#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#20#16#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b>Apendicectomia. 
Apendicite. Procedimentos cir&uacute;rgicos operat&oacute;rios. Ensaio cl&iacute
;nico controlado aleat&oacute;rio. </font></p> <hr size="1" noshade>     ^cY#v24
n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#21#17#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#22#18#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#23#19#article#137#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b> </fo
nt></p>     ^cY#v24n1a04.htm##
00713000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047800076002001300554#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#24#20#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A apendicite aguda &eacute; a doen&c
cedil;a cir&uacute;rgica abdominal de urg&ecirc;ncia mais comum. Estimativas apo
ntam que entre 6,7% e 8,6% das pessoas do mundo ocidental apresentar&atilde;o ap
endicite em algum momento de suas vidas<sup>1,8</sup>. Apesar de milhares de ape
ndicectomias serem realizadas anualmente no mundo, o tratamento do coto apendicu
lar ainda n&atilde;o foi uniformizado. </font></p>     ^cY#v24n1a04.htm##
00783000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054800076002001300624#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#25#21#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Desde as primeiras descri&ccedil;&ot
ilde;es de apendicectomias o coto apendicular foi tratado de maneiras diversas. 
A ligadura simples foi o m&eacute;todo preferencial de tratamento nas primeiras 
opera&ccedil;&otilde;es, at&eacute; surgirem questionamentos sobre sua efic&aacu
te;cia<sup>10</sup>. Alguns autores alertaram para os riscos de soltura da ligad
ura e infec&ccedil;&atilde;o, sugerindo que o coto deveria ser coberto por sutur
a ou sepultado<sup>11</sup>. </font></p>     ^cY#v24n1a04.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#26#22#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na primeira metade do s&eacute;culo 
XX, a ligadura e sepultamento do coto, por meio de sutura em bolsa de tabaco, ga
nhou popularidade sendo defendida por Babcock<sup>4</sup> e Ochsner<sup>17</sup>
, cirurgi&otilde;es renomados na &eacute;poca. Ambos consideravam que a confec&c
cedil;&atilde;o da bolsa era superior por tr&ecirc;s motivos: o coto ligado era 
fonte de contamina&ccedil;&atilde;o na cavidade peritoneal, o fechamento da pare
de intestinal era inadequado com a ligadura simples e existiria risco maior de f
orma&ccedil;&atilde;o de ader&ecirc;ncias ao redor do coto apendicular n&atilde;
o sepultado. </font></p>     ^cY#v24n1a04.htm##
00851000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061600076002001300692#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#27#23#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os primeiros estudos comparativos en
tre as t&eacute;cnicas de ligadura simples e ligadura e sepultamento foram retro
spectivos e mostram superioridade da ligadura simples<sup>11,21,22</sup>. Os est
udos prospectivos randomizados e controlados sobre o tema mostram equival&ecirc;
ncia entre as duas t&eacute;cnicas<sup>3,12,13,23</sup> ou superioridade da liga
dura simples com menor dura&ccedil;&atilde;o da opera&ccedil;&atilde;o<sup>12</s
up> ou menor incid&ecirc;ncia de infec&ccedil;&atilde;o de ferida operat&oacute;
ria<sup>9</sup>. </font></p>     ^cY#v24n1a04.htm##
00875000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064000076002001300716#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#28#24#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Atualmente, o coto apendicular conti
nua sendo tratado, preferencialmente, por duas t&eacute;cnicas: ligadura simples
 e ligadura com sepultamento do coto apendicular<sup>19</sup>. No Hospital J&uac
ute;lia Kubitscheck, com a introdu&ccedil;&atilde;o da cirurgia laparosc&oacute;
pica para tratamento da apendicite aguda o coto apendicular passou a ser tratado
 de duas formas diferentes. Nas apendicectomias laparot&ocirc;micas &eacute; rea
lizada ligadura e sepultamento do coto, enquanto, nas laparosc&oacute;picas, &ea
cute; realizada apenas ligadura simples. </font></p>     ^cY#v24n1a04.htm##
00742000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050700076002001300583#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#29#25#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Este fato motivou a realiza&ccedil;&
atilde;o desta pesquisa com o objetivo de comparar as duas t&eacute;cnicas de tr
atamento do coto apendicular (ligadura simples vs ligadura com confec&ccedil;&at
ilde;o de bolsa de tabaco para sepultamento) por meio de an&aacute;lise prospect
iva e randomizada em rela&ccedil;&atilde;o a morbimortalidade,  dura&ccedil;&ati
lde;o da opera&ccedil;&atilde;o, tempo de interna&ccedil;&atilde;o. </font></p> 
    ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#30#26#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#31#27#article#137#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODO </b></font></p>    
 ^cY#v24n1a04.htm##
01452000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704121700076002001301293#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#32#28#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Entre 2003 e 2005 foram operados 120
 pacientes por apendicite aguda. Os pacientes foram distribu&iacute;dos em dois 
grupos de acordo com o dia da opera&ccedil;&atilde;o. Nos dias pares as apendice
tomias foram realizadas pela t&eacute;cnica de ligadura e sepultamento (ligadura
 do coto, confec&ccedil;&atilde;o de bolsa de tabaco e sepultamento do coto), en
quanto, nos &iacute;mpares foi utilizada a ligadura simples isolada do coto. A s
ele&ccedil;&atilde;o dos pacientes seguiu os seguintes crit&eacute;rios de inclu
s&atilde;o: pacientes com idade entre 13 e 60 anos, submetidos &agrave; apendice
ctomia por apendicite aguda; aceita&ccedil;&atilde;o do paciente e assinatura de
 termo de consentimento livre e esclarecido; confirma&ccedil;&atilde;o operat&oa
cute;ria e anatomopatol&oacute;gica do diagn&oacute;stico de apendicite aguda. O
s crit&eacute;rios de exclus&atilde;o foram: gestantes; pacientes imunodeprimido
s ou portadores de doen&ccedil;as auto-imunes; pacientes em uso de corticoster&o
acute;ides; pacientes portadores de doen&ccedil;as graves complicadas pelo ato a
nest&eacute;sico; uso de laparoscopia diagn&oacute;stica. </font></p>     ^cY#v2
4n1a04.htm##
00612000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037700076002001300453#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#33#29#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Realizou-se estudo piloto com 20 ind
iv&iacute;duos, sendo 10 submetidos a cada t&eacute;cnica cir&uacute;rgica, com 
o objetivo de calcular o tamanho amostral. De acordo com Callegari-Jacques<sup>6
</sup>, se n (tamanho da popula&ccedil;&atilde;o) &eacute; desconhecido, tem-se 
a f&oacute;rmula: </font></p>     ^cY#v24n1a04.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#34#30#article#137#<p align="center"><
img src="/img/revistas/abcd/v24n1/a04form1.jpg"></p>     ^cY#v24n1a04.htm##
00607000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037200076002001300448#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#35#31#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">em que: p=propor&ccedil;&atilde;o de
 complica&ccedil;&otilde;es em cada t&eacute;cnica cir&uacute;rgica, principal v
ari&aacute;vel do estudo; Z</font>&#945;<font size="2" face="Verdana, Arial, Hel
vetica, sans-serif">/2=intervalo de confian&ccedil;a; d= precis&atilde;o, neste 
estudo de 5% </font></p>     ^cY#v24n1a04.htm##
00510000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027500076002001300351#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#36#32#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O c&aacute;lculo amostral indicou o 
n&uacute;mero m&iacute;nimo de 42 indiv&iacute;duos em cada t&eacute;cnica cir&u
acute;rgica o que totalizava 84 indiv&iacute;duos para a amostra final (n). </fo
nt></p>     ^cY#v24n1a04.htm##
00737000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050200076002001300578#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#37#33#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Para an&aacute;lise estat&iacute;sti
ca utilizou-se o programa Epi Info (TM) 3.5.1 e o n&iacute;vel de signific&acirc
;ncia adotado foi p&lt;0,05. Para se comparar as vari&aacute;veis quantitativas 
entre as duas t&eacute;cnicas cir&uacute;rgicas, utilizou-se o teste T-independe
nte de compara&ccedil;&atilde;o de m&eacute;dias. Para avaliar as vari&aacute;ve
is qualitativas utilizou-se o teste de quiquadrado de Pearson. </font></p>     ^
cY#v24n1a04.htm##
00631000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039600076002001300472#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#38#34#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os grupos foram semelhantes em rela&
ccedil;&atilde;o &agrave;s m&eacute;dias de idade, g&ecirc;nero, manifesta&ccedi
l;&otilde;es cl&iacute;nicas (<a href="#tab1">Tabela 1</a>), tempo de evolu&cced
il;&atilde;o da doen&ccedil;a (<a href="#tab2">Tabela 2</a>) e fase da apendicit
e ao exame anatomopatol&oacute;gico. </font></p>     ^cY#v24n1a04.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#39#35#article#137#<p><a name="tab1"><
/a></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#40#36#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#41#37#article#137#<p align="center"><
img src="/img/revistas/abcd/v24n1/a04tab01.jpg"></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#42#38#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#43#39#article#137#<p><a name="tab2"><
/a></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#44#40#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#45#41#article#137#<p align="center"><
img src="/img/revistas/abcd/v24n1/a04tab02.jpg"></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#46#42#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#47#43#article#137#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b> </font></p>     ^c
Y#v24n1a04.htm##
00549000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031400076002001300390#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#48#44#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Dos 120 pacientes operados, sete for
am exclu&iacute;dos do estudo (<a href="#tab3">Tabela 3</a>). Assim sendo, obtev
e-se, para an&aacute;lise, 49 pacientes no grupo ligadura simples e 64 pacientes
 no grupo ligadura e sepultamento. </font></p>     ^cY#v24n1a04.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#49#45#article#137#<p><a name="tab3"><
/a></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#50#46#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#51#47#article#137#<p align="center"><
img src="/img/revistas/abcd/v24n1/a04tab03.jpg"></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#52#48#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022200076002001300298#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#53#49#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os grupos foram semelhantes em relaç
ão   a fase da apendicite, diagnosticada pelo exame   anatomopatológico (<a href
="#tab4">Tabela 4</a>).</font></p>     ^cY#v24n1a04.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#54#50#article#137#<p><a name="tab4"><
/a></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#55#51#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#56#52#article#137#<p align="center"><
img src="/img/revistas/abcd/v24n1/a04tab04.jpg"></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#57#53#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00585000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035000076002001300426#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#58#54#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tempo de duração da operação (<a h
ref="#tab5">Tabela 5</a>) foi,   em média, de 69,8 minutos no grupo ligadura sim
ples   e 75,3 minutos no grupo ligadura e sepultamento. Não   houve diferença es
tatística entre o tempo de internação   entre os dois grupos (p=0,325).</font></
p>     ^cY#v24n1a04.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#59#55#article#137#<p><a name="tab5"><
/a></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#60#56#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#61#57#article#137#<p align="center"><
img src="/img/revistas/abcd/v24n1/a04tab05.jpg"></p>     ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#62#58#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00942000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070700076002001300783#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#63#59#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o ao per&iacu
te;odo p&oacute;s-operat&oacute;rio 15,1% dos pacientes evolu&iacute;ram com com
plica&ccedil;&otilde;es. N&atilde;o houve nenhum &oacute;bito. A complica&ccedil
;&atilde;o mais comum foi infec&ccedil;&atilde;o deferida operat&oacute;ria pres
ente em 9,7% dos casos. As demais complica&ccedil;&otilde;es foram abscesso, f&i
acute;stula &ecirc;ntero-cut&acirc;nea, &iacute;leo prolongado, seroma e choque 
s&eacute;ptico com incid&ecirc;ncia 0,9% cada. N&atilde;o existiu diferen&ccedil
;a estat&iacute;stica significativa na incid&ecirc;ncia de complica&ccedil;&otil
de;es entre os dois grupos. </font></p>     ^cY#v24n1a04.htm##
00657000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042200076002001300498#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#64#60#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tempo de dura&ccedil;&atilde;o de 
interna&ccedil;&atilde;o p&oacute;s-operat&oacute;rio foi, em m&eacute;dia, 1,9 
dias no grupo ligadura simples e 2,4 dias no grupo ligadura e sepultamento. N&at
ilde;o houve diferen&ccedil;a estat&iacute;stica em rela&ccedil;&atilde;o ao tem
po de interna&ccedil;&atilde;o entre os dois grupos (p=0,814). </font></p>     ^
cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#65#61#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#66#62#article#137#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b> </font></p> 
    ^cY#v24n1a04.htm##
01105000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087000076002001300946#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#67#63#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Dos 120 pacientes operados, sete for
am exclu&iacute;dos do estudo. A apendicectomia realizada por outro diagn&oacute
;stico ocorre em cerca de 10,0% dos casos de laparotomia por suspeita de apendic
ite<sup>18</sup>. Apenas um paciente foi operado com diagn&oacute;stico de c&aci
rc;ncer, correspondendo a menos de 1% dos casos. O acometimento do ceco pelo pro
cesso inflamat&oacute;rio da apendicite ocorreu em 2,8% e foi a principal causa 
de exclus&atilde;o de pacientes. Tr&ecirc;s  apresentaram friabilidade e necrose
 do ceco e foram tratados com ileocolectomia segmentar com boa evolu&ccedil;&ati
lde;o. Verifica-se, na literatura, que o acometimento do ceco &eacute; uma condi
&ccedil;&atilde;o frequente e que pode acontecer em at&eacute; 4,8% dos casos de
 apendicite aguda<sup>7</sup>. </font></p>     ^cY#v24n1a04.htm##
00743000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050800076002001300584#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#68#64#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A amostra obtida, 113 pacientes, sup
erou o valor m&iacute;nimo, de 84 pacientes, determinado pelo c&aacute;lculo amo
stral e constitui a maior casu&iacute;stica entre estudos semelhantes no Brasil<
sup>2,3,12</sup>. Este fato ocorreu n&atilde;o s&oacute; pela disponibilidade de
 casos, como tamb&eacute;m pelo baixo percentual de exclus&atilde;o de pacientes
 e aus&ecirc;ncia de perda de pacientes por falta de acompanhamento. </font></p>
     ^cY#v24n1a04.htm##
00629000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039400076002001300470#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#69#65#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os grupos obtidos foram homog&ecirc;
neos em rela&ccedil;&atilde;o &agrave;s caracter&iacute;sticas no per&iacute;odo
 pr&eacute;-operat&oacute;rio e em rela&ccedil;&atilde;o ao resultado do exame a
natomopatol&oacute;gico do ap&ecirc;ndice possibilitando a compara&ccedil;&atild
e;o entre as duas t&eacute;cnicas. </font></p>     ^cY#v24n1a04.htm##
01544000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704130900076002001301385#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#70#66#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tempo operat&oacute;rio foi, em m&
eacute;dia, 5,5 minutos maior nos casos em que foi realizada a ligadura e confec
&ccedil;&atilde;o da bolsa em compara&ccedil;&atilde;o a ligadura simples. Esta 
diferen&ccedil;a, no entanto, n&atilde;o foi significativa levando-se em conta o
 tempo m&eacute;dio das opera&ccedil;&otilde;es, que foram, respectivamente, de 
69,8 minutos para o grupo ligadura simples e 75,3 minutos para o grupo ligadura 
e sepultamento. Todas as opera&ccedil;&otilde;es foram realizadas por m&eacute;d
icos residentes, fato que justifica o tempo operat&oacute;rio mais prolongado. E
m estudo semelhante, por&eacute;m sem detalhamento sobre a equipe cir&uacute;rgi
ca, o tempo operat&oacute;rio mostrou-se significativamente maior na t&eacute;cn
ica de ligadura e sepultamento do coto, com mediana de 40 minutos para ligadura 
simples e 45 minutos para ligadura e sepultamento<sup>7</sup>. Lavonius, et al.<
sup>13</sup> tamb&eacute;m encontraram maior tempo para o grupo de ligadura e se
pultamento, por&eacute;m, neste grupo, as opera&ccedil;&otilde;es foram realizad
as por cirurgi&otilde;es menos experientes e foi realizada sutura do perit&ocirc
;nio, procedimento n&atilde;o realizado no grupo de ligadura simples. </font></p
>     ^cY#v24n1a04.htm##
01702000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704146700076002001301543#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#71#67#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ao acrescentar um tempo cir&uacute;r
gico na apendicectomia (confec&ccedil;&atilde;o da bolsa de tabaco para o sepult
amento do coto) o tempo gasto com este procedimento aumentar&aacute;, obrigatori
amente, o tempo cir&uacute;rgico final. No presente estudo, a diferen&ccedil;a d
e 5,5 minutos entre as duas t&eacute;cnicas n&atilde;o foi significativa do pont
o de vista estat&iacute;stico, provavelmente, pelo fato do tempo operat&oacute;r
io ter sido mais prolongado que o habitual. A m&eacute;dia de tempo observada fo
i superior &agrave; referida em 11 s&eacute;ries, nas quais cirurgi&otilde;es, p
ossivelmente mais experientes, foram os respons&aacute;veis pelas opera&ccedil;&
otilde;es. Nestas, a m&eacute;dia de tempo variou entre 20 (± 12,6) minutos a 66
,9 (± 21,6) minutos<sup>19</sup>. Possivelmente em estudo onde o tempo operat&oa
cute;rio fosse menor, esta vari&aacute;vel poderia se tornar significativa, como
 sugerido em estudo retrospectivo<sup>21</sup> e constatado em estudo prospectiv
o<sup>7</sup>. Al&eacute;m do tempo gasto para confeccionar a bolsa de tabaco e 
o sepultamento do coto, h&aacute; necessidade de se utilizar fio para sutura adi
cional. Apesar de n&atilde;o ter-se inclu&iacute;do esta vari&aacute;vel no estu
do, &eacute; poss&iacute;vel que o consumo de fios de sutura seja maior no grupo
 do sepultamento, com aumento dos custos da opera&ccedil;&atilde;o. </font></p> 
    ^cY#v24n1a04.htm##
00497000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026200076002001300338#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#72#68#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">N&atilde;o houve &oacute;bito no est
udo. A mortalidade ap&oacute;s apendicectomia &eacute; baixa e o resultado encon
trado foi semelhante ao relatado na literatura<sup>2,12</sup>. </font></p>     ^
cY#v24n1a04.htm##
01201000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704096600076002001301042#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#73#69#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A complica&ccedil;&atilde;o mais com
um foi infec&ccedil;&atilde;o de ferida operat&oacute;ria presente em 9,7% dos c
asos. A taxa de infec&ccedil;&atilde;o em trabalhos semelhantes variou entre 3,0
%13 e 18,4%<sup>23</sup>. A maior taxa, do estudo de Watters, et al.<sup>23</sup
>, &eacute; justificada pelo fato de n&atilde;o ter sido utilizada antibioticote
rapia profil&aacute;tica. A menor taxa de infec&ccedil;&atilde;o encontrada, 3,0
%, ocorreu em estudo que n&atilde;o especificou o tempo de evolu&ccedil;&atilde;
o dos sinais e sintomas ou a fase da apendicite aguda<sup>13</sup>, fatores que 
alteram a incid&ecirc;ncia de complica&ccedil;&otilde;es<sup>5,18</sup>. As taxa
s de infec&ccedil;&atilde;o encontradas em outros estudos, que inclu&iacute;ram 
pacientes em todas as fases da apendicite aguda, foram semelhantes &agrave;s obs
ervadas no presente estudo<sup>2,3,7,12</sup>. </font></p>     ^cY#v24n1a04.htm#
#
01345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704111000076002001301186#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#74#70#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O coto apendicular &eacute; consider
ado estrutura contaminada e, segundo os defensores do sepultamento do coto, sua 
presen&ccedil;a na cavidade abdominal aumentaria o risco de infec&ccedil;&atilde
;o<sup>17</sup>. No entanto, os primeiros estudos retrospectivos comparando as t
&eacute;cnicas demonstraram menor incid&ecirc;ncia de infec&ccedil;&atilde;o qua
ndo apenas a ligadura simples foi realizada<sup>11,21</sup>. Este achado n&atild
e;o se repetiu nos estudos prospectivos onde a incid&ecirc;ncia de infec&ccedil;
&atilde;o de ferida foi semelhante entre os dois grupos<sup>3,7,12,12,22,23</sup
>. Acredita-se que esta mudan&ccedil;a ocorreu em decorr&ecirc;ncia do avan&cced
il;o da terapia antimicrobiana e inclus&atilde;o da profilaxia de infec&ccedil;&
atilde;o pr&eacute; operat&oacute;ria. No presente estudo n&atilde;o houve difer
en&ccedil;a significativa na incid&ecirc;ncia de infec&ccedil;&atilde;o de ferid
a operat&oacute;ria entre os dois grupos, corroborando outras pesquisas mais rec
entes<sup>3,12,13,22,23</sup>. </font></p>     ^cY#v24n1a04.htm##
01464000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122900076002001301305#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#75#71#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Abscessos intracavit&aacute;rios s&a
tilde;o complica&ccedil;&otilde;es incomuns das apendicectomias<sup>21</sup>. A 
presen&ccedil;a de abscesso intracavit&aacute;rio, para os defensores do sepulta
mento, seria maior nos casos em que o coto contaminado permanecesse sem invagina
&ccedil;&atilde;o na cavidade abdominal<sup>17</sup>. Em oposi&ccedil;&atilde;o,
 os defensores da ligadura simples defendem que o coto, na cavidade peritoneal, 
entraria em contato com os mecanismos de defesa do perit&ocirc;nio, que seriam c
apazes de impedir a forma&ccedil;&atilde;o de abscessos intraperitoneais. Segund
o esta teoria, os abscessos surgiriam com maior incid&ecirc;ncia nos casos em qu
e o coto fosse sepultado, na parede do ceco, permanecendo isolado da defesa peri
toneal<sup>21</sup>. Encontramos apenas um caso de abscesso intracavit&aacute;ri
o no grupo da ligadura e sepultamento, resultado sem signific&acirc;ncia estat&i
acute;stica (p=0,379). A literatura atual mostra que n&atilde;o h&aacute; difere
n&ccedil;a na incid&ecirc;ncia de abscessos intracavit&aacute;rios ap&oacute;s l
igadura simples ou ligadura e sepultamento do coto<sup>3,12,13</sup>. </font></p
>     ^cY#v24n1a04.htm##
01551000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704131600076002001301392#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#76#72#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A f&iacute;stula enterocut&acirc;nea
, como complica&ccedil;&atilde;o da apendicectomia, pode ocorrer devido ao fecha
mento inadequado da parede intestinal. Apesar de incomum, constitui complica&cce
dil;&atilde;o temida, pois o tratamento pode ser dif&iacute;cil<sup>15</sup>. A 
preocupa&ccedil;&atilde;o de que o fechamento do coto apendicular seria inadequa
do com a ligadura simples foi o principal argumento dos defensores do sepultamen
to ou invers&atilde;o do coto<sup>10,17</sup>. Teoricamente, a ligadura seguida 
do sepultamento por meio da bolsa de tabaco traria seguran&ccedil;a dupla ao fec
hamento da parede intestinal, diminuindo o risco de forma&ccedil;&atilde;o de f&
iacute;stulas<sup>21</sup>. A evid&ecirc;ncia indica, no entanto, que n&atilde;o
 h&aacute; diferen&ccedil;a na incid&ecirc;ncia de f&iacute;stulas entre as t&ea
cute;cnicas de ligadura simples e de sepultamento do coto e que o fechamento do 
coto apendicular por ligadura simples &eacute; adequado<sup>3,12,21</sup>. Neste
 estudo encontrou-se um caso de f&iacute;stula, no grupo ligadura e sepultamento
, que teoricamente seria o mais seguro. Por&eacute;m, este dado n&atilde;o teve 
signific&acirc;ncia estat&iacute;stica (p=0,479), corroborando a literatura. </f
ont></p>     ^cY#v24n1a04.htm##
01712000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704147700076002001301553#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#77#73#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A forma&ccedil;&atilde;o de ader&eci
rc;ncias levando ao &iacute;leo prolongado e obstru&ccedil;&atilde;o intestinal 
s&atilde;o complica&ccedil;&otilde;es raras, cujas manifesta&ccedil;&otilde;es p
odem ocorrer desde os primeiros dias at&eacute; v&aacute;rios anos ap&oacute;s a
 apendicectomia<sup>7</sup>. Teoricamente, o coto apendicular ligado na cavidade
 abdominal seria local prop&iacute;cio para forma&ccedil;&atilde;o de ader&ecirc
;ncias<sup>17,21</sup>. Esta teoria n&atilde;o foi comprovada. Estudos retrospec
tivos, com seguimento dos pacientes at&eacute; cinco anos, demonstram exatamente
 o contr&aacute;rio. Pacientes submetidos &agrave; ligadura e sepultamento apres
entam maior incid&ecirc;ncia de ader&ecirc;ncias e obstru&ccedil;&otilde;es inte
stinais em compara&ccedil;&atilde;o aos submetidos &agrave; ligadura simples<sup
>11,22</sup>. Nos estudos prospectivos, o tempo de seguimento dos pacientes foi,
 no m&aacute;ximo, de um ano, limitando o diagn&oacute;stico das ader&ecirc;ncia
s. Mesmo assim, a ocorr&ecirc;ncia de ader&ecirc;ncias e obstru&ccedil;&atilde;o
 intestinal tamb&eacute;m foi superior no grupo de ligadura e sepultamento no es
tudo de Engstrom &amp; Fenyo<sup>7</sup>. No presente estudo, n&atilde;o houve d
iferen&ccedil;a significativa na incid&ecirc;ncia de &iacute;leo prolongado entr
e os dois grupos, corroborando outros estudos prospectivos<sup>3,12,13</sup>. </
font></p>     ^cY#v24n1a04.htm##
00789000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055400076002001300630#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#78#74#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m das complica&ccedil;&oti
lde;es relatadas, houve um caso de choque s&eacute;ptico e um caso de seroma nos
 grupos ligadura e sepultamento e ligadura simples, respectivamente. Estas compl
ica&ccedil;&otilde;es n&atilde;o apresentaram diferen&ccedil;a estat&iacute;stic
a significante entre os dois grupos, s&atilde;o incomuns ap&oacute;s apendicecto
mias e n&atilde;o foram mencionadas na literatura comparativa entre as duas t&ea
cute;cnicas ora dispon&iacute;vel. </font></p>     ^cY#v24n1a04.htm##
01039000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080400076002001300880#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#79#75#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tempo de interna&ccedil;&atilde;o 
ap&oacute;s a apendicectomia foi, em m&eacute;dia, de 1,9 dias no grupo ligadura
 simples e 2,4 dias no grupo ligadura e sepultamento. N&atilde;o houve diferen&c
cedil;a estat&iacute;stica significativa entre os dois grupos em rela&ccedil;&at
ilde;o ao tempo de interna&ccedil;&atilde;o. Na literatura comparativa, ora disp
on&iacute;vel, o tempo de interna&ccedil;&atilde;o foi maior nos pacientes subme
tidos &agrave; confec&ccedil;&atilde;o da bolsa em rela&ccedil;&atilde;o &agrave
; ligadura simples em apenas um estudo<sup>21</sup>. Nos demais estudos, que inc
lu&iacute;ram esta vari&aacute;vel, os resultados foram semelhantes aos obtidos 
no presente estudo<sup>3,7,12,13,22,23</sup>.</font></p>     ^cY#v24n1a04.htm##
00869000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063400076002001300710#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#80#76#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A confec&ccedil;&atilde;o da bolsa d
e tabaco para sepultamento do coto provoca altera&ccedil;&otilde;es na anatomia 
do ceco. Estas altera&ccedil;&otilde;es podem ser confundidas com neoplasias aos
 exames de imagem induzindo o paciente a ser submetido, desnecessariamente, ao s
tress da d&uacute;vida diagn&oacute;stica e/ou exames invasivos ou mesmo opera&c
cedil;&otilde;es<sup>14,16</sup>. Para evitar esta situa&ccedil;&atilde;o, algun
s autores recomendam a t&eacute;cnica de ligadura simples para o tratamento do c
oto apendicular<sup>7,14,16</sup>. </font></p>     ^cY#v24n1a04.htm##
01221000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704098600076002001301062#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#81#77#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em diversas doen&ccedil;as de tratam
ento cir&uacute;rgico existem as chamadas t&eacute;cnicas cir&uacute;rgicas padr
&atilde;o, que apresentam melhores resultados<sup>20</sup>. O presente estudo mo
strou que as t&eacute;cnicas de ligadura simples e ligadura com sepultamento s&a
tilde;o equivalentes em rela&ccedil;&atilde;o ao tempo de dura&ccedil;&atilde;o 
da opera&ccedil;&atilde;o, incid&ecirc;ncia de complica&ccedil;&otilde;es e temp
o de interna&ccedil;&atilde;o. No entanto, a confec&ccedil;&atilde;o da bolsa de
 tabaco, constitui um tempo cir&uacute;rgico adicional que pode alterar a anatom
ia do ceco, com risco de iatrogenia futura. A t&eacute;cnica da ligadura simples
 &eacute; de execu&ccedil;&atilde;o mais f&aacute;cil e causa menos altera&ccedi
l;&otilde;es na anatomia do ceco, raz&atilde;o pela qual poderia ser considerada
 a t&eacute;cnica preferida para o tratamento do coto apendicular. </font></p>  
   ^cY#v24n1a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#82#78#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#83#79#article#137#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Otilde;ES </b></font></p>
     ^cY#v24n1a04.htm##
00721000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048600076002001300562#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#84#80#article#137#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As t&eacute;cnicas de ligadura simpl
es e ligadura e sepultamento do coto apendicular s&atilde;o equivalentes em rela
&ccedil;&atilde;o ao tempo de dura&ccedil;&atilde;o da opera&ccedil;&atilde;o, m
orbimortalidade e tempo de interna&ccedil;&atilde;o p&oacute;soperat&oacute;rio,
 sendo que a ligadura simples isolada pode ser a preferida pela sua simplicidade
 e maior facilidade de execu&ccedil;&atilde;o. </font></p>     ^cY#v24n1a04.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#85#81#article#137#<p>&nbsp;</p>     ^
cY#v24n1a04.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#86#82#article#137#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b> </font></p>
     ^cY#v24n1a04.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022800078002001300306#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#87#83#article#137#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Addiss DG, Shaffer 
N, Fowler BS, Tauxe RV. The epidemiology of appendicitis and appendectomy in the
 United States. Am J Epidemiol. 1990 Nov;132(5):910-25.    ^cY#v24n1a04.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#88#84#article#137# </font></p>     ^c
Y#v24n1a04.htm##
00579000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033000078002001300408#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#89#85#article#137#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Andrade JI, Hsien 
CT, Martins Junior A, Ceneviva R. Apendicite aguda: estudo prospectivo de 90 cas
os, com especial refer&ecirc;ncia a compara&ccedil;&atilde;o entre duas t&eacute
;cnicas de tratamento do coto apendicular. Rev Col Bras Cir 1989; 16(1): 3-6.   
 ^cY#v24n1a04.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026400078002001300342#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#90#86#article#137#3# </fo
nt></p>  <font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Andrade 
JI, Sandoval EGB, Gomes CAP, Scarpelini S, Seneviva R. Apendicectomia: tratament
o do coto apendicular por ligadura e por sepultamento. Rev Col Bras Cir 1996; 11
(6): 314-9.    ^cY#v24n1a04.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704001700076002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#91#87#article#137# </font>     ^cY#v2
4n1a04.htm##
00429000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018000078002001300258#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#92#88#article#137#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Babcock WW. A Textb
ook of Surgery for Students and Physicians. Philadelphia, WB Saunders Co, 1928; 
214-21.    ^cY#v24n1a04.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#93#89#article#137# </font></p>     ^c
Y#v24n1a04.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019600078002001300274#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#94#90#article#137#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Bergeron E, Richer 
B, Gharib R, Giard A. Appendicitis is a place for clinical judgement. Am J Surg.
 1999 Jun;177(6):460-2.    ^cY#v24n1a04.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021100078002001300289#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#95#91#article#137#6# </fo
nt></p>  <font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Callegar
i-Jacques, S.M. Bioestat&iacute;stica: princ&iacute;pios e aplica&ccedil;&otilde
;es. Artmed, Porto Alegre, 2003. 374p.    ^cY#v24n1a04.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704001700076002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#96#92#article#137# </font>     ^cY#v2
4n1a04.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024500078002001300323#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#97#93#article#137#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. 	Engstr&ouml;m L, F
eny&ouml; G. Appendicectomy: assessment of stump invagination versus simple liga
tion: a prospective, randomized trial. Br J Surg. 1985 Dec;72(12):971-2.    ^cY#
v24n1a04.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#98#94#article#137# </font></p>     ^c
Y#v24n1a04.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025200078002001300330#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#99#95#article#137#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 8. Franzon O, Piccoli
 MC, Neves TT, Volpato MG. Apendicite aguda: an&aacute;lise institucional no man
ejo peri-operat&oacute;rio. ABCD Arq Bras Cir Dig 2009;22(2):72-5 </font></p>   
   ^cY#v24n1a04.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704025800079002001300337#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#100#96#article#137#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Jacobs PP, Koeyers
 GF, Bruyninckx CM. Simple ligation superior to inversion of the appendiceal stu
mp; a prospective randomized study. Ned Tijdschr Geneeskd. 1992 May 23;136(21):1
020-3.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#101#97#article#137# </font></p>      
^cY#v24n1a04.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704019400080002001300274#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#102#98#article#137#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Kelly HA. The ap
pendicitis and other diseases of the vermiform appendix. WB Saunders Company: Ph
iladelphia, 1905. 502p.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#103#99#article#137# </font></p>      
^cY#v24n1a04.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019100081002001300272#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#104#100#article#137#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Kingsley DPE. S
ome observations on appendicectomy with particular reference to technique. Br J 
Surg 1969; 56: 491-6.    ^cY#v24n1a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#105#101#article#137# </font></p>     
 ^cY#v24n1a04.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026300081002001300344#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#106#102#article#137#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Kruel NF, Novel
letto ST, El Haje AA, Franzon O, Susuki H, Andrian AC. Estudo comparativo do tra
tamento do coto apendicular por ligadura e por sepultamento. Rev Bras Cir 1996; 
86(6): 293-6.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#107#103#article#137# </font></p>     
^cY#v24n1a04.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024400081002001300325#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#108#104#article#137#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Lavonius MI, Li
esj&auml;rvi S, Niskanen RO, Ristkari SK, Korkala O, Mokka RE. Simple ligation v
s stump inversion in appendicectomy. Ann Chir Gynaecol 1996; 85(3): 222-4.    ^c
Y#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#109#105#article#137# </font></p>     
^cY#v24n1a04.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019100081002001300272#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#110#106#article#137#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 14. Maier WP, Rose
mond GP. A late complication of inversion of the appendiceal stump. Am J Surg. 1
969 Sep;118(3):467-8.    ^cY#v24n1a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#111#107#article#137# </font></p>     
 ^cY#v24n1a04.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016700081002001300248#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#112#108#article#137#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Maykel JA, Fisc
her JE. Current management of intestinal fistulas. Adv Surg 2003; 37: 283-99.   
 ^cY#v24n1a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#113#109#article#137# </font></p>     
 ^cY#v24n1a04.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022700081002001300308#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#114#110#article#137#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Myll&auml;rniem
i H, Perttala Y, Peltokallio P. Tumor-like lesions of the cecum following invers
ion of the appendix. Am J Dig Dis. 1974 Jun;19(6):547-56.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#115#111#article#137# </font></p>     
^cY#v24n1a04.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#116#112#article#137#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Ochsner A, Lill
y G. The technique of appendicectomy: With particular reference to the treatment
 of the appendiceal stump. Surgery 1937; 2: 532-54.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#117#113#article#137# </font></p>     
^cY#v24n1a04.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#118#114#article#137#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Pittman-Waller 
VA, Myers JG, Stewart RM, Dent DL, Page CP, Gray GA, Pruitt BA Jr, Root HD. Appe
ndicitis: why so complicated? Analysis of 5755 consecutive appendectomies. Am Su
rg. 2000 Jun;66(6):548-54.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#119#115#article#137# </font></p>     
^cY#v24n1a04.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027400081002001300355#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#120#116#article#137#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Sauerland S, Ka
zemier G. Appendix stump closure during laparoscopic appendectomy (Protocol). Co
chrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD006437. DOI: 10
.1002/14651858.CD006437.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#121#117#article#137# </font></p>     
^cY#v24n1a04.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022500081002001300306#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#122#118#article#137#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Seelig MG. The 
Treatment of the Stump in Appendicectomy: Based on a Pathologic and Bacteriologi
c Study of the Appendix. Ann Surg. 1904; 40(5): 710-20.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#123#119#article#137# </font></p>     
^cY#v24n1a04.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018900081002001300270#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#124#120#article#137#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Sinha AP. Appen
dicectomy: an assessment of the advisability of stump invagination. Br J Surg 19
77; 64(7): 499-500.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#125#121#article#137# </font></p>     
^cY#v24n1a04.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022500081002001300306#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#126#122#article#137#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Street D, Bodai
 BI, Owens LJ, Moore DB, Walton CB, Holcroft JW. Simple ligation vs stump invers
ion in appendectomy. Arch Surg. 1988 Jun;123(6):689-90.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#127#123#article#137# </font></p>     
^cY#v24n1a04.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020000081002001300281#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#128#124#article#137#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Watters DA, Wal
ker MA, Abernethy BC. The appendix stump: should it be invaginated? Ann R Coll S
urg Engl. 1984 Mar;66(2):92-3.    ^cY#v24n1a04.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#129#125#article#137#</font></p>      
^cY#v24n1a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#130#126#article#137#<p>&nbsp;</p>    
 ^cY#v24n1a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#131#127#article#137#<p>&nbsp;</p>    
 ^cY#v24n1a04.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019900078002001300277#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#132#128#article#137#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><a href="#note
1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> <b>Correspond&ec
irc;ncia:</b>     ^cY#v24n1a04.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#133#129#article#137#<br>Lauro Jos&eac
ute; Victor Avell&aacute;n Neves    ^cY#v24n1a04.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#134#130#article#137#<br>  e-mail: <a 
href="mailto:elisvania@gmail.com">elisvania@gmail.com</a> </font></p>     ^cY#v2
4n1a04.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012200078002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#135#131#article#137#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 29/09/2010     ^cY#v24n1a04.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#136#132#article#137#<br>Aceito para p
ublica&ccedil;&atilde;o: 21/12/2010     ^cY#v24n1a04.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005600078002001300134#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#137#133#article#137#<br>Fonte de fina
nciamento: n&atilde;o h&aacute;    ^cY#v24n1a04.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006900078002001300147#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#138#134#article#137#<br>Conflito de i
nteresses: n&atilde;o h&aacute; </font></p>     ^cY#v24n1a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#139#135#article#137#<p>&nbsp;</p>    
 ^cY#v24n1a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#140#136#article#137#<p>&nbsp;</p>    
 ^cY#v24n1a04.htm##
00404000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704016700078002001300245#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a04.htm#S#p#141#137#article#137#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Hospital J&u
acute;lia Kubitschek, Belo Horizonte, MG, Brasil. </font></p>     ^cY#v24n1a04.h
tm##
00624000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01700111010001600128012007500144030001500219065000900234064000700243031000400250
032000200254014000700256865000900263002001300272035001000285801001500295#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#142#1#article#23#1#^rND^sAddi
ss^nDG#^rND^sShaffer^nN#^rND^sFowler^nBS#^rND^sTauxe^nRV#The epidemiology of app
endicitis and appendectomy in the United States^len#Am J Epidemiol#19901100#1990
11#132#5#910-25#20110300#v24n1a04.htm#0002-9262#Am J Epidemiol##
00701000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
02400111010001800135012014500153030001700298065000900315064000500324031000300329
032000200332014000400334865000900338002001300347035001000360801001700370#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#143#2#article#23#2#^rND^sAndr
ade^nJI#^rND^sHsien^nCT#^rND^sMartins Junior^nA#^rND^sCeneviva^nR#Apendicite agu
da: estudo prospectivo de 90 casos, com especial referência a comparação entre d
uas técnicas de tratamento do coto apendicular^lpt#Rev Col Bras Cir#19890000#198
9#16#1#3-6#20110300#v24n1a04.htm#0100-6991#Rev Col Bras Cir##
00670000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100020000950100
01700115010002000132010001800152012008300170030001700253065000900270064000500279
03100030028403200020028701400060028986500090029500200130030403500100031780100170
0327#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#144#3#article#23#
3#^rND^sAndrade^nJI#^rND^sSandoval^nEGB#^rND^sGomes^nCAP#^rND^sScarpelini^nS#^rN
D^sSeneviva^nR#Apendicectomia: tratamento do coto apendicular por ligadura e por
 sepultamento^lpt#Rev Col Bras Cir#19960000#1996#11#6#314-9#20110300#v24n1a04.ht
m#0100-6991#Rev Col Bras Cir##
00462000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770180054000950660
01300149062001500162065000900177064000500186014000700191865000900198002001300207
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#145#4#article#23#4#^r
ND^sBabcock^nWW#A Textbook of Surgery for Students and Physicians^len#Philadelph
ia#WB Saunders Co#19280000#1928#214-21#20110300#v24n1a04.htm##
00587000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01600111010001500127012005100142030001000193065000900203064000700212031000400219
032000200223014000600225865000900231002001300240035001000253801001000263#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#146#5#article#23#5#^rND^sBerg
eron^nE#^rND^sRicher^nB#^rND^sGharib^nR#^rND^sGiard^nA#Appendicitis is a place f
or clinical judgement^len#Am J Surg#19990600#199906#177#6#460-2#20110300#v24n1a0
4.htm#0002-9610#Am J Surg##
00437000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160030000770180044001070620
00700151066001300158065000900171064000500180865000900185002001300194#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#147#6#article#23#6#^rND^sCallegar
i-Jacques^nS M.#Bioestatística: princípios e aplicações^lpt#Artmed#Porto Alegre#
20030000#2003#20110300#v24n1a04.htm##
00589000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100015000950120
10900110030001000219065000900229064000700238031000300245032000300248014000600251
865000900257002001300266035001000279801001000289#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a04.htm#S#c#148#7#article#23#7#^rND^sEngström^nL#^rND^sFenyö^nG#A
ppendicectomy: assessment of stump invagination versus simple ligation: a prospe
ctive, randomized trial^len#Br J Surg#19851200#198512#72#12#971-2#20110300#v24n1
a04.htm#0007-1323#Br J Surg##
00588000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01600112010001800128012007000146030002200216710000200238065000900240064000500249
031000300254032000200257014000500259865000900264002001300273#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a04.htm#S#c#149#8#article#23#8#^rND^sFranzon^nO#^rND^
sPiccoli^nMC#^rND^sNeves^nTT#^rND^sVolpato^nMG#Apendicite aguda: análise institu
cional no manejo peri-operatório^lpt#ABCD Arq Bras Cir Dig#2#20090000#2009#22#2#
72-5#20110300#v24n1a04.htm##
00642000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
02100112012009900133030002200232065000900254064000900263031000400272032000300276
014000700279865000900286002001300295035001000308801002200318#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a04.htm#S#c#150#9#article#23#9#^rND^sJacobs^nPP#^rND^
sKoeyers^nGF#^rND^sBruyninckx^nCM#Simple ligation superior to inversion of the a
ppendiceal stump; a prospective randomized study^len#Ned Tijdschr Geneeskd#19920
523#19920523#136#21#1020-3#20110300#v24n1a04.htm#0028-2162#Ned Tijdschr Geneeskd
##
00476000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790180066000950660
02000161062001300181065000900194064000500203014000400208865000900212002001300221
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#151#10#article#23#10#
^rND^sKelly^nHA#The appendicitis and other diseases of the vermiform appendix^le
n#WB Saunders Company#Philadelphia#19050000#1905#502#20110300#v24n1a04.htm##
00519000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790120079000990300
01000178065000900188064000500197031000300202014000600205865000900211002001300220
035001000233801001000243#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S
#c#152#11#article#23#11#^rND^sKingsley^nDPE#Some observations on appendicectomy 
with particular reference to technique^len#Br J Surg#19690000#1969#56#491-6#2011
0300#v24n1a04.htm#0007-1323#Br J Surg##
00695000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100021000950100
01800116010001700134010001600151010001800167012008900185030001300274065000900287
06400050029603100030030103200020030401400060030686500090031200200130032103500100
0334801001300344#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#153#1
2#article#23#12#^rND^sKruel^nNF#^rND^sNovelletto^nST#^rND^sEl Haje^nAA#^rND^sFra
nzon^nO#^rND^sSusuki^nH#^rND^sAndrian^nAC#Estudo comparativo do tratamento do co
to apendicular por ligadura e por sepultamento^lpt#Rev Bras Cir#19960000#1996#86
#6#293-6#20110300#v24n1a04.htm#0034-7124#Rev Bras Cir##
00676000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01900117010001900136010001700155010001600172012005700188030001800245065000900263
06400050027203100030027703200020028001400060028286500090028800200130029703500100
0310801001800320#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#154#1
3#article#23#13#^rND^sLavonius^nMI#^rND^sLiesjärvi^nS#^rND^sNiskanen^nRO#^rND^sR
istkari^nSK#^rND^sKorkala^nO#^rND^sMokka^nRE#Simple ligation vs stump inversion 
in appendicectomy^len#Ann Chir Gynaecol#19960000#1996#85#3#222-4#20110300#v24n1a
04.htm#0355-9521#Ann Chir Gynaecol##
00546000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950120
06200114030001000176065000900186064000700195031000400202032000200206014000600208
865000900214002001300223035001000236801001000246#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a04.htm#S#c#155#14#article#23#14#^rND^sMaier^nWP#^rND^sRosemond^n
GP#A late complication of inversion of the appendiceal stump^len#Am J Surg#19690
900#196909#118#3#467-8#20110300#v24n1a04.htm#0002-9610#Am J Surg##
00512000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960120
04600114030000900160065000900169064000500178031000300183014000700186865000900193
002001300202035001000215801000900225#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a04.htm#S#c#156#15#article#23#15#^rND^sMaykel^nJA#^rND^sFischer^nJE#Current m
anagement of intestinal fistulas^len#Adv Surg#20030000#2003#37#283-99#20110300#v
24n1a04.htm#0065-3411#Adv Surg##
00599000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100018001000100
02100118012007200139030001300211065000900224064000700233031000300240032000200243
014000700245865000900252002001300261035001000274801001300284#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a04.htm#S#c#157#16#article#23#16#^rND^sMyllärniemi^nH
#^rND^sPerttala^nY#^rND^sPeltokallio^nP#Tumor-like lesions of the cecum followin
g inversion of the appendix^len#Am J Dig Dis#19740600#197406#19#6#547-56#2011030
0#v24n1a04.htm#0002-9211#Am J Dig Dis##
00565000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960120
10500111030000800216065000900224064000500233031000200238014000700240865000900247
002001300256035001000269801000800279#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a04.htm#S#c#158#17#article#23#17#^rND^sOchsner^nA#^rND^sLilly^nG#The techniqu
e of appendicectomy: With particular reference to the treatment of the appendice
al stump^len#Surgery#19370000#1937#2#532-54#20110300#v24n1a04.htm#0039-6060#Surg
ery##
00738000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790100016001040100
01800120010001500138010001500153010001500168010002000183010001500203012008200218
03000080030006500090030806400070031703100030032403200020032701400070032986500090
0336002001300345035001000358801000800368#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a04.htm#S#c#159#18#article#23#18#^rND^sPittman-Waller^nVA#^rND^sMyers^nJG
#^rND^sStewart^nRM#^rND^sDent^nDL#^rND^sPage^nCP#^rND^sGray^nGA#^rND^sPruitt Jr^
nBA#^rND^sRoot^nHD#Appendicitis: why so complicated? Analysis of 5755 consecutiv
e appendectomies^len#Am Surg#20000600#200006#66#6#548-54#20110300#v24n1a04.htm#0
003-1348#Am Surg##
00560000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980120
07100117030004000188710000200228065000900230064000500239032000200244237002600246
865000900272002001300281#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S
#c#160#19#article#23#19#^rND^sSauerland^nS#^rND^sKazemier^nG.#Appendix stump clo
sure during laparoscopic appendectomy (Protocol)^len#Cochrane Database of System
atic Reviews#2#20070000#2007#2#10.1002/14651858.CD006437#20110300#v24n1a04.htm##
00562000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120112000960300
00900208065000900217064000500226031000300231032000200234014000700236865000900243
002001300252035001000265801000900275#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a04.htm#S#c#161#20#article#23#20#^rND^sSeelig^nMG#The Treatment of the Stump 
in Appendicectomy: Based on a Pathologic and Bacteriologic Study of the Appendix
^len#Ann Surg#19040000#1904#40#5#710-20#20110300#v24n1a04.htm#0003-4932#Ann Surg
##
00528000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120076000950300
01000171065000900181064000500190031000300195032000200198014000800200865000900208
002001300217035001000230801001000240#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a04.htm#S#c#162#21#article#23#21#^rND^sSinha^nAP#Appendicectomy: an assessmen
t of the advisability of stump invagination^len#Br J Surg#19770000#1977#64#7#499
-500#20110300#v24n1a04.htm#0007-1323#Br J Surg##
00653000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01600111010001600127010001700143010001900160012005500179030001000234065000900244
06400070025303100040026003200020026401400070026686500090027300200130028203500100
0295801001000305#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a04.htm#S#c#163#2
2#article#23#22#^rND^sStreet^nD#^rND^sBodai^nBI#^rND^sOwens^nLJ#^rND^sMoore^nDB#
^rND^sWalton^nCB#^rND^sHolcroft^nJW#Simple ligation vs stump inversion in append
ectomy^len#Arch Surg#19880600#198806#123#6#689-90#20110300#v24n1a04.htm#0004-001
0#Arch Surg##
00586000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
02000114012005000134030002100184065000900205064000700214031000300221032000200224
014000500226865000900231002001300240035001000253801002100263#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a04.htm#S#c#164#23#article#23#23#^rND^sWatters^nDA#^r
ND^sWalker^nMA#^rND^sAbernethy^nBC#The appendix stump: should it be invaginated?
^len#Ann R Coll Surg Engl#19840300#198403#66#2#92-3#20110300#v24n1a04.htm#0035-8
843#Ann R Coll Surg Engl##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#o#1#1#article#1
#20110411#103844#v24n1a05.htm#146##
05130000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000270011203100030013903200020014206500090014401400090015303500100016201200980
01720120102002700100038003720100031004100100033004410100040004740100034005140100
03000548083155000578085001002128085002302138085002302161085003002184085002102214
08500310223508320340226608500100430008500240431008500290433408500200436308500330
43831170008044160720003044241120009044271110011044361140009044471130011044560020
01304467#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#h#2#1#article#1
#oa#pt#br1.1#1#4.0#ILUS#TAB#5#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#2011030
0#^f20^l25#0102-6720#Atividade mioelétrica do intestino delgado de cães submetid
os à oclusão parcial da veia porta^lpt#Myoelectric activity of the small bowel o
f dogs submitted to partial occlusion of the portal vein^len#^rND^nÁlvaro Antôni
o Bandeira^sFerraz#^rND^nJosemberg Marins^sCampos#^rND^nLuis Fernando^sEvangelis
ta#^rND^nAntonio Roberto de Barros^sCoelho#^rND^nJosé Guido de^sAraújo-Filho#^rN
D^nEdmundo Machado^sFerraz#^lpt^aRACIONAL: A oclusão temporária da veia porta ca
usa estase esplâncnica e pode causar dismotilidade intestinal. OBJETIVO: Avaliar
 as alterações da atividade mioelétrica e da histologia do intestino delgado, al
ém da pressão arterial média (PAM), frequência cardíaca (FC), pressão venosa cen
tral (PVC) e pressão portal (PP), na fase de pré-oclusão e de oclusão portal. MÉ
TODO: Realizou-se anestesia geral em seis cães, seguido de monitorização da PAM,
 FC e PVC, laparotomia, aferição da PP, fixação de três pares de eletrodos na pa
rede intestinal, biópsias jejunais e oclusão parcial da veia porta, sendo progra
mado aumento da PP entre 2,5 e 3 vezes. Os eletrodos foram conectados a um micro
computador com software de aquisição para armazenamento e análise da atividade m
ioelétrica, cujo registro ocorreu nos 30 minutos da fase de pré-oclusão e nos 60
 minutos de oclusão. Determinouse a variância e a média do RMS (root mean square
) da atividade mioelétrica. RESULTADOS: Na fase de oclusão, houve diminuição sig
nificativa da média do RMS e aumento da frequência de hemorragia da lâmina própr
ia, sendo proporcional ao tempo de estase.Infiltrado inflamatório, dilatação vas
cular e desprendimento epitelial não apresentaram diferença entre as duas fases.
 Durante a estase, PAM, FC e PVC diminuíram (p=0,326; 0,375 e 0,008; respectivam
ente), e PP aumentou (p=0,015). CONCLUSÃO: A oclusão parcial da veia porta de cã
es promoveu diminuição da atividade mioelétrica e aumento da frequência percentu
al da hemorragia da lâmina própria, além de queda da PVC#^ddecs^i1#^tm^lpt^kVeia
 porta^i1#^tm^lpt^kHistologia^i1#^tm^lpt^kIntestino delgado^i1#^tm^lpt^kCirurgia
^i1#^tm^lpt^kHipertensão portal^i1#^len^aBACKGROUND: Temporary occlusion of the 
portal vein causes splancnic venous stasis and intestinal disfunction, that can 
produce alterations in the motility, and this fact is not vastly known. AIM: To 
evaluate the small bowel myoelectric activity and histology in the six dogs, als
o covering mean arterial blood pressure (AP), pulse rate (PR), central venous pr
essure (CVP) e portal pressure (PP), in two phases: pre-occlusion and occlusion.
 METHODS: It was done general anesthesia, invasive monitorization of the AP, PR 
e CVP, laparotomy, measure of the PP, fixation of the three pairs of electrodes 
in the intestinal wall, jejunal biopsy and parcial occlusion of the portal vein,
 being programmed the increase of the PP between 2.5 and 3 times baseline. Elect
rodes were connected to a computer system that captured electrical signals from 
the intestine. The computer has a software of acquisition to store and analyse t
he myoelectric activity after registering, what happened in 30 minutes of the pr
e-occlusion phase and in 60 minutes of occlusion. The variance and the mean RMS(
root mean square) of the myoeletric activity were determined. The statistical an
alysis was done with Friedman, Dunn, Cochran and Students t tests. RESULTS: Mean
 RMS of myoeletric activity showed significant decrease in the phase of portal o
cclusion, in comparison to preocclusion phase. The frequency of hemorrhage of th
e lamina propria was major during occlusion. It was proportional at stasis time,
 with significant difference between the preocclusion and the occlusion of 60 mi
nutes. Inflammatory infiltration, vascular dilation and epithelial detachment di
d not show any differences between two phases. During the stasis, AP, PR and CVP
 decreased (p=0,326; 0,375 e 0,008, respectively), and PP increased(p=0,015). CO
NCLUSIONS: Parcial occlusion of the portal vein produced reduction of the myoele
tric activity and elevation of the percentage frequency of hemorrhage in lamina 
propria, and a fall of CVP, with relative hemodynamic stabilization.#^ddecs^i2#^
tm^len^kPortal vein^i2#^tm^len^kIntestine, small^i2#^tm^len^kSurgery^i2#^tm^len^
kHypertension, portal^i2#vancouv#13#20101117#17/11/2010#20101221#21/12/2010#v24n
1a05.htm##
05215000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000270011203100030013903200020014206500090014401400090015303500100016201201050
01720120109002770100038003860100031004240100033004550100040004880100034005280100
03000562083158500592085001002177085002302187085002302210085003002233085002102263
08500310228408320700231508500100438508500240439508500290441908500200444808500330
44681170008045010720003045091120009045121110011045211140009045321130011045410020
01304552#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#f#3#1#article#1
#oa#pt#br1.1#1#4.0#ILUS#TAB#5#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#2011030
0#^f20^l25#0102-6720#<b>Atividade mioelétrica do intestino delgado de cães subme
tidos à oclusão parcial da veia porta</b>^lpt#<b>Myoelectric activity of the sma
ll bowel of dogs submitted to partial occlusion of the portal vein</b>^len#^rND^
nÁlvaro Antônio Bandeira^sFerraz#^rND^nJosemberg Marins^sCampos#^rND^nLuis Ferna
ndo^sEvangelista#^rND^nAntonio Roberto de Barros^sCoelho#^rND^nJosé Guido de^sAr
aújo-Filho#^rND^nEdmundo Machado^sFerraz#^lpt^a<b>RACIONAL:</b> A oclusão tempor
ária da veia porta causa estase esplâncnica e pode causar dismotilidade intestin
al. <b>OBJETIVO:</b> Avaliar as alterações da atividade mioelétrica e da histolo
gia do intestino delgado, além da pressão arterial média (PAM), frequência cardí
aca (FC), pressão venosa central (PVC) e pressão portal (PP), na fase de pré-ocl
usão e de oclusão portal. <b>MÉTODO: </b>Realizou-se anestesia geral em seis cãe
s, seguido de monitorização da PAM, FC e PVC, laparotomia, aferição da PP, fixaç
ão de três pares de eletrodos na parede intestinal, biópsias jejunais e oclusão 
parcial da veia porta, sendo programado aumento da PP entre 2,5 e 3 vezes. Os el
etrodos foram conectados a um microcomputador com software de aquisição para arm
azenamento e análise da atividade mioelétrica, cujo registro ocorreu nos 30 minu
tos da fase de pré-oclusão e nos 60 minutos de oclusão. Determinouse a variância
 e a média do RMS (root mean square) da atividade mioelétrica. <b>RESULTADOS:</b
> Na fase de oclusão, houve diminuição significativa da média do RMS e aumento d
a frequência de hemorragia da lâmina própria, sendo proporcional ao tempo de est
ase.Infiltrado inflamatório, dilatação vascular e desprendimento epitelial não a
presentaram diferença entre as duas fases. Durante a estase, PAM, FC e PVC dimin
uíram (p=0,326; 0,375 e 0,008; respectivamente), e PP aumentou (p=0,015). <b>CON
CLUSÃO:</b> A oclusão parcial da veia porta de cães promoveu diminuição da ativi
dade mioelétrica e aumento da frequência percentual da hemorragia da lâmina próp
ria, além de queda da PVC#^ddecs^i1#^tm^lpt^kVeia porta^i1#^tm^lpt^kHistologia^i
1#^tm^lpt^kIntestino delgado^i1#^tm^lpt^kCirurgia^i1#^tm^lpt^kHipertensão portal
^i1#^len^a<b>BACKGROUND: </b>Temporary occlusion of the portal vein causes splan
cnic venous stasis and intestinal disfunction, that can produce alterations in t
he motility, and this fact is not vastly known. <b>AIM: </b>To evaluate the smal
l bowel myoelectric activity and histology in the six dogs, also covering mean a
rterial blood pressure (AP), pulse rate (PR), central venous pressure (CVP) e po
rtal pressure (PP), in two phases: pre-occlusion and occlusion. <b>METHODS: </b>
It was done general anesthesia, invasive monitorization of the AP, PR e CVP, lap
arotomy, measure of the PP, fixation of the three pairs of electrodes in the int
estinal wall, jejunal biopsy and parcial occlusion of the portal vein, being pro
grammed the increase of the PP between 2.5 and 3 times baseline. Electrodes were
 connected to a computer system that captured electrical signals from the intest
ine. The computer has a software of acquisition to store and analyse the myoelec
tric activity after registering, what happened in 30 minutes of the pre-occlusio
n phase and in 60 minutes of occlusion. The variance and the mean RMS(root mean 
square) of the myoeletric activity were determined. The statistical analysis was
 done with Friedman, Dunn, Cochran and Students t tests. <b> RESULTS: </b>Mean R
MS of myoeletric activity showed significant decrease in the phase of portal occ
lusion, in comparison to preocclusion phase. The frequency of hemorrhage of the 
lamina propria was major during occlusion. It was proportional at stasis time, w
ith significant difference between the preocclusion and the occlusion of 60 minu
tes. Inflammatory infiltration, vascular dilation and epithelial detachment did 
not show any differences between two phases. During the stasis, AP, PR and CVP d
ecreased (p=0,326; 0,375 e 0,008, respectively), and PP increased(p=0,015). <b>C
ONCLUSIONS:</b> Parcial occlusion of the portal vein produced reduction of the m
yoeletric activity and elevation of the percentage frequency of hemorrhage in la
mina propria, and a fall of CVP, with relative hemodynamic stabilization.#^ddecs
^i2#^tm^len^kPortal vein^i2#^tm^len^kIntestine, small^i2#^tm^len^kSurgery^i2#^tm
^len^kHypertension, portal^i2#vancouv#13#20101117#17/11/2010#20101221#21/12/2010
#v24n1a05.htm##
05260000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000260013003100030015603200020015906500090016101400090017003500100
01790120098001890120102002870100038003890100031004270100033004580100040004910100
03400531010003000565083155000595085001002145085002302155085002302178085003002201
08500210223108500310225208320340228308500100431708500240432708500290435108500200
43800850033044001170008044330720003044411120009044441110011044531140009044641130
01104473002001304484008008904497#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a
05.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab#5#ABCD060#
nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f20^l25#0102-6720#Atividade mioelétr
ica do intestino delgado de cães submetidos à oclusão parcial da veia porta^lpt#
Myoelectric activity of the small bowel of dogs submitted to partial occlusion o
f the portal vein^len#^rND^nÁlvaro Antônio Bandeira^sFerraz#^rND^nJosemberg Mari
ns^sCampos#^rND^nLuis Fernando^sEvangelista#^rND^nAntonio Roberto de Barros^sCoe
lho#^rND^nJosé Guido de^sAraújo-Filho#^rND^nEdmundo Machado^sFerraz#^lpt^aRACION
AL: A oclusão temporária da veia porta causa estase esplâncnica e pode causar di
smotilidade intestinal. OBJETIVO: Avaliar as alterações da atividade mioelétrica
 e da histologia do intestino delgado, além da pressão arterial média (PAM), fre
quência cardíaca (FC), pressão venosa central (PVC) e pressão portal (PP), na fa
se de pré-oclusão e de oclusão portal. MÉTODO: Realizou-se anestesia geral em se
is cães, seguido de monitorização da PAM, FC e PVC, laparotomia, aferição da PP,
 fixação de três pares de eletrodos na parede intestinal, biópsias jejunais e oc
lusão parcial da veia porta, sendo programado aumento da PP entre 2,5 e 3 vezes.
 Os eletrodos foram conectados a um microcomputador com software de aquisição pa
ra armazenamento e análise da atividade mioelétrica, cujo registro ocorreu nos 3
0 minutos da fase de pré-oclusão e nos 60 minutos de oclusão. Determinouse a var
iância e a média do RMS (root mean square) da atividade mioelétrica. RESULTADOS:
 Na fase de oclusão, houve diminuição significativa da média do RMS e aumento da
 frequência de hemorragia da lâmina própria, sendo proporcional ao tempo de esta
se.Infiltrado inflamatório, dilatação vascular e desprendimento epitelial não ap
resentaram diferença entre as duas fases. Durante a estase, PAM, FC e PVC diminu
íram (p=0,326; 0,375 e 0,008; respectivamente), e PP aumentou (p=0,015). CONCLUS
ÃO: A oclusão parcial da veia porta de cães promoveu diminuição da atividade mio
elétrica e aumento da frequência percentual da hemorragia da lâmina própria, alé
m de queda da PVC#^ddecs^i1#^tm^lpt^kVeia porta^i1#^tm^lpt^kHistologia^i1#^tm^lp
t^kIntestino delgado^i1#^tm^lpt^kCirurgia^i1#^tm^lpt^kHipertensão portal^i1#^len
^aBACKGROUND: Temporary occlusion of the portal vein causes splancnic venous sta
sis and intestinal disfunction, that can produce alterations in the motility, an
d this fact is not vastly known. AIM: To evaluate the small bowel myoelectric ac
tivity and histology in the six dogs, also covering mean arterial blood pressure
 (AP), pulse rate (PR), central venous pressure (CVP) e portal pressure (PP), in
 two phases: pre-occlusion and occlusion. METHODS: It was done general anesthesi
a, invasive monitorization of the AP, PR e CVP, laparotomy, measure of the PP, f
ixation of the three pairs of electrodes in the intestinal wall, jejunal biopsy 
and parcial occlusion of the portal vein, being programmed the increase of the P
P between 2.5 and 3 times baseline. Electrodes were connected to a computer syst
em that captured electrical signals from the intestine. The computer has a softw
are of acquisition to store and analyse the myoelectric activity after registeri
ng, what happened in 30 minutes of the pre-occlusion phase and in 60 minutes of 
occlusion. The variance and the mean RMS(root mean square) of the myoeletric act
ivity were determined. The statistical analysis was done with Friedman, Dunn, Co
chran and Students t tests. RESULTS: Mean RMS of myoeletric activity showed sign
ificant decrease in the phase of portal occlusion, in comparison to preocclusion
 phase. The frequency of hemorrhage of the lamina propria was major during occlu
sion. It was proportional at stasis time, with significant difference between th
e preocclusion and the occlusion of 60 minutes. Inflammatory infiltration, vascu
lar dilation and epithelial detachment did not show any differences between two 
phases. During the stasis, AP, PR and CVP decreased (p=0,326; 0,375 e 0,008, res
pectively), and PP increased(p=0,015). CONCLUSIONS: Parcial occlusion of the por
tal vein produced reduction of the myoeletric activity and elevation of the perc
entage frequency of hemorrhage in lamina propria, and a fall of CVP, with relati
ve hemodynamic stabilization.#^ddecs^i2#^tm^len^kPortal vein^i2#^tm^len^kIntesti
ne, small^i2#^tm^len^kSurgery^i2#^tm^len^kHypertension, portal^i2#vancouv#13#201
01117#17/11/2010#20101221#21/12/2010#v24n1a05.htm#Internet^ihttp://www.scielo.br
/scielo.php?script=sci_arttext&pid=S0102-67202011000100005##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#5#1#article#129#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> <
/font></p>     ^cY#v24n1a05.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#6#2#article#129#<p>&nbsp;</p>     ^cY
#v24n1a05.htm##
00531000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704029800074002001300372#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#7#3#article#129#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a></font><font size=
"4" face="Verdana, Arial, Helvetica, sans-serif"><b>Atividade mioel&eacute;trica
 do intestino delgado de c&atilde;es submetidos &agrave; oclus&atilde;o parcial 
da veia porta</b></font></p>     ^cY#v24n1a05.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#8#4#article#129#<p>&nbsp;</p>     ^cY
#v24n1a05.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#9#5#article#129#<p>&nbsp;</p>     ^cY
#v24n1a05.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704028500075002001300360#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#10#6#article#129#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>&Aacute;lvaro Ant&ocirc;nio Bandei
ra Ferraz; Josemberg Marins Campos; Luis Fernando Evangelista; Antonio Roberto d
e Barros Coelho; Jos&eacute; Guido de Ara&uacute;jo-Filho; Edmundo Machado Ferra
z</b></font></p>     ^cY#v24n1a05.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#11#7#article#129#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a05.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#12#8#article#129#<p>&nbsp;</p>     ^c
Y#v24n1a05.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#13#9#article#129#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a05.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#14#10#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a05.htm##
00443000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020800076002001300284#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#15#11#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL:</b> A oclus&atilde;o te
mpor&aacute;ria da veia porta causa estase espl&acirc;ncnica e pode causar dismo
tilidade intestinal.     ^cY#v24n1a05.htm##
00599000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036400076002001300440#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#16#12#article#129#<br> <b>OBJETIVO:</
b> Avaliar as altera&ccedil;&otilde;es da atividade mioel&eacute;trica e da hist
ologia do intestino delgado, al&eacute;m da press&atilde;o arterial m&eacute;dia
 (PAM), frequ&ecirc;ncia card&iacute;aca (FC), press&atilde;o venosa central (PV
C) e press&atilde;o portal (PP), na fase de pr&eacute;-oclus&atilde;o e de oclus
&atilde;o portal.    ^cY#v24n1a05.htm##
00990000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075500076002001300831#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#17#13#article#129#<br> <b>M&Eacute;TO
DO: </b> Realizou-se anestesia geral em seis c&atilde;es, seguido de monitoriza&
ccedil;&atilde;o da PAM, FC e PVC, laparotomia, aferi&ccedil;&atilde;o da PP, fi
xa&ccedil;&atilde;o de tr&ecirc;s pares de eletrodos na parede intestinal, bi&oa
cute;psias jejunais e oclus&atilde;o parcial da veia porta, sendo programado aum
ento da PP entre 2,5 e 3 vezes. Os eletrodos foram conectados a um microcomputad
or com software de aquisi&ccedil;&atilde;o para armazenamento e an&aacute;lise d
a atividade mioel&eacute;trica, cujo registro ocorreu nos 30 minutos da fase de 
pr&eacute;-oclus&atilde;o e nos 60 minutos de oclus&atilde;o. Determinouse a var
i&acirc;ncia e a m&eacute;dia do RMS (root mean square) da atividade mioel&eacut
e;trica.    ^cY#v24n1a05.htm##
00748000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051300076002001300589#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#18#14#article#129#<br> <b>RESULTADOS:
</b> Na fase de oclus&atilde;o, houve diminui&ccedil;&atilde;o significativa da 
m&eacute;dia do RMS e aumento da frequ&ecirc;ncia de hemorragia da l&acirc;mina 
pr&oacute;pria, sendo proporcional ao tempo de estase.Infiltrado inflamat&oacute
;rio, dilata&ccedil;&atilde;o vascular e desprendimento epitelial n&atilde;o apr
esentaram diferen&ccedil;a entre as duas fases. Durante a estase, PAM, FC e PVC 
diminu&iacute;ram (p=0,326;  0,375 e 0,008; respectivamente), e PP aumentou (p=0
,015).    ^cY#v24n1a05.htm##
00521000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028600076002001300362#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#19#15#article#129#<br>  <b>CONCLUS&At
ilde;O:</b>  A oclus&atilde;o parcial da veia porta de c&atilde;es promoveu dimi
nui&ccedil;&atilde;o da atividade mioel&eacute;trica e aumento da frequ&ecirc;nc
ia percentual da hemorragia da l&acirc;mina pr&oacute;pria, al&eacute;m de queda
 da PVC</font></p>     ^cY#v24n1a05.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020400076002001300280#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#20#16#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b>Veia porta. Hist
ologia. Intestino delgado. Cirurgia. Hipertens&atilde;o portal.</font></p> <hr s
ize="1" noshade>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#21#17#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#22#18#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#23#19#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></fon
t></p>     ^cY#v24n1a05.htm##
00685000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045000076002001300526#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#24#20#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nos &uacute;ltimos anos, vem ocorren
do aumento no n&uacute;mero de opera&ccedil;&otilde;es hep&aacute;ticas de grand
e porte. Hepatectomia extensa e transplante parcial de f&iacute;gado determinam 
eleva&ccedil;&atilde;o da resist&ecirc;ncia ao fluxo portal, em fun&ccedil;&atil
de;o da redu&ccedil;&atilde;o do espa&ccedil;o vascular intra-hep&aacute;tico<su
p>10</sup>.</font></p>     ^cY#v24n1a05.htm##
00711000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047600076002001300552#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#25#21#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Isto resulta em hipertens&atilde;o p
ortal aguda e estase venosa espl&acirc;ncnica, com consequente dist&uacute;rbio 
da fun&ccedil;&atilde;o do intestino delgado, podendo ser uma das causas do &iac
ute;leo paral&iacute;tico p&oacute;s-operat&oacute;rio, o qual decorre da altera
&ccedil;&atilde;o eletrofisiol&oacute;gica intestinal, que ainda n&atilde;o &eac
ute; bem conhecida<sup>8,11,12</sup>.</font></p>     ^cY#v24n1a05.htm##
01086000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085100076002001300927#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#26#22#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Hipertens&atilde;o portal aguda tamb
&eacute;m pode determinar dist&uacute;rbios hemodin&acirc;micos sist&ecirc;micos
, tais como, diminui&ccedil;&atilde;o do retorno venoso e da press&atilde;o arte
rial sist&ecirc;mica - cuja situa&ccedil;&atilde;o pode induzir hipoperfus&atild
e;o espl&acirc;ncnica e consequente altera&ccedil;&atilde;o da histologia da muc
osa - e da motilidade intestinal. Al&eacute;m disso, Moriura et al.<sup>11</sup>
 mostraram redu&ccedil;&atilde;o no d&eacute;bito card&iacute;aco e manuten&cced
il;&atilde;o da press&atilde;o do &aacute;trio esquerdo, indicando aus&ecirc;nci
a de queda no retorno venoso. Assim, os mecanismos das altera&ccedil;&otilde;es 
hemodin&acirc;micas ap&oacute;s oclus&atilde;o parcial da veia porta continuam c
ontroversos.</font></p>     ^cY#v24n1a05.htm##
00725000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049000076002001300566#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#27#23#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Algumas peculiaridades da atividade 
mioel&eacute;trica do intestino delgado, secund&aacute;rias &agrave; estase port
al, ainda n&atilde;o s&atilde;o bem compreendidas e, at&eacute; o momento, n&ati
lde;o h&aacute; estudo experimental, com observa&ccedil;&atilde;o da repercuss&a
tilde;o cardiovascular, que mostre associa&ccedil;&otilde;es com a atividade mio
el&eacute;trica e com aspectos morfol&oacute;gicos.</font></p>     ^cY#v24n1a05.
htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027400076002001300350#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#28#24#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A determina&ccedil;&atilde;o desses 
aspectos poderia contribuir para o melhor entendimento dos dist&uacute;rbios fun
cionais do intestino delgado induzidos por hipertens&atilde;o portal aguda.</fon
t></p>     ^cY#v24n1a05.htm##
00747000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051200076002001300588#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#29#25#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Desta maneira, objetiva-se avaliar a
s altera&ccedil;&otilde;es da atividade mioel&eacute;trica do intestino delgado,
 atrav&eacute;s do seu RMS (root mean square), e da histologia, na fase de pr&ea
cute;-oclus&atilde;o e de oclus&atilde;o portal. Tamb&eacute;m foi mensurada a p
ress&atilde;o arterial m&eacute;dia (PAM), a frequ&ecirc;ncia card&iacute;aca (F
C), a press&atilde;o venosa central (PVC) e a press&atilde;o portal (PP).</font>
</p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#30#26#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#31#27#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>M&Eacute;TODO</b></font></p>    
 ^cY#v24n1a05.htm##
00742000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050700076002001300583#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#32#28#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Seis c&atilde;es adultos mesti&ccedi
l;os foram submetidos &agrave; opera&ccedil;&atilde;o abdominal experimental com
o modelo de hipertens&atilde;o portal aguda. Selecionaram-se sete c&atilde;es se
m enfermidades, sendo cinco machos e duas f&ecirc;meas, com peso entre 14 e 16,5
 kg, havendo exclus&atilde;o de um animal devido &agrave; ocorr&ecirc;ncia de ex
travasamento abdominal de linfa e hipotens&atilde;o arterial severa.</font></p> 
    ^cY#v24n1a05.htm##
01170000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093500076002001301011#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#33#29#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">&Eacute; um estudo experimental cont
rolado e dividido em duas fases, tomando-se a oclus&atilde;o parcial da veia por
ta como o par&acirc;metro de divis&atilde;o entre a fase de pr&eacute;oclus&atil
de;o e de oclus&atilde;o portal, que tiveram dura&ccedil;&atilde;o de 30 e 60 mi
nutos. O momento da oclus&atilde;o portal foi o divisor entre o grupo controle e
 o experimental, os quais estavam presentes em cada animal, em fases diferentes 
ao longo do experimento, que corresponderam, respectivamente, a fase de pr&eacut
e;-oclus&atilde;o e a de oclus&atilde;o portal, de maneira que cada animal era o
 seu pr&oacute;prio controle. A fase de oclus&atilde;o portal foi subdividida em
 tr&ecirc;s etapas a cada 20 minutos para realiza&ccedil;&atilde;o das bi&oacute
;psias jejunais e monitoriza&ccedil;&atilde;o hemodin&acirc;mica (<a href="#fig1
">Figura 1</a>).</font></p>     ^cY#v24n1a05.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#34#30#article#129#<p><a name="fig1"><
/a></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#35#31#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#36#32#article#129#<p align="center"><
img src="/img/revistas/abcd/v24n1/a05fig1.jpg"></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#37#33#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00592000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035700076002001300433#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#38#34#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foi determinado previamente que a oc
lus&atilde;o da veia porta dos c&atilde;es, durante 60 minutos, elevasse a PP a 
n&iacute;veis situados entre 2,5 e 3 vezes em rela&ccedil;&atilde;o aos valores 
basais, medidos antes da oclus&atilde;o portal (<a href="#fig2">Figura 2)</a>.</
font></p>     ^cY#v24n1a05.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#39#35#article#129#<p><a name="fig2"><
/a></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#40#36#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#41#37#article#129#<p align="center"><
img src="/img/revistas/abcd/v24n1/a05fig2.jpg"></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#42#38#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00936000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070100076002001300777#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#43#39#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Inicialmente, ap&oacute;s jejum de 1
2 horas, cada animal foi submetido &agrave; intuba&ccedil;&atilde;o traqueal sob
 indu&ccedil;&atilde;o anest&eacute;sica com tiopental s&oacute;dico, por acesso
 venoso perif&eacute;rico, na dose de 0,08 mg/kg de peso. Na mesma via, administ
rou-se quetamina e cloridrato de pancur&ocirc;nio, na dose de 2 mg/kg, sendo usa
da quetamina na mesma dosagem para manuten&ccedil;&atilde;o anest&eacute;sica (<
a href="#fig1">Figura 1</a>). A hidrata&ccedil;&atilde;o foi mantida com soro fi
siol&oacute;gico a 0,9% na dose de 10 ml/kg/h, sendo infundido durante todo o ex
perimento<sup>4</sup>.</font></p>     ^cY#v24n1a05.htm##
01144000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090900076002001300985#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#44#40#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Antes da opera&ccedil;&atilde;o prop
riamente dita, foram executados os seguintes procedimentos: monitoriza&ccedil;&a
tilde;o cont&iacute;nua do ritmo e da FC atrav&eacute;s de eletrodos na pele, e 
dissec&ccedil;&atilde;o da art&eacute;ria e da veia braquial para aferi&ccedil;&
atilde;o, respectivamente, da PAM e da PVC. Em seguida, realizou-se laparotomia 
para execu&ccedil;&atilde;o dos seguintes procedimentos: dissec&ccedil;&atilde;o
 das veias porta e jejunal, fixa&ccedil;&atilde;o dos eletrodos no jejuno, bi&oa
cute;psias da parede intestinal e oclus&atilde;o parcial da veia porta, na fase 
pr&eacute; e durante a oclus&atilde;o. Objetivando aferir a PP, a dissec&ccedil;
&atilde;o da veia jejunal foi pr&oacute;xima &agrave; veia mesent&eacute;rica cr
anial e ao &acirc;ngulo duodenojejunal (<a href="#fig3">Figura 3</a>).</font></p
>     ^cY#v24n1a05.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#45#41#article#129#<p><a name="fig3"><
/a></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#46#42#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#47#43#article#129#<p align="center"><
img src="/img/revistas/abcd/v24n1/a05fig3.jpg"></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#48#44#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00619000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038400076002001300460#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#49#45#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Para iniciar a fase de oclus&atilde;
o portal, a fita card&iacute;aca envolvendo a veia porta foi tracionada e o tubo
 branco foi fixado com pin&ccedil;a hemost&aacute;tica, at&eacute; aumentar a PP
 ao n&iacute;vel desejado, entre 2,5 e 3 vezes maior do que o valor basal (<a hr
ef="#fig2">Figura 2</a>).</font></p>     ^cY#v24n1a05.htm##
00901000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066600076002001300742#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#50#46#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Para o registro da atividade mioel&e
acute;trica, utilizouse eletrodos bipolares do tipo MP-285-B, Monicrom 2-0, que 
s&atilde;o fios de marca-passo cardiovascular, e t&ecirc;m segmento de 4 cm desc
oberto na extremidade, cuja &aacute;rea foi implantada e fixada com fio de catgu
te 3-0<sup>&reg; </sup>nas camadas mais externas (seromuscular) da parede do jej
uno<sup>5</sup>. Assim, os eletrodos foram posicionados aos pares, iniciando-se 
a 25 cm do &acirc;ngulo duodenojejunal, mantendo dist&acirc;ncia de 15 cm entre 
cada par, resultando na aposi&ccedil;&atilde;o de tr&ecirc;s pares.</font></p>  
   ^cY#v24n1a05.htm##
00959000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072400076002001300800#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#51#47#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A outra extremidade de cada eletrodo
 foi exteriorizada atrav&eacute;s da incis&atilde;o mediana no abdome para ser c
onectada a um amplificador acoplado a um microcomputador contendo sistema de aqu
isi&ccedil;&atilde;o de dados - DATAQ Akron OH, s&eacute;rie 200, que capta freq
u&ecirc;ncias entre 0,02 e 10 Hertz, o qual registrou sinais de atividade mioel&
eacute;trica continuamente durante as duas fases do estudo. Para an&aacute;lise 
espectral da atividade mioel&eacute;trica intestinal, considerou-se a vari&acirc
;ncia e o RMS, que &eacute; capaz de determinar a voltagem efetiva da onda el&ea
cute;trica nos tr&ecirc;s pares de eletrodos.</font></p>     ^cY#v24n1a05.htm##
01029000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079400076002001300870#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#52#48#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nas duas fases do experimento, em ca
da animal, foram realizadas quatro bi&oacute;psias jejunais de aproximadamente 1
,5 cm, totalizando 24 fragmentos retirados dos seis animais; uma bi&oacute;psia 
foi executada no in&iacute;cio da fase de pr&eacute;-oclus&atilde;o portal e tr&
ecirc;s na fase de oclus&atilde;o, sendo uma em cada etapa (<a href="#fig1">Figu
ra 1</a>). Os esp&eacute;cimes foram fixados em formol a 10% seguido de an&aacut
e;lise histol&oacute;gica. Em microscopia &oacute;ptica, foram pesquisadas as se
guintes altera&ccedil;&otilde;es da mucosa: infiltrado inflamat&oacute;rio, dila
ta&ccedil;&atilde;o vascular, hemorragia da l&acirc;mina pr&oacute;pria e despre
ndimento do revestimento epitelial.</font></p>     ^cY#v24n1a05.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025000076002001300326#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#53#49#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foram aplicados os seguintes testes 
estat&iacute;sticos: Friedman, Dunn, t de Student, Cochran, sendo adotado um n&i
acute;vel de signific&acirc;ncia de 5% (p&lt;0,05).</font></p>     ^cY#v24n1a05.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#54#50#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#55#51#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY
#v24n1a05.htm##
01016000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078100076002001300857#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#56#52#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na fase de pr&eacute;-oclus&atilde;o
 portal, a m&eacute;dia do RMS foi igual a 0,5327 mV, havendo redu&ccedil;&atild
e;o estatisticamente significativa (p=0,0022) nos primeiros 20 minutos de oclus&
atilde;o portal. Com 40 e 60 minutos, a m&eacute;dia do RMS continuou em pequena
 queda, mantendo diferen&ccedil;a estatisticamente significativa em rela&ccedil;
&atilde;o &agrave; fase de pr&eacute;oclus&atilde;o portal (p=0,0002 e p=0,0001,
 respectivamente), conforme o teste t de Student. A compara&ccedil;&atilde;o ent
re as tr&ecirc;s etapas da fase de oclus&atilde;o n&atilde;o apresentou diferen&
ccedil;a estatisticamente significativa (<a href="/img/revistas/abcd/v24n1/a05ta
b1.jpg">Tabela 1</a>).</font></p>     ^cY#v24n1a05.htm##
00725000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049000076002001300566#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#57#53#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Dos 24 fragmentos jejunais dos seis 
animais, as an&aacute;lises histol&oacute;gicas identificaram infiltrado inflama
t&oacute;rio em 21 esp&eacute;cimes (21/24 - 87,5%), dilata&ccedil;&atilde;o vas
cular em 23 (23/24 - 95,8%), hemorragia da l&acirc;mina pr&oacute;pria em oito (
8/24 -33,3%) e desprendimento epitelial em tr&ecirc;s (3/24 - 12,5%) (<a href="/
img/revistas/abcd/v24n1/a05tab1.jpg">Tabela 1</a>).</font></p>     ^cY#v24n1a05.
htm##
00986000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075100076002001300827#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#58#54#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Infiltrado inflamat&oacute;rio e dil
ata&ccedil;&atilde;o vascular foram os &uacute;nicos identificados nas duas fase
s do estudo, pois a hemorragia da l&acirc;mina pr&oacute;pria ficou restrita &ag
rave;s tr&ecirc;s etapas da fase de oclus&atilde;o portal, e o desprendimento ep
itelial ocorreu apenas nas etapas com 40 e 60 minutos. Em geral, observou-se aum
ento na frequ&ecirc;ncia percentual de todas as altera&ccedil;&otilde;es histol&
oacute;gicas na fase de oclus&atilde;o portal, de forma proporcional ao tempo de
 estase, especificamente quando se avalia a hemorragia da l&acirc;mina e o despr
endimento (<a href="/img/revistas/abcd/v24n1/a05tab1.jpg">Tabela 1</a>).</font><
/p>     ^cY#v24n1a05.htm##
01090000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085500076002001300931#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#59#55#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Apesar dessa observa&ccedil;&atilde
;o, o teste de Cochran n&atilde;o mostrou diferen&ccedil;a estatisticamente sign
ificativa entre as quatro etapas do estudo, que inclui as duas fases, consideran
do a frequ&ecirc;ncia percentual do infiltrado inflamat&oacute;rio (p=0,500), da
 dilata&ccedil;&atilde;o vascular (p=0,392) e do desprendimento epitelial (p=0,5
00). A hemorragia da l&acirc;mina pr&oacute;pria foi a &uacute;nica a apresentar
 signific&acirc;ncia estat&iacute;stica entre as quatro etapas (p=0,015), especi
ficamente na compara&ccedil;&atilde;o entre a fase de pr&eacute;-oclus&atilde;o 
portal e a etapa de 60 minutos de oclus&atilde;o (p&lt;0,05). Todas as vari&aacu
te;veis est&atilde;o sumarizadas na <a href="/img/revistas/abcd/v24n1/a05tab1.jp
g">Tabela 1</a>.</font></p>     ^cY#v24n1a05.htm##
01056000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082100076002001300897#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#60#56#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na fase de pr&eacute;-oclus&atilde;o
 portal, a PP m&eacute;dia dos seis c&atilde;es foi igual a 8,3 cmH<sub>2</sub>O
, havendo aumento de 2,8 vezes nos primeiros 20 minutos de oclus&atilde;o, que r
esultou na eleva&ccedil;&atilde;o da PP para 23 cmH<sub>2</sub>O, enquanto que o
s demais par&acirc;metros hemodin&acirc;micos (PAM, FC e PVC) apresentaram queda
. Na etapa seguinte, com 40 minutos de oclus&atilde;o portal, a PP e a PAM evolu
&iacute;ram com discreta diminui&ccedil;&atilde;o, enquanto que FC e PVC apresen
taram eleva&ccedil;&atilde;o de diferentes intensidades. Aos 60 minutos de oclus
&atilde;o da veia porta, houve queda de intensidade vari&aacute;vel em todos os 
quatro par&acirc;metros avaliados, sendo mais marcante na PAM.</font></p>     ^c
Y#v24n1a05.htm##
00754000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051900076002001300595#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#61#57#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o isolada da
 PAM evidenciou queda proporcional ao tempo de estase, todavia, o teste de Fried
man mostrou que esse comportamento n&atilde;o apresentou diferen&ccedil;a estati
sticamente significativa entre as quatro etapas do estudo (p=0,326). A FC tamb&e
acute;m diminuiu na fase de oclus&atilde;o, mas n&atilde;o houve signific&acirc;
ncia estat&iacute;stica na compara&ccedil;&atilde;o das quatro etapas (p=0,375).
</font></p>     ^cY#v24n1a05.htm##
01344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110900076002001301185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#62#58#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Houve redu&ccedil;&atilde;o dos n&ia
cute;veis da PVC em intensidade vari&aacute;vel nas tr&ecirc;s etapas da fase de
 oclus&atilde;o portal, em rela&ccedil;&atilde;o &agrave; fase de pr&eacute;-ocl
us&atilde;o, ocorrendo diferen&ccedil;a estatisticamente significativa entre as 
quatro etapas, conforme o teste de Friedman (p=0,015). A PP apresentou evidente 
aumento na fase de oclus&atilde;o portal, havendo diferen&ccedil;a estatisticame
nte significativa entre as quatro etapas, conforme o teste de Friedman (p=0,008)
. Durante a oclus&atilde;o, observou-se discreta queda da PP, de forma proporcio
nal ao tempo, e, devido a isso, o teste de compara&ccedil;&otilde;es m&uacute;lt
iplas de Dunn mostrou que, somente aos 20 minutos de oclus&atilde;o portal, os n
&iacute;veis de PP tenderam a superar os n&iacute;veis na fase de pr&eacute;-ocl
us&atilde;o portal, sendo a diferen&ccedil;a estatisticamente significativa (p&l
t;0,01). Entre as demais etapas, n&atilde;o houve diferen&ccedil;a estatisticame
nte significativa (p&gt;0,05).</font></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#63#59#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#64#60#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>DISCUSS&Atilde;O</b></font></p> 
    ^cY#v24n1a05.htm##
00844000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060900076002001300685#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#65#61#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Apesar da motilidade gastrintestinal
 ser conhecida h&aacute; mais de um s&eacute;culo, somente a partir das &uacute;
ltimas tr&ecirc;s d&eacute;cadas houve maior interesse pelo assunto. Assim, fora
m realizadas in&uacute;meras pesquisas experimentais, enquanto que estudos cl&ia
cute;nicos t&ecirc;m sido executados com menor frequ&ecirc;ncia<sup>1,7,9,13</su
p>, provavelmente devido &agrave; maior necessidade de se respeitar aspectos &ea
cute;ticos e log&iacute;sticos, al&eacute;m da maior probabilidade de ocorrer vi
&eacute;s.</font></p>     ^cY#v24n1a05.htm##
01115000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088000076002001300956#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#66#62#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os poucos estudos experimentais que 
correlacionam motilidade do intestino delgado e hipertens&atilde;o portal enfati
zam as repercuss&otilde;es intestinais cr&ocirc;nicas promovidas pela prolongada
 estase espl&acirc;ncnica, ou ent&atilde;o, utilizam outros m&eacute;todos de an
&aacute;lise, como o tempo de tr&acirc;nsito intestinal com radiois&oacute;topos
, em detrimento da an&aacute;lise da atividade mioel&eacute;trica, cujo meio dia
gn&oacute;stico foi empregado nesta pesquisa, atrav&eacute;s da implanta&ccedil;
&atilde;o de eletrodos na camada serosa do intestino de c&atilde;es<sup>9,13</su
p>. Assim, na literatura, ainda n&atilde;o h&aacute; avalia&ccedil;&atilde;o esp
ec&iacute;fica do comportamento mioel&eacute;trico da fun&ccedil;&atilde;o intes
tinal, resultante da estase portal aguda.</font></p>     ^cY#v24n1a05.htm##
01056000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082100076002001300897#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#67#63#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As duas fases do presente estudo se 
constitu&iacute;ram em vari&aacute;veis determinadas em fun&ccedil;&atilde;o do 
n&iacute;vel da PP, sendo esta uma vari&aacute;vel independente, que foi rigoros
amente controlada durante os experimentos. Com isso, os valores da PP foram dete
rminados pelo pesquisador com o objetivo de tornar as duas fases diferentes entr
e si apenas em rela&ccedil;&atilde;o a esses n&iacute;veis press&oacute;ricos, b
uscando-se a homogeneidade em rela&ccedil;&atilde;o &agrave;s demais vari&aacute
;veis. Na fase de oclus&atilde;o portal, a PP foi aumentada 2,5 a 3 vezes em rel
a&ccedil;&atilde;o ao n&iacute;vel basal, atrav&eacute;s de adequada tra&ccedil;
&atilde;o da fita card&iacute;aca que circundava a veia porta.</font></p>     ^c
Y#v24n1a05.htm##
00943000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070800076002001300784#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#68#64#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Todos os demais par&acirc;metros est
udados se constitu&iacute;am em vari&aacute;veis dependentes, e assim, n&atilde;
o foram controlados pelo pesquisador, sendo apresentados resultados aleat&oacute
;rios em fun&ccedil;&atilde;o da vari&aacute;vel causal, que foi determinada pel
a medida da PP, ou em &uacute;ltima an&aacute;lise, pelas duas fases do estudo. 
Presumidamente, estas fases determinaram os resultados das seguintes vari&aacute
;veis dependentes: m&eacute;dia do RMS, infiltrado inflamat&oacute;rio, dilata&c
cedil;&atilde;o vascular, hemorragia da l&acirc;mina pr&oacute;pria, desprendime
nto epitelial, PAM, FC e PVC.</font></p>     ^cY#v24n1a05.htm##
01129000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089400076002001300970#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#69#65#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os n&iacute;veis da PP foram elevado
s na fase de oclus&atilde;o portal, buscando-se semelhan&ccedil;a com a situa&cc
edil;&atilde;o cl&iacute;nica de hipertens&atilde;o portal aguda, que comumente 
ocorre ap&oacute;s hepatectomia extensa ou transplante parcial de f&iacute;gado,
 nos quais a PP aumenta em torno de duas vezes em rela&ccedil;&atilde;o aos valo
res basais pr&eacute;-operat&oacute;rios<sup>8,11,13</sup>. As aferi&ccedil;&oti
lde;es da PP durante a oclus&atilde;o da veia porta tamb&eacute;m foram guiadas 
pela possibilidade de se desenvolver um modelo de hipertens&atilde;o portal com 
repercuss&otilde;es hemodin&acirc;micas aceit&aacute;veis, o que levou &agrave; 
pequena queda da PAM e da FC, n&atilde;o havendo assim, diferen&ccedil;a estatis
ticamente significativa entre as duas fases observadas.</font></p>     ^cY#v24n1
a05.htm##
00718000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048300076002001300559#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#70#66#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Outro motivo para a escolha de um mo
delo de oclus&atilde;o parcial foi o conhecimento de que o c&atilde;o n&atilde;o
 resiste ao completo clampeamento portal, devido &agrave; escassez de veias cola
terais porto-sist&ecirc;micas, que resultaria em colapso cardiovascular por insu
fici&ecirc;ncia de sangue para a manuten&ccedil;&atilde;o da circula&ccedil;&ati
lde;o sist&ecirc;mica efetiva<sup>2,3</sup>.</font></p>     ^cY#v24n1a05.htm##
00791000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055600076002001300632#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#71#67#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No in&iacute;cio dos experimentos, f
oram levantadas as seguintes hip&oacute;teses: a hipertens&atilde;o portal aguda
, com PP situada entre 2,5 e 3 vezes acima do n&iacute;vel basal; pode promover 
redu&ccedil;&atilde;o na m&eacute;dia do RMS da atividade mioel&eacute;trica do 
intestino delgado de c&atilde;es; possibilitar a ocorr&ecirc;ncia de altera&cced
il;&atilde;o na histologia da mucosa jejunal, em rela&ccedil;&atilde;o ao estado
 de pr&eacute;-oclus&atilde;o portal.</font></p>     ^cY#v24n1a05.htm##
00669000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043400076002001300510#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#72#68#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ao longo do experimento, o grupo con
trole e o experimental estavam presentes no mesmo animal, respectivamente, na fa
se de pr&eacute;-oclus&atilde;o e na fase de oclus&atilde;o portal. Este tipo de
 desenho do estudo reduziu a probabilidade do surgimento de vari&aacute;veis de 
confus&atilde;o, uma vez que cada animal era o seu pr&oacute;prio controle.</fon
t></p>     ^cY#v24n1a05.htm##
00858000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062300076002001300699#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#73#69#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No presente estudo, os tr&ecirc;s pa
res de eletrodos implantados diretamente na camada seromuscular do intestino del
gado foram capazes de detectar pequenas altera&ccedil;&otilde;es na atividade el
&eacute;trica da parede do &oacute;rg&atilde;o, a partir da utiliza&ccedil;&atil
de;o de um amplificador acoplado a um microcomputador contendo um sistema de aqu
isi&ccedil;&atilde;o de dados, que captava frequ&ecirc;ncias entre 0,02 e 10 Her
tz, e registrava sinais de atividade mioel&eacute;trica continuamente durante to
do ato cir&uacute;rgico.</font></p>     ^cY#v24n1a05.htm##
00695000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046000076002001300536#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#74#70#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A principal desvantagem desse m&eacu
te;todo &eacute; a necessidade de laparotomia para o implante de eletrodos, mas,
 no modelo canino utilizado n&atilde;o houve inconveniente devido &agrave; reali
za&ccedil;&atilde;o de opera&ccedil;&atilde;o abdominal para execu&ccedil;&atild
e;o de outro procedimento fundamental ao experimento, que foi a oclus&atilde;o p
arcial da veia porta.</font></p>     ^cY#v24n1a05.htm##
00791000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055600076002001300632#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#75#71#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na pesquisa atual, considerando as d
iversas evid&ecirc;ncias discutidas acima, observou-se a confiabilidade dos m&ea
cute;todos empregados, al&eacute;m de que foram afastadas as possibilidades de i
nterfer&ecirc;ncias externas, sendo assim bastante sugestivo de que o aumento da
 PP seja o principal respons&aacute;vel pelas altera&ccedil;&otilde;es da ativid
ade mioel&eacute;trica, histol&oacute;gicas e hemodin&acirc;micas, cujos resulta
dos ser&atilde;o discutidos a seguir.</font></p>     ^cY#v24n1a05.htm##
00650000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041500076002001300491#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#76#72#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na fase de oclus&atilde;o portal, a 
m&eacute;dia do RMS apresentou redu&ccedil;&atilde;o estatisticamente significat
iva em rela&ccedil;&atilde;o aos n&iacute;veis basais. A compara&ccedil;&atilde;
o das tr&ecirc;s etapas da fase de oclus&atilde;o portal entre si n&atilde;o apr
esentou diferen&ccedil;a estatisticamente significativa.</font></p>     ^cY#v24n
1a05.htm##
00704000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046900076002001300545#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#77#73#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ao contr&aacute;rio dos resultados d
a atual pesquisa, em 1990, Jacobs, et al.<sup>9 </sup>mostraram que n&atilde;o h
ouve altera&ccedil;&atilde;o na motilidade intestinal no modelo de hipertens&ati
lde;o portal cr&ocirc;nica, de acordo com o registro da atividade mioel&eacute;t
rica realizado a partir de eletrodos colocados na camada serosa da al&ccedil;a j
ejunal isolada de c&atilde;es.</font></p>     ^cY#v24n1a05.htm##
00822000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058700076002001300663#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#78#74#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Corroborando com os resultados do es
tudo atual, em 1994, Wang, et al.<sup>13</sup> mostraram aumento do tempo de tr&
acirc;nsito intestinal com uma hora de experimento no grupo submetido &agrave; h
epatectomia. O tempo de tr&acirc;nsito intestinal foi avaliado atrav&eacute;s do
 uso de radiois&oacute;topos, em ratos submetidos &agrave; hepatectomia com 90% 
de ressec&ccedil;&atilde;o do par&ecirc;nquima, e em outro grupo com hipertens&a
tilde;o portal aguda decorrente de estenose calibrada da veia porta.</font></p> 
    ^cY#v24n1a05.htm##
00715000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048000076002001300556#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#79#75#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na pesquisa em discuss&atilde;o, os 
resultados histol&oacute;gicos dos 24 fragmentos jejunais retirados dos seis c&a
tilde;es demonstraram infiltrado inflamat&oacute;rio em 87,5% dos animais, e dil
ata&ccedil;&atilde;o vascular em 95,8%, enquanto que hemorragia da l&acirc;mina 
pr&oacute;pria e desprendimento epitelial ocorreram em menores propor&ccedil;&ot
ilde;es (33,3% e 12,5%, respectivamente).</font></p>     ^cY#v24n1a05.htm##
01281000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104600076002001301122#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#80#76#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Infiltrado inflamat&oacute;rio e dil
ata&ccedil;&atilde;o vascular foram os &uacute;nicos identificados com grande fr
equ&ecirc;ncia percentual na fase de pr&eacute;-oclus&atilde;o portal. Considera
ndo que esta fase representa o estado de normalidade tecidual, esperava-se que t
ais altera&ccedil;&otilde;es ocorressem em menores propor&ccedil;&otilde;es, no 
entanto, a elevada taxa de infiltrado inflamat&oacute;rio foi considerada dentro
 dos limites normais para os padr&otilde;es caninos submetidos &agrave; manipula
&ccedil;&atilde;o intestinal durante laparotomia, uma vez que o intestino delgad
o foi mobilizado para a realiza&ccedil;&atilde;o de monitoriza&ccedil;&atilde;o 
invasiva da PP e para aposi&ccedil;&atilde;o dos eletrodos na parede jejunal. Is
to pode ter causado aumento no n&uacute;mero de c&eacute;lulas inflamat&oacute;r
ias na mucosa intestinal, al&eacute;m da possibilidade de ter ocorrido dilata&cc
edil;&atilde;o vascular em pequena intensidade.</font></p>     ^cY#v24n1a05.htm#
#
00851000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061600076002001300692#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#81#77#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A partir dos primeiros minutos da fa
se de oclus&atilde;o portal, a mucosa apresentava infiltrado inflamat&oacute;rio
 e dilata&ccedil;&atilde;o vascular em maior frequ&ecirc;ncia percentual, em rel
a&ccedil;&atilde;o a fase de pr&eacute;-oclus&atilde;o, chegando a ocorrer em to
dos os casos ap&oacute;s 40 minutos de oclus&atilde;o da veia porta, provavelmen
te, devido ao maior tempo de estase espl&acirc;ncnica. Apesar dessas observa&cce
dil;&otilde;es, n&atilde;o houve diferen&ccedil;a significativa entre as quatro 
etapas avaliadas.</font></p>     ^cY#v24n1a05.htm##
01235000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704100000076002001301076#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#82#78#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">S&eacute;be, et al.<sup>12</sup> est
udaram as altera&ccedil;&otilde;es histopatol&oacute;gicas do intestino delgado 
em tr&ecirc;s grupos de ratos submetidos a oclus&atilde;o total do ped&iacute;cu
lo hep&aacute;tico por 10, 20 e 30 minutos, e tamb&eacute;m observaram que a int
ensidade da congest&atilde;o espl&acirc;ncnica foi proporcional ao tempo de esta
se, enquanto que o grupo controle, n&atilde;o submetido &agrave; oclus&atilde;o 
dos vasos pediculares, apresentou l&acirc;mina pr&oacute;pria t&iacute;pica com 
poucos linf&oacute;citos e plasm&oacute;citos, e sem dilata&ccedil;&atilde;o dos
 vasos sangu&iacute;neos e linf&aacute;ticos. Com 10 minutos de oclus&atilde;o t
otal, os aspectos histol&oacute;gicos estiveram quase normais, havendo apenas in
filtra&ccedil;&atilde;o linfoplasmocit&aacute;ria e dilata&ccedil;&atilde;o vasc
ular leves, as quais se tornaram intensas com 20 minutos de oclus&atilde;o total
.</font></p>     ^cY#v24n1a05.htm##
00700000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046500076002001300541#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#83#79#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na presente pesquisa, dilata&ccedil;
&atilde;o vascular intensa foi diagnosticada a partir de 40 minutos da oclus&ati
lde;o parcial, cuja diferen&ccedil;a de intensidade e frequ&ecirc;ncia entre tai
s estudos, pode ser explicada pelo grau de oclus&atilde;o, uma vez que esta pesq
uisa aplicou estenose e n&atilde;o clampeamento total, como referido por S&eacut
e;be, et al.<sup>12</sup>.</font></p>     ^cY#v24n1a05.htm##
00591000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035600076002001300432#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#84#80#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na literatura, h&aacute; experimento
 sobre oclus&atilde;o parcial da veia porta que mostra edema intersticial e seve
ra dilata&ccedil;&atilde;o dos vasos da mucosa intestinal, o que demonstra conco
rd&acirc;ncia com os achados da investiga&ccedil;&atilde;o atual<sup>6</sup>.</f
ont></p>     ^cY#v24n1a05.htm##
01072000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083700076002001300913#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#85#81#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na pesquisa vigente, a hemorragia da
 l&acirc;mina pr&oacute;pria e o desprendimento epitelial ocorreram apenas duran
te a fase de oclus&atilde;o portal, demonstrando que essas altera&ccedil;&otilde
;es n&atilde;o s&atilde;o encontradas em situa&ccedil;&otilde;es de normalidade,
 estando assim relacionadas &agrave; estase do sistema portal, de forma proporci
onal ao tempo de obstru&ccedil;&atilde;o venosa, principalmente quando se avalia
 isoladamente a hemorragia da l&acirc;mina pr&oacute;pria, pois esta foi a &uacu
te;nica a apresentar signific&acirc;ncia estat&iacute;stica entre as quatro etap
as do estudo, especificamente na compara&ccedil;&atilde;o da fase de pr&eacute;-
oclus&atilde;o portal com a etapa de 60 minutos de oclus&atilde;o (p&lt;0,05).</
font></p>     ^cY#v24n1a05.htm##
00957000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072200076002001300798#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#86#82#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O aumento da PP determina dilata&cce
dil;&atilde;o vascular nas vilosidades da mucosa intestinal, resultando na ruptu
ra dos vasos e na consequente hemorragia na l&acirc;mina pr&oacute;pria. Concomi
tantemente, o processo congestivo determina a perda da ades&atilde;o entre o epi
t&eacute;lio e a l&acirc;mina pr&oacute;pria, que leva ao desprendimento do reve
stimento epitelial, chegando em alguns casos a ocorrer hemorragia para o l&uacut
e;men intestinal. Em geral, de acordo com os resultados deste experimento, a fre
qu&ecirc;ncia e a gravidade das altera&ccedil;&otilde;es histol&oacute;gicas for
am proporcionais ao tempo de estase portal.</font></p>     ^cY#v24n1a05.htm##
00916000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068100076002001300757#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#87#83#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O desprendimento do revestimento epi
telial foi identificado apenas com 40 e 60 minutos de oclus&atilde;o portal, que
 correspondem a est&aacute;gios avan&ccedil;ados da estase venosa espl&acirc;ncn
ica, refletindo assim a gravidade da situa&ccedil;&atilde;o. Conforme Sebe, et a
l.<sup>12</sup>, a hemorragia da l&acirc;mina pr&oacute;pria e o desprendimento 
epitelial de grandes &aacute;reas das vilosidades intestinais dos ratos ocorrera
m com 30 minutos de clampeamento pedicular, cujo momento foi mais precoce do que
 no presente estudo, provavelmente devido &agrave; completa oclus&atilde;o porta
l.</font></p>     ^cY#v24n1a05.htm##
01161000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092600076002001301002#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#88#84#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Durante a fase de oclus&atilde;o por
tal, houve discreta queda da PP, que iniciou com 23 cmH<sub>2</sub>O e terminou 
em 22 cmH<sub>2</sub>O com 60 minutos de oclus&atilde;o, o que reflete a acomoda
&ccedil;&atilde;o que habitualmente ocorre no sistema espl&acirc;ncnico devido &
agrave; complac&ecirc;ncia dos &oacute;rg&atilde;os parenquimatosos envolvidos. 
O ba&ccedil;o &eacute; o principal respons&aacute;vel por esse fen&ocirc;meno, d
evido ao sequestro de sangue portal no seu interior, chegando a apresentar grand
e aumento de volume durante o experimento. Na presente pesquisa, a oclus&atilde;
o da veia porta foi realizada visando avaliar os efeitos da hipertens&atilde;o p
ortal aguda sobre o intestino delgado, do ponto de vista histol&oacute;gico e da
 motilidade, procurando-se afastar a interfer&ecirc;ncia da hipotens&atilde;o ar
terial.</font></p>     ^cY#v24n1a05.htm##
00708000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047300076002001300549#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#89#85#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A oclus&atilde;o parcial da veia por
ta de c&atilde;es promoveu as seguintes altera&ccedil;&otilde;es estatisticament
e significativas: diminui&ccedil;&atilde;o da atividade mioel&eacute;trica do in
testino delgado, hemorragia da l&acirc;mina pr&oacute;pria, a qual foi proporcio
nal ao tempo de estase venosa espl&acirc;ncnica, e diminui&ccedil;&atilde;o da P
VC e eleva&ccedil;&atilde;o da PP.</font></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#90#86#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#91#87#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>  
   ^cY#v24n1a05.htm##
00553000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031800076002001300394#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#92#88#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A oclus&atilde;o parcial da veia por
ta de c&atilde;es promoveu diminui&ccedil;&atilde;o da atividade mioel&eacute;tr
ica e aumento da frequ&ecirc;ncia percentual da hemorragia da l&acirc;mina pr&oa
cute;pria, al&eacute;m de queda da PVC.</font></p>     ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#93#89#article#129#<p>&nbsp;</p>     ^
cY#v24n1a05.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#94#90#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p> 
    ^cY#v24n1a05.htm##
00446000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019700078002001300275#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#95#91#article#129#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Battersby C, Balder
son G, Winch J, Burnett W. Acute occlusion of the portal vein in the calf. J Sur
g Res 1971;11(2):95-100.    ^cY#v24n1a05.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#96#92#article#129#</font></p>     ^cY
#v24n1a05.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019100078002001300269#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#97#93#article#129#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Beach PM, Torres E,
 Litton A, Kundsin R. Acute occlusion of the portal vein in dogs. Surg Gyn Obst 
1965;121(4):761-6.    ^cY#v24n1a05.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#98#94#article#129# </font></p>     ^c
Y#v24n1a05.htm##
00390000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704014100078002001300219#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#99#95#article#129#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Child CG. The porta
l circulation. N Engl J Med 1955;252(20):837-50.    ^cY#v24n1a05.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#100#96#article#129#</font></p>     ^c
Y#v24n1a05.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704022900079002001300308#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#101#97#article#129#4#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Cortopassi SRG. Fl
uidoterapia na anestesia. In Fantoni DT, Cortopassi SRG, ed. Anestesia em c&atil
de;es e gatos. S&atilde;o Paulo: Ed. Roca; 2002;1:109-19.    ^cY#v24n1a05.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#102#98#article#129#</font></p>     ^c
Y#v24n1a05.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704029700079002001300376#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#103#99#article#129#5#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 5. Ferraz AAB, Bacel
ar TS, Santos Jr MA, Vasconcelos HG, Figueiredo FL, Vasconcelos HMC, Ferraz EM. 
Atividade mioel&eacute;trica do c&oacute;lon: Descri&ccedil;&atilde;o de metodol
ogia. Rev Bras Coloproctol 1995;15(3):114-21.    ^cY#v24n1a05.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#104#100#article#129# </font></p>     
^cY#v24n1a05.htm##
00455000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704020400080002001300284#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#105#101#article#129#6#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Granger DN, Barro
wman JA. Microcirculation of the alimentary tract. Pathophysiology of edema. Gas
troenterology 1983;84(5):1035-49.    ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#106#102#article#129#</font></p>     ^
cY#v24n1a05.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704018900080002001300269#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#107#103#article#129#7#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Gullstrand PM, Ve
rnon WB, Bollinger RR. Temporary occlusion of the portal vein in the rat. Trans 
Proc 1986;18:1220.    ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#108#104#article#129#</font></p>     ^
cY#v24n1a05.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704021000080002001300290#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#109#105#article#129#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Heaton N. Small-f
or-size liver syndrome after auxiliary and split liver transplantation: donor se
lection. Liver Transpl 2003;9(9):S26-8.    ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#110#106#article#129#</font></p>     ^
cY#v24n1a05.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704022900080002001300309#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#111#107#article#129#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Jacobs DL, Lof J,
 Quigley EM, Spanta AD, Rikkers LF. The effect of mesenteric venous hypertension
 on gut motility and absorption. J Surg Res 1990;48:562-7.    ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#112#108#article#129#</font></p>     ^
cY#v24n1a05.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#113#109#article#129#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Lee SS, Hadengu
e A, Girod C. Reduction of intrahepatic vascular space in the pathogenesis of po
rtal hypertension. Gastroenterology 1987;93:157-61.    ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#114#110#article#129#</font></p>     ^
cY#v24n1a05.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024800081002001300329#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#115#111#article#129#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Moriura S, Nimu
ra Y, Kato M, Sato T, Shionoya S. Effects of acute portal hypertension by portal
 venous stenosis on systemic hemodynamics in dogs. Eur Surg Res 1990;22:113-9.  
  ^cY#v24n1a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#116#112#article#129#</font></p>     ^
cY#v24n1a05.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023500081002001300316#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#117#113#article#129#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 12. S&eacute;be AA
, 	Nigro AJT, Gomes PO, Sim&otilde;es MJ. Efeitos do clampeamento do ped&iacute;
culo hep&aacute;tico nos intestinos. Acta Cir Bras 2000;15:39-41.    ^cY#v24n1a0
5.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#118#114#article#129#</font></p>     ^
cY#v24n1a05.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031200081002001300393#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#119#115#article#129#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 13. Wang XD, Guo W
D, Wang Q, Andersson R, Ekblad E, Soltesz V. The association between enteric bac
terial overgrowth and gastrointestinal motility after subtotal liver resection o
r portal vein obstruction in rats. Eur J Surg 1994;160:153-60.    ^cY#v24n1a05.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#120#116#article#129#</font></p>     ^
cY#v24n1a05.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#121#117#article#129#<p>&nbsp;</p>    
 ^cY#v24n1a05.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#122#118#article#129#<p>&nbsp;</p>    
 ^cY#v24n1a05.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019800078002001300276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#123#119#article#129#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ec
irc;ncia:</b>    ^cY#v24n1a05.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005600078002001300134#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#124#120#article#129#<br> &Aacute;lvar
o Ant&ocirc;nio Bandeira Ferraz    ^cY#v24n1a05.htm##
00317000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008000078002001300158#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#125#121#article#129#<br>e-mail: <a hr
ef="mailto:aabf@truenet.com.br">aabf@truenet.com.br</a>    ^cY#v24n1a05.htm##
00262000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002500078002001300103#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#126#122#article#129#<br> </font></p> 
    ^cY#v24n1a05.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#127#123#article#129#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publicação: 17/11/20
10    ^cY#v24n1a05.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004700078002001300125#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#128#124#article#129#<br> Aceito para 
publicação: 21/12/2010    ^cY#v24n1a05.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#129#125#article#129#<br> Fonte de fin
anciamento: n&atilde;o h&aacute;    ^cY#v24n1a05.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006900078002001300147#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#130#126#article#129#<br> Conflito de 
interesses: n&atilde;o h&aacute;</font></p>     ^cY#v24n1a05.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#131#127#article#129#<p>&nbsp;</p>    
 ^cY#v24n1a05.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#132#128#article#129#<p>&nbsp;</p>    
 ^cY#v24n1a05.htm##
00493000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704025600078002001300334#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a05.htm#S#p#133#129#article#129#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Laborat&oacu
te;rio do N&uacute;cleo de Cirurgia Experimental do Hospital das Cl&iacute;nicas
 da Universidade Federal de Pernambuco, Recife, PE, Brasil.</font></p>     ^cY#v
24n1a05.htm##
00592000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100019000960100
01500115010001700130012005100147030001100198065000900209064000500218031000300223
032000200226014000700228865000900235002001300244035001000257801001100267#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#c#134#1#article#13#1#^rND^sBatt
ersby^nC#^rND^sBalderson^nG#^rND^sWinch^nJ#^rND^sBurnett^nW#Acute occlusion of t
he portal vein in the calf^len#J Surg Res#19710000#1971#11#2#95-100#20110300#v24
n1a05.htm#0022-4804#J Surg Res##
00555000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109010001700125012004700142030001400189710000200203065000900205064000500214
031000400219032000200223014000600225865000900231002001300240#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a05.htm#S#c#135#2#article#13#2#^rND^sBeach^nPM#^rND^s
Torres^nE#^rND^sLitton^nA#^rND^sKundsin^nR#Acute occlusion of the portal vein in
 dogs^len#Surg Gyn Obst#2#19650000#1965#121#4#761-6#20110300#v24n1a05.htm##
00484000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120027000930300
01300120065000900133064000500142031000400147032000300151014000700154865000900161
002001300170035001000183801001300193#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a05.htm#S#c#136#3#article#13#3#^rND^sChild^nCG#The portal circulation^len#N E
ngl J Med#19550000#1955#252#20#837-50#20110300#v24n1a05.htm#0028-4793#N Engl J M
ed##
00537000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770120031001000160
01800131016002200149018003000171066001000201062000500211065000900216064000500225
014000700230865000900237002001300246#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a05.htm#S#c#137#4#article#13#4#^rND^sCortopassi^nSRG.#Fluidoterapia na aneste
sia^lpt#^rED^sFantoni^nDT#^rED^sCortopassi^nSRG#Anestesia em cães e gatos^lpt#Sã
o Paulo#Roca#20020000#2002#109-19#20110300#v24n1a05.htm##
00686000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
02000113010002200133010002100155010002300176010001700199012006100216030002100277
71000020029806500090030006400050030903100030031403200020031701400070031986500090
0326002001300335#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#c#138#5
#article#13#5#^rND^sFerraz^nAAB#^rND^sBacelar^nTS#^rND^sSantos Jr^nMA#^rND^sVasc
oncelos^nHG#^rND^sFigueiredo^nFL#^rND^sVasconcelos^nHMC#^rND^sFerraz^nEM#Ativida
de mioelétrica do cólon: Descrição de metodologia^lpt#Rev Bras Coloproctol#2#199
50000#1995#15#3#114-21#20110300#v24n1a05.htm##
00569000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100020000950120
07100115030001700186065000900203064000500212031000300217032000200220014000800222
865000900230002001300239035001000252801001700262#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a05.htm#S#c#139#6#article#13#6#^rND^sGranger^nDN#^rND^sBarrowman^
nJA#Microcirculation of the alimentary tract: Pathophysiology of edema^len#Gastr
oenterology#19830000#1983#84#5#1035-49#20110300#v24n1a05.htm#0016-5085#Gastroent
erology##
00524000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100017000980100
02000115012005400135030001100189710000200200065000900202064000500211031000300216
014000500219865000900224002001300233#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a05.htm#S#c#140#7#article#13#7#^rND^sGullstrand^nPM#^rND^sVernon^nWB#^rND^sBo
llinger^nRR#Temporary occlusion of the portal vein in the rat^len#Trans Proc#2#1
9860000#1986#18#1220#20110300#v24n1a05.htm##
00520000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120099000930300
01400192710000200206065000900208064000500217031000200222032000200224014000600226
865000900232002001300241#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S
#c#141#8#article#13#8#^rND^sHeaton^nN#Small-for-size liver syndrome after auxili
ary and split liver transplantation: donor selection^len#Liver Transpl#2#2003000
0#2003#9#9#S26-8#20110300#v24n1a05.htm##
00631000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100013000940100
01800107010001700125010001800142012008000160030001100240065000900251064000500260
031000300265014000600268865000900274002001300283035001000296801001100306#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#c#142#9#article#13#9#^rND^sJaco
bs^nDL#^rND^sLof^nJ#^rND^sQuigley^nEM#^rND^sSpanta^nAD#^rND^sRikkers^nLF#The eff
ect of mesenteric venous hypertension on gut motility and absorption^len#J Surg 
Res#19900000#1990#48#562-7#20110300#v24n1a05.htm#0022-4804#J Surg Res##
00594000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100018000930100
01500111012008800126030001700214065000900231064000500240031000300245014000700248
865000900255002001300264035001000277801001700287#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a05.htm#S#c#143#10#article#13#10#^rND^sLee^nSS#^rND^sHadengue^nA#
^rND^sGirod^nC#Reduction of intrahepatic vascular space in the pathogenesis of p
ortal hypertension^len#Gastroenterology#19870000#1987#93#157-61#20110300#v24n1a0
5.htm#0016-5085#Gastroenterology##
00653000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01400112010001400126010001800140012010000158030001300258065000900271064000500280
031000300285014000600288865000900294002001300303035001000316801001300326#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#c#144#11#article#13#11#^rND^sMo
riura^nS#^rND^sNimura^nY#^rND^sKato^nM#^rND^sSato^nT#^rND^sShionoya^nS#Effects o
f acute portal hypertension by portal venous stenosis on systemic hemodynamics i
n dogs^len#Eur Surg Res#19900000#1990#22#113-9#20110300#v24n1a05.htm#0014-312X#E
ur Surg Res##
00559000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01600111010001700127012006400144030001400208710000200222065000900224064000500233
031000300238014000600241865000900247002001300256#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a05.htm#S#c#145#12#article#13#12#^rND^sSébe^nAA#^rND^sNigro^nAJT#
^rND^sGomes^nPO#^rND^sSimões^nMJ#Efeitos do clampeamento do pedículo hepático no
s intestinos^lpt#Acta Cir Bras#2#20000000#2000#15#39-41#20110300#v24n1a05.htm##
00732000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01400108010001900122010001600141010001700157012015300174030001100327065000900338
06400050034703100040035201400070035686500090036300200130037203500100038580100110
0395#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a05.htm#S#c#146#13#article#13
#13#^rND^sWang^nXD#^rND^sGuo^nWD#^rND^sWang^nQ#^rND^sAndersson^nR#^rND^sEkblad^n
E#^rND^sSoltesz^nV#The association between enteric bacterial overgrowth and gast
rointestinal motility after subtotal liver resection or portal vein obstruction 
in rats^len#Eur J Surg#19940000#1994#160#153-60#20110300#v24n1a05.htm#1102-4151#
Eur J Surg##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#o#1#1#article#1
#20110411#103846#v24n1a06.htm#122##
04107000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000270011203100030013903200020014206500090014401400090015303500100016201200370
01720120032002090100021002410100022002620100032002840100034003160100043003500831
51800393085001001911085002501921085002901946083142701975085001003402085002603412
08500270343811700080346507200030347311200090347611100110348511400090349611300110
3505002001303516#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#h#2#1#a
rticle#1#oa#pt#br1.1#1#4.0#ILUS#TAB#6#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1
#20110300#^f26^l29#0102-6720#Endometrioma de parede abdominal^lpt#Abdominal wall
 endometrioma^len#^rND^nItalo^sAccetta#^rND^nPietro^sAccetta#^rND^nAndré Figueir
edo^sAccetta#^rND^nFrancisco José Santos^sMaia#^rND^nAna Paula Félix de Andrade^
sOliveira#^lpt^aRACIONAL: A incidência exata da endometriose na população geral 
é desconhecida. A confirmação desta doença só é possível através da análise hist
opatológica de um fragmento obtido por algum procedimento invasivo, pois não exi
ste até o momento, nenhum marcador clínico seguro. OBJETIVO: Relatar a experiênc
ia com as manifestações clínicas e o tratamento cirúrgico em pacientes com endom
etrioma de parede abdominal. MÉTODO: Análise retrospectiva das pacientes operada
s por endometrioma de parede abdominal, dando ênfase aos dados relativos à idade
, sintomas, cesariana prévia, relação dos sintomas com o ciclo menstrual, exames
 físicos e complementares, tratamento cirúrgico, evolução pósoperatória e result
ado histopatológico dos espécimes. RESULTADOS: Foram operadas 14 pacientes no pe
ríodo estudado, com idade entre 28 e 40 anos. A presença de massa e dor local qu
e piorava durante a menstruação foram as queixas principais. Ultrassonografia e 
tomografia computadorizada foram exames importantes em localizar precisamente a 
doença. O tratamento cirúrgico foi exérese ampla da tumoração e dos tecidos comp
rometidos. As pacientes evoluíram satisfatoriamente e o histopatológico confirmo
u a suspeita de endometrioma de parede abdominal em todos os casos. CONCLUSÂO: F
oi nítida a relação entre cesariana prévia e endometrioma de parede abdominal e 
estudos ultrassonográficos e tomográficos auxiliaram a planejar a abordagem cirú
rgica permitindo a exérese da tumoração e de todos os tecidos adjacentes comprom
etidos.#^ddecs^i1#^tm^lpt^kEndometriose^i1#^tm^lpt^kParede abdominal^i1#^len^aBA
CKGROND: The exact incidence of endometriosis in the general population is unkno
wn. Confirmation of this disease is only possible by histopathological analysis 
of a fragment obtained by some invasive procedure, because there is so far, no c
linical secure marker. AIM: To report the experience with the clinical manifesta
tions and surgical treatment in patients with abdominal wall endometrioma. METHO
DS: Retrospective analysis of patients operated for abdominal wall endometrioma 
with emphasis on data relating to age, symptoms, previous cesarean, relation of 
symptoms with the menstrual cycle, physical examinations and additional surgical
 treatment, postoperative course and histopathological results of specimens. RES
ULTS: Forteen patients were operated during the study period, aged between 28 an
d 40 years. The presence of local mass and pain that worsened during menstruatio
n were the main complaints. Ultrasound and CT examinations were important to pre
cisely localize the disease. Surgical excision was a wide excision of the tumor 
and affected tissues. The patient progressed satisfactorily and histopathology c
onfirmed the diagnosis of abdominal wall endometrioma in all cases. CONCLUSION: 
Exists a clear relationship between cesarean operation and abdominal wall endome
trioma; ultrasound studies and CT scans help to plan the surgical resection allo
wing resection of tumor and all affected adjacent tissues.#^ddecs^i2#^tm^len^kEn
dometriosis^i2#^tm^len^kAbdominal wall^i2#vancouv#15#20101013#13/10/2010#2010122
1#21/12/2010#v24n1a06.htm##
04191000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000270011203100030013903200020014206500090014401400090015303500100016201200440
01720120039002160100021002550100022002760100032002980100034003300100043003640831
55300407085001001960085002501970085002901995083146202024085001003486085002603496
08500270352211700080354907200030355711200090356011100110356911400090358011300110
3589002001303600#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#f#3#1#a
rticle#1#oa#pt#br1.1#1#4.0#ILUS#TAB#6#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1
#20110300#^f26^l29#0102-6720#<b>Endometrioma de parede abdominal</b>^lpt#<b>Abdo
minal wall endometrioma</b>^len#^rND^nItalo^sAccetta#^rND^nPietro^sAccetta#^rND^
nAndré Figueiredo^sAccetta#^rND^nFrancisco José Santos^sMaia#^rND^nAna Paula Fél
ix de Andrade^sOliveira#^lpt^a<b>RACIONAL: </b>A incidência exata da endometrios
e na população geral é desconhecida. A confirmação desta doença só é possível at
ravés da análise histopatológica de um fragmento obtido por algum procedimento i
nvasivo, pois não existe até o momento, nenhum marcador clínico seguro. <b>OBJET
IVO:</b> Relatar a experiência com as manifestações clínicas e o tratamento cirú
rgico em pacientes com endometrioma de parede abdominal. <b>MÉTODO:</b> Análise 
retrospectiva das pacientes operadas por endometrioma de parede abdominal, dando
 ênfase aos dados relativos à idade, sintomas, cesariana prévia, relação dos sin
tomas com o ciclo menstrual, exames físicos e complementares, tratamento cirúrgi
co, evolução pósoperatória e resultado histopatológico dos espécimes. <b>RESULTA
DOS:</b> Foram operadas 14 pacientes no período estudado, com idade entre 28 e 4
0 anos. A presença de massa e dor local que piorava durante a menstruação foram 
as queixas principais. Ultrassonografia e tomografia computadorizada foram exame
s importantes em localizar precisamente a doença. O tratamento cirúrgico foi exé
rese ampla da tumoração e dos tecidos comprometidos. As pacientes evoluíram sati
sfatoriamente e o histopatológico confirmou a suspeita de endometrioma de parede
 abdominal em todos os casos. <b>CONCLUSÂO:</b> Foi nítida a relação entre cesar
iana prévia e endometrioma de parede abdominal e estudos ultrassonográficos e to
mográficos auxiliaram a planejar a abordagem cirúrgica permitindo a exérese da t
umoração e de todos os tecidos adjacentes comprometidos.#^ddecs^i1#^tm^lpt^kEndo
metriose^i1#^tm^lpt^kParede abdominal^i1#^len^a<b>BACKGROND:</b> The exact incid
ence of endometriosis in the general population is unknown. Confirmation of this
 disease is only possible by histopathological analysis of a fragment obtained b
y some invasive procedure, because there is so far, no clinical secure marker. <
b>AIM:</b> To report the experience with the clinical manifestations and surgica
l treatment in patients with abdominal wall endometrioma. <b>METHODS: </b>Retros
pective analysis of patients operated for abdominal wall endometrioma with empha
sis on data relating to age, symptoms, previous cesarean, relation of symptoms w
ith the menstrual cycle, physical examinations and additional surgical treatment
, postoperative course and histopathological results of specimens. <b>RESULTS:</
b> Forteen patients were operated during the study period, aged between 28 and 4
0 years. The presence of local mass and pain that worsened during menstruation w
ere the main complaints. Ultrasound and CT examinations were important to precis
ely localize the disease. Surgical excision was a wide excision of the tumor and
 affected tissues. The patient progressed satisfactorily and histopathology conf
irmed the diagnosis of abdominal wall endometrioma in all cases. <b>CONCLUSION:<
/b> Exists a clear relationship between cesarean operation and abdominal wall en
dometrioma; ultrasound studies and CT scans help to plan the surgical resection 
allowing resection of tumor and all affected adjacent tissues.#^ddecs^i2#^tm^len
^kEndometriosis^i2#^tm^len^kAbdominal wall^i2#vancouv#15#20101013#13/10/2010#201
01221#21/12/2010#v24n1a06.htm##
04237000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000260013003100030015603200020015906500090016101400090017003500100
01790120037001890120032002260100021002580100022002790100032003010100034003330100
04300367083151800410085001001928085002501938085002901963083142701992085001003419
08500260342908500270345511700080348207200030349011200090349311100110350211400090
3513113001103522002001303533008008903546#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a06.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab#6#
ABCD060#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f26^l29#0102-6720#Endometrio
ma de parede abdominal^lpt#Abdominal wall endometrioma^len#^rND^nItalo^sAccetta#
^rND^nPietro^sAccetta#^rND^nAndré Figueiredo^sAccetta#^rND^nFrancisco José Santo
s^sMaia#^rND^nAna Paula Félix de Andrade^sOliveira#^lpt^aRACIONAL: A incidência 
exata da endometriose na população geral é desconhecida. A confirmação desta doe
nça só é possível através da análise histopatológica de um fragmento obtido por 
algum procedimento invasivo, pois não existe até o momento, nenhum marcador clín
ico seguro. OBJETIVO: Relatar a experiência com as manifestações clínicas e o tr
atamento cirúrgico em pacientes com endometrioma de parede abdominal. MÉTODO: An
álise retrospectiva das pacientes operadas por endometrioma de parede abdominal,
 dando ênfase aos dados relativos à idade, sintomas, cesariana prévia, relação d
os sintomas com o ciclo menstrual, exames físicos e complementares, tratamento c
irúrgico, evolução pósoperatória e resultado histopatológico dos espécimes. RESU
LTADOS: Foram operadas 14 pacientes no período estudado, com idade entre 28 e 40
 anos. A presença de massa e dor local que piorava durante a menstruação foram a
s queixas principais. Ultrassonografia e tomografia computadorizada foram exames
 importantes em localizar precisamente a doença. O tratamento cirúrgico foi exér
ese ampla da tumoração e dos tecidos comprometidos. As pacientes evoluíram satis
fatoriamente e o histopatológico confirmou a suspeita de endometrioma de parede 
abdominal em todos os casos. CONCLUSÂO: Foi nítida a relação entre cesariana pré
via e endometrioma de parede abdominal e estudos ultrassonográficos e tomográfic
os auxiliaram a planejar a abordagem cirúrgica permitindo a exérese da tumoração
 e de todos os tecidos adjacentes comprometidos.#^ddecs^i1#^tm^lpt^kEndometriose
^i1#^tm^lpt^kParede abdominal^i1#^len^aBACKGROND: The exact incidence of endomet
riosis in the general population is unknown. Confirmation of this disease is onl
y possible by histopathological analysis of a fragment obtained by some invasive
 procedure, because there is so far, no clinical secure marker. AIM: To report t
he experience with the clinical manifestations and surgical treatment in patient
s with abdominal wall endometrioma. METHODS: Retrospective analysis of patients 
operated for abdominal wall endometrioma with emphasis on data relating to age, 
symptoms, previous cesarean, relation of symptoms with the menstrual cycle, phys
ical examinations and additional surgical treatment, postoperative course and hi
stopathological results of specimens. RESULTS: Forteen patients were operated du
ring the study period, aged between 28 and 40 years. The presence of local mass 
and pain that worsened during menstruation were the main complaints. Ultrasound 
and CT examinations were important to precisely localize the disease. Surgical e
xcision was a wide excision of the tumor and affected tissues. The patient progr
essed satisfactorily and histopathology confirmed the diagnosis of abdominal wal
l endometrioma in all cases. CONCLUSION: Exists a clear relationship between ces
arean operation and abdominal wall endometrioma; ultrasound studies and CT scans
 help to plan the surgical resection allowing resection of tumor and all affecte
d adjacent tissues.#^ddecs^i2#^tm^len^kEndometriosis^i2#^tm^len^kAbdominal wall^
i2#vancouv#15#20101013#13/10/2010#20101221#21/12/2010#v24n1a06.htm#Internet^ihtt
p://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202011000100006##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011900074002001300193#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#5#1#article#103#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b></
font></p>     ^cY#v24n1a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#6#2#article#103#<p>&nbsp;</p>     ^cY
#v24n1a06.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704014300074002001300217#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#7#3#article#103#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Endometrioma de
 parede abdominal </b></font></p>     ^cY#v24n1a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#8#4#article#103#<p>&nbsp;</p>     ^cY
#v24n1a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#9#5#article#103#<p>&nbsp;</p>     ^cY
#v24n1a06.htm##
00465000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704023100075002001300306#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#10#6#article#103#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Italo Accetta; Pietro Accetta; And
r&eacute; Figueiredo Accetta; Francisco Jos&eacute; Santos Maia; Ana Paula F&eac
ute;lix de Andrade Oliveira</b></font></p>     ^cY#v24n1a06.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#11#7#article#103#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#12#8#article#103#<p>&nbsp;</p>     ^c
Y#v24n1a06.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#13#9#article#103#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a06.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#14#10#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b> </font></p>     ^cY#v2
4n1a06.htm##
00702000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046700076002001300543#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#15#11#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">   <b>RACIONAL: </b>A incid&ecirc;nc
ia exata da endometriose na popula&ccedil;&atilde;o geral &eacute; desconhecida.
 A confirma&ccedil;&atilde;o desta doen&ccedil;a s&oacute; &eacute; poss&iacute;
vel atrav&eacute;s da an&aacute;lise histopatol&oacute;gica de um fragmento obti
do por algum procedimento invasivo, pois n&atilde;o existe at&eacute; o momento,
 nenhum marcador cl&iacute;nico seguro.     ^cY#v24n1a06.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019300076002001300269#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#16#12#article#103#<br>   <b>OBJETIVO:
</b> Relatar a experi&ecirc;ncia com as manifesta&ccedil;&otilde;es cl&iacute;ni
cas e o tratamento cir&uacute;rgico em pacientes com endometrioma de parede abdo
minal.    ^cY#v24n1a06.htm##
00688000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045300076002001300529#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#17#13#article#103#<br>    <b>M&Eacute
;TODO:</b> An&aacute;lise retrospectiva das pacientes operadas por endometrioma 
de parede abdominal, dando &ecirc;nfase aos dados relativos &agrave; idade, sint
omas, cesariana pr&eacute;via, rela&ccedil;&atilde;o dos sintomas com o ciclo me
nstrual, exames f&iacute;sicos e complementares, tratamento cir&uacute;rgico, ev
olu&ccedil;&atilde;o p&oacute;soperat&oacute;ria e resultado histopatol&oacute;g
ico dos esp&eacute;cimes.     ^cY#v24n1a06.htm##
00846000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061100076002001300687#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#18#14#article#103#<br>   <b>RESULTADO
S:</b> Foram operadas 14 pacientes no per&iacute;odo estudado, com idade entre 2
8 e 40 anos. A presen&ccedil;a de massa e dor local que piorava durante a menstr
ua&ccedil;&atilde;o foram as queixas principais. Ultrassonografia e tomografia c
omputadorizada foram exames importantes em localizar precisamente a doen&ccedil;
a. O tratamento cir&uacute;rgico foi ex&eacute;rese ampla da tumora&ccedil;&atil
de;o e dos tecidos comprometidos. As pacientes evolu&iacute;ram satisfatoriament
e e o histopatol&oacute;gico confirmou a suspeita de endometrioma de parede abdo
minal em todos os casos.    ^cY#v24n1a06.htm##
00609000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037400076002001300450#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#19#15#article#103#<br>   <b>CONCLUS&A
circ;O:</b> Foi n&iacute;tida a rela&ccedil;&atilde;o entre cesariana pr&eacute;
via e  endometrioma de parede abdominal e estudos ultrassonogr&aacute;ficos e to
mogr&aacute;ficos    auxiliaram a planejar a abordagem cir&uacute;rgica permitin
do a ex&eacute;rese da tumora&ccedil;&atilde;o e de todos os tecidos adjacentes 
comprometidos. </font></p>     ^cY#v24n1a06.htm##
00459000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022400076002001300300#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#20#16#article#103#<p><b><font size="2
" face="Verdana, Arial, Helvetica, sans-serif">Descritores: </font></b><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif">Endometriose. Parede abdomina
l. </font></p> <hr size="1" noshade>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#21#17#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#22#18#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#23#19#article#103#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O </b></fo
nt></p>     ^cY#v24n1a06.htm##
00591000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035600076002001300432#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#24#20#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Define-se endometriose como a presen
&ccedil;a de tecido endometrial funcionante (gl&acirc;ndulas endometriais e estr
oma) em localiza&ccedil;&atilde;o fora da cavidade endometrial e da musculatura 
uterina que geralmente responde &agrave; estimula&ccedil;&atilde;o hormonal. </f
ont></p>     ^cY#v24n1a06.htm##
00942000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070700076002001300783#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#25#21#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A sua incid&ecirc;ncia exata na popu
la&ccedil;&atilde;o geral &eacute; desconhecida. A confirma&ccedil;&atilde;o des
ta doen&ccedil;a s&oacute; &eacute; poss&iacute;vel atrav&eacute;s da an&aacute;
lise histopatol&oacute;gica de um fragmento obtido por algum procedimento invasi
vo, pois n&atilde;o existe at&eacute; o momento, nenhum marcador cl&iacute;nico 
seguro. Quando a endometriose encontra-se circunscrita &agrave; uma massa, passa
 a denominar-se endometrioma, que &eacute; doen&ccedil;a pouco observada pelo ci
rurgi&atilde;o geral, sobretudo se sua localiza&ccedil;&atilde;o ocorrer em topo
grafia extrap&eacute;lvica. </font></p>     ^cY#v24n1a06.htm##
00596000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036100076002001300437#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#26#22#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O objetivo deste trabalho consiste e
m relatar experi&ecirc;ncia em 14 casos de endometrioma de parede abdominal, dan
do &ecirc;nfase &agrave; apresenta&ccedil;&atilde;o cl&iacute;nica, a import&aci
rc;ncia da tomografia computadorizada e ao tratamento cir&uacute;rgico empregado
. </font></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#27#23#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#28#24#article#103#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b> </font></p>   
  ^cY#v24n1a06.htm##
00940000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070500076002001300781#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#29#25#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Realizou-se estudo retrospectivo das
 pacientes tratadas de endometrioma de parede abdominal no Hospital Estadual Aze
vedo Lima e no Hospital Universit&aacute;rio Ant&ocirc;nio Pedro, no per&iacute;
odo compreendido entre janeiro de 2000 a dezembro de 2008, analisando os dados r
elativos &agrave; idade, sintomas e tempo de evolu&ccedil;&atilde;o, cesariana p
r&eacute;via, rela&ccedil;&atilde;o dos sintomas com o ciclo menstrual, exames f
&iacute;sico e complementares, tratamento cir&uacute;rgico, evolu&ccedil;&atilde
;o p&oacute;s-operat&oacute;ria e resultado histopatol&oacute;gico dos esp&eacut
e;cimes cir&uacute;rgicos.</font></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#30#26#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#31#27#article#103#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY
#v24n1a06.htm##
00698000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046300076002001300539#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#32#28#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foram operadas 14 pacientes (<a href
="#tab1">Tabela 1</a>) no per&iacute;odo estudado, com idade entre 28 e 40 anos 
(m&eacute;dia de 33,42). O tempo decorrido dos sinais e sintomas variou de seis 
meses a tr&ecirc;s anos (m&eacute;dia de 2,63). Treze pacientes tinham passado d
e cesariana, que ocorreu entre quatro e doze anos (m&eacute;dia de 6,9) antes do
 aparecimento do tumor. </font></p>     ^cY#v24n1a06.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#33#29#article#103#<p><a name="tab1"><
/a></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#34#30#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#35#31#article#103#<p align="center"><
img src="/img/revistas/abcd/v24n1/a06tab1.jpg"></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#36#32#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
01165000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093000076002001301006#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#37#33#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A queixa principal em todos os casos
 foi de tumora&ccedil;&atilde;o na parede abdominal que aumentava de volume e se
 tornava mais dolorosa na vig&ecirc;ncia do per&iacute;odo menstrual. O tumor lo
calizava-se nas fossas il&iacute;acas em 11 pacientes (cinco &agrave; direita e 
seis &agrave; esquerda), e no flanco esquerdo em uma. Todos localizavam-se nas p
roximidades da cicatriz operat&oacute;ria de cesariana (<a href="#fig1">Figura1<
/a>). Em dois casos, situavam-se na regi&atilde;o umbilical. Uma delas apresenta
va tumora&ccedil;&atilde;o exof&iacute;tica, com aspecto cerebriforme e sangrame
nto externo durante o per&iacute;odo menstrual. As dimens&otilde;es das les&otil
de;es situaram-se entre 1,6 x 1,5 cm e 6,0 x 4,0 cm. Todas tinham &agrave; palpa
&ccedil;&atilde;o, limites imprecisos, consist&ecirc;ncia macia e sensibilidade 
aumentada. </font></p>     ^cY#v24n1a06.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#38#34#article#103#<p><a name="fig1"><
/a></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#39#35#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#40#36#article#103#<p align="center"><
img src="/img/revistas/abcd/v24n1/a06fig1.jpg"></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#41#37#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00582000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034700076002001300423#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#42#38#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Realizou-se ultrassonografia em 13 e
 tomografia computadorizada abdominal em nove casos. Em tr&ecirc;s o exame tomog
r&aacute;fico mostrou capta&ccedil;&atilde;o de contraste pela tumora&ccedil;&at
ilde;o (apenas uma delas encontrava-se menstruada durante o exame). </font></p> 
    ^cY#v24n1a06.htm##
00662000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042700076002001300503#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#43#39#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tratamento cir&uacute;rgico utiliz
ado foi a ex&eacute;rese ampla do tumor e dos tecidos adjacentes comprometidos. 
Em quatro oportunidades foi necess&aacute;rio usar tela de polipropileno na reco
nstru&ccedil;&atilde;o da parede abdominal, associada &agrave; drenagem por aspi
ra&ccedil;&atilde;o ativa durante 48 horas em duas ocasi&otilde;es. </font></p> 
    ^cY#v24n1a06.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021000076002001300286#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#44#40#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A evolu&ccedil;&atilde;o p&oacute;s-
operat&oacute;ria das pacientes foi satisfat&oacute;ria, sem nenhuma intercorr&e
circ;ncia. </font></p>     ^cY#v24n1a06.htm##
00483000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024800076002001300324#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#45#41#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O exame histopatol&oacute;gico dos e
sp&eacute;cimes confirmou a impress&atilde;o diagn&oacute;stica pr&eacute;-opera
t&oacute;ria de endometrioma, em todos os casos. </font></p>     ^cY#v24n1a06.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#46#42#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#47#43#article#103#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b> </font></p> 
    ^cY#v24n1a06.htm##
00904000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066900076002001300745#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#48#44#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A endometriose &eacute; entidade cl&
iacute;nica bastante conhecida na literatura ginecol&oacute;gica, por&eacute;m n
&atilde;o &eacute; ainda bem compreendida entre os cirurgi&otilde;es gerais. A s
ua localiza&ccedil;&atilde;o extrap&eacute;lvica &eacute; bem menos frequente do
 que a p&eacute;lvica e j&aacute; foi observada nos mais variados &oacute;rg&ati
lde;os e sistemas (pulm&otilde;es, br&ocirc;nquios, pleura, ves&iacute;cula bili
ar, rim, bexiga, intestino delgado, intestino grosso, ap&ecirc;ndice cecal, omen
tos, linfonodos, espa&ccedil;o sub-aracn&oacute;ide)<sup>4,6,8</sup>. </font></p
>     ^cY#v24n1a06.htm##
00878000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064300076002001300719#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#49#45#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nenhuma teoria consegue explicar com
pletamente o mecanismo exato de forma&ccedil;&atilde;o da endometriose, sendo pr
ov&aacute;vel que resulte de uma combina&ccedil;&atilde;o de eventos. A hip&oacu
te;tese mais aceita &eacute; que ocorreria refluxo  atrav&eacute;s das tubas, de
 part&iacute;culas do endom&eacute;trio para a cavidade abdominal, vasos sangu&i
acute;neos e linf&aacute;ticos. Outra possibilidade seria a presen&ccedil;a de c
&eacute;lulas multipotenciais primitivas extra&uacute;tero, que em certas condi&
ccedil;&otilde;es produziriam endometriose. </font></p>     ^cY#v24n1a06.htm##
00525000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029000076002001300366#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#50#46#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os focos endometriais ect&oacute;pic
os est&atilde;o quase sempre sob influ&ecirc;ncia dos horm&ocirc;nios ovarianos,
 apresentando todas as altera&ccedil;&otilde;es do ciclo menstrual, inclusive sa
ngramento. </font></p>     ^cY#v24n1a06.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022600076002001300302#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#51#47#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">De acordo com Han, et al.<sup>5</sup
> a transforma&ccedil;&atilde;o maligna da endometriose &eacute; rara, mas n&ati
lde;o pode ser descartada. </font></p>     ^cY#v24n1a06.htm##
01453000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704121800076002001301294#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#52#48#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Conforme constatado nestes casos, o 
endometrioma geralmente acomete mulheres na faixa et&aacute;ria de reprodu&ccedi
l;&atilde;o, com incid&ecirc;ncia m&aacute;xima na terceira e quarta d&eacute;ca
das<sup>15</sup>. Quando na parede abdominal, localiza-se preferencialmente pr&o
acute;ximo de ou em uma cicatriz cir&uacute;rgica. Embora ocorra na maioria dos 
casos em pacientes com passado de cesariana<sup>13</sup>, o endometrioma tem sid
o tamb&eacute;m observado em incis&atilde;o operat&oacute;ria p&oacute;s histere
ctomia convencional ou laparosc&oacute;pica<sup>9,14</sup>, apendicectomia e h&e
acute;rnia inguinal, assim como j&aacute; foi descrito em pacientes sem qualquer
 interven&ccedil;&atilde;o pr&eacute;via<sup>12</sup>, fato este constatado em u
m dos casos desta s&eacute;rie. Para a profilaxia da endometriose p&oacute;s-ces
ariana, Wasfie<sup>13</sup> recomenda a irriga&ccedil;&atilde;o vigorosa da feri
da operat&oacute;ria com solu&ccedil;&atilde;o salina antes do fechamento da par
ede abdominal. A &uacute;nica paciente desta casu&iacute;stica sem opera&ccedil;
&atilde;o pr&eacute;via relatou parto normal 12 anos antes.</font></p>     ^cY#v
24n1a06.htm##
00589000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035400076002001300430#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#53#49#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tempo decorrido entre a opera&cced
il;&atilde;o pr&eacute;via e o aparecimento dos sintomas decorrentes da instala&
ccedil;&atilde;o do processo pode variar de seis meses at&eacute; 20 anos<sup>8,
12</sup>. Nestas pacientes, este per&iacute;odo foi entre quatro a 12 anos.</fon
t></p>     ^cY#v24n1a06.htm##
00587000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035200076002001300428#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#54#50#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A sintomatologia cl&aacute;ssica do 
endometrioma de parede abdominal consiste em tumora&ccedil;&atilde;o bastante se
ns&iacute;vel &agrave; palpa&ccedil;&atilde;o, intermitentemente dolorosa, que a
umenta de volume e sensibilidade de acordo com a fase do ciclo menstrual.</font>
</p>     ^cY#v24n1a06.htm##
00988000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075300076002001300829#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#55#51#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A suspei&ccedil;&atilde;o diagn&oacu
te;stica deve sempre ser aventada quando os sinais e sintomas nitidamente coinci
dem com as fases do per&iacute;odo menstrual. Por&eacute;m, nem sempre essa rela
&ccedil;&atilde;o se apresenta de forma bastante clara, dificultando assim, esta
belecer a real causa do problema. &Eacute; importante estabelecer diagn&oacute;s
tico diferencial com os seguintes tumores: sarcomas, carcinoma metast&aacute;tic
o, h&eacute;rnias, hematomas e granulomas entre outros. Nestes casos a n&iacute;
tida rela&ccedil;&atilde;o dos sinais e sintomas com a menstrua&ccedil;&atilde;o
 favoreceu a correta impress&atilde;o diagn&oacute;stica de endometrioma. </font
></p>     ^cY#v24n1a06.htm##
01029000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079400076002001300870#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#56#52#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A ultrassonografia e a tomografia co
mputadorizada s&atilde;o importantes para delimitar n&atilde;o s&oacute; o taman
ho da les&atilde;o, mas tamb&eacute;m o grau de comprometimento da parede abdomi
nal. A tomografia computadorizada mostra massa heterog&ecirc;nea, sem c&aacute;p
sula, capaz de captar contraste, al&eacute;m de localizar perfeitamente a tumora
&ccedil;&atilde;o, identificando quais estruturas da parede abdominal que est&at
ilde;o comprometidas. Estas informa&ccedil;&otilde;es s&atilde;o muito important
es no planejamento da t&aacute;tica cir&uacute;rgica. A tomografia permite ainda
 estudo de toda a cavidade p&eacute;lvica que porventura tamb&eacute;m possa est
ar comprometida pela doen&ccedil;a.</font></p>     ^cY#v24n1a06.htm##
00632000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039700076002001300473#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#57#53#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Koger<sup>8</sup>, Patterson<sup>10<
/sup>, e Calabrese<sup>1</sup> defendem ainda a pun&ccedil;&atilde;o bi&oacute;p
sia com agulha fina aspirativa, que em na opini&atilde;o destes autores estaria 
contraindicada pela possibilidade de disseminar a doen&ccedil;a nos tecidos sadi
os no trajeto da pun&ccedil;&atilde;o.</font></p>     ^cY#v24n1a06.htm##
01142000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090700076002001300983#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#58#54#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tratamento do endometrioma de pare
de abdominal &eacute; essencialmente cir&uacute;rgico e tem como objetivo princi
pal a completa ressec&ccedil;&atilde;o do processo, uma vez que n&atilde;o deve 
permanecer nenhum resto de tecido endometrial na &aacute;rea comprometida. Por i
sso, a excis&atilde;o deve ser ampla<sup>2,3,7,8,11</sup> para retirar todos os 
segmentos de pele, tecido subcut&acirc;neo, m&uacute;sculos, aponeuroses e perit
&ocirc;nio potencialmente envolvidos (<a href="#fig2">Figura 2</a>). Se poss&iac
ute;vel, o defeito criado pela excis&atilde;o alargada deve ser corrigido com os
 pr&oacute;prios m&uacute;sculos e aponeuroses abdominais. Por&eacute;m, quando 
isto implicar em alguma tens&atilde;o nas linhas de suturas, a op&ccedil;&atilde
;o mais utilizada &eacute; o uso de pr&oacute;tese de polipropileno.</font></p> 
    ^cY#v24n1a06.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#59#55#article#103#<p><a name="fig2"><
/a></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#60#56#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#61#57#article#103#<p align="center"><
img src="/img/revistas/abcd/v24n1/a06fig2.jpg" ></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#62#58#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#63#59#article#103#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b> </font></p> 
    ^cY#v24n1a06.htm##
00637000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040200076002001300478#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#64#60#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foi n&iacute;tida a rela&ccedil;&ati
lde;o entre cesariana pr&eacute;via e endometrioma de parede abdominal e estudos
 ultrassonogr&aacute;ficos e tomogr&aacute;ficos auxiliaram a planejar a abordag
em cir&uacute;rgica permitindo a ex&eacute;rese da tumora&ccedil;&atilde;o e de 
todos os tecidos adjacentes comprometidos. </font></p>     ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#65#61#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#66#62#article#103#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p> 
    ^cY#v24n1a06.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023000078002001300308#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#67#63#article#103#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Calabrese L, Delmon
te O, Mari R. Endometriosis of the abdominal wall. Clinical case and review of l
iterature. Acta Biomed. Atheneo Parmense 1997; 68; 35-43.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#68#64#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024200078002001300320#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#69#65#article#103#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Celik M, Bulbuloglu
, E, Buyukbese, MA, Cetinkaya AS. Abdominal wall endometrioma localizing in rect
us abdominal shealth. Turk. J. Med. Sci. 2004; 34: 341-3 </font></p>     ^cY#v24
n1a06.htm##
00423000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017400078002001300252#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#70#66#article#103#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Chun JT, Nelson H.S
, Maull K.J. Endometriosis of the abdominal wall. South Med. J. 1990; 83: 1491-2
.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#71#67#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020900078002001300287#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#72#68#article#103#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Gupta S, Shah S, Mo
tashaw ND, Shah N, Darshana V, Daye V. Case report: Bladder wall endometrioma. I
nd. J. Radiol. Imag. 2001; 11:23-24.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#73#69#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023200078002001300310#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#74#70#article#103#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Han AC. Hovendensen
 S, Rosemblum NG, Salazar H. Adenocarcinoma arising in extra gonadal endometrios
is: an immunohistochemical study. Cancer, 1998; 83; 1163-9.    ^cY#v24n1a06.htm#
#
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#75#71#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021200078002001300290#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#76#72#article#103#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Healy JT, Wilkinson
 NW, Sawyer M. Abdominsl wall endometrioma in a laparoscopic trocar tract. A cas
e report. Am. Surgeon, 1995; 61: 962-3.    ^cY#v24n1a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#77#73#article#103#</font></p>     ^cY
#v24n1a06.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024200078002001300320#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#78#74#article#103#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Kocakusak A, Arpina
r E, Arikan S, Dermirbag N, Tarlaci A, Kabaca C. Abdominal wall endometriosis: a
 diagnostic dilemma for surgeons. Med. Princ. Pract. 2005; 14: 434-7.    ^cY#v24
n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#79#75#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019400078002001300272#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#80#76#article#103#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Koger KE, Shatney C
H, Hodge K, Mcclenathan JH. Surgical scar endometrioma. Surg. Gynecol &amp; Obst
et. 1993; 177; 242-6.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#81#77#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020900078002001300287#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#82#78#article#103#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Nirula R, Greaney G
C. Incisional endometriosis: an underappreciated diagnosis in general surgery. J
. Am. Coll. Surg. 2000; 190:404-407.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#83#79#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00433000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018300079002001300262#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#84#80#article#103#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 10. Patterson GK, Wi
nburn GB. Abdominal wall endometriomas; report of eight cases. Am. Surgeon. 1999
; 65; 36-9.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#85#81#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024400079002001300323#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#86#82#article#103#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Singh KK, Lessels
 AM, Adam DJ, Jordan C, Miles WFA, Macyntyre IMC. Presentation of endometriosis 
to general surgeons: a 10-year experience. Br.J.Surg. 1995, 82: 1349-51.    ^cY#
v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#87#83#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021100079002001300290#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#88#84#article#103#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Thylan S. Letter 
to the editor. Re: Abominal wall endometrioma in a laparoscopic trocar tract. A 
case report Am. Surgeon. 1996; 62: 617.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#89#85#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021800079002001300297#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#90#86#article#103#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Wasfie T, Gomez E
, Seon S, Zado B. Abdominal wall endometrioma after cesarian section: A preventa
ble complication. Int. Surg. 2002; 87:175-177.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#91#87#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023000079002001300309#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#92#88#article#103#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Wilson H, Shaxted
 E. Implatation endometrioma at a port site after laparoscopic abdominal suprace
rvical hysterectomy. Gynaecological endoscopy 1999; 8:245.    ^cY#v24n1a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#93#89#article#103# </font></p>     ^c
Y#v24n1a06.htm##
00439000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018900079002001300268#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#94#90#article#103#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Wolf Y, Haddad R,
 Werbin N, Skornick Y, Kaplan O. Endometriosis in abdominal scars. Am. Surgeon, 
1996; 62; 1042-4.    ^cY#v24n1a06.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002400076002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#95#91#article#103# </font></p>       
 ^cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#96#92#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#97#93#article#103#<p>&nbsp;</p>     ^
cY#v24n1a06.htm##
00434000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019900076002001300275#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#98#94#article#103#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b><a name="note2"></a><a href="#not
e1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0" ></a> Correspond&eci
rc;ncia:</b>    ^cY#v24n1a06.htm##
00260000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002500076002001300101#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#99#95#article#103#<br>Italo Accetta  
  ^cY#v24n1a06.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704009200077002001300169#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#100#96#article#103#<br>    E-mail: <a
 href="mailto:italo@urbi.com.br">italo@urbi.com.br</a></font></p>     ^cY#v24n1a
06.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704012100077002001300198#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#101#97#article#103#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atild
e;o: 13/10/2010    ^cY#v24n1a06.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704006100077002001300138#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#102#98#article#103#<br> Aceito para p
ublica&ccedil;&atilde;o: 21/12/2010    ^cY#v24n1a06.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704005700077002001300134#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#103#99#article#103#<br> Fonte de fina
nciamento: n&atilde;o h&aacute;    ^cY#v24n1a06.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007000078002001300148#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#104#100#article#103#<br> Conflito de 
interesses: n&atilde;o h&aacute; </font></p>     ^cY#v24n1a06.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#105#101#article#103#<p>&nbsp;</p>    
 ^cY#v24n1a06.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#106#102#article#103#<p>&nbsp;</p>    
 ^cY#v24n1a06.htm##
00512000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704027500078002001300353#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a06.htm#S#p#107#103#article#103#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado na Faculdade de
 Medicina da Universidade Federal Fluminense, Hospital Estadual Azevedo Lima e H
ospital Universit&aacute;rio Ant&ocirc;nio Pedro, Niter&oacute;i, RJ, Brasil. </
font></p>     ^cY#v24n1a06.htm##
00564000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100018000960100
01500114012008000129030003000209710000200239065000900241064000500250031000300255
014000600258865000900264002001300273#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a06.htm#S#c#108#1#article#15#1#^rND^sCalabrese^nL#^rND^sDelmonte^nO#^rND^sMar
i^nR.#Endometriosis of the abdominal wall: Clinical case and review of literatur
e^len#Acta Biomed. Atheneo Parmense#2#19970000#1997#68#35-43#20110300#v24n1a06.h
tm##
00579000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100020000920100
02100112010002100133012007100154030001700225710000200242065000900244064000500253
031000300258014000600261865000900267002001300276#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a06.htm#S#c#109#2#article#15#2#^rND^sCelik^nM#^rND^sBulbuloglu^nE
#^rND^sBuyukbese^nMA.#^rND^sCetinkaya^nAS.#Abdominal wall endometrioma localizin
g in rectus abdominal shealth^len#Turk. J. Med Sci#2#20040000#2004#34#341-3#2011
0300#v24n1a06.htm##
00507000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100018000920100
01800110012004000128030001300168710000200181065000900183064000500192031000300197
014000700200865000900207002001300216#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a06.htm#S#c#110#3#article#15#3#^rND^sChun^nJT#^rND^sNelson^nH.S#^rND^sMaull^n
K.J.#Endometriosis of the abdominal wall^len#South Med. J#2#19900000#1990#83#149
1-2#20110300#v24n1a06.htm##
00595000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100014000920100
01900106010001400125010001800139010001400157012004300171030002000214710000200234
065000900236064000500245031000300250014000600253865000900259002001300268#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#c#111#4#article#15#4#^rND^sGupt
a^nS#^rND^sShah^nS#^rND^sMotashaw^nND#^rND^sShah^nN#^rND^sDarshana^nV#^rND^sDaye
^nV#Case report: Bladder wall endometrioma^len#Ind. J. Radiol Imag#2#20010000#20
01#11#23-24#20110300#v24n1a06.htm##
00611000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100021000920100
02000113010001800133012008800151030000700239065000900246064000500255031000300260
014000700263865000900270002001300279035001000292801000700302#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a06.htm#S#c#112#5#article#15#5#^rND^sHan^nAC.#^rND^sH
ovendensen^nS#^rND^sRosemblum^nNG#^rND^sSalazar^nH.#Adenocarcinoma arising in ex
tra gonadal endometriosis: an immunohistochemical study^len#Cancer#19980000#1998
#83#1163-9#20110300#v24n1a06.htm#0008-543X#Cancer##
00545000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100020000930100
01700113012007800130030001200208710000200220065000900222064000500231031000300236
014000600239865000900245002001300254#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a06.htm#S#c#113#6#article#15#6#^rND^sHealy^nJT#^rND^sWilkinson^nNW#^rND^sSawy
er^nM.#Abdominsl wall endometrioma in a laparoscopic trocar tract: A case report
^len#Am. Surgeon#2#19950000#1995#61#962-3#20110300#v24n1a06.htm##
00627000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960100
01600113010001900129010001700148010001600165012006800181030001700249710000200266
065000900268064000500277031000300282014000600285865000900291002001300300#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#c#114#7#article#15#7#^rND^sKoca
kusak^nA#^rND^sArpinar^nE#^rND^sArikan^nS#^rND^sDermirbag^nN#^rND^sTarlaci^nA#^r
ND^sKabaca^nC#Abdominal wall endometriosis: a diagnostic dilemma for surgeons^le
n#Med. Princ Pract#2#20050000#2005#14#434-7#20110300#v24n1a06.htm##
00541000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
01500111010002300126012003100149030002300180710000200203065000900205064000500214
031000400219014000600223865000900229002001300238#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a06.htm#S#c#115#8#article#15#8#^rND^sKoger^nKE#^rND^sShatney^nCH#
^rND^sHodge^nK#^rND^sMcclenathan^nJH.#Surgical scar endometrioma^len#Surg. Gynec
ol & Obstet#2#19930000#1993#177#242-6#20110300#v24n1a06.htm##
00523000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930120
07900111030001700190710000200207065000900209064000500218031000400223014000800227
865000900235002001300244#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S
#c#116#9#article#15#9#^rND^sNirula^nR#^rND^sGreaney^nGC#Incisional endometriosis
: an underappreciated diagnosis in general surgery^len#J. Am. Coll Surg#2#200000
00#2000#190#404-407#20110300#v24n1a06.htm##
00498000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100019000990120
05600118030001200174710000200186065000900188064000500197031000300202014000500205
865000900210002001300219#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S
#c#117#10#article#15#10#^rND^sPatterson^nGK#^rND^sWinburn^nGB.#Abdominal wall en
dometriomas: report of eight cases^len#Am. Surgeon#2#19990000#1999#65#36-9#20110
300#v24n1a06.htm##
00632000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01500113010001600128010001700144010002200161012007600183030001000259710000200269
065000900271064000500280031000300285014000800288865000900296002001300305#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#c#118#11#article#15#11#^rND^sSi
ngh^nKK#^rND^sLessels^nAM#^rND^sAdam^nDJ#^rND^sJordan^nC#^rND^sMiles^nWFA#^rND^s
Macyntyre^nIMC.#Presentation of endometriosis to general surgeons: a 10-year exp
erience^len#Br.J.Surg#2#19950000#1995#82#1349-51#20110300#v24n1a06.htm##
00508000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120103000950300
01100198710000200209065000900211064000500220031000300225014000400228865000900232
002001300241#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a06.htm#S#c#119#12#ar
ticle#15#12#^rND^sThylan^nS#Letter to the editor: Re: Abominal wall endometrioma
 in a laparoscopic trocar tract. A case report^len#Am Surgeon#2#19960000#1996#62
#617#20110300#v24n1a06.htm##
00598000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01400110010001400124012008300138030000900221065000900230064000500239031000300244
014000800247865000900255002001300264035001000277801000900287#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a06.htm#S#c#120#13#article#15#13#^rND^sWasfie^nT#^rND
^sGomez^nE#^rND^sSeon^nS#^rND^sZado^nB#Abdominal wall endometrioma after cesaria
n section: A preventable complication^len#Int Surg#20020000#2002#87#175-177#2011
0300#v24n1a06.htm#0020-8868#Int Surg##
00592000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950120
10000112030002500212065000900237064000500246031000200251014000400253865000900257
002001300266035001000279801002500289#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a06.htm#S#c#121#14#article#15#14#^rND^sWilson^nH#^rND^sShaxted^nE#Implatation
 endometrioma at a port site after laparoscopic abdominal supracervical hysterec
tomy^len#Gynaecological endoscopy#19990000#1999#8#245#20110300#v24n1a06.htm#0962
-1091#GYNAECOLOGICAL ENDOSCOPY##
00559000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01600109010001800125010001700143012003700160030001200197710000200209065000900211
064000500220031000300225014000700228865000900235002001300244#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a06.htm#S#c#122#15#article#15#15#^rND^sWolf^nY#^rND^s
Haddad^nR#^rND^sWerbin^nN#^rND^sSkornick^nY#^rND^sKaplan^nO.#Endometriosis in ab
dominal scars^len#Am. Surgeon#2#19960000#1996#62#1042-4#20110300#v24n1a06.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#o#1#1#article#1
#20110411#103849#v24n1a07.htm#168##
05165000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000200095049000800097158000300105030002700108
03100030013503200020013806500090014001400090014903500100015801201130016801201170
02810100033003980100028004310100037004590100029004960100030005250100040005550831
92400595085001002519085002602529085003102555083186902586085001004455085002604465
08500320449111700080452307200030453111200090453411100110454311400090455411300110
4563002001304574#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#h#2#1#a
rticle#1#oa#pt#br1.1#1#4.0#ILUS#7#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#201
10300#^f30^l35#0102-6720#Análise das complicações da esofagectomia transmediasti
nal no tratamento cirurgico do megaesôfago recidivado^lpt#Evaluation of complica
tions of transmediastina esophagectomy in the surgical treatment of relapsed meg
aesophagus^len#^rND^nJosé Luis Braga de^sAquino#^rND^nMarcelo Manzano^sSaid#^rND
^nVania Aparecida^sLeandro-Merhi#^rND^nLiliana Hana^sIchinohe#^rND^nJoão Paulo Z
enum^sRamos#^rND^nDaniel Gustavo Guimarães^sMachado#^lpt^aRACIONAL: A melhor opç
ão para o tratamento dos pacientes com megaesôfago e recidiva de sintomas após t
ratamento prévio sempre foi muito controversa. Em resultados de trabalhos analis
ados, não há seleção da técnica cirúrgica mais adequada para a doença. Assim, su
rge a ideia de se realizar um estudo mais seletivo com esofagectomia transmedias
tinal sem toracotomia em pacientes com megaesôfago avançado recidivado após card
iomiotomia prévia. OBJETIVO: Avaliar os resultados da esofagectomia transmediast
inal no megaesôfago recidivado quanto às complicações sistêmicas e locais. MÉTOD
O: Trinta e dois pacientes foram atendidos todos com recidiva de sintomas após o
peração prévia e indicação para esofagectomia transmediastinal com transposição 
gástrica pelo mediastino posterior por apresentarem megaesôfago grau IV. Dos 32 
pacientes, 25 eram homens (78,1%) e sete, mulheres (21,9%), com idade entre 34 a
 72 anos. Todos foram submetidos à miotomia prévia com tempo variável de 5 a 39 
anos até a realização da esofagectomia transmediastinal. RESULTADOS: Alguns paci
entes apresentaram complicações. Dentre eles oito com infecção pulmonar (25,0%) 
resultando em boa evolução ao tratamento clínico específico; dois evoluíram para
 óbito devido a repercussão hemodinâmica causada por lesão de veia ázigos e o ou
tro por lesão de traqueia; nove (28,1%) com deiscência da anastomose esofagogást
rica cervical evoluindo bem com tratamento conservador. Dos 21 pacientes nos qua
is se realizou o acompanhamento em longo prazo, seis meses a 14 anos, 17 referir
am boa deglutição para sólidos e/ou pastosos; quatro (19,0%) apresentaram reflux
o gastroesofágico com melhora ao tratamento clínico. CONCLUSÕES: A esofagectomia
 transmediastinal, apesar de proporcionar deglutição adequada na maioria dos cas
os, é procedimento de grande morbidade. Ela não deve ser indicada como primeira 
opção no tratamento do megaesôfago avançado recidivado.#^ddecs^i1#^tm^lpt^kEsofa
gectomia^i1#^tm^lpt^kAcalasia esofágica^i1#^len^aBACKGROUND: The best option for
 the treatment of patients with achalasia and recurrent symptoms after previous 
treatment, has always been very controversial. In literature review, there is no
 surgical technique considered the best to deal with this condition. The idea to
 use a more selective treatment with transmediastinal esophagectomy without thor
acotomy in patients with advanced megaesophagus in relapsed cases after prior ca
rdiomyotomy can be considered. AIM: To evaluate the results of transmediastinal 
esophagectomy in recurrent megaesophagus regarding local and systemic complicati
ons. METHODS: Thrity two patients were treated with recurrent symptoms after pre
vious surgery to achalasia and indication for esophagectomy with gastric transme
diastinal transposition through the posterior mediastinum for grade IV megaesoph
agus. They were 25 men (78.1%) and seven women (21.9%), aged from 34 to 72 years
. All underwent previous myotomy varying from five to 39 years to the day of tra
nsmediastinal esophagectomy. RESULTS: Some patients had complications. Among the
se, eight had pulmonary infection (25.0%) resulting in good outcome to the speci
fic clinical treatment; two died due to hemodynamic effect caused by injury to t
he azygos vein and the other due to trachea injury; nine (28.1% ) had cervical e
sophagogastric anastomotic dehiscence doing well with conservative treatment. Of
 the 21 patients in whom monitoring was carried out in the long term - six month
s to 14 years -, 17 reported good swallowing solids and pastes, four (19.0%) had
 gastroesophageal reflux with clinical improvement with specific medical treatme
nt. CONCLUSIONS: Transmediastinal esophagectomy, although providing adequate swa
llowing in most cases, is a procedure of high morbidity. This technique should n
ot be recommended as first treatment option for relapsed megaesophagus.#^ddecs^i
2#^tm^len^kEsophagectomy^i2#^tm^len^kEsophageal ahalasia^i2#vancouv#28#20101029#
29/10/2010#20101221#21/12/2010#v24n1a07.htm##
05249000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000200095049000800097158000300105030002700108
03100030013503200020013806500090014001400090014903500100015801201200016801201240
02880100033004120100028004450100037004730100029005100100030005390100040005690831
95900609085001002568085002602578085003102604083190402635085001004539085002604549
08500320457511700080460707200030461511200090461811100110462711400090463811300110
4647002001304658#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#f#3#1#a
rticle#1#oa#pt#br1.1#1#4.0#ILUS#7#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#201
10300#^f30^l35#0102-6720#<b>Análise das complicações da esofagectomia transmedia
stinal no tratamento cirurgico do megaesôfago recidivado</b>^lpt#<b>Evaluation o
f complications of transmediastina esophagectomy in the surgical treatment of re
lapsed megaesophagus</b>^len#^rND^nJosé Luis Braga de^sAquino#^rND^nMarcelo Manz
ano^sSaid#^rND^nVania Aparecida^sLeandro-Merhi#^rND^nLiliana Hana^sIchinohe#^rND
^nJoão Paulo Zenum^sRamos#^rND^nDaniel Gustavo Guimarães^sMachado#^lpt^a<b>RACIO
NAL: </b>A melhor opção para o tratamento dos pacientes com megaesôfago e recidi
va de sintomas após tratamento prévio sempre foi muito controversa. Em resultado
s de trabalhos analisados, não há seleção da técnica cirúrgica mais adequada par
a a doença. Assim, surge a ideia de se realizar um estudo mais seletivo com esof
agectomia transmediastinal sem toracotomia em pacientes com megaesôfago avançado
 recidivado após cardiomiotomia prévia. <b>OBJETIVO:</b> Avaliar os resultados d
a esofagectomia transmediastinal no megaesôfago recidivado quanto às complicaçõe
s sistêmicas e locais. <b>MÉTODO: </b>Trinta e dois pacientes foram atendidos to
dos com recidiva de sintomas após operação prévia e indicação para esofagectomia
 transmediastinal com transposição gástrica pelo mediastino posterior por aprese
ntarem megaesôfago grau IV. Dos 32 pacientes, 25 eram homens (78,1%) e sete, mul
heres (21,9%), com idade entre 34 a 72 anos. Todos foram submetidos à miotomia p
révia com tempo variável de 5 a 39 anos até a realização da esofagectomia transm
ediastinal. <b>RESULTADOS:</b> Alguns pacientes apresentaram complicações. Dentr
e eles oito com infecção pulmonar (25,0%) resultando em boa evolução ao tratamen
to clínico específico; dois evoluíram para óbito devido a repercussão hemodinâmi
ca causada por lesão de veia ázigos e o outro por lesão de traqueia; nove (28,1%
) com deiscência da anastomose esofagogástrica cervical evoluindo bem com tratam
ento conservador. Dos 21 pacientes nos quais se realizou o acompanhamento em lon
go prazo, seis meses a 14 anos, 17 referiram boa deglutição para sólidos e/ou pa
stosos; quatro (19,0%) apresentaram refluxo gastroesofágico com melhora ao trata
mento clínico. <b>CONCLUSÕES:</b> A esofagectomia transmediastinal, apesar de pr
oporcionar deglutição adequada na maioria dos casos, é procedimento de grande mo
rbidade. Ela não deve ser indicada como primeira opção no tratamento do megaesôf
ago avançado recidivado.#^ddecs^i1#^tm^lpt^kEsofagectomia^i1#^tm^lpt^kAcalasia e
sofágica^i1#^len^a<b>BACKGROUND:</b> The best option for the treatment of patien
ts with achalasia and recurrent symptoms after previous treatment, has always be
en very controversial. In literature review, there is no surgical technique cons
idered the best to deal with this condition. The idea to use a more selective tr
eatment with transmediastinal esophagectomy without thoracotomy in patients with
 advanced megaesophagus in relapsed cases after prior cardiomyotomy can be consi
dered. <b>AIM:</b> To evaluate the results of transmediastinal esophagectomy in 
recurrent megaesophagus regarding local and systemic complications. <b>METHODS:<
/b> Thrity two patients were treated with recurrent symptoms after previous surg
ery to achalasia and indication for esophagectomy with gastric transmediastinal 
transposition through the posterior mediastinum for grade IV megaesophagus. They
 were 25 men (78.1%) and seven women (21.9%), aged from 34 to 72 years. All unde
rwent previous myotomy varying from five to 39 years to the day of transmediasti
nal esophagectomy. <b>RESULTS: </b>Some patients had complications. Among these,
 eight had pulmonary infection (25.0%) resulting in good outcome to the specific
 clinical treatment; two died due to hemodynamic effect caused by injury to the 
azygos vein and the other due to trachea injury; nine (28.1% ) had cervical esop
hagogastric anastomotic dehiscence doing well with conservative treatment. Of th
e 21 patients in whom monitoring was carried out in the long term - six months t
o 14 years -, 17 reported good swallowing solids and pastes, four (19.0%) had ga
stroesophageal reflux with clinical improvement with specific medical treatment.
 <b>CONCLUSIONS: </b>Transmediastinal esophagectomy, although providing adequate
 swallowing in most cases, is a procedure of high morbidity. This technique shou
ld not be recommended as first treatment option for relapsed megaesophagus.#^dde
cs^i2#^tm^len^kEsophagectomy^i2#^tm^len^kEsophageal ahalasia^i2#vancouv#28#20101
029#29/10/2010#20101221#21/12/2010#v24n1a07.htm##
05375000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000200113049000800115158000300123
03000260012603100030015203200020015506500090015701400090016603500100017501201130
01850120117002980100033004150100028004480100037004760100029005130100030005420100
04000572083196900612085001002581085002602591085003102617083190402648085001004552
08500260456208500320458811700080462007200030462811200090463111100110464011400090
4651113001104660002001304671008008904684#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a07.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#7#ABCD
060#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f30^l35#0102-6720#Análise das co
mplicações da esofagectomia transmediastinal no tratamento cirurgico do megaesôf
ago recidivado^lpt#Evaluation of complications of transmediastina esophagectomy 
in the surgical treatment of relapsed megaesophagus^len#^rND^nJosé Luis Braga de
^sAquino#^rND^nMarcelo Manzano^sSaid#^rND^nVania Aparecida^sLeandro-Merhi#^rND^n
Liliana Hana^sIchinohe#^rND^nJoão Paulo Zenum^sRamos#^rND^nDaniel Gustavo Guimar
ães^sMachado#^lpt^aRACIONAL: A melhor opção para o tratamento dos pacientes com 
megaesôfago e recidiva de sintomas após tratamento prévio sempre foi muito contr
oversa. Em resultados de trabalhos analisados, não há seleção da técnica cirúrgi
ca mais adequada para a doença. Assim, surge a ideia de se realizar um estudo ma
is seletivo com esofagectomia transmediastinal sem toracotomia em pacientes com 
megaesôfago avançado recidivado após cardiomiotomia prévia. OBJETIVO: Avaliar os
 resultados da esofagectomia transmediastinal no megaesôfago recidivado quanto à
s complicações sistêmicas e locais. MÉTODO: Trinta e dois pacientes foram atendi
dos todos com recidiva de sintomas após operação prévia e indicação para esofage
ctomia transmediastinal com transposição gástrica pelo mediastino posterior por 
apresentarem megaesôfago grau IV. Dos 32 pacientes, 25 eram homens (78,1 por cen
to) e sete, mulheres (21,9 por cento), com idade entre 34 a 72 anos. Todos foram
 submetidos à miotomia prévia com tempo variável de 5 a 39 anos até a realização
 da esofagectomia transmediastinal. RESULTADOS: Alguns pacientes apresentaram co
mplicações. Dentre eles oito com infecção pulmonar (25,0 por cento) resultando e
m boa evolução ao tratamento clínico específico; dois evoluíram para óbito devid
o a repercussão hemodinâmica causada por lesão de veia ázigos e o outro por lesã
o de traqueia; nove (28,1 por cento) com deiscência da anastomose esofagogástric
a cervical evoluindo bem com tratamento conservador. Dos 21 pacientes nos quais 
se realizou o acompanhamento em longo prazo, seis meses a 14 anos, 17 referiram 
boa deglutição para sólidos e/ou pastosos; quatro (19,0 por cento) apresentaram 
refluxo gastroesofágico com melhora ao tratamento clínico. CONCLUSÕES: A esofage
ctomia transmediastinal, apesar de proporcionar deglutição adequada na maioria d
os casos, é procedimento de grande morbidade. Ela não deve ser indicada como pri
meira opção no tratamento do megaesôfago avançado recidivado.#^ddecs^i1#^tm^lpt^
kEsofagectomia^i1#^tm^lpt^kAcalasia esofágica^i1#^len^aBACKGROUND: The best opti
on for the treatment of patients with achalasia and recurrent symptoms after pre
vious treatment, has always been very controversial. In literature review, there
 is no surgical technique considered the best to deal with this condition. The i
dea to use a more selective treatment with transmediastinal esophagectomy withou
t thoracotomy in patients with advanced megaesophagus in relapsed cases after pr
ior cardiomyotomy can be considered. AIM: To evaluate the results of transmedias
tinal esophagectomy in recurrent megaesophagus regarding local and systemic comp
lications. METHODS: Thrity two patients were treated with recurrent symptoms aft
er previous surgery to achalasia and indication for esophagectomy with gastric t
ransmediastinal transposition through the posterior mediastinum for grade IV meg
aesophagus. They were 25 men (78.1 percent) and seven women (21.9 percent), aged
 from 34 to 72 years. All underwent previous myotomy varying from five to 39 yea
rs to the day of transmediastinal esophagectomy. RESULTS: Some patients had comp
lications. Among these, eight had pulmonary infection (25.0 percent) resulting i
n good outcome to the specific clinical treatment; two died due to hemodynamic e
ffect caused by injury to the azygos vein and the other due to trachea injury; n
ine (28.1 percent ) had cervical esophagogastric anastomotic dehiscence doing we
ll with conservative treatment. Of the 21 patients in whom monitoring was carrie
d out in the long term - six months to 14 years -, 17 reported good swallowing s
olids and pastes, four (19.0 percent) had gastroesophageal reflux with clinical 
improvement with specific medical treatment. CONCLUSIONS: Transmediastinal esoph
agectomy, although providing adequate swallowing in most cases, is a procedure o
f high morbidity. This technique should not be recommended as first treatment op
tion for relapsed megaesophagus.#^ddecs^i2#^tm^len^kEsophagectomy^i2#^tm^len^kEs
ophageal ahalasia^i2#vancouv#28#20101029#29/10/2010#20101221#21/12/2010#v24n1a07
.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-6720
2011000100007##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011900074002001300193#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#5#1#article#136#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b></
font></p>     ^cY#v24n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#6#2#article#136#<p>&nbsp;</p>     ^cY
#v24n1a07.htm##
00478000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704024500074002001300319#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#7#3#article#136#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>An&aacute;lise 
das complica&ccedil;&otilde;es da esofagectomia transmediastinal no tratamento c
irurgico do megaes&ocirc;fago recidivado</b></font></p>     ^cY#v24n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#8#4#article#136#<p>&nbsp;</p>     ^cY
#v24n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#9#5#article#136#<p>&nbsp;</p>     ^cY
#v24n1a07.htm##
00505000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704027100075002001300346#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#10#6#article#136#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Jos&eacute; Luis Braga de Aquino; 
Marcelo Manzano Said; Vania Aparecida Leandro-Merhi; Liliana Hana Ichinohe; Jo&a
tilde;o Paulo Zenum Ramos; Daniel Gustavo Guimar&atilde;es Machado </b></font></
p>     ^cY#v24n1a07.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#11#7#article#136#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a07.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#12#8#article#136#<p>&nbsp;</p>     ^c
Y#v24n1a07.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#13#9#article#136#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a07.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#14#10#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a07.htm##
00863000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062800076002001300704#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#15#11#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL: </b>A melhor op&ccedil;
&atilde;o para o tratamento dos pacientes com megaes&ocirc;fago e recidiva de si
ntomas ap&oacute;s tratamento pr&eacute;vio sempre foi muito controversa. Em res
ultados de trabalhos analisados, n&atilde;o h&aacute; sele&ccedil;&atilde;o da t
&eacute;cnica cir&uacute;rgica mais adequada para a doen&ccedil;a. Assim, surge 
a ideia de se realizar um estudo mais seletivo com esofagectomia transmediastina
l sem toracotomia em pacientes com megaes&ocirc;fago avan&ccedil;ado recidivado 
ap&oacute;s cardiomiotomia pr&eacute;via.    ^cY#v24n1a07.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018800076002001300264#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#16#12#article#136#<br> <b>OBJETIVO:</
b> Avaliar os resultados da esofagectomia transmediastinal no megaes&ocirc;fago 
recidivado quanto &agrave;s complica&ccedil;&otilde;es sist&ecirc;micas e locais
.    ^cY#v24n1a07.htm##
00834000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059900076002001300675#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#17#13#article#136#<br> <b>M&Eacute;TO
DO: </b>Trinta e dois pacientes foram atendidos todos com recidiva de sintomas a
p&oacute;s opera&ccedil;&atilde;o pr&eacute;via e indica&ccedil;&atilde;o para e
sofagectomia transmediastinal com transposi&ccedil;&atilde;o g&aacute;strica pel
o mediastino posterior por apresentarem megaes&ocirc;fago grau IV. Dos 32 pacien
tes, 25 eram homens (78,1%) e sete, mulheres (21,9%), com idade entre 34 a 72 an
os. Todos foram submetidos &agrave; miotomia pr&eacute;via com tempo vari&aacute
;vel de 5 a 39 anos at&eacute; a realiza&ccedil;&atilde;o da esofagectomia trans
mediastinal.    ^cY#v24n1a07.htm##
01043000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080800076002001300884#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#18#14#article#136#<br>  <b>RESULTADOS
:</b> Alguns pacientes apresentaram complica&ccedil;&otilde;es. Dentre eles oito
 com infec&ccedil;&atilde;o pulmonar (25,0%) resultando em boa evolu&ccedil;&ati
lde;o ao tratamento cl&iacute;nico espec&iacute;fico; dois evolu&iacute;ram para
 &oacute;bito devido a repercuss&atilde;o hemodin&acirc;mica causada por les&ati
lde;o de veia &aacute;zigos e o outro por les&atilde;o de traqueia; nove (28,1%)
 com deisc&ecirc;ncia da anastomose esofagog&aacute;strica cervical evoluindo be
m com tratamento conservador. Dos 21 pacientes nos quais se realizou o acompanha
mento em longo prazo, seis meses a 14 anos, 17 referiram boa degluti&ccedil;&ati
lde;o para s&oacute;lidos e/ou pastosos; quatro (19,0%) apresentaram refluxo gas
troesof&aacute;gico com melhora ao tratamento cl&iacute;nico.    ^cY#v24n1a07.ht
m##
00572000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033700076002001300413#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#19#15#article#136#<br> <b>CONCLUS&Oti
lde;ES:</b> A esofagectomia transmediastinal, apesar de proporcionar degluti&cce
dil;&atilde;o adequada na maioria dos casos, &eacute; procedimento de grande mor
bidade. Ela n&atilde;o deve ser indicada como primeira op&ccedil;&atilde;o no tr
atamento do megaes&ocirc;fago avan&ccedil;ado recidivado. </font></p>     ^cY#v2
4n1a07.htm##
00404000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016900076002001300245#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#20#16#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b> Esofagectomia. A
calasia esof&aacute;gica. </font></p> <hr size="1" noshade>       ^cY#v24n1a07.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#21#17#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#22#18#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#23#19#article#136#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O </b></fo
nt></p>     ^cY#v24n1a07.htm##
00676000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044100076002001300517#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#24#20#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Apesar dos bem sucedidos programas g
overnamentais realizados no controle do seu vetor, a doen&ccedil;a de Chagas con
tinua bastante prevalente na America Latina. Os n&uacute;meros de pessoas infect
adas gira em torno de 16 a 18 milh&otilde;es de indiv&iacute;duos e mais de 100 
milh&otilde;es est&atilde;o em risco de contrair a doen&ccedil;a<sup>13,14</sup>
. </font></p>     ^cY#v24n1a07.htm##
00923000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068800076002001300764#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#25#21#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O megaes&ocirc;fago - uma das manife
sta&ccedil;&otilde;es cr&ocirc;nicas dessa afec&ccedil;&atilde;o -, apresenta-se
 com frequ&ecirc;ncia de 8% a 40%, ocasionando grande problema s&oacute;cio-econ
&ocirc;mico no nosso pa&iacute;s. Por apresentar car&aacute;ter cr&ocirc;nico e 
progressivo afeta principalmente o estado nutricional, dessa maneira compromete 
a qualidade de vida de seu portador pela presen&ccedil;a da disfagia<sup>16,18</
sup>. Da&iacute; a import&acirc;ncia de se realizar terap&ecirc;utica eficaz e c
om baixa morbidade, para tentar resgatar de maneira adequada a degluti&ccedil;&a
tilde;o. </font></p>     ^cY#v24n1a07.htm##
00772000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053700076002001300613#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#26#22#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A cirurgia representa a melhor forma
 de tratamento, por proporcionar al&iacute;vio dos sintomas e melhora do estado 
nutricional. Isto se torna bem evidente no megaes&ocirc;fago n&atilde;o avan&cce
dil;ado e sem tratamento pr&eacute;vio, no qual a miotomia com fundoplicatura - 
opera&ccedil;&atilde;o n&atilde;o complexa e conservadora -, tem proporcionado m
elhores resultados em compara&ccedil;&atilde;o &agrave; outras t&eacute;cnicas <
sup>7,9,15</sup>. </font></p>     ^cY#v24n1a07.htm##
00741000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050600076002001300582#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#27#23#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">J&aacute; para o megaes&ocirc;fago a
van&ccedil;ado e tamb&eacute;m sem tratamento pr&eacute;vio, a terap&ecirc;utica
 de escolha tem sido a esofagectomia sem toracotomia ou a mucosectomia esof&aacu
te;gica com conserva&ccedil;&atilde;o da t&uacute;nica muscular, com a substitui
&ccedil;&atilde;o do es&ocirc;fago realizada pela transposi&ccedil;&atilde;o g&a
acute;strica at&eacute; a regi&atilde;o cervical<sup>5,8,17</sup>. </font></p>  
   ^cY#v24n1a07.htm##
01146000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091100076002001300987#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#28#24#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Entretanto, com a impossibilidade de
 padronizar uma t&aacute;tica ideal, maiores controv&eacute;rsias surgem quanto 
&agrave; melhor op&ccedil;&atilde;o cir&uacute;rgica para o megaes&ocirc;fago av
an&ccedil;ado recidivado ap&oacute;s tratamento pr&eacute;vio. Isso ocorre devid
o aos erros t&eacute;cnicos na execu&ccedil;&atilde;o da primeira opera&ccedil;&
atilde;o, a escolha inadequada da t&eacute;cnica cir&uacute;rgica para determina
do grau de megaes&ocirc;fago, os diferentes tempos de seguimento nos quais se en
contram os pacientes, &agrave;s m&aacute;s condi&ccedil;&otilde;es anat&ocirc;mi
cas locais e ao estado nutricional, muitas vezes bastante deficit&aacute;rio naq
ueles com doen&ccedil;a avan&ccedil;ada. Soma-se a isto o fato de nem sempre con
hecer-se a primeira opera&ccedil;&atilde;o realizada<sup>7,21,25</sup>. </font><
/p>     ^cY#v24n1a07.htm##
00676000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044100076002001300517#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#29#25#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As alternativas variam desde procedi
mentos mais conservadores com menor potencial de morbidade, como a re-miotomia e
 a esofagocardioplastia com gastrectomia, at&eacute; opera&ccedil;&otilde;es mai
s complexas e mutiladoras como a esofagectomia distal ou cardiectomia com interp
osi&ccedil;&atilde;o jejunal e a esofagectomia subtotal<sup>1,7,9,11,17,26</sup>
. </font></p>     ^cY#v24n1a07.htm##
00787000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055200076002001300628#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#30#26#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Essas diverg&ecirc;ncias demonstram 
a import&acirc;ncia da tentativa de padroniza&ccedil;&atilde;o da t&eacute;cnica
 cir&uacute;rgica de maneira seletiva em rela&ccedil;&atilde;o ao grau de megaes
&ocirc;fago com recidiva de sintomas de maneira a obter melhores resultados. Por
 isso, surgiu a id&eacute;ia de se padronizar a esofagectomia transmediastinal e
m pacientes com megaes&ocirc;fago avan&ccedil;ado e com recidiva de sintomas ap&
oacute;s miotomia pr&eacute;via. </font></p>     ^cY#v24n1a07.htm##
00517000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028200076002001300358#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#31#27#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Assim, o objetivo deste estudo &eacu
te; avaliar os resultados da esofagectomia transmediastinal no megaes&ocirc;fago
 recidivado quanto &agrave;s complica&ccedil;&otilde;es sist&ecirc;micas e locai
s. </font></p>     ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#32#28#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#33#29#article#136#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODO</b> </font></p>    
 ^cY#v24n1a07.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#34#30#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Casu&iacute;stica </b></font></p>
     ^cY#v24n1a07.htm##
00746000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051100076002001300587#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#35#31#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">De agosto de 1995 a julho de 2010 fo
ram atendidos 32 pacientes no Servi&ccedil;o de Cirurgia do Hospital Celso Pierr
o-PUC Campinas, todos apresentavando megaes&ocirc;fago avan&ccedil;ado e com rec
idiva de sintomas ap&oacute;s miotomia pr&eacute;via. Tiveram indica&ccedil;&ati
lde;o para realiza&ccedil;&atilde;o de esofagectomia transmediastinal, sendo que
 o tempo da realiza&ccedil;&atilde;o da miotomia variou de 5 a 39 anos. </font><
/p>     ^cY#v24n1a07.htm##
00652000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041700076002001300493#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#36#32#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Vinte e cinco pacientes (78,1%) eram
 do sexo masculino e sete do feminino (21,9%), com idade entre 34 e 72 anos. Tod
os eram tabagistas consumindo de 10 a 30 cigarros/dia em tempo vari&aacute;vel d
e 12 a 36 anos. Dezoitos deles eram etilistas de uma a duas doses di&aacute;rias
 de destilados com tempo vari&aacute;vel de 10 a 46 anos. </font></p>     ^cY#v2
4n1a07.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014300076002001300219#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#37#33#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Avalia&ccedil;&atilde;o pr&eacute
;-operat&oacute;ria </b></font></p>     ^cY#v24n1a07.htm##
00596000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036100076002001300437#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#38#34#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O diagn&oacute;stico foi feito atrav
&eacute;s da avalia&ccedil;&atilde;o cl&iacute;nica, radiol&oacute;gica, endosc&
oacute;pica e manom&eacute;trica, al&eacute;m da sorologia para doen&ccedil;a de
 Chagas, resultando em imunofluoresc&ecirc;ncia positiva para todos os pacientes
. </font></p>     ^cY#v24n1a07.htm##
00668000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043300076002001300509#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#39#35#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na avalia&ccedil;&atilde;o cl&iacute
;nica foram observados 21 pacientes (65,6%) com disfagia intensa (dieta l&iacute
;quida) e 11 (34,4%) com moderada (dieta pastosa). A regurgita&ccedil;&atilde;o 
foi constatada em 15 deles (46.8%), enquanto o emagrecimento foi de todo o grupo
, com perda vari&aacute;vel de sete a 23 kg nos &uacute;ltimos dois anos. </font
></p>     ^cY#v24n1a07.htm##
00527000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029200076002001300368#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#40#36#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Estudo radiogr&aacute;fico contrasta
do demonstrou a presen&ccedil;a de megaes&ocirc;fago grau IV, segundo a classifi
ca&ccedil;&atilde;o de Rezende, et al.<sup>24</sup> em todos (<a href="#fig1">Fi
gura 1</a>). </font></p>     ^cY#v24n1a07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#41#37#article#136#<p><a name="fig1"><
/a></p>     ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#42#38#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#43#39#article#136#<p align="center"><
img src="/img/revistas/abcd/v24n1/a07fig1.jpg"></p>     ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#44#40#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00604000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036900076002001300445#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#45#41#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No estudo endosc&oacute;pico, foi ev
idenciada esofagite de grau B/C, segundo a classifica&ccedil;&atilde;o de Los An
geles, em 19 (59,3%) e o restante n&atilde;o apresentou nenhum grau de esofagite
. Em todos os pacientes esse exame demonstrou a dilata&ccedil;&atilde;o do es&oc
irc;fago. </font></p>     ^cY#v24n1a07.htm##
00569000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033400076002001300410#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#46#42#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Apenas seis foram submetidos &agrave
; manometria, cujo resultado foi de aus&ecirc;ncia de contratilidade do corpo de
 es&ocirc;fago e diminui&ccedil;&atilde;o do relaxamento do esf&iacute;ncter eso
f&aacute;gico inferior (<a href="#fig2">Figura 2</a>). </font></p>     ^cY#v24n1
a07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#47#43#article#136#<p><a name="fig2"><
/a></p>     ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#48#44#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#49#45#article#136#<p align="center"><
img src="/img/revistas/abcd/v24n1/a07fig2.jpg"></p>     ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#50#46#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00725000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049000076002001300566#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#51#47#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em todos os pacientes, foi feita ava
lia&ccedil;&atilde;o cl&iacute;nica e nutricional, para ver se os mesmos tinham 
condi&ccedil;&otilde;es de serem submetidos ao ato cir&uacute;rgico proposto. De
vido &agrave; constata&ccedil;&atilde;o de perda de mais de 10% do peso ideal em
 13 pacientes preconizou-se suporte nutricional atrav&eacute;s de sonda enteral 
por 20 a 30 dias, antes da opera&ccedil;&atilde;o. </font></p>     ^cY#v24n1a07.
htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017600076002001300252#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#52#48#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>T&eacute;cnica cir&uacute;rgica e
 avalia&ccedil;&atilde;o p&oacute;s-operat&oacute;ria</b></font></p>     ^cY#v24
n1a07.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017200076002001300248#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#53#49#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A t&eacute;cnica cir&uacute;rgica ut
ilizada foi proposta por Pinotti (1976)<sup>22 </sup></font></p>     ^cY#v24n1a0
7.htm##
00604000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036900076002001300445#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#54#50#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o p&oacute;s
-operat&oacute;ria foi principalmente focada nas complica&ccedil;&otilde;es sist
&ecirc;micas - cardiovasculares, pleuropulmonares ou infecciosas - e as locais q
uanto &agrave; deisc&ecirc;ncia e estenose da anastomose esofagog&aacute;strica 
cervical. </font></p>     ^cY#v24n1a07.htm##
00975000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074000076002001300816#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#55#51#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na ocorr&ecirc;ncia de sa&iacute;da 
de secre&ccedil;&atilde;o digestiva pelo dreno cervical ou pela incis&atilde;o e
ntre o 3ª e o 7ª dia de p&oacute;s-operat&oacute;rio, confirmava-se deisc&ecirc;
ncia com consequente f&iacute;stula da anastomose esofagog&aacute;strica cervica
l. Na aus&ecirc;ncia de evid&ecirc;ncia cl&iacute;nica da f&iacute;stula na anas
tomose, era realizado no 7º dia de p&oacute;s-operat&oacute;rio estudo radiogr&a
acute;fico contrastado para observar se houve extravasamento do contraste. No ca
so de resultado negativo, era liberada a dieta l&iacute;quida via oral, evoluind
o progressivamente para as formas pastosas e s&oacute;lidas. </font></p>     ^cY
#v24n1a07.htm##
00627000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039200076002001300468#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#56#52#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No entanto, na constata&ccedil;&atil
de;o de disfagia a partir do 30ª dia de p&oacute;s-operat&oacute;rio e diminui&c
cedil;&atilde;o do di&acirc;metro da anastomose - comprovado pela radiografia co
ntrastada e endoscopia digestiva alta -, confirmava-se a estenose da anastomose 
esofagog&aacute;strica cervical. </font></p>     ^cY#v24n1a07.htm##
00547000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031200076002001300388#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#57#53#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A qualidade de vida tamb&eacute;m fo
i avaliada em rela&ccedil;&atilde;o &agrave; degluti&ccedil;&atilde;o e, nos cas
os de disfagia, houve especifica&ccedil;&otilde;es quanto &agrave; sua intensida
de em leve, moderada ou intensa. </font></p>     ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#58#54#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#59#55#article#136#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY
#v24n1a07.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012200076002001300198#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#60#56#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Avalia&ccedil;&atilde;o precoce</
b> </font></p>     ^cY#v24n1a07.htm##
01362000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112700076002001301203#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#61#57#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em avalia&ccedil;&atilde;o precoce n
os primeiros 30 dias, dois pacientes (6,2%) apresentaram hemot&oacute;rax e hemo
mediastino maci&ccedil;o por les&atilde;o de veia &aacute;zigos com necessidade 
de re-interven&ccedil;&atilde;o cir&uacute;rgica de urg&ecirc;ncia atrav&eacute;
s de toracotomia. Devido &agrave; grande repercuss&atilde;o hemodin&acirc;mica, 
um paciente (3,1%) morreu por choque hemorr&aacute;gico mesmo se conseguindo a r
ealizar a rafia desse vaso e o outro teve boa evolu&ccedil;&atilde;o. Um outro p
aciente (3,1%), tamb&eacute;m foi submetido &agrave; toracotomia de urg&ecirc;nc
ia por les&atilde;o da face membranosa da traqu&eacute;ia. Apesar de se realizar
 a sutura deste &oacute;rg&atilde;o, ele morreu no 7º dia de p&oacute;s-operat&o
acute;rio, consequente &agrave; complica&ccedil;&otilde;es infecciosas. Outros o
ito pacientes (25,0%)) apresentaram infec&ccedil;&atilde;o pulmonar - em tr&ecir
c;s associada a pequeno derrame pleural -, sendo que todos evolu&iacute;ram bem 
com tratamento cl&iacute;nico espec&iacute;fico.</font></p>     ^cY#v24n1a07.htm
##
01275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104000076002001301116#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#62#58#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Nove pacientes (28,1%) apresentaram
 deisc&ecirc;ncia da anastomose esofagog&aacute;strica cervical com sa&iacute;da
 de secre&ccedil;&atilde;o digestiva pelo dreno cervical e incis&atilde;o cir&ua
cute;rgica entre o 3º e o 6º dia de p&oacute;s-operat&oacute;rio. Dois foram os 
que tamb&eacute;m apresentaram infec&ccedil;&atilde;o pulmonar. Em todos, o trat
amento foi conservador com curativos di&aacute;rios, dieta zero via oral e supor
te nutricional por jejunostomia. Esse tratamento variou entre o 13º e o 17º dia 
de p&oacute;s-operat&oacute;rio, quando n&atilde;o houve evid&ecirc;ncia de sa&i
acute;da de secre&ccedil;&atilde;o digestiva pela regi&atilde;o cervical. A part
ir desse per&iacute;odo foi realizado estudo radiogr&aacute;fico para avaliar a 
anastomose, sendo que ele n&atilde;o evidenciou extravasamento de contraste e po
r isso foi liberada a dieta via oral, inicialmente para l&iacute;quidos e poster
iormente para pastosos e s&oacute;lidos. </font></p>     ^cY#v24n1a07.htm##
00732000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049700076002001300573#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#63#59#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nos outros 21 pacientes devido &agra
ve; aus&ecirc;ncia de evid&ecirc;ncia cl&iacute;nica de f&iacute;stula da anasto
mose esofagog&aacute;strica cervical no 7º dia de p&oacute;s-operat&oacute;rio, 
foi realizado estudo radiogr&aacute;fico, sem extravasamento de contraste ao n&i
acute;vel da anastomose. Foi indicada tamb&eacute;m a dieta oral inicialmente l&
iacute;quida, e progressivamente pastosa e s&oacute;lida. </font></p>     ^cY#v2
4n1a07.htm##
01010000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077500076002001300851#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#64#60#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na avalia&ccedil;&atilde;o entre 30 
a 60 dias, realizada em 30 pacientes, nove apresentaram disfagia para dieta s&oa
cute;lida (30%) e tr&ecirc;s para dieta pastosa (10%). A endoscopia digestiva al
ta e a radiografia contrastada evidenciaram estenose da anastomose esofagog&aacu
te;strica cervical. Nove desses pacientes foram os que apresentaram f&iacute;stu
la da anastomose esofagog&aacute;strica cervical. Nos 12 que apresentaram essa c
omplica&ccedil;&atilde;o foi indicada dilata&ccedil;&atilde;o endosc&oacute;pica
 com boa evolu&ccedil;&atilde;o ap&oacute;s cinco a nove sess&otilde;es do proce
dimento, sendo que os pacientes resgataram a degluti&ccedil;&atilde;o para dieta
 s&oacute;lida. </font></p>     ^cY#v24n1a07.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012100076002001300197#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#65#61#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Avalia&ccedil;&atilde;o tardia </
b></font></p>     ^cY#v24n1a07.htm##
01082000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084700076002001300923#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#66#62#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Avalia&ccedil;&atilde;o a m&eacute;d
io e longo prazo entre seis meses a 14 anos foi realizada em 21 pacientes (65,6%
), j&aacute; que houve perda de seguimento em nove deles e os outros dois  resta
ntes foram a &oacute;bito por complica&ccedil;&otilde;es imediatas no p&oacute;s
-operat&oacute;rio, como j&aacute; referido. Nesse per&iacute;odo, quatro pacien
tes (19,0%) referiram disfagia intermitente para dieta s&oacute;lida, sendo que 
a avalia&ccedil;&atilde;o endosc&oacute;pica realizada nesse tempo de estudo n&a
tilde;o evidenciou estenose da anastomose esofagog&aacute;strica cervical, mas e
sofagite de coto esof&aacute;gico o que sugere refluxo gastroesof&aacute;gico. E
sses pacientes foram tratados com inibidor de bomba de pr&oacute;tons, com boa m
elhora. </font></p>     ^cY#v24n1a07.htm##
00611000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037600076002001300452#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#67#63#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Tanto esses pacientes como os demais
 estudados nesse per&iacute;odo referiram-se satisfeitos com o ato cir&uacute;rg
ico, pois conseguiram retornar de maneira adequada &agrave; degluti&ccedil;&atil
de;o, com aumento do peso corporal, sendo que 15 retornaram &agrave;s suas ativi
dades habituais. </font></p>     ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#68#64#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#69#65#article#136#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b> </font></p> 
    ^cY#v24n1a07.htm##
00795000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056000076002001300636#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#70#66#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O megaes&ocirc;fago avan&ccedil;ado 
sem tratamento anterior tem como caracter&iacute;stica a aus&ecirc;ncia de contr
atilidade adequada do corpo do es&ocirc;fago. Assim, procedimentos mais conserva
dores como a miotomia, n&atilde;o proporcionam bons resultados no al&iacute;vio 
da disfagia, embora na recidiva esse aspecto torna-se ainda mais evidente, devid
o &agrave; presen&ccedil;a de fibrose cicatricial, resultado da opera&ccedil;&at
ilde;o pr&eacute;via<sup>2,7,9,15</sup>. </font></p>     ^cY#v24n1a07.htm##
00959000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072400076002001300800#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#71#67#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Esses fatores incentivaram a padroni
za&ccedil;&atilde;o de procedimentos de melhora na drenagem do es&ocirc;fago de 
maior di&acirc;metro, principalmente em casos de recidiva. S&atilde;o recomendad
as as cardioplastias, dentre as quais se destacam as t&eacute;cnicas descritas p
or Thal, et al.<sup>27</sup> e Serra-D&oacute;ria, et al.<sup>26</sup>. Recentem
ente, alguns autores demonstraram bons resultados apenas em curto prazo, pois em
 maior tempo de seguimento, a maioria dos pacientes estudados nessas s&eacute;ri
es apresentou recidiva dos sintomas, o que requereu outro tipo de interven&ccedi
l;&atilde;o cir&uacute;rgica<sup>1,23</sup>. </font></p>     ^cY#v24n1a07.htm##
00550000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031500076002001300391#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#72#68#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O advento da esofagectomia sem torac
otomia preconizada por Pinotti<sup>22</sup>, instigou v&aacute;rios autores a em
pregar essa t&eacute;cnica para o megaes&ocirc;fago avan&ccedil;ado sem tratamen
to pr&eacute;vio<sup>4,10,28</sup>. </font></p>     ^cY#v24n1a07.htm##
00812000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057700076002001300653#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#73#69#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A grande vantagem desse procedimento
 &eacute; a ampla vis&atilde;o do es&ocirc;fago ao n&iacute;vel mediastinal para
 a sua ressec&ccedil;&atilde;o, pois &eacute; realizada frenotomia ampla na por&
ccedil;&atilde;o m&eacute;dia do diafragma, desde o hiato esof&aacute;gico at&ea
cute; o ap&ecirc;ndice xif&oacute;ide. Dessa forma, torna-se t&eacute;cnica cir&
uacute;rgica mais racionalizada pela via c&eacute;rvico-abdominal, conhecida com
o esofagectomia transmediastinal de Pinotti<sup>22</sup>. </font></p>     ^cY#v2
4n1a07.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066000076002001300736#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#74#70#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Outra vantagem &eacute; o fato de ev
itar o comprometimento da din&acirc;mica pulmonar pela n&atilde;o realiza&ccedil
;&atilde;o da toracotomia. Isso &eacute; de grande relev&acirc;ncia, pois muitos
 dos pacientes com megaes&ocirc;fago de grandes dimens&otilde;es apresentam afec
&ccedil;&otilde;es pulmonares, que se podem manifestar de maneira sub-cl&iacute;
nica, secund&aacute;ria &agrave; aspira&ccedil;&atilde;o intermitente e cr&ocirc
;nica do conte&uacute;do esof&aacute;gico para &aacute;rvore traqueobr&ocirc;nqu
ica, al&eacute;m do comprometimento pulmonar pelo tabagismo. </font></p>     ^cY
#v24n1a07.htm##
00838000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060300076002001300679#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#75#71#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Assim sendo, surgiu a ideia de reali
zar esse tipo de procedimento nos pacientes deste estudo, pois, al&eacute;m de s
erem portadores de megaes&ocirc;fago recidivado e de grandes dimens&otilde;es, 1
3 deles ainda apresentavam grande comprometimento do estado nutricional, com nec
essidade de suporte nutricional no pr&eacute;-operat&oacute;rio; ademais h&aacut
e; o fato de todos serem tabagistas. Assim, ao evitar a toracotomia consegue-se 
evitar maiores complica&ccedil;&otilde;es pulmonares para este perfil de pacient
es. </font></p>     ^cY#v24n1a07.htm##
01701000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704146600076002001301542#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#76#72#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Embora a ressec&ccedil;&atilde;o do 
es&ocirc;fago pela t&eacute;cnica transmediastinal tenha como proveito evitar o 
comprometimento da din&acirc;mica pulmonar, n&atilde;o h&aacute; isen&ccedil;&at
ilde;o de complica&ccedil;&otilde;es, principalmente se realizada na vig&ecirc;n
cia de recidiva. Dentre as intercorr&ecirc;ncias, destacase a abertura da pleura
 com consequente pneumot&oacute;rax, acarretando em maior morbidade p&oacute;s-o
perat&oacute;ria<sup>4,7,19,20</sup>. Isso pode ocorrer porque no megaes&ocirc;f
ago avan&ccedil;ado e recidivado al&eacute;m de existir a periesofagite que ader
e o es&ocirc;fago &agrave; face mediastinal da pleura, predisp&otilde;e tamb&eac
ute;m ader&ecirc;ncias cicatriciais pela opera&ccedil;&atilde;o pr&eacute;via, o
 que faz com que o cirurgi&atilde;o ao realizar o descolamento do es&ocirc;fago 
a n&iacute;vel mediastinal pela t&eacute;cnica proposta, pode lesar a pleura com
 a evolu&ccedil;&atilde;o para o pneumot&oacute;rax. Essa complica&ccedil;&atild
e;o acontece em at&eacute; 83%, como tem sido demonstrado em v&aacute;rias s&eac
ute;ries que utilizam esse procedimento para o tratamento do megaes&ocirc;fago a
van&ccedil;ado e recidivado<sup>4,17,19,20,22</sup>. Para prevenir essa complica
&ccedil;&atilde;o, nos casos deste estudo realizou-se drenagem de t&oacute;rax b
ilateral, no final do ato operat&oacute;rio em todos os pacientes. </font></p>  
   ^cY#v24n1a07.htm##
01192000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095700076002001301033#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#77#73#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Outra complica&ccedil;&atilde;o cons
equente &agrave; periesofagite com intensa ades&atilde;o do es&ocirc;fago &agrav
e;s estruturas mediastinais, &eacute; a les&atilde;o da veia &aacute;zigos e da 
traqu&eacute;ia. Apesar de pouco frequente, n&atilde;o ultrapassando a 8% na mai
oria das s&eacute;ries estudadas, uma vez presente pela grande repercuss&atilde;
o hemodin&acirc;mica, pode evoluir com grande morbimortalidade, mesmo realizando
 a toracotomia de imediato para tentar reparar essas lesadas<sup>17,19,20</sup> 
estruturas . Esse fato ocorreu em tr&ecirc;s pacientes, pois mesmo com a realiza
&ccedil;&atilde;o da sutura da veia &aacute;zigos e traqueia pela toracotomia di
reita, que foi indicada imediatamente ap&oacute;s a detec&ccedil;&atilde;o da in
stabilidade hemodin&acirc;mica e respirat&oacute;ria durante o ato operat&oacute
;rio, dois destes pacientes morreram. </font></p>     ^cY#v24n1a07.htm##
01052000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081700076002001300893#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#78#74#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A incid&ecirc;ncia de 28,1%% de deis
c&ecirc;ncia da anastomose esofagog&aacute;strica cervical, apesar de ser consid
erada elevada nesse estudo, &eacute; compat&iacute;vel com as s&eacute;ries que 
tamb&eacute;m preconizam a esofagectomia transmediastinal para esse tipo de afec
&ccedil;&atilde;o<sup>3,12,20</sup>. Geralmente essa complica&ccedil;&atilde;o &
eacute; ocasionada porque se atua em pacientes potencialmente desnutridos, como 
a maioria dos pacientes aqui relatados, al&eacute;m da possibilidade de ocorr&ec
irc;ncia de isquemia do fundo g&aacute;strico devido &agrave; tens&atilde;o da v
&iacute;scera ao se transpor a regi&atilde;o cervical para a realiza&ccedil;&ati
lde;o da anastomose com o coto do es&ocirc;fago cervical. </font></p>     ^cY#v2
4n1a07.htm##
01195000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704096000076002001301036#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#79#75#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Outra causa para essa complica&ccedi
l;&atilde;o seria o fato de todos os pacientes apresentarem a anastomose esofago
g&aacute;strica cervical realizada com a t&eacute;cnica manual. Isso porque em v
&aacute;rias s&eacute;ries, seja em afec&ccedil;&otilde;es benignas seja em mali
gnas, tem sido demonstrado que a sutura mec&acirc;nica, por ser invertida e dupl
a proporciona melhor coapta&ccedil;&atilde;o da linha de anastomose, favorecendo
, assim, a diminui&ccedil;&atilde;o desta complica&ccedil;&atilde;o<sup>3,6,8,20
</sup>. Entretanto, a f&iacute;stula consequente &agrave; anastomose esofagog&aa
cute;strica cervical &eacute; controlada na grande maioria das vezes, com o trat
amento conservador. Esse fato corrobora com o este estudo, pois todos os pacient
es com essa complica&ccedil;&atilde;o evolu&iacute;ram bem sem apresentar nenhum
a repercuss&atilde;o hemodin&acirc;mica. </font></p>     ^cY#v24n1a07.htm##
00853000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061800076002001300694#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#80#76#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Apesar da evolu&ccedil;&atilde;o ade
quada 40,0% dos pacientes apresentaram estenose da anastomose esofagog&aacute;st
rica cervical, o que retardou o in&iacute;cio da degluti&ccedil;&atilde;o plena 
para dieta s&oacute;lida com resolu&ccedil;&atilde;o desta complica&ccedil;&atil
de;o com a dilata&ccedil;&atilde;o endosc&oacute;pica. Isso tamb&eacute;m &eacut
e; demonstrado por outros, sendo a estenose normalmente ocasionada pela rea&cced
il;&atilde;o cicatricial que ocorre no fechamento da fistula da anastomose <sup>
3,5,7,16,19</sup>. </font></p>     ^cY#v24n1a07.htm##
00926000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069100076002001300767#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#81#77#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Significativa porcentagem de pacient
es apresentou infec&ccedil;&atilde;o pulmonar, (25,0%) mas com boa evolu&ccedil;
&atilde;o com o tratamento espec&iacute;fico, similar a outros estudos<sup>3,19,
20</sup>. Isso se deve &agrave; idade mais avan&ccedil;ada desses pacientes, j&a
acute; que cinco dos oito pacientes que apresentaram esta complica&ccedil;&atild
e;o tinham idade superior a 65 anos. Isto pode predispor &agrave; afec&ccedil;&o
tilde;es pulmonares muitas vezes subcl&iacute;nicas, associadas ao uso cont&iacu
te;nuo do tabaco, condi&ccedil;&atilde;o tamb&eacute;m presente nos pacientes de
ste estudo. </font></p>     ^cY#v24n1a07.htm##
01357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112200076002001301198#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#82#78#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nos 21 doentes analisados no per&iac
ute;odo de seis meses a 14 anos demonstraram estarem satisfeitos com ato operat&
oacute;rio realizado, pois conseguiram resgatar de modo adequado &agrave; deglut
i&ccedil;&atilde;o, o que melhorou em muito a qualidade de vida, j&aacute; que n
o pr&eacute;-operat&oacute;rio, a maioria deles apresentavam disfagia intensa. O
s quatro pacientes que apresentaram disfagia intermitente e de pequena intensida
de n&atilde;o tiveram a qualidade de vida comprometida retornando &agrave;s ativ
idades habituais. Poucos pacientes tiveram esofagite no coto cervical consequent
e ao refluxo do conte&uacute;do do est&ocirc;mago transposto; tiveram confirma&c
cedil;&atilde;o endosc&oacute;pica e melhoraram clinicamente com o uso de anti&a
acute;cido. A esofagite tamb&eacute;m tem sido demonstrada por outros autores na
 realiza&ccedil;&atilde;o desse tipo de procedimento, sendo ocasionada em sua gr
ande maioria pela estase g&aacute;strica do est&ocirc;mago transposto com o cons
equente refluxo<sup>2,4,10,17,19,20</sup>. </font></p>     ^cY#v24n1a07.htm##
00642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040700076002001300483#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#83#79#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Assim, apesar da esofagectomia trans
mediastinal no megaes&ocirc;fago avan&ccedil;ado recidivado apresentar vantagens
 por proporcionar qualidade de vida satisfat&oacute;ria, resgatando a degluti&cc
edil;&atilde;o adequada nos pacientes estudados da nossa s&eacute;rie, ela n&ati
lde;o foi isenta de complica&ccedil;&otilde;es. </font></p>     ^cY#v24n1a07.htm
##
00656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042100076002001300497#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#84#80#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Assim, procedimentos  que possam pro
porcionar menor morbidade, como a mucosectomia esof&aacute;gica com conserva&cce
dil;&atilde;o da t&uacute;nica muscular - t&eacute;cnica j&aacute; bem padroniza
da por estes autores -, pode ser op&ccedil;&atilde;o em pacientes com megaes&oci
rc;fago avan&ccedil;ado e n&atilde;o recidivado<sup>5,8. </sup></font></p>    ^c
Y#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#85#81#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#86#82#article#136#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Otilde;ES</b> </font></p>
      ^cY#v24n1a07.htm##
00604000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036900076002001300445#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#87#83#article#136#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A esofagectomia transmediastinal, ap
esar de proporcionar degluti&ccedil;&atilde;o adequada na maioria dos casos, &ea
cute; procedimento de grande morbidade. Ela n&atilde;o deve ser indicada como pr
imeira op&ccedil;&atilde;o no tratamento do megaes&ocirc;fago avan&ccedil;ado re
cidivado. </font></p>     ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#88#84#article#136#<p>&nbsp;</p>     ^
cY#v24n1a07.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#89#85#article#136#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS </b></font></p>
     ^cY#v24n1a07.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030600078002001300384#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#90#86#article#136#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Alves L, Zilberstei
n B, Trevenzol HP, Penhavel FAS. Opera&ccedil;&atilde;o de Serra-D&oacute;ria no
 Tratamento do Megaesofago Chagasico Avan&ccedil;ado: resultados imediatos. Arq 
Br&aacute;s Cir Dig. 2003;16(3): 120-123 </font></p>     ^cY#v24n1a07.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022000078002001300298#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#91#87#article#136#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Aquino JLB, Aquino-
Netto PA, Reis-Neto JA. Megaesofago Grau III: cirurgia conservadora ou radical? 
Rev Col Bras Cir 1988; 15(2): 76-9 </font></p>     ^cY#v24n1a07.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032000078002001300398#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#92#88#article#136#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Aquino JLB, Camardo
 JGT, Said MM, Palu B, Merhi VAL. Avalia&ccedil;&atilde;o da anastomose esofagog
&aacute;strica cervical com sutura mec&acirc;nica e manual em pacientes com mega
es&ocirc;fago avan&ccedil;ado. Rev Col Bras Cir 2009; 36(1): 19-23.    ^cY#v24n1
a07.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#93#89#article#136# </font></p>     ^c
Y#v24n1a07.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031500078002001300393#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#94#90#article#136#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 4. Aquino JLB, Ishida
 P, Muraro COM, Said MM, Reis-Neto JA. Megaes&ocirc;fago avan&ccedil;ado: analis
e de 54 casos. In Congresso Brasileiro de Gastroenterologia , 32. e Congresso Br
asileiro de Endoscopia Digestiva, 8. Natal 1992. Anais..pg 89.    ^cY#v24n1a07.h
tm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#95#91#article#136# </font></p>     ^c
Y#v24n1a07.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027400078002001300352#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#96#92#article#136#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 5. Aquino JLB, Reis-N
eto JA, Muraro CPM, Camargo JGT. Mucosectomia esof&aacute;gica no tratamento do 
megaes&ocirc;fago avan&ccedil;ado: analise de 60 casos. Rev Col Bras Cir 2000;27
: 109-16 </font></p>     ^cY#v24n1a07.htm##
00592000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034300078002001300421#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#97#93#article#136#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 6. Aquino JLB, Said M
M, Brandi LA, Oliveira JMVP, Maziero D, Merhi VAL. Tubo gastrico isoperistaltico
 de grande curvatura gastrica com sutura mec&acirc;nica no tratamento cirurgico 
do c&acirc;ncer de es&ocirc;fago irressec&aacute;vel. Arq Bras Cir Dig 2009; 22(
3):147-52.    ^cY#v24n1a07.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#98#94#article#136# </font></p>     ^c
Y#v24n1a07.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025200078002001300330#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#99#95#article#136#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Aquino JLB, Said MM
, Pereira EVA, 	Kelmann BV, Oliveira MB. Tratamento cir&uacute;rgico do megaes&o
circ;fago recidivado. Rev Col Br&aacute;s Cir. 2007; 34(5): 310-13 </font></p>  
   ^cY#v24n1a07.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704026700079002001300346#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#100#96#article#136#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 8. Aquino JLB. Avali
a&ccedil;&atilde;o da anastomose esofagog&aacute;strica cervical com sutura mec&
acirc;nica em pacientes com megaes&ocirc;fago avan&ccedil;ado. Rev Col Bras Cir.
2005; 3:143-46.    ^cY#v24n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#101#97#article#136# </font></p>     ^
cY#v24n1a07.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704029200079002001300371#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#102#98#article#136#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Barbosa H, Bariche
llo AW, Mendelssonh P. Tratamento cirurgicodo megaes&ocirc;fago cahgasico: duas 
d&eacute;cadas de experi&ecirc;ncia numa regi&atilde;o end&ecirc;mcia. Rev Goi&a
circ;nia Med. 1989; 35:1-23 </font></p>     ^cY#v24n1a07.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704020900080002001300289#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#103#99#article#136#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 10. Ceconello I, Do
mene CE, Sallum RA, Pinotti HW. Esofagectomia transmediastinal no megaes&ocirc;f
ago. Rev Col Bras Cir 1988; 15: 76-81.    ^cY#v24n1a07.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#104#100#article#136# </font></p>     
^cY#v24n1a07.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031600081002001300397#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#105#101#article#136#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 11. Ceconello I, F
elix VN, Pinotti HW. 	Reaplica&ccedil;&atilde;o de Miotomia e Fundoplicatura par
a Tratamento Cirurgico da Recidiva de Disfagia nos Casos de Miotomia Incompleta.
 Rev Hosp Clin Fac Med S. Paulo. 1998; 53(3): 129-133 </font></p>     ^cY#v24n1a
07.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#106#102#article#136#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 12. Ceconello I, R
ocha JMR, Zilberstein B, Domene CE, Pinotti HW. Esofagectomia sem toracotomia no
 megaesofago avan&ccedil;ado. In Congresso Brasileiro do Col&eacute;gio Brasilei
ro de Cirurgi&otilde;es, 19. Rio de janeiro, 1991. Anais pg 325.    ^cY#v24n1a07
.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#107#103#article#136# </font></p>     
^cY#v24n1a07.htm##
00647000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039500081002001300476#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#108#104#article#136#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Del Grande JC, 
Herbella FA. Megaes&ocirc;fago: Perspectivas Futuras. In Nakano SMS, Faintuch J,
 Cecconello I. Megaes&ocirc;fago Chag&aacute;sico. Avalia&ccedil;&atilde;o e Tra
tamento Clinico e Cir&uacute;rgico. 1ªedi&ccedil;&atilde;o. Goi&acirc;nia. Edito
ra da Universidade de Goi&aacute;s, 2006, pg:375-380 </font></p>     ^cY#v24n1a0
7.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022200081002001300303#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#109#105#article#136#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Dias JC, Silvei
ra AC, Schofield CJ. The impact of Chagas disease  control in Latin America: a r
eview. Mem Inst Oswaldo Cruz. 2002 Jul;97(5):603-12.    ^cY#v24n1a07.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#110#106#article#136# </font></p>     
^cY#v24n1a07.htm##
00592000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034000081002001300421#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#111#107#article#136#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 15. Herbella FAM, 
Del Grande JC, Louren&ccedil;o LG, Mansur NS, Haddad MC. Resultados tardios da o
pera&ccedil;&atilde;o de Heller associada &agrave; fundoplicatura no tratamento 
do megaes&ocirc;fago: analise de 83 casos. Rev Ass Med Bras. 1999; 45: 317-22 </
font></p>     ^cY#v24n1a07.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022000081002001300301#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#112#108#article#136#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 16. Martins P, Mor
ais BB, Cunha-Melo JR. Postoperative complications in the treatment of chagasic 
megaesophagus. Int Surg. 1993 AprJun;78(2):99-102.    ^cY#v24n1a07.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#113#109#article#136# </font></p>     
^cY#v24n1a07.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022000081002001300301#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#114#110#article#136#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 17. Miller DL, All
en MS, Trastek VF, Deschamps C, Pairolero PC. Esophageal resection for recurrent
 achalasia. Ann Thorac Surg. 1995 Oct;60(4):922-5.    ^cY#v24n1a07.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#115#111#article#136# </font></p>     
^cY#v24n1a07.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023000081002001300311#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#116#112#article#136#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 18. Muraro CPM, Ca
margo JGT, Aquino JLB. Megaes&ocirc;fago. In Muraro COM. 1ª edi&ccedil;&atilde;o
. Rio de Janeiro. Editora Rubio, 2009. pg:19-27 </font></p>     ^cY#v24n1a07.htm
##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#117#113#article#136#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Orringer MB, Ma
rshall B, Chang AC, Lee J, Pickens A, Lau CL. Two thousand transhiatal esophagec
tomies. Changing trends, lessons learned. Ann Surg 2007: 246: 363-74 </font></p>
     ^cY#v24n1a07.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021600081002001300297#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#118#114#article#136#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Orringer MB, Ma
rshall B, Stirling MC. Transhiatal esophagectomy for benign and malignant diseas
e. J Thorac Cardiovasc Surg 1993: 105: 265-76.    ^cY#v24n1a07.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#119#115#article#136# </font></p>     
^cY#v24n1a07.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019100081002001300272#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#120#116#article#136#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 21. Pearson FG. Ac
halasia  Long Term follow-up and late complications. Brasilia Med. 1995; 32(3/4
): 34-36 </font></p>     ^cY#v24n1a07.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020900081002001300290#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#121#117#article#136#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Pinotti HW. Eso
fagectomia subtotal por t&uacute;nel transmediastinal sem toracotomia. Rev Assoc
 Med Bras. 1977; 23: 395-8 </font></p>     ^cY#v24n1a07.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030300081002001300384#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#122#118#article#136#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Ponciano H, Cec
onello I, Alves L, Ferreira BD, Gama Rodrigues J. Cardioplasty and Roux  en  Y
 partial gastrectomy (SERRA-D&Oacute;RIA procedure) for reoperation of achalasia
. Arq Gastroenterol. 2004; 41(3): 155-61 </font></p>     ^cY#v24n1a07.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024200081002001300323#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#123#119#article#136#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Rezende JM, Lau
ar 	KM, Oliveira AR. Aspectos cl&iacute;nicos e radiol&oacute;gicos da aperistal
se do es&ocirc;fago. Rev Bras Gastroenterol 1960; 12:247-51 </font></p>     ^cY#
v24n1a07.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032500081002001300406#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#124#120#article#136#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Richards WO, To
rquati A, Holzman MD, Khaitan L, Byrne D, Lutfi R, Sharp KW. Heller myotomy vers
us Heller myotomy with Dor fundoplication for achalasia: a prospective randomize
d doubleblind clinical trial. Ann Surg. 2004 Sep;240(3):405-12 </font></p>     ^
cY#v24n1a07.htm##
00587000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033500081002001300416#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#125#121#article#136#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Serra D&oacute;
ria OB, Silva Doria OM, Silva D&oacute;ria OR. Opera&ccedil;&atilde;o de SerraD
&oacute;ria para Tratamento do Megaes&ocirc;fago. Considera&ccedil;&otilde;es qu
anto a Originalidade do m&eacute;todo. An Paul Med Cir. 1972; 99: 113-20 </font>
</p>     ^cY#v24n1a07.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022500081002001300306#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#126#122#article#136#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Thal AP, Hatafu
ku T, Kurtzman R. A new method for reconstruction of the esophagogastric junctio
n. Surg Gynecol Obstet. 1965; 120: 1225-31 </font></p>     ^cY#v24n1a07.htm##
00437000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018500081002001300266#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#127#123#article#136#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Ximenes Netto M
. Megaesophagus: current review of techiques and results. Rev Sa&uacute;de. 1991
; 2(4): 207-36.    ^cY#v24n1a07.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#128#124#article#136# </font></p>     
^cY#v24n1a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#129#125#article#136#<p>&nbsp;</p>    
 ^cY#v24n1a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#130#126#article#136#<p>&nbsp;</p>    
 ^cY#v24n1a07.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019800078002001300276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#131#127#article#136#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ec
irc;ncia:</b>    ^cY#v24n1a07.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002700078002001300105#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#132#128#article#136#<br> Italo Accett
a     ^cY#v24n1a07.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#133#129#article#136#<br> E-mail: <a h
ref="mailto:italo@urbi.com.br">italo@urbi.com.br</a> </font></p>      ^cY#v24n1a
07.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012200078002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#134#130#article#136#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 29/10/2010     ^cY#v24n1a07.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#135#131#article#136#<br> Aceito para 
publica&ccedil;&atilde;o: 21/12/2010    ^cY#v24n1a07.htm##
00295000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005800078002001300136#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#136#132#article#136#<br>  Fonte de fi
nanciamento: n&atilde;o h&aacute;    ^cY#v24n1a07.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007000078002001300148#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#137#133#article#136#<br> Conflito de 
interesses: n&atilde;o h&aacute; </font></p>     ^cY#v24n1a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#138#134#article#136#<p>&nbsp;</p>    
 ^cY#v24n1a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#139#135#article#136#<p>&nbsp;</p>    
 ^cY#v24n1a07.htm##
00523000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704028600078002001300364#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a07.htm#S#p#140#136#article#136#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Departamento
 de Cirurgia do Hospital Celso Pierro da Faculdade de Ci&ecirc;ncias M&eacute;di
cas da Pontif&iacute;cia Universidade Cat&oacute;lica de Campinas, Campinas, SP,
 Brasil. </font></p>     ^cY#v24n1a07.htm##
00621000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100021000920100
02000113010002000133012009800153030001700251710000200268065000900270064000500279
031000300284032000200287014000800289865000900297002001300306#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a07.htm#S#c#141#1#article#28#1#^rND^sAlves^nL#^rND^sZ
ilberstein^nB#^rND^sTrevenzol^nHP#^rND^sPenhavel^nFAS#Operação de Serra-Dória no
 Tratamento do Megaesofago Chagasico Avançado: resultados imediatos^lpt#Arq Brás
 Cir Dig#2#20030000#2003#16#3#120-123#20110300#v24n1a07.htm##
00590000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100023000950100
02000118012006000138030001700198065000900215064000500224031000300229032000200232
014000500234865000900239002001300248035001000261801001700271#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a07.htm#S#c#142#2#article#28#2#^rND^sAquino^nJLB#^rND
^sAquino-Netto^nPA#^rND^sReis-Neto^nJA#Megaesofago Grau III: cirurgia conservado
ra ou radical?^lpt#Rev Col Bras Cir#19880000#1988#15#2#76-9#20110300#v24n1a07.ht
m#0100-6991#Rev Col Bras Cir##
00697000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100019000950100
01500114010001400129010001700143012012000160030001700280065000900297064000500306
03100030031103200020031401400060031686500090032200200130033103500100034480100170
0354#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#c#143#3#article#28#
3#^rND^sAquino^nJLB#^rND^sCamardo^nJGT#^rND^sSaid^nMM#^rND^sPalu^nB#^rND^sMerhi^
nVAL#Avaliação da anastomose esofagogástrica cervical com sutura mecânica e manu
al em pacientes com megaesôfago avançado^lpt#Rev Col Bras Cir#20090000#2009#36#1
#19-23#20110300#v24n1a07.htm#0100-6991#Rev Col Bras Cir##
00697000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01800111010001500129010002100144012004600165053005200211053005400263056000900317
055001200326054000800338018001200346014000300358865000900361002001300370#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#c#144#4#article#28#4#^rND^sAqui
no^nJLB#^rND^sIshida^nP#^rND^sMuraro^nCOM#^rND^sSaid^nMM#^rND^sReis-Neto^nJA.#Me
gaesôfago avançado: analise de 54 casos^lpt#Congresso Brasileiro de Gastroentero
logia^i1^n32^i1#Congresso Brasileiro de Endoscopia Digestiva^i1^n8^i1#Natal^i1#1
9920000^i1#1992^i1#Anais..^lpt#89#20110300#v24n1a07.htm##
00630000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100020000950100
01800115010001900133012008600152030001700238065000900255064000500264031000300269
014000700272865000900279002001300288035001000301801001700311#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a07.htm#S#c#145#5#article#28#5#^rND^sAquino^nJLB#^rND
^sReis-Neto^nJA#^rND^sMuraro^nCPM#^rND^sCamargo^nJGT#Mucosectomia esofágica no t
ratamento do megaesôfago avançado: analise de 60 casos^lpt#Rev Col Bras Cir#2000
0000#2000#27#109-16#20110300#v24n1a07.htm#0100-6991#Rev Col Bras Cir##
00716000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100015000950100
01700110010002100127010001700148010001700165012014100182030001700323710000200340
06500090034206400050035103100030035603200020035901400070036186500090036800200130
0377#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#c#146#6#article#28#
6#^rND^sAquino^nJLB#^rND^sSaid^nMM#^rND^sBrandi^nLA#^rND^sOliveira^nJMVP#^rND^sM
aziero^nD#^rND^sMerhi^nVAL#Tubo gastrico isoperistaltico de grande curvatura gas
trica com sutura mecânica no tratamento cirurgico do câncer de esôfago irressecá
vel^lpt#Arq Bras Cir Dig#2#20090000#2009#22#3#147-52#20110300#v24n1a07.htm##
00598000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100015000950100
01900110010001800129010001900147012005100166030001700217710000200234065000900236
064000500245031000300250032000200253014000700255865000900262002001300271#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#c#147#7#article#28#7#^rND^sAqui
no^nJLB#^rND^sSaid^nMM#^rND^sPereira^nEVA#^rND^sKelmann^nBV#^rND^sOliveira^nMB#T
ratamento cirúrgico do megaesôfago recidivado^lpt#Rev Col Brás Cir#2#20070000#20
07#34#5#310-13#20110300#v24n1a07.htm##
00561000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120111000950300
01700206065000900223064000500232031000200237014000700239865000900246002001300255
035001000268801001700278#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S
#c#148#8#article#28#8#^rND^sAquino^nJLB#Avaliação da anastomose esofagogástrica 
cervical com sutura mecânica em pacientes com megaesôfago avançado^lpt#Rev Col B
ras Cir#20050000#2005#3#143-46#20110300#v24n1a07.htm#0100-6991#Rev Col Bras Cir#
#
00575000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100021000940100
02100115012009900136030001600235710000200251065000900253064000500262031000300267
014000500270865000900275002001300284#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a07.htm#S#c#149#9#article#28#9#^rND^sBarbosa^nH#^rND^sBarichello^nAW#^rND^sMe
ndelssonh^nP#Tratamento cirurgicodo megaesôfago cahgasico: duas décadas de exper
iência numa região endêmcia^lpt#Rev Goiânia Med#2#19890000#1989#35#1-23#20110300
#v24n1a07.htm##
00591000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001800132012005000150030001700200065000900217064000500226031000300231
014000600234865000900240002001300249035001000262801001700272#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a07.htm#S#c#150#10#article#28#10#^rND^sCeconello^nI#^
rND^sDomene^nCE#^rND^sSallum^nRA#^rND^sPinotti^nHW#Esofagectomia transmediastina
l no megaesôfago^lpt#Rev Col Bras Cir#19880000#1988#15#76-81#20110300#v24n1a07.h
tm#0100-6991#Rev Col Bras Cir##
00631000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01800114012012800132030003000260710000200290065000900292064000500301031000300306
032000200309014000800311865000900319002001300328#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a07.htm#S#c#151#11#article#28#11#^rND^sCeconello^nI#^rND^sFelix^n
VN#^rND^sPinotti^nHW#Reaplicação de Miotomia e Fundoplicatura para Tratamento Ci
rurgico da Recidiva de Disfagia nos Casos de Miotomia Incompleta^lpt#Rev Hosp Cl
in Fac Med S Paulo#2#19980000#1998#53#3#129-133#20110300#v24n1a07.htm##
00635000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
02100115010001700136010001900153012005800172053006700230056001800297055001200315
054000800327865000900335002001300344#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a07.htm#S#c#152#12#article#28#12#^rND^sCeconello^nI#^rND^sRocha^nJMR#^rND^sZi
lberstein^nB#^rND^sDomene^nCE#^rND^sPinotti^nHW.#Esofagectomia sem toracotomia n
o megaesofago avançado^lpt#Congresso Brasileiro do Colégio Brasileiro de Cirurgi
ões^i1^n19^i1#Rio de janeiro^i1#19910000^i1#1991^i1#20110300#v24n1a07.htm##
00686000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100020001000120
03800120016001800158016001800176016002100194018007000215063000200285066000800287
062003300295065000900328064000500337014000800342865000900350002001300359#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#c#153#13#article#28#13#^rND^sDe
l Grande^nJC#^rND^sHerbella^nFA.#Megaesôfago: Perspectivas Futuras^lpt#^rND^sNak
ano^nSMS#^rND^sFaintuch^nJ#^rND^sCecconello^nI.#Megaesôfago Chagásico: Avaliação
 e Tratamento Clinico e Cirúrgico^lpt#1#Goiânia#Editora da Universidade de Goiás
#20060000#2006#375-380#20110300#v24n1a07.htm##
00607000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
02000113012006800133030002200201065000900223064000700232031000300239032000200242
014000700244865000900251002001300260035001000273801002200283#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a07.htm#S#c#154#14#article#28#14#^rND^sDias^nJC#^rND^
sSilveira^nAC#^rND^sSchofield^nCJ#The impact of Chagas disease control in Latin 
America: a review^len#Mem Inst Oswaldo Cruz#20020700#200207#97#5#603-12#20110300
#v24n1a07.htm#0074-0276#Mem Inst Oswaldo Cruz##
00662000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100021000990100
01900120010001700139010001700156012012200173030001700295710000200312065000900314
064000500323031000300328014000700331865000900338002001300347#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a07.htm#S#c#155#15#article#28#15#^rND^sHerbella^nFAM#
^rND^sDel Grande^nJC#^rND^sLourenço^nLG#^rND^sMansur^nNS#^rND^sHaddad^nMC#Result
ados tardios da operação de Heller associada à fundoplicatura no tratamento do m
egaesôfago: analise de 83 casos^lpt#Rev Ass Med Bras#2#19990000#1999#45#317-22#2
0110300#v24n1a07.htm##
00596000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
02200113012007500135030000900210065000900219064001300228031000300241032000200244
014000700246865000900253002001300262035001000275801000900285#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a07.htm#S#c#156#16#article#28#16#^rND^sMartins^nP#^rN
D^sMorais^nBB#^rND^sCunha-Melo^nJR.#Postoperative complications in the treatment
 of chagasic megaesophagus^len#Int Surg#19930600#1993 Apr-Jun#78#2#99-102#201103
00#v24n1a07.htm#0020-8868#Int Surg##
00635000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01800112010001900130010002000149012004900169030001600218065000900234064000700243
03100030025003200020025301400060025586500090026100200130027003500100028380100160
0293#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#c#157#17#article#28
#17#^rND^sMiller^nDL#^rND^sAllen^nMS#^rND^sTrastek^nVF#^rND^sDeschamps^nC#^rND^s
Pairolero^nPC#Esophageal resection for recurrent achalasia^len#Ann Thorac Surg#1
9951000#199510#60#4#922-5#20110300#v24n1a07.htm#0003-4975#Ann Thorac Surg##
00533000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01900116012001600135016001900151063000200170066001500172062001400187065000900201
064000500210014000600215865000900221002001300230#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a07.htm#S#c#158#18#article#28#18#^rND^sMuraro^nCPM#^rND^sCamargo^
nJGT#^rND^sAquino^nJLB.#Megaesôfago^lpt#^rND^sMuraro^nCOM.#1#Rio de Janeiro#Edit
ora Rubio#20090000#2009#19-27#20110300#v24n1a07.htm##
00657000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01600116010001300132010001700145010001500162012007900177030000900256065000900265
06400050027403100040027901400070028386500090029000200130029903500100031280100090
0322#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#c#159#19#article#28
#19#^rND^sOrringer^nMB#^rND^sMarshall^nB#^rND^sChang^nAC#^rND^sLee^nJ#^rND^sPick
ens^nA#^rND^sLau^nCL.#Two thousand transhiatal esophagectomies: Changing trends,
 lessons learned^len#Ann Surg#20070000#2007#246#363-74#20110300#v24n1a07.htm#000
3-4932#Ann Surg##
00596000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
02000116012006300136030002500199065000900224064000500233031000400238014000700242
865000900249002001300258035001000271801002500281#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a07.htm#S#c#160#20#article#28#20#^rND^sOrringer^nMB#^rND^sMarshal
l^nB#^rND^sStirling^nMC.#Transhiatal esophagectomy for benign and malignant dise
ase^len#J Thorac Cardiovasc Surg#19930000#1993#105#265-76#20110300#v24n1a07.htm#
0022-5223#J Thorac Cardiovasc Surg##
00486000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120058000980300
01300156710000200169065000900171064000500180031000300185032000400188014000600192
865000900198002001300207#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S
#c#161#21#article#28#21#^rND^sPearson^nFG.#Achalasia: Long Term follow-up and la
te complications^len#Brasilia Med#2#19950000#1995#32#3/4#34-36#20110300#v24n1a07
.htm##
00526000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120070000970300
01900167065000900186064000500195031000300200014000600203865000900209002001300218
035001000231801001900241#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S
#c#162#22#article#28#22#^rND^sPinotti^nHW#Esofagectomia subtotal por túnel trans
mediastinal sem toracotomia^lpt#Rev Assoc Med Bras#19770000#1977#23#395-8#201103
00#v24n1a07.htm#0004-5241#Rev Assoc Med Bras##
00702000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01500116010001900131010002400150012010800174030001800282065000900300064000500309
03100030031403200020031701400070031986500090032600200130033503500100034880100180
0358#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S#c#163#23#article#28
#23#^rND^sPonciano^nH#^rND^sCeconello^nI#^rND^sAlves^nL#^rND^sFerreira^nBD#^rND^
sGama Rodrigues^nJ#Cardioplasty and Roux - en - Y partial gastrectomy (SERRA-DÓR
IA procedure) for reoperation of achalasia^len#Arq Gastroenterol#20040000#2004#4
1#3#155-61#20110300#v24n1a07.htm#0004-2803#Arq Gastroenterol##
00587000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01900113012006300132030002300195065000900218064000500227031000300232014000700235
865000900242002001300251035001000264801002300274#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a07.htm#S#c#164#24#article#28#24#^rND^sRezende^nJM#^rND^sLauar^nK
M#^rND^sOliveira^nAR#Aspectos clínicos e radiológicos da aperistalse do esôfago^
lpt#Rev Bras Gastroenterol#19600000#1960#12#247-51#20110300#v24n1a07.htm#0034-72
21#Rev Bras Gastroenterol##
00758000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01800116010001700134010001500151010001500166010001600181012013200197030000900329
06500090033806400070034703100040035403200020035801400070036086500090036700200130
0376035001000389801000900399#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.h
tm#S#c#165#25#article#28#25#^rND^sRichards^nWO#^rND^sTorquati^nA#^rND^sHolzman^n
MD#^rND^sKhaitan^nL#^rND^sByrne^nD#^rND^sLutfi^nR#^rND^sSharp^nKW#Heller myotomy
 versus Heller myotomy with Dor fundoplication for achalasia: a prospective rand
omized doubleblind clinical trial^len#Ann Surg#20040900#200409#240#3#405-12#2011
0300#v24n1a07.htm#0003-4932#Ann Surg##
00630000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100022001010100
02200123012010700145030001600252065000900268064000500277031000300282014000700285
865000900292002001300301035001000314801001600324#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a07.htm#S#c#166#26#article#28#26#^rND^sSerra Dória^nOB#^rND^sSilv
a Doria^nOM#^rND^sSilva Dória^nOR#Operação de Serra-Dória para Tratamento do Meg
aesôfago: Considerações quanto a Originalidade do método^lpt#An Paul Med Cir#197
20000#1972#99#113-20#20110300#v24n1a07.htm#0003-245X#An Paul Med Cir##
00586000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01800112012006800130030002000198065000900218064000500227031000400232014000800236
865000900244002001300253035001000266801002000276#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a07.htm#S#c#167#27#article#28#27#^rND^sThal^nAP#^rND^sHatafuku^nT
#^rND^sKurtzman^nR#A new method for reconstruction of the esophagogastric juncti
on^len#Surg Gynecol Obstet#19650000#1965#120#1225-31#20110300#v24n1a07.htm#0039-
6087#Surg Gynecol Obstet##
00486000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790120059001020300
01000161710000200171065000900173064000500182031000200187032000200189014000700191
865000900198002001300207#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a07.htm#S
#c#168#28#article#28#28#^rND^sXimenes Netto^nM#Megaesophagus: current review of 
techiques and results^len#Rev Saúde#2#19910000#1991#2#4#207-36#20110300#v24n1a07
.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#o#1#1#article#1
#20110411#103854#v24n1a08.htm#208##
05320000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000270011203100030013903200020014206500090014401400090015303500100016201200710
01720120070002430100047003130100027003600100026003870100025004130100029004380100
02900467010001600496010003600512010002300548083185700571085001002428085004602438
08500310248408500420251508500270255708318490258408500100443308500450444308500300
44880850037045180850027045551170008045820720003045901120009045931110011046021140
00904613113001104622002001304633#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a
08.htm#S#h#2#1#article#1#oa#pt#dados#1#4.0#ILUS#TAB#8#ABCD060#nd#ABCD, arq. bras
. cir. dig.#24#1#20110300#^f36^l42#0102-6720#Avaliação de refluxo ultra-distal c
om pHmetria de múltiplos canais^lpt#Ultra-distal reflux evaluation with multiple
 channel pHmonitoring^len#^rND^nFrancisco Carlos Bernal da Costa^sSeguro#^rND^nM
arco Aurélio^sSanto#^rND^nSérgio^sSzachnowicz#^rND^nFauze^sMaluf-Filho#^rND^nHum
berto Setsuo^sKishi#^rND^nÂngela Marinho^sFalcão#^rND^nAry^sNasi#^rND^nRubens An
tônio Aissar^sSallum#^rND^nIvan^sCecconello#^lpt^aRACIONAL: Displasia e adenocar
cinoma esofágico surge em pacientes com esôfago de Barrett submetidos a tratamen
to cirúrgico (fundoplicatura) com pHmetria esofágica sem evidência de acidez, o 
que sugere existir refluxo distal ao cateter de pHmetria convencional. OBJETIVO:
 Desenvolver metodologia para avaliar refluxo ultra-distal (1 cm acima da borda 
superior de esfíncter inferior do esôfago). MÉTODO: Foram selecionados 11 pacien
tes com esôfago de Barrett previamente submetidos à fundoplicatura à Nissen, sem
 sintomas de refluxo, com endoscopia e estudo contrastado de esôfago sem sinais 
de recidiva. Foi realizada manometria esofágica para avaliar a localização e a e
xtensão do esfíncter esofágico inferior (EIE). Realizou-se então pHmetria esofág
ica com quatro canais: canal A a 5 cm acima da borda superior do EIE; canal B a 
1 cm acima; canal C intraesfincteriano; canal D intragástrico. Avaliou-se o esco
re de DeMeester no canal A. Comparou-se o número de episódios de refluxo ácido, 
o número de episódios de refluxo prolongado e a fração de tempo com pH<4,0 nos c
anais A e B. Comparou-se a fração de tempo de pH<4,0 nos canais B e C. A fração 
de tempo com pH<4,0 acima de 50% no canal D foi usada como parâmetro para não mi
gração proximal do cateter. RESULTADOS: Houve aumento significativo do número de
 episódios de refluxo e da fração de tempo com pH<4,0 no canal B em relação ao c
anal A. Houve redução do tempo de pH<4,0 no canal B em comparação ao canal C. Do
is casos de adenocarcinoma esofágico foram diagnosticados nos pacientes do grupo
 estudado. CONCLUSÕES: A região 1 cm acima da borda superior do EIE está mais ex
posta à acidez do que a região 5 cm acima, embora em níveis reduzidos. A região 
1 cm acima da borda superior do EIE está menos exposta à acidez do que a região 
intraesfincteriana, demonstrando eficácia da fundoplicatura.#^ddecs^i1#^tm^lpt^k
Refluxo gastroesofágico^i1^scirurgia#^tm^lpt^kEsôfago de Barrett^i1#^tm^lpt^kMon
itoramento do pH esofágico^i1#^tm^lpt^kFundoplicatura^i1#^len^aBACKGROUND: Esoph
ageal adenocarcinoma and dysplasia in patients with Barrett's esophagus are seen
 after surgical treatment of GERD (fundoplication).Esophageal pH monitoring show
s no evidence of acidity, suggesting distal reflux to the conventional catheter 
positioning. AIM: To develop methodology for assessing ultra-distal reflux (1 cm
 above the top edge of the lower esophageal sphincter). METHOD: Were selected 11
 patients with Barrett's esophagus previously submitted to Nissen fundoplication
, without reflux symptoms and with endoscopy and contrasted study of esophagus w
ithout signs of relapse. Esophageal manometry was used to evaluate the location 
and length of the lower sphincter of the esophagus (LES). After that, esophageal
 pH monitoring with four channels was done: channel A at 5 cm above the top edge
 of the LES; channel B at 1 cm above; channel C, intra-sphincteric; channel D, i
ntragastric. The DeMeester score was assessed on channel A. The number of episod
es of acid reflux, the number of episodes of prolonged reflux and fraction of ti
me pH<4.0 were compared on channels A and B. The fraction of time pH<4.0 was com
pared on channels B and C. The fraction of time with pH<4.0 above 50% on channel
 D was used as parameter of no proximal migration of the catheter. RESULTS: Sign
ificant increase in the number of reflux episodes and fraction of time pH<4.0 in
 channel B in relation to channel A. Reduced fraction of time pH<4.0 in channel 
B compared to channel C was seen. Two cases of esophageal adenocarcinoma were di
agnosed in the group. CONCLUSIONS: The zone 1 cm above the top edge of the LES i
s more exposed to acidity than the one 5 cm above, although at reduced levels. T
he region 1 cm above the top edge of the LES is less exposed to acidity than the
 intrasphincteric zone, demonstrating efficacy of fundoplication.#^ddecs^i2#^tm^
len^kGastroesophageal reflux^i2^ssurgery#^tm^len^kBarrett esophagus^i2#^tm^len^k
Esophageal pH monitoring^i2#^tm^len^kFundoplication^i2#vancouv#32#20110106#06/01
/2011#20110125#25/01/2011#v24n1a08.htm##
05434000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000270011203100030013903200020014206500090014401400090015303500100016201200780
01720120077002500100047003270100027003740100026004010100025004270100029004520100
02900481010001600510010003600526010002300562083190700585085001002492085004602502
08500310254808500420257908500270262108318990264808500100454708500450455708500300
46020850037046320850027046691170008046960720003047041120009047071110011047161140
00904727113001104736002001304747#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a
08.htm#S#f#3#1#article#1#oa#pt#dados#1#4.0#ILUS#TAB#8#ABCD060#nd#ABCD, arq. bras
. cir. dig.#24#1#20110300#^f36^l42#0102-6720#<b>Avaliação de refluxo ultra-dista
l com pHmetria de múltiplos canais</b>^lpt#<b>Ultra-distal reflux evaluation wit
h multiple channel pHmonitoring</b>^len#^rND^nFrancisco Carlos Bernal da Costa^s
Seguro#^rND^nMarco Aurélio^sSanto#^rND^nSérgio^sSzachnowicz#^rND^nFauze^sMaluf-F
ilho#^rND^nHumberto Setsuo^sKishi#^rND^nÂngela Marinho^sFalcão#^rND^nAry^sNasi#^
rND^nRubens Antônio Aissar^sSallum#^rND^nIvan^sCecconello#^lpt^a<b>RACIONAL:</b>
 Displasia e adenocarcinoma esofágico surge em pacientes com esôfago de Barrett 
submetidos a tratamento cirúrgico (fundoplicatura) com pHmetria esofágica sem ev
idência de acidez, o que sugere existir refluxo distal ao cateter de pHmetria co
nvencional. <b>OBJETIVO: </b>Desenvolver metodologia para avaliar refluxo ultra-
distal (1 cm acima da borda superior de esfíncter inferior do esôfago). <b>MÉTOD
O:</b> Foram selecionados 11 pacientes com esôfago de Barrett previamente submet
idos à fundoplicatura à Nissen, sem sintomas de refluxo, com endoscopia e estudo
 contrastado de esôfago sem sinais de recidiva. Foi realizada manometria esofági
ca para avaliar a localização e a extensão do esfíncter esofágico inferior (EIE)
. Realizou-se então pHmetria esofágica com quatro canais: canal A a 5 cm acima d
a borda superior do EIE; canal B a 1 cm acima; canal C intraesfincteriano; canal
 D intragástrico. Avaliou-se o escore de DeMeester no canal A. Comparou-se o núm
ero de episódios de refluxo ácido, o número de episódios de refluxo prolongado e
 a fração de tempo com pH&lt;4,0 nos canais A e B. Comparou-se a fração de tempo
 de pH&lt;4,0 nos canais B e C. A fração de tempo com pH&lt;4,0 acima de 50% no 
canal D foi usada como parâmetro para não migração proximal do cateter. <b>RESUL
TADOS:</b> Houve aumento significativo do número de episódios de refluxo e da fr
ação de tempo com pH&lt;4,0 no canal B em relação ao canal A. Houve redução do t
empo de pH&lt;4,0 no canal B em comparação ao canal C. Dois casos de adenocarcin
oma esofágico foram diagnosticados nos pacientes do grupo estudado. <b>CONCLUSÕE
S:</b> A região 1 cm acima da borda superior do EIE está mais exposta à acidez d
o que a região 5 cm acima, embora em níveis reduzidos. A região 1 cm acima da bo
rda superior do EIE está menos exposta à acidez do que a região intraesfincteria
na, demonstrando eficácia da fundoplicatura.#^ddecs^i1#^tm^lpt^kRefluxo gastroes
ofágico^i1^scirurgia#^tm^lpt^kEsôfago de Barrett^i1#^tm^lpt^kMonitoramento do pH
 esofágico^i1#^tm^lpt^kFundoplicatura^i1#^len^a<b>BACKGROUND:</b> Esophageal ade
nocarcinoma and dysplasia in patients with Barrett's esophagus are seen after su
rgical treatment of GERD (fundoplication).Esophageal pH monitoring shows no evid
ence of acidity, suggesting distal reflux to the conventional catheter positioni
ng. <b>AIM: </b>To develop methodology for assessing ultra-distal reflux (1 cm a
bove the top edge of the lower esophageal sphincter). <b>METHOD: </b>Were select
ed 11 patients with Barrett's esophagus previously submitted to Nissen fundoplic
ation, without reflux symptoms and with endoscopy and contrasted study of esopha
gus without signs of relapse. Esophageal manometry was used to evaluate the loca
tion and length of the lower sphincter of the esophagus (LES). After that, esoph
ageal pH monitoring with four channels was done: channel A at 5 cm above the top
 edge of the LES; channel B at 1 cm above; channel C, intra-sphincteric; channel
 D, intragastric. The DeMeester score was assessed on channel A. The number of e
pisodes of acid reflux, the number of episodes of prolonged reflux and fraction 
of time pH&lt;4.0 were compared on channels A and B. The fraction of time pH&lt;
4.0 was compared on channels B and C. The fraction of time with pH&lt;4.0 above 
50% on channel D was used as parameter of no proximal migration of the catheter.
 <b>RESULTS:</b> Significant increase in the number of reflux episodes and fract
ion of time pH&lt;4.0 in channel B in relation to channel A. Reduced fraction of
 time pH&lt;4.0 in channel B compared to channel C was seen. Two cases of esopha
geal adenocarcinoma were diagnosed in the group. <b>CONCLUSIONS:</b> The zone 1 
cm above the top edge of the LES is more exposed to acidity than the one 5 cm ab
ove, although at reduced levels. The region 1 cm above the top edge of the LES i
s less exposed to acidity than the intrasphincteric zone, demonstrating efficacy
 of fundoplication.#^ddecs^i2#^tm^len^kGastroesophageal reflux^i2^ssurgery#^tm^l
en^kBarrett esophagus^i2#^tm^len^kEsophageal pH monitoring^i2#^tm^len^kFundoplic
ation^i2#vancouv#32#20110106#06/01/2011#20110125#25/01/2011#v24n1a08.htm##
05466000000000697000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000260013003100030015603200020015906500090016101400090017003500100
01790120071001890120070002600100047003300100027003770100026004040100025004300100
02900455010002900484010001600513010003600529010002300565083186600588085001002454
08500460246408500310251008500420254108500270258308318560261008500100446608500450
44760850030045210850037045510850027045881170008046150720003046231120009046261110
01104635114000904646113001104655002001304666008008904679#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a08.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#dados#1
#4.0#ilus#tab#8#ABCD060#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f36^l42#0102
-6720#Avaliação de refluxo ultra-distal com pHmetria de múltiplos canais^lpt#Ult
ra-distal reflux evaluation with multiple channel pHmonitoring^len#^rND^nFrancis
co Carlos Bernal da Costa^sSeguro#^rND^nMarco Aurélio^sSanto#^rND^nSérgio^sSzach
nowicz#^rND^nFauze^sMaluf-Filho#^rND^nHumberto Setsuo^sKishi#^rND^nÂngela Marinh
o^sFalcão#^rND^nAry^sNasi#^rND^nRubens Antônio Aissar^sSallum#^rND^nIvan^sCeccon
ello#^lpt^aRACIONAL: Displasia e adenocarcinoma esofágico surge em pacientes com
 esôfago de Barrett submetidos a tratamento cirúrgico (fundoplicatura) com pHmet
ria esofágica sem evidência de acidez, o que sugere existir refluxo distal ao ca
teter de pHmetria convencional. OBJETIVO: Desenvolver metodologia para avaliar r
efluxo ultra-distal (1 cm acima da borda superior de esfíncter inferior do esôfa
go). MÉTODO: Foram selecionados 11 pacientes com esôfago de Barrett previamente 
submetidos à fundoplicatura à Nissen, sem sintomas de refluxo, com endoscopia e 
estudo contrastado de esôfago sem sinais de recidiva. Foi realizada manometria e
sofágica para avaliar a localização e a extensão do esfíncter esofágico inferior
 (EIE). Realizou-se então pHmetria esofágica com quatro canais: canal A a 5 cm a
cima da borda superior do EIE; canal B a 1 cm acima; canal C intraesfincteriano;
 canal D intragástrico. Avaliou-se o escore de DeMeester no canal A. Comparou-se
 o número de episódios de refluxo ácido, o número de episódios de refluxo prolon
gado e a fração de tempo com pH<4,0 nos canais A e B. Comparou-se a fração de te
mpo de pH<4,0 nos canais B e C. A fração de tempo com pH<4,0 acima de 50 por cen
to no canal D foi usada como parâmetro para não migração proximal do cateter. RE
SULTADOS: Houve aumento significativo do número de episódios de refluxo e da fra
ção de tempo com pH<4,0 no canal B em relação ao canal A. Houve redução do tempo
 de pH<4,0 no canal B em comparação ao canal C. Dois casos de adenocarcinoma eso
fágico foram diagnosticados nos pacientes do grupo estudado. CONCLUSÕES: A regiã
o 1 cm acima da borda superior do EIE está mais exposta à acidez do que a região
 5 cm acima, embora em níveis reduzidos. A região 1 cm acima da borda superior d
o EIE está menos exposta à acidez do que a região intraesfincteriana, demonstran
do eficácia da fundoplicatura.#^ddecs^i1#^tm^lpt^kRefluxo gastroesofágico^i1^sci
rurgia#^tm^lpt^kEsôfago de Barrett^i1#^tm^lpt^kMonitoramento do pH esofágico^i1#
^tm^lpt^kFundoplicatura^i1#^len^aBACKGROUND: Esophageal adenocarcinoma and dyspl
asia in patients with Barrett's esophagus are seen after surgical treatment of G
ERD (fundoplication).Esophageal pH monitoring shows no evidence of acidity, sugg
esting distal reflux to the conventional catheter positioning. AIM: To develop m
ethodology for assessing ultra-distal reflux (1 cm above the top edge of the low
er esophageal sphincter). METHOD: Were selected 11 patients with Barrett's esoph
agus previously submitted to Nissen fundoplication, without reflux symptoms and 
with endoscopy and contrasted study of esophagus without signs of relapse. Esoph
ageal manometry was used to evaluate the location and length of the lower sphinc
ter of the esophagus (LES). After that, esophageal pH monitoring with four chann
els was done: channel A at 5 cm above the top edge of the LES; channel B at 1 cm
 above; channel C, intra-sphincteric; channel D, intragastric. The DeMeester sco
re was assessed on channel A. The number of episodes of acid reflux, the number 
of episodes of prolonged reflux and fraction of time pH<4.0 were compared on cha
nnels A and B. The fraction of time pH<4.0 was compared on channels B and C. The
 fraction of time with pH<4.0 above 50 percent on channel D was used as paramete
r of no proximal migration of the catheter. RESULTS: Significant increase in the
 number of reflux episodes and fraction of time pH<4.0 in channel B in relation 
to channel A. Reduced fraction of time pH<4.0 in channel B compared to channel C
 was seen. Two cases of esophageal adenocarcinoma were diagnosed in the group. C
ONCLUSIONS: The zone 1 cm above the top edge of the LES is more exposed to acidi
ty than the one 5 cm above, although at reduced levels. The region 1 cm above th
e top edge of the LES is less exposed to acidity than the intrasphincteric zone,
 demonstrating efficacy of fundoplication.#^ddecs^i2#^tm^len^kGastroesophageal r
eflux^i2^ssurgery#^tm^len^kBarrett esophagus^i2#^tm^len^kEsophageal pH monitorin
g^i2#^tm^len^kFundoplication^i2#vancouv#32#20110106#06/01/2011#20110125#25/01/20
11#v24n1a08.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid
=S0102-67202011000100008##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#5#1#article#172#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"> <b>ARTIGO ORIGINAL</b><
/font></p>     ^cY#v24n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#6#2#article#172#<p>&nbsp;</p>     ^cY
#v24n1a08.htm##
00431000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704019800074002001300272#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#7#3#article#172#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><b><a name="note1"></a>Avalia&ccedil;&
atilde;o de refluxo ultra-distal com pHmetria de m&uacute;ltiplos canais </b></f
ont></p>     ^cY#v24n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#8#4#article#172#<p>&nbsp;</p>     ^cY
#v24n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#9#5#article#172#<p>&nbsp;</p>     ^cY
#v24n1a08.htm##
00559000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704032500075002001300400#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#10#6#article#172#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Francisco Carlos Bernal da Costa S
eguro; Marco Aur&eacute;lio Santo; S&eacute;rgio Szachnowicz; Fauze Maluf-Filho;
 Humberto Setsuo Kishi; &Acirc;ngela Marinho Falc&atilde;o; Ary Nasi; Rubens Ant
&ocirc;nio Aissar Sallum; Ivan Cecconello</b></font></p>     ^cY#v24n1a08.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#11#7#article#172#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a08.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#12#8#article#172#<p>&nbsp;</p>     ^c
Y#v24n1a08.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#13#9#article#172#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a08.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#14#10#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a08.htm##
00606000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037100076002001300447#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#15#11#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL:</b> Displasia e adenoca
rcinoma esof&aacute;gico surge em pacientes com es&ocirc;fago de Barrett submeti
dos a tratamento cir&uacute;rgico (fundoplicatura) com pHmetria esof&aacute;gica
 sem evid&ecirc;ncia de acidez, o que sugere existir refluxo distal ao cateter d
e pHmetria convencional.    ^cY#v24n1a08.htm##
00401000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016600076002001300242#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#16#12#article#172#<br>  <b>OBJETIVO: 
</b>Desenvolver metodologia para avaliar refluxo ultra-distal (1 cm acima da bor
da superior de esf&iacute;ncter inferior do es&ocirc;fago).    ^cY#v24n1a08.htm#
#
01328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109300076002001301169#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#17#13#article#172#<br> <b>M&Eacute;TO
DO:</b> Foram selecionados 11 pacientes com es&ocirc;fago de Barrett previamente
 submetidos &agrave; fundoplicatura &agrave; Nissen, sem sintomas de refluxo, co
m endoscopia e estudo contrastado de es&ocirc;fago sem sinais de recidiva. Foi r
ealizada manometria esof&aacute;gica para avaliar a localiza&ccedil;&atilde;o e 
a extens&atilde;o do esf&iacute;ncter esof&aacute;gico inferior (EIE). Realizou-
se ent&atilde;o pHmetria esof&aacute;gica com quatro canais: canal A a 5 cm acim
a da borda superior do EIE; canal B a 1 cm acima; canal C intraesfincteriano; ca
nal D intrag&aacute;strico. Avaliou-se o escore de DeMeester no canal A. Comparo
u-se o n&uacute;mero de epis&oacute;dios de refluxo &aacute;cido, o n&uacute;mer
o de epis&oacute;dios de refluxo prolongado e a fra&ccedil;&atilde;o de tempo co
m pH&lt;4,0 nos canais A e B. Comparou-se a fra&ccedil;&atilde;o de tempo de pH&
lt;4,0 nos canais B e C. A fra&ccedil;&atilde;o de tempo com pH&lt;4,0 acima de 
50% no canal D foi usada como par&acirc;metro para n&atilde;o migra&ccedil;&atil
de;o proximal do cateter.     ^cY#v24n1a08.htm##
00640000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040500076002001300481#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#18#14#article#172#<br> <b>RESULTADOS:
</b> Houve aumento significativo do n&uacute;mero de epis&oacute;dios de refluxo
 e da fra&ccedil;&atilde;o de tempo com pH&lt;4,0 no canal B em rela&ccedil;&ati
lde;o ao canal A. Houve redu&ccedil;&atilde;o do tempo de pH&lt;4,0 no canal B e
m compara&ccedil;&atilde;o ao canal C. Dois casos de adenocarcinoma esof&aacute;
gico foram diagnosticados nos pacientes do grupo estudado.    ^cY#v24n1a08.htm##
00636000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040100076002001300477#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#19#15#article#172#<br>  <b>CONCLUS&Ot
ilde;ES:</b>  A regi&atilde;o 1 cm acima da borda superior do EIE est&aacute; ma
is exposta &agrave; acidez do que a regi&atilde;o 5 cm acima, embora em n&iacute
;veis reduzidos. A regi&atilde;o 1 cm acima da borda superior do EIE est&aacute;
 menos exposta &agrave; acidez do que a regi&atilde;o intraesfincteriana, demons
trando efic&aacute;cia da fundoplicatura. </font></p>     ^cY#v24n1a08.htm##
00481000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024600076002001300322#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#20#16#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b>Refluxo gastroes
of&aacute;gico/cirurgia. Es&ocirc;fago de Barrett. Monitoramento do pH esof&aacu
te;gico. Fundoplicatura. </font></p> <hr size="1" noshade>     ^cY#v24n1a08.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#21#17#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#22#18#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#23#19#article#172#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></fon
t></p>         ^cY#v24n1a08.htm##
01035000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080000076002001300876#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#24#20#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A doen&ccedil;a do refluxo gastroeso
f&aacute;gico (DRGE) apresenta alta preval&ecirc;ncia na popula&ccedil;&atilde;o
. No ocidente, a ocorr&ecirc;ncia de queima&ccedil;&atilde;o retroesternal ou re
gurgita&ccedil;&atilde;o &aacute;cida uma vez por semana varia de 15 a 25% da po
pula&ccedil;&atilde;o, enquanto na &Aacute;sia &eacute; inferior a 5%<sup>26</su
p>. No Brasil, cerca de 12% da popula&ccedil;&atilde;o apresenta queima&ccedil;&
atilde;o retroesternal ao menos uma vez por semana<sup>17</sup>. Definese como D
RGE a condi&ccedil;&atilde;o que se desenvolve quando o refluxo de conte&uacute;
do g&aacute;strico causa sintomas ou complica&ccedil;&otilde;es que afetem a qua
lidade de vida do paciente<sup>26</sup>. </font></p>     ^cY#v24n1a08.htm##
00772000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053700076002001300613#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#25#21#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O es&ocirc;fago de Barrett &eacute; 
altera&ccedil;&atilde;o da mucosa esof&aacute;gica decorrente do refluxo gastroe
sof&aacute;gico intenso e prolongado que determina desenvolvimento de metaplasia
 colunar do tipo intestinal e ocorre em 1 a 2% dos casos de DRGE<sup>26</sup>. N
o entanto, at&eacute; 10 a 15% dos pacientes com sintomas cr&ocirc;nicos de refl
uxo submetidos &agrave; endoscopia podem apresentar-se com es&ocirc;fago de Barr
ett<sup>17</sup>. </font></p>     ^cY#v24n1a08.htm##
00739000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050400076002001300580#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#26#22#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A import&acirc;ncia dele reside na s
ua rela&ccedil;&atilde;o potencial com o adenocarcinoma esof&aacute;gico. No mun
do ocidental, a frequ&ecirc;ncia de adenocarcinoma do es&ocirc;fago apresentou g
rande eleva&ccedil;&atilde;o nos &uacute;ltimos anos, atualmente caracterizando-
se como o tumor esof&aacute;gico mais comum em alguns pa&iacute;ses, superando a
 incid&ecirc;ncia do carcinoma espinocelular<sup>24,25,30</sup>. </font></p>    
 ^cY#v24n1a08.htm##
01375000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704114000076002001301216#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#27#23#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A meta do tratamento dos pacientes c
om es&ocirc;fago de Barrett &eacute; interromper a agress&atilde;o tecidual que 
provoca inflama&ccedil;&atilde;o e progress&atilde;o para displasia e c&acirc;nc
er. Para tal fim, deve-se evitar o refluxo &aacute;cido gastroesof&aacute;gico, 
tido como o principal est&iacute;mulo lesivo para a mucosa esof&aacute;gica. O t
ratamento pode ser cl&iacute;nico, baseado em medidas comportamentais para dimin
ui&ccedil;&atilde;o do refluxo e no uso de medicamentos para inibir a produ&cced
il;&atilde;o de &aacute;cido pelo est&ocirc;mago. O tratamento cir&uacute;rgico 
evita a ocorr&ecirc;ncia de refluxo atrav&eacute;s da confec&ccedil;&atilde;o de
 v&aacute;lvula anti-refluxo, determinando aumento dos n&iacute;veis de press&at
ilde;o do esf&iacute;ncter inferior do es&ocirc;fago (EIE) e normaliza&ccedil;&a
tilde;o da exposi&ccedil;&atilde;o do es&ocirc;fago distal ao &aacute;cido e, po
rtanto, maior controle do refluxo, sendo assim o tratamento melhor indicado para
 pacientes com es&ocirc;fago de Barrett<sup>2,8,11,23</sup>. </font></p>     ^cY
#v24n1a08.htm##
00953000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071800076002001300794#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#28#24#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Para se avaliar o sucesso do tratame
nto, podese utilizar par&acirc;metro cl&iacute;nico de controle dos sintomas rel
acionados ao refluxo, ou exames complementares. A endoscopia digestiva alta pode
 detectar falha do tratamento, com presen&ccedil;a de esofagite ou progress&atil
de;o do epit&eacute;lio metapl&aacute;sico. O estudo contrastado do es&ocirc;fag
o avalia a ocorr&ecirc;ncia de refluxo durante o exame. Por&eacute;m, a pHmetria
 esof&aacute;gica prolongada &eacute; o melhor exame para determinar a presen&cc
edil;a de refluxo &aacute;cido gastroesof&aacute;gico, considerado como padr&ati
lde;o para este fim<sup>6,13,18</sup>. </font></p>     ^cY#v24n1a08.htm##
01009000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077400076002001300850#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#29#25#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Chama &agrave; aten&ccedil;&atilde;o
 a exist&ecirc;ncia de alguns pacientes que desenvolvem displasia e mesmo adenoc
arcinoma comprovados por exames complementares - incluindo a pHmetria convencion
al -, durante o seguimento ap&oacute;s tratamento bem sucedido<sup>1,22</sup>. I
sso suscita a hip&oacute;tese de refluxo em segmento de es&ocirc;fago mais dista
l, n&atilde;o detect&aacute;vel pelos m&eacute;todos de investiga&ccedil;&atilde
;o atualmente empregados, pois a pHmetria convencional avalia refluxo em posi&cc
edil;&atilde;o 5 cm acima da borda superior do EIE, com limita&ccedil;&atilde;o 
para avaliar acidez abaixo desse n&iacute;vel, na regi&atilde;o ultra-distal do 
es&ocirc;fago. </font></p>     ^cY#v24n1a08.htm##
00913000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067800076002001300754#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#30#26#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Alguns autores estudaram o padr&atil
de;o de refluxo ultradistal com diferentes m&eacute;todos. Fletcher et al. reali
zaram estudo com cateter de pHmetria com dois canais, fixando o cateter ao es&oc
irc;fago com clips endosc&oacute;picos<sup>9</sup>. Pandolfino et al. e Wenner e
t al utilizaram o sistema Bravo de pHmetria sem cateter, com sensores fixados &a
grave; mucosa esof&aacute;gica logo acima da transi&ccedil;&atilde;o es&ocirc;fa
go g&aacute;strica<sup>20,31,32</sup>. Todos os autores observaram maior exposi&
ccedil;&atilde;o &aacute;cida nos n&iacute;veis mais distais do es&ocirc;fago. <
/font></p>     ^cY#v24n1a08.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031000076002001300386#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#31#27#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Como h&aacute; grande varia&ccedil;&
atilde;o nas t&eacute;cnicas utilizadas, a proposta deste estudo foi o desenvolv
imento de metodologia adequada para padronizar o estudo do refluxo &aacute;cido 
ultra-distal no es&ocirc;fago. </font></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#32#28#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
01355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112000076002001301196#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#33#29#article#172#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODO </b></font>   </p> 
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">Onze pacientes com e
s&ocirc;fago de Barrett previamente submetidos &agrave; fundoplicatura a Nissen 
para tratamento do refluxo gastroesof&aacute;gico foram selecionados, utilizando
-se os seguintes crit&eacute;rios de inclus&atilde;o: tempo de seguimento p&oacu
te;s-operat&oacute;rio de pelo menos um ano; extens&atilde;o de epit&eacute;lio 
colunar com metaplasia intestinal igual ou superior a 1 cm no per&iacute;odo pr&
eacute;-operat&oacute;rio; completo controle dos sintomas de refluxo gastroesof&
aacute;gico; aus&ecirc;ncia de uso de inibidor de bomba prot&ocirc;nica por qual
quer raz&atilde;o; endoscopia digestiva alta com aus&ecirc;ncia de esofagite e d
e h&eacute;rnia hiatal de deslizamento ou paraesof&aacute;gica, fundoplicatura t
&oacute;pica e com morfologia adequada; exame contrastado de es&ocirc;fago mostr
ando presen&ccedil;a de fundoplicatura intra-abdominal e &iacute;ntegra, e aus&e
circ;ncia de refluxo gastroesof&aacute;gico. </font>     ^cY#v24n1a08.htm##
00573000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033800076002001300414#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#34#30#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A seguir, realizou-se manometria eso
f&aacute;gica, com intuito de avaliar a localiza&ccedil;&atilde;o do EIE e de su
as bordas proximal e distal, sua extens&atilde;o e press&atilde;o em repouso, pa
ra permitir correto posicionamento do cateter de pHmetria. </font></p>     ^cY#v
24n1a08.htm##
01547000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704131200076002001301388#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#35#31#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Por fim, o estudo envolvia a realiza
&ccedil;&atilde;o de pHmetria com cateter de quatro canais, dispostos da seguint
e maneira (<a href="#fig1">Figura 1</a>): canal A posicionava-se 5 cm acima da b
orda superior do EIE, conforme padroniza&ccedil;&atilde;o para pHmetria esof&aac
ute;gica prolongada; canal B localizava-se 4 cm abaixo do canal A, ou seja, 1 cm
 acima da borda superior do EIE para avaliar refluxo &aacute;cido em n&iacute;ve
l mais distal do es&ocirc;fago; canal C posicionava-se dentro da extens&atilde;o
 do EIE, 3 cm abaixo do canal B; canal D permanecia no interior do est&ocirc;mag
o, logo abaixo da borda inferior do EIE, 3 cm abaixo do canal C. O canal B perma
necia 2 cm abaixo da borda superior do EIE para avaliar a efetividade da conten&
ccedil;&atilde;o do refluxo da regi&atilde;o intra-esfincteriana para a regi&ati
lde;o 1 cm acima da borda superior do EIE, ao compararem-se os resultados obtido
s nos canais C com os resultados obtidos em B. O canal C teve como fun&ccedil;&a
tilde;o avaliar a perman&ecirc;ncia do cateter em sua posi&ccedil;&atilde;o orig
inal durante o tempo do exame, pois a eleva&ccedil;&atilde;o mantida do pH suger
iria migra&ccedil;&atilde;o proximal do cateter, invalidando o resultado.</font>
</p>     ^cY#v24n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#36#32#article#172#<p><a name="fig1"><
/a></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#37#33#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#38#34#article#172#<p align="center"><
img src="/img/revistas/abcd/v24n1/a08fig1.jpg"></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#39#35#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00669000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043400076002001300510#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#40#36#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os par&acirc;metros analisados no ca
nal A foram o n&uacute;mero de epis&oacute;dios de refluxo &aacute;cido, n&uacut
e;mero de epis&oacute;dios de refluxo prolongado (acima de cinco minutos), fra&c
cedil;&atilde;o de tempo com pH inferior a 4,0 (considerando-se como normal at&e
acute; 4,2% da fra&ccedil;&atilde;o total do tempo) e escore de DeMeester. </fon
t></p>     ^cY#v24n1a08.htm##
00907000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067200076002001300748#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#41#37#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No canal B, avaliaram-se o n&uacute;
mero de epis&oacute;dios de refluxo, o n&uacute;mero de epis&oacute;dios prolong
ados e a fra&ccedil;&atilde;o de tempo com pH inferior a 4,0, considerando-se no
rmal at&eacute; 1,5% da fra&ccedil;&atilde;o total do tempo. O escore de DeMeest
er n&atilde;o foi utilizado por tratar-se de par&acirc;metro bem estabelecido pa
ra avalia&ccedil;&atilde;o de refluxo em pHmetria convencional, com cateter 5 cm
 acima da borda superior do EIE, sem padroniza&ccedil;&atilde;o para interpreta&
ccedil;&atilde;o de resultados em outros n&iacute;veis do es&ocirc;fago. </font>
</p>     ^cY#v24n1a08.htm##
00447000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021200076002001300288#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#42#38#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nos canais C e D, apenas a fra&ccedi
l;&atilde;o de tempo com pH inferior a 4,0 foi utilizada para an&aacute;lise dos
 resultados. </font></p>     ^cY#v24n1a08.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#43#39#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Utilizando-se m&eacute;todo de Wilco
xon, compararamse os resultados obtidos entre os canais A e B e entre os canais 
B e C. </font></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#44#40#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#45#41#article#172#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b> </font> </p>     ^
cY#v24n1a08.htm##
00799000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056400076002001300640#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#46#42#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise dos resultados do c
anal A mostrou n&uacute;mero de epis&oacute;dios de refluxo variando de 0 a 57 o
corr&ecirc;ncias, com mediana de 2. O n&uacute;mero de epis&oacute;dios prolonga
dos variou de 0 a 3, com mediana de 0. Com rela&ccedil;&atilde;o &agrave; fra&cc
edil;&atilde;o de tempo com pH inferior a 4,0, a varia&ccedil;&atilde;o foi de 0
% a 9,8%, com mediana de 0,1%. O escore de DeMeester variou de 0,3 a 52,5, com m
ediana de 1,1 (<a href="#tab1">Tabela 1</a>).</font></p>     ^cY#v24n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#47#43#article#172#<p><a name="tab1"><
/a></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#48#44#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#49#45#article#172#<p align="center"><
img src="/img/revistas/abcd/v24n1/a08tab1.jpg"></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#50#46#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00652000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041700076002001300493#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#51#47#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os resultados do canal B mostraram n
&uacute;mero de epis&oacute;dios de refluxo variando de 2 a 274, com mediana de 
78. O n&uacute;mero de epis&oacute;dios prolongados variou de 0 a 20, com median
a de 0. A fra&ccedil;&atilde;o de tempo com pH inferior a 4,0 variou de 0,1% a 4
1,9%, com mediana de 1,3% (<a href="#tab2">Tabela 2</a>). </font></p>     ^cY#v2
4n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#52#48#article#172#<p><a name="tab2"><
/a></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#53#49#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#54#50#article#172#<p align="center"><
img src="/img/revistas/abcd/v24n1/a08tab2.jpg"></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#55#51#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00497000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026200076002001300338#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#56#52#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ao analisar-se o canal C de todos os
 pacientes, a fra&ccedil;&atilde;o de tempo com pH inferior a 4,0 variou de 19,7
% a 95,2%,com mediana de 38,7% (<a href="#tab3">Tabela 3</a>). </font></p>     ^
cY#v24n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#57#53#article#172#<p><a name="tab3"><
/a></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#58#54#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#59#55#article#172#<p align="center"><
img src="/img/revistas/abcd/v24n1/a08tab3.jpg" ></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#60#56#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00683000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044800076002001300524#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#61#57#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ao compararem-se os resultados obtid
os nos canais A e B, observa-se aumento significativo do n&uacute;mero de epis&o
acute;dios de refluxo no canal B e da fra&ccedil;&atilde;o de tempo com pH&lt;4,
0. H&aacute; aumento do n&uacute;mero de epis&oacute;dios de refluxo prolongado,
 por&eacute;m sem signific&acirc;ncia estat&iacute;stica (<a href="#tab4">Tabela
 4</a>). </font></p>     ^cY#v24n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#62#58#article#172#<p><a name="tab4"><
/a></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#63#59#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#64#60#article#172#<p align="center"><
img src="/img/revistas/abcd/v24n1/a08tab4.jpg"></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#65#61#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00601000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036600076002001300442#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#66#62#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os resultados obtidos nos canais B e
 C permitem observar que em todos os casos houve redução significativa da exposi
ção ácida no nível do canal B quando comparada ao canal C, demonstrando a capaci
dade da fundoplicatura de conter o refluxo ultra-distal (<a href="#tab5">Tabela 
5</a>).</font></p>     ^cY#v24n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#67#63#article#172#<p><a name="tab5"><
/a></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#68#64#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#69#65#article#172#<p align="center"><
img src="/img/revistas/abcd/v24n1/a08tab5.jpg"></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#70#66#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00848000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061300076002001300689#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#71#67#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O que se observa &eacute; que a redu
&ccedil;&atilde;o da exposi&ccedil;&atilde;o &aacute;cida entre os canais C e B 
&eacute; mais acentuada do que o aumento da exposi&ccedil;&atilde;o entre os can
ais A e B, o que tamb&eacute;m refor&ccedil;a a afirma&ccedil;&atilde;o de que a
 fundoplicatura foi eficaz em conter o refluxo, pois a exposi&ccedil;&atilde;o &
aacute;cida no n&iacute;vel do esf&iacute;ncter &eacute; bastante elevada e apes
ar disso o es&ocirc;fago &eacute; pouco exposto a essa acidez (<a href="#fig2">F
igura 2</a>). </font></p>     ^cY#v24n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#72#68#article#172#<p><a name="fig2"><
/a></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#73#69#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#74#70#article#172#<p align="center"><
img src="/img/revistas/abcd/v24n1/a08fig2.jpg"></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#75#71#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018500076002001300261#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#76#72#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Durante o seguimento destes paciente
s, dois foram diagnosticados com adenocarcinoma de es&ocirc;fago. </font></p>   
  ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#77#73#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#78#74#article#172#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>  
   ^cY#v24n1a08.htm##
00792000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055700076002001300633#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#79#75#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O interesse deste trabalho foi avali
ar se h&aacute; m&eacute;todo efetivo de estudo para determinar o controle do re
fluxo &aacute;cido gastroesof&aacute;gico, com maior sensibilidade que os exames
 atualmente utilizados de forma rotineira. Por essa raz&atilde;o, a escolha do g
rupo de pacientes baseou se em crit&eacute;rios r&iacute;gidos de controle do re
fluxo, para evitar a inclus&atilde;o de casos de controle question&aacute;vel qu
e poderiam interferir nos resultados. </font></p>     ^cY#v24n1a08.htm##
00631000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039600076002001300472#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#80#76#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Para tanto, optou-se por incluir pac
ientes com o tratamento considerado mais efetivo em termos de controle do reflux
o, que s&atilde;o aqueles submetidos &agrave; hiatoplastia e fundoplicatura &agr
ave; Nissen, e sem nenhum sinal cl&iacute;nico ou de exames complementares que p
udessem sugerir falha de tratamento. </font></p>     ^cY#v24n1a08.htm##
00823000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058800076002001300664#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#81#77#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O es&ocirc;fago de Barrett &eacute; 
doen&ccedil;a de interesse cl&iacute;nico marcante, em especial por sua associa&
ccedil;&atilde;o com o desenvolvimento do adenocarcinoma esof&aacute;gico. O tra
tamento dos pacientes com essa afec&ccedil;&atilde;o visa &agrave; interrup&cced
il;&atilde;o do refluxo gastroesof&aacute;gico, especialmente do componente &aac
ute;cido, para assim interromper a progress&atilde;o da agress&atilde;o tecidual
 e evitar a degenera&ccedil;&atilde;o para displasia e c&acirc;ncer. </font></p>
     ^cY#v24n1a08.htm##
00835000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060000076002001300676#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#82#78#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">H&aacute; evid&ecirc;ncia que os pac
ientes com falha do tratamento cl&iacute;nico ou cir&uacute;rgico apresentem ris
co aumentado de desenvolvimento de adenocarcinoma do es&ocirc;fago, por manterem
 agress&atilde;o ao epit&eacute;lio metapl&aacute;sico<sup>16</sup>. No entanto,
 h&aacute; dificuldade em explicar a ocorr&ecirc;ncia de casos de c&acirc;ncer e
m pacientes com aparente sucesso do tratamento conforme avalia&ccedil;&atilde;o 
cl&iacute;nica e por exames complementares, mesmo por pHmetria esof&aacute;gica.
 </font></p>     ^cY#v24n1a08.htm##
00650000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041500076002001300491#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#83#79#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A metodologia proposta deve garantir
 que o cateter n&atilde;o influencie nos resultados. Estudos na literatura j&aac
ute; haviam demonstrado que a presen&ccedil;a do cateter atrav&eacute;s do EIE n
&atilde;o induz refluxo gastroesof&aacute;gico, tanto em volunt&aacute;rios saud
&aacute;veis como em pacientes com DRGE<sup>5,15</sup>. </font></p>     ^cY#v24n
1a08.htm##
01352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704111700076002001301193#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#84#80#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Outro ponto crucial &eacute; que o c
anal B deve permanecer sempre em contato com a mucosa esof&aacute;gica. Sabe-se 
que o es&ocirc;fago sofre encurtamento durante o peristaltismo, o que poderia le
var a migra&ccedil;&atilde;o distal do canal B para o interior do est&ocirc;mago
 e dificultar a correta interpreta&ccedil;&atilde;o da detec&ccedil;&atilde;o de
 pH &aacute;cido durante o exame. Apesar disso, o cateter n&atilde;o foi fixado 
&agrave; mucosa do es&ocirc;fago. A fixa&ccedil;&atilde;o dele &eacute; feita po
r via endosc&oacute;pica, o que n&atilde;o possibilita o posicionamento preciso 
dos canais em rela&ccedil;&atilde;o &agrave; borda superior do EIE, como padroni
zado para a realiza&ccedil;&atilde;o da pHmetria prolongada convencional. Al&eac
ute;m disso, a fixa&ccedil;&atilde;o endosc&oacute;pica com clipes dificulta a r
etirada do cateter, com necessidade de tra&ccedil;&atilde;o para desinser&ccedil
;&atilde;o dos clipes, com risco de lacera&ccedil;&atilde;o de mucosa esof&aacut
e;gica e poss&iacute;vel sangramento. </font></p>     ^cY#v24n1a08.htm##
00630000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039500076002001300471#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#85#81#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O encurtamento esof&aacute;gico &eac
ute; componente habitual do peristaltismo, podendo atingir at&eacute; 2 cm<sup>4
,21,28</sup>. Dessa forma, estima-se que o canal B do cateter possa variar sua p
osi&ccedil;&atilde;o em aproximadamente 2 cm distalmente, ou seja, at&eacute; 1 
cm abaixo da borda superior do EIE. </font></p>     ^cY#v24n1a08.htm##
00970000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073500076002001300811#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#86#82#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Csendes, et al.<sup>3</sup>, em estu
do envolvendo grande n&uacute;mero de volunt&aacute;rios saud&aacute;veis, compa
rou a localiza&ccedil;&atilde;o do EIE por manometria e a transi&ccedil;&atilde;
o es&ocirc;fago g&aacute;strica (TEG) localizada por endoscopia e observou que a
 TEG n&atilde;o corresponde &agrave; borda inferior do EIE e sim pr&oacute;ximo 
ao ponto m&eacute;dio entre a borda superior e a borda inferior do EIE. Assim se
ndo, em pacientes com esf&iacute;ncter de 3 cm de extens&atilde;o, localiza-se a
proximadamente 1,5 cm abaixo da borda superior do EIE e em casos em que o EIE me
de 4 cm, aproximadamente 2 cm abaixo da borda superior. </font></p>     ^cY#v24n
1a08.htm##
00953000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071800076002001300794#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#87#83#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Baseado nessa informa&ccedil;&atilde
;o, sabe-se que a migra&ccedil;&atilde;o distal do cateter de pHmetria, que ocor
re normalmente durante a contra&ccedil;&atilde;o esof&aacute;gica, faria com que
 o canal B do cateter posicionasse-se at&eacute; no m&aacute;ximo 1 cm abaixo da
 borda superior do EIE, ainda em es&ocirc;fago distal, mais pr&oacute;ximo da TE
G, por&eacute;m sem migrar para o interior do est&ocirc;mago, mesmo sem a fixa&c
cedil;&atilde;o na mucosa esof&aacute;gica. O canal C, por sua vez, varia sua po
si&ccedil;&atilde;o, sempre pr&oacute;xima &agrave; TEG, ora em es&ocirc;fago di
stal e ora em est&ocirc;mago proximal. </font></p>     ^cY#v24n1a08.htm##
01620000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704138500076002001301461#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#88#84#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O canal D permanece dentro do est&oc
irc;mago e &eacute; utilizado como par&acirc;metro de n&atilde;o migra&ccedil;&a
tilde;o proximal do cateter durante o exame. O est&ocirc;mago n&atilde;o apresen
ta pH inferior a 4,0 em 100% do tempo. A explica&ccedil;&atilde;o para isso &eac
ute; o tamponamento do &aacute;cido g&aacute;strico por saliva e alimentos e a o
corr&ecirc;ncia de refluxo biliar. Estudos de pHmetria g&aacute;strica mostram q
ue isso ocorre entre 80% e 87% do tempo do exame<sup>10,27</sup>, por&eacute;m, 
nestes estudos, o cateter foi posicionado em regi&atilde;o de corpo g&aacute;str
ico, entre 10 cm e 15 cm abaixo da borda inferior do EIE. Estudo de Katzka et al
.<sup>14</sup>, em volunt&aacute;rios saud&aacute;veis, avaliou o pH em regi&ati
lde;o 5 cm abaixo da borda superior do EIE, ou seja, em posi&ccedil;&atilde;o co
incidente com a assumida pelo canal D deste estudo. Os dados demonstram que a fr
a&ccedil;&atilde;o de tempo de pH inferior a 4,0 variou de 0,9% a 76,1%, com m&e
acute;dia de 32,2%. Neste estudo, considerouse que o canal D deveria apresentar 
pelo menos a fra&ccedil;&atilde;o de 50% do tempo com pH inferior a 4,0 como par
&acirc;metro de n&atilde;o migra&ccedil;&atilde;o proximal do cateter de sua pos
i&ccedil;&atilde;o original, o que ocorreu em todos os pacientes. </font></p>   
  ^cY#v24n1a08.htm##
01392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115700076002001301233#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#89#85#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os par&acirc;metros para avalia&cced
il;&atilde;o de refluxo na posi&ccedil;&atilde;o do canal A est&atilde;o bem est
abelecidos, uma vez que ele coincide com a posi&ccedil;&atilde;o padr&atilde;o p
ara realiza&ccedil;&atilde;o de pHmetria esof&aacute;gica prolongada. J&aacute; 
com rela&ccedil;&atilde;o ao canal B, n&atilde;o h&aacute; padroniza&ccedil;&ati
lde;o para interpreta&ccedil;&atilde;o dos resultados encontrados. Existem estud
os que foram realizados em pacientes n&atilde;o operados para comparar a exposi&
ccedil;&atilde;o &aacute;cida analisada no estudo de pHmetria convencional e em 
segmento mais distal do es&ocirc;fago e todos observaram que essa regi&atilde;o 
encontrase mais exposta a pH inferior a 4,0 do que a regi&atilde;o convencionalm
ente estudada (5 cm acima da borda superior do EIE). No entanto, houve grande va
ria&ccedil;&atilde;o dos resultados. Em volunt&aacute;rios saud&aacute;veis, a p
orcentagem de tempo com pH inferior a 4,0 variou de 1,5% a 11,7%. J&aacute; em p
acientes com DRGE, os resultados variaram de 6% a 9,5%<sup>7,9,20,31,32</sup>.</
font></p>     ^cY#v24n1a08.htm##
00769000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053400076002001300610#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#90#86#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Neste estudo, adotou-se como crit&ea
cute;rio paraavalia&ccedil;&atilde;o do canal B a fra&ccedil;&atilde;o de 1,5% d
o tempo como limite de exposi&ccedil;&atilde;o &aacute;cida. Dessa forma, apenas
 os pacientes com exposi&ccedil;&atilde;o igual ou inferior ao m&iacute;nimo obs
ervado em volunt&aacute;rios saud&aacute;veis, como descrito nos estudos acima, 
seriam considerados como sem altera&ccedil;&otilde;es da exposi&ccedil;&atilde;o
 &aacute;cida. </font></p>     ^cY#v24n1a08.htm##
00777000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054200076002001300618#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#91#87#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Um paciente do grupo, apesar de bom 
controle cl&iacute;nico, endosc&oacute;pico e radiol&oacute;gico do refluxo gast
roesof&aacute;gico no p&oacute;s-operat&oacute;rio, apresentou refluxo patol&oac
ute;gico na localiza&ccedil;&atilde;o habitual da pHmetria esof&aacute;gica. Iss
o mostra que apenas a pHmetria pode determinar se h&aacute; realmente controle e
fetivo do refluxo &aacute;cido, conforme j&aacute; sugerido por outros autores<s
up>1,12,19,29,30</sup>.</font></p>     ^cY#v24n1a08.htm##
00976000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074100076002001300817#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#92#88#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A mediana da exposi&ccedil;&atilde;
o &aacute;cida no canal B foi de 1,3%, inferior ao par&acirc;metro adotado para 
an&aacute;lise. Os resultados obtidos identificaram cinco pacientes com fra&cced
il;&atilde;o de tempo de exposi&ccedil;&atilde;o &aacute;cida acima do proposto 
como normal. Portanto, a pHmetria com m&uacute;ltiplos canais permitiu identific
ar alguns casos com exposi&ccedil;&atilde;o &aacute;cida prolongada no epit&eacu
te;lio de Barrett que n&atilde;o seriam identificados pela t&eacute;cnica conven
cional de pHmetria. Isso demonstra que a pHmetria com m&uacute;ltiplos canais po
de acrescentar dados importantes no seguimento dos pacientes. </font></p>     ^c
Y#v24n1a08.htm##
00822000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058700076002001300663#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#93#89#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Comparando-se os resultados obtidos 
no canal A com o canal B, observa-se aumento significativo da exposi&ccedil;&ati
lde;o &aacute;cida em B, embora a mediana do canal B ainda esteja abaixo do par&
acirc;metro adotado como limite. Observa-se tamb&eacute;m redu&ccedil;&atilde;o 
significativa da exposi&ccedil;&atilde;o &aacute;cida, cerca de 30 vezes, do can
al C para o canal B, o que mostra a efic&aacute;cia da fundoplicatura em conter 
o refluxo &aacute;cido para o n&iacute;vel do es&ocirc;fago distal. </font></p> 
    ^cY#v24n1a08.htm##
01926000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704169100076002001301767#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#94#90#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Dois pacientes foram diagnosticados 
com adenocarcinoma durante o estudo. O primeiro encontrava-se com apenas 22 mese
s de p&oacute;s-operat&oacute;rio de fundoplicatura. Estima-se em seis anos o te
mpo necess&aacute;rio para o desenvolvimento de adenocarcinoma no epit&eacute;li
o de Barrett com displasia de baixo grau <sup>32</sup>. Assim, o surgimento de c
&acirc;ncer nos primeiros anos de p&oacute;s-operat&oacute;rio, como ocorreu nes
te caso, pode n&atilde;o significar progress&atilde;o da doen&ccedil;a ap&oacute
;s a opera&ccedil;&atilde;o, mas consequ&ecirc;ncia de altera&ccedil;&atilde;o p
r&eacute;via ao procedimento cir&uacute;rgico. Por&eacute;m, chama a aten&ccedil
;&atilde;o o estudo de pHmetria deste paciente. No canal A, o paciente n&atilde;
o apresentou qualquer altera&ccedil;&atilde;o, com 0% de tempo de pH inferior a 
4,0 e escore de DeMeester de 0,5. Por&eacute;m, no canal B, ele teve 78 epis&oac
ute;dios de refluxo &aacute;cido, com 1,7% de fra&ccedil;&atilde;o de exposi&cce
dil;&atilde;o &aacute;cida. O segundo caso ocorreu ap&oacute;s 72 meses de fundo
plicatura. Este per&iacute;odo de tempo &eacute; o limite para considerar-se que
 poss&iacute;veis altera&ccedil;&otilde;es pr&eacute;vias &agrave; fundoplicatur
a foram respons&aacute;veis pelo desenvolvimento do c&acirc;ncer. Este paciente 
apresentava pHmetria normal nos canais A e B, com 1,3% de tempo de exposi&ccedil
;&atilde;o &aacute;cida no canal B. Isso suscita a hip&oacute;tese de que talvez
 o &aacute;cido n&atilde;o seja &uacute;nico fator envolvido na evolu&ccedil;&at
ilde;o da metaplasia para displasia e c&acirc;ncer. </font></p>     ^cY#v24n1a08
.htm##
00612000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037700076002001300453#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#95#91#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O achado de dois casos de adenocarci
noma nesta casu&iacute;stica n&atilde;o permite afirmar se a fundoplicatura exer
ce papel protetor ou n&atilde;o em rela&ccedil;&atilde;o ao c&acirc;ncer de es&o
circ;fago, pois, o pequeno n&uacute;mero de casos estudados impede este tipo de 
conclus&atilde;o. </font></p>     ^cY#v24n1a08.htm##
00912000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067700076002001300753#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#96#92#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os dois pacientes tiveram o diagn&oa
cute;stico feito por exame de rotina, sem apresentarem sintomas. Apresentavam le
s&otilde;es evidentes, n&atilde;o sendo o diagn&oacute;stico estabelecido por bi
&oacute;psias seriadas do epit&eacute;lio metapl&aacute;sico. Mesmo assim, a end
oscopia permitiu diagn&oacute;stico de neoplasia precoce nos dois casos, com tra
tamento de intuito curativo e com boa evolu&ccedil;&atilde;o tanto precoce como 
tardia. Dessa forma, pode-se sugerir que houve benef&iacute;cio da vigil&acirc;n
cia endosc&oacute;pica rotineira que &eacute; realizada neste servi&ccedil;o. </
font></p>     ^cY#v24n1a08.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012000076002001300196#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#97#93#article#172#<p>&nbsp;</p> <font
 size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Otilde;ES </b>
</font> </p>     ^cY#v24n1a08.htm##
01355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112000076002001301196#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#98#94#article#172#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">H&aacute; redu&ccedil;&atilde;o sign
ificativa da exposi&ccedil;&atilde;o &aacute;cida na regi&atilde;o 1 cm acima da
 borda superior do EIE quando comparada &agrave; regi&atilde;o intra-esfincteria
na, demonstrando efic&aacute;cia da fundoplicatura em conter o refluxo nesse n&i
acute;vel. Al&eacute;m disso, a regi&atilde;o do es&ocirc;fago 1 cm acima da bor
da superior do esf&iacute;ncter inferior do es&ocirc;fago &eacute; mais exposta 
ao &aacute;cido do que a 5 cm acima da borda superior do EIE, embora mantenha-se
 em n&iacute;veis reduzidos. O tratamento cir&uacute;rgico, atrav&eacute;s de fu
ndoplicatura &agrave; Nissen, nos pacientes com es&ocirc;fago de Barrett, possib
ilita redu&ccedil;&atilde;o significativa da exposi&ccedil;&atilde;o &aacute;cid
a em n&iacute;vel ultra-distal do es&ocirc;fago e a pHmetria de m&uacute;ltiplos
 canais constitui-se em importante procedimento t&eacute;cnico para avalia&ccedi
l;&atilde;o comparativa da exposi&ccedil;&atilde;o &aacute;cida nos v&aacute;rio
s n&iacute;veis do es&ocirc;fago distal. </font></p>     ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#99#95#article#172#<p>&nbsp;</p>     ^
cY#v24n1a08.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704010800077002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#100#96#article#172#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS </b></font></p
>     ^cY#v24n1a08.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704029200079002001300371#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#101#97#article#172#1#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Booth MI, Dehn TC.
 Twenty-four-hour pH monitoring is required to confirm acid reflux suppression i
n patients with Barrett's oesophagus undergoing anti-reflux surgery. Eur J Gastr
oenterol Hepatol 2001 Nov;13(11):1323-6.    ^cY#v24n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#102#98#article#172# </font></p>     ^
cY#v24n1a08.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704030200079002001300381#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#103#99#article#172#2#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Crookes PF, Ritter
 MP, Johnson WE, Bremner CG, Peters JH,DeMeester TR. Static and dynamic function
 of the lower esophageal sphincter before and after laparoscopic Nissen fundopli
cation. J Gastrointest Surg 1997 Nov;1(6):499-504.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#104#100#article#172# </font></p>     
^cY#v24n1a08.htm##
00600000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704034900080002001300429#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#105#101#article#172#3#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Csendes A, Maluen
da F, Braghetto I, Csendes P, Henriquez A, Quesada MS. Location of the lower oes
ophageal sphincter and the squamous columnar mucosal junction in 109 healthy con
trols and 778 patients with different degrees of endoscopic oesophagitis. Gut 19
93 Jan;34(1):21-7.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#106#102#article#172# </font></p>     
^cY#v24n1a08.htm##
00495000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704024400080002001300324#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#107#103#article#172#4#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Dai Q, Korimilli 
A, Thangada VK, Chung CY, Parkman H, Brasseur J, et al. Muscle shortening along 
the normal esophagus during swallowing. Dig Dis Sci 2006 Jan;51(1):105-9.    ^cY
#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#108#104#article#172# </font></p>     
^cY#v24n1a08.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704029900080002001300379#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#109#105#article#172#5#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Decktor DL, Krawe
t SH, Rodriguez SL, Robinson M, Castell DO. Dual site ambulatory pH monitoring: 
a probe across the lower esophageal sphincter does not induce gastroesophageal r
eflux. Am J Gastroenterol 1996 Jun;91(6):1162-6.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#110#106#article#172# </font></p>     
^cY#v24n1a08.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704022200080002001300302#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#111#107#article#172#6#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. DeMeester SR, DeM
eester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty yea
rs of controversy. Ann Surg 2000 Mar;231(3):303-21.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#112#108#article#172# </font></p>     
^cY#v24n1a08.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704019900080002001300279#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#113#109#article#172#7#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. DeMeester TR. Sur
gical therapy for Barrett's esophagus: prevention, protection and excision. Dis 
Esophagus 2002;15(2):109-16.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#114#110#article#172# </font></p>     
^cY#v24n1a08.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704029500080002001300375#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#115#111#article#172#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Felix VN, Yogi I,
 Perini M, Echeverria R, Bernardi C. Surgical treatment of the non-complicated g
astroesophageal reflux: fundoplication without division of the short gastric ves
sels. Arq Gastroenterol 2002 Apr;39(2):93-7.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#116#112#article#172# </font></p>     
^cY#v24n1a08.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704026500080002001300345#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#117#113#article#172#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Fletcher J, Wirz 
A, Henry E, McColl KE. Studies of acid exposure immediately above the gastro-oes
ophageal squamocolumnar junction: evidence of short segment reflux. Gut 2004 Feb
;53(2):168-73.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#118#114#article#172# </font></p>     
^cY#v24n1a08.htm##
00625000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037300081002001300454#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#119#115#article#172#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Ghoshal UC, Cho
urasia D, Tripathi S, Misra A, Singh K. Relationship of severity of gastroesopha
geal reflux disease with gastric acid secretory profile and esophageal acid expo
sure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metr
y. Scand J Gastroenterol 2008;43(6):654-61.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#120#116#article#172# </font></p>     
^cY#v24n1a08.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022000081002001300301#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#121#117#article#172#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Gutschow CA, Sc
hroder W, Holscher AH. Barrett's esophagus: what is the poison - alkaline, bilia
ry or acidic reflux? Dis Esophagus 2002;15(1):5-9.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#122#118#article#172# </font></p>     
^cY#v24n1a08.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031600081002001300397#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#123#119#article#172#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Jenkinson AD, K
adirkamanathan SS, Scott SM, Yazaki E, Evans DF. Relationship between symptom re
sponse and oesophageal acid exposure after medical and surgical treatment for ga
stro oesophageal reflux disease. Br J Surg 2004 Nov;91(11):1460-5.    ^cY#v24n1a
08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#124#120#article#172# </font></p>     
^cY#v24n1a08.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022900081002001300310#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#125#121#article#172#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Kahrilas PJ, Qu
igley EM. Clinical esophageal pH recording: a technical review for practice guid
eline development.Gastroenterology 1996 Jun;110(6):1982-96.    ^cY#v24n1a08.htm#
#
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#126#122#article#172# </font></p>     
^cY#v24n1a08.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026500081002001300346#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#127#123#article#172#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 14. Katzka DA, Gid
eon RM, Castell DO. Normal patterns of acid exposure at the gastric cardia: a fu
nctional midpoint between the esophagus and stomach. Am J Gastroenterol 1998 Aug
;93(8):1236-42.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#128#124#article#172# </font></p>     
^cY#v24n1a08.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024000081002001300321#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#129#125#article#172#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 15. Kuo B, Castell
 DO. The effect of nasogastric intubation on gastroesophageal reflux: a comparis
on of different tube sizes. Am J Gastroenterol 1995 Oct;90(10):1804-7.    ^cY#v2
4n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#130#126#article#172# </font></p>     
^cY#v24n1a08.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024200081002001300323#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#131#127#article#172#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Lagergren J, Vi
klund P. Is esophageal adenocarcinoma occurring late after antireflux surgery du
e to persistent postoperative reflux? World J Surg 2007 Mar;31(3):465-9.    ^cY#
v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#132#128#article#172# </font></p>     
^cY#v24n1a08.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#133#129#article#172#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Moraes-Filho JP
. Gastroesophageal reflux disease: prevalence and management in Brazil. Best Pra
ct Res Clin Gastroenterol 2004;18 Suppl:23-6.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#134#130#article#172# </font></p>     
^cY#v24n1a08.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#135#131#article#172#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Nasi A, de Mora
es-Filho JP, Cecconello I. &#91,Gastroesophageal reflux disease: an overview&#93
;. Arq Gastroenterol 2006 Oct;43(4):334-41.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#136#132#article#172# </font></p>     
^cY#v24n1a08.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029300081002001300374#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#137#133#article#172#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Ouatu-Lascar R,
 Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee 
normalization of intraesophageal acid reflux in patients with Barrett's esophagu
s. Am J Gastroenterol 1998 May;93(5):711-6.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#138#134#article#172# </font></p>     
^cY#v24n1a08.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030300081002001300384#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#139#135#article#172#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Pandolfino JE, 
Lee TJ, Schreiner MA, Zhang Q, Roth MP, Kahrilas PJ. Comparison of esophageal ac
id exposure at 1 cm and 6 cm above the squamocolumnar junction using the Bravo p
H monitoring system. Dis Esophagus 2006;19(3):177-82.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#140#136#article#172# </font></p>     
^cY#v24n1a08.htm##
00576000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032400081002001300405#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#141#137#article#172#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Pandolfino JE, 
Zhang QG, Ghosh SK, Han A, Boniquit C, Kahrilas PJ. Transient lower esophageal s
phincter relaxations and reflux: mechanistic analysis using concurrent fluorosco
py and highresolution manometry. Gastroenterology 2006 Dec;131(6):1725-33.    ^c
Y#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#142#138#article#172# </font></p>     
^cY#v24n1a08.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030400081002001300385#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#143#139#article#172#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Parrilla P, Mar
tinez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, et al. Long-term resu
lts of a randomized prospective study comparing medical and surgical treatment o
f Barrett's esophagus. Ann Surg 2003 Mar;237(3):291-8.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#144#140#article#172# </font></p>     
^cY#v24n1a08.htm##
00582000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033000081002001300411#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#145#141#article#172#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Pastore R, Crem
a E, Silveira MC, Presoto AF, Herbella FA, Del Grande JC. &#91,Electromanometry 
and acid pHmetry of 24 hours in postoperative evaluation of the hiatoplasty and 
total antireflux wrap laparoscopic&#93;. Arq Gastroenterol 2006 Apr;43(2):112-6.
    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#146#142#article#172# </font></p>     
^cY#v24n1a08.htm##
00495000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024300081002001300324#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#147#143#article#172#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Provenzale D, S
chmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emer
ging estimates of cancer risk. Am J Gastroenterol 1999 Aug;94(8):2043-53.    ^cY
#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#148#144#article#172# </font></p>     
^cY#v24n1a08.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028000081002001300361#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#149#145#article#172#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Ribeiro U, Jr.,
 Sallum RA, Seguro F, da Rocha JR, Nasi A, Szachnowicz S. Epidemiologic aspects 
of the esophagogastric junction adenocarcinoma in Brazil. J Clin Gastroenterol 4
2&#91,Supp. 1&#93;, S34. 2008.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#150#146#article#172# </font></p>     
^cY#v24n1a08.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#151#147#article#172#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Richter JE. The
 many manifestations of gastroesophageal reflux disease: presentation, evaluatio
n, and treatment. Gastroenterol Clin North Am 2007 Sep;36(3):577-ix.    ^cY#v24n
1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#152#148#article#172# </font></p>     
^cY#v24n1a08.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027200081002001300353#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#153#149#article#172#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Roman S, Serraj
 I, Damon H, Mion F. Correlation between gastric pH and gastro-oesophageal reflu
x contents: ambulatory pH impedance monitoring results. Neurogastroenterol Motil
 2007 Jul;19(7):562-8.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#154#150#article#172# </font></p>     
^cY#v24n1a08.htm##
00580000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032800081002001300409#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#155#151#article#172#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Shi G, Pandolfi
no JE, Joehl RJ, Brasseur JG, Kahrilas PJ. Distinct patterns of oesophageal shor
tening during primary peristalsis, secondary peristalsis and transient lower oes
ophageal sphincter relaxation. Neurogastroenterol Motil 2002 Oct;14(5):505-12.  
  ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#156#152#article#172# </font></p>     
^cY#v24n1a08.htm##
00573000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032100081002001300402#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#157#153#article#172#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 29. Spechler SJ, S
harma P, Traxler B, Levine D, Falk GW. Gastric and esophageal pH in patients wit
h Barrett's esophagus treated with three esomeprazole dosages: a randomized, dou
ble-blind, crossover trial. Am J Gastroenterol 2006 Sep;101(9):1964-71.    ^cY#v
24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#158#154#article#172# </font></p>     
^cY#v24n1a08.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019000081002001300271#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#159#155#article#172#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Watson DI, Mayn
e GC, Hussey DJ. Barrett's Esophagus, fundoplication, and cancer. World J Surg 2
007 Mar;31(3):447-9.    ^cY#v24n1a08.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#160#156#article#172# </font></p>     
^cY#v24n1a08.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031200081002001300393#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#161#157#article#172#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Wenner J, Hall 
M, Hoglund P, Johansson J, Johnsson F, Oberg S. Wireless pH recording immediatel
y above the squamocolumnar junction improves the diagnostic performance of esoph
ageal pH studies. Am J Gastroenterol 2008 Dec;103(12):2977-85.    ^cY#v24n1a08.h
tm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#162#158#article#172# </font></p>     
^cY#v24n1a08.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#163#159#article#172#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Wenner J, Johns
son F, Johansson J, Oberg S. Acid reflux immediately above the squamocolumnar ju
nction and in the distal esophagus: simultaneous pH monitoring using the wireles
s capsule pH system. Am J Gastroenterol 2006 Aug;101(8):1734-41.    ^cY#v24n1a08
.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#164#160#article#172# </font></p>     
^cY#v24n1a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#165#161#article#172#<p>&nbsp;</p>    
 ^cY#v24n1a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#166#162#article#172#<p>&nbsp;</p>    
 ^cY#v24n1a08.htm##
00437000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704020000078002001300278#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#167#163#article#172#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0" ></a> Correspond&e
circ;ncia: </b>    ^cY#v24n1a08.htm##
00289000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005200078002001300130#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#168#164#article#172#<br> Francisco Ca
rlos Bernal da Costa Seguro    ^cY#v24n1a08.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009600078002001300174#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#169#165#article#172#<br> e-mail: <a h
ref="mailto:fc.seguro@uol.com.br">fc.seguro@uol.com.br</a> </font></p>     ^cY#v
24n1a08.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012200078002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#170#166#article#172#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 06/01/2011     ^cY#v24n1a08.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#171#167#article#172#<br>  Aceito para
 publica&ccedil;&atilde;o: 25/01/2011    ^cY#v24n1a08.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004200078002001300120#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#172#168#article#172#<br>Fonte de fina
nciamento: não há    ^cY#v24n1a08.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#173#169#article#172#<br> Conflito de 
interesses: não há  </font></p>     ^cY#v24n1a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#174#170#article#172#<p>&nbsp;</p>    
 ^cY#v24n1a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#175#171#article#172#<p>&nbsp;</p>    
 ^cY#v24n1a08.htm##
00510000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704027300078002001300351#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a08.htm#S#p#176#172#article#172#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Servi&ccedil
;o de Cirurgia do Es&ocirc;fago do Hospital das Cl&iacute;nicas da Faculdade de 
Medicina da Universidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil. </fo
nt></p>     ^cY#v24n1a08.htm##
00666000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930120
15100108030002800259065000900287064000700296031000300303032000300306014000700309
865000900316002001300325035001000338801002800348#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a08.htm#S#c#177#1#article#32#1#^rND^sBooth^nMI#^rND^sDehn^nTC#Twe
nty-four-hour pH monitoring is required to confirm acid reflux suppression in pa
tients with Barrett's oesophagus undergoing anti-reflux surgery^len#Eur J Gastro
enterol Hepatol#20011100#200111#13#11#1323-6#20110300#v24n1a08.htm#0954-691X#Eur
 J Gastroenterol Hepatol##
00741000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
01800112010001800130010001700148010002000165012011800185030002000303065000900323
06400070033203100020033903200020034101400080034386500090035100200130036003500100
0373801002000383#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#178#2
#article#32#2#^rND^sCrookes^nPF#^rND^sRitter^nMP#^rND^sJohnson^nWE#^rND^sBremner
^nCG#^rND^sPeters^nJH#^rND^sDeMeester^nTR#Static and dynamic function of the low
er esophageal sphincter before and after laparoscopic Nissen fundoplication^len#
J Gastrointest Surg#19971100#199711#1#6#499-504#20110300#v24n1a08.htm#1091-255X#
J Gastrointest Surg##
00771000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01900112010001700131010001900148010001800167012018200185030000400367065000900371
06400070038003100030038703200020039001400050039286500090039700200130040603500100
0419801000400429#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#179#3
#article#32#3#^rND^sCsendes^nA#^rND^sMaluenda^nF#^rND^sBraghetto^nI#^rND^sCsende
s^nP#^rND^sHenriquez^nA#^rND^sQuesada^nMS#Location of the lower oesophageal sphi
ncter and the squamous columnar mucosal junction in 109 healthy controls and 778
 patients with different degrees of endoscopic oesophagitis^len#Gut#19930100#199
301#34#1#21-7#20110300#v24n1a08.htm#0017-5749#Gut##
00685000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770100019000900100
01900109010001600128010001700144010001800161810000600179012006700185030001200252
06500090026406400070027303100030028003200020028301400060028586500090029100200130
0300035001000313801001200323#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.h
tm#S#c#180#4#article#32#4#^rND^sDai^nQ#^rND^sKorimilli^nA#^rND^sThangada^nVK#^rN
D^sChung^nCY#^rND^sParkman^nH#^rND^sBrasseur^nJ#et al#Muscle shortening along th
e normal esophagus during swallowing^len#Dig Dis Sci#20060100#200601#51#1#105-9#
20110300#v24n1a08.htm#0163-2116#Dig Dis Sci##
00718000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
02000112010001800132010001800150012012600168030001900294065000900313064000700322
03100030032903200020033201400070033486500090034100200130035003500100036380100190
0373#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#181#5#article#32#
5#^rND^sDecktor^nDL#^rND^sKrawet^nSH#^rND^sRodriguez^nSL#^rND^sRobinson^nM#^rND^
sCastell^nDO#Dual site ambulatory pH monitoring: a probe across the lower esopha
geal sphincter does not induce gastroesophageal reflux^len#Am J Gastroenterol#19
960600#199606#91#6#1162-6#20110300#v24n1a08.htm#0002-9270#Am J Gastroenterol##
00577000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100020000970120
09100117030000900208065000900217064000700226031000400233032000200237014000700239
865000900246002001300255035001000268801000900278#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a08.htm#S#c#182#6#article#32#6#^rND^sDeMeester^nSR#^rND^sDeMeeste
r^nTR#Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of
 controversy^len#Ann Surg#20000300#200003#231#3#303-21#20110300#v24n1a08.htm#000
3-4932#Ann Surg##
00543000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770120082000970300
01400179065000900193064000500202031000300207032000200210014000700212865000900219
002001300228035001000241801001400251#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a08.htm#S#c#183#7#article#32#7#^rND^sDeMeester^nTR#Surgical therapy for Barre
tt's esophagus: prevention, protection and excision^len#Dis Esophagus#20020000#2
002#15#2#109-16#20110300#v24n1a08.htm#1120-8694#Dis Esophagus##
00713000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100014000930100
01600107010002000123010001800143012013200161030001800293065000900311064000700320
03100030032703200020033001400050033286500090033700200130034603500100035980100180
0369#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#184#8#article#32#
8#^rND^sFelix^nVN#^rND^sYogi^nI#^rND^sPerini^nM#^rND^sEcheverria^nR#^rND^sBernar
di^nC#Surgical treatment of the non-complicated gastroesophageal reflux: fundopl
ication without division of the short gastric vessels^len#Arq Gastroenterol#2002
0400#200204#39#2#93-7#20110300#v24n1a08.htm#0004-2803#Arq Gastroenterol##
00651000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100014000950100
01500109010001700124012012800141030000400269065000900273064000700282031000300289
032000200292014000700294865000900301002001300310035001000323801000400333#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#185#9#article#32#9#^rND^sFlet
cher^nJ#^rND^sWirz^nA#^rND^sHenry^nE#^rND^sMcColl^nKE#Studies of acid exposure i
mmediately above the gastro-oesophageal squamocolumnar junction: evidence of sho
rt segment reflux^len#Gut#20040200#200402#53#2#168-73#20110300#v24n1a08.htm#0017
-5749#Gut##
00798000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01800116010001500134010001500149012020600164030002200370065000900392064000500401
03100030040603200020040901400070041186500090041800200130042703500100044080100220
0450#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#186#10#article#32
#10#^rND^sGhoshal^nUC#^rND^sChourasia^nD#^rND^sTripathi^nS#^rND^sMisra^nA#^rND^s
Singh^nK#Relationship of severity of gastroesophageal reflux disease with gastri
c acid secretory profile and esophageal acid exposure during nocturnal acid brea
kthrough: a study using 24-h dual-channel pH-metry^len#Scand J Gastroenterol#200
80000#2008#43#6#654-61#20110300#v24n1a08.htm#0036-5521#Scand J Gastroenterol##
00602000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01900116012008200135030001400217065000900231064000500240031000300245032000200248
014000400250865000900254002001300263035001000276801001400286#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a08.htm#S#c#187#11#article#32#11#^rND^sGutschow^nCA#^
rND^sSchroder^nW#^rND^sHolscher^nAH#Barrett's esophagus: what is the poison - al
kaline, biliary or acidic reflux?^len#Dis Esophagus#20020000#2002#15#1#5-9#20110
300#v24n1a08.htm#1120-8694#Dis Esophagus##
00727000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100026000990100
01600125010001600141010001600157012014700173030001000320065000900330064000700339
03100030034603200030034901400070035286500090035900200130036803500100038180100100
0391#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#188#12#article#32
#12#^rND^sJenkinson^nAD#^rND^sKadirkamanathan^nSS#^rND^sScott^nSM#^rND^sYazaki^n
E#^rND^sEvans^nDF#Relationship between symptom response and oesophageal acid exp
osure after medical and surgical treatment for gastro oesophageal reflux disease
^len#Br J Surg#20041100#200411#91#11#1460-5#20110300#v24n1a08.htm#0007-1323#Br J
 Surg##
00597000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980120
09200117030001700209065000900226064000900235031000400244032000200248014000800250
865000900258002001300267035001000280801001700290#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a08.htm#S#c#189#13#article#32#13#^rND^sKahrilas^nPJ#^rND^sQuigley
^nEM.#Clinical esophageal pH recording: a technical review for practice guidelin
e development^len#Gastroenterology#19960600#1996 Jun#110#6#1982-96#20110300#v24n
1a08.htm#0016-5085#Gastroenterology##
00648000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01800113012011600131030001900247065000900266064000700275031000300282032000200285
014000800287865000900295002001300304035001000317801001900327#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a08.htm#S#c#190#14#article#32#14#^rND^sKatzka^nDA#^rN
D^sGideon^nRM#^rND^sCastell^nDO#Normal patterns of acid exposure at the gastric 
cardia: a functional midpoint between the esophagus and stomach^len#Am J Gastroe
nterol#19980800#199808#93#8#1236-42#20110300#v24n1a08.htm#0002-9270#Am J Gastroe
nterol##
00605000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100018000920120
10600110030001900216065000900235064000700244031000300251032000300254014000700257
865000900264002001300273035001000286801001900296#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a08.htm#S#c#191#15#article#32#15#^rND^sKuo^nB#^rND^sCastell^nDO#T
he effect of nasogastric intubation on gastroesophageal reflux: a comparison of 
different tube sizes^len#Am J Gastroenterol#19951000#199510#90#10#1804-7#2011030
0#v24n1a08.htm#0002-9270#Am J Gastroenterol##
00602000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980120
11200115030001300227065000900240064000700249031000300256032000200259014000600261
865000900267002001300276035001000289801001300299#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a08.htm#S#c#192#16#article#32#16#^rND^sLagergren^nJ#^rND^sViklund
^nP#Is esophageal adenocarcinoma occurring late after antireflux surgery due to 
persistent postoperative reflux^len#World J Surg#20070300#200703#31#3#465-9#2011
0300#v24n1a08.htm#0364-2313#World J Surg##
00529000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790120073001020300
03400175710000200209065000900211064000500220031000300225032000800228014000500236
865000900241002001300250#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S
#c#193#17#article#32#17#^rND^sMoraes-Filho^nJP#Gastroesophageal reflux disease: 
prevalence and management in Brazil^len#Best Pract Res Clin Gastroenterol#2#2004
0000#2004#18#^sSuppl#23-6#20110300#v24n1a08.htm##
00586000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100026000930100
02000119012004900139030001800188065000900206064000700215031000300222032000200225
014000700227865000900234002001300243035001000256801001800266#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a08.htm#S#c#194#18#article#32#18#^rND^sNasi^nA#^rND^s
de Moraes-Filho^nJP#^rND^sCecconello^nI#Gastroesophageal reflux disease: an over
view^len#Arq Gastroenterol#20061000#200610#43#4#334-41#20110300#v24n1a08.htm#000
4-2803#Arq Gastroenterol##
00659000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100026001010120
14500127030001900272065000900291064000700300031000300307032000200310014000600312
865000900318002001300327035001000340801001900350#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a08.htm#S#c#195#19#article#32#19#^rND^sOuatu-Lascar^nR#^rND^sTria
dafilopoulos^nG#Complete elimination of reflux symptoms does not guarantee norma
lization of intraesophageal acid reflux in patients with Barrett's esophagus^len
#Am J Gastroenterol#19980500#199805#93#5#711-6#20110300#v24n1a08.htm#0002-9270#A
m J Gastroenterol##
00738000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100014001000100
02000114010001500134010001500149010001900164012013100183030001400314065000900328
06400050033703100030034203200020034501400070034786500090035400200130036303500100
0376801001400386#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#196#2
0#article#32#20#^rND^sPandolfino^nJE#^rND^sLee^nTJ#^rND^sSchreiner^nMA#^rND^sZha
ng^nQ#^rND^sRoth^nMP#^rND^sKahrilas^nPJ#Comparison of esophageal acid exposure a
t 1 cm and 6 cm above the squamocolumnar junction using the Bravo pH monitoring 
system^len#Dis Esophagus#20060000#2006#19#3#177-82#20110300#v24n1a08.htm#1120-86
94#Dis Esophagus##
00760000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100016001000100
01600116010001300132010001800145010001900163012014400182030001700326065000900343
06400070035203100040035903200020036301400080036586500090037300200130038203500100
0395801001700405#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#197#2
1#article#32#21#^rND^sPandolfino^nJE#^rND^sZhang^nQG#^rND^sGhosh^nSK#^rND^sHan^n
A#^rND^sBoniquit^nC#^rND^sKahrilas^nPJ#Transient lower esophageal sphincter rela
xations and reflux: mechanistic analysis using concurrent fluoroscopy and highre
solution manometry^len#Gastroenterology#20061200#200612#131#6#1725-33#20110300#v
24n1a08.htm#0016-5085#Gastroenterology##
00745000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100027000970100
01500124010001700139010001600156010001700172810000600189012012000195030000900315
06500090032406400090033303100040034203200020034601400060034886500090035400200130
0363035001000376801000900386#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.h
tm#S#c#198#22#article#32#22#^rND^sParrilla^nP#^rND^sMartinez de Haro^nLF#^rND^sO
rtiz^nA#^rND^sMunitiz^nV#^rND^sMolina^nJ#^rND^sBermejo^nJ#et al#Long-term result
s of a randomized prospective study comparing medical and surgical treatment of 
Barrett's esophagus^len#Ann Surg#20030300#2003 Mar#237#3#291-8#20110300#v24n1a08
.htm#0003-4932#Ann Surg##
00757000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01900111010001800130010001900148010002100167012013600188030001800324065000900342
06400070035103100030035803200020036101400060036386500090036900200130037803500100
0391801001800401#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#199#2
3#article#32#23#^rND^sPastore^nR#^rND^sCrema^nE#^rND^sSilveira^nMC#^rND^sPresoto
^nAF#^rND^sHerbella^nFA#^rND^sDel Grande^nJC#Electromanometry and acid pHmetry o
f 24 hours in postoperative evaluation of the hiatoplasty and total antireflux w
rap laparoscopic^len#Arq Gastroenterol#20060400#200604#43#2#112-6#20110300#v24n1
a08.htm#0004-2803#Arq Gastroenterol##
00627000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01500116012009500131030001900226065000900245064000700254031000300261032000200264
014000800266865000900274002001300283035001000296801001900306#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a08.htm#S#c#200#24#article#32#24#^rND^sProvenzale^nD#
^rND^sSchmitt^nC#^rND^sWong^nJB#Barrett's esophagus: a new look at surveillance 
based on emerging estimates of cancer risk^len#Am J Gastroenterol#19990800#19990
8#94#8#2043-53#20110300#v24n1a08.htm#0002-9270#Am J Gastroenterol##
00708000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100017001010100
01600118010001900134010001400153010002200167012008300189030002100272031000300293
03200040029601400030030006500090030306400050031286500090031700200130032603500100
0339801002100349#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#201#2
5#article#32#25#^rND^sRibeiro^nU, Jr.#^rND^sSallum^nRA#^rND^sSeguro^nF#^rND^sda 
Rocha^nJR#^rND^sNasi^nA#^rND^sSzachnowicz^nS.#Epidemiologic aspects of the esoph
agogastric junction adenocarcinoma in Brazil^len#J Clin Gastroenterol#42#^s1#34#
20080000#2008#20110300#v24n1a08.htm#0192-0790#J Clin Gastroenterol##
00595000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120104000970300
02800201065000900229064000700238031000300245032000200248014000700250865000900257
002001300266035001000279801002800289#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a08.htm#S#c#202#26#article#32#26#^rND^sRichter^nJE#The many manifestations of
 gastroesophageal reflux disease: presentation, evaluation, and treatment^len#Ga
stroenterol Clin North Am#20070900#200709#36#3#577-ix#20110300#v24n1a08.htm#0889
-8553#Gastroenterol Clin North Am##
00680000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01500110010001400125012011800139030002500257065000900282064000700291031000300298
032000200301014000600303865000900309002001300318035001000331801002500341#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#203#27#article#32#27#^rND^sRo
man^nS#^rND^sSerraj^nI#^rND^sDamon^nH#^rND^sMion^nF#Correlation between gastric 
pH and gastro-oesophageal reflux contents: ambulatory pH impedance monitoring re
sults^len#Neurogastroenterol Motil#20070700#200707#19#7#562-8#20110300#v24n1a08.
htm#1350-1925#Neurogastroenterol Motil##
00754000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100021000920100
01600113010001900129010001900148012015100167030002500318065000900343064000700352
03100030035903200020036201400070036486500090037100200130038003500100039380100250
0403#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#204#28#article#32
#28#^rND^sShi^nG#^rND^sPandolfino^nJE#^rND^sJoehl^nRJ#^rND^sBrasseur^nJG#^rND^sK
ahrilas^nPJ#Distinct patterns of oesophageal shortening during primary peristals
is, secondary peristalsis and transient lower oesophageal sphincter relaxation^l
en#Neurogastroenterol Motil#20021000#200210#14#5#505-12#20110300#v24n1a08.htm#13
50-1925#Neurogastroenterol Motil##
00740000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01700114010001600131010001500147012015200162030001900314065000900333064000700342
03100040034903200020035301400080035586500090036300200130037203500100038580100190
0395#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#205#29#article#32
#29#^rND^sSpechler^nSJ#^rND^sSharma^nP#^rND^sTraxler^nB#^rND^sLevine^nD#^rND^sFa
lk^nGW#Gastric and esophageal pH in patients with Barrett's esophagus treated wi
th three esomeprazole dosages: a randomized, double-blind, crossover trial^len#A
m J Gastroenterol#20060900#200609#101#9#1964-71#20110300#v24n1a08.htm#0002-9270#
Am J Gastroenterol##
00568000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112012005200129030001300181065000900194064000700203031000300210032000200213
014000600215865000900221002001300230035001000243801001300253#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a08.htm#S#c#206#30#article#32#30#^rND^sWatson^nDI#^rN
D^sMayne^nGC#^rND^sHussey^nDJ#Barrett's Esophagus, fundoplication, and cancer^le
n#World J Surg#20070300#200703#31#3#447-9#20110300#v24n1a08.htm#0364-2313#World 
J Surg##
00750000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01700109010001900126010001800145010001500163012013300178030001900311065000900330
06400070033903100040034603200030035001400080035386500090036100200130037003500100
0383801001900393#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#207#3
1#article#32#31#^rND^sWenner^nJ#^rND^sHall^nM#^rND^sHoglund^nP#^rND^sJohansson^n
J#^rND^sJohnsson^nF#^rND^sOberg^nS#Wireless pH recording immediately above the s
quamocolumnar junction improves the diagnostic performance of esophageal pH stud
ies^len#Am J Gastroenterol#20081200#200812#103#12#2977-85#20110300#v24n1a08.htm#
0002-9270#Am J Gastroenterol##
00716000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01900113010001500132012015500147030001900302065000900321064000700330031000400337
032000200341014000800343865000900351002001300360035001000373801001900383#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a08.htm#S#c#208#32#article#32#32#^rND^sWe
nner^nJ#^rND^sJohnsson^nF#^rND^sJohansson^nJ#^rND^sOberg^nS#Acid reflux immediat
ely above the squamocolumnar junction and in the distal esophagus: simultaneous 
pH monitoring using the wireless capsule pH system^len#Am J Gastroenterol#200608
00#200608#101#8#1734-41#20110300#v24n1a08.htm#0002-9270#Am J Gastroenterol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#o#1#1#article#1
#20110411#103859#v24n1a09.htm#169##
04844000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000270011203100030013903200020014206500090014401400090015303500100016201201320
01720120120003040100030004240100032004540100033004860100044005190100030005630100
04100593010004400634083160200678085001002280085003602290085003402326085002102360
08500220238108315970240308500100400008500380401008500340404808500230408208500250
41051170008041300720003041381120009041411110011041501140009041611130011041700020
01304181#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#h#2#1#article#1
#oa#pt#br1.1#1#4.0#ILUS#TAB#9#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#2011030
0#^f43^l47#0102-6720#Correlação do nível de alfa-feto proteína, índice de sobrev
ida e recidiva tumoral em pacientes submetidosa transplante hepático^lpt#Surviva
l and tumor relapse rate according to alpha-fetoprotein level in patients submit
ted to liver transplantation^len#^rND^nElaine Cristina^sAtaide#^rND^nRicardo Ros
setto^sMachado#^rND^nMaxwel Boga Capsy^sRibeiro#^rND^nThiago Jose Almeida Prado^
sMattosinho#^rND^nFernando Araujo^sRomani#^rND^nCecilia Amelia Fazzio^sEscanhone
la#^rND^nIlka de Fatima Santana Ferreira^sBoin#^lpt^aRACIONAL: O transplante hep
ático para carcinoma hepatocelular pode resultar em potencial cura e melhora da 
sobrevida comparado com operações conservadoras. OBJETIVO: Analisar os índices d
e recorrência e sobrevida em pacientes transplantados hepáticos por carcinoma he
patocelular e com níveis séricos de alfa-fetoproteína maiores que 200 ng/ml. MÉT
ODO: Foram analisados retrospectivamente 90 pacientes cirróticos com carcinoma h
epatocelular submetidos à transplante hepático ortotópico entre 1997 e 2009. As 
lesões hepáticas foram diagnosticadas no pré-operatório por ultrassonografia com
 Doppler, tomografia computadorizada e níveis séricos de alfa fetoproteína. Os p
acientes foram divididos em dois grupos de acordo com o nível de alfa-fetoproteí
na (menor ou maior que 200 ng/ml. O método de Kaplan-Meier foi usado para calcul
ar a taxa de sobrevida. A análise de regressão Cox estudou os fatores preditivos
 de sobrevida. RESULTADOS: Pacientes com alfa-fetoproteína maior que 200 ng/ml (
n=6) apresentaram menor taxa de sobrevida em um e cinco anos e na média de meses
 comparados com o grupo com alfa-fetoproteína menor que 200 ng/ml (n=84); respec
tivamente 35%, 18% e 11,8 meses contra 68%, 43% e 28,1 meses. Além disso, a taxa
 de recidiva foi 16,6% no primeiro grupo, e de 5,6% no outro. Observouse risco d
e óbito de 1% para cada 10 u de alfa-fetoproteína>200 ng/ml e para cada mm da ma
ior medida de tumor acima de 28 mm. CONCLUSÃO: Os pacientes com valores séricos 
de alfa-fetoproteína maiores que 200 ng/ml demonstraram menores taxas de sobrevi
da, porém não foi preditivo de recidiva tumoral.#^ddecs^i1#^tm^lpt^kCarcinoma he
patocelular^i1#^tm^lpt^kTransplante de fígado^i1#^tm^lpt^kRecidiva^i1#^tm^lpt^kS
obrevida^i1#^len^aBACKGROUND: Liver transplantation for hepatocellular carcinoma
 (HCC) can result in a potential cure and greater survival than other less radic
al techniques. AIM: To analyze the survival and recurrence rate in liver transpl
ant recipients with hepatocellular carcinoma and alpha-fetoprotein over 200 ng/m
l. METHOD: Analysis, in this retrospective study, 90 cirrhotic patients with hep
atocellular carcinoma who underwent orthotopic liver transplantation between 199
7 and 2009. Liver lesions were diagnosed by preoperative Doppler ultrasonography
, abdominal computerized tomography and alpha-fetoprotein blood level. Two group
s were studied according to alpha-fetoprotein level over or below 200 ng/ml. The
 Kaplan-Meier method was used to study survival rate. The Cox regression analysi
s was performed to study predictive factor to survival. RESULTS: It was observed
 that risk of death was 1% for each 10 units of alpha-fetoprotein over 200 ng/ml
 and 1% for each mm over 28 mm (tumor size). In this sample average age, gender,
 presence of recidivism, vascular invasion, incidental tumor, Edmondson-Steiner 
grade and Milan criteria were similar when the two groups were submitted to mult
ivarite analysis and the survival rate and the size of great nodule had a signif
icant difference between the two groups. The survival rate was better for those 
patients with alpha-fetoprotein<200 ng/ml. CONCLUSION: Patients who had alpha-fe
toprotein &gt;200 showed worst survival and size of tumor was a predictive risk 
factor for mortality but this did not have influence in relationship to tumor re
currence#^ddecs^i2#^tm^len^kCarcinoma, hepatocellular^i2#^tm^len^kLiver transpla
ntation^i2#^tm^len^kRecurrence^i2#^tm^len^kSurvivorship^i2#vancouv#25#20110120#2
0/01/2011#20110125#25/01/2011#v24n1a09.htm##
04934000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000270011203100030013903200020014206500090014401400090015303500100016201201390
01720120127003110100030004380100032004680100033005000100044005330100030005770100
04100607010004400648083164000692085001002332085003602342085003402378085002102412
08500220243308316350245508500100409008500380410008500340413808500230417208500250
41951170008042200720003042281120009042311110011042401140009042511130011042600020
01304271#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#f#3#1#article#1
#oa#pt#br1.1#1#4.0#ILUS#TAB#9#ABCD060#nd#ABCD, arq. bras. cir. dig.#24#1#2011030
0#^f43^l47#0102-6720#<b>Correlação do nível de alfa-feto proteína, índice de sob
revida e recidiva tumoral em pacientes submetidosa transplante hepático</b>^lpt#
<b>Survival and tumor relapse rate according to alpha-fetoprotein level in patie
nts submitted to liver transplantation</b>^len#^rND^nElaine Cristina^sAtaide#^rN
D^nRicardo Rossetto^sMachado#^rND^nMaxwel Boga Capsy^sRibeiro#^rND^nThiago Jose 
Almeida Prado^sMattosinho#^rND^nFernando Araujo^sRomani#^rND^nCecilia Amelia Faz
zio^sEscanhonela#^rND^nIlka de Fatima Santana Ferreira^sBoin#^lpt^a<b>RACIONAL: 
</b>O transplante hepático para carcinoma hepatocelular pode resultar em potenci
al cura e melhora da sobrevida comparado com operações conservadoras. <b>OBJETIV
O: </b>Analisar os índices de recorrência e sobrevida em pacientes transplantado
s hepáticos por carcinoma hepatocelular e com níveis séricos de alfa-fetoproteín
a maiores que 200 ng/ml. <b>MÉTODO: </b>Foram analisados retrospectivamente 90 p
acientes cirróticos com carcinoma hepatocelular submetidos à transplante hepátic
o ortotópico entre 1997 e 2009. As lesões hepáticas foram diagnosticadas no pré-
operatório por ultrassonografia com Doppler, tomografia computadorizada e níveis
 séricos de alfa fetoproteína. Os pacientes foram divididos em dois grupos de ac
ordo com o nível de alfa-fetoproteína (menor ou maior que 200 ng/ml. O método de
 Kaplan-Meier foi usado para calcular a taxa de sobrevida. A análise de regressã
o Cox estudou os fatores preditivos de sobrevida. <b>RESULTADOS: </b>Pacientes c
om alfa-fetoproteína maior que 200 ng/ml (n=6) apresentaram menor taxa de sobrev
ida em um e cinco anos e na média de meses comparados com o grupo com alfa-fetop
roteína menor que 200 ng/ml (n=84); respectivamente 35%, 18% e 11,8 meses contra
 68%, 43% e 28,1 meses. Além disso, a taxa de recidiva foi 16,6% no primeiro gru
po, e de 5,6% no outro. Observouse risco de óbito de 1% para cada 10 u de alfa-f
etoproteína&gt;200 ng/ml e para cada mm da maior medida de tumor acima de 28 mm.
 <b>CONCLUSÃO: </b>Os pacientes com valores séricos de alfa-fetoproteína maiores
 que 200 ng/ml demonstraram menores taxas de sobrevida, porém não foi preditivo 
de recidiva tumoral.#^ddecs^i1#^tm^lpt^kCarcinoma hepatocelular^i1#^tm^lpt^kTran
splante de fígado^i1#^tm^lpt^kRecidiva^i1#^tm^lpt^kSobrevida^i1#^len^a<b>BACKGRO
UND:</b> Liver transplantation for hepatocellular carcinoma (HCC) can result in 
a potential cure and greater survival than other less radical techniques. <b>AIM
: </b>To analyze the survival and recurrence rate in liver transplant recipients
 with hepatocellular carcinoma and alpha-fetoprotein over 200 ng/ml. <b>METHOD: 
</b>Analysis, in this retrospective study, 90 cirrhotic patients with hepatocell
ular carcinoma who underwent orthotopic liver transplantation between 1997 and 2
009. Liver lesions were diagnosed by preoperative Doppler ultrasonography, abdom
inal computerized tomography and alpha-fetoprotein blood level. Two groups were 
studied according to alpha-fetoprotein level over or below 200 ng/ml. The Kaplan
-Meier method was used to study survival rate. The Cox regression analysis was p
erformed to study predictive factor to survival. <b>RESULTS:</b> It was observed
 that risk of death was 1% for each 10 units of alpha-fetoprotein over 200 ng/ml
 and 1% for each mm over 28 mm (tumor size). In this sample average age, gender,
 presence of recidivism, vascular invasion, incidental tumor, Edmondson-Steiner 
grade and Milan criteria were similar when the two groups were submitted to mult
ivarite analysis and the survival rate and the size of great nodule had a signif
icant difference between the two groups. The survival rate was better for those 
patients with alpha-fetoprotein&lt;200 ng/ml. <b>CONCLUSION:</b> Patients who ha
d alpha-fetoprotein &gt;200 showed worst survival and size of tumor was a predic
tive risk factor for mortality but this did not have influence in relationship t
o tumor recurrence#^ddecs^i2#^tm^len^kCarcinoma, hepatocellular^i2#^tm^len^kLive
r transplantation^i2#^tm^len^kRecurrence^i2#^tm^len^kSurvivorship^i2#vancouv#25#
20110120#20/01/2011#20110125#25/01/2011#v24n1a09.htm##
05051000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000260013003100030015603200020015906500090016101400090017003500100
01790120132001890120120003210100030004410100032004710100033005030100044005360100
03000580010004100610010004400651083166500695085001002360085003602370085003402406
08500210244008500220246108316110248308500100409408500380410408500340414208500230
41760850025041991170008042240720003042321120009042351110011042441140009042551130
01104264002001304275008008904288#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a
09.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab#9#ABCD060#
nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f43^l47#0102-6720#Correlação do níve
l de alfa-feto proteína, índice de sobrevida e recidiva tumoral em pacientes sub
metidosa transplante hepático^lpt#Survival and tumor relapse rate according to a
lpha-fetoprotein level in patients submitted to liver transplantation^len#^rND^n
Elaine Cristina^sAtaide#^rND^nRicardo Rossetto^sMachado#^rND^nMaxwel Boga Capsy^
sRibeiro#^rND^nThiago Jose Almeida Prado^sMattosinho#^rND^nFernando Araujo^sRoma
ni#^rND^nCecilia Amelia Fazzio^sEscanhonela#^rND^nIlka de Fatima Santana Ferreir
a^sBoin#^lpt^aRACIONAL: O transplante hepático para carcinoma hepatocelular pode
 resultar em potencial cura e melhora da sobrevida comparado com operações conse
rvadoras. OBJETIVO: Analisar os índices de recorrência e sobrevida em pacientes 
transplantados hepáticos por carcinoma hepatocelular e com níveis séricos de alf
a-fetoproteína maiores que 200 ng/ml. MÉTODO: Foram analisados retrospectivament
e 90 pacientes cirróticos com carcinoma hepatocelular submetidos à transplante h
epático ortotópico entre 1997 e 2009. As lesões hepáticas foram diagnosticadas n
o pré-operatório por ultrassonografia com Doppler, tomografia computadorizada e 
níveis séricos de alfa fetoproteína. Os pacientes foram divididos em dois grupos
 de acordo com o nível de alfa-fetoproteína (menor ou maior que 200 ng/ml. O mét
odo de Kaplan-Meier foi usado para calcular a taxa de sobrevida. A análise de re
gressão Cox estudou os fatores preditivos de sobrevida. RESULTADOS: Pacientes co
m alfa-fetoproteína maior que 200 ng/ml (n=6) apresentaram menor taxa de sobrevi
da em um e cinco anos e na média de meses comparados com o grupo com alfa-fetopr
oteína menor que 200 ng/ml (n=84); respectivamente 35 por cento, 18 por cento e 
11,8 meses contra 68 por cento, 43 por cento e 28,1 meses. Além disso, a taxa de
 recidiva foi 16,6 por cento no primeiro grupo, e de 5,6 por cento no outro. Obs
ervouse risco de óbito de 1 por cento para cada 10 u de alfa-fetoproteína>200 ng
/ml e para cada mm da maior medida de tumor acima de 28 mm. CONCLUSÃO: Os pacien
tes com valores séricos de alfa-fetoproteína maiores que 200 ng/ml demonstraram 
menores taxas de sobrevida, porém não foi preditivo de recidiva tumoral.#^ddecs^
i1#^tm^lpt^kCarcinoma hepatocelular^i1#^tm^lpt^kTransplante de fígado^i1#^tm^lpt
^kRecidiva^i1#^tm^lpt^kSobrevida^i1#^len^aBACKGROUND: Liver transplantation for 
hepatocellular carcinoma (HCC) can result in a potential cure and greater surviv
al than other less radical techniques. AIM: To analyze the survival and recurren
ce rate in liver transplant recipients with hepatocellular carcinoma and alpha-f
etoprotein over 200 ng/ml. METHOD: Analysis, in this retrospective study, 90 cir
rhotic patients with hepatocellular carcinoma who underwent orthotopic liver tra
nsplantation between 1997 and 2009. Liver lesions were diagnosed by preoperative
 Doppler ultrasonography, abdominal computerized tomography and alpha-fetoprotei
n blood level. Two groups were studied according to alpha-fetoprotein level over
 or below 200 ng/ml. The Kaplan-Meier method was used to study survival rate. Th
e Cox regression analysis was performed to study predictive factor to survival. 
RESULTS: It was observed that risk of death was 1 percent for each 10 units of a
lpha-fetoprotein over 200 ng/ml and 1 percent for each mm over 28 mm (tumor size
). In this sample average age, gender, presence of recidivism, vascular invasion
, incidental tumor, Edmondson-Steiner grade and Milan criteria were similar when
 the two groups were submitted to multivarite analysis and the survival rate and
 the size of great nodule had a significant difference between the two groups. T
he survival rate was better for those patients with alpha-fetoprotein<200 ng/ml.
 CONCLUSION: Patients who had alpha-fetoprotein &gt;200 showed worst survival an
d size of tumor was a predictive risk factor for mortality but this did not have
 influence in relationship to tumor recurrence#^ddecs^i2#^tm^len^kCarcinoma, hep
atocellular^i2#^tm^len^kLiver transplantation^i2#^tm^len^kRecurrence^i2#^tm^len^
kSurvivorship^i2#vancouv#25#20110120#20/01/2011#20110125#25/01/2011#v24n1a09.htm
#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202011
000100009##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#5#1#article#140#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL </b><
/font></p>     ^cY#v24n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#6#2#article#140#<p>&nbsp;</p>     ^cY
#v24n1a09.htm##
00513000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704028000074002001300354#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#7#3#article#140#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Correla&ccedil;
&atilde;o do n&iacute;vel de alfa-feto prote&iacute;na, &iacute;ndice de sobrevi
da e recidiva tumoral em pacientes submetidosa transplante hep&aacute;tico </b><
/font></p>     ^cY#v24n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#8#4#article#140#<p>&nbsp;</p>     ^cY
#v24n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#9#5#article#140#<p>&nbsp;</p>     ^cY
#v24n1a09.htm##
00535000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704030100075002001300376#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#10#6#article#140#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Elaine Cristina Ataide; Ricardo Ro
ssetto Machado; Maxwel Boga Capsy Ribeiro; Thiago Jose Almeida Prado Mattosinho;
 Fernando Araujo Romani; Cecilia Amelia Fazzio Escanhonela; Ilka de Fatima Santa
na Ferreira Boin </b></font></p>     ^cY#v24n1a09.htm##
00360000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012600075002001300201#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#11#7#article#140#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> <a href="#note2">Correspond&ecirc;nc
ia</a></font></p>     ^cY#v24n1a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#12#8#article#140#<p>&nbsp;</p>     ^c
Y#v24n1a09.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004600075002001300121#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#13#9#article#140#<p>&nbsp;</p> <hr si
ze="1" noshade>       ^cY#v24n1a09.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#14#10#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a09.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007100076002001300147#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#15#11#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">    ^cY#v24n1a09.htm##
00434000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019900076002001300275#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#16#12#article#140#<br>   <b>RACIONAL:
 </b> O transplante hep&aacute;tico para carcinoma hepatocelular pode resultar e
m potencial cura e melhora da sobrevida comparado com opera&ccedil;&otilde;es co
nservadoras.    ^cY#v24n1a09.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025000076002001300326#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#17#13#article#140#<br>   <b>OBJETIVO:
 </b>Analisar os &iacute;ndices de recorr&ecirc;ncia e sobrevida em pacientes tr
ansplantados hep&aacute;ticos por carcinoma hepatocelular e com n&iacute;veis s&
eacute;ricos de alfa-fetoprote&iacute;na maiores que 200 ng/ml.    ^cY#v24n1a09.
htm##
00953000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071800076002001300794#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#18#14#article#140#<br>   <b>M&Eacute;
TODO: </b>Foram analisados retrospectivamente 90 pacientes cirr&oacute;ticos com
 carcinoma hepatocelular submetidos &agrave; transplante hep&aacute;tico ortot&o
acute;pico entre 1997 e 2009. As les&otilde;es hep&aacute;ticas foram diagnostic
adas no pr&eacute;-operat&oacute;rio por ultrassonografia com Doppler, tomografi
a computadorizada e n&iacute;veis s&eacute;ricos de alfa fetoprote&iacute;na. Os
 pacientes foram divididos em dois grupos de acordo com o n&iacute;vel de alfa-f
etoprote&iacute;na (menor ou maior que 200 ng/ml. O m&eacute;todo de Kaplan-Meie
r foi usado para calcular a taxa de sobrevida. A an&aacute;lise de regress&atild
e;o Cox estudou os fatores preditivos de sobrevida.    ^cY#v24n1a09.htm##
00802000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056700076002001300643#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#19#15#article#140#<br>   <b>RESULTADO
S: </b>Pacientes com alfa-fetoprote&iacute;na maior que 200 ng/ml (n=6) apresent
aram menor taxa de sobrevida em um e cinco anos e na m&eacute;dia de meses compa
rados com o grupo com alfa-fetoprote&iacute;na menor que 200 ng/ml (n=84); respe
ctivamente 35%, 18% e 11,8 meses contra 68%, 43% e 28,1 meses. Al&eacute;m disso
, a taxa de recidiva foi 16,6% no primeiro grupo, e de 5,6% no outro. Observouse
 risco de &oacute;bito de 1% para cada 10 u de alfa-fetoprote&iacute;na&gt;200 n
g/ml e para cada mm da maior medida de tumor acima de 28 mm.    ^cY#v24n1a09.htm
##
00477000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024200076002001300318#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#20#16#article#140#<br>   <b>CONCLUS&A
tilde;O: </b>Os pacientes com valores s&eacute;ricos de alfa-fetoprote&iacute;na
 maiores que 200 ng/ml demonstraram menores taxas de sobrevida, por&eacute;m n&a
tilde;o foi preditivo de recidiva tumoral. </font></p>     ^cY#v24n1a09.htm##
00438000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020300076002001300279#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#21#17#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b>Carcinoma hepato
celular. Transplante de f&iacute;gado. Recidiva. Sobrevida. </font></p> <hr size
="1" noshade>       ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#22#18#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#23#19#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#24#20#article#140#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b> </fo
nt></p>     ^cY#v24n1a09.htm##
00699000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046400076002001300540#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#25#21#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O carcinoma hepatocelular (CHC) &eac
ute; descrito como a terceira causa de mortalidade por neoplasia no mundo, corre
spondendo a aproximadamente 500 mil mortes por ano<sup>11,13</sup>. &Eacute;</su
b> caracterizado pela incid&ecirc;ncia elevada em pacientes portadores de hepato
patia cr&ocirc;nica, sendo as causas virais as de maior impacto epidemiol&oacute
;gico<sup>8,11,13</sup>. </font></p>     ^cY#v24n1a09.htm##
00628000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039300076002001300469#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#26#22#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sua incid&ecirc;ncia vem crescendo a
nualmente em pa&iacute;ses do ocidente como resultado do crescente aumento de pa
cientes portadores do v&iacute;rus da hepatite C e B. Segundo estimativas epidem
iol&oacute;gicas esta incid&ecirc;ncia tende a aumentar nas pr&oacute;ximas duas
 d&eacute;cadas<sup>2,8,20</sup>. </font></p>     ^cY#v24n1a09.htm##
00667000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043200076002001300508#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#27#23#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tratamento cir&uacute;rgico &eacut
e; atualmente a melhor terap&ecirc;utica para o tratamento do CHC em virtude da 
recorr&ecirc;ncia tumoral ap&oacute;s o transplante hep&aacute;tico total (TOF) 
e vem se demonstrando como uma op&ccedil;&atilde;o adequada em est&aacute;dios p
recoces com potencial de cura e implemento da sobrevida<sup>14,20</sup>. </font>
</p>     ^cY#v24n1a09.htm##
00965000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073000076002001300806#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#28#24#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A sobrevida de cinco anos em 75% dos
 casos &eacute; similar a de pacientes submetidos &agrave; transplante hep&aacut
e;tico sem CHC principalmente naqueles  pacientes que se  encontram dentro dos c
rit&eacute;rios de Mil&atilde;o (n&oacute;dulo &uacute;nico menor que 5 cm no se
u maior di&acirc;metro ou at&eacute; tr&ecirc;s n&oacute;dulos de at&eacute; 3 c
m no seu maior di&acirc;metro)<sup>18</sup>. No entanto, &iacute;ndices de recor
r&ecirc;ncia de CHC p&oacute;s-transplante hep&aacute;tico variam de 3,5 a 26 % 
em diversos estudos realizados em grandes centros e v&ecirc;m despertando aten&c
cedil;&atilde;o e cautela<sup>2,12,14,18,24</sup>. </font></p>     ^cY#v24n1a09.
htm##
00815000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058000076002001300656#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#29#25#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O risco de recorr&ecirc;ncia foi atr
elado a algumas vari&aacute;veis como: tamanho do n&oacute;dulo &agrave; avalia&
ccedil;&atilde;o do explante, diferencia&ccedil;&atilde;o histol&oacute;gica, pr
esen&ccedil;a de invas&atilde;o macrovascular, microvascular e n&iacute;vel pr&e
acute;-operat&oacute;rio de alfa feto-prote&iacute;na (AFP). Essas vari&aacute;v
eis s&atilde;o atualmente os melhores preditores de recorr&ecirc;ncia de CHC ap&
oacute;s o transplante hep&aacute;tico<sup>5,10,23,24</sup>. </font></p>     ^cY
#v24n1a09.htm##
00954000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071900076002001300795#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#30#26#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A dosagem de alfa-feto prote&iacute;
na, inicialmente descrita por Abelev, et al.<sup>1</sup> em 1963, &eacute; o mai
s difundido marcador tumoral empregado para rastreamento e seguimento do CHC ao 
redor do mundo. V&aacute;rios estudos demonstraram que alfa-feto prote&iacute;na
 elevada &eacute; fator de pior progn&oacute;stico em rela&ccedil;&atilde;o &agr
ave; agressividade da doen&ccedil;a estando assim atrelada, em n&iacute;veis ele
vados, &agrave; tumores de di&acirc;metros maiores e invas&atilde;o vascular. Ne
sses estudos o valor de corte associado &agrave; piora do progn&oacute;stico &ea
cute; de 200 ng/ml<sup>1,9,16,19</sup>. </font></p>     ^cY#v24n1a09.htm##
00558000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032300076002001300399#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#31#27#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo foi analisar
 os &iacute;ndices de recidiva e sobrevida em pacientes transplantados hep&aacut
e;ticos por CHC e com n&iacute;veis s&eacute;ricos de alfafetoprote&iacute;na ma
iores que 200 ng/ml<sup>1,9,16,19,21</sup>. </font></p>     ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#32#28#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#33#29#article#140#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODO</b></font></p>     
^cY#v24n1a09.htm##
00559000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032400076002001300400#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#34#30#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foram analisados 90 pacientes cirr&o
acute;ticos com diagn&oacute;stico pr&eacute;-operat&oacute;rio de CHC submetido
s &agrave; transplante hep&aacute;tico no Hospital de Cl&iacute;nicas da Unicamp
, entre janeiro de 1997 e setembro de 2009 . </font></p>     ^cY#v24n1a09.htm##
00743000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050800076002001300584#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#35#31#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O diagn&oacute;stico pr&eacute;-oper
at&oacute;rio foi obtido de acordo com crit&eacute;rios estabelecidos pela EASL 
(European Association for Study of Liver) e AASLD (American Association for Stud
y of Liver Disease). Foram utilizados tomografia de abdome, ultrassonografia com
 Doppler e/ ou resson&acirc;ncia de abdome mostrando hipervasculariza&ccedil;&at
ilde;o arterial e dosagem de alfa-feto prote&iacute;na<sup>12</sup>. </font></p>
     ^cY#v24n1a09.htm##
00574000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033900076002001300415#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#36#32#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Todos os pacientes submetidos &agrav
e; interven&ccedil;&atilde;o cir&uacute;rgica apresentavam-se dentro dos crit&ea
cute;rios de Mil&atilde;o durante a inclus&atilde;o em lista pr&eacute;-transpla
nte e avalia&ccedil;&atilde;o pr&eacute;-operat&oacute;ria. </font></p>     ^cY#
v24n1a09.htm##
00608000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037300076002001300449#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#37#33#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Durante o tempo de espera em lista a
lguns pacientes foram submetidos a tratamento quimioter&aacute;pico seletivo ou 
alcooliza&ccedil;&atilde;o quando necess&aacute;rio, mediante decis&atilde;o de 
equipe multidisciplinar, de acordo com o est&aacute;dio e localiza&ccedil;&atild
e;o do tumor. </font></p>     ^cY#v24n1a09.htm##
00715000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048000076002001300556#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#38#34#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Pacientes que no momento do diagn&oa
cute;stico se encontravam fora dos crit&eacute;rios de Mil&atilde;o foram submet
idos a tratamento para "downstaging" (redu&ccedil;&atilde;o do tumor obtida por 
m&eacute;todos alternativos terap&ecirc;uticos como quimioemboliza&ccedil;&atild
e;o ou alcooliza&ccedil;&atilde;o) e posteriormente submetidos ao transplante, s
eguindo as leis vigentes no pa&iacute;s. </font></p>     ^cY#v24n1a09.htm##
00703000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046800076002001300544#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#39#35#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s o transplante todos os p
acientes foram acompanhados atrav&eacute;s de dosagem de alfa-feto prote&iacute;
na e ultrassonografia de abdome a cada tr&ecirc;s meses at&eacute; o final do pr
imeiro ano e ap&oacute;s a cada seis meses at&eacute; o final do segundo ano. Em
 casos de suspeita de recidiva tumoral foram realizadas tomografia de abdome ou 
resson&acirc;ncia de abdome. </font></p>     ^cY#v24n1a09.htm##
00595000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036000076002001300436#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#40#36#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o da fun&cce
dil;&atilde;o hep&aacute;tica foi obtida atrav&eacute;s do escore MELD (Model fo
r End-stage Liver Disease)<sup>6</sup>. Pacientes transplantados anteriormente a
 2005 tiveram sua fun&ccedil;&atilde;o hep&aacute;tica calculada retroativamente
 </font></p>     ^cY#v24n1a09.htm##
00997000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076200076002001300838#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#41#37#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As vari&aacute;veis estudadas foram:
 idade (anos), sexo (masculino ou feminino), n&iacute;vel sangu&iacute;neo de al
fafetoprote&iacute;na acima ou abaixo de 200 ng/ml, tamanho do tumor (em mm), n&
uacute;mero de n&oacute;dulos, est&aacute;dio histol&oacute;gico segundo Edmonds
on-Steiner (grau I, II, III), presen&ccedil;a de invas&atilde;o macrovascular e 
microvascular observados no explante; estar ou n&atilde;o dentro do crit&eacute;
rio de Mil&atilde;o ap&oacute;s avalia&ccedil;&atilde;o do explante, presen&cced
il;a de tumor incidental ou n&atilde;o, ter apresentado recidiva ou n&atilde;o; 
sobrevida e presen&ccedil;a de recidiva tumoral ao final do primeiro e quinto an
o. </font></p>     ^cY#v24n1a09.htm##
00984000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074900076002001300825#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#42#38#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise estat&iacute;stica 
foi realizada utilizando o programa Statistica 7.5/2007-Softstat-Chicago/USA. Fo
i utilizada an&aacute;lise descritiva para observa&ccedil;&atilde;o da frequ&eci
rc;ncia e das m&eacute;dias. A compara&ccedil;&atilde;o dos grupos com e sem AFP
 maior que 200 ng/ml foi feita utilizandose o teste de Wilcoxon. A sobrevida com
preendendo o per&iacute;odo entre a interven&ccedil;&atilde;o cir&uacute;rgica e
 a &uacute;ltima visita foi calculada utilizando-se o m&eacute;todo estimativo d
e sobrevida de Kaplan-Meyer e os fatores progn&oacute;sticos para recorr&ecirc;n
cia foram avaliados utilizando-se o teste de regress&atilde;o de Cox. </font></p
>     ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#43#39#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#44#40#article#140#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>RESULTADOS</b></font></p>      ^
cY#v24n1a09.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027100076002001300347#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#45#41#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foram avaliados 90 pacientes cirr&oa
cute;ticos transplantados com diagn&oacute;stico pr&eacute;-operat&oacute;rio de
 CHC sendo 72 pacientes do sexo masculino (80%) e 18 do feminino (20%). </font><
/p>     ^cY#v24n1a09.htm##
00399000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016400076002001300240#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#46#42#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A m&eacute;dia de idade no momento d
o transplante foi de 52,3 anos (33-68 anos). </font></p>     ^cY#v24n1a09.htm##
00480000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024500076002001300321#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#47#43#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Como causa encontrou-se a hepatopati
a por virus C em 54% dos pacientes, seguida por &aacute;lcool em 22%, v&iacute;r
us B em 19% dos casos e 5% nas demais causas. </font></p>     ^cY#v24n1a09.htm##
00534000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029900076002001300375#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#48#44#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A m&eacute;dia de seguimento foi de 
42 meses; a m&eacute;dia dos n&iacute;veis de alfa-feto prote&iacute;na foi de 4
2,3ng/ ml e a m&eacute;dia do tamanho dos n&oacute;dulos em seu maior di&acirc;m
etros foi de 32 mm. </font></p>     ^cY#v24n1a09.htm##
00456000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022100076002001300297#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#49#45#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os pacientes apresentaram resultados
 de escore MELD e n&iacute;veis de imunossupressores semelhantes independente do
 n&iacute;vel de AFP. </font></p>     ^cY#v24n1a09.htm##
00497000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026200076002001300338#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#50#46#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tratamento pr&eacute;-operat&oacut
e;rio com quimioemboliza&ccedil;&atilde;o para "downstaging" foi realizado em 13
 pacientes sendo que nenhum deles apresentou recidiva tumoral. </font></p>     ^
cY#v24n1a09.htm##
00535000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030000076002001300376#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#51#47#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A recorr&ecirc;ncia de CHC p&oacute;
s transplante foi encontrada em seis pacientes (6,7%) com m&eacute;dia de tempo 
de nove meses entre a interven&ccedil;&atilde;o cir&uacute;rgica e o diagn&oacut
e;stico de recidiva. </font></p>     ^cY#v24n1a09.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#52#48#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Embora 72% dos pacientes estivessem 
dentro dos crit&eacute;rios de Mil&atilde;o na observa&ccedil;&atilde;o do expla
nte, apenas tr&ecirc;s (dos seis com recidiva) pacientes extrapolavam esses crit
&eacute;rios ap&oacute;s avalia&ccedil;&atilde;o do f&iacute;gado explantado; 39
,2% dos pacientes com AFP&lt;200 ng/ml extrapolaram estes crit&eacute;rios geral
mente devido ao n&uacute;mero de n&oacute;dulos tumorais observados. Notou-se ta
mb&eacute;m que 2% apresentavam invas&atilde;o macrovascular e 18% microvascular
, les&otilde;es estas n&atilde;o observadas nos exames de imagens anteriores ao 
transplante. </font></p>     ^cY#v24n1a09.htm##
00537000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030200076002001300378#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#53#49#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os s&iacute;tios de recorr&ecirc;nci
a tumoral foram: f&iacute;gado em tr&ecirc;s pacientes, pulm&atilde;o em um e m&
uacute;ltiplos s&iacute;tios (pulm&atilde;o, c&eacute;rebro, f&iacute;gado e oss
os) em outro paciente. </font></p>     ^cY#v24n1a09.htm##
00546000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031100076002001300387#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#54#50#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em todos os casos o tratamento da re
corr&ecirc;ncia consistiu em mudan&ccedil;a da imunossupress&atilde;o de inibido
r de calcineurina para sirolimus e em um paciente foi associado o quimioter&aacu
te;pico Sorafenibe<sup>R</sup>. </font></p>     ^cY#v24n1a09.htm##
00635000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040000076002001300476#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#55#51#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na <a href="#tab1">Tabela 1</a> pode
m ser observadas as m&eacute;dias e frequ&ecirc;ncia das vari&aacute;veis estuda
das. Observa-se tamb&eacute;m que apenas seis ( 6,7% ) apresentavam AFP acima de
 200 ng/ml, n&atilde;o havendo diferen&ccedil;a estat&iacute;stica em rela&ccedi
l;&atilde;o ao aparecimento de recidiva. </font></p>     ^cY#v24n1a09.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#56#52#article#140#<p><a name="tab1"><
/a></p>     ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#57#53#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#58#54#article#140#<p align="center"><
img src="/img/revistas/abcd/v24n1/a09tab1.jpg"></p>     ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#59#55#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00499000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026400076002001300340#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#60#56#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Apenas um paciente, com diagn&oacute
;stico de recidiva p&oacute;s-transplante, apresentou AFP superior a 200 ng/ml e
 a m&eacute;dia de AFP entre esses pacientes foi de 64,58 ng/ml. </font></p>    
 ^cY#v24n1a09.htm##
00731000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049600076002001300572#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#61#57#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O teste de regress&atilde;o COX evid
enciou que o n&iacute;vel de AFP e tamanho do tumor puderam ser considerados com
o fator independente de risco para sobrevida (risco de &oacute;bito de 1% para c
ada 10u de AFP acima de 200 ng/ml -p=0,002; HR=0,0178 - IC 95% = 0,0096-0,356) e
 1% de risco de mortalidade para cada mm de tumor acima de 28 mm (p=0,04; HR=0,0
169 - IC95%=0,00940,299) (<a href="#fig1">Figura 1</a>). </font></p>     ^cY#v24
n1a09.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#62#58#article#140#<p><a name="fig1"><
/a></p>     ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#63#59#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#64#60#article#140#<p align="center"><
img src="/img/revistas/abcd/v24n1/a09fig1.jpg"></p>     ^cY#v24n1a09.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#65#61#article#140#<p>&nbsp;</p> <font
 size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></
font>     ^cY#v24n1a09.htm##
00810000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057500076002001300651#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#66#62#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Alfa-feto prote&iacute;na caracteriz
a-se por ser uma glicoprote&iacute;na fetal associada a crescimento tumoral. Fis
iologicamente &eacute; uma prote&iacute;na sintetizada e secretada por hepat&oac
ute;citos fetais, c&eacute;lulas do trato gastrointestinal e c&eacute;lulas germ
inativas, seu n&iacute;vel s&eacute;rico diminui gradativamente ap&oacute;s o na
scimento at&eacute; o primeiro ano de vida quando se mant&ecirc;m est&aacute;vel
 normalmente abaixo de 10 ng/ml<sup>1,9,16,19,21</sup>. </font></p>     ^cY#v24n
1a09.htm##
00804000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056900076002001300645#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#67#63#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">AFP vem sendo utilizada amplamente n
a literatura como marcador tumoral h&aacute; aproximadamente 40 anos, sedimentan
do a participa&ccedil;&atilde;o desse marcador na regula&ccedil;&atilde;o e cres
cimento de oncogenes, havendo evid&ecirc;ncia de seu papel promovendo cresciment
o de hepat&oacute;citos<sup>1,9,16,19,21</sup>. O carcinoma hepatocelular com n&
iacute;vel elevado de AFP tem se caracterizado por maior atividade proliferativa
 celular medida por Ki-67<sup>1,9,16,19,21</sup>. </font></p>     ^cY#v24n1a09.h
tm##
00950000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071500076002001300791#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#68#64#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No entanto, recentemente estudos v&e
circ;m definindo a AFP paulatinamente como um marcador com especificidade e sens
ibilidade deficientes com taxas aproximadas a 60% de sensibilidade e 70% de espe
cificidade suscitando v&aacute;rios esfor&ccedil;os em diversos centros em busca
 de melhores marcadores<sup>4,12,17,22</sup>. A raz&atilde;o para a baixa sensib
ilidade e especificidade encontradas vem sendo atribu&iacute;da ao avan&ccedil;o
 dos m&eacute;todos de imagem que hoje conseguem diagnosticar tumores menores do
s quais encontrados no passado, normalmente associados a n&iacute;veis de AFP de
ntro da normalidade<sup>9,16</sup>. </font></p>     ^cY#v24n1a09.htm##
00633000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039800076002001300474#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#69#65#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em estudo com 170 pacientes com diag
n&oacute;stico de CHC, Trevisani, et al.<sup>25</sup> demonstraram, mesmo estabe
lecendo valor de corte de AFP de 200 ng/ml caracterizado por ser o melhor valor 
no estudo citado, a sensibilidade n&atilde;o ultrapassou de 60%, o que significa
 40% de falsos negativos<sup>25</sup>. </font></p>     ^cY#v24n1a09.htm##
00667000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043200076002001300508#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#70#66#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na aus&ecirc;ncia de malignidade, o 
n&iacute;vel de AFP pode aparecer elevado em casos de replica&ccedil;&atilde;o p
elo v&iacute;rus da hepatite B e C<sup>7,15</sup>, agentes estes comumente corre
lacionados &agrave; hepatopatia cr&ocirc;nica predisponente ao aparecimento de C
HC o que pode muitas vezes dificultar a especificidade do m&eacute;todo. </font>
</p>     ^cY#v24n1a09.htm##
00723000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048800076002001300564#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#71#67#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m disso, o n&iacute;vel de
 AFP pode tamb&eacute;m aparecer elevado em tumores gastrointestinais que n&atil
de;o o CHC, como por exemplo o colangiocarcinoma. Esse fato tem grande relev&aci
rc;ncia visto que o colangiocarcinoma apresenta tratamento e progn&oacute;stico 
diferente ao CHC principalmente no que diz respeito &agrave; indica&ccedil;&atil
de;o de transplante hep&aacute;tico<sup>7</sup>. </font></p>     ^cY#v24n1a09.ht
m##
00817000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058200076002001300658#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#72#68#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A indica&ccedil;&atilde;o de transpl
ante hep&aacute;tico para pacientes cirr&oacute;ticos com diagn&oacute;stico de 
CHC vem se apresentando como uma boa alternativa terap&ecirc;utica, com sobrevid
a semelhante ao transplante realizado por outras causas<sup>2,14,18,20</sup>. No
 entanto, o &iacute;ndice de recidiva tumoral p&oacute;s-transplante varia de 3,
5% a 26% em alguns estudos<sup>4,5,10,12,14,23,24 </sup>e vem suscitando a neces
sidade de m&eacute;todos preditivos de pior recorr&ecirc;ncia. </font></p>     ^
cY#v24n1a09.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018900076002001300265#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#73#69#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O &iacute;ndice de recidiva aqui obt
ido foi de 5,6%, compat&iacute;vel com a literatura<sup>3,6,12</sup>. </font></p
>     ^cY#v24n1a09.htm##
00683000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044800076002001300524#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#74#70#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Entre as vari&aacute;veis atreladas 
&agrave; piora do &iacute;ndice de recorr&ecirc;ncia, foi dada principal &ecirc;
nfase &agrave; alfa-feto prote&iacute;na. Para isso, foram estudados &iacute;ndi
ces mediante um corte de alfa-fetoprote&iacute;na de 200 ng/ml que de acordo com
 a literatura demonstra ser um fator de pior progn&oacute;stico<sup>1,3,9,16,19,
21.</sup></font></p>     ^cY#v24n1a09.htm##
00592000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035700076002001300433#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#75#71#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> O presente estudo, com pacientes di
vididos em dois grupos, AFP acima de 200 ng/ml e AFP menor que 200 ng/ml, confir
ma esse achado, nos quais os pacientes do primeiro grupo apresentam menor sobrev
ida global e menor sobrevida no primeiro e quinto ano p&oacute;s-transplante. </
font></p>     ^cY#v24n1a09.htm##
00781000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054600076002001300622#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#76#72#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Neste estudo, avaliando fatores j&aa
cute; definidos na literatura como de pior progn&oacute;stico como est&aacute;di
o da doen&ccedil;a, diferencia&ccedil;&atilde;o celular, invas&atilde;o vascular
, crit&eacute;rios de Mil&atilde;o e presen&ccedil;a de tumor incidental<sup>5,1
0,23,24</sup>, n&atilde;o houve diferen&ccedil;a estat&iacute;stica entre os gru
pos com AFP maior ou menor que 200 ng/ml exceto pelo tamanho do n&oacute;dulo em
 seu maior di&acirc;metro. </font></p>     ^cY#v24n1a09.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038200076002001300458#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#77#73#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A associa&ccedil;&atilde;o com maior
 di&acirc;metro pode estar associada &agrave; caracter&iacute;stica de promo&cce
dil;&atilde;o de maior atividade celular da AFP, no entanto, n&atilde;o houve co
rrela&ccedil;&atilde;o com piora do grau de diferencia&ccedil;&atilde;o celular<
sup>1,9,16,19,21.</sup></font></p>     ^cY#v24n1a09.htm##
00883000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064800076002001300724#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#78#74#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">N&atilde;o houve tamb&eacute;m difer
en&ccedil;a estat&iacute;stica entre os dois grupos em rela&ccedil;&atilde;o &ag
rave; recidiva tumoral, apenas um paciente com recidiva apresentava AFP superior
 a 200 ng/nl, levando a corroborar a literatura em se encontrar novos m&eacute;t
odos mais espec&iacute;ficos e sens&iacute;veis para predi&ccedil;&atilde;o da r
ecorr&ecirc;ncia <sup>4,5,7,10,12,15,17,22,23,24,25</sup>. Observou-se risco de 
&oacute;bito de 1% para cada 10 u de alfa-fetoprote&iacute;na&gt;200ng/ml e para
 cada mm da maior medida de tumor acima de 28mm. </font></p>     ^cY#v24n1a09.ht
m##
00537000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030200076002001300378#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#79#75#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A alfa-feto prote&iacute;na acima de
 200 ng/ml apenas foi observada em 6,7% dos pacientes mostrando pouca acur&aacut
e;cia no diagn&oacute;stico, conforme referendado por diferentes autores<sup>4,7
,12,15,17,22,25</sup>. </font></p>     ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#80#76#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#81#77#article#140#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>  
   ^cY#v24n1a09.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028400076002001300360#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#82#78#article#140#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os fatores de risco associados a pio
r progn&oacute;stico foram AFP e o tamanho do tumor. A dosagem de AFP mostrou se
r um marcador prec&aacute;rio e novos biomarcadores tumorais devem ser investiga
dos. </font></p>     ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#83#79#article#140#<p>&nbsp;</p>     ^
cY#v24n1a09.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#84#80#article#140#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p> 
    ^cY#v24n1a09.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024400078002001300322#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#85#81#article#140#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. 	Abelev GI, Perova 
SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonal alpha-globuli
n by transplantable mouse hepatoma. Transplantation. 1963 Apr;1:174-80.    ^cY#v
24n1a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#86#82#article#140# </font></p>     ^c
Y#v24n1a09.htm##
00427000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017800078002001300256#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#87#83#article#140#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bruix J, Llovet JM.
 Major achievements in hepatocellular carcinoma. Lancet. 2009 Feb 21;373(9664):6
14-6.    ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#88#84#article#140#. </font></p>     ^
cY#v24n1a09.htm##
00629000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038000078002001300458#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#89#85#article#140#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Bruix J, Sherman M,
 Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Co
lombo M, Rod&eacute;s J. Clinical management of hepatocellular carcinoma. Conclu
sions of the Barcelona-2000 EASL conference. European Association for the Study 
of the Liver. J Hepatol. 2001 Sep;35(3):421-30.    ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#90#86#article#140#. </font></p>     ^
cY#v24n1a09.htm##
00680000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704043100078002001300509#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#91#87#article#140#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. 	Cescon M, Ravaioli
 M, Grazi GL, Ercolani G, Cucchetti A, Bertuzzo V, VetroneG, Del Gaudio M, Vivar
elli M, D'Errico-Grigioni A, Dazzi A, Di Gioia P, Lauro A, Pinna AD. Prognostic 
factors for tumor recurrence after a 12-year, single-center experience of liver 
transplantations in patients with hepatocellular carcinoma. J Transplant. 2010; 
2010. pii: 904152.    ^cY#v24n1a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#92#88#article#140# </font></p>     ^c
Y#v24n1a09.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030200078002001300380#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#93#89#article#140#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. 	De Carlis L, Giaco
moni A, Lauterio A, Slim A, Sammartino C, Pirotta V, Colella G, Forti D.  Liver 
transplantation for hepatocellular cancer: should the current indication criteri
a be changed? Transpl Int. 2003 Feb;16(2):115-22.    ^cY#v24n1a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#94#90#article#140# </font></p>     ^c
Y#v24n1a09.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032800078002001300406#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#95#91#article#140#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. 	Delis S, Biliatis 
I, Athanasiou K, Dervenis C. Model for end-stage liver disease (MELD) score as a
 prognostic factor for postoperative morbidity and mortality in cirrhotic patien
ts undergoing hepatectomy for HCC. Gut 2006; 55(Suppl V):A 153 </font></p>     ^
cY#v24n1a09.htm##
00634000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038500078002001300463#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#96#92#article#140#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. 	Di Bisceglie AM, S
terling RK, Chung RT, Everhart JE, Dienstag JL, BonkovskyHL, Wright EC, Everson 
GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG,Gretch DR; HALT-C Trial Grou
p. Serum alphafetoprotein levels in patients with advanced hepatitis C: results 
from the HALT-C Trial. J Hepatol. 2005;43(3):434-41.    ^cY#v24n1a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#97#93#article#140# </font></p>     ^c
Y#v24n1a09.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020500078002001300283#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#98#94#article#140#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. El-Serag HB, Mason 
AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J 
Med. 1999 Mar 11;340(10):745-50.    ^cY#v24n1a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#99#95#article#140# </font></p>     ^c
Y#v24n1a09.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704023000079002001300309#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#100#96#article#140#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Forner A, Reig M, 
Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of
 a brilliant star. Gastroenterology. 2009 Jul;137(1):26-9.    ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#101#97#article#140# </font></p>     ^
cY#v24n1a09.htm##
00581000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704033000080002001300410#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#102#98#article#140#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Herrero JI, Sang
ro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA, Prieto J. Influence of tumor
 characteristics on the outcome of liver transplantation among patients with liv
er cirrhosis and hepatocellular carcinoma.  Liver Transpl. 2001 Jul;7(7):631-6. 
   ^cY#v24n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#103#99#article#140# </font></p>     ^
cY#v24n1a09.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#104#100#article#140#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. 	Ishak KG, Anth
ony PP, Sobin LH. Histological typing of tumours in the liver. WHO International
 Histological.Classification of Tumours. 2nd ed. New York: Springer Verlag; 1994
.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#105#101#article#140# </font></p>     
^cY#v24n1a09.htm##
00593000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034100081002001300422#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#106#102#article#140#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Jonas S, Bechst
ein WO, Steinm&uuml;ller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P
. Vascular invasion and histopathologic grading determine outcome after liver tr
ansplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001 May;33
(5):1080-6.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#107#103#article#140# </font></p>     
^cY#v24n1a09.htm##
00423000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017100081002001300252#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#108#104#article#140#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Llovet J Hepato
cellular carcinoma.M, Burroughs A, Bruix J. Lancet. 2003 Dec 6;362(9399):1907-17
.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#109#105#article#140# </font></p>     
^cY#v24n1a09.htm##
00667000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704041500081002001300496#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#110#106#article#140#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Llovet JM, Brui
x J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, Franca A, Br&uacute; 
C, Navasa M, Ayuso MC, Sol&eacute; M, Real MI, Vilana R, Rimola A, Visa J, Rod&e
acute;s J. Liver transplantation for treatment of small hepatocellular carcinoma
: the TNM classification does not have prognostic power. Hepatology 1998; 27:6: 
1572.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#111#107#article#140# </font></p>     
^cY#v24n1a09.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026700081002001300348#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#112#108#article#140#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Lok AS, Lai CL.
 alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus
 infection: role in the early detection of hepatocellular carcinoma. Hepatology.
 1989 9(1):110-5.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#113#109#article#140# </font></p>     
^cY#v24n1a09.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027200081002001300353#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#114#110#article#140#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Margarit C, Cha
rco R, Hidalgo E, Allende H, Castells L, Bilbao I. Liver transplantation for mal
ignant diseases: selection and pattern of recurrence. World J Surg. 2002 Feb;26(
2):257-63 </font></p>     ^cY#v24n1a09.htm##
00824000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704057200081002001300653#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#115#111#article#140#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Mazzaferro V, L
lovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwa
rtz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L
, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boi
n I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liv
er transplantation in patients with hepatocellular carcinoma beyond the Milan cr
iteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-4
3.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#116#112#article#140# </font></p>     
^cY#v24n1a09.htm##
00588000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033600081002001300417#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#117#113#article#140#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Mazzaferro V, R
egalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, 
Morabito A, Gennari L. Liver transplantation for the treatment of small hepatoce
llular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):
693-9.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#118#114#article#140# </font></p>     
^cY#v24n1a09.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027500081002001300356#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#119#115#article#140#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Nomura F, Ohnis
hi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with
 reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 
1989 Oct 15;64(8):1700-7.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#120#116#article#140# </font></p>     
^cY#v24n1a09.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019100081002001300272#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#121#117#article#140#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. 	Parkin DM, Bra
y F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 
Mar-Apr;55(2):74-108.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#122#118#article#140# </font></p>     
^cY#v24n1a09.htm##
00619000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036700081002001300448#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#123#119#article#140#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Peng SY, Chen W
J, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alphafetoprotein level correlates with
 high stage, early recurrence and poor prognosis of hepatocellular carcinoma: si
gnificance of hepatitis virus infection, age, p53 and beta-catenin mutations. In
t J Cancer. 2004 Oct 20;112(1):44-50.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#124#120#article#140# </font></p>     
^cY#v24n1a09.htm##
00674000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042200081002001300503#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#125#121#article#140#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Ravaioli M, Gra
zi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, 
D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD. Live
r transplantation for hepatocellular carcinoma: results of down-staging in patie
nts initially outside the Milan selection criteria. Am J Transplant. 2008 Dec;8(
12):2547-57.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#126#122#article#140# </font></p>     
^cY#v24n1a09.htm##
00592000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034000081002001300421#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#127#123#article#140#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. 	Shetty K, Timm
ins K, Brensinger C, Furth EE, Rattan S, Sun W, Rosen M, Soulen M, Shaked A, Red
dy KR, Olthoff KM. Liver transplantation for hepatocellular carcinoma validation
 of present selection criteria in predicting outcome. Liver Transpl. 2004 Jul;10
(7):911-8.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#128#124#article#140# </font></p>     
^cY#v24n1a09.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031900081002001300400#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#129#125#article#140#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. 	Tamura S, Kato
 T, Berho M, Misiakos EP, O'Brien C, Reddy KR, Nery JR, Burke GW, Schiff ER, Mil
ler J, Tzakis AG. Impact of histological grade of hepatocellular carcinoma on th
e outcome of liver transplantation. Arch Surg. 2001 Jan;136(1):25-30.    ^cY#v24
n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#130#126#article#140# </font></p>     
^cY#v24n1a09.htm##
00635000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704038300081002001300464#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#131#127#article#140#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Trevisani F, D'
Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, 
De Notariis S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepa
tocellular carcinoma in patients with chronic liver disease:influence of HBsAg a
nd anti-HCV status. J Hepatol. 2001 Apr; 34(4):570-5.    ^cY#v24n1a09.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#132#128#article#140# </font></p>     
^cY#v24n1a09.htm##
00260000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002300078002001300101#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#133#129#article#140#<p>&nbsp;</p>    
  ^cY#v24n1a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#134#130#article#140#<p>&nbsp;</p>    
 ^cY#v24n1a09.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019800078002001300276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#135#131#article#140#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ec
irc;ncia:</b>    ^cY#v24n1a09.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004200078002001300120#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#136#132#article#140#<br> Elaine Crist
ina Ata&iacute;de    ^cY#v24n1a09.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#137#133#article#140#<br> e-mail: <a h
ref="mailto:elainebataide@yahoo.com.br">elainebataide@yahoo.com.br</a> </font></
p>      ^cY#v24n1a09.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012100078002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#138#134#article#140#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 20/01/2011    ^cY#v24n1a09.htm##
00300000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006300078002001300141#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#139#135#article#140#<br> Aceito para 
publica&ccedil;&atilde;o:  25/01/2011     ^cY#v24n1a09.htm##
00295000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005800078002001300136#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#140#136#article#140#<br> Fonte de fin
anciamento: n&atilde;o h&aacute;     ^cY#v24n1a09.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007000078002001300148#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#141#137#article#140#<br> Conflito de 
interesses: n&atilde;o h&aacute; </font></p>     ^cY#v24n1a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#142#138#article#140#<p>&nbsp;</p>    
 ^cY#v24n1a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#143#139#article#140#<p>&nbsp;</p>    
 ^cY#v24n1a09.htm##
00472000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704023500078002001300313#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#p#144#140#article#140#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado na Unidade de T
ransplante Hep&aacute;tico do Hospital de Cl&iacute;nicas da Universidade de Cam
pinas -Unicamp, Campinas, SP, Brasil. </font></p>     ^cY#v24n1a09.htm##
00647000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
02000111010002100131010001600152012007600168030001600244065000900260064000700269
031000200276014000700278865000900285002001300294035001000307801001600317#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#145#1#article#25#1#^rND^sAbel
ev^nGI#^rND^sPerova^nSD#^rND^sKhramkova^nNI#^rND^sPostnikova^nZA#^rND^sIrlin^nIS
#Production of embryonal alpha-globulin by transplantable mouse hepatoma^len#Tra
nsplantation#19630400#196304#1#174-80#20110300#v24n1a09.htm#0041-1337#Transplant
ation##
00529000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920120
05100109030000700160065000900167064000900176031000400185032000500189014000600194
865000900200002001300209035001000222801000700232#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a09.htm#S#c#146#2#article#25#2#^rND^sBruix^nJ#^rND^sLlovet^nJM#Ma
jor achievements in hepatocellular carcinoma^len#Lancet#20090221#20090221#373#96
64#614-6#20110300#v24n1a09.htm#0099-5355#Lancet##
00872000000000385000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920100
01700109010001900126010001800145010002000163010002100183010001800204010001700222
01000150023901201520025403000100040606500090041606400070042503100030043203200020
0435014000700437865000900444002001300453035001000466801001000476#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#147#3#article#25#3#^rND^sBruix^nJ#^rN
D^sSherman^nM#^rND^sLlovet^nJM#^rND^sBeaugrand^nM#^rND^sLencioni^nR#^rND^sBurrou
ghs^nAK#^rND^sChristensen^nE#^rND^sPagliaro^nL#^rND^sColombo^nM#^rND^sRodés^nJ#C
linical management of hepatocellular carcinoma: Conclusions of the Barcelona-200
0 EASL conference. European Association for the Study of the Liver^len#J Hepatol
#20010900#200109#35#3#421-30#20110300#v24n1a09.htm#0168-8278#J Hepatol##
00921000000000385000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
01600111010001800127010001900145010001800164010001700182010002000199010001900219
01000270023801000150026501000180028001000150029801000170031301201540033003000130
0484710000200497065000900499064000500508865000900513002001300522#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#148#4#article#25#4#^rND^sCescon^nM#^r
ND^sRavaioli^nM#^rND^sGrazi^nGL#^rND^sErcolani^nG#^rND^sCucchetti^nA#^rND^sBertu
zzo^nV#^rND^sVetrone^nG#^rND^sDel Gaudio^nM#^rND^sVivarelli^nM#^rND^sD'Errico-Gr
igioni^nA#^rND^sDazzi^nA#^rND^sDi Gioia^nP#^rND^sLauro^nA#^rND^sPinna^nAD.#Progn
ostic factors for tumor recurrence after a 12-year, single-center experience of 
liver transplantations in patients with hepatocellular carcinoma^len#J Transplan
t#2#20100000#2010#20110300#v24n1a09.htm##
00766000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100019000960100
01800115010001400133010002000147010001700167010001700184010001500201012010400216
03000120032006500090033206400070034103100030034803200020035101400070035386500090
0360002001300369035001000382801001200392#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a09.htm#S#c#149#5#article#25#5#^rND^sDe Carlis^nL#^rND^sGiacomoni^nA#^rND
^sLauterio^nA#^rND^sSlim^nA#^rND^sSammartino^nC#^rND^sPirotta^nV#^rND^sColella^n
G#^rND^sForti^nD#Liver transplantation for hepatocellular cancer: should the cur
rent indication criteria be changed?^len#Transpl Int#20030200#200302#16#2#115-22
#20110300#v24n1a09.htm#0934-0874#Transpl Int##
00697000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100018000920100
02000110010001900130012016900149030000400318065000900322064000500331031000300336
032000400339020000400343865000900347002001300356035001000369801000400379#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#150#6#article#25#6#^rND^sDeli
s^nS#^rND^sBiliatis^nI#^rND^sAthanasiou^nK#^rND^sDervenis^nC.#Model for end-stag
e liver disease (MELD) score as a prognostic factor for postoperative morbidity 
and mortality in cirrhotic patients undergoing hepatectomy for HCC^len#Gut#20060
000#2006#55#^sV#153#20110300#v24n1a09.htm#0017-5749#Gut##
00968000000000445000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770100019001000100
01600119010001900135010001900154010001800173010001700191010001800208010001800226
01000140024401000140025801000170027201000160028901000170030501100190032201201030
03410300010004440650009004540640005004630310003004680320002004710140007004738650
00900480002001300489035001000502801001000512#v24n1#V:\SciELO\serial\abcd\v24n1\m
arkup\v24n1a09.htm#S#c#151#7#article#25#7#^rND^sDi Bisceglie^nAM#^rND^sSterling^
nRK#^rND^sChung^nRT#^rND^sEverhart^nJE#^rND^sDienstag^nJL#^rND^sBonkovskyHL#^rND
^sWright^nEC#^rND^sEverson^nGT#^rND^sLindsay^nKL#^rND^sLok^nAS#^rND^sLee^nWM#^rN
D^sMorgan^nTR#^rND^sGhany^nMG#^rND^sGretch^nDR#HALT-C Trial Group#Serum alphafet
oprotein levels in patients with advanced hepatitis C: results from the HALT-C T
rial^len#J Hepatol#20050000#2005#43#3#434-41#20110300#v24n1a09.htm#0168-8278#J H
epatol##
00562000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100016000960120
07000112030001300182065000900195064000900204031000400213032000300217014000700220
865000900227002001300236035001000249801001300259#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a09.htm#S#c#152#8#article#25#8#^rND^sEl-Serag^nHB#^rND^sMason^nAC
#Rising incidence of hepatocellular carcinoma in the United States^len#N Engl J 
Med#19990311#19990311#340#10#745-50#20110300#v24n1a09.htm#0028-4793#N Engl J Med
##
00610000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100014000930100
01500107012009300122030001700215065000900232064000700241031000400248032000200252
014000500254865000900259002001300268035001000281801001700291#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a09.htm#S#c#153#9#article#25#9#^rND^sForner^nA#^rND^s
Reig^nM#^rND^sBruix^nJ#Alpha-fetoprotein for hepatocellular carcinoma diagnosis:
 the demise of a brilliant star^len#Gastroenterology#20090700#200907#137#1#26-9#
20110300#v24n1a09.htm#0016-5085#Gastroenterology##
00745000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01700113010001500130010001700145010002100162010001600183012014400199030001400343
71000020035706500090035906400070036803100020037503200020037701400060037986500090
0385002001300394#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#154#1
0#article#25#10#^rND^sHerrero^nJI#^rND^sSangro^nB#^rND^sQuiroga^nJ#^rND^sPardo^n
F#^rND^sHerraiz^nM#^rND^sCienfuegos^nJA#^rND^sPrieto^nJ#Influence of tumor chara
cteristics on the outcome of liver transplantation among patients with liver cir
rhosis and hepatocellular carcinoma^len#Liver Transpl#2#20010700#200107#7#7#631-
6#20110300#v24n1a09.htm##
00563000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160018000950160
01600113018010500129063000200234066000900236062001600245065000900261064000500270
865000900275002001300284#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S
#c#155#11#article#25#11#^rND^sIshak^nKG#^rND^sAnthony^nPP#^rND^sSobin^nLH#Histol
ogical typing of tumours in the liver.WHO International Histological.Classificat
ion of Tumours^len#2#New York#Springer Verlag#19940000#1994#20110300#v24n1a09.ht
m##
00801000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
02100114010001800135010001500153010001400168010002000182010001700202012013800219
03000110035706500090036806400070037703100030038403200020038701400070038986500090
0396002001300405035001000418801001100428#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a09.htm#S#c#156#12#article#25#12#^rND^sJonas^nS#^rND^sBechstein^nWO#^rND^
sSteinmüller^nT#^rND^sHerrmann^nM#^rND^sRadke^nC#^rND^sBerg^nT#^rND^sSettmacher^
nU#^rND^sNeuhaus^nP#Vascular invasion and histopathologic grading determine outc
ome after liver transplantation for hepatocellular carcinoma in cirrhosis^len#He
patology#20010500#200105#33#5#1080-6#20110300#v24n1a09.htm#0161-0538#HEPATOLOGY#
#
00485000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120029000950300
00700124065000900131064001100140031000400151032000500155014000800160865000900168
002001300177035001000190801000700200#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a09.htm#S#c#157#13#article#25#13#^rND^sLlovet^nJ#Hepatocellular carcinoma^len
#Lancet#20031206#2003 Dec 6#362#9399#1907-17#20110300#v24n1a09.htm#0099-5355#Lan
cet##
01006000000000457000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01600111010001800127010002800145010001600173010001600189010001300205010001600218
01000160023401000140025001000150026401000160027901000160029501000140031101000160
03250120129003410300011004700650009004810640005004900310003004950320002004980200
00500500865000900505002001300514035001000527801001100537#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a09.htm#S#c#158#14#article#25#14#^rND^sLlovet^nJM#^rND^sB
ruix^nJ#^rND^sFuster^nJ#^rND^sCastells^nA#^rND^sGarcia-Valdecasas^nJC#^rND^sGran
de^nL#^rND^sFranca^nA#^rND^sBrú^nC#^rND^sNavasa^nM#^rND^sAyuso^nMC#^rND^sSolé^nM
#^rND^sReal^nMI#^rND^sVilana^nR#^rND^sRimola^nA#^rND^sVisa^nJ#^rND^sRodés^nJ.#Li
ver transplantation for treatment of small hepatocellular carcinoma: the TNM cla
ssification does not have prognostic power^len#Hepatology#19980000#1998#27#6#157
2#20110300#v24n1a09.htm#0161-0538#HEPATOLOGY##
00627000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930120
15100108030001100259065000900270064000500279031000200284032000200286014000600288
865000900294002001300303035001000316801001100326#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a09.htm#S#c#159#15#article#25#15#^rND^sLok^nAS#^rND^sLai^nCL.#alp
ha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus inf
ection: role in the early detection of hepatocellular carcinoma^len#Hepatology#1
9890000#1989#9#1#110-5#20110300#v24n1a09.htm#0161-0538#HEPATOLOGY##
00691000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01700113010001700130010001800147010001600165012008600181030001300267065000900280
06400070028903100030029603200020029901400070030186500090030800200130031703500100
0330801001300340#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#160#1
6#article#25#16#^rND^sMargarit^nC#^rND^sCharco^nR#^rND^sHidalgo^nE#^rND^sAllende
^nH#^rND^sCastells^nL#^rND^sBilbao^nI#Liver transplantation for malignant diseas
es: selection and pattern of recurrence^len#World J Surg#20020200#200202#26#2#25
7-63#20110300#v24n1a09.htm#0364-2313#World J Surg##
01366000000000589000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01600116010001600132010001700148010001700165010001800182010001700200010001900217
01000160023601000140025201000170026601000190028301000150030201000160031701000190
03330100015003520100020003670100016003870100015004030100018004180100015004360100
01800451010001400469010001900483010001800502010001800520010001500538012015900553
03000130071271000020072506500090072706400070073603100030074303200020074601400060
0748865000900754002001300763#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.h
tm#S#c#161#17#article#25#17#^rND^sMazzaferro^nV#^rND^sLlovet^nJM#^rND^sMiceli^nR
#^rND^sBhoori^nS#^rND^sSchiavo^nM#^rND^sMariani^nL#^rND^sCamerini^nT#^rND^sRoaya
ie^nS#^rND^sSchwartz^nME#^rND^sGrazi^nGL#^rND^sAdam^nR#^rND^sNeuhaus^nP#^rND^sSa
lizzoni^nM#^rND^sBruix^nJ#^rND^sForner^nA#^rND^sDe Carlis^nL#^rND^sCillo^nU#^rND
^sBurroughs^nAK#^rND^sTroisi^nR#^rND^sRossi^nM#^rND^sGerunda^nGE#^rND^sLerut^nJ#
^rND^sBelghiti^nJ#^rND^sBoin^nI#^rND^sGugenheim^nJ#^rND^sRochling^nF#^rND^sVan H
oek^nB#^rND^sMajno^nP#Predicting survival after liver transplantation in patient
s with hepatocellular carcinoma beyond the Milan criteria: a retrospective, expl
oratory analysis^len#Lancet Oncol#2#20090100#200901#10#1#35-43#20110300#v24n1a09
.htm##
00838000000000385000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01400116010001800130010002000148010001800168010001800186010001800204010001800222
01000170024001201060025703000130036306500090037606400090038503100040039403200030
0398014000600401865000900407002001300416035001000429801001300439#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#162#18#article#25#18#^rND^sMazzaferro
^nV#^rND^sRegalia^nE#^rND^sDoci^nR#^rND^sAndreola^nS#^rND^sPulvirenti^nA#^rND^sB
ozzetti^nF#^rND^sMontalto^nF#^rND^sAmmatuna^nM#^rND^sMorabito^nA#^rND^sGennari^n
L#Liver transplantation for the treatment of small hepatocellular carcinomas in 
patients with cirrhosis^len#N Engl J Med#19960314#19960314#334#11#693-9#20110300
#v24n1a09.htm#0028-4793#N Engl J Med##
00645000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01600112012013900128030000700267065000900274064000900283031000300292032000200295
014000700297865000900304002001300313035001000326801000700336#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a09.htm#S#c#163#19#article#25#19#^rND^sNomura^nF#^rND
^sOhnishi^nK#^rND^sTanabe^nY#Clinical features and prognosis of hepatocellular c
arcinoma with reference to serum alpha-fetoprotein levels: Analysis of 606 patie
nts^len#Cancer#19891015#19891015#64#8#1700-7#20110300#v24n1a09.htm#0008-543X#Can
cer##
00592000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100014000960100
01600110010001700126012003500143030001700178065000900195064001300204031000300217
032000200220014000700222865000900229002001300238035001000251801001700261#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#164#20#article#25#20#^rND^sPa
rkin^nDM#^rND^sBray^nF#^rND^sFerlay^nJ#^rND^sPisani^nP.#Global cancer statistics
, 2002^len#CA Cancer J Clin#20050400#2005 Mar-Apr#55#2#74-108#20110300#v24n1a09.
htm#0007-9235#CA Cancer J Clin##
00797000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01400109010001500123010001500138010001400153012020400167030001300371065000900384
06400090039303100040040203200020040601400060040886500090041400200130042303500100
0436801001300446#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#165#2
1#article#25#21#^rND^sPeng^nSY#^rND^sChen^nWJ#^rND^sLai^nPL#^rND^sJeng^nYM#^rND^
sSheu^nJC#^rND^sHsu^nHC#High alphafetoprotein level correlates with high stage, 
early recurrence and poor prognosis of hepatocellular carcinoma: significance of
 hepatitis virus infection, age, p53 and beta-catenin mutations^len#Int J Cancer
#20041020#20041020#112#1#44-50#20110300#v24n1a09.htm#0020-7136#Int J Cancer##
00964000000000421000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01900113010001900132010001600151010001800167010001900185010001800204010002700222
01000170024901000170026601000180028301000170030101000160031801201390033403000160
04737100002004890650009004910640007005000310002005070320003005090140008005128650
00900520002001300529#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#1
66#22#article#25#22#^rND^sRavaioli^nM#^rND^sGrazi^nGL#^rND^sPiscaglia^nF#^rND^sT
revisani^nF#^rND^sCescon^nM#^rND^sErcolani^nG#^rND^sVivarelli^nM#^rND^sGolfieri^
nR#^rND^sD'Errico Grigioni^nA#^rND^sPanzini^nI#^rND^sMorelli^nC#^rND^sBernardi^n
M#^rND^sBolondi^nL#^rND^sPinna^nAD#Liver transplantation for hepatocellular carc
inoma: results of down-staging in patients initially outside the Milan selection
 criteria^len#Am J Transplant#2#20081200#200812#8#12#2547-57#20110300#v24n1a09.h
tm##
00827000000000385000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
02000112010001600132010001600148010001300164010001500177010001600192010001600208
01000160022401000180024001201180025803000140037671000020039006500090039206400070
0401031000300408032000200411014000600413865000900419002001300428#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#167#23#article#25#23#^rND^sShetty^nK#
^rND^sTimmins^nK#^rND^sBrensinger^nC#^rND^sFurth^nEE#^rND^sRattan^nS#^rND^sSun^n
W#^rND^sRosen^nM#^rND^sSoulen^nM#^rND^sShaked^nA#^rND^sReddy^nKR#^rND^sOlthoff^n
KM#Liver transplantation for hepatocellular carcinoma validation of present sele
ction criteria in predicting outcome^len#Liver Transpl#2#20040700#200407#10#7#91
1-8#20110300#v24n1a09.htm##
00836000000000397000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01500109010001900124010001700143010001600160010001500176010001600191010001700207
01000160022401000170024001201010025703000100035806500090036806400070037703100040
0384032000200388014000600390865000900396002001300405035001000418801001000428#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#168#24#article#25#24#^rND
^sTamura^nS#^rND^sKato^nT#^rND^sBerho^nM#^rND^sMisiakos^nEP#^rND^sO'Brien^nC#^rN
D^sReddy^nKR#^rND^sNery^nJR#^rND^sBurke^nGW#^rND^sSchiff^nER#^rND^sMiller^nJ#^rN
D^sTzakis^nAG#Impact of histological grade of hepatocellular carcinoma on the ou
tcome of liver transplantation^len#Arch Surg#20010100#200101#136#1#25-30#2011030
0#v24n1a09.htm#0004-0010#Arch Surg##
00882000000000385000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
02600116010001800142010001700160010001800177010002000195010002100215010001400236
01000180025001201490026803000100041706500090042706400070043603100030044303200020
0446014000600448865000900454002001300463035001000476801001000486#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a09.htm#S#c#169#25#article#25#25#^rND^sTrevisani^
nF#^rND^sD'Intino PE#^rND^sMorselli-Labate^nAM#^rND^sMazzella^nG#^rND^sAccogli^n
E#^rND^sCaraceni^nP#^rND^sDomenicali^nM#^rND^sDe Notariis^nS#^rND^sRoda^nE#^rND^
sBernardi^nM#Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma i
n patients with chronic liver disease: influence of HBsAg and anti-HCV status^le
n#J Hepatol#20010400#200104#34#4#570-5#20110300#v24n1a09.htm#0168-8278#J Hepatol
##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#o#1#1#article#1
#20110411#103902#v24n1a10.htm#117##
04966000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002700108
03100030013503200020013806500090014001400090014903500100015801201130016801201110
02810100022003920100033004140100027004470100033004740100043005070100032005500831
78500582085001002367085003402377085002702411085003502438083171102473085001004184
08500340419408500380422808500340426611700080430007200030430811200090431111100110
4320114000904331113001104340002001304351#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a10.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#10#ABCD060#nd#ABCD, arq. 
bras. cir. dig.#24#1#20110300#^f48^l51#0102-6720#Resultados iniciais da oxigenot
erapia hiperbárica empacientes em lista de espera para o transplante hepático^lp
t#Preliminary results of hyperbaric oxygen therapy on patients on the waiting li
st for liver transplantation^len#^rND^nFlávio^sKreimer#^rND^nGuido Corrêa de^sAr
aúJo-Jr#^rND^nJosemberg M.^sCampos#^rND^nEuclides D.^sMartins-Filho#^rND^nLuiz A
ugusto Carneiro^sD'Albuquerque#^rND^nÁlvaro Antônio B.^sFerraz#^lpt^aRACIONAL: A
 função hepática é um processo complexo que envolve múltiplos eventos celulares.
 Ela, em pacientes cirróticos, pode se beneficiar da terapia com oxigênio hiperb
árico. OBJETIVO: Avaliar, de forma preliminar, os dados clínicos e laboratoriais
 sobre a função hepática em pacientes cirróticos em lista de espera para transpl
ante hepático, submetidos à oxigenoterapia hiperbárica. MÉTODO: Estudo prospecti
vo com intervenção, no qual 10 pacientes foram escolhidos aleatoriamente entre o
s pacientes cirróticos em lista de espera para transplante hepático. A idade var
iou de 20 a 65 anos, e todos apresentaram escore MELD maior que 15. Todos os pac
ientes foram submetidos a nove sessões de terapia com oxigênio hiperbárico, em d
ias alternados com a duração de 60 minutos por sessão, com atmosfera de oxigênio
 de 100% e pressão de 2,8 ATM. As variáveis dependentes foram os valores laborat
oriais bioquímicos e hematológicos, avaliados antes e após sessões de terapia hi
perbárica de oxigênio, além de parâmetros clínicos, considerando-se também o Chi
ld-Turcotte-Pugh e o MELD. A análise estatística foi realizada com o SPSS (Stati
stcal Package for Social Sciences), e incluiu média com desvio-padrão. RESULTADO
S: Trêspacientes (30%) relataram diminuição no número e intensidade da encefalop
atia. Não houve casos de peritonite bacteriana espontânea e sangramento gastroin
testinal, e não houve aumento na gravidade da ascite. Dois pacientes relataram m
elhora no prurido, e quatro melhora no estado geral em poucas semanas após sessõ
es de oxigenoterapia hiperbárica. CONCLUSÃO: A oxigenoterapia hiperbárica pode m
elhorar a função hepática na cirrose e ajudar a controlar as complicações relaci
onadas à insuficiência hepática na avaliação pré-operatória para transplante de 
fígado.#^ddecs^i1#^tm^lpt^kTransplante de fígado^i1#^tm^lpt^kOxigenoterapia^i1#^
tm^lpt^kInsuficiência hepática^i1#^len^aBACKGROUND: Hepatic function is a comple
x process which involves multiple celular events. Liver function in cirrhotic pa
tients may be benefited with hyperbaric oxygen therapy. AIM: To evaluate clinica
l and laboratorial data regarding liver function in cirrhotic patients selected 
for liver transplantation, submitted to hyperbaric oxygen therapy. METHOD: A pro
spective interventional study was designed, wherein 10 patients were randomized 
amongst cirrhotic patients selected for liver transplantation. The ages ranged f
rom 20 to 65 years, and all patients presented with a MELD score greater than 15
. All patients were submitted to nine sessions of hyperbaric oxygen therapy, on 
alternated days with the duration of 60 minutes per session, with oxygen atmosph
ere of 100% and a 2,8 ATM pressure. Dependent parameters included were biochemic
al and hematologic laboratory values, evaluated before and after hyperbaric oxyg
en therapy sessions, besides clinical parameters, evaluated considering the Chil
d-Turcotte-Pugh and the MELD scores. Statistical analysis was performed with SPS
S (Statistcal Package for Social Sciences). RESULTS: Three patients (30%) report
ed decrease in the number and intensity of encephalopathy. There were no cases o
f spontaneous bacterial peritonitis and gastrointestinal bleeding, and there wer
e no increases on the severity of ascitis. Two patients reported improvement on 
pruritus, and four improvement on the general status for few weeks following hyp
erbaric oxygen sessions. CONCLUSION: Hyperbaric oxygen therapy may improve liver
 function in cirrhosis, and may help to control complications related to liver f
ailure on the preoperative evaluation for liver transplantation.#^ddecs^i2#^tm^l
en^kLiver transplantation^i2#^tm^len^kOxygen inhalation therapy^i2#^tm^len^kHepa
tic insufficiency^i2#vancouv#19#20101207#07/12/2010#20101221#21/12/2010#v24n1a10
.htm##
05050000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002700108
03100030013503200020013806500090014001400090014903500100015801201200016801201180
02880100022004060100033004280100027004610100033004880100043005210100032005640831
82000596085001002416085003402426085002702460085003502487083174602522085001004268
08500340427808500380431208500340435011700080438407200030439211200090439511100110
4404114000904415113001104424002001304435#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a10.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#10#ABCD060#nd#ABCD, arq. 
bras. cir. dig.#24#1#20110300#^f48^l51#0102-6720#<b>Resultados iniciais da oxige
noterapia hiperbárica empacientes em lista de espera para o transplante hepático
</b>^lpt#<b>Preliminary results of hyperbaric oxygen therapy on patients on the 
waiting list for liver transplantation</b>^len#^rND^nFlávio^sKreimer#^rND^nGuido
 Corrêa de^sAraúJo-Jr#^rND^nJosemberg M.^sCampos#^rND^nEuclides D.^sMartins-Filh
o#^rND^nLuiz Augusto Carneiro^sD'Albuquerque#^rND^nÁlvaro Antônio B.^sFerraz#^lp
t^a<b>RACIONAL:</b> A função hepática é um processo complexo que envolve múltipl
os eventos celulares. Ela, em pacientes cirróticos, pode se beneficiar da terapi
a com oxigênio hiperbárico. <b>OBJETIVO:</b> Avaliar, de forma preliminar, os da
dos clínicos e laboratoriais sobre a função hepática em pacientes cirróticos em 
lista de espera para transplante hepático, submetidos à oxigenoterapia hiperbári
ca. <b>MÉTODO:</b> Estudo prospectivo com intervenção, no qual 10 pacientes fora
m escolhidos aleatoriamente entre os pacientes cirróticos em lista de espera par
a transplante hepático. A idade variou de 20 a 65 anos, e todos apresentaram esc
ore MELD maior que 15. Todos os pacientes foram submetidos a nove sessões de ter
apia com oxigênio hiperbárico, em dias alternados com a duração de 60 minutos po
r sessão, com atmosfera de oxigênio de 100% e pressão de 2,8 ATM. As variáveis d
ependentes foram os valores laboratoriais bioquímicos e hematológicos, avaliados
 antes e após sessões de terapia hiperbárica de oxigênio, além de parâmetros clí
nicos, considerando-se também o Child-Turcotte-Pugh e o MELD. A análise estatíst
ica foi realizada com o SPSS (Statistcal Package for Social Sciences), e incluiu
 média com desvio-padrão. <b>RESULTADOS:</b> Trêspacientes (30%) relataram dimin
uição no número e intensidade da encefalopatia. Não houve casos de peritonite ba
cteriana espontânea e sangramento gastrointestinal, e não houve aumento na gravi
dade da ascite. Dois pacientes relataram melhora no prurido, e quatro melhora no
 estado geral em poucas semanas após sessões de oxigenoterapia hiperbárica. <b>C
ONCLUSÃO:</b> A oxigenoterapia hiperbárica pode melhorar a função hepática na ci
rrose e ajudar a controlar as complicações relacionadas à insuficiência hepática
 na avaliação pré-operatória para transplante de fígado.#^ddecs^i1#^tm^lpt^kTran
splante de fígado^i1#^tm^lpt^kOxigenoterapia^i1#^tm^lpt^kInsuficiência hepática^
i1#^len^a<b>BACKGROUND: </b>Hepatic function is a complex process which involves
 multiple celular events. Liver function in cirrhotic patients may be benefited 
with hyperbaric oxygen therapy. <b>AIM: </b>To evaluate clinical and laboratoria
l data regarding liver function in cirrhotic patients selected for liver transpl
antation, submitted to hyperbaric oxygen therapy. <b>METHOD:</b> A prospective i
nterventional study was designed, wherein 10 patients were randomized amongst ci
rrhotic patients selected for liver transplantation. The ages ranged from 20 to 
65 years, and all patients presented with a MELD score greater than 15. All pati
ents were submitted to nine sessions of hyperbaric oxygen therapy, on alternated
 days with the duration of 60 minutes per session, with oxygen atmosphere of 100
% and a 2,8 ATM pressure. Dependent parameters included were biochemical and hem
atologic laboratory values, evaluated before and after hyperbaric oxygen therapy
 sessions, besides clinical parameters, evaluated considering the Child-Turcotte
-Pugh and the MELD scores. Statistical analysis was performed with SPSS (Statist
cal Package for Social Sciences). <b>RESULTS:</b> Three patients (30%) reported 
decrease in the number and intensity of encephalopathy. There were no cases of s
pontaneous bacterial peritonitis and gastrointestinal bleeding, and there were n
o increases on the severity of ascitis. Two patients reported improvement on pru
ritus, and four improvement on the general status for few weeks following hyperb
aric oxygen sessions. <b>CONCLUSION:</b> Hyperbaric oxygen therapy may improve l
iver function in cirrhosis, and may help to control complications related to liv
er failure on the preoperative evaluation for liver transplantation.#^ddecs^i2#^
tm^len^kLiver transplantation^i2#^tm^len^kOxygen inhalation therapy^i2#^tm^len^k
Hepatic insufficiency^i2#vancouv#19#20101207#07/12/2010#20101221#21/12/2010#v24n
1a10.htm##
05129000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000260012603100030015203200020015506500090015701400090016603500100017501201130
01850120111002980100022004090100037004310100026004680100032004940100043005260100
03100569083180300600085001002403085003402413085002702447085003502474083172502509
08500100423408500340424408500380427808500340431611700080435007200030435811200090
4361111001104370114000904381113001104390002001304401008008904414#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt
#br1.1#1#4.0#tab#10#ABCD060#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f48^l51#
0102-6720#Resultados iniciais da oxigenoterapia hiperbárica empacientes em lista
 de espera para o transplante hepático^lpt#Preliminary results of hyperbaric oxy
gen therapy on patients on the waiting list for liver transplantation^len#^rND^n
Flávio^sKreimer#^rND^nGuido Corrêa de^sAraúJo-Júnior#^rND^nJosemberg M^sCampos#^
rND^nEuclides D^sMartins-Filho#^rND^nLuiz Augusto Carneiro^sD'Albuquerque#^rND^n
Álvaro Antônio B^sFerraz#^lpt^aRACIONAL: A função hepática é um processo complex
o que envolve múltiplos eventos celulares. Ela, em pacientes cirróticos, pode se
 beneficiar da terapia com oxigênio hiperbárico. OBJETIVO: Avaliar, de forma pre
liminar, os dados clínicos e laboratoriais sobre a função hepática em pacientes 
cirróticos em lista de espera para transplante hepático, submetidos à oxigenoter
apia hiperbárica. MÉTODO: Estudo prospectivo com intervenção, no qual 10 pacient
es foram escolhidos aleatoriamente entre os pacientes cirróticos em lista de esp
era para transplante hepático. A idade variou de 20 a 65 anos, e todos apresenta
ram escore MELD maior que 15. Todos os pacientes foram submetidos a nove sessões
 de terapia com oxigênio hiperbárico, em dias alternados com a duração de 60 min
utos por sessão, com atmosfera de oxigênio de 100 por cento e pressão de 2,8 ATM
. As variáveis dependentes foram os valores laboratoriais bioquímicos e hematoló
gicos, avaliados antes e após sessões de terapia hiperbárica de oxigênio, além d
e parâmetros clínicos, considerando-se também o Child-Turcotte-Pugh e o MELD. A 
análise estatística foi realizada com o SPSS (Statistcal Package for Social Scie
nces), e incluiu média com desvio-padrão. RESULTADOS: Trêspacientes (30 por cent
o) relataram diminuição no número e intensidade da encefalopatia. Não houve caso
s de peritonite bacteriana espontânea e sangramento gastrointestinal, e não houv
e aumento na gravidade da ascite. Dois pacientes relataram melhora no prurido, e
 quatro melhora no estado geral em poucas semanas após sessões de oxigenoterapia
 hiperbárica. CONCLUSÃO: A oxigenoterapia hiperbárica pode melhorar a função hep
ática na cirrose e ajudar a controlar as complicações relacionadas à insuficiênc
ia hepática na avaliação pré-operatória para transplante de fígado.#^ddecs^i1#^t
m^lpt^kTransplante de fígado^i1#^tm^lpt^kOxigenoterapia^i1#^tm^lpt^kInsuficiênci
a hepática^i1#^len^aBACKGROUND: Hepatic function is a complex process which invo
lves multiple celular events. Liver function in cirrhotic patients may be benefi
ted with hyperbaric oxygen therapy. AIM: To evaluate clinical and laboratorial d
ata regarding liver function in cirrhotic patients selected for liver transplant
ation, submitted to hyperbaric oxygen therapy. METHOD: A prospective interventio
nal study was designed, wherein 10 patients were randomized amongst cirrhotic pa
tients selected for liver transplantation. The ages ranged from 20 to 65 years, 
and all patients presented with a MELD score greater than 15. All patients were 
submitted to nine sessions of hyperbaric oxygen therapy, on alternated days with
 the duration of 60 minutes per session, with oxygen atmosphere of 100 percent a
nd a 2,8 ATM pressure. Dependent parameters included were biochemical and hemato
logic laboratory values, evaluated before and after hyperbaric oxygen therapy se
ssions, besides clinical parameters, evaluated considering the Child-Turcotte-Pu
gh and the MELD scores. Statistical analysis was performed with SPSS (Statistcal
 Package for Social Sciences). RESULTS: Three patients (30 percent) reported dec
rease in the number and intensity of encephalopathy. There were no cases of spon
taneous bacterial peritonitis and gastrointestinal bleeding, and there were no i
ncreases on the severity of ascitis. Two patients reported improvement on prurit
us, and four improvement on the general status for few weeks following hyperbari
c oxygen sessions. CONCLUSION: Hyperbaric oxygen therapy may improve liver funct
ion in cirrhosis, and may help to control complications related to liver failure
 on the preoperative evaluation for liver transplantation.#^ddecs^i2#^tm^len^kLi
ver transplantation^i2#^tm^len^kOxygen inhalation therapy^i2#^tm^len^kHepatic in
sufficiency^i2#vancouv#19#20101207#07/12/2010#20101221#21/12/2010#v24n1a10.htm#I
nternet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-6720201100
0100010##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704012100073002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#5#1#article#94#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"> <b> ARTIGO ORIGINAL</b><
/font></p>     ^cY#v24n1a10.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#6#2#article#94#<p>&nbsp;</p>     ^cY#
v24n1a10.htm##
00465000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704023300073002001300306#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#7#3#article#94#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Resultados inici
ais da oxigenoterapia hiperb&aacute;rica empacientes em lista de espera para o t
ransplante hep&aacute;tico</b> </font></p>     ^cY#v24n1a10.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#8#4#article#94#<p>&nbsp;</p>     ^cY#
v24n1a10.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#9#5#article#94#<p>&nbsp;</p>     ^cY#
v24n1a10.htm##
00510000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704027700074002001300351#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#10#6#article#94#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Fl&aacute;vio Kreimer; Guido Corr&e
circ;a de Ara&uacute;Jo-Jr; Josemberg M.Campos; Euclides D. Martins-Filho;  Luiz
 Augusto Carneiro D'Albuquerque; &Aacute;lvaro Ant&ocirc;nio B. Ferraz </b></fon
t></p>      ^cY#v24n1a10.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704012500074002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#11#7#article#94#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;ncia
</a></font></p>     ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#12#8#article#94#<p>&nbsp;</p>     ^cY
#v24n1a10.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704004400074002001300118#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#13#9#article#94#<p>&nbsp;</p> <hr siz
e="1" noshade>     ^cY#v24n1a10.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009700075002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#14#10#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO </b></font></p>     ^cY#v24
n1a10.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704031100075002001300386#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#15#11#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL:</b> A fun&ccedil;&atilde
;o hep&aacute;tica &eacute; um processo complexo que envolve m&uacute;ltiplos ev
entos celulares. Ela, em pacientes cirr&oacute;ticos, pode se beneficiar da tera
pia com oxig&ecirc;nio hiperb&aacute;rico.     ^cY#v24n1a10.htm##
00521000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704028700075002001300362#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#16#12#article#94#<br>   <b>OBJETIVO:<
/b> Avaliar, de forma preliminar, os dados cl&iacute;nicos e laboratoriais sobre
 a fun&ccedil;&atilde;o hep&aacute;tica em pacientes cirr&oacute;ticos em lista 
de espera para transplante hep&aacute;tico, submetidos &agrave; oxigenoterapia h
iperb&aacute;rica.     ^cY#v24n1a10.htm##
01262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704102800075002001301103#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#17#13#article#94#<br>   <b>M&Eacute;T
ODO:</b> Estudo prospectivo com interven&ccedil;&atilde;o, no qual 10 pacientes 
foram escolhidos aleatoriamente entre os pacientes cirr&oacute;ticos em lista de
 espera para transplante hep&aacute;tico. A idade variou de 20 a 65 anos, e todo
s apresentaram escore MELD maior que 15. Todos os pacientes foram submetidos a n
ove sess&otilde;es de terapia com oxig&ecirc;nio hiperb&aacute;rico, em dias alt
ernados com a dura&ccedil;&atilde;o de 60 minutos por sess&atilde;o, com atmosfe
ra de oxig&ecirc;nio de 100% e press&atilde;o de 2,8 ATM. As vari&aacute;veis de
pendentes foram os valores laboratoriais bioqu&iacute;micos e hematol&oacute;gic
os, avaliados antes e ap&oacute;s sess&otilde;es de terapia hiperb&aacute;rica d
e oxig&ecirc;nio, al&eacute;m de par&acirc;metros cl&iacute;nicos, considerando-
se tamb&eacute;m o Child-Turcotte-Pugh e o MELD. A an&aacute;lise estat&iacute;s
tica foi realizada com o SPSS (Statistcal Package for Social Sciences), e inclui
u m&eacute;dia com desvio-padr&atilde;o.    ^cY#v24n1a10.htm##
00687000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704045300075002001300528#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#18#14#article#94#<br>    <b>RESULTADO
S:</b> Tr&ecirc;spacientes (30%) relataram diminui&ccedil;&atilde;o no n&uacute;
mero e intensidade da encefalopatia. N&atilde;o houve casos de peritonite bacter
iana espont&acirc;nea e sangramento gastrointestinal, e n&atilde;o houve aumento
 na gravidade da ascite. Dois pacientes relataram melhora no prurido, e quatro m
elhora no estado geral em poucas semanas ap&oacute;s sess&otilde;es de oxigenote
rapia hiperb&aacute;rica.    ^cY#v24n1a10.htm##
00587000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704035300075002001300428#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#19#15#article#94#<br>    <b>CONCLUS&A
tilde;O:</b> A oxigenoterapia hiperb&aacute;rica pode melhorar a fun&ccedil;&ati
lde;o hep&aacute;tica na cirrose e ajudar a controlar as complica&ccedil;&otilde
;es relacionadas &agrave; insufici&ecirc;ncia hep&aacute;tica na avalia&ccedil;&
atilde;o pr&eacute;-operat&oacute;ria para transplante de f&iacute;gado. </font>
</p>     ^cY#v24n1a10.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704020800075002001300283#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#20#16#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b>  Transplante de f
&iacute;gado. Oxigenoterapia. Insufici&ecirc;ncia hep&aacute;tica.</font></p> <h
r size="1" noshade>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#21#17#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#22#18#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011500075002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#23#19#article#94#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b> </fon
t></p>     ^cY#v24n1a10.htm##
00703000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704046900075002001300544#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#24#20#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A doen&ccedil;a hep&aacute;tica apres
entamorbimortalidade significativa, e quando em fase avan&ccedil;ada tem no tran
splante do f&iacute;gado uma forma de tratamento potencialmente curativo, n&atil
de;o podendo, ainda, ser oferecido a todos os pacientes. Isso faz com que essa d
oen&ccedil;a seja considerada um problema de sa&uacute;de p&uacute;blica em todo
 o mundo<sup>1,2,12,16</sup></font>.</p>     ^cY#v24n1a10.htm##
03384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704315000075002001303225#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#25#21#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na It&aacute;lia, as doen&ccedil;as h
ep&aacute;ticas em est&aacute;gio avan&ccedil;ado promoveram 22.000 mortes em 20
00, ano em que foram realizados 1.016 transplantes. Em 2004,1.416 pacientes agua
rdavam transplante de f&iacute;gado, n&uacute;mero significantemente menor que o
s 4.000 casos novos diagnosticados no mesmo per&iacute;odo<sup>1</sup>. Nos Esta
dos Unidos em 2000, a incid&ecirc;ncia de doen&ccedil;as hep&aacute;ticas em est
&aacute;gio avan&ccedil;ado igualou-se a 5,9:100.000 habitantes, enquanto a taxa
 de mortalidade foi 4,5:100.000 habitantes<sup>17</sup>. Dados do Sistema Nacion
al de Transplantes em 2003, apresentaram 4.287 pacientes na lista de espera para
 transplante de f&iacute;gado, com apenas 637 transplantes realizados, ou seja, 
14,8% dademanda. At&eacute; outubro de 2005, essa lista de espera inclu&iacute;a
 6.834 pacientes e haviam sido realizados 454 transplantes, atendendo &agrave; 6
,6% da necessidade<sup>13</sup>. Esses dados explicam a afirma&ccedil;&atilde;o 
de que o transplante de f&iacute;gado n&atilde;o pode ser oferecido a todos os p
acientes, ainda que preencham os requisitos b&aacute;sicos para serem inscritos 
na lista de espera. Indicam tamb&eacute;m a necessidade de se pesquisarem novas 
op&ccedil;&otilde;es de tratamento. O f&iacute;gado &eacute; o &uacute;nico &oac
ute;rg&atilde;o de mam&iacute;feros capaz de se regenerar, ou seja, de promover 
hipertrofia e hiperplasia do tecido sadio remanescente. Essa caracter&iacute;sti
ca fez com que se desenvolvessem estudos sobre o controle desse crescimento celu
lar, como forma de tratamento da fal&ecirc;ncia hep&aacute;tica<sup>4,11</sup>. 
Dentre as op&ccedil;&otilde;es terap&ecirc;uticas n&atilde;o invasivas, a oxigen
oterapia hiperb&aacute;rica(OXTH) tem sido uma das mais promissoras, e a partir 
dos anos 1990 bastante investigada<sup>6,8,14,15,18,19</sup>. A oxigenoterapia h
iperb&aacute;rica consiste na inala&ccedil;&atilde;o de oxig&ecirc;nio a 100%, s
ob press&atilde;o de duas a tr&ecirc;s atmosferas, em c&acirc;maras especiais, p
or isso denominadas c&acirc;maras hiperb&aacute;ricas<sup>18</sup>. A oxigenoter
apia hiperb&aacute;rica tem sido empregada com sucesso no tratamento de diversas
 doen&ccedil;as, agudas e cr&ocirc;nicas, e em algumas s&iacute;ndromes, tendo s
ido regulamentada no Brasil pelo Conselho Federal de Medicina, em 1995<sup>3</su
p>. Todavia, na &aacute;rea de hepatologia, poucos s&atilde;o os estudos encontr
ados na literatura envolvendo doentes em est&aacute;gio avan&ccedil;ado, em list
a de espera para transplante hep&aacute;tico. No Brasil, estima-se que o tempo e
ntre inclus&atilde;o em lista de espera e transplante seja aproximadamente de 20
 meses, intervalo que tem inviabilizado o transplante para v&aacute;rios pacient
es<sup>9</sup>. Uma tentativa de tornar o processo de transplante mais justo foi
 realizada em 2005 pelo Minist&eacute;rio da Sa&uacute;de ao determinar que o cr
it&eacute;rio de prioridade para esse procedimento deve ser a gravidade do caso 
cl&iacute;nico, e n&atilde;o o tempo de espera em lista<sup>13</sup>. </font></p
>     ^cY#v24n1a10.htm##
00580000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704034600075002001300421#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#26#22#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo do estudo foi avaliar, de 
forma preliminar, os efeitos hematol&oacute;gicos, bioqu&iacute;micos e cl&iacut
e;nicos antes e ap&oacute;s sess&otilde;es de oxigenoterapia hiperb&aacute;rica 
de pacientes em lista de espera para transplante hep&aacute;tico. </font></p>   
  ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#27#23#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010400075002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#28#24#article#94#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font></p>     
^cY#v24n1a10.htm##
00704000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704047000075002001300545#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#29#25#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foi realizado estudo prospectivo, de 
interven&ccedil;&atilde;o, no Departamento de Cirurgia Geral e Transplante Hep&a
acute;tico do Hospital das Cl&iacute;nicas da Universidade Federal de Pernambuco
 (HC-UFPE), o qual se constitui em um servi&ccedil;o de refer&ecirc;ncia para tr
atamento e acompanhamento de pacientes com doen&ccedil;as hep&aacute;ticas em es
t&aacute;gio avan&ccedil;ado. </font></p>     ^cY#v24n1a10.htm##
02665000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704243100075002001302506#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#30#26#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram inclu&iacute;dos 10 pacientes c
om as seguintes caracter&iacute;sticas: encaminhados ao Ambulat&oacute;rio de Ci
rurgia Geral e Transplante Hep&aacute;tico do HC-UFPE; faixa et&aacute;ria entre
 20 e 65 anos, independente de g&ecirc;nero; inscrito como receptor de f&iacute;
gado na lista de espera para transplante; portador de doen&ccedil;a hep&aacute;t
ica por cirrose; MELD igual ou maior que 15; resultado de dosagem de alfa-fetopr
ote&iacute;na n&atilde;o compat&iacute;vel com tumor hep&aacute;tico; resultado 
de ultrassonografia hep&aacute;tica n&atilde;o compat&iacute;vel com tumor hep&a
acute;tico; e por fim, aus&ecirc;ncia de qualquer das enfermidades que contraind
icam a oxigenoterapia hiperb&aacute;rica. Ela foi realizada em c&acirc;mara hipe
rb&aacute;rica da marca Multiplace Marno&reg;, em dias alternados, totalizando n
ove sess&otilde;es, com dura&ccedil;&atilde;o de 60 minutos, em atmosfera de oxi
g&ecirc;nio a 100%, sob press&atilde;o de 2,8 atmosferas absolutas. As vari&aacu
te;veis de an&aacute;lise foram: avalia&ccedil;&otilde;es bioqu&iacute;micas, he
matol&oacute;gicas e cl&iacute;nicas realizadas antes e ap&oacute;s nove sess&ot
ilde;es de OXTH, compreendendo: hematimetria, hemoglobinometria, hemat&oacute;cr
ito, leucometria absoluta e relativa, trombocitometria, dosagens de alanina-amin
otransferase, aspartato-aminotransferase, gama-glutamiltransferase, fosfatase al
calina, bilirrubina total e fra&ccedil;&otilde;es, creatinina, ur&eacute;ia, pro
te&iacute;nas totais, albumina, globulina e raz&atilde;o normalizada internacion
al de coagula&ccedil;&atilde;o (INR). Foram observadas: ocorr&ecirc;ncia de asci
te, peritonite bacteriana espont&acirc;nea, prurido, encefalopatia e hemorragia 
digestiva, al&eacute;m do c&aacute;lculo do Child-Turcotte-Pugh<sup>5</sup> e ME
LD<sup>9</sup>. Os achados pr&eacute;vios &agrave; interven&ccedil;&atilde;o for
am chamados de basais, enquanto os posteriores, finais. Os dados estat&iacute;st
icos foram analisados com o programa Statistcal Package for Social Sciences, apr
esentados sob a forma de tabelas de distribui&ccedil;&atilde;o de frequ&ecirc;nc
ia, com c&aacute;lculo da m&eacute;dia e desvio-padr&atilde;o. O estudo foi apro
vado pelo Comit&ecirc; de &Eacute;tica em Pesquisa em Seres Humanos do Centro de
 Ci&ecirc;ncias da Sa&uacute;de da Universidade Federal de Pernambuco. </font></
p>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#31#27#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010100075002001300176#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#32#28#article#94#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b> </font></p>     ^cY
#v24n1a10.htm##
01121000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704088700075002001300962#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#33#29#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Dos 10 pacientes analisados, seis (60
%) eram do g&ecirc;nero masculino e quatro do feminino, com m&eacute;dia de idad
e igual a 59,00 ± 1,84 anos, variando de 52 e 66 anos. Os &iacute;ndices progn&o
acute;sticos e par&acirc;metros laboratoriais dos pacientes est&atilde;o descrit
os nas <a href="#tab1">Tabelas 1</a> e <a href="#tab2">2</a>. Tr&ecirc;s (30%) a
presentaram diminui&ccedil;&atilde;o no n&uacute;mero e intensidade de epis&oacu
te;dios de encefalopatia. N&atilde;o foram evidenciados quadros de peritonite ba
cteriana espont&acirc;nea, hemorragia digestiva ou altera&ccedil;&atilde;o do gr
au de ascite. Dois (20%) referiram discreta melhora do prurido. Quatro (40%) rel
ataram sensa&ccedil;&atilde;o de bem-estar por algumas semanas ap&oacute;s sess&
otilde;es de oxigenoterapia hiperb&aacute;rica.</font></p>     ^cY#v24n1a10.htm#
#
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003500075002001300110#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#34#30#article#94#<p><a name="tab1"></
a></p>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#35#31#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#36#32#article#94#<p align="center"><i
mg src="/img/revistas/abcd/v24n1/a10tab1.jpg"></p>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#37#33#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003500075002001300110#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#38#34#article#94#<p><a name="tab2"></
a></p>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#39#35#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#40#36#article#94#<p align="center"><i
mg src="/img/revistas/abcd/v24n1/a10tab2.jpg"></p>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#41#37#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010600075002001300181#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#42#38#article#94#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v24n1a10.htm##
02774000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704254000075002001302615#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#43#39#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Todo paciente com doen&ccedil;a hep&a
acute;tica cujo tempo de vida ap&oacute;s transplante seja aumentado, deveria se
r submetido a esse procedimento, sem lista de espera, no momento mais adequado d
o curso de sua doen&ccedil;a e, portanto, com as melhores chances de ter sua qua
lidade de vida resgatada<sup>10</sup>. A evolu&ccedil;&atilde;o ruim dos pacient
es em lista de espera estimula investigadores na utiliza&ccedil;&atilde;o da oxi
genoterapia hiperb&aacute;rica para portadores de doen&ccedil;as hep&aacute;tica
s em est&aacute;gio avan&ccedil;ado em lista, como forma de melhorar seu estado 
e sua qualidade de vida, permitindo, talvez, sua chegada ao transplante em boa c
ondi&ccedil;&atilde;o. Apesar de alguns trabalhos enfatizarem o aumento na veloc
idade de regenera&ccedil;&atilde;o hep&aacute;tica e melhora de fun&ccedil;&atil
de;o hep&aacute;tica em situa&ccedil;&otilde;es graves, inclusive trombose de ar
t&eacute;ria hep&aacute;tica p&oacute;s-transplante, n&atilde;o foram observadas
 altera&ccedil;&otilde;es objetivas<sup>19</sup>. Os par&acirc;metros laboratori
ais e &iacute;ndices progn&oacute;sticos n&atilde;o apresentaram melhora signifi
cante, contrariando o que alguns autores afirmam sobre melhora de n&iacute;veis 
de algumas enzimasap&oacute;s utiliza&ccedil;&atilde;o de oxigenoterapia hiperb&
aacute;rica<sup>8,14,15,18</sup>. Tamb&eacute;m n&atilde;o encontrou-se aqui mel
hora que pudesse alterar o MELD, bem como o Child de modo significativo. Alguns 
dos achados subjetivos, como os observados em rela&ccedil;&atilde;o &agrave; mel
hora na intensidade do prurido e frequ&ecirc;ncia dos epis&oacute;dios da encefa
lopatia, foram relatados. A chamada sensa&ccedil;&atilde;o de bem-estar ou melho
ra referida por poucos pacientes e familiares, apesar de subjetivos, chamam a at
en&ccedil;&atilde;o. Salienta-se o caso de uma paciente com s&iacute;ndrome hepa
to-pulmonar que obteve melhora do n&iacute;vel de consci&ecirc;ncia, press&atild
e;o e satura&ccedil;&atilde;o de oxig&ecirc;nio, tornando-se inclusive relato de
 caso<sup>7</sup>. Seria a oxigenoterapia hiperb&aacute;rica efetiva na melhora 
da qualidade de vida desses pacientes? Pode se tornar tratamento ponte, particul
armente para os pacientes com s&iacute;ndrome hepato-pulmonar, &agrave; espera p
elo transplante hep&aacute;tico? Novas pesquisas ser&atilde;o necess&aacute;rias
, devendo estes achados estimularem outras pesquisas para responder esses e outr
os questionamentos. </font></p>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#44#40#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#45#41#article#94#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b> </font></p>  
   ^cY#v24n1a10.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704038300075002001300458#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#46#42#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A oxigenoterapia hiperb&aacute;rica p
ode melhorar a fun&ccedil;&atilde;o hep&aacute;tica na cirrose e ajudar a contro
lar as complica&ccedil;&otilde;es relacionadas &agrave; insufici&ecirc;ncia hep&
aacute;tica na avalia&ccedil;&atilde;o pr&eacute;-operat&oacute;ria para transpl
ante de f&iacute;gado. </font></p>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#47#43#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010600075002001300181#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#48#44#article#94#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIA</b></font></p>   
  ^cY#v24n1a10.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704028200077002001300359#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#49#45#article#94#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Angelico M, Gridell
i B, Strazzabosco M. Practice of adult liver transplantation in Italy recommenda
tions of the Italian Association for the Study of the Liver (A.I.S.F.). Digestiv
e Liver Dis. 2005; 37:461-7.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#50#46#article#94# </font></p>     ^cY
#v24n1a10.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704029800077002001300375#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#51#47#article#94#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Castro e Silva O, S
ankarankutty AK, Oliveira GR, Pacheco E,Ramalho FS, Dal Sasso K, Tolentino E, Me
nte ED, Fran&ccedil;a AVC, Martinelli ALC. Liver transplantation: indication and
  survival. Acta Cir Bras. 2002;17(3):83-91.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#52#48#article#94# </font></p>     ^cY
#v24n1a10.htm##
00359000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704011100077002001300188#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#53#49#article#94#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 3. Conselho Regional d
e Medicina, 1995.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#54#50#article#94# </font></p>     ^cY
#v24n1a10.htm##
00380000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704013200077002001300209#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#55#51#article#94#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Fausto N. Liver rege
neration. J Hepatology. 2000;32:19-31.    ^cY#v24n1a10.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#56#52#article#94#</font></p>     ^cY#
v24n1a10.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704020300077002001300280#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#57#53#article#94#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Forman L, Lucey M. P
redicting the prognosis of chronic liver disease: An evolution from Child to MEL
D. Hepatology. 2001;33:473-5.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#58#54#article#94# </font></p>     ^cY
#v24n1a10.htm##
00418000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704017000077002001300247#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#59#55#article#94#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Jain KK. HBO in dise
ases of the liver. The text book of hyperbaric. Medicine. 2005;1(2-3):326-8.    
^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#60#56#article#94# </font></p>     ^cY
#v24n1a10.htm##
00617000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704036900077002001300446#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#61#57#article#94#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Kreimer F, Sena B, F
erraz A, Campos J, D&acute;Albuquerque, Ara&uacute;jo-Jr GC, Ferraz E. Efeito da
 oxigenoterapia hiperb&aacute;rica: relato de caso de paciente com s&iacute;ndro
me hepato-pulmonar em lista de espera para transplante hep&aacute;tico. ABCD Arq
 Bras Cir Dig. 2010,; 23(2): 132-4.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#62#58#article#94# </font></p>     ^cY
#v24n1a10.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704024500077002001300322#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#63#59#article#94#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 8. Liu W, Zhao W, Lu X
, Zheng X, Luo C. Clinical pathological study of treatment of chronic hepatitis 
with hyperbaric oxygenation. Chin Med J (Engl). 2002 Aug;115(8):1153-7.    ^cY#v
24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#64#60#article#94# </font></p>     ^cY
#v24n1a10.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704026500077002001300342#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#65#61#article#94#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Massarolo PCB, Ferna
ndes JH, Millan LS, Inacio CAF, Rodrigues Junior, AJ, Mies S. Efeito da escala M
ELD na mortalidade ap&oacute;s o transplante de f&iacute;gado. J Bras Trans. 200
3; 6:14-20.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#66#62#article#94# </font></p>     ^cY
#v24n1a10.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704021500078002001300293#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#67#63#article#94#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 10. Merion RM. When i
s a patient too well and when is a patient too sick for a liver transplant? Live
r Transpl. 2004 Oct;10(10 Suppl 2):S69-73.    ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#68#64#article#94#. </font></p>     ^c
Y#v24n1a10.htm##
00398000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704014900078002001300227#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#69#65#article#94#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Michalopolus GK,	D
efrances MC. Liver regeneration. Science. 1997;276:60-6.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#70#66#article#94# </font></p>     ^cY
#v24n1a10.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704015100078002001300229#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#71#67#article#94#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Mies S. Transplant
e de f&iacute;gado. Rev Ass Med Brasil. 1998;44(2):127-34.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#72#68#article#94# </font></p>     ^cY
#v24n1a10.htm##
00637000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704038800078002001300466#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#73#69#article#94#13#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 13. Minist&eacute;rio
 do Trabalho. Brasil. Portaria nº 397, de 09 de outubro de 2002. Aprova a Classi
fica&ccedil;&atilde;o Brasileira de Ocupa&ccedil;&otilde;es - CBO / 2002,para o 
uso em todo territ&oacute;rio nacional e autoriza a sua publica&ccedil;&atilde;o
. Bras&iacute;lia: Minist&eacute;rio do Trabalho, 2002.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#74#70#article#94# </font></p>     ^cY
#v24n1a10.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704027700078002001300355#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#75#71#article#94#14#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 14. Nagamine K, Kubot
a T, Togo S, Nagashima Y, Mori M, Shimada H. Beneficial effect of hyperbaric oxy
gen therapy on liver regeneration after 90% hepatectomy in rats. Eur Surg Res. 2
004 Nov-Dec;36(6):350-6.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#76#72#article#94# </font></p>     ^cY
#v24n1a10.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704025300078002001300331#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#77#73#article#94#15#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 15. Ozdogan M, Ersoy 
E, Dundar K, Albayrak L, Devay S, Gundogdu H. Beneficial effect of hyperbaric ox
ygenation on liver regeneration in cirrhosis. J Surg Res. 2005 Dec;129(2):260-4.
    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#78#74#article#94# </font></p>     ^cY
#v24n1a10.htm##
00759000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704051000078002001300588#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#79#75#article#94#16#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 16. Ros&aacute;rio RC
V. Estudo sobre os efeitos da oxigenoterapia hiperb&aacute;rica em ratos com hip
ertens&atilde;o porta induzida: avalia&ccedil;&atilde;o da mortalidade, peso e h
istologia hepatoespl&ecirc;nica. Dispon&iacute;vel em: <a href="http://www.medic
ina.ufmg.br/cpg/resumos2004/Ricardo_costa_cir_mestrado.htm" target="_blank">http
://www.medicina.ufmg.br/cpg/resumos2004/Ricardo_costa_cir_mestrado.htm</a>. Aces
so em 18/06/2005.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#80#76#article#94# </font></p>     ^cY
#v24n1a10.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704024900078002001300327#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#81#77#article#94#17#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Russo MW, Wei JT, 
Thiny MT, Gangarosa LM, Brown A, Ringel Y, Shaheen NJ, Sandler RS. Digestive and
 liver diseases statistics, 2004. Gastroenterology. 2004 May;126(5):1448-53.    
^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#82#78#article#94# </font></p>     ^cY
#v24n1a10.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704028800078002001300366#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#83#79#article#94#18#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 18. Tolentino EC, Fer
ez O, Oliveira GR, Ramalho FS, Ramalho LNZ, Zucoloto S, Castro e Silva Jr. O. Ox
igenoterapia hiperb&aacute;rica e regenera&ccedil;&atilde;o hep&aacute;tica. Act
a Cir Bras. 2003; 18(suppl. 5):4-5.    ^cY#v24n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#84#80#article#94# </font></p>     ^cY
#v24n1a10.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704024300078002001300321#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#85#81#article#94#19#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 19. Uwagawa T, Unemur
a Y, Yamazaki Y. Hyperbaric oxygenation alter portal vein emobilization for rege
neration of the predicted remnant liver. J Surg Res. 2001;100(1):63-8.    ^cY#v2
4n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#86#82#article#94# </font></p>     ^cY
#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#87#83#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#88#84#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704019900075002001300274#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#89#85#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#note
1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ecirc
;ncia: </b>    ^cY#v24n1a10.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003100075002001300106#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#90#86#article#94#<br>   Euclides Mart
ins    ^cY#v24n1a10.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011700075002001300192#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#91#87#article#94#<br>   E-mail: <a hr
ef="mailto:euclides_martins@yahoo.com.br ">euclides_martins@yahoo.com.br </a></f
ont></p>     ^cY#v24n1a10.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704012400075002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#92#88#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">  Recebido para publica&ccedil;&atild
e;o: 07/12/2010     ^cY#v24n1a10.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006300075002001300138#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#93#89#article#94#<br>   Aceito para p
ublica&ccedil;&atilde;o: 21/12/2010    ^cY#v24n1a10.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005700075002001300132#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#94#90#article#94#<br> Fonte de financ
iamento: n&atilde;o h&aacute;    ^cY#v24n1a10.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006900075002001300144#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#95#91#article#94#<br> Conflito de int
eresses: n&atilde;o h&aacute;</font></p>     ^cY#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#96#92#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#97#93#article#94#<p>&nbsp;</p>     ^c
Y#v24n1a10.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704022000075002001300295#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a10.htm#S#p#98#94#article#94#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Departamento de
 Cirurgia e Hospital das Cl&iacute;nicas da Universidade Federal de Pernambuco, 
Recife, PE, Brasil. </font></p>     ^cY#v24n1a10.htm##
00612000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100018000760100018000940100
02200112012013300134030002000267710000200287065000900289064000500298031000300303
014000600306865000900312002001300321#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a10.htm#S#c#99#1#article#19#1#^rND^sAngelico^nM#^rND^sGridelli^nB#^rND^sStraz
zabosco^nM#Practice of adult liver transplantation in Italy recommendations of t
he Italian Association for the Study of the Liver (AI.S.F.)^len#Digestive Liver 
Dis#2#20050000#2005#37#461-7#20110300#v24n1a10.htm##
00771000000000373000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100025000770100025001020100
02000127010001800147010001900165010002000184010002000204010001700224010001900241
01000230026001200510028303000140033471000020034806500090035006400050035903100030
0364032000200367014000600369865000900375002001300384#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a10.htm#S#c#100#2#article#19#2#^rND^sCastro e Silva^nO.#^rND^
sSankarankutty^nAK.#^rND^sOliveira^nGR.#^rND^sPacheco^nE.#^rND^sRamalho^nFS.#^rN
D^sDal Sasso^nK.#^rND^sTolentino^nE.#^rND^sMente^nED.#^rND^sFrança^nAVC.#^rND^sM
artinelli^nALC.#Liver transplantation: indication and survival^len#Acta Cir Bras
#2#20020000#2002#17#3#83-91#20110300#v24n1a10.htm##
00337000000000193000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170030000770650009001070640
00500116865000900121002001300130#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a
10.htm#S#c#101#3#article#19#3#Conselho Regional de Medicina#19950000#1995#201103
00#v24n1a10.htm##
00430000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120023000930300
01300116710000200129065000900131064000500140031000300145014000600148865000900154
002001300163#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#c#102#4#art
icle#19#4#^rND^sFausto^nN#Liver regeneration^len#J Hepatology#2#20000000#2000#32
#19-31#20110300#v24n1a10.htm##
00550000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930120
08700108030001100195065000900206064000500215031000300220014000600223865000900229
002001300238035001000251801001100261#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a10.htm#S#c#103#5#article#19#5#^rND^sForman^nL#^rND^sLucey^nM#Predicting the 
prognosis of chronic liver disease: An evolution from Child to MELD^len#Hepatolo
gy#20010000#2001#33#473-5#20110300#v24n1a10.htm#0161-0538#HEPATOLOGY##
00508000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770120062000920300
00900154065000900163064000500172031000200177032000400179014000600183865000900189
002001300198035001000211801000900221#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a10.htm#S#c#104#6#article#19#6#^rND^sJain^nKK#HBO in diseases of the liver: T
he text book of hyperbaric^len#Medicine#20050000#2005#1#2-3#326-8#20110300#v24n1
a10.htm#0025-7974#Medicine##
00749000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100014000940100
01600108010001600124010002000140010002000160010001700180012014300197030002200340
71000020036206500090036406400050037303100030037803200020038101400060038386500090
0389002001300398#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#c#105#7
#article#19#7#^rND^sKreimer^nF#^rND^sSena^nB#^rND^sFerraz^nA#^rND^sCampos^nJ#^rN
D^sD´Albuquerque#^rND^sAraújo-Jr^nGC#^rND^sFerraz^nE.#Efeito da oxigenoterapia h
iperbárica: relato de caso de paciente com síndrome hepato-pulmonar em lista de 
espera para transplante hepático^lpt#ABCD Arq Bras Cir Dig#2#20100000#2010#23#2#
132-4#20110300#v24n1a10.htm##
00661000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770100014000900100
01200104010001500116010001300131012009400144030001800238065000900256064000700265
03100040027203200020027601400070027886500090028500200130029403500100030780100180
0317#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#c#106#8#article#19#
8#^rND^sLiu^nW#^rND^sZhao^nW#^rND^sLu^nX#^rND^sZheng^nX#^rND^sLuo^nC#Clinical pa
thological study of treatment of chronic hepatitis with hyperbaric oxygenation^l
en#Chin Med J (Engl)#20020800#200208#115#8#1153-7#20110300#v24n1a10.htm#0366-699
9#Chin Med J (Engl)##
00637000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100020000980100
01700118010001800135010002700153010001400180012007000194030001300264710000200277
065000900279064000500288031000200293014000600295865000900301002001300310#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#c#107#9#article#19#9#^rND^sMass
arolo^nPCB#^rND^sFernandes^nJH#^rND^sMillan^nLS#^rND^sInacio^nCAF#^rND^sRodrigue
s Junior^nAJ#^rND^sMies^nS#Efeito da escala MELD na mortalidade após o transplan
te de fígado^lpt#J Bras Trans#2#20030000#2003#6#14-20#20110300#v24n1a10.htm##
00517000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120085000960300
01400181710000200195065000900197064000700206031000300213032000600216014000700222
865000900229002001300238#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S
#c#108#10#article#19#10#^rND^sMerion^nRM#When is a patient too well and when is 
a patient too sick for a liver transplant^len#Liver Transpl#2#20041000#200410#10
#10^s2#S69-73#20110300#v24n1a10.htm##
00494000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100020001020120
02300122030000800145065000900153064000500162031000400167014000500171865000900176
002001300185035001000198801000800208#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a10.htm#S#c#109#11#article#19#11#^rND^sMichalopolus^nGK#^rND^sDefrances^nMC#L
iver regeneration^len#Science#19970000#1997#276#60-6#20110300#v24n1a10.htm#0036-
8075#Science##
00454000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790120026000930300
01900119710000200138065000900140064000500149031000300154032000200157014000700159
865000900166002001300175#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S
#c#110#12#article#19#12#^rND^sMies^nS#Transplante de fígado^lpt#Rev Ass Med Bras
il#2#19980000#1998#44#2#127-34#20110300#v24n1a10.htm##
00593000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170023000790170007001020180
17400109066000900283062002300292065000900315064000500324865000900329002001300338
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#c#111#13#article#19#13#
Ministério do Trabalho#Brasil#Portaria nº 397, de 09 de outubro de 2002: Aprova 
a Classificação Brasileira de Ocupações - CBO / 2002,para o uso em todo territór
io nacional e autoriza a sua publicação^lpt#Brasília#Ministério do Trabalho#2002
0000#2002#20110300#v24n1a10.htm##
00710000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01400113010001900127010001400146010001800160012010300178030001300281065000900294
06400130030303100030031603200020031901400060032186500090032700200130033603500100
0349801001300359#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#c#112#1
4#article#19#14#^rND^sNagamine^nK#^rND^sKubota^nT#^rND^sTogo^nS#^rND^sNagashima^
nY#^rND^sMori^nM#^rND^sShimada^nH.#Beneficial effect of hyperbaric oxygen therap
y on liver regeneration after 90% hepatectomy in rats^len#Eur Surg Res#20041200#
2004 Nov-Dec#36#6#350-6#20110300#v24n1a10.htm#0014-312X#Eur Surg Res##
00681000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01600111010001800127010001500145010001800160012008300178030001100261065000900272
06400070028103100040028803200020029201400060029486500090030000200130030903500100
0322801001100332#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#c#113#1
5#article#19#15#^rND^sOzdogan^nM#^rND^sErsoy^nE#^rND^sDundar^nK#^rND^sAlbayrak^n
L#^rND^sDevay^nS#^rND^sGundogdu^nH#Beneficial effect of hyperbaric oxygenation o
n liver regeneration in cirrhosis^len#J Surg Res#20051200#200512#129#2#260-4#201
10300#v24n1a10.htm#0022-4804#J Surg Res##
00593000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160020000790180159000990370
07500258110000900333109001100342865000900353002001300362#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a10.htm#S#c#114#16#article#19#16#^rND^sRosário^nRCV.#Estu
do sobre os efeitos da oxigenoterapia hiperbárica em ratos com hipertensão porta
 induzida: avaliação da mortalidade, peso e histologia hepatoesplênica^lpt#http:
//www.medicina.ufmg.br/cpg/resumos2004/Ricardo_costa_cir_mestrado.htm#20050618#1
8/06/2005#20110300#v24n1a10.htm##
00720000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01600109010002000125010001500145010001600160010001800176010001800194012005000212
03000170026206500090027906400070028803100040029503200020029901400080030186500090
0309002001300318035001000331801001700341#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a10.htm#S#c#115#17#article#19#17#^rND^sRusso^nMW#^rND^sWei^nJT#^rND^sThin
y^nMT#^rND^sGangarosa^nLM#^rND^sBrown^nA#^rND^sRingel^nY#^rND^sShaheen^nNJ#^rND^
sSandler^nRS#Digestive and liver diseases statistics, 2004^len#Gastroenterology#
20040500#200405#126#5#1448-53#20110300#v24n1a10.htm#0016-5085#Gastroenterology##
00671000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100015000990100
01900114010001800133010001900151010001800170010002800188012005400216030001400270
71000020028406500090028606400050029503100030030003200040030301400040030786500090
0311002001300320#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a10.htm#S#c#116#1
8#article#19#18#^rND^sTolentino^nEC#^rND^sFerez^nO#^rND^sOliveira^nGR#^rND^sRama
lho^nFS#^rND^sRamalho^nLNZ#^rND^sZucoloto^nS#^rND^sCastro e Silva^nJr O.#Oxigeno
terapia hiperbárica e regeneração hepática^lpt#Acta Cir Bras#2#20030000#2003#18#
^s5#4-5#20110300#v24n1a10.htm##
00619000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01800113012010700131030001100238065000900249064000500258031000400263032000200267
014000500269865000900274002001300283035001000296801001100306#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a10.htm#S#c#117#19#article#19#19#^rND^sUwagawa^nT#^rN
D^sUnemura^nY#^rND^sYamazaki^nY#Hyperbaric oxygenation alter portal vein emobili
zation for regeneration of the predicted remnant liver^len#J Surg Res#20010000#2
001#100#1#63-8#20110300#v24n1a10.htm#0022-4804#J Surg Res##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#o#1#1#article#1
#20110411#103904#v24n1a11.htm#111##
03870000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002700107
03100030013403200020013706500090013901400090014803500100015701200620016701200580
02290100033002870100026003200100028003460100039003740100040004130100032004530831
33800485085001001823085002201833085003701855085002601892083120301918085001003121
08500200313108500280315108500250317911700080320407200030321211200090321511100110
3224114000903235113001103244002001303255#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a11.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ND#11#ABCD060#nd#ABCD, arq. b
ras. cir. dig.#24#1#20110300#^f52^l54#0102-6720#Tratamento da obesidade mórbida 
com gastrectomia vertical^lpt#Treatment of morbid obesity with vertical gastrect
omy^len#^rND^nAlcides José^sBranco-Filho#^rND^nLuis Sérgio^sNassif#^rND^nAline M
oraes^sMenacho#^rND^nRicardo Augusto Eineck^sAurichio#^rND^nDaniel Emílio Dalled
one^sSiqueira#^rND^nRobson Matsuda^sFernandez#^lpt^aRACIONAL: A gastrectomia ver
tical constitui-se em uma das opções de tratamento para a obesidade mórbida. Com
 a remoção de parte relevante da grande curvatura gástrica, cria-se um estômago 
tubular com pequena capacidade volumétrica, dando a característica restritiva à 
operação. OBJETIVOS: Avaliar os pacientes submetidos à gastrectomia vertical qua
nto ao gênero, idade, índice de massa corporal, co-morbidades associadas, tempo 
de internamento e evolução pósoperatória a curto prazo. MÉTODOS: Realizou-se um 
estudo descritivo e retrospectivo em que foram analisados os prontuários de 114 
pacientes obesos mórbidos submetidos à gastrectomia vertical. RESULTADOS: Dos 11
4 pacientes, 107 (93,8%) eram do gênero masculino, sendo que a idade média foi d
e 38 anos (19 a 55). O índice de massa corporal médio foi de 45,9 kg/m² (35 a 65
). O tempo de internamento teve um mínimo de 3 e máximo de 48 dias. A principal 
co-morbidade associada foi a hipertensão arterial sistêmica (63%). Como evolução
 pós-operatória, 24 pacientes (21%) necessitaram de cuidados em unidade de terap
ia intensiva e houve um total de quatro óbitos (3,5%). CONCLUSÕES: A gastrectomi
a vertical constitui-se em método seguro e eficaz para perda de peso em obesos m
órbidos, sendo uma técnica cirúrgica com baixa morbimortalidade e bons resultado
s cirúrgicos imediatos.#^ddecs^i1#^tm^lpt^kObesidade^i1#^tm^lpt^kÍndice de massa
 corporal^i1#^tm^lpt^kGastroplastia^i1#^len^aBACKGROUND: Vertical gastrectomy is
 an option to morbid obesity treatment.Removing a relevant part of the stomach's
 great curvature, a gastric tube is created with low volumetric capacity, giving
 to the operation the restrictive characteristic. AIM: To evaluate the patients 
submitted to vertical gastrectomy regarding gender, age, body mass index, associ
ated comorbidities, time of hospitalization and evolution on the early postopera
tive period. METHODS: This was a descriptive and retrospective study that analyz
ed the medical records of 114 morbidly obese patients submitted to vertical gast
rectomy. RESULTS: A hundred and seven (93,8%) of the patients were male and the 
average age was 38 years old. The body mass index was 45,9 kg/m². About the time
 of hospitalization, there was a minimum of 3 and maximum of 48 days. The main c
omorbidity was systemic arterial hypertension (63%). About the evolution after t
he surgery, 24 patients (21%) needed intensive care and four patients died (3,5%
). CONCLUSIONS: Vertical gastrectomy constitutes a safe and effective method to 
the weight loss on morbid obeses, being a surgical technique with low morbimorta
lity and good immediate surgical results.#^ddecs^i2#^tm^len^kObesity^i2#^tm^len^
kBody mass index^i2#^tm^len^kGastroplasty^i2#vancouv#16#20110127#27/01/2011#2011
0215#15/02/2011#v24n1a11.htm##
03976000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002700107
03100030013403200020013706500090013901400090014803500100015701200690016701200650
02360100033003010100026003340100028003600100039003880100040004270100032004670831
38400499085001001883085002201893085003701915085002601952083124901978085001003227
08500200323708500280325708500250328511700080331007200030331811200090332111100110
3330114000903341113001103350002001303361#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a11.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ND#11#ABCD060#nd#ABCD, arq. b
ras. cir. dig.#24#1#20110300#^f52^l54#0102-6720#<b>Tratamento da obesidade mórbi
da com gastrectomia vertical</b>^lpt#<b>Treatment of morbid obesity with vertica
l gastrectomy</b>^len#^rND^nAlcides José^sBranco-Filho#^rND^nLuis Sérgio^sNassif
#^rND^nAline Moraes^sMenacho#^rND^nRicardo Augusto Eineck^sAurichio#^rND^nDaniel
 Emílio Dalledone^sSiqueira#^rND^nRobson Matsuda^sFernandez#^lpt^a<b>RACIONAL: <
/b>A gastrectomia vertical constitui-se em uma das opções de tratamento para a o
besidade mórbida. Com a remoção de parte relevante da grande curvatura gástrica,
 cria-se um estômago tubular com pequena capacidade volumétrica, dando a caracte
rística restritiva à operação. <b>OBJETIVOS: </b>Avaliar os pacientes submetidos
 à gastrectomia vertical quanto ao gênero, idade, índice de massa corporal, co-m
orbidades associadas, tempo de internamento e evolução pósoperatória a curto pra
zo. <b>MÉTODOS:</b> Realizou-se um estudo descritivo e retrospectivo em que fora
m analisados os prontuários de 114 pacientes obesos mórbidos submetidos à gastre
ctomia vertical. <b>RESULTADOS: </b>Dos 114 pacientes, 107 (93,8%) eram do gêner
o masculino, sendo que a idade média foi de 38 anos (19 a 55). O índice de massa
 corporal médio foi de 45,9 kg/m<sup>2 </sup>(35 a 65). O tempo de internamento 
teve um mínimo de 3 e máximo de 48 dias. A principal co-morbidade associada foi 
a hipertensão arterial sistêmica (63%). Como evolução pós-operatória, 24 pacient
es (21%) necessitaram de cuidados em unidade de terapia intensiva e houve um tot
al de quatro óbitos (3,5%). <b>CONCLUSÕES: </b>A gastrectomia vertical constitui
-se em método seguro e eficaz para perda de peso em obesos mórbidos, sendo uma t
écnica cirúrgica com baixa morbimortalidade e bons resultados cirúrgicos imediat
os.#^ddecs^i1#^tm^lpt^kObesidade^i1#^tm^lpt^kÍndice de massa corporal^i1#^tm^lpt
^kGastroplastia^i1#^len^a<b>BACKGROUND:</b> Vertical gastrectomy is an option to
 morbid obesity treatment.Removing a relevant part of the stomach's great curvat
ure, a gastric tube is created with low volumetric capacity, giving to the opera
tion the restrictive characteristic. <b>AIM: </b>To evaluate the patients submit
ted to vertical gastrectomy regarding gender, age, body mass index, associated c
omorbidities, time of hospitalization and evolution on the early postoperative p
eriod. <b>METHODS: </b>This was a descriptive and retrospective study that analy
zed the medical records of 114 morbidly obese patients submitted to vertical gas
trectomy. <b>RESULTS: </b>A hundred and seven (93,8%) of the patients were male 
and the average age was 38 years old. The body mass index was 45,9 kg/m<sup>2</s
up>. About the time of hospitalization, there was a minimum of 3 and maximum of 
48 days. The main comorbidity was systemic arterial hypertension (63%). About th
e evolution after the surgery, 24 patients (21%) needed intensive care and four 
patients died (3,5%). <b>CONCLUSIONS: </b>Vertical gastrectomy constitutes a saf
e and effective method to the weight loss on morbid obeses, being a surgical tec
hnique with low morbimortality and good immediate surgical results.#^ddecs^i2#^t
m^len^kObesity^i2#^tm^len^kBody mass index^i2#^tm^len^kGastroplasty^i2#vancouv#1
6#20110127#27/01/2011#20110215#15/02/2011#v24n1a11.htm##
04049000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104121000300108049000800111158000300119030002600122
03100030014803200020015106500090015301400090016203500100017101200620018101200580
02430100033003010100026003340100028003600100039003880100040004270100032004670831
37400499085001001873085002201883085003701905085002601942083123101968085001003199
08500200320908500280322908500250325711700080328207200030329011200090329311100110
3302114000903313113001103322002001303333008008903346#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a11.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0
#11#ABCD060#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f52^l54#0102-6720#Tratam
ento da obesidade mórbida com gastrectomia vertical^lpt#Treatment of morbid obes
ity with vertical gastrectomy^len#^rND^nAlcides José^sBranco-Filho#^rND^nLuis Sé
rgio^sNassif#^rND^nAline Moraes^sMenacho#^rND^nRicardo Augusto Eineck^sAurichio#
^rND^nDaniel Emílio Dalledone^sSiqueira#^rND^nRobson Matsuda^sFernandez#^lpt^aRA
CIONAL: A gastrectomia vertical constitui-se em uma das opções de tratamento par
a a obesidade mórbida. Com a remoção de parte relevante da grande curvatura gást
rica, cria-se um estômago tubular com pequena capacidade volumétrica, dando a ca
racterística restritiva à operação. OBJETIVOS: Avaliar os pacientes submetidos à
 gastrectomia vertical quanto ao gênero, idade, índice de massa corporal, co-mor
bidades associadas, tempo de internamento e evolução pósoperatória a curto prazo
. MÉTODOS: Realizou-se um estudo descritivo e retrospectivo em que foram analisa
dos os prontuários de 114 pacientes obesos mórbidos submetidos à gastrectomia ve
rtical. RESULTADOS: Dos 114 pacientes, 107 (93,8 por cento) eram do gênero mascu
lino, sendo que a idade média foi de 38 anos (19 a 55). O índice de massa corpor
al médio foi de 45,9 kg/m² (35 a 65). O tempo de internamento teve um mínimo de 
3 e máximo de 48 dias. A principal co-morbidade associada foi a hipertensão arte
rial sistêmica (63 por cento). Como evolução pós-operatória, 24 pacientes (21 po
r cento) necessitaram de cuidados em unidade de terapia intensiva e houve um tot
al de quatro óbitos (3,5 por cento). CONCLUSÕES: A gastrectomia vertical constit
ui-se em método seguro e eficaz para perda de peso em obesos mórbidos, sendo uma
 técnica cirúrgica com baixa morbimortalidade e bons resultados cirúrgicos imedi
atos.#^ddecs^i1#^tm^lpt^kObesidade^i1#^tm^lpt^kÍndice de massa corporal^i1#^tm^l
pt^kGastroplastia^i1#^len^aBACKGROUND: Vertical gastrectomy is an option to morb
id obesity treatment.Removing a relevant part of the stomach's great curvature, 
a gastric tube is created with low volumetric capacity, giving to the operation 
the restrictive characteristic. AIM: To evaluate the patients submitted to verti
cal gastrectomy regarding gender, age, body mass index, associated comorbidities
, time of hospitalization and evolution on the early postoperative period. METHO
DS: This was a descriptive and retrospective study that analyzed the medical rec
ords of 114 morbidly obese patients submitted to vertical gastrectomy. RESULTS: 
A hundred and seven (93,8 percent) of the patients were male and the average age
 was 38 years old. The body mass index was 45,9 kg/m². About the time of hospita
lization, there was a minimum of 3 and maximum of 48 days. The main comorbidity 
was systemic arterial hypertension (63 percent). About the evolution after the s
urgery, 24 patients (21 percent) needed intensive care and four patients died (3
,5 percent). CONCLUSIONS: Vertical gastrectomy constitutes a safe and effective 
method to the weight loss on morbid obeses, being a surgical technique with low 
morbimortality and good immediate surgical results.#^ddecs^i2#^tm^len^kObesity^i
2#^tm^len^kBody mass index^i2#^tm^len^kGastroplasty^i2#vancouv#16#20110127#27/01
/2011#20110215#15/02/2011#v24n1a11.htm#Internet^ihttp://www.scielo.br/scielo.php
?script=sci_arttext&pid=S0102-67202011000100011##
00351000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704011900073002001300192#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#5#1#article#91#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b></f
ont></p>     ^cY#v24n1a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#6#2#article#91#<p>&nbsp;</p>     ^cY#
v24n1a11.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704017500073002001300248#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#7#3#article#91#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Tratamento da ob
esidade m&oacute;rbida com gastrectomia vertical </b></font></p>     ^cY#v24n1a1
1.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#8#4#article#91#<p>&nbsp;</p>     ^cY#
v24n1a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#9#5#article#91#<p>&nbsp;</p>     ^cY#
v24n1a11.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704027300074002001300347#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#10#6#article#91#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Alcides Jos&eacute; Branco-Filho; L
uis S&eacute;rgio Nassif; Aline Moraes Menacho; Ricardo Augusto Eineck Aurichio;
 Daniel Em&iacute;lio Dalledone Siqueira; Robson Matsuda Fernandez</b> </font></
p>      ^cY#v24n1a11.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704012500074002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#11#7#article#91#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;ncia
</a></font></p>     ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#12#8#article#91#<p>&nbsp;</p>     ^cY
#v24n1a11.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704004400074002001300118#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#13#9#article#91#<p>&nbsp;</p> <hr siz
e="1" noshade>     ^cY#v24n1a11.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009600075002001300171#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#14#10#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24n
1a11.htm##
00672000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704043800075002001300513#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#15#11#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL: </b>A gastrectomia verti
cal constitui-se em uma das op&ccedil;&otilde;es de tratamento para a obesidade 
m&oacute;rbida. Com a remo&ccedil;&atilde;o de parte relevante da grande curvatu
ra g&aacute;strica, cria-se um est&ocirc;mago tubular com pequena capacidade vol
um&eacute;trica, dando a caracter&iacute;stica restritiva &agrave; opera&ccedil;
&atilde;o.    ^cY#v24n1a11.htm##
00508000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704027400075002001300349#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#16#12#article#91#<br> <b>OBJETIVOS: <
/b>Avaliar os pacientes submetidos &agrave; gastrectomia vertical quanto ao g&ec
irc;nero, idade, &iacute;ndice de massa corporal, co-morbidades associadas, temp
o de internamento e evolu&ccedil;&atilde;o p&oacute;soperat&oacute;ria a curto p
razo.     ^cY#v24n1a11.htm##
00450000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704021600075002001300291#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#17#13#article#91#<br>   <b>M&Eacute;T
ODOS:</b> Realizou-se um estudo descritivo e retrospectivo em que foram analisad
os os prontu&aacute;rios de 114 pacientes obesos m&oacute;rbidos submetidos &agr
ave; gastrectomia vertical.     ^cY#v24n1a11.htm##
00828000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704059400075002001300669#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#18#14#article#91#<br>   <b>RESULTADOS
: </b>Dos 114 pacientes, 107 (93,8%) eram do g&ecirc;nero masculino, sendo que a
 idade m&eacute;dia foi de 38 anos (19 a 55). O &iacute;ndice de massa corporal 
m&eacute;dio foi de 45,9 kg/m<sup>2 </sup>(35 a 65). O tempo de internamento tev
e um m&iacute;nimo de 3 e m&aacute;ximo de 48 dias. A principal co-morbidade ass
ociada foi a hipertens&atilde;o arterial sist&ecirc;mica (63%). Como evolu&ccedi
l;&atilde;o p&oacute;s-operat&oacute;ria, 24 pacientes (21%) necessitaram de cui
dados em unidade de terapia intensiva e houve um total de quatro &oacute;bitos (
3,5%).    ^cY#v24n1a11.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704028500075002001300360#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#19#15#article#91#<br>   <b>CONCLUS&Ot
ilde;ES: </b>A gastrectomia vertical constitui-se em m&eacute;todo seguro e efic
az para perda de peso em obesos m&oacute;rbidos, sendo uma t&eacute;cnica cir&ua
cute;rgica com baixa morbimortalidade e bons resultados cir&uacute;rgicos imedia
tos. </font></p>     ^cY#v24n1a11.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018500075002001300260#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#20#16#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b>Obesidade. &Iacut
e;ndice de massa corporal. Gastroplastia. </font></p> <hr size="1" noshade >    
 ^cY#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#21#17#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#22#18#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011500075002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#23#19#article#91#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O </b></fon
t></p>     ^cY#v24n1a11.htm##
01173000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704093900075002001301014#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#24#20#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No mundo ocidental, a preval&ecirc;nc
ia da obesidade - definida como pacientes que apresentam &iacute;ndice de massa 
corporal &#91;IMC = peso (kg)/altura (m)&#93; maior que 30 kg/m - est&aacute; au
mentando em todas as faixas et&aacute;rias. Nos Estados Unidos da Am&eacute;rica
, baseado em dados das tabelas de seguro de vida metropolitano, estima-se que, n
a d&eacute;cada de 80, 20% dos homens e 27% das mulheres estavam acima do peso i
deal e o Estudo Nacional de Exames de Sa&uacute;de e Nutri&ccedil;&atilde;o suge
re que esse aumento seria de 31% para homens e 35% para mulheres. Estimativas da
 d&eacute;cada de 90 s&atilde;o de que 58 milh&otilde;es de norte-americanos est
ariam obesos e 40% desta popula&ccedil;&atilde;o estar&aacute; obesa em 2025. At
ualmente, aproximadamente dois ter&ccedil;os encontram-se com sobrepeso ou obesi
dade<sup>12</sup>. </font></p>     ^cY#v24n1a11.htm##
01145000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704091100075002001300986#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#25#21#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Neste mesmo pa&iacute;s, calcula-se q
ue s&atilde;o gastos anualmente, com programas de emagrecimento, drogas para tra
tamento da obesidade e programas de condicionamento f&iacute;sico cerca de 33 bi
lh&otilde;es de d&oacute;lares, isso sem levar em conta os cerca de um bilh&atil
de;o de d&oacute;lares necess&aacute;rios para o processo que vai da pesquisa ao
 lan&ccedil;amento de cada nova droga para tratamento da obesidade. Para tratar 
as co-morbidades diretamente ligadas &agrave; obesidade, s&atilde;o gastos tr&ec
irc;s vezes mais (99 bilh&otilde;es de d&oacute;lares ao ano)<sup>16</sup>. Base
ado nestes n&uacute;meros, deduz-se que a obesidade &eacute; um problema de sa&u
acute;de p&uacute;blica com implica&ccedil;&otilde;es socioecon&ocirc;micas repr
esentativas e que t&ecirc;m propor&ccedil;&otilde;es epid&ecirc;micas. </font></
p>     ^cY#v24n1a11.htm##
00898000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704066400075002001300739#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#26#22#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Considerando-se o &iacute;ndice de ma
ssa corporal para definir obesidade, a Sociedade Americana de Cirurgia Bari&aacu
te;trica considera &iacute;ndice de at&eacute; 25 como normal(eutr&oacute;fico);
 entre 25 e 30 como sobrepeso; entre 30 e 35 como obesidade grau I; entre 35 e 4
0 como obesidade grau II e acima de 40 como obesidade grau III ou obesidade clin
icamente m&oacute;rbida"<sup>9</sup>. Defini&ccedil;&atilde;o mais ampla de obes
idade m&oacute;rbida deve obrigatoriamente incluir pacientes que tenham co-morbi
dade grave relacionada diretamente com a obesidade<sup>3</sup>. </font></p>     
^cY#v24n1a11.htm##
00753000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704051900075002001300594#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#27#23#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As co-morbidades associadas &agrave; 
obesidade s&atilde;o in&uacute;meras, podendo ser nomeadas em uma lista, na qual
 incluem-se: diabetes tipo II, hipertens&atilde;o arterial sist&ecirc;mica, card
iomiopatia hipertr&oacute;fica, hiperlipidemia, colelit&iacute;ase, apn&eacute;i
a do sono, hipoventila&ccedil;&atilde;o, artrite degenerativa, desajustes psicos
sociais, diversos tipos de neoplasias, dorsalgia cr&ocirc;nica<sup>1,10</sup>. <
/font></p>     ^cY#v24n1a11.htm##
01249000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704101500075002001301090#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#28#24#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os crit&eacute;rios para indica&ccedi
l;&atilde;o de tratamento cir&uacute;rgico para a obesidade foram definidos pelo
 Painel da Confer&ecirc;ncia de Desenvolvimento de Consenso do Instituto Naciona
l de Sa&uacute;de dos Estados Unidos, em 1991<sup>10</sup>, e incluem os pacient
es com &iacute;ndice de massa corporal maior que 40, pacientes com este &iacute;
ndice maior que 35 que apresentem co-morbidade cardiopulmonar grave ou diabetes 
severa e, ainda, pacientes que, avaliados por m&eacute;dico experiente em mat&ea
cute;ria de tratamento da obesidade, tenham pequena probabilidade de sucesso com
 medidas n&atilde;o cir&uacute;rgicas, demonstradas, por exemplo, por n&atilde;o
 conseguir redu&ccedil;&atilde;o de peso em programas reconhecidos de controle d
e peso ou por relut&acirc;ncia em participar destes programas (nestes pacientes,
 em especial, a indica&ccedil;&atilde;o n&atilde;o &eacute; formal, mas deve ser
 considerada). </font></p>     ^cY#v24n1a11.htm##
00866000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704063200075002001300707#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#29#25#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O tratamento cir&uacute;rgico para ob
esidade m&oacute;rbida &eacute; uma forma eficaz de manuten&ccedil;&atilde;o do 
controle ponderal por longo prazo<sup>7,14,15</sup>. Consegue-se perda sustentad
a durante 16 anos de cerca de 67% do peso em excesso<sup>5</sup>. H&aacute; tr&e
circ;s formas de tratamento cir&uacute;rgico da obesidade: os procedimentos rest
ritivos, os disabsortivos e os combinados (restri&ccedil;&atilde;o e disabsor&cc
edil;&atilde;o), cada qual com seus resultados e seus &iacute;ndices de complica
&ccedil;&otilde;es<sup>5</sup>. </font></p>     ^cY#v24n1a11.htm##
01520000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704128600075002001301361#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#30#26#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Sabe-se que os melhores resultados s&
atilde;o obtidos com os procedimentos combinados quando comparados com os purame
nte restritivos, apesar de apresentarem maiores &iacute;ndices de complica&ccedi
l;&otilde;es e mortalidade<sup>4,6</sup>. &Eacute; importante o acompanhamento d
os pacientes no p&oacute;s-operat&oacute;rio imediato e tardio para melhor avali
ar os resultados e complica&ccedil;&otilde;es poss&iacute;veis. A cirurgia bari&
aacute;trica mista envolve interven&ccedil;&atilde;o sobre o est&ocirc;mago que 
pode resultar em complica&ccedil;&otilde;es ou sequelas anat&ocirc;micas e/ou fu
ncionais correspondentes. Essas opera&ccedil;&otilde;es alteram de maneira signi
ficativa a fun&ccedil;&atilde;o secret&oacute;ria e o esvaziamento do est&ocirc;
mago e podem resultar em s&iacute;ndromes p&oacute;s-operat&oacute;rias: s&iacut
e;ndrome de dumping, gastrite de refluxo alcalino, de m&aacute; absor&ccedil;&at
ilde;o, estase em Y de Roux, al&ccedil;a aferente e eferente, &uacute;lcera p&ea
cute;ptica, colelit&iacute;ase e altera&ccedil;&otilde;es nutricionais (perda de
 peso, anemia, osteomal&aacute;cia e osteoporose, desnutri&ccedil;&atilde;o prot
&eacute;ica e vitam&iacute;nica)<sup>8</sup>. </font></p>     ^cY#v24n1a11.htm##
01156000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704092200075002001300997#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#31#27#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O sleeve g&aacute;strico ou gastrecto
mia vertical &eacute; um procedimento puramente restritivo que consiste na remo&
ccedil;&atilde;o da grande curvatura do est&ocirc;mago, iniciando a partir de 4 
a 6 cm do piloro at&eacute; o &acirc;ngulo esofagog&aacute;strico, deixando o re
servat&oacute;rio novo com formato tubular e alongado de volume entre 150 e 200 
ml. &Eacute; indicado para todos os tipos de pacientes obesos, sendo muito efica
z para pacientes super obesos, ou seja, aqueles que possuem &iacute;ndice de mas
sa corporal maior que 50 kg/m e para os que se alimentam de grande quantidade de
 comida a cada refei&ccedil;&atilde;o. &Eacute; um procedimento simples, sem ana
stomoses e com risco menor de complica&ccedil;&otilde;es quando comparado a outr
os procedimentos bari&aacute;tricos mais demorados e mais complexos<sup>13</sup>
. </font></p>     ^cY#v24n1a11.htm##
00634000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704040000075002001300475#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#32#28#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Como o objetivo da cirurgia bari&aacu
te;trica &eacute; alcan&ccedil;ar os melhores resultados com m&iacute;nimos efei
tos adversos, foi realizado, neste estudo retrospectivo, um levantamento das car
acter&iacute;sticas e dos resultados no p&oacute;s-operat&oacute;rio de paciente
s submetidos ao sleeve g&aacute;strico. </font></p>     ^cY#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#33#29#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010500075002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#34#30#article#91#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS </b></font></p>    
 ^cY#v24n1a11.htm##
00507000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704027300075002001300348#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#35#31#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O presente estudo foi realizado no Ho
spital de Caridade Irmandade Santa Casa de Miseric&oacute;rdia de Curitiba, PR, 
Brasil no per&iacute;odo de mar&ccedil;o de 2008 a mar&ccedil;o de 2010. </font>
</p>     ^cY#v24n1a11.htm##
00771000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704053700075002001300612#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#36#32#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s revis&atilde;o e aprova&c
cedil;&atilde;o do Comit&ecirc; de &Eacute;tica e Pesquisa da institui&ccedil;&a
tilde;o, foram revisados, retrospectivamente, os prontu&aacute;rios de 114 pacie
ntes submetidos &agrave; gastroplastia. Foram analisados os seguintes dados: g&e
circ;nero, idade, peso, altura, &iacute;ndice de massa corporal, co-morbidades a
ssociadas, tempo de internamento e evolu&ccedil;&atilde;o p&oacute;s-operat&oacu
te;ria imediata. </font></p>     ^cY#v24n1a11.htm##
01018000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704078400075002001300859#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#37#33#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Como crit&eacute;rios de inclus&atild
e;o, foram selecionados os pacientes com &iacute;ndice de massa corporal igual o
u superior a 40 kg/m ou &iacute;ndice entre 35 e 39 kg/m com co-morbidades encam
inhados das unidades b&aacute;sicas de sa&uacute;de, submetidos &agrave; gastrec
tomia por sleeve atrav&eacute;s do Sistema &Uacute;nico de Sa&uacute;de. Foram c
onsiderados crit&eacute;rios de exclus&atilde;o: aus&ecirc;ncia de prontu&aacute
;rio, prontu&aacute;rios incompletamente preenchidos e dados inconsistentes ou d
ivergentes entre o escrito no atendimento ambulatorial e hospitalar. Caso o paci
ente n&atilde;o se encaixasse em nenhum destes itens, ele era inclu&iacute;do no
 protocolo de pesquisa. </font></p>     ^cY#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#38#34#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010000075002001300175#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#39#35#article#91#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v24n1a11.htm##
01706000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704147200075002001301547#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#40#36#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Do total de 114 pacientes analisados,
 107 (93,8%) eram do g&ecirc;nero masculino, sendo que a idade m&eacute;dia foi 
de 38 anos (19 a 55). O &iacute;ndice de massa corporal m&eacute;dio foi de 45,9
 kg/m<sup>2</sup> (35 a 65). A principal co-morbidade associada foi a hipertens&
atilde;o arterial sist&ecirc;mica (63%), seguida de diabetes mellitus tipo 2 (23
%) e dislipidemia (15%). O tempo de internamento dos pacientes foi de tr&ecirc;s
 dias, sendo que permaneceram no hospital por mais tempo (m&aacute;ximo de 48 di
as) os poucos pacientes que necessitaram de cuidado hospitalar por mais tempo, s
eja por necessidade de terapia intensiva mais prolongada e/ou intercorr&ecirc;nc
ias ap&oacute;s a opera&ccedil;&atilde;o. Como evolu&ccedil;&atilde;o p&oacute;s
-operat&oacute;ria, 21% necessitaram de cuidados em unidade de terapia intensiva
 por no m&iacute;nimo 1 e no m&aacute;ximo 15 dias. Em rela&ccedil;&atilde;o aos
 &oacute;bitos, houve total de quatro (3,5%): dois por insufici&ecirc;ncia respi
rat&oacute;ria aguda - no 13º e 24º dias p&oacute;s-operat&oacute;rios; um por p
neumonia nosocomial no 16º dia; um desencadeado por s&iacute;ndrome de Fournier 
no 36º dia p&oacute;s-operat&oacute;rio. Todos os pacientes que evolu&iacute;ram
 com &oacute;bito possu&iacute;am &iacute;ndice de massa corporal maior que 60 k
g/m<sup>2 </sup>e apresentavam no m&iacute;nimo co-morbidade associada. </font><
/p>     ^cY#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#41#37#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#42#38#article#91#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O </b></font></p>  
   ^cY#v24n1a11.htm##
01096000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704086200075002001300937#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#43#39#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A obesidade pode ser considerada uma 
das doen&ccedil;as cr&ocirc;nicas mais importantes que atinge indiv&iacute;duos 
de todas as idades. Os resultados dos tratamentos cir&uacute;rgicos demonstram-s
e superiores na perda de peso em pacientes com obesidade moderada ou severa quan
do comparados aos resultados cl&iacute;nicos. Mesmo que os com &iacute;ndice de 
massa corporal muito elevado sejam beneficiados com outros procedimentos cir&uac
ute;rgicos destinados &agrave; perda de peso, o risco elevado de complica&ccedil
;&otilde;es p&oacute;s-operat&oacute;rias n&atilde;o os torna candidatos favor&a
acute;veis a tais opera&ccedil;&otilde;es. Assim, alguns procedimentos t&ecirc;m
 sido propostos para associar perda de peso efetiva com reduzido risco de compli
ca&ccedil;&otilde;es. </font></p>     ^cY#v24n1a11.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704044800075002001300523#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#44#40#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A gastrectomia vertical constitui um 
destes m&eacute;todos seguros e eficazes, apresentando baixa morbimortalidade, b
ons resultados p&oacute;s-operat&oacute;rios e baixo &iacute;ndice de complica&c
cedil;&otilde;es. Al&eacute;m disso, pode ser utilizado como tratamento inicial 
isolado ou secund&aacute;rio - por exemplo, ap&oacute;s falha de banda g&aacute;
strica. </font></p>     ^cY#v24n1a11.htm##
00778000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704054400075002001300619#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#45#41#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Mesmo representando uma pequena porce
ntagem no total das opera&ccedil;&otilde;es para perda de peso, h&aacute; a tend
&ecirc;ncia do sleeve g&aacute;strico ter seu uso cada vez mais frequente, uma v
ez que ele j&aacute; provou ser efetivo em perda consider&aacute;vel de peso ass
ociada &agrave; baixa morbimortalidade<sup>2</sup>. Assim, esta t&eacute;cnica e
st&aacute; sendo aceita e proposta por muitos como procedimento bari&aacute;tric
o isolado<sup>11</sup>. </font></p>     ^cY#v24n1a11.htm##
00488000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704025400075002001300329#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#46#42#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ainda assim, existe a necessidade de 
pesquisas mais detalhadas, principalmente ao longo prazo, para o encontro do m&e
acute;todo cir&uacute;rgico ideal para cada paciente. </font></p>     ^cY#v24n1a
11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#47#43#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010600075002001300181#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#48#44#article#91#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>   
  ^cY#v24n1a11.htm##
00530000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704029600075002001300371#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#49#45#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A gastrectomia vertical constitui-se 
em m&eacute;todo seguro e eficaz na perda de peso em obesos m&oacute;rbidos, nec
essitando de estudos ao longo prazo para que possa ser comparada com as demais t
&eacute;cnicas. </font></p>     ^cY#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#50#46#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#51#47#article#91#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v24n1a11.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704024500077002001300322#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#52#48#article#91#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Ali MR, Maguire MB,
 Wolfe BM. Assessment of obesity -related comorbidities: a novel scheme for eval
uating bariatric surgical patients. J Am Coll Surg 2006; 202 (1); 70-7.    ^cY#v
24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#53#49#article#91# </font></p>     ^cY
#v24n1a11.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704021000077002001300287#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#54#50#article#91#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Andriani AC, Neves 
TT. A gastroplastia em manga (Sleeve gastrectomy) e o Diabetes Mellitus. ABCD Ar
q Bras Cir Dig, 2008; 21 (3): 133-5.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#55#51#article#91# </font></p>     ^cY
#v24n1a11.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023400077002001300311#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#56#52#article#91#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 3. Balsiger BM, Murr M
M, Poggio JL, Sarr MG. Bariatric Surgery. Surgery for weight control in patients
 with morbid obesity. Med Clin North Am 2000; 84(2): 477-89.    ^cY#v24n1a11.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#57#53#article#91# </font></p>     ^cY
#v24n1a11.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704025800077002001300335#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#58#54#article#91#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Balsiger BM, Poggio 
JL, Mai J, Kelly KA, Sarr MG. Ten and more years after vertical banded gastropla
sty as primary operation for morbid obesity. J Gastrointest Surg, 2000;4(6):598-
605.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#59#55#article#91# </font></p>     ^cY
#v24n1a11.htm##
00408000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704016000077002001300237#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#60#56#article#91#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Benotti P, Burchard 
KW, Kelly JJ, Thayer BA. Obesity. Arch Surg, 2004; 139 (4):406-14.    ^cY#v24n1a
11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#61#57#article#91# </font></p>     ^cY
#v24n1a11.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704024200077002001300319#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#62#58#article#91#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 6. Buchwald H, Avidor 
Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery:
 a systematic review and metaanalysis. JAMA; 2004; 292 (14):1724-37.    ^cY#v24n
1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#63#59#article#91# </font></p>     ^cY
#v24n1a11.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704027500077002001300352#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#64#60#article#91#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 7. Christou NV, Sampal
is JS, Liberman, Look D, Auger S, McLean AP, MacLean LD. Surgery decreases long-
term mortality, morbidity, and health care use in morbidly obese patients. Ann S
urg, 2004,240:416-24.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#65#61#article#91# </font></p>     ^cY
#v24n1a11.htm##
00430000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704018200077002001300259#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#66#62#article#91#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Colquitt JL, Picot J
, Loveman E, Clegg AJ. 	Surgery for obesity. Cochrane Database Syst Rev, 2009; C
D003641.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#67#63#article#91# </font></p>     ^cY
#v24n1a11.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704022800077002001300305#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#68#64#article#91#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Gastrointestinal sur
gery for morbid obesity: National Institutes of Health Consensus Development Con
ference Statement. Am J Clin Nutr 1992; 55(2): 615-19.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#69#65#article#91# </font></p>     ^cY
#v24n1a11.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704027400078002001300352#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#70#66#article#91#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 10. Guh DP, Zhang W, 
Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities re
lated to obesity and overweight: a systematic review and meta-analysis. BMC Publ
ic Health 2009; 9:88.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#71#67#article#91# </font></p>     ^cY
#v24n1a11.htm##
00574000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704032500078002001300403#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#72#68#article#91#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 11. Lemos SLS, Doming
os TA, Vinha JM, Nadai AP, Vasconcellos CP, Ferragut CB. Nova proposta de tratam
ento cir&uacute;rgico da obesidade: gastrectomia vertical e bypass intestinal pa
rcial: resultados preliminares. Rev Bras Videocir, 2005; 3 (3): 131-142.    ^cY#
v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#73#69#article#91# </font></p>     ^cY
#v24n1a11.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704023000078002001300308#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#74#70#article#91#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 12. May J, 	Buckman E
. The role of disease management in the treatment and prevetion of obesity with 
associated comorbidities. Dis Manag 2007; 10 (3): 156-63.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#75#71#article#91# </font></p>     ^cY
#v24n1a11.htm##
00602000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704035300078002001300431#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#76#72#article#91#13#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 13. Picot J, Jones J,
 Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ. The clinical eff
ectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity
: a systematic review and economic evaluation. Health Technol Assess, 2009; 13 (
41): 1-190, 215-357.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#77#73#article#91# </font></p>     ^cY
#v24n1a11.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704027500078002001300353#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#78#74#article#91#14#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Rationale for the 
surgical treatment of morbid obesity. American Society of Bariatric Surgery (ASB
S), 2001. Dispon&iacute;vel em: <a href="http://www.asbs.com" target="_blank">ht
tp://www.asbs.com</a>.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#79#75#article#91# </font></p>     ^cY
#v24n1a11.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704030000078002001300378#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#80#76#article#91#15#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Thomusch O, Keck T
, Dobsch&uuml;tz EV, Wagner C, R&uuml;ckauer KD, Hopt UT. Risk factors for the i
ntermediate outcome of morbid obesity after laparoscopically placed adjustable g
astric banding. Am J Surg, 2005;189 (2):214-18.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#81#77#article#91# </font></p>     ^cY
#v24n1a11.htm##
00444000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704019500078002001300273#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#82#78#article#91#16#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 16. Wolf AM, Colditz 
GA. Current estimates of the economic cost of obesity in the United States. Obes
 Res. 1998; 6: 97-106.    ^cY#v24n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#83#79#article#91# </font></p>     ^cY
#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#84#80#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#85#81#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704019900075002001300274#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#86#82#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#note
1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0" ></a> Correspond&ecir
c;ncia:</b>    ^cY#v24n1a11.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004500075002001300120#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#87#83#article#91#<br> Alcides Jos&eac
ute; Branco Filho    ^cY#v24n1a11.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#88#84#article#91#<br>  e-mail: <a hre
f="mailto:ajbranco@terra.com.br">ajbranco@terra.com.br</a></font></p>     ^cY#v2
4n1a11.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011000075002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#89#85#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">   Recebido para publicação: 27/01/20
11    ^cY#v24n1a11.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004900075002001300124#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#90#86#article#91#<br>   Aceito para p
ublicação: 15/02/2011    ^cY#v24n1a11.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005900075002001300134#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#91#87#article#91#<br>   Fonte de fina
nciamento: n&atilde;o h&aacute;    ^cY#v24n1a11.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006900075002001300144#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#92#88#article#91#<br> Conflito de int
eresses: n&atilde;o h&aacute;</font></p>     ^cY#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#93#89#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#94#90#article#91#<p>&nbsp;</p>     ^c
Y#v24n1a11.htm##
00477000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704024300075002001300318#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a11.htm#S#p#95#91#article#91#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Servi&ccedil;o 
de Cirurgia Geral e Obesidade do Hospital de Caridade Irmandade Santa Casa de Mi
seric&oacute;rdia de Curitiba, PR, Brasil. </font></p>     ^cY#v24n1a11.htm##
00622000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100014000760100018000900100
01700108012010800125030001500233065000900248064000500257031000400262032000200266
014000500268865000900273002001300282035001000295801001500305#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a11.htm#S#c#96#1#article#16#1#^rND^sAli^nMR#^rND^sMag
uire^nMB#^rND^sWolfe^nBM.#Assessment of obesity -related comorbidities: a novel 
scheme for evaluating bariatric surgical patients^len#J Am Coll Surg#20060000#20
06#202#1#70-7#20110300#v24n1a11.htm#1072-7515#J Am Coll Surg##
00533000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100019000760100016000950120
07200111030002300183710000200206065000900208064000500217031000300222032000200225
014000600227865000900233002001300242#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a11.htm#S#c#97#2#article#16#2#^rND^sAndriani^nAC#^rND^sNeves^nTT#A gastroplas
tia em manga (Sleeve gastrectomy) e o Diabetes Mellitus^lpt#ABCD Arq Bras Cir Di
g,#2#20080000#2008#21#3#133-5#20110300#v24n1a11.htm##
00632000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100019000760100015000950100
01700110010001500127012008200142030001800224065000900242064000500251031000300256
032000200259014000700261865000900268002001300277035001000290801001800300#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#c#98#3#article#16#3#^rND^sBalsi
ger^nBM#^rND^sMurr^nMM#^rND^sPoggio^nJL#^rND^sSarr^nMG#Bariatric Surgery: Surger
y for weight control in patients with morbid obesity^len#Med Clin North Am#20000
000#2000#84#2#477-89#20110300#v24n1a11.htm#0025-7125#Med Clin North Am##
00639000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100019000760100017000950100
01300112010001600125010001500141012009800156030002100254710000200275065000900277
064000500286031000200291032000200293014000800295865000900303002001300312#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#c#99#4#article#16#4#^rND^sBalsi
ger^nBM#^rND^sPoggio^nJL#^rND^sMai^nJ#^rND^sKelly^nKA#^rND^sSarr^nMG#Ten and mor
e years after vertical banded gastroplasty as primary operation for morbid obesi
ty^len#J Gastrointest Surg,#2#20000000#2000#4#6#598-605#20110300#v24n1a11.htm##
00522000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01600113010001700129012001200146030001100158710000200169065000900171064000500180
031000400185032000200189014000700191865000900198002001300207#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a11.htm#S#c#100#5#article#16#5#^rND^sBenotti^nP#^rND^
sBurchard^nKW#^rND^sKelly^nJJ#^rND^sThayer^nBA#Obesity^len#Arch Surg,#2#20040000
#2004#139#4#406-14#20110300#v24n1a11.htm##
00657000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01900111010001700130010001600147010001800163010001900181012006000200030000600260
71000020026606500090026806400050027703100040028203200030028601400080028986500090
0297002001300306#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#c#101#6
#article#16#6#^rND^sBuchwald^nH#^rND^sAvidor^nY#^rND^sBraunwald^nE#^rND^sJensen^
nMD#^rND^sPories^nW#^rND^sFahrbach^nK#^rND^sSchoelles^nK#Bariatric surgery: a sy
stematic review and metaanalysis^len#JAMA;#2#20040000#2004#292#14#1724-37#201103
00#v24n1a11.htm##
00709000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100019000960100
01500115010001400130010001500144010001700159010001900176012010100195030000900296
06500090030506400050031403100040031901400070032386500090033000200130033903500100
0352801000900362#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#c#102#7
#article#16#7#^rND^sChristou^nNV#^rND^sSampalis^nJS#^rND^sLiberman#^rND^sLook^nD
#^rND^sAuger^nS#^rND^sMcLean^nAP#^rND^sMacLean^nLD.#Surgery decreases long-term 
mortality, morbidity, and health care use in morbidly obese patients^len#Ann Sur
g#20040000#2004#240#416-24#20110300#v24n1a11.htm#0003-4932#Ann Surg##
00486000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160019000770160015000960160
01700111016001700128018002400145062002700169065000900196064000500205865000900210
002001300219#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#c#103#8#art
icle#16#8#^rND^sColquitt^nJL#^rND^sPicot^nJ#^rND^sLoveman^nE#^rND^sClegg^nAJ.#Su
rgery for obesity^len#Cochrane Database Syst Rev#20090000#2009#20110300#v24n1a11
.htm##
00553000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750120122000770300015001990650
00900214064000500223031000300228032000200231014000700233865000900240002001300249
035001000262801001500272#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S
#c#104#9#article#16#9#Gastrointestinal surgery for morbid obesity: National Inst
itutes of Health Consensus Development Conference Statement^len#Am J Clin Nutr#1
9920000#1992#55#2#615-19#20110300#v24n1a11.htm#0002-9165#Am J Clin Nutr##
00662000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930100
01800108010001600126010002100142010001500163012010900178030001800287710000200305
065000900307064000500316031000200321014000300323865000900326002001300335#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#c#105#10#article#16#10#^rND^sGu
h^nDP#^rND^sZhang^nW#^rND^sBansback^nN#^rND^sAmarsi^nZ#^rND^sBirmingham^nCL#^rND
^sAnis^nAH#The incidence of co-morbidities related to obesity and overweight: a 
systematic review and meta-analysis^len#BMC Public Health#2#20090000#2009#9#88#2
0110300#v24n1a11.htm##
00715000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01600115010001600131010002300147010001900170012013100189030001900320710000200339
06500090034106400050035003100020035503200020035701400080035986500090036700200130
0376#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#c#106#11#article#16
#11#^rND^sLemos^nSLS#^rND^sDomingos^nTA#^rND^sVinha^nJM#^rND^sNadai^nAP#^rND^sVa
sconcellos^nCP#^rND^sFerragut^nCB#Nova proposta de tratamento cirúrgico da obesi
dade: gastrectomia vertical e bypass intestinal parcial: resultados preliminares
^lpt#Rev Bras Videocir,#2#20050000#2005#3#3#131-142#20110300#v24n1a11.htm##
00554000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100017000920120
10700109030001000216710000200226065000900228064000500237031000300242032000200245
014000700247865000900254002001300263#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a11.htm#S#c#107#12#article#16#12#^rND^sMay^nJ#^rND^sBuckman^nE#The role of di
sease management in the treatment and prevetion of obesity with associated comor
bidities^len#Dis Manag#2#20070000#2007#10#3#156-63#20110300#v24n1a11.htm##
00821000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01900109010002500128010001700153010001600170010001700186012014600203030002200349
06500090037106400050038003100030038503200030038801400060039101400080039786500090
0405002001300414035001000427801002200437#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a11.htm#S#c#108#13#article#16#13#^rND^sPicot^nJ#^rND^sJones^nJ#^rND^sColq
uitt^nJL#^rND^sGospodarevskaya^nE#^rND^sLoveman^nE#^rND^sBaxter^nL#^rND^sClegg^n
AJ.#The clinical effectiveness and cost-effectiveness of bariatric (weight loss)
 surgery for obesity: a systematic review and economic evaluation^len#Health Tec
hnol Assess#20090000#2009#13#41#1-190#215-357#20110300#v24n1a11.htm#1366-5278#He
alth Technol Assess##
00457000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180059000790620045001380650
00900183064000500192037002000197865000900217002001300226#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a11.htm#S#c#109#14#article#16#14#Rationale for the surgic
al treatment of morbid obesity^len#American Society of Bariatric Surgery (ASBS)#
20010000#2001#http://www.asbs.com#20110300#v24n1a11.htm##
00690000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
02000111010001600131010001900147010001500166012012100181030001100302710000200313
06500090031506400050032403100040032903200020033301400070033586500090034200200130
0351#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a11.htm#S#c#110#15#article#16
#15#^rND^sThomusch^nO#^rND^sKeck^nT#^rND^sDobschütz^nEV#^rND^sWagner^nC#^rND^sRü
ckauer^nKD#^rND^sHopt^nUT#Risk factors for the intermediate outcome of morbid ob
esity after laparoscopically placed adjustable gastric banding^len#Am J Surg,#2#
20050000#2005#189#2#214-18#20110300#v24n1a11.htm##
00538000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940120
07500112030000900187065000900196064000500205031000200210014000700212865000900219
002001300228035001000241801000900251#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a11.htm#S#c#111#16#article#16#16#^rND^sWolf^nAM#^rND^sColditz^nGA#Current est
imates of the economic cost of obesity in the United States^len#Obes Res#1998000
0#1998#6#97-106#20110300#v24n1a11.htm#1071-7323#Obes Res##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#o#1#1#article#1
#20110411#103907#v24n1a12.htm#151##
03935000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000270011303100030014003200020014306500090014501400090015403500100016301201510
01730120131003240100023004550100028004780100027005060100020005330100031005530831
23500584085001001819085002501829085004301854085003301897083114701930085001003077
08500240308708500380311108500300314905800780317911700080325707200030326511200090
3268111001103277114000903288113001103297002001303308#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a12.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#12#ABCD0
60#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f55^l58#0102-6720#O modelo exper
imental de carcinogênese gástrica induzido por n-methyl-n-nitrosourea em ratos F
344 e camundongos C3H é válido para os ratos Wistar?^lpt#Experimental model of g
astric carcinogenesis with N-methyl-N-nitrosourea for F344 rats and C3H mices is
 valid for Wistar rats?^len#^rND^nLissandro^sTarso#^rND^nFabíola Schons^sMeyer#^
rND^nMarta Giotti^sCioato#^rND^nLuíse^sMeurer#^rND^nCarlos Cauduro^sSchirmer#^lp
t^aINTRODUÇÃO: O N-metil-N-nitrosourea (MNU) tem ação cancerígena direta, induzi
ndo tumores em várias espécies em uma variedade de órgãos, incluindo o estômago 
de ratos. Tratamento do MNU na água de beber por 25-42 semanas, seletivamente, i
nduz carcinoma gástrico glandular de ratos F344 e camundongos C3H. OBJETIVO: Est
abelecer um modelo experimental para indução seletiva de câncer no estômago glan
dular de ratos Wistar com MNU. MÉTODOS: Um total de 48 ratos Wistar machos com o
ito semanas, foram utilizados no presente estudo. MNU (Sigma-Aldrich) foi dissol
vido em DMSO e liberada água potável ad libitum por um período variando de 16 a 
70 semanas. Após 16 semanas, quatro ratos foram selecionados aleatoriamente e mo
rtos. Depois, de seis em seis semanas, quatro animais também foram mortos até 70
 semanas. RESULTADOS: A taxa de sobrevivência foi superior a 90%. Ocorreu a indu
ção de dois adenocarcinomas, um carcinoma espinocelular e um sarcoma. A incidênc
ia de adenocarcinoma gástrico foi de 4,5% (0,5 a 15). CONCLUSÕES: O modelo exper
imental de carcinogênese gástrica em ratos Wistar, utilizando MNU dissolvido na 
água, não mostrou viabilidade prática neste estudo, devido à baixa taxa de adeno
carcinoma gástrico que ocorreu.#^ddecs^i1#^tm^lpt^kRatos Wistar^i1#^tm^lpt^kMarc
adores biológicos de tumor^i1#^tm^lpt^kNeoplasias gástricas^i1#^len^aBACKGROUND:
 The N-methyl-N-nitrosourea (MNU) is a direct acting carcinogen, inducing tumors
 in several species in a variety of organs, including stomach of rats. Treatment
 of MNU in the drinking water for 25-42 weeks selectively induced glandular gast
ric carcinoma in F344 rats and C3H mice. AIM: To establish an experimental model
 for selective MNU induction of glandular stomach cancer in Wistar rats. METHODS
: A total of 48 males eight-week-old Wistar rats were used in the present study.
 MNU (Sigma-Aldrich) was dissolved in DMSO and provided as the drinking water ad
 libitum for a period ranging from 16 to 70 weeks. After 16 weeks, four rats wer
e randomly selected and killed. After every six weeks four animals were killed u
ntil 70 weeks. RESULTS: Survival rate was higher than 90%. It had the induction 
of two adenocarcinomas, one squamous cell carcinoma and one sarcoma. The inciden
ce of gastric adenocarcinoma was 4.5% (0.5 to 15). CONCLUSIONS: The experimental
 model of gastric carcinogenesis in Wistar rats, using MNU dissolved in water, s
howed not practice viability in this study due to the low rate of gastric adenoc
arcinoma.#^ddecs^i2#^tm^len^kWistar Rats^i2#^tm^len^kTumor markers, biological^i
2#^tm^len^kStomach neoplasms^i2#Hospital de Clínicas de Porto Alegre^dFundo de I
ncentivo à Pesquisa e Eventos#vancouv#22#20101029#29/10/2010#20101221#21/12/2010
#v24n1a12.htm##
04019000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000270011303100030014003200020014306500090014501400090015403500100016301201580
01730120138003310100023004690100028004920100027005200100020005470100031005670831
27000598085001001868085002501878085004301903085003301946083118201979085001003161
08500240317108500380319508500300323305800780326311700080334107200030334911200090
3352111001103361114000903372113001103381002001303392#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a12.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#12#ABCD0
60#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f55^l58#0102-6720#<b>O modelo ex
perimental de carcinogênese gástrica induzido por n-methyl-n-nitrosourea em rato
s F344 e camundongos C3H é válido para os ratos Wistar?</b>^lpt#<b>Experimental 
model of gastric carcinogenesis with N-methyl-N-nitrosourea for F344 rats and C3
H mices is valid for Wistar rats?</b>^len#^rND^nLissandro^sTarso#^rND^nFabíola S
chons^sMeyer#^rND^nMarta Giotti^sCioato#^rND^nLuíse^sMeurer#^rND^nCarlos Cauduro
^sSchirmer#^lpt^a<b>INTRODUÇÃO:</b> O N-metil-N-nitrosourea (MNU) tem ação cance
rígena direta, induzindo tumores em várias espécies em uma variedade de órgãos, 
incluindo o estômago de ratos. Tratamento do MNU na água de beber por 25-42 sema
nas, seletivamente, induz carcinoma gástrico glandular de ratos F344 e camundong
os C3H. <b>OBJETIVO:</b> Estabelecer um modelo experimental para indução seletiv
a de câncer no estômago glandular de ratos Wistar com MNU. <b>MÉTODOS:</b> Um to
tal de 48 ratos Wistar machos com oito semanas, foram utilizados no presente est
udo. MNU (Sigma-Aldrich) foi dissolvido em DMSO e liberada água potável ad libit
um por um período variando de 16 a 70 semanas. Após 16 semanas, quatro ratos for
am selecionados aleatoriamente e mortos. Depois, de seis em seis semanas, quatro
 animais também foram mortos até 70 semanas. <b>RESULTADOS: </b>A taxa de sobrev
ivência foi superior a 90%. Ocorreu a indução de dois adenocarcinomas, um carcin
oma espinocelular e um sarcoma. A incidência de adenocarcinoma gástrico foi de 4
,5% (0,5 a 15). <b>CONCLUSÕES:</b> O modelo experimental de carcinogênese gástri
ca em ratos Wistar, utilizando MNU dissolvido na água, não mostrou viabilidade p
rática neste estudo, devido à baixa taxa de adenocarcinoma gástrico que ocorreu.
#^ddecs^i1#^tm^lpt^kRatos Wistar^i1#^tm^lpt^kMarcadores biológicos de tumor^i1#^
tm^lpt^kNeoplasias gástricas^i1#^len^a<b>BACKGROUND:</b> The N-methyl-N-nitrosou
rea (MNU) is a direct acting carcinogen, inducing tumors in several species in a
 variety of organs, including stomach of rats. Treatment of MNU in the drinking 
water for 25-42 weeks selectively induced glandular gastric carcinoma in F344 ra
ts and C3H mice. <b>AIM:</b> To establish an experimental model for selective MN
U induction of glandular stomach cancer in Wistar rats. <b>METHODS: </b>A total 
of 48 males eight-week-old Wistar rats were used in the present study. MNU (Sigm
a-Aldrich) was dissolved in DMSO and provided as the drinking water ad libitum f
or a period ranging from 16 to 70 weeks. After 16 weeks, four rats were randomly
 selected and killed. After every six weeks four animals were killed until 70 we
eks. <b>RESULTS:</b> Survival rate was higher than 90%. It had the induction of 
two adenocarcinomas, one squamous cell carcinoma and one sarcoma. The incidence 
of gastric adenocarcinoma was 4.5% (0.5 to 15). <b>CONCLUSIONS: </b>The experime
ntal model of gastric carcinogenesis in Wistar rats, using MNU dissolved in wate
r, showed not practice viability in this study due to the low rate of gastric ad
enocarcinoma.#^ddecs^i2#^tm^len^kWistar Rats^i2#^tm^len^kTumor markers, biologic
al^i2#^tm^len^kStomach neoplasms^i2#Hospital de Clínicas de Porto Alegre^dFundo 
de Incentivo à Pesquisa e Eventos#vancouv#22#20101029#29/10/2010#20101221#21/12/
2010#v24n1a12.htm##
04097000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000260013103100030015703200020016006500090016201400090017103500100
01800120151001900120131003410100023004720100028004950100027005230100020005500100
03100570083125300601085001001854085002501864085004301889085003301932083116101965
08500100312608500240313608500380316008500300319805800780322811700080330607200030
3314112000903317111001103326114000903337113001103346002001303357008008903370#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#l#4#1#article#1#^mjan./mar.
^a2011#oa#pt#br1.1#1#4.0#ilus#tab#12#ABCD060#nd#ABCD, arq. bras. cir. dig#24#1#2
0110300#^f55^l58#0102-6720#O modelo experimental de carcinogênese gástrica induz
ido por n-methyl-n-nitrosourea em ratos F344 e camundongos C3H é válido para os 
ratos Wistar?^lpt#Experimental model of gastric carcinogenesis with N-methyl-N-n
itrosourea for F344 rats and C3H mices is valid for Wistar rats?^len#^rND^nLissa
ndro^sTarso#^rND^nFabíola Schons^sMeyer#^rND^nMarta Giotti^sCioato#^rND^nLuíse^s
Meurer#^rND^nCarlos Cauduro^sSchirmer#^lpt^aINTRODUÇÃO: O N-metil-N-nitrosourea 
(MNU) tem ação cancerígena direta, induzindo tumores em várias espécies em uma v
ariedade de órgãos, incluindo o estômago de ratos. Tratamento do MNU na água de 
beber por 25-42 semanas, seletivamente, induz carcinoma gástrico glandular de ra
tos F344 e camundongos C3H. OBJETIVO: Estabelecer um modelo experimental para in
dução seletiva de câncer no estômago glandular de ratos Wistar com MNU. MÉTODOS:
 Um total de 48 ratos Wistar machos com oito semanas, foram utilizados no presen
te estudo. MNU (Sigma-Aldrich) foi dissolvido em DMSO e liberada água potável ad
 libitum por um período variando de 16 a 70 semanas. Após 16 semanas, quatro rat
os foram selecionados aleatoriamente e mortos. Depois, de seis em seis semanas, 
quatro animais também foram mortos até 70 semanas. RESULTADOS: A taxa de sobrevi
vência foi superior a 90 por cento. Ocorreu a indução de dois adenocarcinomas, u
m carcinoma espinocelular e um sarcoma. A incidência de adenocarcinoma gástrico 
foi de 4,5 por cento (0,5 a 15). CONCLUSÕES: O modelo experimental de carcinogên
ese gástrica em ratos Wistar, utilizando MNU dissolvido na água, não mostrou via
bilidade prática neste estudo, devido à baixa taxa de adenocarcinoma gástrico qu
e ocorreu.#^ddecs^i1#^tm^lpt^kRatos Wistar^i1#^tm^lpt^kMarcadores biológicos de 
tumor^i1#^tm^lpt^kNeoplasias gástricas^i1#^len^aBACKGROUND: The N-methyl-N-nitro
sourea (MNU) is a direct acting carcinogen, inducing tumors in several species i
n a variety of organs, including stomach of rats. Treatment of MNU in the drinki
ng water for 25-42 weeks selectively induced glandular gastric carcinoma in F344
 rats and C3H mice. AIM: To establish an experimental model for selective MNU in
duction of glandular stomach cancer in Wistar rats. METHODS: A total of 48 males
 eight-week-old Wistar rats were used in the present study. MNU (Sigma-Aldrich) 
was dissolved in DMSO and provided as the drinking water ad libitum for a period
 ranging from 16 to 70 weeks. After 16 weeks, four rats were randomly selected a
nd killed. After every six weeks four animals were killed until 70 weeks. RESULT
S: Survival rate was higher than 90 percent. It had the induction of two adenoca
rcinomas, one squamous cell carcinoma and one sarcoma. The incidence of gastric 
adenocarcinoma was 4.5 percent (0.5 to 15). CONCLUSIONS: The experimental model 
of gastric carcinogenesis in Wistar rats, using MNU dissolved in water, showed n
ot practice viability in this study due to the low rate of gastric adenocarcinom
a.#^ddecs^i2#^tm^len^kWistar Rats^i2#^tm^len^kTumor markers, biological^i2#^tm^l
en^kStomach neoplasms^i2#Hospital de Clínicas de Porto Alegre^dFundo de Incentiv
o à Pesquisa e Eventos#vancouv#22#20101029#29/10/2010#20101221#21/12/2010#v24n1a
12.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67
202011000100012##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011900074002001300193#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#5#1#article#125#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b></
font></p>     ^cY#v24n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#6#2#article#125#<p>&nbsp;</p>     ^cY
#v24n1a12.htm##
00517000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704028400074002001300358#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#7#3#article#125#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>O modelo experi
mental de carcinog&ecirc;nese g&aacute;strica induzido por n-methyl-n-nitrosoure
a em ratos F344 e camundongos C3H &eacute; v&aacute;lido para os ratos Wistar? <
/b></font></p>     ^cY#v24n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#8#4#article#125#<p>&nbsp;</p>     ^cY
#v24n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#9#5#article#125#<p>&nbsp;</p>     ^cY
#v24n1a12.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020200075002001300277#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#10#6#article#125#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Lissandro Tarso; Fab&iacute;ola Sc
hons Meyer; Marta Giotti Cioato; Lu&iacute;se Meurer; Carlos Cauduro Schirmer </
b></font></p>     ^cY#v24n1a12.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#11#7#article#125#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#12#8#article#125#<p>&nbsp;</p>     ^c
Y#v24n1a12.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#13#9#article#125#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a12.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#14#10#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a12.htm##
00699000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046400076002001300540#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#15#11#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O:</b> O N
-metil-N-nitrosourea (MNU) tem a&ccedil;&atilde;o cancer&iacute;gena direta, ind
uzindo tumores em v&aacute;rias esp&eacute;cies em uma variedade de &oacute;rg&a
tilde;os, incluindo o est&ocirc;mago de ratos. Tratamento do MNU na &aacute;gua 
de beber por 25-42 semanas, seletivamente, induz carcinoma g&aacute;strico gland
ular de ratos F344 e camundongos C3H.    ^cY#v24n1a12.htm##
00406000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017100076002001300247#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#16#12#article#125#<br>   <b>OBJETIVO:
</b> Estabelecer um modelo experimental para indu&ccedil;&atilde;o seletiva de c
&acirc;ncer no est&ocirc;mago glandular de ratos Wistar com MNU.    ^cY#v24n1a12
.htm##
00685000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045000076002001300526#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#17#13#article#125#<br>   <b>M&Eacute;
TODOS:</b> Um total de 48 ratos Wistar machos com oito semanas, foram utilizados
 no presente estudo. MNU (Sigma-Aldrich) foi dissolvido em DMSO e liberada &aacu
te;gua pot&aacute;vel ad libitum por um per&iacute;odo variando de 16 a 70 seman
as. Ap&oacute;s 16 semanas, quatro ratos foram selecionados aleatoriamente e mor
tos. Depois, de seis em seis semanas, quatro animais tamb&eacute;m foram mortos 
at&eacute; 70 semanas.     ^cY#v24n1a12.htm##
00494000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025900076002001300335#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#18#14#article#125#<br>   <b>RESULTADO
S: </b>A taxa de sobreviv&ecirc;ncia foi superior a 90%. Ocorreu a indu&ccedil;&
atilde;o de dois adenocarcinomas, um carcinoma espinocelular e um sarcoma. A inc
id&ecirc;ncia de adenocarcinoma g&aacute;strico foi de 4,5% (0,5 a 15).     ^cY#
v24n1a12.htm##
00542000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030700076002001300383#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#19#15#article#125#<br>   <b>CONCLUS&O
tilde;ES:</b> O modelo experimental de carcinog&ecirc;nese g&aacute;strica em ra
tos Wistar, utilizando MNU dissolvido na &aacute;gua, n&atilde;o mostrou  viabil
idade pr&aacute;tica neste estudo, devido &agrave; baixa taxa de adenocarcinoma 
g&aacute;strico que ocorreu.</font></p>     ^cY#v24n1a12.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020700076002001300283#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#20#16#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b> Ratos Wistar. Ma
rcadores biol&oacute;gicos de tumor. Neoplasias g&aacute;stricas. </font></p> <h
r size="1" noshade>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#21#17#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#22#18#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#23#19#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O </b></fo
nt></p>     ^cY#v24n1a12.htm##
00941000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070600076002001300782#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#24#20#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Desde o primeiro relato da produ&cce
dil;&atilde;o experimental de adenocarcinomas do est&ocirc;mago glandular de rat
os com N-metil-N';-nitro-N nitrosoguanidina (MNNG)<sup>16</sup>, muitos outros m
am&iacute;feros, t&ecirc;m se mostrado sens&iacute;veis a essa subst&acirc;ncia 
cancer&iacute;gena, incluindo hamsters, fur&otilde;es e c&atilde;es<sup>2,3</sup
>. N-metil-N-nitrosourea (MNU) tem a&ccedil;&atilde;o cancer&iacute;gena direta,
 induzindo tumores em v&aacute;rias esp&eacute;cies e em variedade de &oacute;rg
&atilde;os, incluindo o sistema nervoso central, est&ocirc;mago, intestino, rim 
e pele<sup>1,4,9,10</sup>. </font></p>     ^cY#v24n1a12.htm##
00969000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073400076002001300810#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#25#21#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O camundongo e rato s&atilde;o parti
cularmente &uacute;teis para estudos de esp&eacute;cies de carcinog&ecirc;nese, 
devido &agrave; disponibilidade de mutantes e linhagens quim&eacute;ricas transg
&ecirc;nicas. O uso do MNU na &aacute;gua de beber por 25-42 semanas seletivamen
te induz carcinoma g&aacute;strico glandular de ratos F344 e camundongos C3H<sup
>5,8,11,13,14,18,21</sup>.Esses modelos animais t&ecirc;m sido amplamente utiliz
ados n&atilde;o apenas para investigar a patog&ecirc;nese da carcinog&ecirc;nese
 g&aacute;strica, mas tamb&eacute;m para identificar poss&iacute;veis promotores
 de tumor e agentes quimiopreventivos<sup>11,14</sup>. </font></p>     ^cY#v24n1
a12.htm##
00561000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032600076002001300402#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#26#22#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O objetivo do presente estudo foi es
tabelecer um modelo experimental para indu&ccedil;&atilde;o MNU seletiva de c&ac
irc;ncer no est&ocirc;mago glandular de ratos Wistar e descrever o tempo para ob
ter n&iacute;vel de profundidade do tumor (T). </font></p>     ^cY#v24n1a12.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#27#23#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#28#24#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font></p>    
 ^cY#v24n1a12.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#29#25#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>O delineamento experimental</b> <
/font></p>     ^cY#v24n1a12.htm##
01459000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122400076002001301300#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#30#26#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Um total de 48 ratos Wistar machos d
e oito semanas foram acomodados em gaiolas pl&aacute;sticas (tr&ecirc;s ratos/ga
iola) em ambiente com ar-condicionado e ciclo de 12 horas a claro e 12 horas no 
escuro. Foram aclimatados por duas semanas antes do in&iacute;cio dos experiment
os.MNU (Sigma-Aldrich) foi dissolvido em dimetilsulf&oacute;xido (DMSO) e estoca
do em lugar escuro e fresco. A solu&ccedil;&atilde;o foi dilu&iacute;da a 200 pp
m com &aacute;gua imediatamente antes de usar (tr&ecirc;s vezes por semana), e l
iberada como &aacute;gua pot&aacute;vel ad libitum em garrafas opacas para prote
&ccedil;&atilde;o contra fot&oacute;lise por 16 a 70 semanas. Ra&ccedil;&atilde;
o regular (Nuvilab CR-1 - Nuvital S/A) foi dispon&iacute;vel ad libitum<i>. </i>
Ap&oacute;s 16 semanas, quatro ratos foram selecionados aleatoriamente e mortos,
 e a seguir a cada outras seis semanas quatro animais eram tamb&eacute;m mortos 
at&eacute; 70ª. Semana. O protocolo do estudo foi aprovado pelo Comit&ecirc; de 
&Eacute;tica do Grupo de Pesquisa e P&oacute;s-Gradua&ccedil;&atilde;o do Hospit
al de Cl&iacute;nicas de Porto Alegre, Porto Alegre, RS, Brasil. </font></p>    
 ^cY#v24n1a12.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012900076002001300205#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#31#27#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Os crit&eacute;rios de exclus&ati
lde;o</b> </font></p>     ^cY#v24n1a12.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022500076002001300301#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#32#28#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os animais que sobreviveram menos de
 16 semanas, foram exclu&iacute;dos. Necr&oacute;psias foram realizadas em todos
 os animais que morreram. </font></p>     ^cY#v24n1a12.htm##
00365000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013000076002001300206#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#33#29#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>A an&aacute;lise histopatol&oacut
e;gica</b> </font></p>     ^cY#v24n1a12.htm##
00712000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047700076002001300553#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#34#30#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os est&ocirc;magos excisados foram f
ixados em formalina tamponada, cortado em cerca de oito bandas, e rotineiramente
 processados para inclus&atilde;o em parafina. Os tecidos foram corados com HE p
ara avalia&ccedil;&atilde;o histopatol&oacute;gica de desenvolvimento da les&ati
lde;o. Les&otilde;es neopl&aacute;sicas foram classificadas como adenocarcinomas
, carcinoma espinocelular e sarcomas. </font></p>     ^cY#v24n1a12.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012400076002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#35#31#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>An&aacute;lise estat&iacute;stica
 </b></font></p>     ^cY#v24n1a12.htm##
00597000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036200076002001300438#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#36#32#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Intervalo de confian&ccedil;a para p
ropor&ccedil;&otilde;es utilizando o M&eacute;todo Binomial foi aplicado para c&
aacute;lculo da incid&ecirc;ncia do adenocarcinoma g&aacute;strico. Teste <i>t <
/i>de Student foi realizado para m&eacute;dias das vari&aacute;veis quantitativa
s. </font></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#37#33#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#38#34#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS </b></font></p>     ^c
Y#v24n1a12.htm##
01008000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077300076002001300849#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#39#35#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Um total de 48 ratos foi usado. Quat
ro animais morreram antes das 16 semanas iniciais e foram submetidos &agrave; au
t&oacute;psia. Estas mortes foram causadas por pneumonia, e eles foram exclu&iac
ute;dos do n&uacute;mero efetivo final. As taxas de sobreviv&ecirc;ncia foram su
periores a 90%. O peso m&eacute;dio inicial foi de 346 ± 33 g. O ganho de peso c
orporal por semana durante o seguimento foi menor nos ratos que desenvolveram c&
acirc;ncer do que naqueles que n&atilde;o o fizeram (2.1 g x 3,2 g, p=0,07). Um 
total de 44 animais foram mortos entre a 16º. e 70º. semana. Caracter&iacute;sti
cas do n&uacute;mero efetivo de ratos est&atilde;o resumidos na <a href="#tab1">
Tabela 1</a>. </font></p>     ^cY#v24n1a12.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#40#36#article#125#<p><a name="tab1"><
/a></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#41#37#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#42#38#article#125#<p align="center"><
img src="/img/revistas/abcd/v24n1/a12tab1.jpg"></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#43#39#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012600076002001300202#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#44#40#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Achados macro e microsc&oacute;pi
cos</b></font></p>     ^cY#v24n1a12.htm##
01283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104800076002001301124#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#45#41#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A partir de semana 52ª. at&eacute; a
 70ª. foi encontrado infiltrado inflamat&oacute;rio difuso na mucosa g&aacute;st
rica (<a href="#fig1">Figura 1</a>). Metaplasia intestinal n&atilde;o foi encont
rada no est&ocirc;mago de qualquer rato neste experimento. Em 64 semanas, uma ex
tensa les&atilde;o na parede anterior do est&ocirc;mago foi encontrada e an&aacu
te;lise histopatol&oacute;gica revelou ser um sarcoma. Em 70 semanas, um tumor a
drenal foi encontrado. No pr&eacute;-est&ocirc;mago dos animais, apenas um carci
noma epiderm&oacute;ide foi encontrado na semana 22. Nas semanas 52 e 70, dois a
denocarcinomas bem diferenciados foram observados no est&ocirc;mago glandular. O
s tumores invadiram a muscular pr&oacute;pria superficialmente (T2a) (<a href="#
fig2">Figura 2</a>). A incid&ecirc;ncia de adenocarcinoma g&aacute;strico foi de
 4,5% (0,5 a 15). Os achados histopatol&oacute;gicos para o est&ocirc;mago s&ati
lde;o resumidos na <a href="#tab2">Tabela 2</a>. </font></p>     ^cY#v24n1a12.ht
m##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#46#42#article#125#<p><a name="fig1"><
/a></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#47#43#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#48#44#article#125#<p align="center"><
img src="/img/revistas/abcd/v24n1/a12fig1.jpg" ></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#49#45#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#50#46#article#125#<p><a name="fig2"><
/a></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#51#47#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#52#48#article#125#<p align="center"><
img src="/img/revistas/abcd/v24n1/a12fig2.jpg"></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#53#49#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#54#50#article#125#<p><a name="tab2"><
/a></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#55#51#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#56#52#article#125#<p align="center"><
img src="/img/revistas/abcd/v24n1/a12tab2.jpg" ></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#57#53#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#58#54#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUS&Atilde;O </b></font></p>  
   ^cY#v24n1a12.htm##
01025000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079000076002001300866#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#59#55#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">N&atilde;o se conseguiu confirmar qu
e MNU na &aacute;gua pot&aacute;vel pode induzir a uma alta incid&ecirc;ncia de 
carcinomas do est&ocirc;mago glandular em ratos Wistar. Apenas dois adenocarcino
mas se desenvolveram nos animais que receberam 200 ppm MNU. Estudos anteriores i
ndicam que o c&acirc;ncer do est&ocirc;mago glandular podeser produzido em ratos
 F344 e camundongos C3H pela administra&ccedil;&atilde;o do MNU, um agente mutag
&ecirc;nico utilizado amplamente. Estudos mostram que quando o MNU &eacute; admi
nistrado em &aacute;gua pot&aacute;vel em per&iacute;odo de 25 a 42 semanas, sel
etivamente induziu carcinoma g&aacute;strico glandular em ratos F344 e mouse C3H
<sup>5,8,11,13,14,18,21</sup>. </font></p>     ^cY#v24n1a12.htm##
01265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704103000076002001301106#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#60#56#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Maekava, et al.<sup>8</sup>examinara
m os efeitos do MNU na &aacute;gua pot&aacute;vel a 100 ppm, em ratos F344. Ap&o
acute;s 42 semanas, 18% dos animais tinham adenocarcinoma g&aacute;strico. Tatem
atsu, et al.<sup>18</sup> induziu c&acirc;ncer no est&ocirc;mago glandular de ra
tos C3H com MNU na &aacute;gua pot&aacute;vel a 120 ppm por 30 semanas e obtiver
am 40% de adenocarcinomas, ap&oacute;s 54 semanas. Hirota utilizado MNU em 400 p
pm, em ratos F344 por 25 semanas teve 100% de adenocarcinomas invasivos<sup>5</s
up>. Foi usado aqui uma concentra&ccedil;&atilde;o intermedi&aacute;ria do MNU (
200 ppm), porque os estudos com as menores concentra&ccedil;&otilde;es mostraram
 baixa incid&ecirc;ncia de adenocarcinoma, e maiores concentra&ccedil;&otilde;es
 desenvolveram tumores avan&ccedil;ados. O objetivo foi a obten&ccedil;&atilde;o
 de les&otilde;es precoces, a fim de descrever o tempo para obter um n&iacute;ve
l de profundidade do tumor (T).</font></p>     ^cY#v24n1a12.htm##
00909000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067400076002001300750#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#61#57#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Lee<sup>7</sup> examinou os efeitos
 da administra&ccedil;&atilde;oconcomitante de dimethylitaconate (CMS) e apresen
taram aumento significativo da incid&ecirc;ncia do adenocarcinoma, que foi de 95
% em compara&ccedil;&atilde;o com 12% do grupo MNU (p&lt;0,005). Existem evid&ec
irc;ncias de que a administra&ccedil;&atilde;o de cloreto de s&oacute;dio potenc
ializa os efeitos cancer&iacute;genos de MMNG no est&ocirc;mago do rato<sup>17</
sup>. Talvez a adi&ccedil;&atilde;o desta subst&acirc;ncia com MNU poderia ter a
umentado a incid&ecirc;ncia de adenocarcinoma g&aacute;strico aqui obtida. </fon
t></p>     ^cY#v24n1a12.htm##
00778000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054300076002001300619#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#62#58#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Tatsuta et al.<sup>19 </sup>examinar
am os efeitos de uma muitobaixa-prote&iacute;na sobre a incid&ecirc;ncia de c&ac
irc;ncer g&aacute;strico induzido por MNNU em ratos Wistar. Administra&ccedil;&a
tilde;o oral de dieta com baixa prote&iacute;na resultou em aumento significativ
o na incid&ecirc;ncia de c&acirc;ncer g&aacute;strico. Mecanismo desta dieta n&a
tilde;o &eacute; conhecida, mas pelo menos tr&ecirc;s maneiras poss&iacute;veis 
podem ser consideradas. </font></p>     ^cY#v24n1a12.htm##
01178000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094300076002001301019#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#63#59#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Um deles &eacute; a imunomodula&cced
il;&atilde;o pela prote&iacute;na da dieta. Componentes da dieta pode influencia
r o desenvolvimento de neoplasias por efeitos sobre o sistema imunol&oacute;gico
. Em particular, o n&iacute;vel do tipo de gordura tem sido mostrado modular a r
esposta imune<sup>12,20</sup>. Outro mecanismo &eacute; um efeito sobre a secre&
ccedil;&atilde;o de diversos horm&ocirc;nios, incluindo o horm&ocirc;nio do cres
cimento, horm&ocirc;nios da tir&oacute;ide, gastrina e somatostatina<sup>6,15</s
up>. Horm&ocirc;nio do crescimento e horm&ocirc;nios da tire&oacute;ide est&atil
de;o intimamente relacionados com o crescimento da mucosa gastrointestinal. Uma 
terceira possibilidade, &eacute; aumento na atividade do sistema nervoso simp&aa
cute;tico. A dieta influencia a atividade do sistema nervoso simp&aacute;tico em
 animais experimentais. </font></p>     ^cY#v24n1a12.htm##
00495000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026000076002001300336#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#64#60#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">H&aacute; evid&ecirc;ncias de envolv
imento neural no controle da prolifera&ccedil;&atilde;o celular<sup>22</sup>.Nes
te estudo, foi utilizada uma dieta da prote&iacute;na normal.</font></p>     ^cY
#v24n1a12.htm##
01108000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087300076002001300949#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#65#61#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">&Eacute; sabido que o MNU &eacute; c
ancer&iacute;geno e multipotentes; sua a&ccedil;&atilde;o carcinog&ecirc;nica va
ria com a ra&ccedil;a de ratos utilizados e a via de administra&ccedil;&atilde;o
<sup>8</sup>. Al&eacute;m disso, foi demonstrado que a especificidade do &oacute
;rg&atilde;oa compostos N-nitrosos administrado por via oral &eacute; influencia
da n&atilde;o s&oacute; pela estrutura qu&iacute;mica deles ou pela linhagem de 
ratos utilizados, mas tamb&eacute;m pelo n&iacute;vel de dose dos compostos util
izados no teste<sup>8</sup>. Neste experimento, tamb&eacute;m foi demonstrado qu
e a especificidade do &oacute;rg&atilde;o do MNU foi influenciada pelalinhagem d
e ratos e/ou o n&iacute;vel da dose. Mais estudos s&atilde;o necess&aacute;rios 
para explicar esse fen&ocirc;meno.</font></p>     ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#66#62#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#67#63#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Otilde;ES</b></font></p> 
    ^cY#v24n1a12.htm##
00563000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032800076002001300404#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#68#64#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O modelo experimental de carcinog&ec
irc;nese em ratos Wistar, utilizando-se 200 ppm do MNU dissolvido na &aacute;gua
, n&atilde;o mostrou a viabilidade pr&aacute;tica neste estudo, devido &agrave; 
baixa taxa de desenvolvimento de adenocarcinoma. </font></p>     ^cY#v24n1a12.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#69#65#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#70#66#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>AGRADECIMENTOS</b></font></p>    
 ^cY#v24n1a12.htm##
00496000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026100076002001300337#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#71#67#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Agradecimentos ao apoio financeiro c
oncedido pelo Fundo de Incentivo &agrave; Pesquisa e Eventos (FIPE) do Hospital 
de Cl&iacute;nicas de Porto Alegre, Porto Alegre, RS, Brasil. </font></p>     ^c
Y#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#72#68#article#125#<p>&nbsp;</p>     ^
cY#v24n1a12.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#73#69#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b> </font></p>
     ^cY#v24n1a12.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019400078002001300272#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#74#70#article#125#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Alexandrov VA. Uter
ine, vaginal and mammary tumours induced bynitrosoureas in pregnant rats. Nature
 1969; 222:1064-1065.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#75#71#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024200078002001300320#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#76#72#article#125#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Fox JG, Wishnok JS,
 Murphy JC, Tannenbaum SR, Correa P. MNNGinduced gastric carcinoma in ferrets in
fected with Helicobacter mustelae. Carcinogenesis 1993; 14:1957-1961.    ^cY#v24
n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#77#73#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024800078002001300326#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#78#74#article#125#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Fujimura S, Kogure 
K, Oboshi S, Sugimura T. Production of tumorsin glandular stomach of hamsters by
 N-methyl-N&acute;-nitro-N nitrosoguanidina. Cancer Res 1970; 30:1444-1448.    ^
cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#79#75#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021400078002001300292#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#80#76#article#125#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Graffi A, Hoffmann 
F, Schutt M. N-Methyl-N-nitrosourea as a strong topical carcinogen when painted 
on skin of rodents. Nature 1967; 214:611.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#81#77#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026200078002001300340#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#82#78#article#125#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Hirota N, Aonuma T,
 Yamada S, Kawai T, Saito K, Yokoyama T. Selective induction of glandular stomac
h carcinoma in F344 rats by N-Methyl-N-nitrosurea. Jpn J Cancer Res 1987; 78 (7)
:634-638.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#83#79#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030400078002001300382#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#84#80#article#125#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Kaptein EM, Fisler 
JS, Duda MJ, Nicoloff JT, Drenick EJ. Relationship between the changes in serum 
thyroid hormone levels and protein status during prolonged protein supplemented 
caloric deprivation. Clin Endocrinol 1985; 22:1-15.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#85#81#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023000078002001300308#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#86#82#article#125#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Lee YS and Jang J. 
Potent promoting activity of dimethylitaconate on gastric carcinogenesis induced
 by N-methylnitrosourea. Cancer Lett 1994; 85(2):177-184.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#87#83#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028400078002001300362#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#88#84#article#125#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Maekawa A, Matsuoka
 C, Onodera H, Tanigawa H, Furuta K, Ogiu T, Mitsumori K, Hayashi Y. Organ-speci
fic carcinogenicity of N-Methyl-N-Nitrosurea in F344 and ACI/N rats. J Cancer Re
s Clin Oncol 1985; 109:178-182.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#89#85#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00408000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015900078002001300237#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#90#86#article#125#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Magee PN, Barnes JM
. Carcinogenic nitroso compounds. Adv Cancer Res 1967; 10:163-246.    ^cY#v24n1a
12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#91#87#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029400079002001300373#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#92#88#article#125#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Narisawa T, Wong 
CQ, Maronpot RR, Weisburger JH. Large bowel carcinogenesis in mice and rats by s
everal intrarectal doses of methylnitrosourea and negative effect of nitrite plu
s methylurea. Cancer Res 1976; 36:505-510.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#93#89#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028400079002001300363#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#94#90#article#125#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Ohgaki H, Ludeke 
BI, Meier I, Kleihues P, Lutz WK, Schlatter C. DNA methylation in the digestive 
tract of F344 rats during chronic exposure to N-methyl-N-nitrosurea. J Cancer Re
s Clin Oncol 1991; 117(1):13-18.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#95#91#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029400079002001300373#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#96#92#article#125#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Olson LM, Clinton
 SK, Everitt JI, Johnston PV, Visek WJ.. Lymphocyte activation, cell-mediated cy
totoxicity and their relationship to dietary fa-enhanced mammary tumorogenisis i
n C3H/OUJ mice. J. Nutr 1987; 117:955-963.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#97#93#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027700079002001300356#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#98#94#article#125#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Shimizu M, Suzui 
M, Moriwaki H, Mori H, Yoshimi N.. No involvement of b-catenin gene mutation in 
gastric carcinomas induced by N-methyl-N-nitrosourea in male F344 rats. Cancer L
etters 2003; 195:147-152.    ^cY#v24n1a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#99#95#article#125# </font></p>     ^c
Y#v24n1a12.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704031600080002001300396#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#100#96#article#125#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Shimizu M, Yoshi
mi N, Yamada Y, Matsunaga K, Kawabata K, Hara A, Moriwaki H, Mori H.. Suppressiv
e effects of clorogenic acid on N-methyl-N-nitrosurea-induced glandular stomach 
carcinogenesis in male F433 rats. J Toxicol Sci 1999; 24:433-439.    ^cY#v24n1a1
2.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#101#97#article#125# </font></p>     ^
cY#v24n1a12.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704026400080002001300344#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#102#98#article#125#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 15. Sommervile BA, 
Harvey S. The effect of low levels of dietary protein and calcium o growth rate,
 growth hormone, and vitamin D metabolism in the chicken. Gen Comp Endocrinol 19
88, 71:93-96.    ^cY#v24n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#103#99#article#125# </font></p>     ^
cY#v24n1a12.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#104#100#article#125#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 16. Sugimura T and
 Sugimura S. Tumor production in glandular stomach of rats by N-methyl-N&acute;-
nitro-N-nitrosoguanidina. Nature 1967; 216:943-944.    ^cY#v24n1a12.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#105#101#article#125# </font></p>     
^cY#v24n1a12.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028300081002001300364#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#106#102#article#125#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 17. Takahashi M, K
okubo T, Furukawa F, Kurokawa Y, Tatematsu M, Hayashi Y. Effect of high salt die
t on rat gastric carcinogenesis induced by N-methyl-N-nitro-N-nitrosoguanidine. 
Carcinogenesis 1982; 3:1419-1422.    ^cY#v24n1a12.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#107#103#article#125# </font></p>     
^cY#v24n1a12.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030600081002001300387#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#108#104#article#125#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Tatematsu M, Ya
mamoto M, Iwata H, Fukami H, Yuasa H, Tezuka N, Masui T, Nakanishi H. Induction 
of glandular stomach cancers in C3H mice treated with N-methyl-N-nitrosourea in 
the drinking water. Jpn J Cancer Res 1993; 84:1258-1264.    ^cY#v24n1a12.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#109#105#article#125# </font></p>     
^cY#v24n1a12.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030500081002001300386#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#110#106#article#125#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Tatsuta M, Iish
i H, Baba M, Uehara H, Nakaizumi A, Taniguchi H.. Enhanced induction of gastric 
carcinogenisis by N-Methyl-N&acute; nitro-N-nitrosoguanidine in Wistar rats fed 
a low-protein diet. Cancer Research 1991; 51:3493-3496.    ^cY#v24n1a12.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#111#107#article#125# </font></p>     
^cY#v24n1a12.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#112#108#article#125#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 20. Thomas IK and 
Erickon KL. Lipid modulation of mammary tumor cell cytolysis: direct influence o
f dietary fats on the effector component of cell-mediated cytotoxicity. J Natl C
ancer Inst 1885; 74:675-680.    ^cY#v24n1a12.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#113#109#article#125# </font></p>     
^cY#v24n1a12.htm##
00612000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036000081002001300441#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#114#110#article#125#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 21. Yamachika T, N
akanishi H, Inada K, Tsukamoto T, Shimizu N,Kobayashi K, Fukushima S, Tatematsu 
M. N-Methyl-N-Nitrosurea concentration-dependent, rather than total intake-depen
dent, induction of adenocarcinoma in the glandular stomach of BALB/c mice. Jpn J
 Cacer Res 1998; (89):385-391.    ^cY#v24n1a12.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#115#111#article#125# </font></p>     
^cY#v24n1a12.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023300081002001300314#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#116#112#article#125#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Young JB, Kaufm
an LN, Saville ME, Landsberg L. Increased sympathetic nervous system activity in
 rats fed a low-protein diet. Am J Physiol 1985; 248:R627-R637.    ^cY#v24n1a12.
htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#117#113#article#125# </font></p>     
^cY#v24n1a12.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#118#114#article#125#<p>&nbsp;</p>    
 ^cY#v24n1a12.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#119#115#article#125#<p>&nbsp;</p>    
 ^cY#v24n1a12.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019800078002001300276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#120#116#article#125#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><a href="#note
1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> <b>Correspond&ec
irc;ncia:</b>    ^cY#v24n1a12.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002900078002001300107#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#121#117#article#125#<br> Lissandro Ta
rso     ^cY#v24n1a12.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010800078002001300186#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#122#118#article#125#<br> e-mail: <a h
ref="mailto:lissandrotarso@hotmail.com">lissandrotarso@hotmail.com</a> </font></
p>     ^cY#v24n1a12.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012100078002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#123#119#article#125#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 29/10/2010    ^cY#v24n1a12.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#124#120#article#125#<br> Aceito para 
publica&ccedil;&atilde;o: 21/12/2010    ^cY#v24n1a12.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004300078002001300121#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#125#121#article#125#<br> Fonte de fin
anciamento: não há    ^cY#v24n1a12.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#126#122#article#125#<br>  Conflito de
 interesses: não há </font></p>     ^cY#v24n1a12.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#127#123#article#125#<p>&nbsp;</p>    
 ^cY#v24n1a12.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#128#124#article#125#<p>&nbsp;</p>    
 ^cY#v24n1a12.htm##
00539000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704030200078002001300380#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a12.htm#S#p#129#125#article#125#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado na Unidade de E
xperimenta&ccedil;&atilde;o Animal do Hospital de Cl&iacute;nicas de Porto Alegr
e - Faculdade de Medicina - Universidade Federal do Rio Grande do Sul (UFRGS), P
orto Alegre, RS, Brasil. </font></p>     ^cY#v24n1a12.htm##
00519000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770120081000980300
00700179065000900186064000500195031000400200014001000204865000900214002001300223
035001000236801000700246#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S
#c#130#1#article#22#1#^rND^sAlexandrov^nVA#Uterine, vaginal and mammary tumours 
induced bynitrosoureas in pregnant rats^len#Nature#19690000#1969#222#1064-1065#2
0110300#v24n1a12.htm#0028-0836#Nature##
00647000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100018000910100
01700109010002100126010001600147012008100163030001500244065000900259064000500268
031000300273014001000276865000900286002001300295035001000308801001500318#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#c#131#2#article#22#2#^rND^sFox^
nJG#^rND^sWishnok^nJS#^rND^sMurphy^nJC#^rND^sTannenbaum^nSR#^rND^sCorrea^nP#MNNG
induced gastric carcinoma in ferrets infected with Helicobacter mustelae^len#Car
cinogenesis#19930000#1993#14#1957-1961#20110300#v24n1a12.htm#0143-3334#Carcinoge
nesis##
00625000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01600111010001800127012009700145030001100242065000900253064000500262031000300267
014001000270865000900280002001300289035001000302801001100312#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a12.htm#S#c#132#3#article#22#3#^rND^sFujimura^nS#^rND
^sKogure^nK#^rND^sOboshi^nS#^rND^sSugimura^nT#Production of tumorsin glandular s
tomach of hamsters by N-methyl-N´-nitro-N nitrosoguanidina^len#Cancer Res#197000
00#1970#30#1444-1448#20110300#v24n1a12.htm#0008-5472#Cancer res##
00575000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
01600111012009000127030000700217065000900224064000500233031000400238014000400242
865000900246002001300255035001000268801000700278#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a12.htm#S#c#133#4#article#22#4#^rND^sGraffi^nA#^rND^sHoffmann^nF#
^rND^sSchutt^nM#N-Methyl-N-nitrosourea as a strong topical carcinogen when paint
ed on skin of rodents^len#Nature#19670000#1967#214#611#20110300#v24n1a12.htm#002
8-0836#Nature##
00697000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109010001500125010001500140010001800155012009300173030001700266065000900283
06400050029203100030029703200020030001400080030286500090031000200130031903500100
0332801001700342#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#c#134#5
#article#22#5#^rND^sHirota^nN#^rND^sAonuma^nT#^rND^sYamada^nS#^rND^sKawai^nT#^rN
D^sSaito^nK#^rND^sYokoyama^nT#Selective induction of glandular stomach carcinoma
 in F344 rats by N-Methyl-N-nitrosurea^len#Jpn J Cancer Res#19870000#1987#78#7#6
34-638#20110300#v24n1a12.htm#0910-5050#Jpn J Cancer Res##
00674000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
01500112010001900127010001800146012014600164030001600310710000200326065000900328
064000500337031000300342014000500345865000900350002001300359#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a12.htm#S#c#135#6#article#22#6#^rND^sKaptein^nEM#^rND
^sFisler^nJS#^rND^sDuda^nMJ#^rND^sNicoloff^nJT#^rND^sDrenick^nEJ#Relationship be
tween the changes in serum thyroid hormone levels and protein status during prol
onged protein supplemented caloric deprivation^len#Clin Endocrinol#2#19850000#19
85#22#1-15#20110300#v24n1a12.htm##
00564000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110018000770120108000950300
01200203065000900215064000500224031000300229032000200232014000800234865000900242
002001300251035001000264801001200274#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a12.htm#S#c#136#7#article#22#7#Lee YS and Jang J#Potent promoting activity of
 dimethylitaconate on gastric carcinogenesis induced by N-methylnitrosourea^len#
Cancer Lett#19940000#1994#85#2#177-184#20110300#v24n1a12.htm#0096-3917#Cancer Le
tt##
00752000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01700112010001800129010001600147010001400163010001900177010001700196012008300213
03000240029606500090032006400050032903100040033401400080033886500090034600200130
0355035001000368801002400378#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.h
tm#S#c#137#8#article#22#8#^rND^sMaekawa^nA#^rND^sMatsuoka^nC#^rND^sOnodera^nH#^r
ND^sTanigawa^nH#^rND^sFuruta^nK#^rND^sOgiu^nT#^rND^sMitsumori^nK#^rND^sHayashi^n
Y#Organ-specific carcinogenicity of N-Methyl-N-Nitrosurea in F344 and ACI/N rats
^len#J Cancer Res Clin Oncol#19850000#1985#109#178-182#20110300#v24n1a12.htm#017
1-5216#J Cancer Res Clin Oncol##
00510000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930120
03500110030001500145065000900160064000500169031000300174014000800177865000900185
002001300194035001000207801001500217#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a12.htm#S#c#138#9#article#22#9#^rND^sMagee^nPN#^rND^sBarnes^nJM#Carcinogenic 
nitroso compounds^len#Adv Cancer Res#19670000#1967#10#163-246#20110300#v24n1a12.
htm#0065-230X#Adv Cancer Res##
00678000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01900112010002100131012014500152030001100297065000900308064000500317031000300322
014000800325865000900333002001300342035001000355801001100365#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a12.htm#S#c#139#10#article#22#10#^rND^sNarisawa^nT#^r
ND^sWong^nCQ#^rND^sMaronpot^nRR#^rND^sWeisburger^nJH#Large bowel carcinogenesis 
in mice and rats by several intrarectal doses of methylnitrosourea and negative 
effect of nitrite plus methylurea^len#Cancer Res#19760000#1976#36#505-510#201103
00#v24n1a12.htm#0008-5472#Cancer res##
00728000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01500112010001800127010001500145010001900160012010500179030002400284065000900308
06400050031703100040032203200020032601400060032886500090033400200130034303500100
0356801002400366#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#c#140#1
1#article#22#11#^rND^sOhgaki^nH#^rND^sLudeke^nBI#^rND^sMeier^nI#^rND^sKleihues^n
P#^rND^sLutz^nWK#^rND^sSchlatter^nC#DNA methylation in the digestive tract of F3
44 rats during chronic exposure to N-methyl-N-nitrosurea^len#J Cancer Res Clin O
ncol#19910000#1991#117#1#13-18#20110300#v24n1a12.htm#0171-5216#J Cancer Res Clin
 Oncol##
00692000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01800113010001900131010001600150012013800166030000800304065000900312064000500321
031000400326014000800330865000900338002001300347035001000360801000800370#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#c#141#12#article#22#12#^rND^sOl
son^nLM#^rND^sClinton^nSK#^rND^sEveritt^nJI#^rND^sJohnston^nPV#^rND^sVisek^nWJ#L
ymphocyte activation, cell-mediated cytotoxicity and their relationship to dieta
ry fa-enhanced mammary tumorogenisis in C3H/OUJ mice^len#J. Nutr#19870000#1987#1
17#955-963#20110300#v24n1a12.htm#0022-3166#J. nutr##
00682000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01800111010001400129010001700143012012000160030001500280065000900295064000500304
031000400309014000800313865000900321002001300330035001000343801001500353#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#c#142#13#article#22#13#^rND^sSh
imizu^nM#^rND^sSuzui^nM#^rND^sMoriwaki^nH#^rND^sMori^nH#^rND^sYoshimi^nN#No invo
lvement of b-catenin gene mutation in gastric carcinomas induced by N-methyl-N-n
itrosourea in male F344 rats^len#Cancer Letters#20030000#2003#195#147-152#201103
00#v24n1a12.htm#0304-3835#Cancer letters##
00774000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01600113010001900129010001800148010001400166010001800180010001400198012012700212
03000140033906500090035306400050036203100030036701400080037086500090037800200130
0387035001000400801001400410#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.h
tm#S#c#143#14#article#22#14#^rND^sShimizu^nM#^rND^sYoshimi^nN#^rND^sYamada^nY#^r
ND^sMatsunaga^nK#^rND^sKawabata^nK#^rND^sHara^nA#^rND^sMoriwaki^nH#^rND^sMori^nH
#Suppressive effects of clorogenic acid on N-methyl-N-nitrosurea-induced glandul
ar stomach carcinogenesis in male F433 rats^len#J Toxicol Sci#19990000#1999#24#4
33-439#20110300#v24n1a12.htm#0388-1350#J Toxicol Sci##
00621000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100017001000120
13100117030002000248065000900268064000500277031000300282014000600285865000900291
002001300300035001000313801002000323#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a12.htm#S#c#144#15#article#22#15#^rND^sSommervile^nBA#^rND^sHarvey^nS.#The ef
fect of low levels of dietary protein and calcium o growth rate, growth hormone,
 and vitamin D metabolism in the chicken^len#Gen Comp Endocrinol#19880000#1988#7
1#93-96#20110300#v24n1a12.htm#0016-6480#Gen Comp Endocrinol##
00556000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970120
09000116030000700206065000900213064000500222031000400227014000800231865000900239
002001300248035001000261801000700271#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a12.htm#S#c#145#16#article#22#16#^rND^sSugimura^nT#^rND^sSugimura^nS.#Tumor p
roduction in glandular stomach of rats by N-methyl-N´-nitro-N-nitrosoguanidina^l
en#Nature#19670000#1967#216#943-944#20110300#v24n1a12.htm#0028-0836#Nature##
00706000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01800114010001800132010001900150010001700169012010600186030001500292065000900307
06400050031603100020032101400100032386500090033300200130034203500100035580100150
0365#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#c#146#17#article#22
#17#^rND^sTakahashi^nM#^rND^sKokubo^nT#^rND^sFurukawa^nF#^rND^sKurokawa^nY#^rND^
sTatematsu^nM#^rND^sHayashi^nY#Effect of high salt diet on rat gastric carcinoge
nesis induced by N-methyl-N-nitro-N-nitrosoguanidine^len#Carcinogenesis#19820000
#1982#3#1419-1422#20110300#v24n1a12.htm#0143-3334#Carcinogenesis##
00768000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01500116010001600131010001500147010001600162010001500178010001900193012011300212
03000170032506500090034206400050035103100030035601400100035986500090036900200130
0378035001000391801001700401#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.h
tm#S#c#147#18#article#22#18#^rND^sTatematsu^nM#^rND^sYamamoto^nM#^rND^sIwata^nH#
^rND^sFukami^nH#^rND^sYuasa^nH#^rND^sTezuka^nN#^rND^sMasui^nT#^rND^sNakanishi^nH
#Induction of glandular stomach cancers in C3H mice treated with N-methyl-N-nitr
osourea in the drinking water^len#Jpn J Cancer Res#19930000#1993#84#1258-1264#20
110300#v24n1a12.htm#0910-5050#Jpn J Cancer Res##
00723000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01400111010001600125010001900141010001900160012012700179030001600306065000900322
06400050033103100030033601400100033986500090034900200130035803500100037180100160
0381#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#c#148#19#article#22
#19#^rND^sTatsuta^nM#^rND^sIishi^nH#^rND^sBaba^nM#^rND^sUehara^nH#^rND^sNakaizum
i^nA#^rND^sTaniguchi^nH#Enhanced induction of gastric carcinogenisis by N-Methyl
-N´ nitro-N-nitrosoguanidine in Wistar rats fed a low-protein diet^len#Cancer Re
search#19910000#1991#51#3493-3496#20110300#v24n1a12.htm#0008-5472#Cancer Researc
h##
00631000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960120
14300115030001900258065000900277064000500286031000300291014000800294865000900302
002001300311035001000324801001900334#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a12.htm#S#c#149#20#article#22#20#^rND^sThomas^nIK#^rND^sErickon^nKL.#Lipid mo
dulation of mammary tumor cell cytolysis: direct influence of dietary fats on th
e effector component of cell-mediated cytotoxicity^len#J Natl Cancer Inst#188500
00#1885#74#675-680#20110300#v24n1a12.htm#0027-8874#J Natl Cancer Inst##
00783000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01500117010001900132010001700151010001900168010001900187010001900206012015500225
03000160038071000020039606500090039806400050040703200030041201400080041586500090
0423002001300432#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a12.htm#S#c#150#2
1#article#22#21#^rND^sYamachika^nT#^rND^sNakanishi^nH#^rND^sInada^nK#^rND^sTsuka
moto^nT#^rND^sShimizu^nN#^rND^sKobayashi^nK#^rND^sFukushima^nS#^rND^sTatematsu^n
M#N-Methyl-N-Nitrosurea concentration-dependent, rather than total intake-depend
ent, induction of adenocarcinoma in the glandular stomach of BALB/c mice^len#Jpn
 J Cacer Res#2#19980000#1998#89#385-391#20110300#v24n1a12.htm##
00619000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01800113010001900131012008100150030001300231065000900244064000500253031000400258
014001000262865000900272002001300281035001000294801001300304#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a12.htm#S#c#151#22#article#22#22#^rND^sYoung^nJB#^rND
^sKaufman^nLN#^rND^sSaville^nME#^rND^sLandsberg^nL#Increased sympathetic nervous
 system activity in rats fed a low-protein diet^len#Am J Physiol#19850000#1985#2
48#R627-R637#20110300#v24n1a12.htm#0002-9513#Am J Physiol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#o#1#1#article#1
#20110411#103912#v24n1a13.htm#197##
04830000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002700108
03100030013503200020013806500090014001400090014903500100015801200870016801200770
02550100025003320100021003570100028003780100018004060100031004240100023004550100
02500478010002300503083179100526085001002317085003302327085003202360083170002392
08500100409208500300410208500320413211700080416407200030417211200090417511100110
4184114000904195113001104204002001304215#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a13.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#13#ABCD060#nd#ABCD, arq. 
bras. cir. dig.#24#1#20110300#^f59^l63#0102-6720#Determinação histopatológica da
 presença do helicobacter pylori em câncer gástrico^lpt#Histopathological determ
ination of helicobacter pylori in gastric cancer^len#^rND^nClaudio^sBresciani#^r
ND^nIbrahim^sLatif#^rND^nRoger Beltrati^sCoser#^rND^nOsmar^sYagi#^rND^nClaudio R
oberto^sDeutsch#^rND^nDonato^sMucerino#^rND^nBruno^sZilberstein#^rND^nIvan^sCecc
onello#^lpt^aRACIONAL: A causa do câncer gástrico (CG) é controversa e tem vário
s fatores envolvidos no seu processo de carcinogênese, incluindo o Helicobacter 
pylori (Hp) O papel da infecção pelo Hp no CG permanece incerto, com vários estu
dos controversos. OBJETIVO: Correlacionar a presença da infecção pelo Hp com cân
cer gástrico, através de exame anatomopatológico convencional do estômago ressec
ado. MÉTODO: Noventa e um pacientes tratados por ressecção cirúrgica foram revis
tos. O exame anatomopatológico foi feito em todos os pacientes para determinar a
 presença de infecção por Hp, metaplasia intestinal (MI) e confirmação do tipo h
istológico por hematoxilina-eosina. A análise estatística foi realizada através 
do qui-quadrado e testes de log-rank. RESULTADOS: MI foi observada em 81 tumores
 (89%). Em geral, a presença de infecção pelo Hp foi observada em 46 casos (50,5
%). Não houve associação entre idade e Hp. Nos grupos de pacientes com CG avança
do e precoce, a infecção pelo Hp estava presente em 47,7% e 54% dos tumores. A i
nfecção pelo Hp ocorreu em 40 tumores (49%) no grupo de pacientes com MI. Nos co
m tumores sem MI, Hp estava presente em cinco (50%). Tumores proximais tiveram m
ais infecção por Hp, quando comparados aos tumores distais. CONCLUSÕES: A taxa d
e infecção não teve associação significativa com o tipo histológico, sexo, MI ou
 estágio de desenvolvimento tumoral. Esses resultados podem indicar que a partic
ipação da infecção pelo Hp durante o desenvolvimento do CG não pode ser descarta
da; no entanto, provavelmente não é essencial em todas as fases e o mecanismo do
 CG pode ser distinto da gastrite crônica e MI. Finalmente, é possível que a ass
ociação proposta é mera coincidência e que não há nenhuma influência real das ba
ctérias no processo de carcinogênese.#^ddecs^i1#^tm^lpt^kNeoplasias gástricas^i1
#^tm^lpt^kHelicobacter pylori^i1#^len^aINTRODUCTION: Etiology of gastric cancer 
(GC) remains controversial and several factors have implicated in its carcinogen
esis process, including Helicobacter pylori (Hp) infection. Hp infection's role 
on GC remains uncertain, with several conflicting studies. METHOD: Ninety-one pa
tients with diagnosis of adenocarcinoma of the stomach treated by surgical resec
tion were reviewed. Pathological examination was repeated in all patients to det
ermine the presence of Hp infection, intestinal metaplasia (IM) and confirmation
 of the hystologic type by conventional haematoxylin-eosin staining. Statistical
 analysis was performed using Chi-quadrate and log-rank tests. RESULTS: IM was o
bserved in 81 tumours (89%). Overall, the presence of Hp infection was observed 
in 46 tumours (50.5%). There was no association between age and Hp status. In th
e group of patients with early and advanced GC, Hp infection was present in 47.7
% and 54% of tumours. Hp infection was present in 40 tumours (49%) in the group 
of patients with IM. In patients with tumours without IM Hp was present in five 
(50%) tumours. Proximal tumours had more Hp infection when compared to distal tu
mours. CONCLUSIONS: The infection rate had no significant association with histo
logic type, IM, gender or stage. These results may indicate that participation o
f Hp infection during GC development cannot be ruled out; however, it is probabl
y not essential during all stages of GC development and the mechanism may be dis
tinct of the chronic gastritis and IM progression. Finally, it is possible that 
the proposed association is merely coincidental and that there is no actual infl
uence of the bacteria in the carcinogenesis process.#^ddecs^i2#^tm^len^kStomach 
Neoplasms^i2#^tm^len^kHelicobacter pylori^i2#vancouv#39#20100916#16/09/2010#2010
1221#21/12/2010#v24n1a13.htm##
04921000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002700108
03100030013503200020013806500090014001400090014903500100015801200940016801200840
02620100025003460100021003710100028003920100018004200100031004380100023004690100
02500492010002300517083183300540085001002373085003302383085003202416083173502448
08500100418308500300419308500320422311700080425507200030426311200090426611100110
4275114000904286113001104295002001304306#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a13.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#13#ABCD060#nd#ABCD, arq. 
bras. cir. dig.#24#1#20110300#^f59^l63#0102-6720#<b>Determinação histopatológica
 da presença do helicobacter pylori em câncer gástrico</b>^lpt#<b>Histopathologi
cal determination of helicobacter pylori in gastric cancer</b>^len#^rND^nClaudio
^sBresciani#^rND^nIbrahim^sLatif#^rND^nRoger Beltrati^sCoser#^rND^nOsmar^sYagi#^
rND^nClaudio Roberto^sDeutsch#^rND^nDonato^sMucerino#^rND^nBruno^sZilberstein#^r
ND^nIvan^sCecconello#^lpt^a<b>RACIONAL:</b> A causa do câncer gástrico (CG) é co
ntroversa e tem vários fatores envolvidos no seu processo de carcinogênese, incl
uindo o <i>Helicobacter pylori</i> (Hp) O papel da infecção pelo Hp no CG perman
ece incerto, com vários estudos controversos. <b>OBJETIVO:</b> Correlacionar a p
resença da infecção pelo Hp com câncer gástrico, através de exame anatomopatológ
ico convencional do estômago ressecado. <b>MÉTODO:</b> Noventa e um pacientes tr
atados por ressecção cirúrgica foram revistos. O exame anatomopatológico foi fei
to em todos os pacientes para determinar a presença de infecção por Hp, metaplas
ia intestinal (MI) e confirmação do tipo histológico por hematoxilina-eosina. A 
análise estatística foi realizada através do qui-quadrado e testes de log-rank. 
<b>RESULTADOS:</b> MI foi observada em 81 tumores (89%). Em geral, a presença de
 infecção pelo Hp foi observada em 46 casos (50,5%). Não houve associação entre 
idade e Hp. Nos grupos de pacientes com CG avançado e precoce, a infecção pelo H
p estava presente em 47,7% e 54% dos tumores. A infecção pelo Hp ocorreu em 40 t
umores (49%) no grupo de pacientes com MI. Nos com tumores sem MI, Hp estava pre
sente em cinco (50%). Tumores proximais tiveram mais infecção por Hp, quando com
parados aos tumores distais. <b>CONCLUSÕES:</b> A taxa de infecção não teve asso
ciação significativa com o tipo histológico, sexo, MI ou estágio de desenvolvime
nto tumoral. Esses resultados podem indicar que a participação da infecção pelo 
Hp durante o desenvolvimento do CG não pode ser descartada; no entanto, provavel
mente não é essencial em todas as fases e o mecanismo do CG pode ser distinto da
 gastrite crônica e MI. Finalmente, é possível que a associação proposta é mera 
coincidência e que não há nenhuma influência real das bactérias no processo de c
arcinogênese.#^ddecs^i1#^tm^lpt^kNeoplasias gástricas^i1#^tm^lpt^kHelicobacter p
ylori^i1#^len^a<b>INTRODUCTION: </b>Etiology of gastric cancer (GC) remains cont
roversial and several factors have implicated in its carcinogenesis process, inc
luding <i>Helicobacter pylori</i> (Hp) infection. Hp infection's role on GC rema
ins uncertain, with several conflicting studies. <b>METHOD: </b>Ninety-one patie
nts with diagnosis of adenocarcinoma of the stomach treated by surgical resectio
n were reviewed. Pathological examination was repeated in all patients to determ
ine the presence of Hp infection, intestinal metaplasia (IM) and confirmation of
 the hystologic type by conventional haematoxylin-eosin staining. Statistical an
alysis was performed using Chi-quadrate and log-rank tests. <b>RESULTS: </b>IM w
as observed in 81 tumours (89%). Overall, the presence of Hp infection was obser
ved in 46 tumours (50.5%). There was no association between age and Hp status. I
n the group of patients with early and advanced GC, Hp infection was present in 
47.7% and 54% of tumours. Hp infection was present in 40 tumours (49%) in the gr
oup of patients with IM. In patients with tumours without IM Hp was present in f
ive (50%) tumours. Proximal tumours had more Hp infection when compared to dista
l tumours. <b>CONCLUSIONS: </b>The infection rate had no significant association
 with histologic type, IM, gender or stage. These results may indicate that part
icipation of Hp infection during GC development cannot be ruled out; however, it
 is probably not essential during all stages of GC development and the mechanism
 may be distinct of the chronic gastritis and IM progression. Finally, it is pos
sible that the proposed association is merely coincidental and that there is no 
actual influence of the bacteria in the carcinogenesis process.#^ddecs^i2#^tm^le
n^kStomach Neoplasms^i2#^tm^len^kHelicobacter pylori^i2#vancouv#39#20100916#16/0
9/2010#20101221#21/12/2010#v24n1a13.htm##
05056000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000260012603100030015203200020015506500090015701400090016603500100017501200870
01850120077002720100025003490100021003740100028003950100018004230100031004410100
02300472010002500495010002300520083184500543085001002388085003302398085003202431
08317420246308500100420508500300421508500320424511700080427707200030428511200090
4288111001104297114000904308113001104317002001304328008008904341#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt
#br1.1#1#4.0#tab#13#ABCD060#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f59^l63#
0102-6720#Determinação histopatológica da presença do helicobacter pylori em cân
cer gástrico^lpt#Histopathological determination of helicobacter pylori in gastr
ic cancer^len#^rND^nClaudio^sBresciani#^rND^nIbrahim^sLatif#^rND^nRoger Beltrati
^sCoser#^rND^nOsmar^sYagi#^rND^nClaudio Roberto^sDeutsch#^rND^nDonato^sMucerino#
^rND^nBruno^sZilberstein#^rND^nIvan^sCecconello#^lpt^aRACIONAL: A causa do cânce
r gástrico (CG) é controversa e tem vários fatores envolvidos no seu processo de
 carcinogênese, incluindo o Helicobacter pylori (Hp) O papel da infecção pelo Hp
 no CG permanece incerto, com vários estudos controversos. OBJETIVO: Correlacion
ar a presença da infecção pelo Hp com câncer gástrico, através de exame anatomop
atológico convencional do estômago ressecado. MÉTODO: Noventa e um pacientes tra
tados por ressecção cirúrgica foram revistos. O exame anatomopatológico foi feit
o em todos os pacientes para determinar a presença de infecção por Hp, metaplasi
a intestinal (MI) e confirmação do tipo histológico por hematoxilina-eosina. A a
nálise estatística foi realizada através do qui-quadrado e testes de log-rank. R
ESULTADOS: MI foi observada em 81 tumores (89 por cento). Em geral, a presença d
e infecção pelo Hp foi observada em 46 casos (50,5 por cento). Não houve associa
ção entre idade e Hp. Nos grupos de pacientes com CG avançado e precoce, a infec
ção pelo Hp estava presente em 47,7 por cento e 54 por cento dos tumores. A infe
cção pelo Hp ocorreu em 40 tumores (49 por cento) no grupo de pacientes com MI. 
Nos com tumores sem MI, Hp estava presente em cinco (50 por cento). Tumores prox
imais tiveram mais infecção por Hp, quando comparados aos tumores distais. CONCL
USÕES: A taxa de infecção não teve associação significativa com o tipo histológi
co, sexo, MI ou estágio de desenvolvimento tumoral. Esses resultados podem indic
ar que a participação da infecção pelo Hp durante o desenvolvimento do CG não po
de ser descartada; no entanto, provavelmente não é essencial em todas as fases e
 o mecanismo do CG pode ser distinto da gastrite crônica e MI. Finalmente, é pos
sível que a associação proposta é mera coincidência e que não há nenhuma influên
cia real das bactérias no processo de carcinogênese.#^ddecs^i1#^tm^lpt^kNeoplasi
as gástricas^i1#^tm^lpt^kHelicobacter pylori^i1#^len^aINTRODUCTION: Etiology of 
gastric cancer (GC) remains controversial and several factors have implicated in
 its carcinogenesis process, including Helicobacter pylori (Hp) infection. Hp in
fection's role on GC remains uncertain, with several conflicting studies. METHOD
: Ninety-one patients with diagnosis of adenocarcinoma of the stomach treated by
 surgical resection were reviewed. Pathological examination was repeated in all 
patients to determine the presence of Hp infection, intestinal metaplasia (IM) a
nd confirmation of the hystologic type by conventional haematoxylin-eosin staini
ng. Statistical analysis was performed using Chi-quadrate and log-rank tests. RE
SULTS: IM was observed in 81 tumours (89 percent). Overall, the presence of Hp i
nfection was observed in 46 tumours (50.5 percent). There was no association bet
ween age and Hp status. In the group of patients with early and advanced GC, Hp 
infection was present in 47.7 percent and 54 percent of tumours. Hp infection wa
s present in 40 tumours (49 percent) in the group of patients with IM. In patien
ts with tumours without IM Hp was present in five (50 percent) tumours. Proximal
 tumours had more Hp infection when compared to distal tumours. CONCLUSIONS: The
 infection rate had no significant association with histologic type, IM, gender 
or stage. These results may indicate that participation of Hp infection during G
C development cannot be ruled out; however, it is probably not essential during 
all stages of GC development and the mechanism may be distinct of the chronic ga
stritis and IM progression. Finally, it is possible that the proposed associatio
n is merely coincidental and that there is no actual influence of the bacteria i
n the carcinogenesis process.#^ddecs^i2#^tm^len^kStomach Neoplasms^i2#^tm^len^kH
elicobacter pylori^i2#vancouv#39#20100916#16/09/2010#20101221#21/12/2010#v24n1a1
3.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-672
02011000100013##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#5#1#article#154#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL </b><
/font></p>     ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#6#2#article#154#<p>&nbsp;</p>     ^cY
#v24n1a13.htm##
00466000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704023300074002001300307#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#7#3#article#154#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Determina&ccedi
l;&atilde;o histopatol&oacute;gica da presen&ccedil;a do helicobacter pylori em 
c&acirc;ncer g&aacute;strico</b></font></p>     ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#8#4#article#154#<p>&nbsp;</p>     ^cY
#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#9#5#article#154#<p>&nbsp;</p>     ^cY
#v24n1a13.htm##
00468000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704023400075002001300309#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#10#6#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Claudio Bresciani; Ibrahim Latif; 
Roger Beltrati Coser; Osmar Yagi; Claudio Roberto Deutsch; Donato Mucerino; Brun
o Zilberstein; Ivan Cecconello</b></font></p>     ^cY#v24n1a13.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#11#7#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#12#8#article#154#<p>&nbsp;</p>     ^c
Y#v24n1a13.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004300075002001300118#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#13#9#article#154#<p>&nbsp;</p><hr siz
e="1" noshade>     ^cY#v24n1a13.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#14#10#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b>  </font></p>     ^cY#v
24n1a13.htm##
00619000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038400076002001300460#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#15#11#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RACIONAL:</b> A causa do c&acirc;
ncer g&aacute;strico (CG) &eacute; controversa e tem v&aacute;rios fatores envol
vidos no seu processo de carcinog&ecirc;nese, incluindo o <i>Helicobacter pylori
</i> (Hp) O papel da infec&ccedil;&atilde;o pelo Hp no CG permanece incerto, com
 v&aacute;rios estudos controversos.     ^cY#v24n1a13.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022000076002001300296#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#16#12#article#154#<br><b>OBJETIVO:</b
> Correlacionar a presen&ccedil;a da infec&ccedil;&atilde;o pelo Hp com c&acirc;
ncer g&aacute;strico, atrav&eacute;s de exame anatomopatol&oacute;gico convencio
nal do est&ocirc;mago ressecado.     ^cY#v24n1a13.htm##
00705000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047000076002001300546#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#17#13#article#154#<br><b>M&Eacute;TOD
O:</b> Noventa e um pacientes tratados por ressec&ccedil;&atilde;o cir&uacute;rg
ica foram revistos. O exame anatomopatol&oacute;gico foi feito em todos os pacie
ntes para determinar a presen&ccedil;a de infec&ccedil;&atilde;o por Hp, metapla
sia intestinal (MI) e confirma&ccedil;&atilde;o do tipo histol&oacute;gico por h
ematoxilina-eosina. A an&aacute;lise estat&iacute;stica foi realizada atrav&eacu
te;s do qui-quadrado e testes de log-rank.     ^cY#v24n1a13.htm##
00849000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061400076002001300690#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#18#14#article#154#<br> <b>RESULTADOS:
</b>  MI foi observada em 81 tumores (89%). Em geral, a presen&ccedil;a de infec
&ccedil;&atilde;o pelo Hp foi observada em 46 casos (50,5%). N&atilde;o houve as
socia&ccedil;&atilde;o entre idade e Hp. Nos grupos de pacientes com CG avan&cce
dil;ado e precoce, a infec&ccedil;&atilde;o pelo Hp estava presente em 47,7% e 5
4% dos tumores. A infec&ccedil;&atilde;o pelo Hp ocorreu em 40 tumores (49%) no 
grupo de pacientes com MI. Nos com tumores sem MI, Hp estava presente em cinco (
50%). Tumores proximais tiveram mais infec&ccedil;&atilde;o por Hp, quando compa
rados aos tumores distais.     ^cY#v24n1a13.htm##
00989000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075400076002001300830#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#19#15#article#154#<br> <b>CONCLUS&Oti
lde;ES:</b> A taxa de infec&ccedil;&atilde;o n&atilde;o teve associa&ccedil;&ati
lde;o significativa com o tipo histol&oacute;gico, sexo, MI ou est&aacute;gio de
 desenvolvimento tumoral. Esses resultados podem indicar que a participa&ccedil;
&atilde;o da infec&ccedil;&atilde;o pelo Hp durante o desenvolvimento do CG n&at
ilde;o pode ser descartada; no entanto, provavelmente n&atilde;o &eacute; essenc
ial em todas as fases e o mecanismo do CG pode ser distinto da gastrite cr&ocirc
;nica e MI. Finalmente, &eacute; poss&iacute;vel que a associa&ccedil;&atilde;o 
proposta &eacute; mera coincid&ecirc;ncia e que n&atilde;o h&aacute; nenhuma inf
lu&ecirc;ncia real das bact&eacute;rias no processo de carcinog&ecirc;nese.</fon
t></p>     ^cY#v24n1a13.htm##
00410000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017500076002001300251#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#20#16#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b>Neoplasias g&aac
ute;stricas. Helicobacter pylori.</font></p> <hr size="1" noshade >     ^cY#v24n
1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#21#17#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#22#18#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#23#19#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></fon
t></p>     ^cY#v24n1a13.htm##
00762000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052700076002001300603#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#24#20#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">C&acirc;ncer g&aacute;strico (CG) co
ntinua sendo uma das neoplasias mais importantes a n&iacute;vel mundial, com sig
nificativa incid&ecirc;ncia e mortalidade<sup>27,33,35,39</sup>. Sua causa perma
nece controversa e v&aacute;rios fatores t&ecirc;m sido implicados no seu proces
so de carcinog&ecirc;nese. Entre esses fatores, os eventos gen&eacute;ticos, amb
ientais, e caracter&iacute;sticas da dieta parecem ser relevantes <sup>3,19,33,3
5</sup>.</font></p>     ^cY#v24n1a13.htm##
00939000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070400076002001300780#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#25#21#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Helicobacter pylori</i> (Hp) tamb
&eacute;m tem sido implicado na carcinog&ecirc;nese do c&acirc;ncer g&aacute;str
ico. Esta associa&ccedil;&atilde;o tem sido sugerida pela observa&ccedil;&atilde
;o de taxas mais elevadas de infec&ccedil;&atilde;o pelo Hp em pacientes com c&a
circ;ncer g&aacute;strico, quando comparados aos controles normais em pa&iacute;
ses ocidentais<sup>6,7,25</sup>. Por outro lado, em pa&iacute;ses com alta incid
&ecirc;ncia da neoplasia, a preval&ecirc;ncia da infec&ccedil;&atilde;o pelo Hp 
parece ser ainda maior, ocorrendo em idades precoces da popula&ccedil;&atilde;o 
em geral<sup>13,25</sup>.</font></p>     ^cY#v24n1a13.htm##
01026000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079100076002001300867#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#26#22#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O papel da infec&ccedil;&atilde;o pe
lo Hp no desenvolvimento do c&acirc;ncer g&aacute;strico pode estar associado co
m a produ&ccedil;&atilde;o de citocinas espec&iacute;ficas e enzimas levando &ag
rave; gastrite cr&ocirc;nica atr&oacute;fica e metaplasia intestinal<sup>3,19,35
</sup>. Contudo, esta associa&ccedil;&atilde;o ainda &eacute; controversa, algun
s estudos relatam a associa&ccedil;&atilde;o de Hp infec&ccedil;&atilde;o de gas
trite cr&ocirc;nica, mas n&atilde;o para c&acirc;ncer g&aacute;strico<sup>13</su
p>. Al&eacute;m disso, alguns pa&iacute;ses com baixa incid&ecirc;ncia de c&acir
c;ncer g&aacute;strico podem apresentar elevada preval&ecirc;ncia de infec&ccedi
l;&atilde;o pelo Hp<sup>8</sup>.</font></p>     ^cY#v24n1a13.htm##
00726000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049100076002001300567#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#27#23#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Por estas raz&otilde;es, em um pa&ia
cute;s com elevada preval&ecirc;ncia da infec&ccedil;&atilde;o pelo Hp entre a p
opula&ccedil;&atilde;o em geral como no Brasil, seria de se esperar encontrar al
tas taxas de infec&ccedil;&atilde;o pelo Hp em pacientes com CG. Tamb&eacute;m, 
seria de se esperar associa&ccedil;&atilde;o entre infec&ccedil;&atilde;o pelo H
p, metaplasia intestinal (MI) ou tipo intestinal CG.</font></p>     ^cY#v24n1a13
.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031000076002001300386#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#28#24#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo foi verifica
r a presen&ccedil;a de infec&ccedil;&atilde;o pelo Hp em pacientes com c&acirc;n
cer g&aacute;strico, atrav&eacute;s de exame anatomopatol&oacute;gico convencion
al do est&ocirc;mago ressecado.</font></p>     ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#29#25#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#30#26#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font></p>    
 ^cY#v24n1a13.htm##
00796000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056100076002001300637#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#31#27#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foram revisados noventa e um pacient
es com diagn&oacute;stico desta neoplasia e tratados por ressec&ccedil;&atilde;o
 cir&uacute;rgica entre 2000 e 2002. Os dados coletados inclu&iacute;ram idade a
o diagn&oacute;stico, sexo, localiza&ccedil;&atilde;o do tumor, tipo histol&oacu
te;gico (de acordo com a classifica&ccedil;&atilde;o de Lauren), relat&oacute;ri
o anatomopatol&oacute;gico completo e est&aacute;gio de evolu&ccedil;&atilde;o d
a doen&ccedil;a de acordo com a UICC-1998.</font></p>     ^cY#v24n1a13.htm##
01110000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087500076002001300951#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#32#28#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Quarenta mulheres (44%) e 51 (56%) h
omens foram eleg&iacute;veis para o estudo. A idade m&eacute;dia foi de 61 varia
ndo de 19 a 87 anos. Tr&ecirc;s pacientes (3,3%) tiveram seus tumores localizado
s no ter&ccedil;o proximal (U), 33 (36,3%), no ter&ccedil;o m&eacute;dio (M) e 4
2 (46,1%) no ter&ccedil;o distal (L) do est&ocirc;mago. Treze pacientes tinham t
umores localizados em mais de uma regi&atilde;o, sendo oito (8,8%) nos ter&ccedi
l;os distal e m&eacute;dio (LM), dois (2,2%) no ter&ccedil;o proximal e m&eacute
;dio (UM) e tr&ecirc;s tumores (3,3%) no &oacute;rg&atilde;o inteiro (LMU). A fi
m de realizar an&aacute;lises estat&iacute;sticas sobre a localiza&ccedil;&atild
e;o, os tumores de localiza&ccedil;&atilde;o proximal e m&eacute;dia foram agreg
ados e nomeados "tumores proximais".</font></p>     ^cY#v24n1a13.htm##
00814000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057900076002001300655#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#33#29#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O exame patol&oacute;gico foi revist
o por um patologista experiente em todos os pacientes, a fim de determinar a pre
sen&ccedil;a de infec&ccedil;&atilde;o pelo Hp, metaplasia intestinal MI) e a co
nfirma&ccedil;&atilde;o do tipo histol&oacute;gico (classifica&ccedil;&atilde;o 
de Lauren) por hematoxilina-eosina. A presen&ccedil;a de infec&ccedil;&atilde;o 
pelo Hp foi determinada por visualiza&ccedil;&atilde;o direta da bact&eacute;ria
 na mucosa normal adjacente de c&acirc;ncer g&aacute;strico.</font></p>     ^cY#
v24n1a13.htm##
00577000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034200076002001300418#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#34#30#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Correla&ccedil;&atilde;o entre infec
&ccedil;&atilde;o e HP, caracter&iacute;sticas epidemiol&oacute;gicas, cl&iacute
;nicas e patol&oacute;gicas foram realizadas. A an&aacute;lise estat&iacute;stic
a foi feira atrav&eacute;s do quiquadrado e testes de log-rank.</font></p>     ^
cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#35#31#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#36#32#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY
#v24n1a13.htm##
00811000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057600076002001300652#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#37#33#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No geral, 61 pacientes (68%) tinham 
o tipo intestinal de adenocarcinoma de acordo com a classifica&ccedil;&atilde;o 
de Laur&eacute;n, enquanto 30 (32%) tiveram o tipo difuso. Sessenta e sete pacie
ntes (74%) tinham CG precoce, enquanto 24 (26%) avan&ccedil;ado. No grupo de pac
ientes com CG precoce, 21 (31%) tiveram o tipo difuso e 46 (69%) tipo intestinal
. No grupo de pacientes com CG avan&ccedil;ado, nove (30%) apresentaram tipo dif
uso e 15 (70%) intestinal (<a href="#tab1">Tabela 1</a>).</font></p>     ^cY#v24
n1a13.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#38#34#article#154#<p><a name="tab1"><
/a></p>     ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#39#35#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#40#36#article#154#<p align="center"><
img src="/img/revistas/abcd/v24n1/a13tab1.jpg"></p>     ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#41#37#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00923000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068800076002001300764#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#42#38#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Metaplasia intestinal (MI) associada
 foi observada em 81 tumores (89%). No grupo de pacientes com tipo intestinal, e
la esteve presente em 54 tumores (88%). No grupo de pacientes com GC difusa, MI 
foi observada em 27 tumores (90%). No grupo de pacientes com c&acirc;ncer g&aacu
te;strico precoce, 63 (94%) tumores tinham metaplasia intestinal, enquanto que n
o grupo avan&ccedil;ado, 21 (87%) tumores tinham IM. N&atilde;o houve correla&cc
edil;&atilde;o significativa entre a presen&ccedil;a de MI, est&aacute;gio avan&
ccedil;ado/precoce ou tipo histol&oacute;gico (p&gt;0,05) (<a href="#tab2">Tabel
a 2</a>).</font></p>     ^cY#v24n1a13.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#43#39#article#154#<p><a name="tab2"><
/a></p>     ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#44#40#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#45#41#article#154#<p align="center"><
img src="/img/revistas/abcd/v24n1/a13tab2.jpg"></p>     ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#46#42#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00965000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073000076002001300806#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#47#43#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em geral, a presen&ccedil;a da infec
&ccedil;&atilde;o pelo Hp foi observada em 46 tumores (50,5%). Frequ&ecirc;ncias
 semelhantes foram observadas em homens (45%) e mulheres (55%). N&atilde;o houve
 associa&ccedil;&atilde;o entre idade e estado de Hp. Em pacientes com CG do tip
o difuso, Hp estava presente em 14 tumores (47%), enquanto nos pacientes com tip
o intestinal, presente em 31 tumores (51%). Al&eacute;m disso, no grupo de pacie
ntes com CG precoce, Hp era positivo em 32 tumores (47,7%), enquanto nos avan&cc
edil;ado em 13 pacientes (54%). Estas diferen&ccedil;as n&atilde;o apresentaram 
signific&acirc;ncia estat&iacute;stica (p&gt;0,05).</font></p>     ^cY#v24n1a13.
htm##
01087000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085200076002001300928#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#48#44#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A infec&ccedil;&atilde;o pelo Hp es
tava presente em 40 tumores (49%) com MI. Em pacientes com tumores sem MI, Hp es
tava presente em cinco (50%). No subgrupo com CG do tipo intestinal e com o MI a
 presen&ccedil;a de Hp foi detectada em 27 tumores (50%). Estas diferen&ccedil;a
s n&atilde;o apresentaram signific&acirc;ncia estat&iacute;stica (p&gt;0,05).Cur
iosamente, em pacientes com CG localizado no ter&ccedil;o distal do est&ocirc;ma
go, a presen&ccedil;a de infec&ccedil;&atilde;o pelo Hp foi observada em 14 tumo
res (37%). Nos pacientes com CG localizado proximalmente, ela estava presente em
 28 casos (56%). Tumores proximais tiveram maior frequ&ecirc;ncia de infec&ccedi
l;&atilde;o Hp quando comparados aos tumores distais (p=0,03) (<a href="#tab3">T
abela 3</a>).</font></p>     ^cY#v24n1a13.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#49#45#article#154#<p><a name="tab3"><
/a></p>     ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#50#46#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#51#47#article#154#<p align="center"><
img src="/img/revistas/abcd/v24n1/a13tab3.jpg"></p>     ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#52#48#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#53#49#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>  
   ^cY#v24n1a13.htm##
00701000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046600076002001300542#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#54#50#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No in&iacute;cio de 1900, a presen&c
cedil;a de Hp na superf&iacute;cie da mucosa g&aacute;strica foi descrita pela p
rimeira vez, coincidentemente em uma amostra de c&acirc;ncer g&aacute;strico<sup
>16</sup>. No entanto, somente no in&iacute;cio dos anos 80 foi proposta rela&cc
edil;&atilde;o entre a infec&ccedil;&atilde;o pelo Hp e doen&ccedil;as do est&oc
irc;mago<sup>7,11,18</sup>.</font></p>     ^cY#v24n1a13.htm##
00839000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060400076002001300680#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#55#51#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Durante a infec&ccedil;&atilde;o ini
cial pelo Hp, infiltrado inflamat&oacute;rio polim&oacute;rfico neutrof&iacute;l
ico &eacute; observado na superf&iacute;cie g&aacute;strica na fase aguda. Poste
riormente, h&aacute; diminui&ccedil;&atilde;o na produ&ccedil;&atilde;o de muco,
 resultando em diminui&ccedil;&atilde;o na espessura da mucosa. A infec&ccedil;&
atilde;o cr&ocirc;nica &eacute; caracterizada por aumento na contagem de linf&oa
cute;citos e plasm&oacute;citos na l&acirc;mina pr&oacute;pria<sup>19,29,33,35</
sup>.</font></p>     ^cY#v24n1a13.htm##
01651000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704141600076002001301492#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#56#52#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Propor&ccedil;&atilde;o significativ
a de pacientes com infec&ccedil;&atilde;o pelo Hp permanecem assintom&aacute;tic
os apresentando gastrite cr&ocirc;nica ativa<sup>21,28,33,35</sup>. Alguns podem
 desenvolver &uacute;lceras. Uma minoria com infec&ccedil;&atilde;o pelo Hp dese
nvolve gastrite cr&ocirc;nica atr&oacute;fica e metaplasia intestinal<sup>17,32<
/sup>. A progress&atilde;o para a doen&ccedil;a podem ser influenciados por fato
res diet&eacute;ticos, como vitamina C<sup>3,23,24</sup>, sal e ingest&atilde;o 
de nitrato<sup>9,23,24</sup>. O mecanismo proposto para a progress&atilde;o para
 gastrite atr&oacute;fica e metaplasia intestinal cr&ocirc;nica pode estar assoc
iado com a produ&ccedil;&atilde;o de citocinas e enzimas com a&ccedil;&atilde;o 
direta ou indireta sobre a mucosa g&aacute;strica<sup>33</sup>. Al&eacute;m diss
o, o processo inflamat&oacute;rio na parede g&aacute;strica pode levar &agrave; 
maior produ&ccedil;&atilde;o de citocinas, tais como IL-6, IL-8, TNF-alfa e per&
oacute;xidos contribuindo para o dano da mucosa<sup>10,15</sup>. Atividade da ur
ease do Hp, por exemplo, pode resultar na produ&ccedil;&atilde;o de am&ocirc;nia
, que por sua vez, diminui a integridade da mucosa e eleva o pH da secre&ccedil;
&atilde;o g&aacute;strica favorecendo a prolifera&ccedil;&atilde;o bacteriana<su
p>19,33,35</sup>.</font></p>     ^cY#v24n1a13.htm##
00811000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057600076002001300652#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#57#53#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O mecanismo de a&ccedil;&atilde;o pr
oposto pelo Hp na g&ecirc;nese do CG &eacute; atrav&eacute;s do desenvolvimento 
de gastrite cr&ocirc;nica e metaplasia intestinal<sup>6,31,36</sup>. Estas situa
&ccedil;&otilde;es podem ser consideradas nas condi&ccedil;&otilde;es pr&eacute;
-malignas, especificamente para o tipo de c&acirc;ncer g&aacute;strico intestina
l e, portanto, infec&ccedil;&atilde;o pelo Hp pode ser tamb&eacute;m considerado
 por alguns como pr&eacute;-maligna<sup>6,12,19,36</sup>.</font></p>     ^cY#v24
n1a13.htm##
01313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704107800076002001301154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#58#54#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nesse cen&aacute;rio, seria de grand
e interesse determinar a frequ&ecirc;ncia da infec&ccedil;&atilde;o pelo Hp em C
G. Seria de se esperar encontrar taxas mais elevadas de Hp em pacientes com CG, 
quando comparados a controles normais na popula&ccedil;&atilde;o em geral. Al&ea
cute;m disso, se o mecanismo de a&ccedil;&atilde;o da infec&ccedil;&atilde;o pel
o Hp em CG &eacute; considerado, seria esperado encontrar ainda maiores taxas de
 infec&ccedil;&atilde;o pelo Hp em c&acirc;ncer intestinal associada com metapla
sia intestinal. A confirma&ccedil;&atilde;o de tais proposi&ccedil;&otilde;es fa
voreceria a participa&ccedil;&atilde;o do Hp na carcinog&ecirc;nese g&aacute;str
ica e for&ccedil;a a import&acirc;ncia da erradica&ccedil;&atilde;o dele em paci
entes assintom&aacute;ticos, incluindo a possibilidade de medidas de preven&cced
il;&atilde;o populacional, tais como vacina&ccedil;&atilde;o em massa de &aacute
;reas de alto risco para reduzir a incid&ecirc;ncia de CG<sup>6,28,31,33</sup>.<
/font></p>     ^cY#v24n1a13.htm##
02208000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704197300076002001302049#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#59#55#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Determina&ccedil;&atilde;o da infec&
ccedil;&atilde;o pelo Hp em alguns pa&iacute;ses, como Holanda e Reino Unido, ap
resentaram &iacute;ndices maiores em pacientes com CG (61-69%) quando comparada 
a indiv&iacute;duos normais (31-47%)<sup>6</sup>. No entanto, em outras regi&oti
lde;es, como na It&aacute;lia, estas diferen&ccedil;as n&atilde;o foram observad
as<sup>26,37</sup>. Al&eacute;m disso, regi&otilde;es com alta incid&ecirc;ncia 
de CG parece ter altas preval&ecirc;ncias de infec&ccedil;&atilde;o pelo Hp, com
o o Jap&atilde;o, onde aproximadamente 75% da popula&ccedil;&atilde;o em geral t
em evid&ecirc;ncia sorol&oacute;gica de infec&ccedil;&atilde;o, onde a incid&eci
rc;ncia CG &eacute; muito elevada em compara&ccedil;&atilde;o com outros pa&iacu
te;ses e do mundo ocidental<sup>1,6</sup>. Nesse pa&iacute;s, considera-se que h
&aacute; risco aumentado em tr&ecirc;s para o desenvolvimento da CG em indiv&iac
ute;duos com infec&ccedil;&atilde;o pelo Hp quando comparados aos indiv&iacute;d
uos livres Hp, desde que a grande maioria das infec&ccedil;&otilde;es parece oco
rrer precocemente durante a vida<sup>4,6</sup>.Por outro lado, na &Aacute;frica,
 onde h&aacute; alta preval&ecirc;ncia de infec&ccedil;&atilde;o pelo Hp na popu
la&ccedil;&atilde;o em geral, h&aacute; incid&ecirc;ncia muito baixa de CG<sup>8
,31</sup>. Al&eacute;m disso, a alta frequ&ecirc;ncia de tipo intestinal e dista
l em idosos pode facilitar a prolifera&ccedil;&atilde;o bacteriana, sendo a infe
c&ccedil;&atilde;o Hp meramente circunstancial<sup>22</sup>. Finalmente, o baixo
 estado dos pa&iacute;ses em desenvolvimento pode estar associado com altas taxa
s de doen&ccedil;as infecciosas (incluindo a infec&ccedil;&atilde;o pelo Hp). Es
pecificamente no Brasil, onde a preval&ecirc;ncia de doen&ccedil;as infecciosas 
e GC s&atilde;o altos, a associa&ccedil;&atilde;o entre elas pode ser mera coinc
id&ecirc;ncia.</font></p>     ^cY#v24n1a13.htm##
01386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115100076002001301227#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#60#56#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">H&aacute; algumas outras evid&ecirc;
ncias que n&atilde;o favorecem correla&ccedil;&atilde;o entre a infec&ccedil;&at
ilde;o por Hp e carcinog&ecirc;nese no CG. Em primeiro lugar, a associa&ccedil;&
atilde;o entre a infec&ccedil;&atilde;o pelo Hp e gastrite cr&ocirc;nica est&aac
ute; bem estabelecida, mas a associa&ccedil;&atilde;o entre a infec&ccedil;&atil
de;o pelo Hp e CG n&atilde;o &eacute; amplamente aceita<sup>31,38</sup>. Alguns 
autores acreditam que a CG surge "de novo" e n&atilde;o atrav&eacute;s de gastri
te cr&ocirc;nica e metaplasia intestinal<sup>13,38</sup>. Al&eacute;m disso, h&a
acute; associa&ccedil;&atilde;o significativa entre o CG e sexo (homens s&atilde
;o mais frequentemente afetados). Portanto, seria de se esperar encontrar a mesm
a associa&ccedil;&atilde;o entre sexo e infec&ccedil;&atilde;o pelo Hp. No entan
to, a preval&ecirc;ncia da infec&ccedil;&atilde;o dele mostra a distribui&ccedil
;&atilde;o igualit&aacute;ria entre homens e mulheres controles, incluindo os re
sultados observados no presente estudo em pacientes com CG<sup>38</sup>.</font><
/p>     ^cY#v24n1a13.htm##
01066000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083100076002001300907#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#61#57#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Neste estudo, a determina&ccedil;&at
ilde;o da infec&ccedil;&atilde;o pelo Hp em 91 amostras de CG foi feita por exam
e anatomopatol&oacute;gico convencional, utilizando hematoxilina-eosina. Este m&
eacute;todo &eacute; muito caro, minucioso e a presen&ccedil;a de um patologista
 experiente &eacute; crucial. Por outro lado d&aacute; informa&ccedil;&atilde;o 
inequ&iacute;voca sobre a presen&ccedil;a de infec&ccedil;&atilde;o pelo Hp. Al&
eacute;m disso, ele pode ser &uacute;til em casos de CG, onde ressec&ccedil;&ati
lde;o cir&uacute;rgica, foi realizada, mas question&aacute;vel em controles norm
ais em bi&oacute;psias endosc&oacute;picas por vezes escassas e insuficientes pa
ra a determina&ccedil;&atilde;o exata da infec&ccedil;&atilde;o pelo Hp.</font><
/p>     ^cY#v24n1a13.htm##
01293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105800076002001301134#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#62#58#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A preval&ecirc;ncia da infec&ccedil
;&atilde;o pelo Hp neste estudo foi surpreendentemente baixa, de 50,5%. Um estud
o anterior realizado em nosso pa&iacute;s, com 18 pacientes com CG, mostrou  pre
val&ecirc;ncia de infec&ccedil;&atilde;o de mais de 80%, muito superior a estes 
resultados<sup>25</sup>. Al&eacute;m disso, a taxa de infec&ccedil;&atilde;o no 
presente estudo &eacute; consideravelmente menor do que a  preval&ecirc;ncia da 
infec&ccedil;&atilde;o em controles normais no Brasil, determinado por estudos s
orol&oacute;gicos<sup>20,30</sup>. Nosso pa&iacute;s &eacute; considerado como a
presentando alta preval&ecirc;ncia de infec&ccedil;&atilde;o na popula&ccedil;&a
tilde;o geral, atingindo taxas de infec&ccedil;&atilde;o de at&eacute; 80%<sup>2
0,30</sup>. A infec&ccedil;&atilde;o pelo Hp em pacientes com CG neste estudo oc
orreram em taxas similares entre ambos os sexos, de acordo com observa&ccedil;&o
tilde;es anteriores em controles normais<sup>1,30,38</sup>.</font></p>     ^cY#v
24n1a13.htm##
01210000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704097500076002001301051#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#63#59#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Curiosamente, houve correla&ccedil;&
atilde;o significativa entre a infec&ccedil;&atilde;o pelo Hp e localiza&ccedil;
&atilde;o do tumor no CG. No entanto, a baixa incid&ecirc;ncia de tumores proxim
ais pode ser respons&aacute;vel por esta diferen&ccedil;a, j&aacute; que por raz
&otilde;es estat&iacute;sticas, tumores localizados no ter&ccedil;o proximal e m
&eacute;dio tiveram que ser agregados. Surpreendentemente, a taxa de infec&ccedi
l;&atilde;o n&atilde;o teve associa&ccedil;&atilde;o significativa com o tipo hi
stol&oacute;gico, sexo ou est&aacute;gio (inicial vs avan&ccedil;ado), quando de
veria serem esperadas taxas mais altas de infec&ccedil;&atilde;o do tipo intesti
nal. Surpreendentemente, n&atilde;o houve associa&ccedil;&atilde;o entre a infec
&ccedil;&atilde;o pelo Hp e MI, uma das evid&ecirc;ncias propostas para correla&
ccedil;&atilde;o da infec&ccedil;&atilde;o pelo Hp e CG.</font></p>     ^cY#v24n
1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#64#60#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#65#61#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>  
   ^cY#v24n1a13.htm##
01211000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704097600076002001301052#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#66#62#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os resultados da infec&ccedil;&atild
e;o pelo Hp em pacientes com CG indicam que ela ocorre aproximadamente em 50% do
s pacientes pelo estudo histopatol&oacute;gico do esp&eacute;cime ressecado. Par
ticipa&ccedil;&atilde;o dele durante o desenvolvimento do CG n&atilde;o pode ser
 descartada, por&eacute;m provavelmente n&atilde;o &eacute; essencial durante to
das as fases do desenvolvimento da doen&ccedil;a. Al&eacute;m disso, se houver a
 participa&ccedil;&atilde;o da infec&ccedil;&atilde;o pelo Hp no desenvolvimento
 do c&acirc;ncer g&aacute;strico, o mecanismo pode ser distinto do da gastrite c
r&ocirc;nica e a progress&atilde;o MI. Finalmente, &eacute; poss&iacute;vel que 
a associa&ccedil;&atilde;o entre a infec&ccedil;&atilde;o pelo Hp e CG &eacute; 
mera coincid&ecirc;ncia e que n&atilde;o h&aacute; nenhuma influ&ecirc;ncia real
 das bact&eacute;rias no processo de carcinog&ecirc;nese.</font></p>     ^cY#v24
n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#67#63#article#154#<p>&nbsp;</p>     ^
cY#v24n1a13.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#68#64#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p> 
    ^cY#v24n1a13.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022400078002001300302#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#69#65#article#154#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. An international as
sociation between <i>Helicobacter pylori</i> infection and gastric cancer. The E
UROGAST Study Group. Lancet 1993;341(8857):1359-62.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#70#66#article#154#</font></p>     ^cY
#v24n1a13.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031000078002001300388#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#71#67#article#154#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2.<i> Helicobacter pyl
ori</i> in patients with intestinal metaplasia and in controls: a serological an
d biopsy study in four UK centres. UK Sub-Group of the ECP-EURONUT-Intestinal Me
taplasia Study Group. Eur J Cancer Prev 1995;4(2):175-80.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#72#68#article#154#</font></p>     ^cY
#v24n1a13.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022100078002001300299#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#73#69#article#154#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Asaka M, Takeda H, 
Sugiyama T, Kato M. What role does <i>Helicobacter pylori</i> play in gastric ca
ncer? Gastroenterology 1997;113(6 Suppl):S56-60.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#74#70#article#154#</font></p>     ^cY
#v24n1a13.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029500078002001300373#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#75#71#article#154#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Barreto R, Maruyama
 M, Kato Y, Aizu K. Gastric cancer and <i>Helicobacter pylori</i> infection: a s
eroprevalence study in Cancer Institute Hospital Japan. In: 1st International Ga
stric Cancer Congress.; 1995;Kyoto, Japan.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#76#72#article#154#</font></p>     ^cY
#v24n1a13.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019100078002001300269#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#77#73#article#154#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Craanen ME, Blok P,
 Dekker W, Tytgat GN. <i>Helicobacter pylori</i> and early gastric cancer. Gut 1
994;35(10):1372-4.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#78#74#article#154#</font></p>     ^cY
#v24n1a13.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030400078002001300382#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#79#75#article#154#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Endo S, Ohkusa T, S
aito Y, Fujiki K, Okayasu I, Sato C. Detection of <i>Helicobacter pylori</i> inf
ection in early gastric cancer. A comparison between intestinal and diffuse-type
 gastric adenocarcinomas. Cancer 1995;75(9):2203-8.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#80#76#article#154#</font></p>     ^cY
#v24n1a13.htm##
00576000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032700078002001300405#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#81#77#article#154#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Fox JG, Correa P, T
aylor NS, Zavala D, Fontham E, Janney F, Rodriguez E, Hunter F, Diavolitsis S. C
ampylobacter pylori-associated gastritis and immune response in a population at 
increased risk of gastric carcinoma. Am J Gastroenterol 1989;84(7):775-81.    ^c
Y#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#82#78#article#154#</font></p>     ^cY
#v24n1a13.htm##
00406000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015700078002001300235#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#83#79#article#154#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Holcombe 	C. <i>Hel
icobacter pylori</i>: the African enigma. Gut 1992;33(4):429-31.    ^cY#v24n1a13
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#84#80#article#154#</font></p>     ^cY
#v24n1a13.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023400078002001300312#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#85#81#article#154#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Hu JF, Zhang SF, Ji
a EM, Wang QQ, Liu SD, Liu YY, Wu YP, Cheng YT. Diet and cancer of the stomach: 
a case-control study in China. Int J Cancer 1988;41(3):331-5.    ^cY#v24n1a13.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#86#82#article#154#</font></p>     ^cY
#v24n1a13.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029700079002001300376#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#87#83#article#154#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Innocenti M, Thor
eson AC, Ferrero RL, Str&ouml;mberg E, B&ouml;lin I, Eriksson L, Svennerholm AM,
 Quiding-J&auml;rbrink M. Helicobacter pylori-induced activation of human endoth
elial cells. Infect Immun 2002;70(8):4581-90.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#88#84#article#154#</font></p>     ^cY
#v24n1a13.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028400079002001300363#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#89#85#article#154#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Jaskiewicz K, Lou
wrens HD, Woodroof CW, van Wyk MJ, Price SK. The association of Campylobacter py
lori with mucosal pathological changes in a population at risk for gastric cance
r. S Afr Med J 1989;75(9):417-9.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#90#86#article#154#</font></p>     ^cY
#v24n1a13.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030400079002001300383#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#91#87#article#154#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Kato S, Onda M, M
atsukura N, Tokunaga A, Matsuda N, Yamashita K, Shields PG. <i>Helicobacter pylo
ri</i> infection and genetic polymorphisms for cancer-related genes in gastric c
arcinogenesis. Biomed Pharmacother 1997;51(4):145-9.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#92#88#article#154#</font></p>     ^cY
#v24n1a13.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024300079002001300322#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#93#89#article#154#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Kato T, Saito Y, 
Matsumura S, Akiyama N. <i>Helicobacter pylori</i> infection in early gastric ca
ncer. In: 1st International Gastric Cancer Congress; 1995;Kyoto, Japan.    ^cY#v
24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#94#90#article#154#</font></p>     ^cY
#v24n1a13.htm##
00425000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704017500079002001300254#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#95#91#article#154#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Kelley JR, Duggan
 JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56(1):1
-9.    ^cY#v24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#96#92#article#154#</font></p>     ^cY
#v24n1a13.htm##
00573000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704032300079002001300402#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#97#93#article#154#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Klausz G, Tiszai 
A, Tiszlavicz L, Gyulai Z, L&eacute;n&aacute;rt Z, Lonovics J, M&aacute;ndi Y. L
ocal and peripheral cytokine response and CagA status of Helicobacter pylori-pos
itive patients with duodenal ulcer. Eur Cytokine Netw 2003;14(3):143-8.    ^cY#v
24n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#98#94#article#154#</font></p>     ^cY
#v24n1a13.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021600079002001300295#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#99#95#article#154#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Krienitz W. Ueber
 das Auftreten von spirochaten verschiedener form im mageninhalt bei carcinoma v
entriculi. Dtsch Med Wochenschr 1906;332872.    ^cY#v24n1a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#100#96#article#154#</font></p>     ^c
Y#v24n1a13.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704026400080002001300344#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#101#97#article#154#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Kuipers EJ, Uyte
rlinde AM, Pe&ntilde;a AS, Roosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen 
SG. Long-term sequelae of <i>Helicobacter pylori</i> gastritis. Lancet 1995;345(
8964):1525-8.    ^cY#v24n1a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#102#98#article#154#</font></p>     ^c
Y#v24n1a13.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704021900080002001300299#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#103#99#article#154#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Marshall BJ, War
ren JR. Unidentified curved bacilli in the stomach of patients with gastritis an
d peptic ulceration. Lancet 1984;1(8390):1311-5.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#104#100#article#154#</font></p>     ^
cY#v24n1a13.htm##
00579000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032700081002001300408#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#105#101#article#154#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Matsukura N, On
da M, Tokunaga A. Mucosal IgA antibody against <i>Helicobacter pylori</i> in chr
onic gastritis and intestinal metaplasia in resected stomach for gastric cancer.
 In: 1<sup>st</sup> International Gastric Cancer Congress; 1995;Kyoto, Japan.   
 ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#106#102#article#154#</font></p>     ^
cY#v24n1a13.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#107#103#article#154#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Mattar R, Silva
 F, Birbojm I, Zilberstein B. <i>Helicobacter pylori</i> infection: a risk facto
r for gastric cancer? Serological study. In: Fifth International Gastric Cancer 
Congress; 2003; Rome, Italy.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#108#104#article#154#</font></p>     ^
cY#v24n1a13.htm##
00425000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017300081002001300254#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#109#105#article#154#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. McFarlane GA, M
unro A. <i>Helicobacter pylori</i> and gastric cancer. Br J Surg 1997;84(9):1190
-9.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#110#106#article#154#</font></p>     ^
cY#v24n1a13.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026800081002001300349#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#111#107#article#154#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Megraud F. Epid
emiology of Helicopbacter pylori infection. In: Rathbone Be, RV, eds. (ed) <i>He
licobacter pylori</i> and Gastroduodenal Disease. 2nd ed. Blachwell Scientific P
iblications; 1992.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#112#108#article#154#</font></p>     ^
cY#v24n1a13.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021200081002001300293#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#113#109#article#154#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 23. Mirvish SS. Th
e etiology of gastric cancer. Intragastric nitrosamide formation and other theor
ies. J Natl Cancer Inst 1983;71(3):629 47.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#114#110#article#154#</font></p>     ^
cY#v24n1a13.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020800081002001300289#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#115#111#article#154#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Mirvish SS. Eff
ects of vitamins C and E on N-nitroso compound formation, carcinogenesis, and ca
ncer. Cancer 1986;58(8 Suppl):1842-50.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#116#112#article#154#</font></p>     ^
cY#v24n1a13.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#117#113#article#154#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Nogueira AM, Ri
beiro GM, Rodrigues MA, Queiroz DM, Mendes EN, Rocha GA, Barbosa AJ. Prevalence 
of <i>Helicobacter pylori</i> in Brazilian patients with gastric carcinoma. Am J
 Clin Pathol 1993;100(3):236-9.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#118#114#article#154#</font></p>     ^
cY#v24n1a13.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031500081002001300396#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#119#115#article#154#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Palli D, Decarl
i A, Cipriani F, Sitas F, Forman D, Amadori D, Avellini C, Giacosa A, Manca P, R
usso A. <i>Helicobacter pylori</i> antibodies in areas of Italy at varying gastr
ic cancer risk. Cancer Epidemiol Biomarkers Prev 1993;2(1):37-40.    ^cY#v24n1a1
3.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#120#116#article#154#</font></p>     ^
cY#v24n1a13.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019800081002001300279#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#121#117#article#154#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 27. Parkin DM, Mui
r CS. Cancer Incidence in Five Continents.Comparability and quality of data. IAR
C Sci Publ 1992(120):45-173.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#122#118#article#154#</font></p>     ^
cY#v24n1a13.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027200081002001300353#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#123#119#article#154#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Parsonnet J, Ha
rris RA, Hack HM, Owens DK. Modelling costeffectiveness of <i>Helicobacter pylor
i</i> screening to prevent gastric cancer: a mandate for clinical trials. Lancet
 1996;348(9021):150-4.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#124#120#article#154#</font></p>     ^
cY#v24n1a13.htm##
00415000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016300081002001300244#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#125#121#article#154#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Price A. The Si
dney system: histological division. J Gastroenterol Hepatol 1991;6209-22.    ^cY
#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#126#122#article#154#</font></p>     ^
cY#v24n1a13.htm##
00594000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034200081002001300423#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#127#123#article#154#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Rocha GA, Queir
oz DM, Mendes EN, Oliveira AM, Moura SB, Barbosa MT, Mendes CC, Lima J&uacute;ni
or GF, Oliveira CA. Indirect immunofluorescence determination of the frequency o
f anti-H. pylori antibodies in Brazilian blood donors. Braz J Med Biol Res 1992;
25(7):683-9.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#128#124#article#154#</font></p>     ^
cY#v24n1a13.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#129#125#article#154#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Rugge M, Cassar
o M, Leandro G, Baffa R, Avellini C, Bufo P, Stracca V, Battaglia G, Fabiano A, 
Guerini A, Di Mario F. <i>Helicobacter pylori</i> in promotion of gastric carcin
ogenesis. Dig Dis Sci 1996;41(5):950 5.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#130#126#article#154#</font></p>     ^
cY#v24n1a13.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031500081002001300396#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#131#127#article#154#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Sakaki N, Momma
 K, Egawa N, Yamada Y, Kan T, Ishiwata J. The influence of <i>Helicobacter pylor
i</i> infection on the progression of gastric mucosal atrophy and occurrence of 
gastric cancer. Eur J Gastroenterol Hepatol 1995;7 Suppl 1S59-62.    ^cY#v24n1a1
3.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#132#128#article#154#</font></p>     ^
cY#v24n1a13.htm##
00425000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017300081002001300254#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#133#129#article#154#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Scheiman JM, Cu
tler AF. <i>Helicobacter pylori</i> and gastric cancer. Am J Med 1999;106(2):222
-6.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#134#130#article#154#</font></p>     ^
cY#v24n1a13.htm##
00616000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036400081002001300445#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#135#131#article#154#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Solcia E, Fiocc
a R, Luinetti O, Villani L, Padovan L, Calistri D, Ranzani GN, Chiaravalli A, Ca
pella C. Intestinal and diffuse gastric cancers arise in a different background 
of <i>Helicobacter pylori</i> gastritis through different gene involvement. Am J
 Surg Pathol 1996;20 Suppl 1S8-22.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#136#132#article#154#</font></p>     ^
cY#v24n1a13.htm##
00422000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017000081002001300251#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#137#133#article#154#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Stolte M, Meini
ng A. <i>Helicobacter pylori</i> and Gastric Cancer. Oncologist 1998;3(2):124-8.
    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#138#134#article#154#</font></p>     ^
cY#v24n1a13.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024400081002001300325#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#139#135#article#154#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Takeuchi K, Ohn
o Y, Tsuzuki Y, Ando T, Sekihara M, Hara T, KuwanoH. <i>Helicobacter pylori</i> 
infection and early gastric cancer. J Clin Gastroenterol 2003;36(4):321-4.    ^c
Y#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#140#136#article#154#</font></p>     ^
cY#v24n1a13.htm##
00436000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018400081002001300265#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#141#137#article#154#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 37. Tomaselli G, C
itarda F, Crespi M. <i>Helicobacter pylori</i> and gastric cancer. Clin Ter 1999
;150(3):221-4.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#142#138#article#154#</font></p>     ^
cY#v24n1a13.htm##
00548000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029600081002001300377#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#143#139#article#154#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Watanabe Y, Kur
ata JH, Mizuno S, Mukai M, Inokuchi H, Miki K, Ozasa K, Kawai K. <i>Helicobacter
 pylori</i> infection and gastric cancer. A nested case-control study in a rural
 area of Japan. Dig Dis Sci 1997;42(7):1383-7.    ^cY#v24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#144#140#article#154#</font></p>     ^
cY#v24n1a13.htm##
00413000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016100081002001300242#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#145#141#article#154#39#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Wingo PA, Tong 
T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45(1):8-30.    ^cY#v
24n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#146#142#article#154#</font></p>     ^
cY#v24n1a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#147#143#article#154#<p>&nbsp;</p>    
 ^cY#v24n1a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#148#144#article#154#<p>&nbsp;</p>    
 ^cY#v24n1a13.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019900078002001300277#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#149#145#article#154#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0" ></a> Correspond&e
circ;ncia:</b>    ^cY#v24n1a13.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002800078002001300106#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#150#146#article#154#<br>Ivan Cecconel
lo     ^cY#v24n1a13.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010200078002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#151#147#article#154#<br>  e-mail: <a 
href="mailto:cecconello@terra.com.br">cecconello@terra.com.br</a></font></p>    
 ^cY#v24n1a13.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012100078002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#152#148#article#154#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 16/09/2010    ^cY#v24n1a13.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#153#149#article#154#<br> Aceito para 
publica&ccedil;&atilde;o: 21/12/2010    ^cY#v24n1a13.htm##
00295000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005800078002001300136#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#154#150#article#154#<br> Fonte de fin
anciamento: n&atilde;o h&aacute;     ^cY#v24n1a13.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006800078002001300146#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#155#151#article#154#<br>Conflito de i
nteresses: n&atilde;o h&aacute;</font></p>     ^cY#v24n1a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#156#152#article#154#<p>&nbsp;</p>    
 ^cY#v24n1a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#157#153#article#154#<p>&nbsp;</p>    
 ^cY#v24n1a13.htm##
00467000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704023000078002001300308#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#p#158#154#article#154#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado na Faculdade de
 Medicina da Universidade de S&atilde;o Paulo, Departamento de Gastroenterologia
, , S&atilde;o Paulo, SP, Brasil.</font></p>     ^cY#v24n1a13.htm##
00536000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750120116000770300007001930650
00900200064000500209031000400214032000500218014000800223865000900231002001300240
035001000253801000700263#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S
#c#159#1#article#39#1#An international association between Helicobacter pylori i
nfection and gastric cancer: The EUROGAST Study Group^len#Lancet#19930000#1993#3
41#8857#1359-62#20110300#v24n1a13.htm#0099-5355#Lancet##
00633000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750120197000770300018002740650
00900292064000500301031000200306032000200308014000700310865000900317002001300326
035001000339801001800349#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S
#c#160#2#article#39#2#Helicobacter pylori in patients with intestinal metaplasia
 and in controls: a serological and biopsy study in four UK centres. UK Sub-Grou
p of the ECP-EURONUT-Intestinal Metaplasia Study Group^len#Eur J Cancer Prev#199
50000#1995#4#2#175-80#20110300#v24n1a13.htm#0959-8278#Eur J Cancer Prev##
00611000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01800108010001400126012006200140030001700202065000900219064000500228031000400233
032000400237014000700241865000900248002001300257035001000270801001700280#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#161#3#article#39#3#^rND^sAsak
a^nM#^rND^sTakeda^nH#^rND^sSugiyama^nT#^rND^sKato^nM#What role does Helicobacter
 pylori play in gastric cancer^len#Gastroenterology#19970000#1997#113#^s6#S56-60
#20110300#v24n1a13.htm#0016-5085#Gastroenterology##
00638000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01400112010001500126012011200141053004700253055001200300054000800312056000900320
057000900329865000900338002001300347#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a13.htm#S#c#162#4#article#39#4#^rND^sBarreto^nR#^rND^sMaruyama^nM#^rND^sKato^
nY#^rND^sAizu^nK.#Gastric cancer and Helicobacter pylori infection: a seropreval
ence study in Cancer Institute Hospital Japan^len#International Gastric Cancer C
ongress^n1^i1^i1#19950000^i1#1995^i1#Kyoto^i1#Japan^i1#20110300#v24n1a13.htm##
00572000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100014000950100
01600109010001700125012004900142030000400191065000900195064000500204031000300209
032000300212014000700215865000900222002001300231035001000244801000400254#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#163#5#article#39#5#^rND^sCraa
nen^nME#^rND^sBlok^nP#^rND^sDekker^nW#^rND^sTytgat^nGN#Helicobacter pylori and e
arly gastric cancer^len#Gut#19940000#1994#35#10#1372-4#20110300#v24n1a13.htm#001
7-5749#Gut##
00724000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100016000910100
01500107010001600122010001700138010001400155012014500169030000700314065000900321
06400050033003100030033503200020033801400070034086500090034700200130035603500100
0369801000700379#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#164#6
#article#39#6#^rND^sEndo^nS#^rND^sOhkusa^nT#^rND^sSaito^nY#^rND^sFujiki^nK#^rND^
sOkayasu^nI#^rND^sSato^nC#Detection of Helicobacter pylori infection in early ga
stric cancer: A comparison between intestinal and diffuse-type gastric adenocarc
inomas^len#Cancer#19950000#1995#75#9#2203-8#20110300#v24n1a13.htm#0008-543X#Canc
er##
00820000000000373000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100016000910100
01700107010001600124010001700140010001600157010001900173010001600192010002100208
01201210022903000190035006500090036906400050037803100030038303200020038601400070
0388865000900395002001300404035001000417801001900427#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a13.htm#S#c#165#7#article#39#7#^rND^sFox^nJG#^rND^sCorrea^nP#
^rND^sTaylor^nNS#^rND^sZavala^nD#^rND^sFontham^nE#^rND^sJanney^nF#^rND^sRodrigue
z^nE#^rND^sHunter^nF#^rND^sDiavolitsis^nS#Campylobacter pylori-associated gastri
tis and immune response in a population at increased risk of gastric carcinoma^l
en#Am J Gastroenterol#19890000#1989#84#7#775-81#20110300#v24n1a13.htm#0002-9270#
Am J Gastroenterol##
00483000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120044000950300
00400139065000900143064000500152031000300157032000200160014000700162865000900169
002001300178035001000191801000400201#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a13.htm#S#c#166#8#article#39#8#^rND^sHolcombe^nC#Helicobacter pylori: the Afr
ican enigma^len#Gut#19920000#1992#33#4#429-31#20110300#v24n1a13.htm#0017-5749#Gu
t##
00703000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770100016000900100
01400106010001500120010001400135010001400149010001300163010001600176012006600192
03000130025806500090027106400050028003100030028503200020028801400060029086500090
0296002001300305035001000318801001300328#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a13.htm#S#c#167#9#article#39#9#^rND^sHu^nJF#^rND^sZhang^nSF#^rND^sJia^nEM
#^rND^sWang^nQQ#^rND^sLiu^nSD#^rND^sLiu^nYY#^rND^sWu^nYP#^rND^sCheng^nYT#Diet an
d cancer of the stomach: a case-control study in China^len#Int J Cancer#19880000
#1988#41#3#331-5#20110300#v24n1a13.htm#0020-7136#Int J Cancer##
00752000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01800117010001900135010001500154010001800169010002200187010002600209012007000235
03000130030506500090031806400050032703100030033203200020033501400080033786500090
0345002001300354035001000367801001300377#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a13.htm#S#c#168#10#article#39#10#^rND^sInnocenti^nM#^rND^sThoreson^nAC#^r
ND^sFerrero^nRL#^rND^sStrömberg^nE#^rND^sBölin^nI#^rND^sEriksson^nL#^rND^sSvenne
rholm^nAM#^rND^sQuiding-Järbrink^nM#Helicobacter pylori-induced activation of hu
man endothelial cells^len#Infect Immun#20020000#2002#70#8#4581-90#20110300#v24n1
a13.htm#0019-9567#Infect Immun##
00699000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100019000990100
01900118010001800137010001600155012012100171030001200292065000900304064000500313
03100030031803200020032101400060032386500090032900200130033803500100035180100120
0361#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#169#11#article#39
#11#^rND^sJaskiewicz^nK#^rND^sLouwrens^nHD#^rND^sWoodroof^nCW#^rND^svan Wyk^nMJ#
^rND^sPrice^nSK#The association of Campylobacter pylori with mucosal pathologica
l changes in a population at risk for gastric cancer^len#S Afr Med J#19890000#19
89#75#9#417-9#20110300#v24n1a13.htm#0038-2469#S Afr Med J##
00756000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100014000930100
01900107010001800126010001700144010001900161010001800180012011100198030002000309
06500090032906400050033803100030034303200020034601400060034886500090035400200130
0363035001000376801002000386#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.h
tm#S#c#170#12#article#39#12#^rND^sKato^nS#^rND^sOnda^nM#^rND^sMatsukura^nN#^rND^
sTokunaga^nA#^rND^sMatsuda^nN#^rND^sYamashita^nK#^rND^sShields^nPG#Helicobacter 
pylori infection and genetic polymorphisms for cancer-related genes in gastric c
arcinogenesis^len#Biomed Pharmacother#19970000#1997#51#4#145-9#20110300#v24n1a13
.htm#0753-3322#Biomed Pharmacother##
00588000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930100
01900108010001800127012005800145053004700203055001200250054000800262056000900270
057000900279865000900288002001300297#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a13.htm#S#c#171#13#article#39#13#^rND^sKato^nT#^rND^sSaito^nY#^rND^sMatsumura
^nS#^rND^sAkiyama^nN.#Helicobacter pylori infection in early gastric cancer^len#
International Gastric Cancer Congress^n1^i1^i1#19950000^i1#1995^i1#Kyoto^i1#Japa
n^i1#20110300#v24n1a13.htm##
00541000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960120
04900113030001700162065000900179064000500188031000300193032000200196014000400198
865000900202002001300211035001000224801001700234#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a13.htm#S#c#172#14#article#39#14#^rND^sKelley^nJR#^rND^sDuggan^nJ
M#Gastric cancer epidemiology and risk factors^len#J Clin Epidemiol#20030000#200
3#56#1#1-9#20110300#v24n1a13.htm#0895-4356#J Clin Epidemiol##
00759000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
02000111010001600131010001600147010001800163010001500181012012000196030001800316
06500090033406400050034303100030034803200020035101400060035386500090035900200130
0368035001000381801001800391#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.h
tm#S#c#173#15#article#39#15#^rND^sKlausz^nG#^rND^sTiszai^nA#^rND^sTiszlavicz^nL#
^rND^sGyulai^nZ#^rND^sLénárt^nZ#^rND^sLonovics^nJ#^rND^sMándi^nY#Local and perip
heral cytokine response and CagA status of Helicobacter pylori-positive patients
 with duodenal ulcer^len#Eur Cytokine Netw#20030000#2003#14#3#143-8#20110300#v24
n1a13.htm#1148-5493#Eur Cytokine Netw##
00527000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120099000980300
02100197065000900218064000500227865000900232002001300241035001000254801002100264
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#174#16#article#39#16#
^rND^sKrienitz^nW.#Ueber das Auftreten von spirochaten verschiedener form im mag
eninhalt bei carcinoma ventriculi^lde#Dtsch Med Wochenschr#19060000#1906#2011030
0#v24n1a13.htm#0012-0472#Dtsch Med Wochenschr##
00714000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100021000970100
01500118010002000133010001400153010001600167010001700183010002000200012005600220
03000070027606500090028306400050029203100040029703200050030101400070030686500090
0313002001300322035001000335801000700345#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a13.htm#S#c#175#17#article#39#17#^rND^sKuipers^nEJ#^rND^sUyterlinde^nAM#^
rND^sPeña^nAS#^rND^sRoosendaal^nR#^rND^sPals^nG#^rND^sNelis^nGF#^rND^sFesten^nHP
#^rND^sMeuwissen^nSG#Long-term sequelae of Helicobacter pylori gastritis^len#Lan
cet#19950000#1995#345#8964#1525-8#20110300#v24n1a13.htm#0099-5355#Lancet##
00575000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980120
09600115030000700211065000900218064000500227031000200232032000500234014000700239
865000900246002001300255035001000268801000700278#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a13.htm#S#c#176#18#article#39#18#^rND^sMarshall^nBJ#^rND^sWarren^
nJR#Unidentified curved bacilli in the stomach of patients with gastritis and pe
ptic ulceration^len#Lancet#19840000#1984#1#8390#1311-5#20110300#v24n1a13.htm#009
9-5355#Lancet##
00643000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100014000980100
01900112012013900131053004700270055001200317054000800329056000900337057000900346
865000900355002001300364#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S
#c#177#19#article#39#19#^rND^sMatsukura^nN#^rND^sOnda^nM#^rND^sTokunaga^nA.#Muco
sal IgA antibody against Helicobacter pylori in chronic gastritis and intestinal
 metaplasia in resected stomach for gastric cancer^len#International Gastric Can
cer Congress^n1^i1^i1#19950000^i1#1995^i1#Kyoto^i1#Japan^i1#20110300#v24n1a13.ht
m##
00624000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01700110010002200127012008700149053005100236055001200287054000800299056000800307
057000900315865000900324002001300333#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a13.htm#S#c#178#20#article#39#20#^rND^sMattar^nR#^rND^sSilva^nF#^rND^sBirbojm
^nI#^rND^sZilberstein^nB.#Helicobacter pylori infection: a risk factor for gastr
ic cancer? Serological study^len#International Gastric Cancer Congress^nFifth^i1
^i1#20030000^i1#2003^i1#Rome^i1#Italy^i1#20110300#v24n1a13.htm##
00525000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100015000990120
04300114030001000157065000900167064000500176031000300181032000200184014000700186
865000900193002001300202035001000215801001000225#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a13.htm#S#c#179#21#article#39#21#^rND^sMcFarlane^nGA#^rND^sMunro^
nA#Helicobacter pylori and gastric cancer^len#Br J Surg#19970000#1997#84#9#1190-
9#20110300#v24n1a13.htm#0007-1323#Br J Surg##
00547000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120051000970160
02200148018005100170063000200221062003400223065000900257064000500266865000900271
002001300280#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#180#22#ar
ticle#39#22#^rND^sMegraud^nF.#Epidemiology of Helicopbacter pylori infection^len
#^rED^sRathbone Be^nRV#Helicobacter pylori and Gastroduodenal Disease^len#2#Blac
hwell Scientific Piblications#19920000#1992#20110300#v24n1a13.htm##
00562000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120090000980300
01900188065000900207064000500216031000300221032000200224014000700226865000900233
002001300242035001000255801001900265#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a13.htm#S#c#181#23#article#39#23#^rND^sMirvish^nSS.#The etiology of gastric c
ancer: Intragastric nitrosamide formation and other theories^len#J Natl Cancer I
nst#19830000#1983#71#3#629 47#20110300#v24n1a13.htm#0027-8874#J Natl Cancer Inst
##
00542000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120092000970300
00700189065000900196064000500205031000300210032000400213014000800217865000900225
002001300234035001000247801000700257#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a13.htm#S#c#182#24#article#39#24#^rND^sMirvish^nSS#Effects of vitamins C and 
E on N-nitroso compound formation, carcinogenesis, and cancer^len#Cancer#1986000
0#1986#58#^s8#1842-50#20110300#v24n1a13.htm#0008-543X#Cancer##
00730000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
02000116010001800136010001700154010001600171010001800187012008300205030001700288
06500090030506400050031403100040031903200020032301400060032586500090033100200130
0340035001000353801001700363#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.h
tm#S#c#183#25#article#39#25#^rND^sNogueira^nAM#^rND^sRibeiro^nGM#^rND^sRodrigues
^nMA#^rND^sQueiroz^nDM#^rND^sMendes^nEN#^rND^sRocha^nGA#^rND^sBarbosa^nAJ#Preval
ence of Helicobacter pylori in Brazilian patients with gastric carcinoma^len#Am 
J Clin Pathol#19930000#1993#100#3#236-9#20110300#v24n1a13.htm#0002-9173#Am J Cli
n Pathol##
00834000000000385000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01800111010001500129010001600144010001700160010001800177010001700195010001500212
01000150022701200840024203000330032606500090035906400050036803100020037303200020
0375014000600377865000900383002001300392035001000405801003300415#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#184#26#article#39#26#^rND^sPalli^nD#^
rND^sDecarli^nA#^rND^sCipriani^nF#^rND^sSitas^nF#^rND^sForman^nD#^rND^sAmadori^n
D#^rND^sAvellini^nC#^rND^sGiacosa^nA#^rND^sManca^nP#^rND^sRusso^nA#Helicobacter 
pylori antibodies in areas of Italy at varying gastric cancer risk^len#Cancer Ep
idemiol Biomarkers Prev#19930000#1993#2#1#37-40#20110300#v24n1a13.htm#1055-9965#
Cancer Epidemiol Biomarkers Prev##
00550000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960120
07500112030001400187065000900201064000500210032000400215014000700219865000900226
002001300235035001000248801001400258#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a13.htm#S#c#185#27#article#39#27#^rND^sParkin^nDM#^rND^sMuir^nCS.#Cancer Inci
dence in Five Continents: Comparability and quality of data^len#IARC Sci Publ#19
920000#1992#120#45-173#20110300#v24n1a13.htm#0300-5038#IARC Sci Publ##
00657000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01500115010001600130012012200146030000700268065000900275064000500284031000400289
032000500293014000600298865000900304002001300313035001000326801000700336#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#186#28#article#39#28#^rND^sPa
rsonnet^nJ#^rND^sHarris^nRA#^rND^sHack^nHM#^rND^sOwens^nDK#Modelling costeffecti
veness of Helicobacter pylori screening to prevent gastric cancer: a mandate for
 clinical trials^len#Lancet#19960000#1996#348#9021#150-4#20110300#v24n1a13.htm#0
099-5355#Lancet##
00496000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120045000950300
02400140065000900164064000500173014000800178865000900186002001300195035001000208
801002400218#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#187#29#ar
ticle#39#29#^rND^sPrice^nA.#The Sidney system: histological division^len#J Gastr
oenterol Hepatol#19910000#1991#6209-22#20110300#v24n1a13.htm#0815-9319#J Gastroe
nterol Hepatol##
00830000000000373000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01700113010001900130010001600149010001800165010001700183010002200200010001900222
01201180024103000200035906500090037906400050038803100030039303200020039601400060
0398865000900404002001300413035001000426801002000436#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a13.htm#S#c#188#30#article#39#30#^rND^sRocha^nGA#^rND^sQueiro
z^nDM#^rND^sMendes^nEN#^rND^sOliveira^nAM#^rND^sMoura^nSB#^rND^sBarbosa^nMT#^rND
^sMendes^nCC#^rND^sLima Júnior^nGF#^rND^sOliveira^nCA#Indirect immunofluorescenc
e determination of the frequency of anti-H: pylori antibodies in Brazilian blood
 donors^len#Braz J Med Biol Res#19920000#1992#25#7#683-9#20110300#v24n1a13.htm#0
100-879X#Braz J Med Biol Res##
00803000000000397000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01700111010001500128010001800143010001400161010001700175010001900192010001700211
01000170022801000180024501200630026303000120032606500090033806400050034703100030
0352032000200355014000400357865000900361002001300370035001000383801001200393#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#189#31#article#39#31#^rND
^sRugge^nM#^rND^sCassaro^nM#^rND^sLeandro^nG#^rND^sBaffa^nR#^rND^sAvellini^nC#^r
ND^sBufo^nP#^rND^sStracca^nV#^rND^sBattaglia^nG#^rND^sFabiano^nA#^rND^sGuerini^n
A#^rND^sDi Mario^nF#Helicobacter pylori in promotion of gastric carcinogenesis^l
en#Dig Dis Sci#19960000#1996#41#5#950#20110300#v24n1a13.htm#0163-2116#Dig Dis Sc
i##
00755000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01500110010001600125010001300141010001900154012013000173030002800303065000900331
06400050034003100020034503200040034701400060035186500090035700200130036603500100
0379801002800389#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.htm#S#c#190#3
2#article#39#32#^rND^sSakaki^nN#^rND^sMomma^nK#^rND^sEgawa^nN#^rND^sYamada^nY#^r
ND^sKan^nT#^rND^sIshiwata^nJ.#The influence of Helicobacter pylori infection on 
the progression of gastric mucosal atrophy and occurrence of gastric cancer^len#
Eur J Gastroenterol Hepatol#19950000#1995#7#^s1#59-62#20110300#v24n1a13.htm#0954
-691X#Eur J Gastroenterol Hepatol##
00524000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980120
04300115030000900158065000900167064000500176031000400181032000200185014000600187
865000900193002001300202035001000215801000900225#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a13.htm#S#c#191#33#article#39#33#^rND^sScheiman^nJM#^rND^sCutler^
nAF#Helicobacter pylori and gastric cancer^len#Am J Med#19990000#1999#106#2#222-
6#20110300#v24n1a13.htm#0002-9343#Am J Med##
00847000000000373000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01800111010001700129010001700146010001800163010001800181010002100199010001800220
01201430023803000170038106500090039806400050040703100030041203200040041501400050
0419865000900424002001300433035001000446801001700456#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a13.htm#S#c#192#34#article#39#34#^rND^sSolcia^nE#^rND^sFiocca
^nR#^rND^sLuinetti^nO#^rND^sVillani^nL#^rND^sPadovan^nL#^rND^sCalistri^nD#^rND^s
Ranzani^nGN#^rND^sChiaravalli^nA#^rND^sCapella^nC.#Intestinal and diffuse gastri
c cancers arise in a different background of Helicobacter pylori gastritis throu
gh different gene involvement^len#Am J Surg Pathol#19960000#1996#20#^s1#8-22#201
10300#v24n1a13.htm#0147-5185#Am J Surg Pathol##
00523000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950120
04300112030001100155065000900166064000500175031000200180032000200182014000600184
865000900190002001300199035001000212801001100222#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a13.htm#S#c#193#35#article#39#35#^rND^sStolte^nM#^rND^sMeining^nA
#Helicobacter pylori and Gastric Cancer^len#Oncologist#19980000#1998#3#2#124-8#2
0110300#v24n1a13.htm#1083-7159#ONCOLOGIST##
00696000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
01700111010001400128010001800142010001400160010001400174012005900188030002100247
06500090026806400050027703100030028203200020028501400060028786500090029300200130
0302035001000315801002100325#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a13.h
tm#S#c#194#36#article#39#36#^rND^sTakeuchi^nK#^rND^sOhno^nY#^rND^sTsuzuki^nY#^rN
D^sAndo^nT#^rND^sSekihara^nM#^rND^sHara^nT#^rND^sKuwanoH#Helicobacter pylori inf
ection and early gastric cancer^len#J Clin Gastroenterol#20030000#2003#36#4#321-
4#20110300#v24n1a13.htm#0192-0790#J Clin Gastroenterol##
00552000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01600115012004300131030000900174065000900183064000500192031000400197032000200201
014000600203865000900209002001300218035001000231801000900241#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a13.htm#S#c#195#37#article#39#37#^rND^sTomaselli^nG#^
rND^sCitarda^nF#^rND^sCrespi^nM#Helicobacter pylori and gastric cancer^len#Clin 
Ter#19990000#1999#150#3#221-4#20110300#v24n1a13.htm#0009-9047#Clin Ter##
00758000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01600114010001500130010001800145010001400163010001500177010001500192012010700207
03000120031406500090032606400050033503100030034003200020034301400070034586500090
0352002001300361035001000374801001200384#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a13.htm#S#c#196#38#article#39#38#^rND^sWatanabe^nY#^rND^sKurata^nJH#^rND^
sMizuno^nS#^rND^sMukai^nM#^rND^sInokuchi^nH#^rND^sMiki^nK#^rND^sOzasa^nK#^rND^sK
awai^nK#Helicobacter pylori infection and gastric cancer: A nested case-control 
study in a rural area of Japan^len#Dig Dis Sci#19970000#1997#42#7#1383-7#2011030
0#v24n1a13.htm#0163-2116#Dig Dis Sci##
00545000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01600109012002800125030001700153065000900170064000500179031000300184032000200187
014000500189865000900194002001300203035001000216801001700226#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a13.htm#S#c#197#39#article#39#39#^rND^sWingo^nPA#^rND
^sTong^nT#^rND^sBolden^nS#Cancer statistics, 1995^len#CA Cancer J Clin#19950000#
1995#45#1#8-30#20110300#v24n1a13.htm#0007-9235#CA Cancer J Clin##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#o#1#1#article#1
#20110411#103915#v24n1a14.htm#138##
03137000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002700108
03100030013503200020013806500090014001400090014903500100015801200480016801200450
02160100040002610100026003010100018003270100020003450100022003650100022003870830
97600409085001001385085003501395085002501430085002101455083090801476085001002384
08500330239408500240242708500200245111700080247107200030247911200090248211100110
2491114000902502113001102511002001302522#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a14.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#14#ABCD070#nd#ABCD, arq. 
bras. cir. dig.#24#1#20110300#^f64^l67#0102-6720#Excisão total do mesorreto por 
laparoscopia^lpt#Total mesorectal excision by laparoscopy^len#^rND^nGuilherme Cu
tait de Castro^sCotti#^rND^nUlysses^sRibeiro-Jr#^rND^nCaio^sNahas#^rND^nSergio^s
Nahas#^rND^nWilson^sPollara#^rND^nIvan^sCeconnelo#^lpt^aINTRODUÇÃO: O tratamento
 cirúrgico do câncer do reto passou por grande refinamento técnico após a incorp
oração da excisão total do mesorreto. A possibilidade de tratamento por laparosc
opia ainda permanece como motivo de controvérsia. Assim, uma revisão atualizada 
do assunto é pertinente para ajudar a orientar a conduta aos pacientes com esse 
tumor. MÉTODO: Foram consultadas as bases de dados disponíveis pelo Medline/Pubm
ed, Scielo e Lilacs cruzando os seguintes unitermos: câncer colorretal, laparosc
opia, cirurgia. CONCLUSÃO: Até a presente data, ainda permanece motivo de contro
vérsia se o tratamento do câncer de reto deve ser realizado de forma rotineira p
or laparoscopia. Não existem dados na literatura que suportem a realização minim
amente invasiva da excisão total do mesorreto para o tratamento do câncer de ret
o fora de protocolo de pesquisa, especialmente pela ausência de índices de sobre
vida e de recidiva local com pelo menos cinco anos de seguimento.#^ddecs^i1#^tm^
lpt^kNeoplasias colorretais^i1#^tm^lpt^kLaparoscopia^i1#^tm^lpt^kCirurgia^i1#^le
n^aINTRODUCTION: Surgical treatment of rectal cancer has undergone great technic
al refinement after total mesorectal excision. The possibility of laparoscopic a
pproach still remains controversial. Thus, an updated review of the matter is re
levant to help to guide physicians in surgical treatment. METHOD: It was done an
 extensive review of papers on databases available through Medline / Pubmed, Lil
acs and Scielo crossing the following keywords: colorectal cancer, laparoscopic 
surgery, surgery. CONCLUSION: To date, there still remains a matter of controver
sy whether the treatment of rectal cancer should be routinely performed by lapar
oscopy. There are no published data that support the achievement of minimally in
vasive total mesorectal excision for rectal cancer treatment outside the researc
h protocol, notably a lack of survival rates and local recurrence with at least 
five years of follow-up.#^ddecs^i2#^tm^len^kColorectal neoplasms^i2#^tm^len^kLap
aroscopy^i2#^tm^len^kSurgery^i2#vancouv#24#20100819#19/08/2010#20101221#21/12/20
10#v24n1a14.htm##
03193000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002700108
03100030013503200020013806500090014001400090014903500100015801200550016801200520
02230100040002750100026003150100018003410100020003590100022003790100022004010830
99700423085001001420085003501430085002501465085002101490083092901511085001002440
08500330245008500240248308500200250711700080252707200030253511200090253811100110
2547114000902558113001102567002001302578#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a14.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#14#ABCD070#nd#ABCD, arq. 
bras. cir. dig.#24#1#20110300#^f64^l67#0102-6720#<b>Excisão total do mesorreto p
or laparoscopia</b>^lpt#<b>Total mesorectal excision by laparoscopy</b>^len#^rND
^nGuilherme Cutait de Castro^sCotti#^rND^nUlysses^sRibeiro-Jr#^rND^nCaio^sNahas#
^rND^nSergio^sNahas#^rND^nWilson^sPollara#^rND^nIvan^sCeconnelo#^lpt^a<b>INTRODU
ÇÃO: </b>O tratamento cirúrgico do câncer do reto passou por grande refinamento 
técnico após a incorporação da excisão total do mesorreto. A possibilidade de tr
atamento por laparoscopia ainda permanece como motivo de controvérsia. Assim, um
a revisão atualizada do assunto é pertinente para ajudar a orientar a conduta ao
s pacientes com esse tumor. <b>MÉTODO:</b> Foram consultadas as bases de dados d
isponíveis pelo Medline/Pubmed, Scielo e Lilacs cruzando os seguintes unitermos:
 câncer colorretal, laparoscopia, cirurgia. <b>CONCLUSÃO:</b> Até a presente dat
a, ainda permanece motivo de controvérsia se o tratamento do câncer de reto deve
 ser realizado de forma rotineira por laparoscopia. Não existem dados na literat
ura que suportem a realização minimamente invasiva da excisão total do mesorreto
 para o tratamento do câncer de reto fora de protocolo de pesquisa, especialment
e pela ausência de índices de sobrevida e de recidiva local com pelo menos cinco
 anos de seguimento.#^ddecs^i1#^tm^lpt^kNeoplasias colorretais^i1#^tm^lpt^kLapar
oscopia^i1#^tm^lpt^kCirurgia^i1#^len^a<b>INTRODUCTION:</b> Surgical treatment of
 rectal cancer has undergone great technical refinement after total mesorectal e
xcision. The possibility of laparoscopic approach still remains controversial. T
hus, an updated review of the matter is relevant to help to guide physicians in 
surgical treatment. <b>METHOD:</b> It was done an extensive review of papers on 
databases available through Medline / Pubmed, Lilacs and Scielo crossing the fol
lowing keywords: colorectal cancer, laparoscopic surgery, surgery. <b>CONCLUSION
:</b> To date, there still remains a matter of controversy whether the treatment
 of rectal cancer should be routinely performed by laparoscopy. There are no pub
lished data that support the achievement of minimally invasive total mesorectal 
excision for rectal cancer treatment outside the research protocol, notably a la
ck of survival rates and local recurrence with at least five years of follow-up.
#^ddecs^i2#^tm^len^kColorectal neoplasms^i2#^tm^len^kLaparoscopy^i2#^tm^len^kSur
gery^i2#vancouv#24#20100819#19/08/2010#20101221#21/12/2010#v24n1a14.htm##
03271000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000260012603100030015203200020015506500090015701400090016603500100017501200480
01850120045002330100040002780100030003180100018003480100020003660100022003860100
02200408083097600430085001001406085003501416085002501451085002101476083090801497
08500100240508500330241508500240244808500200247211700080249207200030250011200090
2503111001102512114000902523113001102532002001302543008008902556#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt
#br1.1#1#4.0#tab#14#ABCD070#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f64^l67#
0102-6720#Excisão total do mesorreto por laparoscopia^lpt#Total mesorectal excis
ion by laparoscopy^len#^rND^nGuilherme Cutait de Castro^sCotti#^rND^nUlysses^sRi
beiro-Júnior#^rND^nCaio^sNahas#^rND^nSergio^sNahas#^rND^nWilson^sPollara#^rND^nI
van^sCeconnelo#^lpt^aINTRODUÇÃO: O tratamento cirúrgico do câncer do reto passou
 por grande refinamento técnico após a incorporação da excisão total do mesorret
o. A possibilidade de tratamento por laparoscopia ainda permanece como motivo de
 controvérsia. Assim, uma revisão atualizada do assunto é pertinente para ajudar
 a orientar a conduta aos pacientes com esse tumor. MÉTODO: Foram consultadas as
 bases de dados disponíveis pelo Medline/Pubmed, Scielo e Lilacs cruzando os seg
uintes unitermos: câncer colorretal, laparoscopia, cirurgia. CONCLUSÃO: Até a pr
esente data, ainda permanece motivo de controvérsia se o tratamento do câncer de
 reto deve ser realizado de forma rotineira por laparoscopia. Não existem dados 
na literatura que suportem a realização minimamente invasiva da excisão total do
 mesorreto para o tratamento do câncer de reto fora de protocolo de pesquisa, es
pecialmente pela ausência de índices de sobrevida e de recidiva local com pelo m
enos cinco anos de seguimento.#^ddecs^i1#^tm^lpt^kNeoplasias colorretais^i1#^tm^
lpt^kLaparoscopia^i1#^tm^lpt^kCirurgia^i1#^len^aINTRODUCTION: Surgical treatment
 of rectal cancer has undergone great technical refinement after total mesorecta
l excision. The possibility of laparoscopic approach still remains controversial
. Thus, an updated review of the matter is relevant to help to guide physicians 
in surgical treatment. METHOD: It was done an extensive review of papers on data
bases available through Medline / Pubmed, Lilacs and Scielo crossing the followi
ng keywords: colorectal cancer, laparoscopic surgery, surgery. CONCLUSION: To da
te, there still remains a matter of controversy whether the treatment of rectal 
cancer should be routinely performed by laparoscopy. There are no published data
 that support the achievement of minimally invasive total mesorectal excision fo
r rectal cancer treatment outside the research protocol, notably a lack of survi
val rates and local recurrence with at least five years of follow-up.#^ddecs^i2#
^tm^len^kColorectal neoplasms^i2#^tm^len^kLaparoscopy^i2#^tm^len^kSurgery^i2#van
couv#24#20100819#19/08/2010#20101221#21/12/2010#v24n1a14.htm#Internet^ihttp://ww
w.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202011000100014##
00362000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012900074002001300203#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#5#1#article#110#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO DE REVIS&Atild
e;O </b></font></p>     ^cY#v24n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#6#2#article#110#<p>&nbsp;</p>     ^cY
#v24n1a14.htm##
00394000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016100074002001300235#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#7#3#article#110#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Excis&atilde;o 
total do mesorreto por laparoscopia</b> </font></p>     ^cY#v24n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#8#4#article#110#<p>&nbsp;</p>     ^cY
#v24n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#9#5#article#110#<p>&nbsp;</p>     ^cY
#v24n1a14.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020100075002001300276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#10#6#article#110#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Guilherme Cutait de Castro Cotti; 
Ulysses Ribeiro-Jr; Caio Nahas; Sergio Nahas; Wilson Pollara; Ivan Ceconnelo </b
></font></p>     ^cY#v24n1a14.htm##
00360000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012600075002001300201#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#11#7#article#110#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a> </font></p>     ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#12#8#article#110#<p>&nbsp;</p>     ^c
Y#v24n1a14.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#13#9#article#110#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a14.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#14#10#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a14.htm##
00747000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051200076002001300588#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#15#11#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>INTRODU&Ccedil;&Atilde;O: </b>O 
tratamento cir&uacute;rgico do c&acirc;ncer do reto passou por grande refinament
o t&eacute;cnico ap&oacute;s a incorpora&ccedil;&atilde;o da excis&atilde;o tota
l do mesorreto. A possibilidade de tratamento por laparoscopia ainda permanece c
omo motivo de controv&eacute;rsia. Assim, uma revis&atilde;o atualizada do assun
to &eacute; pertinente para ajudar a orientar a conduta aos pacientes com esse t
umor.    ^cY#v24n1a14.htm##
00443000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020800076002001300284#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#16#12#article#110#<br> <b>M&Eacute;TO
DO:</b> Foram consultadas as bases de dados dispon&iacute;veis pelo Medline/Pubm
ed, Scielo e Lilacs cruzando os seguintes unitermos: c&acirc;ncer colorretal, la
paroscopia, cirurgia.    ^cY#v24n1a14.htm##
00792000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055700076002001300633#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#17#13#article#110#<br> <b>CONCLUS&Ati
lde;O:</b> At&eacute; a presente data, ainda permanece motivo de controv&eacute;
rsia se o tratamento do c&acirc;ncer de reto deve ser realizado de forma rotinei
ra por laparoscopia. N&atilde;o existem dados na literatura que suportem a reali
za&ccedil;&atilde;o minimamente invasiva da excis&atilde;o total do mesorreto pa
ra o tratamento do c&acirc;ncer de reto fora de protocolo de pesquisa, especialm
ente pela aus&ecirc;ncia de &iacute;ndices de sobrevida e de recidiva local com 
pelo menos cinco anos de seguimento. </font></p>      ^cY#v24n1a14.htm##
00409000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017400076002001300250#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#18#14#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b> Neoplasias color
retais. Laparoscopia. Cirurgia. </font></p> <hr size="1" noshade>      ^cY#v24n1
a14.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002300076002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#19#15#article#110#<p>&nbsp;</p>      
^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#20#16#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#21#17#article#110#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O </b></fo
nt></p>     ^cY#v24n1a14.htm##
00885000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065000076002001300726#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#22#18#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tratamento cir&uacute;rgico do c&a
circ;ncer do reto passou por grande refinamento t&eacute;cnico ap&oacute;s a inc
orpora&ccedil;&atilde;o da excis&atilde;o total do mesorreto (ETM), proposta ini
cialmente por Heald em 1982<sup>9</sup>. Um dos principais benef&iacute;cios atr
ibu&iacute;dos a ETM foi a expressiva redu&ccedil;&atilde;o nos &iacute;ndices d
e recidiva local associados ao tratamento cir&uacute;rgico, uma vez que na ETM p
romove-se a ressec&ccedil;&atilde;o do reto com toda a gordura perirretal, que c
ont&eacute;m tecido linfo-vascular<sup>6,10</sup>. </font></p>     ^cY#v24n1a14.
htm##
01748000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704151300076002001301589#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#23#19#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Embora a primeira s&eacute;rie de ca
sos de opera&ccedil;&atilde;o colorretal laparosc&oacute;pica publicada em 1991<
sup>12</sup> j&aacute; apresentasse pacientes portadores de adenocarcinoma color
retal submetidos &agrave; ressec&ccedil;&atilde;o laparosc&oacute;pica, a possib
ilidade de tratamento do c&acirc;ncer colorretal por laparoscopia permaneceu mot
ivo de controv&eacute;rsia at&eacute; recentemente, quando foram publicados os p
rimeiros grandes estudos prospectivos e randomizados, mostrando equival&ecirc;nc
ia entre os resultados oncol&oacute;gicos comparando a cirurgia laparosc&oacute;
pica com a cirurgia convencional<sup>5,23</sup>. Assim, confirmou-se que &eacute
; poss&iacute;vel -atrav&eacute;s de acesso minimamente invasivo - realizar ress
ec&ccedil;&atilde;o com crit&eacute;rios oncol&oacute;gicos satisfat&oacute;rios
; com linfadenectomia adequada, sem risco aumentado de implantes nas regi&otilde
;es dos troc&aacute;rteres e com sobrevida de cinco anos estatisticamente semelh
ante &agrave; realizada por via convencional<sup>7</sup>. Portanto, com igual be
nef&iacute;cio do ponto de vista oncol&oacute;gico radical, torna-se ainda poss&
iacute;vel a obten&ccedil;&atilde;o das demais vantagens associadas ao uso da la
paroscopia, como por exemplo: menor perda sangu&iacute;nea, menor taxa da perman
&ecirc;ncia hospitalar, retorno precoce as atividades e menor taxa de infec&cced
il;&atilde;o<sup>3,5,20,23</sup>. </font></p>     ^cY#v24n1a14.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#24#20#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Contudo, estes trabalhos apresentam 
in&uacute;meros crit&eacute;rios de sele&ccedil;&atilde;o de seus pacientes e, q
uase sempre, n&atilde;o incluem doentes portadores de adenocarcinoma do reto ext
raperitoneal. Desta forma, embora o tratamento cir&uacute;rgico do c&acirc;ncer 
de reto por laparoscopia com realiza&ccedil;&atilde;o de ETM seja fact&iacute;ve
l<sup>4,24</sup> e venha sendo executado em diversos centros, ainda carece de va
lida&ccedil;&atilde;o cientifica atrav&eacute;s de estudos prospectivos e rand&o
circ;micos, em especial no que diz respeito aos resultados oncol&oacute;gicos a 
longo prazo. </font></p>     ^cY#v24n1a14.htm##
00556000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032100076002001300397#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#25#21#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo foi realizar
 revis&atilde;o de literatura a respeito das evid&ecirc;ncias dispon&iacute;veis
 que comparam os resultados cir&uacute;rgicos entre a ETM por via laparosc&oacut
e;pica versus a ETM por via convencional. </font></p>     ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#26#22#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#27#23#article#110#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS </b></font></p>   
  ^cY#v24n1a14.htm##
00492000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025700076002001300333#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#28#24#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Foram consultadas as bases de dados 
dispon&iacute;veis pelo Medline/Pubmed, Scielo e Lilacs cruzando os seguintes un
itermos: c&acirc;ncer colorretal, laparoscopia, cirurgia. </font></p>     ^cY#v2
4n1a14.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016300076002001300239#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#29#25#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Resultados da ETM laparosc&oacute
;pica (ETML) vs ETM convencional (ETMC) </b></font></p>     ^cY#v24n1a14.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015700076002001300233#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#30#26#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Esp&eacute;cime cir&uacute;rgico 
- margem radial e linfadenectomia </i></font></p>     ^cY#v24n1a14.htm##
01770000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704153500076002001301611#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#31#27#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A obten&ccedil;&atilde;o de margens 
cir&uacute;rgicas adequadas atrav&eacute;s da realiza&ccedil;&atilde;o de ETM mo
strou-se fundamental no tratamento do c&acirc;ncer de reto extra-peritoneal, uma
 vez que as margens livres - em especial a margem radial (ou circunferencial) - 
t&ecirc;m rela&ccedil;&atilde;o direta com menores &iacute;ndices de recidiva lo
cal e melhor sobrevida em pacientes submetidos &agrave; opera&ccedil;&atilde;o d
e ETMC<sup>11</sup>. In&uacute;meros trabalhos atestam taxas de comprometimento 
da margem radial semelhantes entre a ETML e ETMC de forma que Aziz, et al.<sup>1
</sup> publicaram metan&aacute;lise incluindo oito estudos (n=783) que comparava
m o tema e, de fato, n&atilde;o houve diferen&ccedil;a na incid&ecirc;ncia de ma
rgem radial positiva entre as duas t&eacute;cnicas (9,5% na ETML vs 10,8% ETMC).
 Nesta mesma metan&aacute;lise, avaliando 18 estudos, foi poss&iacute;vel verifi
car que n&atilde;o houve diferen&ccedil;a entre o n&uacute;mero de linfonodos re
tirados por esp&eacute;cime comparando a ETML e ETMC. Esses dados apontam que &e
acute; poss&iacute;vel realizar ETML com a mesma radicalidade oncol&oacute;gica 
que a ETMC<sup>1</sup>, pelo menos com rela&ccedil;&atilde;o ao esp&eacute;cime 
cir&uacute;rgico obtido, uma vez que ainda n&atilde;o existem estudos prospectiv
os e randomizados que comparem a incid&ecirc;ncia de recidiva local e sobrevida 
em pacientes submetidos &agrave;s duas t&eacute;cnicas. </font></p>     ^cY#v24n
1a14.htm##
01258000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102300076002001301099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#32#28#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Na an&aacute;lise preliminar publica
da em 2005 do estudo prospectivo randomizado ingl&ecirc;s MRC-CLASSIC<sup>8 </su
p>tamb&eacute;m n&atilde;o houve diferen&ccedil;a estat&iacute;stica significant
e na ocorr&ecirc;ncia de margem radial positiva entre ETMC e ETML (14% vs 16%, r
espectivamente). Contudo, embora n&atilde;o atingisse diferen&ccedil;a estatisti
camente significativa, nesta publica&ccedil;&atilde;o a ocorr&ecirc;ncia de marg
em radial positiva em pacientes submetidos &agrave; ETML com preserva&ccedil;&at
ilde;o esfincteriana foi maior que no grupo submetido &agrave; ETMC com preserva
&ccedil;&atilde;o esfincteriana (12% vs 6%, respectivamente). Quando foram compa
raram os pacientes submetidos &agrave; ETM sem preserva&ccedil;&atilde;o esfinct
eriana (amputa&ccedil;&atilde;o abdominoperineal do reto), n&atilde;o houve dife
ren&ccedil;a nas taxas de margem circunferencial positiva entre os dois  grupos 
(20% ETML vs 26% ETMC). </font></p>     ^cY#v24n1a14.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#33#29#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Recidiva local</b></font></p>    
 ^cY#v24n1a14.htm##
01818000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704158300076002001301659#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#34#30#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Praticamente inexistem dados de estu
dos prospectivos e randomizados avaliando a ocorr&ecirc;ncia de recidiva local a
p&oacute;s ETM por laparoscopia. Uma vez que a maioria dos trabalhos atesta a si
milaridade entre os esp&eacute;cimes cir&uacute;rgicos obtidos pela via laparosc
&oacute;pica e pela via convencional, n&atilde;o se espera encontrar diferen&cce
dil;as estatisticamente significativas na recidiva local p&oacute;s ETML. Entre 
os poucos dados dispon&iacute;veis na literatura, no &uacute;nico trabalho prosp
ectivo e randomizado<sup>14</sup> a an&aacute;lise de sobrevida de tr&ecirc;s an
os n&atilde;o encontrou diferen&ccedil;a significativa entre as taxas de recidiv
a no grupo ETML (9,7%) e ETMC (10,1%). Mesmo analisando exclusivamente o subgrup
o de pacientes submetidos &agrave; ETM com preserva&ccedil;&atilde;o esfincteria
na, onde conforme mencionado acima, o estudo encontrou maiores taxas (sem signif
ic&acirc;ncia estat&iacute;stica) de margens circunferenciais positivas em pacie
ntes submetidos &agrave; ETML com preserva&ccedil;&atilde;o esfincteriana, n&ati
lde;o houve diferen&ccedil;a na recidiva local nestes dois subgrupos (7,8% ETML 
vs 7,0% ETMC) ap&oacute;s tr&ecirc;s anos de seguimento - o que pode ter ocorrid
o em virtude do tamanho da amostra ou em fun&ccedil;&atilde;o do tempo de seguim
ento ainda curto. &Eacute; necess&aacute;rio aguardar a publica&ccedil;&atilde;o
 de estudos prospectivos randomizados com maior tempo de seguimento e maior n&ua
cute;mero de pacientes. </font></p>     ^cY#v24n1a14.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#35#31#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Sobrevida</b> </font></p>     ^cY
#v24n1a14.htm##
01202000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704096700076002001301043#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#36#32#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os mesmos coment&aacute;rios iniciai
s do item "Recidiva local" s&atilde;o aplic&aacute;veis quando o enfoque &eacute
; a compara&ccedil;&atilde;o entre a sobrevida ap&oacute;s ETML e ETMC. Os dados
 de estudos prospectivos e randomizados enfocando ETML vs ETMC s&atilde;o escass
os, h&aacute; apenas o estudo CLASSIC, cujos dados publicados em 2007 fazem refe
r&ecirc;ncia &agrave; sobrevida de tr&ecirc;s anos<sup>14</sup>, e n&atilde;o de
monstram diferen&ccedil;as estatisticamente significativas entre os dois grupos 
tanto com rela&ccedil;&atilde;o &agrave; sobrevida global quanto com rela&ccedil
;&atilde;o &agrave; sobrevida livre de doen&ccedil;a. Quando estratificados por 
estadiamento da doen&ccedil;a ou pela possiblidade de preserva&ccedil;&atilde;o 
esfincteriana, tamb&eacute;m n&atilde;o foi verificada nenhuma diferen&ccedil;a 
estat&iacute;stica entre os grupos ETML e ETMC. </font></p>     ^cY#v24n1a14.htm
##
00371000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013600076002001300212#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#37#33#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Fun&ccedil;&atilde;o urin&aacute;
ria e sexual</b> </font></p>     ^cY#v24n1a14.htm##
02765000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704253000076002001302606#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#38#34#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A ocorr&ecirc;ncia de disfun&ccedil;
&atilde;o urin&aacute;ria e sexual &eacute; uma complica&ccedil;&atilde;o previs
ta em qualquer opera&ccedil;&atilde;o p&eacute;lvica, incluindo as ressec&ccedil
;&otilde;es de c&acirc;ncer do reto com ETM. Mesmo com a incorpora&ccedil;&atild
e;o de t&eacute;cnicas de preserva&ccedil;&atilde;o auton&ocirc;mica &agrave; ET
M, a incid&ecirc;ncia de dist&uacute;rbios da fun&ccedil;&atilde;o urin&aacute;r
ia e sexual varia entre 0% a 12% e 10% a 35%, respectivamente<sup>13</sup>. Embo
ra existam evid&ecirc;ncias de que &eacute; tecnicamente poss&iacute;vel preserv
ar a fun&ccedil;&atilde;o urin&aacute;ria e sexual em pacientes submetidos &agra
ve; ETML, com destaque ao sexo masculino<sup>15</sup>, existem poucas publica&cc
edil;&otilde;es dispon&iacute;veis sobre o tema na literatura. Em 2002, Quah et 
al.<sup>21</sup> publicaram an&aacute;lise retrospectiva da incid&ecirc;ncia de 
disfun&ccedil;&atilde;o urin&aacute;ria e sexual em pacientes com c&acirc;ncer d
e reto submetidos &agrave; ressec&ccedil;&atilde;o ETML e ETMC e notaram que: 1)
 houve maior incid&ecirc;ncia de disfun&ccedil;&atilde;o sexual em homens submet
idos &agrave; ETML (especialmente em pacientes com tumores volumosos ou tumores 
do reto distal); 2) n&atilde;o houve diferen&ccedil;as com rela&ccedil;&atilde;o
 &agrave; disfun&ccedil;&atilde;o urin&aacute;ria entre as duas t&eacute;cnicas 
tanto em homens quanto em mulheres; e 3) n&atilde;o houve diferen&ccedil;as na f
un&ccedil;&atilde;o sexual das mulheres. Recentemente, foi publicada uma an&aacu
te;lise prospectiva e randomizada sobre a fun&ccedil;&atilde;o urin&aacute;ria e
 sexual comparando a ETML e a ETMC, derivado do estudo CLASSIC<sup>18</sup>, com
 conclus&otilde;es semelhantes ao estudo de Quah et al.<sup>21</sup>: a ETML n&a
tilde;o teve impacto negativo sobre a fun&ccedil;&atilde;o urin&aacute;ria, cont
udo houve tend&ecirc;ncia &agrave; piora da fun&ccedil;&atilde;o sexual em homen
s, mas n&atilde;o nas mulheres. Este estudo conseguiu avaliar 71,2% (247/347) do
s pacientes operados atrav&eacute;s de question&aacute;rios espec&iacute;ficos e
 constitui certamente a melhor evid&ecirc;ncia dispon&iacute;vel at&eacute; o mo
mento acerca deste tema, tendo identificado que a realiza&ccedil;&atilde;o da ET
M e a necessidade de convers&atilde;o foram fatores preditivos independentes da 
ocorr&ecirc;ncia de disfun&ccedil;&atilde;o sexual masculina p&oacute;s-operat&o
acute;ria. </font></p>     ^cY#v24n1a14.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#39#35#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Convers&atilde;o</b></font></p>  
   ^cY#v24n1a14.htm##
02048000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704181300076002001301889#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#40#36#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tratamento cir&uacute;rgico do c&a
circ;ncer de reto por laparoscopia &eacute; fact&iacute;vel, todavia os poucos t
rabalhos dispon&iacute;veis apontam para alta taxa de convers&atilde;o, especial
mente nos casos de ETML com preserva&ccedil;&atilde;o esfincteriana<sup>19,22</s
up>. O estudo CLASSIC, demonstrou taxa de convers&atilde;o de 34% para casos de 
pacientes com c&acirc;ncer do reto submetidos ao tratamento por laparoscopia (vs
 taxa de convers&atilde;o de 25% para colectomias laparosc&oacute;picas no trata
mento do c&acirc;ncer de c&oacute;lon)<sup>8</sup>. Centros especializados e com
 grande experi&ecirc;ncia v&ecirc;m conseguindo taxas de convers&atilde;o menore
s. Por exemplo, o grupo do Prof. Rullier, na Fran&ccedil;a, publicou em 2007 sua
 experi&ecirc;ncia com 200 pacientes submetidos &agrave; ETML com preserva&ccedi
l;&atilde;o esfincteriana, apresentando taxa de convers&atilde;o de 15,5%<sup>18
</sup>. Neste estudo, o risco de convers&atilde;o foi tr&ecirc;s vezes maior par
a pacientes do sexo masculino com anastomose colorretal mec&acirc;nica (34% vs 1
1% demais pacientes). A fixa&ccedil;&atilde;o do tumor foi fator predisponente p
ara convers&atilde;o. &Eacute; interessante ressaltar ainda que a maioria dos es
tudos indica aumento expressivo na morbidade dos casos submetidos &agrave; conve
rs&atilde;o para via convencional<sup>8,18</sup>. Portanto, conhecer os fatores 
predisponentes para convers&otilde;es - e principalmente buscar formas para mini
miz&aacute;-los - deve ser meta a ser atingida pelos cirurgi&otilde;es. Acredita
se que a melhoria dos grampeadores laparosc&oacute;picos deve ajudar a reduzir a
 necessidade de convers&otilde;es especialmente nos pacientes do sexo masculino<
sup>18</sup>. </font></p>     ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#41#37#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#42#38#article#110#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b> </font></p> 
    ^cY#v24n1a14.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#43#39#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s 17 anos da publica&ccedi
l;&atilde;o sobre as primeiras colectomias laparosc&oacute;picas<sup>12 </sup>e 
anos de discuss&otilde;es acerca da adequa&ccedil;&atilde;o da radicalidade onco
l&oacute;gica pela via laparosc&oacute;pica, in&uacute;meros trabalhos prospecti
vos e randomizados demonstraram que o c&acirc;ncer de c&oacute;lon pode ser trat
ado de forma curativa atrav&eacute;s de acesso minimamente invasivo, com todas a
s principais vantagens associadas a esta metodologia, e sobrevida equivalente &a
grave; obtida pela via convencional (<a href="#tab1">Tabelas 1 </a>e <a href="#t
ab2">2</a>). </font></p>     ^cY#v24n1a14.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#44#40#article#110#<p><a name="tab1"><
/a></p>     ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#45#41#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#46#42#article#110#<p align="center"><
img src="/img/revistas/abcd/v24n1/a14tab1.jpg" ></p>     ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#47#43#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#48#44#article#110#<p><a name="tab2"><
/a></p>     ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#49#45#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#50#46#article#110#<p align="center"><
img src="/img/revistas/abcd/v24n1/a14tab2.jpg"></p>     ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#51#47#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
01782000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704154700076002001301623#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#52#48#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Contudo, pelo que pode ser observado
 atrav&eacute;s da revis&atilde;o da literatura dispon&iacute;vel at&eacute; o m
omento, o mesmo n&atilde;o pode ainda ser afirmado para o tratamento com inten&c
cedil;&atilde;o curativa do c&acirc;ncer de reto. Embora in&uacute;meros trabalh
os tenham confirmado que a ETML &eacute; fact&iacute;vel do ponto de vista t&eac
ute;cnico e capaz de produzir resultados semelhantes a curto prazo quando compar
ada com a ETMC, n&atilde;o existem dados com n&iacute;vel de evid&ecirc;ncia suf
iciente no que diz respeito &agrave; sobrevida global, sobrevida livre de doen&c
cedil;a e &iacute;ndices de recidiva local que suportem seu uso sistem&aacute;ti
co. O &uacute;nico trabalho prospectivo e randomizado que avaliou estes dados co
m rigor cient&iacute;fico adequado foi publicado em 2007<sup>14</sup>, com apena
s tr&ecirc;s anos de seguimento. A aus&ecirc;ncia de sobrevida de cinco anos vem
 fazendo com que as principais sociedades internacionais envolvidas com o tema, 
como a Sociedade Americana de Coloproctologia e a Sociedade de Cirurgi&otilde;es
 e Endoscopistas Gastrointestinais, n&atilde;o reconhe&ccedil;am ainda a ETML co
mo padr&atilde;o no tratamento do c&acirc;ncer de reto com inten&ccedil;&atilde;
o curativa, recomendando sua utiliza&ccedil;&atilde;o apenas dentro de protocolo
s de servi&ccedil;o em centros de excel&ecirc;ncia e grande experi&ecirc;ncia em
 opera&ccedil;&otilde;es colorretais por laparoscopia<sup>17</sup>. </font></p> 
    ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#53#49#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#54#50#article#110#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>  
   ^cY#v24n1a14.htm##
00868000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063300076002001300709#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#55#51#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">At&eacute; a presente data, ainda pe
rmanece motivo de controv&eacute;rsia se o tratamento do c&acirc;ncer de reto, e
specialmente nos casos de tumores localizados em sua por&ccedil;&atilde;o extra-
peritoneal, deve ser realizado de forma rotineira por laparoscopia. N&atilde;o e
xistem dados na literatura que suportem a realiza&ccedil;&atilde;o da ETML para 
o tratamento do c&acirc;ncer de reto fora de protocolo de pesquisa, especialment
e pela aus&ecirc;ncia de &iacute;ndices de sobrevida e de recidiva local com pel
o menos cinco anos de seguimento. </font></p>     ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#56#52#article#110#<p>&nbsp;</p>     ^
cY#v24n1a14.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#57#53#article#110#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b> </font></p>
     ^cY#v24n1a14.htm##
00539000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029000078002001300368#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#58#54#article#110#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. 	Aziz O, Constantin
ides V, Tekkis PP, Athanasiou T, Purkayastha S, Paraskeva P, Darzi AW, Heriot AG
. Laparoscopic versus open surgery for rectal cancer: a meta-analysis. Ann Surg 
Oncol. 2006;13(3):413-24 </font></p>     ^cY#v24n1a14.htm##
00666000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704041700078002001300495#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#59#55#article#110#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. 	Bonjer HJ, Hop WC,
 Nelson H, Sargent DJ, Lacy AM, Castells A, Guillou PJ, Thorpe H, Brown J, Delga
do S, Kuhrij E, Haglind E, P&aring;hlman L; Transatlantic Laparoscopically Assis
ted vs Open Colectomy Trials Study Group. Laparoscopically assisted vs open cole
ctomy for colon cancer: a meta-analysis. Arch Surg. 2007;142(3):298-303 </font><
/p>     ^cY#v24n1a14.htm##
00548000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029900078002001300377#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#60#56#article#110#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. 	Braga M, Vignali A
, Gianotti L, Zuliani W, Radaelli G, Gruarin P, Dellabona P, Di Carlo V. Laparos
copic versus open colorectal surgery: a randomized trial on short-term outcome. 
Ann Surg. 2002;236(6):759-66; disscussion 767.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#61#57#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026000078002001300338#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#62#58#article#110#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Chung CC, Ha JP, Ts
ang WW, Li MK. Laparoscopic-assisted total mesorectal excision and colonic J pou
ch reconstruction in the treatment of rectal cancer. Surg Endosc. 2001;15(10):10
98-101.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#63#59#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023700078002001300315#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#64#60#article#110#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Clinical Outcomes o
f Surgical Therapy Study Group.A comparison of laparoscopically assisted and ope
n colectomy for colon cancer. N Engl J Med. 2004;350(20):2050-9.    ^cY#v24n1a14
.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#65#61#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023200078002001300310#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#66#62#article#110#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Enker WE, Thaler HT
, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of c
arcinoma of the rectum. J Am Coll Surg. 1995;181(4):335-46.    ^cY#v24n1a14.htm#
#
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#67#63#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00665000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704041600078002001300494#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#68#64#article#110#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Fleshman J, Sargent
 DJ, Green E, Anvari M, Stryker SJ, Beart RW Jr, Hellinger M, Flanagan R Jr, Pet
ers W, Nelson H; for The Clinical Outcomes of Surgical Therapy Study Group. Lapa
roscopic colectomy for cancer is not inferior to open surgery based on 5-year da
ta from the COST Study Group trial. Ann Surg. 2007;246(4):655-62; discussion 662
-4.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#69#65#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00637000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038800078002001300466#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#70#66#article#110#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. 	Guillou PJ, Quirke
 P, Thorpe H , Walker J , Jayne DG, Smith AM, Heath RM , Brown JM ; MRC CLASICC 
trial group. Shortterm endpoints of conventional versus laparoscopic-assisted su
rgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, rando
mised controlled trial. Lancet. 2005;365(9472):1718-26.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#71#67#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020800078002001300286#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#72#68#article#110#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. 	Heald RJ, Husband 
EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurr
ence? Br J Surg. 1982;69(10):613-6.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#73#69#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019900079002001300278#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#74#70#article#110#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Heald RJ, Ryall R
D. Recurrence and survival after total mesorectal excision for rectal cancer. La
ncet. 1986;1(8496):1479-82.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#75#71#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00455000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020500079002001300284#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#76#72#article#110#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Heald RJ. Total m
esorectal excision is optimal surgery for rectal cancer: a Scandinavian consensu
s. Br J Surg. 1995;82(10):1297-9.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#77#73#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021200079002001300291#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#78#74#article#110#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. 	Jacobs M, Verdej
a JC, Goldstein HS. Minimally invasive colon resection (laparoscopic colectomy).
 Surg Laparosc Endosc. 1991;1(3):144-50.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#79#75#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030400079002001300383#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#80#76#article#110#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. 	Jayne DG, Brown 
JM, Thorpe H, Walker J, Quirke P, Guillou PJ. Bladder and sexual function follow
ing resection for rectal cancer in a randomized clinical trial of laparoscopic v
ersus open technique. Br J Surg. 2005;92(9):1124-32.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#81#77#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00598000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704034800079002001300427#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#82#78#article#110#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. 	Jayne DG, Guillo
u PJ, Thorpe H, Quirke P, Copeland J, Smith AM, Heath RM, Brown JM; UK MRC CLASI
CC Trial Group. Randomized trial of laparoscopic-assisted resection of colorecta
l carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 200
7;25(21):3061-8.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#83#79#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031600079002001300395#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#84#80#article#110#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. 	Kim NK, Aahn TW,
 Park JK, Lee KY, Lee WH, Sohn SK, Min JS. Assessment of sexual and voiding func
tion after total mesorectal excision with pelvic autonomic nerve preservation in
 males with rectal cancer. Dis Colon Rectum. 2002;45(9):1178-85.    ^cY#v24n1a14
.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#85#81#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704032700079002001300406#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#86#82#article#110#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. 	Lacy AM, Garc&ia
cute;a-Valdecasas JC, Delgado S, Castells A, Taur&aacute; P, Piqu&eacute; JM, Vi
sa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-
metastatic colon cancer: a randomised trial. Lancet. 2002;359(9325):2224-9.    ^
cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#87#83#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00607000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704035700079002001300436#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#88#84#article#110#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. 	Laparoscopic Pro
ctectomy for Curable Cancer. Position Statement - ASCRS &amp; SAGES. <a href="ht
tp://www.fascrs.org/displaycommon.cfm?an=1&amp;subarticlenbr=349" target="_blank
">http://www.fascrs.org/displaycommon.cfm?an=1&subarticlenbr=349</a>, acessado e
m 29/12/2007 </font></p>     ^cY#v24n1a14.htm##
00475000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022500079002001300304#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#89#85#article#110#18#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Laurent C, Leblan
c F, Gineste C, Saric J, Rullier E. Laparoscopic approach in surgical treatment 
of rectal cancer. Br J Surg. 2007 Dec;94(12):1555-61.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#90#86#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025200079002001300331#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#91#87#article#110#19#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Morino M, Parini 
U, Giraudo G, Salval M, Brachet Contul R, Garrone C. Laparoscopic total mesorect
al excision: a consecutive series of 100 patients. Ann Surg. 2003;237(3):335-42.
    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#92#88#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019300079002001300272#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#93#89#article#110#20#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Pikarsky AJ, Rose
nthal R, Weiss EG, Wexner SD. Laparoscopic total mesorectal excision. Surg Endos
c. 2002;16(4):558-62.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#94#90#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026800079002001300347#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#95#91#article#110#21#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. 	Quah HM, Jayne D
G, Eu KW, Seow-Choen F. Bladder and sexual dysfunction following laparoscopicall
y assisted and conventional open mesorectal resection for cancer. Br J Surg. 200
2;89(12):1551-6.    ^cY#v24n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#96#92#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00572000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704032200079002001300401#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#97#93#article#110#22#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. 	Scheidbach H, Sc
hneider C, Konradt J, B&auml;rlehner E, K&ouml;hler L, Wittekind Ch, K&ouml;cker
ling F. Laparoscopic abdominoperineal resection and anterior resection with cura
tive intent for carcinoma of the rectum. Surg Endosc. 2002;16(1):7-13.    ^cY#v2
4n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#98#94#article#110# </font></p>     ^c
Y#v24n1a14.htm##
00653000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704040300079002001300482#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#99#95#article#110#23#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. 	Veldkamp R, Kuhr
y E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ, Haglind E, P&aring;hlman L, Cuesta
 MA, Msika S, Morino M, Lacy AM; COlon cancer Laparoscopic or Open Resection Stu
dy Group (COLOR). Laparoscopic surgery versus open surgery for colon cancer: sho
rt-term outcomes of a randomised trial. Lancet Oncol. 2005;6(7):477-84.    ^cY#v
24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#100#96#article#110# </font></p>     ^
cY#v24n1a14.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704020900080002001300289#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#101#97#article#110#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. 	Weiser MR, Mils
om JW. Laparoscopic total mesorectal excision with autonomic nerve preservation.
 Semin Surg Oncol. 2000;19(4):396-403.    ^cY#v24n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#102#98#article#110# </font></p>     ^
cY#v24n1a14.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#103#99#article#110#<p>&nbsp;</p>     
^cY#v24n1a14.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#104#100#article#110#<p>&nbsp;</p>    
 ^cY#v24n1a14.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019900078002001300277#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#105#101#article#110#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0" ></a> Correspond&e
circ;ncia:</b>    ^cY#v24n1a14.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004500078002001300123#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#106#102#article#110#<br> Guilherme Cu
tait de Castro Cotti    ^cY#v24n1a14.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#107#103#article#110#<br> e-mail: <a h
ref="mailto:gustavo.onco@terra.com.br">gustavo.onco@terra.com.br</a> </font></p>
      ^cY#v24n1a14.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012100078002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#108#104#article#110#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 19/08/2010    ^cY#v24n1a14.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#109#105#article#110#<br> Aceito para 
publica&ccedil;&atilde;o: 21/12/2010    ^cY#v24n1a14.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#110#106#article#110#<br>Fonte de fina
nciamento: n&atilde;o h&aacute;     ^cY#v24n1a14.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006900078002001300147#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#111#107#article#110#<br>Conflito de i
nteresses: n&atilde;o h&aacute;</font></p>      ^cY#v24n1a14.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#112#108#article#110#<p>&nbsp;</p>    
 ^cY#v24n1a14.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#113#109#article#110#<p>&nbsp;</p>    
 ^cY#v24n1a14.htm##
00495000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704025800078002001300336#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a14.htm#S#p#114#110#article#110#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Departamento
 de Gastroenterologia, Divis&atilde;o Cirurgica, da Faculdade de Medicina da Uni
versidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil. </font></p>     ^cY
#v24n1a14.htm##
00747000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100024000910100
01700115010002000132010002100152010001900173010001600192010001700208012007200225
03000150029706500090031206400050032103100030032603200020032901400070033186500090
0338002001300347035001000360801001500370#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a14.htm#S#c#115#1#article#24#1#^rND^sAziz^nO#^rND^sConstantinides^nV#^rND
^sTekkis^nPP#^rND^sAthanasiou^nT#^rND^sPurkayastha^nS#^rND^sParaskeva^nP#^rND^sD
arzi^nAW#^rND^sHeriot^nAG#Laparoscopic versus open surgery for rectal cancer: a 
meta-analysis^len#Ann Surg Oncol#20060000#2006#13#3#413-24#20110300#v24n1a14.htm
#1068-9265#Ann Surg Oncol##
00973000000000445000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100014000940100
01600108010001800124010001500142010001800157010001800175010001600193010001500209
01000170022401000160024101000170025701000170027401100400029101100340033101200820
03650300010004470650009004570640005004660310004004710320002004750140008004778650
00900485002001300494035001000507801001000517#v24n1#V:\SciELO\serial\abcd\v24n1\m
arkup\v24n1a14.htm#S#c#116#2#article#24#2#^rND^sBonjer^nHJ#^rND^sHop^nWC#^rND^sN
elson^nH#^rND^sSargent^nDJ#^rND^sLacy^nAM#^rND^sCastells^nA#^rND^sGuillou^nPJ#^r
ND^sThorpe^nH#^rND^sBrown^nJ#^rND^sDelgado^nS#^rND^sKuhrij^nE#^rND^sHaglind^nE#^
rND^sPåhlman^nL#Transatlantic Laparoscopically Assisted#Open Colectomy Trials St
udy Group#Laparoscopically assisted vs open colectomy for colon cancer: a meta-a
nalysis^len#Arch Surg#20070000#2007#142#3#298-303#20110300#v24n1a14.htm#0004-001
0#Arch Surg##
00746000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920100
01800109010001700127010001800144010001700162010001900179010001900198012009000217
03000090030706500090031606400050032503100040033003200020033401400070033686500090
0343002001300352035001000365801000900375#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a14.htm#S#c#117#3#article#24#3#^rND^sBraga^nM#^rND^sVignali^nA#^rND^sGian
otti^nL#^rND^sZuliani^nW#^rND^sRadaelli^nG#^rND^sGruarin^nP#^rND^sDellabona^nP#^
rND^sDi Carlo^nV.#Laparoscopic versus open colorectal surgery: a randomized tria
l on short-term outcome^len#Ann Surg#20020000#2002#236#6#759-66#20110300#v24n1a1
4.htm#0003-4932#Ann Surg##
00655000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100013000930100
01600106010001300122012012100135030001200256065000900268064000500277031000300282
032000300285014000900288865000900297002001300306035001000319801001200329#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#118#4#article#24#4#^rND^sChun
g^nCC#^rND^sHa^nJP#^rND^sTsang^nWW#^rND^sLi^nMK#Laparoscopic-assisted total meso
rectal excision and colonic J pouch reconstruction in the treatment of rectal ca
ncer^len#Surg Endosc#20010000#2001#15#10#1098-101#20110300#v24n1a14.htm#0930-279
4#Surg Endosc##
00573000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110050000770120082001270300
01300209065000900222064000500231031000400236032000300240014000700243865000900250
002001300259035001000272801001300282#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a14.htm#S#c#119#5#article#24#5#Clinical Outcomes of Surgical Therapy Study Gr
oup#A comparison of laparoscopically assisted and open colectomy for colon cance
r^len#N Engl J Med#20040000#2004#350#20#2050-9#20110300#v24n1a14.htm#0028-4793#N
 Engl J Med##
00630000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01700110010001600127012008400143030001500227065000900242064000500251031000400256
032000200260014000700262865000900269002001300278035001000291801001500301#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#120#6#article#24#6#^rND^sEnke
r^nWE#^rND^sThaler^nHT#^rND^sCranor^nML#^rND^sPolyak^nT#Total mesorectal excisio
n in the operative treatment of carcinoma of the rectum^len#J Am Coll Surg#19950
000#1995#181#4#335-46#20110300#v24n1a14.htm#1072-7515#J Am Coll Surg##
00909000000000397000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01500113010001600128010001800144010001900162010001900181010002100200010001600221
01000160023701100580025301201230031103000090043406500090044306400050045203100040
0457032000200461014000700463865000900470002001300479035001000492801000900502#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#121#7#article#24#7#^rND^s
Fleshman^nJ#^rND^sSargent^nDJ#^rND^sGreen^nE#^rND^sAnvari^nM#^rND^sStryker^nSJ#^
rND^sBeart Jr^nRW#^rND^sHellinger^nM#^rND^sFlanagan Jr^nR#^rND^sPeters^nW#^rND^s
Nelson^nH#for The Clinical Outcomes of Surgical Therapy Study Group#Laparoscopic
 colectomy for cancer is not inferior to open surgery based on 5-year data from 
the COST Study Group trial^len#Ann Surg#20070000#2007#246#4#655-62#20110300#v24n
1a14.htm#0003-4932#Ann Surg##
00856000000000373000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01600111010001600127010001600143010001600159010001600175010001600191011002400207
01201740023103000070040506500090041206400050042103100040042603200050043001400080
0435865000900443002001300452035001000465801000700475#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a14.htm#S#c#122#8#article#24#8#^rND^sGuillou^nPJ#^rND^sQuirke
^nP#^rND^sThorpe^nH#^rND^sWalker^nJ#^rND^sJayne^nDG#^rND^sSmith^nAM#^rND^sHeath^
nRM#^rND^sBrown^nJM#MRC CLASICC trial group#Shortterm endpoints of conventional 
versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLA
SICC trial): multicentre, randomised controlled trial^len#Lancet#20050000#2005#3
65#9472#1718-26#20110300#v24n1a14.htm#0099-5355#Lancet##
00582000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
01600111012007500127030001000202065000900212064000500221031000300226032000300229
014000600232865000900238002001300247035001000260801001000270#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a14.htm#S#c#123#9#article#24#9#^rND^sHeald^nRJ#^rND^s
Husband^nEM#^rND^sRyall^nRD#The mesorectum in rectal cancer surgery--the clue to
 pelvic recurrence^len#Br J Surg#19820000#1982#69#10#613-6#20110300#v24n1a14.htm
#0007-1323#Br J Surg##
00554000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950120
07800111030000700189065000900196064000500205031000200210032000500212014000800217
865000900225002001300234035001000247801000700257#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a14.htm#S#c#124#10#article#24#10#^rND^sHeald^nRJ#^rND^sRyall^nRD#
Recurrence and survival after total mesorectal excision for rectal cancer^len#La
ncet#19860000#1986#1#8496#1479-82#20110300#v24n1a14.htm#0099-5355#Lancet##
00545000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120093000950300
01000188065000900198064000500207031000300212032000300215014000700218865000900225
002001300234035001000247801001000257#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a14.htm#S#c#125#11#article#24#11#^rND^sHeald^nRJ#Total mesorectal excision is
 optimal surgery for rectal cancer: a Scandinavian consensus^len#Br J Surg#19950
000#1995#82#10#1297-9#20110300#v24n1a14.htm#0007-1323#Br J Surg##
00598000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
02000113012006400133030002100197065000900218064000500227031000200232032000200234
014000700236865000900243002001300252035001000265801002100275#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a14.htm#S#c#126#12#article#24#12#^rND^sJacobs^nM#^rND
^sVerdeja^nJC#^rND^sGoldstein^nHS#Minimally invasive colon resection (laparoscop
ic colectomy)^len#Surg Laparosc Endosc#19910000#1991#1#3#144-50#20110300#v24n1a1
4.htm#1051-7200#Surg Laparosc Endosc##
00733000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01600111010001600127010001600143010001800159012013900177030001000316065000900326
06400050033503100030034003200020034301400080034586500090035300200130036203500100
0375801001000385#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#127#1
3#article#24#13#^rND^sJayne^nDG#^rND^sBrown^nJM#^rND^sThorpe^nH#^rND^sWalker^nJ#
^rND^sQuirke^nP#^rND^sGuillou^nPJ#Bladder and sexual function following resectio
n for rectal cancer in a randomized clinical trial of laparoscopic versus open t
echnique^len#Br J Surg#20050000#2005#92#9#1124-32#20110300#v24n1a14.htm#0007-132
3#Br J Surg##
00827000000000373000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113010001600129010001800145010001600163010001600179010001600195011002700211
01201300023803000130036806500090038106400050039003100030039503200030039801400070
0401865000900408002001300417035001000430801001300440#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a14.htm#S#c#128#14#article#24#14#^rND^sJayne^nDG#^rND^sGuillo
u^nPJ#^rND^sThorpe^nH#^rND^sQuirke^nP#^rND^sCopeland^nJ#^rND^sSmith^nAM#^rND^sHe
ath^nRM#^rND^sBrown^nJM#UK MRC CLASICC Trial Group#Randomized trial of laparosco
pic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLA
SICC Trial Group^len#J Clin Oncol#20070000#2007#25#21#3061-8#20110300#v24n1a14.h
tm#0732-183X#J Clin Oncol##
00770000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930100
01500108010001400123010001400137010001500151010001400166012014700180030001700327
06500090034406400050035303100030035803200020036101400080036386500090037100200130
0380035001000393801001700403#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.h
tm#S#c#129#15#article#24#15#^rND^sKim^nNK#^rND^sAahn^nTW#^rND^sPark^nJK#^rND^sLe
e^nKY#^rND^sLee^nWH#^rND^sSohn^nSK#^rND^sMin^nJS#Assessment of sexual and voidin
g function after total mesorectal excision with pelvic autonomic nerve preservat
ion in males with rectal cancer^len#Dis Colon Rectum#20020000#2002#45#9#1178-85#
20110300#v24n1a14.htm#0012-3706#Dis Colon Rectum##
00750000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100028000940100
01700122010001800139010001500157010001600172010001400188012012200202030000700324
06500090033106400050034003100040034503200050034901400070035486500090036100200130
0370035001000383801000700393#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.h
tm#S#c#130#16#article#24#16#^rND^sLacy^nAM#^rND^sGarcía-Valdecasas^nJC#^rND^sDel
gado^nS#^rND^sCastells^nA#^rND^sTaurá^nP#^rND^sPiqué^nJM#^rND^sVisa^nJ#Laparosco
py-assisted colectomy versus open colectomy for treatment of non-metastatic colo
n cancer: a randomised trial^len#Lancet#20020000#2002#359#9325#2224-9#20110300#v
24n1a14.htm#0099-5355#Lancet##
00485000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180048000790620035001270370
06300162110000900225109001100234865000900245002001300254#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a14.htm#S#c#131#17#article#24#17#Laparoscopic Proctectomy
 for Curable Cancer^len#Position Statement - ASCRS & SAGES#http://www.fascrs.org
/displaycommon.cfm?an=1&subarticlenbr=349#20071229#29/12/2007#20110300#v24n1a14.
htm##
00635000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01700113010001500130010001700145012006500162030001000227065000900237064000700246
03100030025303200030025601400080025986500090026700200130027603500100028980100100
0299#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#132#18#article#24
#18#^rND^sLaurent^nC#^rND^sLeblanc^nF#^rND^sGineste^nC#^rND^sSaric^nJ#^rND^sRull
ier^nE#Laparoscopic approach in surgical treatment of rectal cancer^len#Br J Sur
g#20071200#200712#94#12#1555-61#20110300#v24n1a14.htm#0007-1323#Br J Surg##
00681000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01700111010001600128010002400144010001700168012008100185030000900266065000900275
06400050028403100040028903200020029301400070029586500090030200200130031103500100
0324801000900334#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#133#1
9#article#24#19#^rND^sMorino^nM#^rND^sParini^nU#^rND^sGiraudo^nG#^rND^sSalval^nM
#^rND^sBrachet Contul^nR#^rND^sGarrone^nC#Laparoscopic total mesorectal excision
: a consecutive series of 100 patients^len#Ann Surg#20030000#2003#237#3#335-42#2
0110300#v24n1a14.htm#0003-4932#Ann Surg##
00589000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01600117010001700133012004300150030001200193065000900205064000500214031000300219
032000200222014000700224865000900231002001300240035001000253801001200263#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#134#20#article#24#20#^rND^sPi
karsky^nAJ#^rND^sRosenthal^nR#^rND^sWeiss^nEG#^rND^sWexner^nSD#Laparoscopic tota
l mesorectal excision^len#Surg Endosc#20020000#2002#16#4#558-62#20110300#v24n1a1
4.htm#0930-2794#Surg Endosc##
00661000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01300110010002000123012012500143030001000268065000900278064000500287031000300292
032000300295014000700298865000900305002001300314035001000327801001000337#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#135#21#article#24#21#^rND^sQu
ah^nHM#^rND^sJayne^nDG#^rND^sEu^nKW#^rND^sSeow-Choen^nF#Bladder and sexual dysfu
nction following laparoscopically assisted and conventional open mesorectal rese
ction for cancer^len#Br J Surg#20020000#2002#89#12#1551-6#20110300#v24n1a14.htm#
0007-1323#Br J Surg##
00755000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100019000990100
01700118010001900135010001600154010001900170010002000189012011600209030001200325
06500090033706400050034603100030035103200020035401400050035686500090036100200130
0370035001000383801001200393#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.h
tm#S#c#136#22#article#24#22#^rND^sScheidbach^nH#^rND^sSchneider^nC#^rND^sKonradt
^nJ#^rND^sBärlehner^nE#^rND^sKöhler^nL#^rND^sWittekind Ch#^rND^sKöckerling^nF#La
paroscopic abdominoperineal resection and anterior resection with curative inten
t for carcinoma of the rectum^len#Surg Endosc#20020000#2002#16#1#7-13#20110300#v
24n1a14.htm#0930-2794#Surg Endosc##
00907000000000409000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01400112010001600126010001800142010001700160010001700177010001700194010001700211
01000150022801000160024301000150025901100560027401201050033003000130043571000020
04480650009004500640005004590310002004640320002004660140007004688650009004750020
01300484#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a14.htm#S#c#137#23#articl
e#24#23#^rND^sVeldkamp^nR#^rND^sKuhry^nE#^rND^sHop^nWC#^rND^sJeekel^nJ#^rND^sKaz
emier^nG#^rND^sBonjer^nHJ#^rND^sHaglind^nE#^rND^sPåhlman^nL#^rND^sCuesta^nMA#^rN
D^sMsika^nS#^rND^sMorino^nM#^rND^sLacy^nAM#COlon cancer Laparoscopic or Open Res
ection Study Group#Laparoscopic surgery versus open surgery for colon cancer: sh
ort-term outcomes of a randomised trial^len#Lancet Oncol#2#20050000#2005#6#7#477
-84#20110300#v24n1a14.htm##
00573000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960120
07700113030001700190065000900207064000500216031000300221032000200224014000800226
865000900234002001300243035001000256801001700266#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a14.htm#S#c#138#24#article#24#24#^rND^sWeiser^nMR#^rND^sMilsom^nJ
W#Laparoscopic total mesorectal excision with autonomic nerve preservation^len#S
emin Surg Oncol#20000000#2000#19#4#396-403#20110300#v24n1a14.htm#8756-0437#Semin
 Surg Oncol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#o#1#1#article#1
#20110411#103918#v24n1a15.htm#222##
03670000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002700107
03100030013403200020013706500090013901400090014803500100015701200640016701200510
02310100043002820100042003250831283003670850010016500850022016600850026016820850
02501708083123401733085001002967085002002977085002602997085002903023117000803052
072000303060112000903063111001103072114000903083113001103092002001303103#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4
.0#ND#15#ABCD070#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f68^l73#0102-6720#
As principais alterações dermatológicas em pacientes obesos^lpt#Major dermatolog
ical changes in obese patients^len#^rND^nRosimeri da Silva Castanho^sMendonça#^r
ND^nGeruza Baima de Oliveira^sRodrigues#^lpt^aINTRODUÇÃO: A obesidade é consider
ada grave doença crônica que vem atingindo proporções mundiais gerando transtorn
os sérios para a saúde pública. No Brasil, a prevalência desta doença denota aum
ento progressivo em relação ao número de pessoas com sobrepeso e/ou obesidade. A
pesar disso, as manifestações dermatológicas da obesidade têm sido pouco estudad
as. OBJETIVO: Abordar as dermatoses que mais acometem pacientes obesos e seu tra
tamento, principalmente na aplicação adequada da fisioterapia dermatofuncional. 
MÉTODO: Revisão da literatura, entre 2000 e 2010, de artigos indexados nas bases
 Medline/Pubmed, Scielo e Lilacs, livros e monografias das bibliotecas da Univer
sidade de Fortaleza e Universidade Federal do Ceará, Fortaleza, CE, Brasil, cruz
ando os descritores obesidade, dermatose e fisioterapia. Foram reconhecidas como
 mais importantes as seguintes situações patológicas: estrias, celulite, acantho
sis nigricans, acrocórdons, flacidez, úlcera e impetigo. Entre as formas de trat
amento deuse destaque à atuação da fisioterapia dermatofuncional. CONCLUSÃO: O t
ratamento das dermatoses por meio da fisioterapia dermatofuncional é possível po
dendo trazer consigo resultados que satisfaçam a expectativa dos pacientes e pro
porcionando-lhes melhor qualidade de vida.#^ddecs^i1#^tm^lpt^kObesidade^i1#^tm^l
pt^kdermatopatias^i1#^tm^lpt^kFisioterapia^i1#^len^aINTRODUCTION: Obesity is a s
erious chronic disease that has reached global proportions causing problems to p
ublic health. In Brazil, the prevalence of this disease shows a progressive incr
ease in the number of people with overweight or obesity. Nevertheless, the skin 
manifestations have not been well studied. OBJECTIVE: To analyse the dermatosis 
most affecting obese patients and its treatment, particularly in proper applicat
ion of dermatological therapy. METHOD: Was made a literature review between 2000
 and 2010 of articles published in Medline/ PubMed, SciELO and Lilacs, books and
 monographs of the libraries of the University of Fortaleza and the Federal Univ
ersity of Ceará, Fortaleza, CE, Brazil, crossing the headings obesity, dermatosi
s, therapy and physiotherapy. Were recognized as most important the following pa
thological conditions: stretch marks, cellulitis, acanthosis nigricans, acrochod
ons, tenderness, ulcers and impetigo. Among the forms of treatment was highlight
ed the role of dermatological physiotherapy. CONCLUSION: Dermatosis treatment by
 dermatological therapy and physiotherapy is possible and can bring result that 
satisfy the expectations of patients and providing them better quality of life.#
^ddecs^i2#^tm^len^kObesity^i2#^tm^len^kSkin diseases^i2#^tm^len^kPhysical therap
y^i2#vancouv#39#20101019#19/10/2010#20110125#25/01/2011#v24n1a15.htm##
03740000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002700107
03100030013403200020013706500090013901400090014803500100015701200710016701200580
02380100043002960100042003390831311003810850010016920850022017020850026017240850
02501750083126201775085001003037085002003047085002603067085002903093117000803122
072000303130112000903133111001103142114000903153113001103162002001303173#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4
.0#ND#15#ABCD070#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f68^l73#0102-6720#
<b>As principais alterações dermatológicas em pacientes obesos</b>^lpt#<b>Major 
dermatological changes in obese patients</b>^len#^rND^nRosimeri da Silva Castanh
o^sMendonça#^rND^nGeruza Baima de Oliveira^sRodrigues#^lpt^a<b>INTRODUÇÃO: </b>A
 obesidade é considerada grave doença crônica que vem atingindo proporções mundi
ais gerando transtornos sérios para a saúde pública. No Brasil, a prevalência de
sta doença denota aumento progressivo em relação ao número de pessoas com sobrep
eso e/ou obesidade. Apesar disso, as manifestações dermatológicas da obesidade t
êm sido pouco estudadas. <b>OBJETIVO:</b> Abordar as dermatoses que mais acomete
m pacientes obesos e seu tratamento, principalmente na aplicação adequada da fis
ioterapia dermatofuncional. <b>MÉTODO: </b>Revisão da literatura, entre 2000 e 2
010, de artigos indexados nas bases Medline/Pubmed, Scielo e Lilacs, livros e mo
nografias das bibliotecas da Universidade de Fortaleza e Universidade Federal do
 Ceará, Fortaleza, CE, Brasil, cruzando os descritores obesidade, dermatose e fi
sioterapia. Foram reconhecidas como mais importantes as seguintes situações pato
lógicas: estrias, celulite, acanthosis nigricans, acrocórdons, flacidez, úlcera 
e impetigo. Entre as formas de tratamento deuse destaque à atuação da fisioterap
ia dermatofuncional. <b>CONCLUSÃO:</b> O tratamento das dermatoses por meio da f
isioterapia dermatofuncional é possível podendo trazer consigo resultados que sa
tisfaçam a expectativa dos pacientes e proporcionando-lhes melhor qualidade de v
ida.#^ddecs^i1#^tm^lpt^kObesidade^i1#^tm^lpt^kdermatopatias^i1#^tm^lpt^kFisioter
apia^i1#^len^a<b>INTRODUCTION:</b> Obesity is a serious chronic disease that has
 reached global proportions causing problems to public health. In Brazil, the pr
evalence of this disease shows a progressive increase in the number of people wi
th overweight or obesity. Nevertheless, the skin manifestations have not been we
ll studied. <b>OBJECTIVE:</b> To analyse the dermatosis most affecting obese pat
ients and its treatment, particularly in proper application of dermatological th
erapy. <b>METHOD: </b>Was made a literature review between 2000 and 2010 of arti
cles published in Medline/ PubMed, SciELO and Lilacs, books and monographs of th
e libraries of the University of Fortaleza and the Federal University of Ceará, 
Fortaleza, CE, Brazil, crossing the headings obesity, dermatosis, therapy and ph
ysiotherapy. Were recognized as most important the following pathological condit
ions: stretch marks, cellulitis, acanthosis nigricans, acrochodons, tenderness, 
ulcers and impetigo. Among the forms of treatment was highlighted the role of de
rmatological physiotherapy. <b>CONCLUSION: </b>Dermatosis treatment by dermatolo
gical therapy and physiotherapy is possible and can bring result that satisfy th
e expectations of patients and providing them better quality of life.#^ddecs^i2#
^tm^len^kObesity^i2#^tm^len^kSkin diseases^i2#^tm^len^kPhysical therapy^i2#vanco
uv#39#20101019#19/10/2010#20110125#25/01/2011#v24n1a15.htm##
03785000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104121000300108049000800111158000300119030002600122
03100030014803200020015106500090015301400090016203500100017101200640018101200510
02450100043002960100042003390831283003810850010016640850022016740850026016960850
02501722083123401747085001002981085002002991085002603011085002903037117000803066
07200030307411200090307711100110308611400090309711300110310600200130311700800890
3130#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#l#4#1#article#1#^mj
an./mar.^a2011#oa#pt#br1.1#1#4.0#15#ABCD070#nd#ABCD, arq. bras. cir. dig#24#1#20
110300#^f68^l73#0102-6720#As principais alterações dermatológicas em pacientes o
besos^lpt#Major dermatological changes in obese patients^len#^rND^nRosimeri da S
ilva Castanho^sMendonça#^rND^nGeruza Baima de Oliveira^sRodrigues#^lpt^aINTRODUÇ
ÃO: A obesidade é considerada grave doença crônica que vem atingindo proporções 
mundiais gerando transtornos sérios para a saúde pública. No Brasil, a prevalênc
ia desta doença denota aumento progressivo em relação ao número de pessoas com s
obrepeso e/ou obesidade. Apesar disso, as manifestações dermatológicas da obesid
ade têm sido pouco estudadas. OBJETIVO: Abordar as dermatoses que mais acometem 
pacientes obesos e seu tratamento, principalmente na aplicação adequada da fisio
terapia dermatofuncional. MÉTODO: Revisão da literatura, entre 2000 e 2010, de a
rtigos indexados nas bases Medline/Pubmed, Scielo e Lilacs, livros e monografias
 das bibliotecas da Universidade de Fortaleza e Universidade Federal do Ceará, F
ortaleza, CE, Brasil, cruzando os descritores obesidade, dermatose e fisioterapi
a. Foram reconhecidas como mais importantes as seguintes situações patológicas: 
estrias, celulite, acanthosis nigricans, acrocórdons, flacidez, úlcera e impetig
o. Entre as formas de tratamento deuse destaque à atuação da fisioterapia dermat
ofuncional. CONCLUSÃO: O tratamento das dermatoses por meio da fisioterapia derm
atofuncional é possível podendo trazer consigo resultados que satisfaçam a expec
tativa dos pacientes e proporcionando-lhes melhor qualidade de vida.#^ddecs^i1#^
tm^lpt^kObesidade^i1#^tm^lpt^kdermatopatias^i1#^tm^lpt^kFisioterapia^i1#^len^aIN
TRODUCTION: Obesity is a serious chronic disease that has reached global proport
ions causing problems to public health. In Brazil, the prevalence of this diseas
e shows a progressive increase in the number of people with overweight or obesit
y. Nevertheless, the skin manifestations have not been well studied. OBJECTIVE: 
To analyse the dermatosis most affecting obese patients and its treatment, parti
cularly in proper application of dermatological therapy. METHOD: Was made a lite
rature review between 2000 and 2010 of articles published in Medline/ PubMed, Sc
iELO and Lilacs, books and monographs of the libraries of the University of Fort
aleza and the Federal University of Ceará, Fortaleza, CE, Brazil, crossing the h
eadings obesity, dermatosis, therapy and physiotherapy. Were recognized as most 
important the following pathological conditions: stretch marks, cellulitis, acan
thosis nigricans, acrochodons, tenderness, ulcers and impetigo. Among the forms 
of treatment was highlighted the role of dermatological physiotherapy. CONCLUSIO
N: Dermatosis treatment by dermatological therapy and physiotherapy is possible 
and can bring result that satisfy the expectations of patients and providing the
m better quality of life.#^ddecs^i2#^tm^len^kObesity^i2#^tm^len^kSkin diseases^i
2#^tm^len^kPhysical therapy^i2#vancouv#39#20101019#19/10/2010#20110125#25/01/201
1#v24n1a15.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=
S0102-67202011000100015##
00363000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704013000074002001300204#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#5#1#article#180#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO DE REVIS&Atild
e;O </b> </font></p>     ^cY#v24n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#6#2#article#180#<p>&nbsp;</p>     ^cY
#v24n1a15.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704019100074002001300265#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#7#3#article#180#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>As principais a
ltera&ccedil;&otilde;es dermatol&oacute;gicas em pacientes obesos </b></font></p
>     ^cY#v24n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#8#4#article#180#<p>&nbsp;</p>     ^cY
#v24n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#9#5#article#180#<p>&nbsp;</p>     ^cY
#v24n1a15.htm##
00403000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704016900075002001300244#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#10#6#article#180#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Rosimeri da Silva Castanho Mendon&
ccedil;a; Geruza Baima de Oliveira Rodrigues </b></font></p>     ^cY#v24n1a15.ht
m##
00360000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012600075002001300201#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#11#7#article#180#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a </a></font></p>     ^cY#v24n1a15.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#12#8#article#180#<p>&nbsp;</p>     ^c
Y#v24n1a15.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004500075002001300120#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#13#9#article#180#<p>&nbsp;</p> <hr si
ze="1" noshade>      ^cY#v24n1a15.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#14#10#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24
n1a15.htm##
00802000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056700076002001300643#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#15#11#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b> INTRODU&Ccedil;&Atilde;O: </b>A 
obesidade &eacute; considerada grave doen&ccedil;a cr&ocirc;nica que vem atingin
do propor&ccedil;&otilde;es mundiais gerando transtornos s&eacute;rios para a sa
&uacute;de p&uacute;blica. No Brasil, a preval&ecirc;ncia desta doen&ccedil;a de
nota aumento progressivo em rela&ccedil;&atilde;o ao n&uacute;mero de pessoas co
m sobrepeso e/ou obesidade. Apesar disso, as manifesta&ccedil;&otilde;es dermato
l&oacute;gicas da obesidade t&ecirc;m sido pouco estudadas.     ^cY#v24n1a15.htm
##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019300076002001300269#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#16#12#article#180#<br>   <b>OBJETIVO:
</b>  Abordar as dermatoses que mais acometem pacientes obesos e seu tratamento,
 principalmente na aplica&ccedil;&atilde;o adequada da fisioterapia dermatofunci
onal.     ^cY#v24n1a15.htm##
00880000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064500076002001300721#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#17#13#article#180#<br>   <b>M&Eacute;
TODO: </b> Revis&atilde;o da literatura, entre 2000 e 2010, de artigos indexados
 nas bases Medline/Pubmed, Scielo e Lilacs, livros e monografias das bibliotecas
 da Universidade de Fortaleza e Universidade Federal do Cear&aacute;, Fortaleza,
 CE, Brasil, cruzando os descritores obesidade, dermatose e fisioterapia. Foram 
reconhecidas como mais importantes as seguintes situa&ccedil;&otilde;es patol&oa
cute;gicas: estrias, celulite, acanthosis nigricans, acroc&oacute;rdons, flacide
z, &uacute;lcera e impetigo. Entre as formas de tratamento deuse destaque &agrav
e; atua&ccedil;&atilde;o da fisioterapia dermatofuncional.    ^cY#v24n1a15.htm##
00515000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028000076002001300356#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#18#14#article#180#<br>   <b>CONCLUS&A
tilde;O:</b>  O tratamento das dermatoses por meio da fisioterapia dermatofuncio
nal &eacute; poss&iacute;vel podendo trazer consigo resultados que satisfa&ccedi
l;am a expectativa dos pacientes e proporcionando-lhes melhor qualidade de vida.
 </font></p>     ^cY#v24n1a15.htm##
00403000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016800076002001300244#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#19#15#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b>  Obesidade. derm
atopatias. Fisioterapia. </font></p>  <hr size="1" noshade>      ^cY#v24n1a15.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#20#16#article#180#<p>&nbsp;</p>     ^
cY#v24n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#21#17#article#180#<p>&nbsp;</p>     ^
cY#v24n1a15.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#22#18#article#180#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O </b></fo
nt></p>     ^cY#v24n1a15.htm##
00769000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053400076002001300610#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#23#19#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Para iniciar-se estudo sobre obesida
de faz-se necess&aacute;rio considerar a diversidade dos fatores etiol&oacute;gi
cos que a determinam e tamb&eacute;m compreender as dimens&otilde;es fisiopatol&
oacute;gicas, sociais, culturais, econ&ocirc;micas e psicol&oacute;gicas que est
&atilde;o inseridas nesse contexto. Soma-se a isso necessidade de compreens&atil
de;o e de re-estrutura&ccedil;&atilde;o desses fatores ap&oacute;s cirurgia bari
&aacute;trica. </font></p>     ^cY#v24n1a15.htm##
00821000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058600076002001300662#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#24#20#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A obesidade (lati pm obesus = muito;
 edere = comer) na antiguidade era conhecida como sinal de riqueza, "boa vida", 
as pessoas obesas eram bem vistas, por serem consideradas mais saud&aacute;veis,
 que as pessoas de porte magro. Atualmente atrav&eacute;s de pesquisa e estudos 
foram avaliadas as consequ&ecirc;ncias e dimensionadas as complica&ccedil;&otild
e;es, sendo hoje considerada doen&ccedil;a universal de preval&ecirc;ncia epid&e
circ;mica e conhecida como o mal do s&eacute;culo XX<sup>34</sup>. </font></p>  
   ^cY#v24n1a15.htm##
00565000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033000076002001300406#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#25#21#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O Consenso Latino Americano de Obesi
dade definiu-a como doen&ccedil;a cr&ocirc;nica associada &agrave; grande varied
ade de complica&ccedil;&otilde;es resultantes da deposi&ccedil;&atilde;o e ac&ua
cute;mulo excessivo de tecido adiposo<sup>4</sup>. </font></p>     ^cY#v24n1a15.
htm##
00648000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041300076002001300489#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#26#22#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O padr&atilde;o da alimenta&ccedil;&
atilde;o humana nos dias atuais tem gerado mudan&ccedil;a no estilo de vida adot
ado pela popula&ccedil;&atilde;o, em que ela teve que ser adaptada &agrave;s nov
as condi&ccedil;&otilde;es de tempo, recursos financeiros, local de trabalho, pe
riodicidade de compra, dentre outros<sup>22,23</sup>. </font></p>     ^cY#v24n1a
15.htm##
00779000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054400076002001300620#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#27#23#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A obesidade est&aacute; diretamente 
relacionada &agrave; alta preval&ecirc;ncia e &agrave; intensidade das dermatose
s, relacionadas ao grande volume de dobras e pregas cut&acirc;neas, altera&ccedi
l;&otilde;es circulat&oacute;rias, metab&oacute;licas e dificuldade do manejo hi
gi&ecirc;nico de regi&otilde;es mais acometidas pela pr&oacute;pria limita&ccedi
l;&atilde;o f&iacute;sica. Vale ressaltar a precariedade de estudos nessa linha 
de pesquisa<sup>9</sup>. </font></p>     ^cY#v24n1a15.htm##
00530000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029500076002001300371#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#28#24#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O presente estudo ressalta a anatomi
a e fisiologia da pele, a obesidade e/ou excesso de peso e as altera&ccedil;&oti
lde;es dermatol&oacute;gicas relacionadas a ela, enfatizando o tratamento fisiot
er&aacute;pico. </font></p>     ^cY#v24n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#29#25#article#180#<p>&nbsp;</p>     ^
cY#v24n1a15.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#30#26#article#180#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODO</b> </font></p>    
 ^cY#v24n1a15.htm##
00621000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038600076002001300462#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#31#27#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Revis&atilde;o da literatura, entre 
2000 e 2010, de artigos indexados nas bases Medline/Pubmed, Scielo e Lilacs, liv
ros e monografias das bibliotecas da Universidade de Fortaleza e Universidade Fe
deral do Cear&aacute;, Fortaleza, CE, Brasil, cruzando os descritores obesidade,
 dermatose e fisioterapia. </font></p>     ^cY#v24n1a15.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012000076002001300196#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#32#28#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Anatomia e fisiologia da pele</b>
 </font></p>     ^cY#v24n1a15.htm##
00874000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063900076002001300715#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#33#29#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A pele ou c&uacute;tis &eacute; o ma
nto de revestimento do organismo, indispens&aacute;vel &agrave; vida e que isola
 os componentes org&acirc;nicos do meio exterior<sup>36</sup>. Ela representa 12
% do peso seco total do corpo, com aproximadamente 4,5 quilos, e &eacute; o maio
r sistema de &oacute;rg&atilde;os expostos ao meio ambiente<sup>20</sup>. Embora
 ela represente menos de 15% do peso do corpo, &eacute; considerada o maior &oac
ute;rg&atilde;o humano, pois a sua extens&atilde;o corresponde a uma &aacute;rea
 de dois metros quadrados<sup>24</sup>. </font></p>     ^cY#v24n1a15.htm##
00640000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040500076002001300481#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#34#30#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">&Eacute; formada por tecidos de orig
em ectod&eacute;rmica e mesod&eacute;rmica que se arranjam em tr&ecirc;s camadas
 distintas: epiderme, derme e hipoderme. Esta &uacute;ltima n&atilde;o &eacute; 
considerada por muitos autores como parte integrante da pele, embora seja estuda
da dentro do sistema tegumentar<sup>24</sup>. </font></p>     ^cY#v24n1a15.htm##
00570000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033500076002001300411#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#35#31#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O limite entre a epiderme e a derme 
n&atilde;o &eacute; regular, mas caracteriza-se pela presen&ccedil;a de sali&eci
rc;ncias e reentr&acirc;ncias das duas camadas que se embricam e se ajustam entr
e si, formando as papilas d&eacute;rmicas<sup>20</sup>. </font></p>     ^cY#v24n
1a15.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009900076002001300175#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#36#32#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Epiderme</i> </font></p>     ^cY#
v24n1a15.htm##
00910000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067500076002001300751#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#37#33#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A epiderme &eacute;, basicamente, um
 tecido epitelial estratificado queratinizado, com varia&ccedil;&otilde;es estru
turais e funcionais significativas na depend&ecirc;ncia do seu s&iacute;tio anat
&ocirc;mico. &Eacute; constitu&iacute;da por: sistema ceratinoc&iacute;tico, res
pons&aacute;vel pelo corpo da epiderme e de seus anexos (pelos, unhas e gl&acirc
;ndulas); sistema mel&acirc;nico, com fun&ccedil;&atilde;o imunol&oacute;gica; c
&eacute;lulas de merkel integrada ao sistema nervoso e c&eacute;lulas dendr&iacu
te;ticas indeterminadas, com fun&ccedil;&atilde;o mal definida<sup>3</sup>. </fo
nt></p>     ^cY#v24n1a15.htm##
00585000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035000076002001300426#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#38#34#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A sua principal fun&ccedil;&atilde;o
 &eacute; produzir queratina, prote&iacute;na fibrosa male&aacute;vel respons&aa
cute;vel pela impermeabilidade cut&acirc;nea; as c&eacute;lulas que est&atilde;o
 envolvidas s&atilde;o denominadas queratin&oacute;citos<sup>24</sup>. </font></
p>     ^cY#v24n1a15.htm##
01074000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083900076002001300915#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#39#35#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A por&ccedil;&atilde;o mais profunda
 da epiderme &eacute; constitu&iacute;da de c&eacute;lulas epiteliais que se pro
liferam continuamente para que seja mantido o seu n&uacute;mero. Tipicamente com
o em todos os epit&eacute;lios, n&atilde;o h&aacute; vasos sangu&iacute;neos na 
epiderme, embora a derme subjacente seja bem vascularizada. Como resultado, o &u
acute;nico meio pelo qual as c&eacute;lulas de epiderme podem obter alimento &ea
cute; atrav&eacute;s da difus&atilde;o dos leitos capilares da derme. Esse m&eac
ute;todo &eacute; suficiente para que as c&eacute;lulas mais pr&oacute;ximas viv
am, mas &agrave; medida que elas se dividem e s&atilde;o empurradas para a super
f&iacute;cie, ficam longe da fonte de alimento (derme),  e morrem<sup>20</sup>. 
</font></p>     ^cY#v24n1a15.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#40#36#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Derme </i></font></p>     ^cY#v24
n1a15.htm##
00623000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038800076002001300464#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#41#37#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Abaixo da epiderme, fica a principal
 massa de pele, a derme, um tecido forte, male&aacute;vel, com propriedades visc
oel&aacute;sticas, e que consiste em um tecido conjuntivo frouxo composto de pro
te&iacute;nas fibrosas (col&aacute;geno e elastina) embebidas em subst&acirc;nci
a basal amorfa<sup>19</sup>. </font></p>     ^cY#v24n1a15.htm##
01886000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704165100076002001301727#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#42#38#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A derme est&aacute; conectada com a 
f&aacute;scia dos m&uacute;sculos subjacentes por uma camada de tecido conjuntiv
o frouxo, a hipoderme. Nela situam-se algumas fibras el&aacute;sticas e reticula
res, bem como muitas fibras col&aacute;genas, sendo suprida por vasos sangu&iacu
te;neos, vasos linf&aacute;ticos e nervos. Tamb&eacute;m cont&eacute;m gl&acirc;
ndulas especializadas e &oacute;rg&atilde;os do sentido<sup>20</sup>. Tem espess
ura vari&aacute;vel ao longo do organismo, desde 1 mm at&eacute; 4 mm, e comp&ot
ilde;e-se de tr&ecirc;s por&ccedil;&otilde;es: a derme papilar, a perianexial e 
a reticular<sup>36</sup>. Derme papilar ou superficial &eacute; mais delgada e p
reenche as concavidades entre as cristas epid&eacute;rmicas, dando origem as pap
ilas ou cristas d&eacute;rmicas. Constitu&iacute;da de tecido conjuntivo frouxo,
 &eacute; formada por feixes delicados de fibras col&aacute;genas, reticulares e
 el&aacute;sticas, dispostas em uma rede frouxa. A camada papilar &eacute; separ
ada da epiderme pela lamina basal<sup>15</sup>. A derme perianexial &eacute; est
ruturalmente id&ecirc;ntica &agrave; papilar, dispondo-se, por&eacute;m, em torn
o dos anexos; comp&otilde;e, juntamente com a derme papilar, a unidade anat&ocir
c;mica denominada derme adventicial<sup>36</sup>. A derme reticular ou profunda 
&eacute; a mais espessa, constitu&iacute;da por tecido conjuntivo denso, e &eacu
te; assim denominada devido ao fato de que os feixes de fibras col&aacute;genas 
que a comp&otilde;em entrela&ccedil;am-se em um arranjo semelhante a uma rede<su
p>20</sup>. </font></p>     ^cY#v24n1a15.htm##
00687000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045200076002001300528#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#43#39#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Como todo tecido conjuntivo, a derme
 cont&eacute;m muitos tipos diferentes de c&eacute;lulas incluindo fibroblasto e
 fibr&oacute;citos, macr&oacute;fagos teciduais, melan&oacute;fagos, mast&oacute
;citos e leuc&oacute;citos sangu&iacute;neos, particularmente neutr&oacute;filos
, eosin&oacute;filos, linf&oacute;citos, mon&oacute;citos e plasm&oacute;citos<s
up>15</sup>. </font></p>     ^cY#v24n1a15.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012100076002001300197#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#44#40#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Obesidade e/ou excesso de peso </
b></font></p>     ^cY#v24n1a15.htm##
00736000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050100076002001300577#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#45#41#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Esses dois termos que s&atilde;o err
oneamente empregados como sin&ocirc;nimos apresentam diferen&ccedil;as important
es do ponto de vista da natureza desses estados, dos n&iacute;veis de risco para
 as taxas de morbidade e mortalidade, assim como para a determina&ccedil;&atilde
;o das contribui&ccedil;&otilde;es e limita&ccedil;&otilde;es de atividade f&iac
ute;sica regular nessas popula&ccedil;&otilde;es<sup>8</sup>. </font></p>     ^c
Y#v24n1a15.htm##
01023000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078800076002001300864#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#46#42#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Castro<sup>13</sup> aponta consider&
aacute;vel diferen&ccedil;a entre indiv&iacute;duos obesos e aqueles que apresen
tam sobrepeso. Para os autores, o ac&uacute;mulo excessivo de tecido adiposo car
acteriza os indiv&iacute;duos obesos. J&aacute; os que apresentam sobrepeso, exc
edem o peso m&eacute;dio da popula&ccedil;&atilde;o por apresentarem um conjunto
 de componentes f&iacute;sicos gerais, como m&uacute;sculos, ossos, &oacute;rg&a
tilde;os viscerais e l&iacute;quidos org&acirc;nicos em n&iacute;veis superiores
 aos da m&eacute;dia da popula&ccedil;&atilde;o. Como exemplo, pode-se citar o f
isiculturismo, em que os indiv&iacute;duos apresentam peso excessivo com percent
ual baixo de tecido adiposo. </font></p>     ^cY#v24n1a15.htm##
00787000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055200076002001300628#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#47#43#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No ano de 1998, a Organiza&ccedil;&a
tilde;o Mundial de Sa&uacute;de, prop&ocirc;s uma classifica&ccedil;&atilde;o pa
ra o peso corporal baseado no &iacute;ndice de massa corporal (IMC) tamb&eacute;
m conhecido como &iacute;ndice de Quatelet, determinado pelo peso em quilogramas
 dividido pela altura em metros ao quadrado (kg/m). O valor assim obtido estabel
ece o diagn&oacute;stico da obesidade e caracteriza tamb&eacute;m os graus de ri
sco associados a ela<sup>8</sup>.</font></p>     ^cY#v24n1a15.htm##
00965000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073000076002001300806#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#48#44#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> De acordo com a distribui&ccedil;&a
tilde;o da gordura corporal pode-se classificar a obesidade em tr&ecirc;s grupos
: difusa ou generalizada; andr&oacute;ide (mais comum aos homens), associada &ag
rave; maior concentra&ccedil;&atilde;o de gorduras na regi&atilde;o abdominal, i
ntravisceral e intensamente relacionada com altos riscos para doen&ccedil;as met
ab&oacute;licas e cardiovasculares; e a obesidade ginec&oacute;ide (mais comuns 
&agrave;s mulheres) em que a reposi&ccedil;&atilde;o de gordura est&aacute; pred
ominantemente na regi&atilde;o do quadril e associada a riscos maiores de artros
e e varizes de membros inferiores<sup>16,30</sup>. </font></p>     ^cY#v24n1a15.
htm##
00976000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074100076002001300817#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#49#45#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Com base nessa classifica&ccedil;&at
ilde;o a rela&ccedil;&atilde;o cinturaquadril - obtida pela divis&atilde;o da ci
rcunfer&ecirc;ncia da cintura pela circunfer&ecirc;ncia do quadril - tamb&eacute
;m &eacute; considerada como indicador de risco para poss&iacute;veis complica&c
cedil;&otilde;es da obesidade. Homens e mulheres que apresentam a rela&ccedil;&a
tilde;o cintura-quadril de 94 e 80 cm, respectivamente, oferecem risco; j&aacute
; quando esse valor for de 100 cm para homens e 88 cm para mulheres esse risco a
umenta ainda mais, de acordo com as recomenda&ccedil;&otilde;es para a perda de 
peso do National Heart Lung and Blood Institute<sup>17</sup>. </font></p>     ^c
Y#v24n1a15.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013700076002001300213#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#50#46#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Altera&ccedil;&otilde;es dermatol
&oacute;gicas </i></font></p>     ^cY#v24n1a15.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#51#47#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Estrias </i></font></p>     ^cY#v
24n1a15.htm##
00625000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039000076002001300466#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#52#48#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As estrias - fragilidade da pele nas
 regi&otilde;es das dobras, tend&ecirc;ncia &agrave;s infec&ccedil;&otilde;es f&
uacute;ngicas e acantose nigricans, escurecimento da pele nas axilas e no pesco&
ccedil;o -, s&atilde;o altera&ccedil;&otilde;es dermatol&oacute;gicas mais comum
ente encontradas na obesidade. </font></p>     ^cY#v24n1a15.htm##
00560000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032500076002001300401#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#53#49#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">S&atilde;o rupturas das fibras el&aa
cute;sticas, localizada na segunda camada da pele, a derme. Este rompimento gera
 atrofia, sendo definida como atrofia tegumentar adquirida, linear, com um ou ma
is mil&iacute;metros de largura<sup>29</sup>. </font></p>     ^cY#v24n1a15.htm##
00547000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031200076002001300388#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#54#50#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Apresentam-se perpendiculares &agrav
e;s fendas da pele e se disp&otilde;e paralelamente em rela&ccedil;&atilde;o &ag
rave;s outras estrias. Tendem a ser bilaterais, distribuindo-se simetricamente n
os dois hemicorpos<sup>14</sup>. </font></p>     ^cY#v24n1a15.htm##
00919000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068400076002001300760#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#55#51#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Elas surgem como les&otilde;es erite
mato-purp&uacute;ricas que evoluem para altera&ccedil;&otilde;es brancas e atr&o
acute;ficas. Fatores mec&acirc;nicos, hormonais e gen&eacute;ticos contribuem pa
ra o seu aparecimento. Podem ser consideradas cicatrizes resultantes da les&atil
de;o d&eacute;rmica dos tecidos de conex&atilde;o, nas quais o col&aacute;geno c
ede em resposta &agrave;s for&ccedil;as estressoras locais. Obesidade, gesta&cce
dil;&atilde;o, s&iacute;ndrome de Cushing e uso de corticoster&oacute;ides t&oac
ute;picos ou sist&ecirc;micos est&atilde;o associadas ao seu surgimento<sup>9</s
up>. </font></p>     ^cY#v24n1a15.htm##
00741000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050600076002001300582#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#56#52#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Medidas de tratamento fisioter&aacut
e;pico interessantes para as estrias<sup>7</sup>, s&atilde;o as realizadas com m
icrodermoabras&atilde;o (peeling de cristal); t&ecirc;m a vantagem de possuir te
cnologia n&atilde;o evasiva e n&atilde;o cir&uacute;rgica, devido &agrave; sua t
&eacute;cnica especial de remover c&eacute;lulas envelhecidas, estimular a produ
&ccedil;&atilde;o de c&eacute;lulas jovens e novo col&aacute;geno. </font></p>  
   ^cY#v24n1a15.htm##
00717000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048200076002001300558#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#57#53#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O striat<sup>25</sup>, &eacute; um a
parelho utilizado para o tratamento das estrias, permitindo alcan&ccedil;ar at&e
acute; 40% de melhora no aspecto em que estria se apresenta. Este equipamento ut
iliza uma agulha, que &eacute; introduzida na subepiderme desencadeando processo
 inflamat&oacute;rio local, que leva &agrave; cicatriza&ccedil;&atilde;o, promov
endo melhor apar&ecirc;ncia &agrave; pele. </font></p>     ^cY#v24n1a15.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009900076002001300175#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#58#54#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Celulite</i> </font></p>     ^cY#
v24n1a15.htm##
00597000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036200076002001300438#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#59#55#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">&Eacute; afec&ccedil;&atilde;o frequ
ente que atinge preferencialmente as mulheres e &eacute; causa de desconforto es
t&eacute;tico<sup>18</sup>. Os termos utilizados para definir estas altera&ccedi
l;&otilde;es do tecido subcut&acirc;neo, s&atilde;o os mais diversos<sup>31</sup
>. </font></p>     ^cY#v24n1a15.htm##
00608000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037300076002001300449#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#60#56#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ela surge a partir de mudan&ccedil;a
 do tecido gorduroso, dos tecidos conectivos e dos vasos. O estr&oacute;geno, ho
rm&ocirc;nio feminino, pode agir nos vasos, aumentando ou diminuindo a irriga&cc
edil;&atilde;o da &aacute;rea. Isso compromete os tecidos que ficam fibrosados <
sup>32</sup>. </font></p>     ^cY#v24n1a15.htm##
01008000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077300076002001300849#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#61#57#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Segundo Souza<sup>38</sup>, a celuli
te &eacute; infec&ccedil;&atilde;o da derme e tecido celular subcut&acirc;neo, c
aracterizada por eritema, edema e dor, geralmente causada pelo Streptococcus bet
ahemol&iacute;tico do grupo A e S. aureus nos adultos, e H. influenza tipo B em 
crian&ccedil;as com menos de tr&ecirc;s anos de idade. Ocorre pr&oacute;ximo &ag
rave; feridas cir&uacute;rgicas, &uacute;lceras ou sobre pele normal. J&aacute; 
os epis&oacute;dios recorrentes ocorrem por anomalias linf&aacute;ticas e/ou ven
osas determinadas por surtos de celulite anteriores, opera&ccedil;&atilde;o de r
essec&ccedil;&atilde;o de n&oacute;dulos linf&aacute;ticos ou mesmo irradia&cced
il;&atilde;o. </font></p>     ^cY#v24n1a15.htm##
00508000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027300076002001300349#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#62#58#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nova classifica&ccedil;&atilde;o, qu
e enfatiza os aspectos cl&iacute;nicos, exame f&iacute;sico e o aspecto celul&ia
cute;tico, &eacute; proposta por Godoy<sup>21</sup> nos seguintes termos: </font
></p>     ^cY#v24n1a15.htm##
00579000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034400076002001300420#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#63#59#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">1) Aspecto edematoso: ocorre predom&
iacute;nio das altera&ccedil;&otilde;es de permeabilidade capilar, na qual a mul
her pode ter dor decorrente da sobrecarga h&iacute;drica do sistema venoso, send
o agravado pela postura e durante os per&iacute;odos menstruais; </font></p>    
 ^cY#v24n1a15.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018800076002001300264#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#64#60#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">2) aspecto endurecido: &eacute; a fo
rma predominante da celulite "pura", normalmente n&atilde;o dolorosa;</font></p>
     ^cY#v24n1a15.htm##
00512000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027700076002001300353#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#65#61#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">3) aspecto lipoedematoso: &eacute; o
 padr&atilde;o no qual ocorre o predom&iacute;nio da obesidade, podendo estar as
sociada ou n&atilde;o ao edema, e a flacidez normalmente &eacute; exacerbada.</f
ont></p>      ^cY#v24n1a15.htm##
00588000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035300076002001300429#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#66#62#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A celulite &eacute; de dif&iacute;ci
l tratamento, mas a combina&ccedil;&atilde;o dos v&aacute;rios meios dispon&iacu
te;veis na fisioterapia dermatofuncional, associada &agrave; participa&ccedil;&a
tilde;o dos pacientes, poder&aacute; levar a bons resultados<sup>20</sup>.</font
></p>     ^cY#v24n1a15.htm##
00956000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072100076002001300797#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#67#63#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A a&ccedil;&atilde;o metab&oacute;l
ica do ultrassom na celulite &eacute; muito ben&eacute;fica, produzindo microvib
ra&ccedil;&otilde;es moleculares que se caracterizam como micromassagem nas jun&
ccedil;&otilde;es tissulares. A a&ccedil;&atilde;o t&eacute;rmica resultante das
 fric&ccedil;&otilde;es produzidas pela micromassagem tamb&eacute;m estimula de 
maneira marcante a microcircula&ccedil;&atilde;o. Como consequ&ecirc;ncia, os ef
eitos metab&oacute;licos, os fonofor&eacute;ticos (pelo aumento da permeabilidad
e da membrana celular) e os fibrinol&iacute;ticos fazem dele m&eacute;todo valio
so no tratamento a celulite<sup>35</sup>. </font></p>     ^cY#v24n1a15.htm##
00762000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052700076002001300603#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#68#64#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A eletrolipoforese &eacute; t&eacute
;cnica destinada ao tratamento das adiposidades e ac&uacute;mulo de &aacute;cido
s graxos localizados. Caracteriza-se pela aplica&ccedil;&atilde;o de microcorren
tes espec&iacute;ficas de baixa frequ&ecirc;ncia (ao redor de 25 Hz) que atuam d
iretamente nos adip&oacute;citos e lip&iacute;dios acumulados, produzindo sua de
strui&ccedil;&atilde;o e favorecendo posterior elimina&ccedil;&atilde;o<sup>7,37
</sup>. </font></p>     ^cY#v24n1a15.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#69#65#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Acanthosis nigricans</i></font></
p>     ^cY#v24n1a15.htm##
00549000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031400076002001300390#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#70#66#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">&Eacute; condi&ccedil;&atilde;o derm
atol&oacute;gica caracterizada por espessamento, hiperpigmenta&ccedil;&atilde;o 
e acentua&ccedil;&atilde;o das linhas da pele, gerando aspecto grosseiro e avelu
dado no local afetado<sup>2</sup>. </font></p>     ^cY#v24n1a15.htm##
00750000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051500076002001300591#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#71#67#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Apresenta-se como placas hipercr&oci
rc;micas, de superf&iacute;cie papilomatosa, vegetante ou liquenificada, de colo
ra&ccedil;&atilde;o castanho escura &agrave; preta, localizada nas axilas, viril
ha, regi&atilde;o cervical e outras &aacute;reas intertriginosas. Endocrinopatia
s representam a causa mais frequente dessa dermatose, sendo a obesidade o dist&u
acute;rbio mais comumente relacionado &agrave; pseudo acantose<sup>9</sup>. </fo
nt></p>     ^cY#v24n1a15.htm##
00602000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036700076002001300443#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#72#68#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O diagn&oacute;stico dessa les&atild
e;o -papilomatose, hiperceratose e hiperpigmenta&ccedil;&atilde;o da epiderme -,
 se d&aacute; por exame cl&iacute;nico das regi&otilde;es cervical, axilar, ante
cubital, face interna da coxa e superf&iacute;cies extensoras falangeanas<sup>11
</sup>. </font></p>     ^cY#v24n1a15.htm##
00573000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033800076002001300414#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#73#69#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">N&atilde;o existe abordagem terap&ec
irc;utica espec&iacute;fica para ela<sup>5</sup>. O melhor &eacute; corrigir a d
oen&ccedil;a associada. A corre&ccedil;&atilde;o da hiperinsulinemia em geral &e
acute; capaz de reduzir o n&uacute;mero das les&otilde;es. </font></p>     ^cY#v
24n1a15.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#74#70#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Acroc&oacute;rdons </i></font></p
>     ^cY#v24n1a15.htm##
00878000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064300076002001300719#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#75#71#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">S&atilde;o les&otilde;es dermatol&oa
cute;gicas comuns na popula&ccedil;&atilde;o e est&atilde;o associados &agrave; 
obesidade. A identifica&ccedil;&atilde;o precoce de pacientes com resist&ecirc;n
cia insul&iacute;nica pode ter papel preventivo prim&aacute;rio<sup>39</sup>. S&
atilde;o pequenos papilomas geralmente localizados nas faces laterais do pesco&c
cedil;o, axilas, por&ccedil;&atilde;o superior do tronco e p&aacute;lpebras de p
acientes de meia-idade ou idosos. Essas hiperplasias epiteliais benignas s&atild
e;o favorecidas pela obesidade<sup>6</sup>. </font></p>     ^cY#v24n1a15.htm##
00712000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047700076002001300553#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#76#72#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">S&atilde;o p&aacute;pulas filiformes
, pedunculadas, cor da pele ou castanho escuras, localizadas principalmente na r
egi&atilde;o cervical e axilas. Est&atilde;o frequentemente associados &agrave; 
acantose nigricans e s&atilde;o tamb&eacute;m relacionados com a resist&ecirc;nc
ia &agrave; insulina. Parece haver correla&ccedil;&atilde;o entre as les&otilde;
es e o grau de obesidade<sup>9</sup>. </font></p>     ^cY#v24n1a15.htm##
00795000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056000076002001300636#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#77#73#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Conforme Matoso<sup>28</sup>, como o
p&ccedil;&otilde;es de tratamento tem-se a toxina botul&iacute;nica, os preenchi
mentos e os peelings qu&iacute;micos ou a laser objetivando o rejuvenescimento. 
H&aacute; casos em que este tratamento &eacute; feito ap&oacute;s tratamento da 
parte superior da face pela blefaroplastia ou lifting cir&uacute;rgico, ou ritid
ectomia para melhorar a apar&ecirc;ncia da por&ccedil;&atilde;o inferior do rost
o e da parte superior do pesco&ccedil;o. </font></p>     ^cY#v24n1a15.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009900076002001300175#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#78#74#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Flacidez </i></font></p>     ^cY#
v24n1a15.htm##
00909000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067400076002001300750#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#79#75#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Refere-se &agrave; diminui&ccedil;&a
tilde;o do t&ocirc;nus muscular, estando o m&uacute;sculo pouco consistente. Est
a situa&ccedil;&atilde;o pode apresentar-se de duas formas distintas: a flacidez
 muscular e a da pele. &Eacute; muito comum que os dois tipos apare&ccedil;am as
sociados, dando aspecto ainda pior &agrave;s partes do corpo afetadas pelo probl
ema. Os m&uacute;sculos ficam fl&aacute;cidos, principalmente por causa da falta
 de exerc&iacute;cios f&iacute;sicos. Se eles n&atilde;o s&atilde;o solicitados,
 as fibras musculares ficam hipoatrofiadas e fl&aacute;cidas<sup>26</sup>. </fon
t></p>     ^cY#v24n1a15.htm##
00663000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042800076002001300504#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#80#76#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A flacidez da pele &eacute; devida a
o comportamento viscoel&aacute;stico que, quando seu limite el&aacute;stico &eac
ute; ultrapassado por algum motivo - exemplo em magros que se tornam obesos em c
urto per&iacute;odo de tempo e depois emagrecem novamente -, ao cessar o est&iac
ute;mulo, ela n&atilde;o volta ao seu tamanho original<sup>20</sup>. </font></p>
     ^cY#v24n1a15.htm##
00878000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064300076002001300719#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#81#77#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A aplica&ccedil;&atilde;o da corrent
e russa tem como objetivo principal minimizar a flacidez e a perda de t&ocirc;nu
s muscular. Com nova tecnologia para a constru&ccedil;&atilde;o de aparelhos de 
corrente russa, o seu uso cl&iacute;nico pode envolver o controle da dor e, se u
sada corretamente, pode-se obter al&iacute;vio efetivo da dor durante mobiliza&c
cedil;&otilde;es ou exerc&iacute;cios para aumento do arco de movimento articula
r. Essas aplica&ccedil;&otilde;es aprendem de eliciamento principalmente de term
ina&ccedil;&otilde;es nervosas<sup>1</sup>. </font></p>     ^cY#v24n1a15.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#82#78#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>&Uacute;lcera </i></font></p>    
 ^cY#v24n1a15.htm##
00569000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033400076002001300410#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#83#79#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Maffei<sup>27</sup> elucidam que &ua
cute;lceras s&atilde;o complica&ccedil;&otilde;es importantes da insufici&ecirc;
ncia venosa aguda ou cr&ocirc;nica, que podem ser classificadas em &uacute;lcera
s por press&atilde;o, arteriais e neurop&aacute;ticas. </font></p>     ^cY#v24n1
a15.htm##
00627000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039200076002001300468#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#84#80#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Segundo Potter<sup>33</sup>, as por 
press&atilde;o - tamb&eacute;m denominada de &uacute;lceras de dec&uacute;bito -
, s&atilde;o les&otilde;es ocasionadas na pele, devido &agrave; aus&ecirc;ncia d
e sangue para uma &aacute;rea do corpo. Essas &uacute;lceras surgem por fatores 
internos do paciente e externos. </font></p>     ^cY#v24n1a15.htm##
00780000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054500076002001300621#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#85#81#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os estudos de Carrara e Brito<sup>12
</sup> sugerem que a atua&ccedil;&atilde;o do laser tipo InGaAs pode ser eficaz 
no processo de cicatriza&ccedil;&atilde;o dessas feridas. N&atilde;o se pode, no
 entanto, provar cientificamente que o comprimento de onda seja a causa de tal r
esposta, pois a terapia com laser de baixa pot&ecirc;ncia ainda n&atilde;o defin
iu par&acirc;metros com rela&ccedil;&atilde;o dose, comprimento de onda e pot&ec
irc;ncia a ser utilizado. </font></p>     ^cY#v24n1a15.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#86#82#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Impetigo</i></font></p>     ^cY#v
24n1a15.htm##
00896000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066100076002001300737#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#87#83#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">&Eacute; infec&ccedil;&atilde;o que 
ataca a superf&iacute;cie cut&acirc;nea, causada pela penetra&ccedil;&atilde;o d
e bact&eacute;rias na pele aberta por feridas e coceiras. Pode tamb&eacute;m ser
 chamado de piodermite<sup>10</sup>. &Eacute; causado por Staphylococcus ou por 
Streptococcus, e caracteriza por p&uacute;stulas. Pode aparecer em qualquer part
e do corpo, embora seja mais frequente na face, nos bra&ccedil;os e nas pernas. 
Pode seguir-se a pequenos traumas ou doen&ccedil;a que provoque les&atilde;o na 
pele, como micoses, queimaduras pelo sol ou picada de inseto. </font></p>     ^c
Y#v24n1a15.htm##
00556000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032100076002001300397#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#88#84#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O tratamento se faz com antibi&oacut
e;tico t&oacute;pico, assepsia com remo&ccedil;&atilde;o de crostas e compressas
 com antiss&eacute;pticos. Nos casos mais extensos, antibioticoterapia sist&ecir
c;mica est&aacute; indicada<sup>10</sup>. </font></p>     ^cY#v24n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#89#85#article#180#<p>&nbsp;</p>     ^
cY#v24n1a15.htm##
00360000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012500076002001300201#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#90#86#article#180#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONSIDERA&Ccedil;&Otilde;ES FINAI
S </b></font></p>     ^cY#v24n1a15.htm##
00883000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064800076002001300724#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#91#87#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os cuidados com a pele dos pacientes
 obesos merecem aten&ccedil;&atilde;o especial, principalmente devido &agrave; d
ificuldade na cicatriza&ccedil;&atilde;o de ferimentos. Ainda, o risco aumentado
 de infec&ccedil;&otilde;es cut&acirc;neas e de linfedema observado nestes pacie
ntes, contribui para maior morbidade nessa popula&ccedil;&atilde;o. Em pacientes
 hospitalizados, a obesidade leva ao aumento do risco de &uacute;lceras de press
&atilde;o, al&eacute;m do retardo na cicatriza&ccedil;&atilde;o, o que deve ser 
manejado principalmente com medidas preventivas. </font></p>     ^cY#v24n1a15.ht
m##
00657000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042200076002001300498#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#92#88#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Existem dermatoses que ocorrem predo
minantemente ap&oacute;s o tratamento da obesidade por cirurgia bari&aacute;tric
a e outras que se manifestam de forma diversa do usual. No Brasil, apesar da alt
a preval&ecirc;ncia da obesidade, n&atilde;o h&aacute; trabalhos quanto &agrave;
 preval&ecirc;ncia das dermatoses neste subgrupo de pacientes. </font></p>     ^
cY#v24n1a15.htm##
00649000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041400076002001300490#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#93#89#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Portanto, sendo a obesidade um probl
ema freq&uuml;ente com v&aacute;rias dermatoses associadas com dificuldades no m
anejo e, tendo em vista a escassez da literatura dispon&iacute;vel no assunto, c
resce a necessidade de se estudar o comportamento das manifesta&ccedil;&otilde;e
s dermatol&oacute;gicas nessa popula&ccedil;&atilde;o. </font></p>     ^cY#v24n1
a15.htm##
00603000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036800076002001300444#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#94#90#article#180#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A fisioterapia dermatofuncional pode
 acompanhar os pacientes obesos, com tratamento no pr&eacute; e p&oacute;s opera
t&oacute;rio, trazendo benef&iacute;cios est&eacute;ticos na flacidez tissular e
 muscular, celulite, estrias, entre outros, proporcionando melhora na qualidade 
de vida. </font></p>     ^cY#v24n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#95#91#article#180#<p>&nbsp;</p>     ^
cY#v24n1a15.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#96#92#article#180#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b> </font></p>
     ^cY#v24n1a15.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029300078002001300371#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#97#93#article#180#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. 	Ara&uacute;jo AM. 
An&aacute;lise comparativa da efetividade da corrente russa na regi&atilde;o gl&
uacute;tea. Fortaleza: Faculdade Integrada do Cear&aacute;, 2009. Monografia de 
gradua&ccedil;&atilde;o em Fisioterapia.    ^cY#v24n1a15.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#98#94#article#180# </font></p>     ^c
Y#v24n1a15.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032800078002001300406#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#99#95#article#180#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. 	Ara&uacute;joI LBM
, Viveiros AMC, Lopes RC, Viana AC, Fukui RT, Ursich MJM. Acanthosis nigricans e
m mulheres obesas de uma popula&ccedil;&atilde;o miscigenada: um marcador de dis
t&uacute;rbios metab&oacute;licos. An. Bras. Dermatol. 2002; 77(5):537-543.    ^
cY#v24n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#100#96#article#180# </font></p>     ^
cY#v24n1a15.htm##
00399000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704014900079002001300228#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#101#97#article#180#3#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Azulay RD, Azulay 
DR. Dermatologia. Rio de Janeiro: Guanabara Koogan, 2006.    ^cY#v24n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#102#98#article#180# </font></p>     ^
cY#v24n1a15.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704024400079002001300323#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#103#99#article#180#4#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Batista Filho M, R
issin A. A transi&ccedil;&atilde;o nutricional no Brasil: tend&ecirc;ncias regio
nais e temporais. Cad. Sa&uacute;de P&uacute;blica, 2003; 19(1):181-191.    ^cY#
v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#104#100#article#180# </font></p>     
^cY#v24n1a15.htm##
00594000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704034300080002001300423#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#105#101#article#180#5#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. 	BIBLIOMED. Acant
ose nigricans. 2004. Dispon&iacute;vel em: &lt;<a href="http://boasaude.uol.com.
br/realce/emailorprint.cfm?id=14814&amp;type=lib" target="_blank">http://boasaud
e.uol.com.br/realce/emailorprint.cfm?id=14814&amp;type=lib</a>&gt;. Acesso em: 0
2 abr. 2010.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#106#102#article#180# </font></p>     
^cY#v24n1a15.htm##
00599000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704034800080002001300428#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#107#103#article#180#6#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. BIBLIOMED. Acroc&
oacute;rdons. 2000. Dispon&iacute;vel em: &lt;<a href="http://www.bibliomed.com.
br/bibliomed/bmbooks/dermato/livro5/cap/ cap30.htm" target="_blank">http://www.b
ibliomed.com.br/bibliomed/bmbooks/dermato/livro5/cap/ cap30.htm</a>&gt;. Acesso 
em: 04 abr. 2010.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#108#104#article#180# </font></p>     
^cY#v24n1a15.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704021300080002001300293#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#109#105#article#180#7#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Borges FS. Dermat
o funcional: modalidades terap&ecirc;uticas nas disfun&ccedil;&otilde;es est&eac
ute;ticas. S&atilde;o Paulo: Phorte, 2006.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#110#106#article#180# </font></p>     
^cY#v24n1a15.htm##
00396000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704014500080002001300225#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#111#107#article#180#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Bouchard C. Ativi
dade f&iacute;sica e obesidade. Barueri: Manole, 2003.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#112#108#article#180# </font></p>     
^cY#v24n1a15.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704021800080002001300298#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#113#109#article#180#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Boza JC, Rech L, 
Sachett L, Menegon DB, Cestari TF. Manifesta&ccedil;&otilde;es dermatol&oacute;g
icas da obesidade. Rev HCPA, 2010; 30(1):55-62.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#114#110#article#180# </font></p>     
^cY#v24n1a15.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#115#111#article#180#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. 	Campos S. Impe
tigo. Dispon&iacute;vel em: &lt;<a href="http://www.drashirleydecampos.com.br/im
primir.php?noticiaid=23566" target="_blank">http://www.drashirleydecampos.com.br
/imprimir.php?noticiaid=23566</a>&gt;. Acesso em: 11 abr. 2010.    ^cY#v24n1a15.
htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#116#112#article#180# </font></p>     
^cY#v24n1a15.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030700081002001300388#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#117#113#article#180#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. 	Carneiro JRI, 
Kushnir MC, Clemente ELS, Brand&atilde;o MG, Gomes MB. Obesidade na adolesc&ecir
c;ncia: fator de risco para complica&ccedil;&otilde;es cl&iacute;nico-metab&oacu
te;licas. Arq Bras Endocrinol Metab. 2000; 44(5):390-396.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#118#114#article#180# </font></p>     
^cY#v24n1a15.htm##
00622000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037000081002001300451#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#119#115#article#180#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. 	Carrara AH, Br
ito MAP. O uso do laser de 905 nm na repara&ccedil;&atilde;o de ferida aberta. D
ispon&iacute;vel em: &lt;<a href="http://www.fisionet.com.br/monografias/interna
.php?cod=17" target="_blank">http://www.fisionet.com.br/monografias/interna.php?
cod=17</a>&gt;. Acesso em: 10 abr. 2010.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#120#116#article#180# </font></p>     
^cY#v24n1a15.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029100081002001300372#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#121#117#article#180#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. 	Castro APPL. O
besidade feminina: um estudo de sua rela&ccedil;&atilde;o com a sexualidade. Bra
s&iacute;lia: Universidade Cat&oacute;lica de Bras&iacute;lia, 2006. Disserta&cc
edil;&atilde;o de Mestrado em Psicologia.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#122#118#article#180# </font></p>     
^cY#v24n1a15.htm##
00663000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704041100081002001300492#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#123#119#article#180#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. 	Cavalcante FH,
 Talhari S, Ferreira LCL, Andrade RV. Elastose focal linear. Anais brasileiros d
e dermatologia. 2007. Dispon&iacute;vel em: &lt;<a href="http://www.anaisdederma
tologia.org.br/artigo_imprimir.php?id=10244" target="_blank">http://www.anaisded
ermatologia.org.br/artigo_imprimir.php?id=10244</a>&gt;. Acesso em: 02 abr. 2010
.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#124#120#article#180# </font></p>     
^cY#v24n1a15.htm##
00414000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016200081002001300243#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#125#121#article#180#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Cuc&eacute; LC,
 Neto CF. Manual de dermatologia. 2.ed. S&atilde;o Paulo: Atheneu, 2001.    ^cY#
v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#126#122#article#180# </font></p>     
^cY#v24n1a15.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019700081002001300278#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#127#123#article#180#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Fisberg M. Atua
liza&ccedil;&atilde;o em obesidade na inf&acirc;ncia e adolesc&ecirc;ncia. S&ati
lde;o Paulo: Atheneu, 2005.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#128#124#article#180# </font></p>     
^cY#v24n1a15.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031700081002001300398#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#129#125#article#180#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Francischi RPP,
 Pereira LO, Freitas CS, Klopfer M, Santos RC, Vieira P, Lancha J&uacute;nior AH
. Obesidade: Atualiza&ccedil;&atilde;o Sobre Sua Etiologia, Morbidade e Tratamen
to. Revista de Nutri&ccedil;&atilde;o 2000; 13(1)17-28 </font></p>     ^cY#v24n1
a15.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028000081002001300361#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#130#126#article#180#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Francischelli N
eto M. A celulite. 2007. Dispon&iacute;vel em: &lt;<a href="http://www.naturale.
med.br/celulite.htm" target="_blank">http://www.naturale.med.br/celulite.htm</a>
&gt;. Acesso em: 14 abr. 2010.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#131#127#article#180# </font></p>     
^cY#v24n1a15.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#132#128#article#180#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">19, Goldman L, Bennett JC. Cecil: 
tratado de medicina interna. 21.ed. Rio de Janeiro: Guanabara Koogan, 2001. </fo
nt></p>     ^cY#v24n1a15.htm##
00416000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016400081002001300245#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#133#129#article#180#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Guirro E, Guirr
o R. Fisioterapia dermato-funcional. 3.ed. S&atilde;o Paulo: Manole, 2004.    ^c
Y#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#134#130#article#180# </font></p>     
^cY#v24n1a15.htm##
00427000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017500081002001300256#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#135#131#article#180#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21;.Godoy JMP, Godo
y MFG. Celulite, do diagn&oacute;stico ao tratamento. S&atilde;o Paulo: Riocor, 
2003.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#136#132#article#180# </font></p>     
^cY#v24n1a15.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028200081002001300363#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#137#133#article#180#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. 	Isomaa B, Henr
icsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influ
ences the risk of chronic complications in patients with type II diabetes. Diabe
tologia. 2001 Sep;44(9):1148-54.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#138#134#article#180# </font></p>     
^cY#v24n1a15.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018900081002001300270#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#139#135#article#180#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. James PT, Leach
 R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res. 2001 Nov;9
 Suppl 4:228S-233S.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#140#136#article#180# </font></p>     
^cY#v24n1a15.htm##
00413000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016100081002001300242#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#141#137#article#180#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Kede MPV, Sabat
ovich O. Dermatologia Est&eacute;tica. S&atilde;o Paulo: Atheneu, 2004.    ^cY#v
24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#142#138#article#180# </font></p>     
^cY#v24n1a15.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018800081002001300269#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#143#139#article#180#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Lima KS, Press 
L. O uso da microgalvanopuntura no tratamento de estrias atr&oacute;ficas. Passo
 Fundo: UPS, 2005.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#144#140#article#180# </font></p>     
^cY#v24n1a15.htm##
00680000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042800081002001300509#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#145#141#article#180#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. 	Lopes SC, Brou
ngholi K. A utiliza&ccedil;&atilde;o da corrente russa no tratamento da flacidez
 muscular abdominal. 2009. Dispon&iacute;vel em: &lt;<a href="http://www.fisio-t
b.unisul.br/Tccs/04a/cristiana/artigocristinasouza.pdf" target="_blank">http://w
ww.fisio-tb.unisul.br/Tccs/04a/cristiana/artigocristinasouza.pdf</a>&gt;. Acesso
 em: 25 maio 2010.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#146#142#article#180# </font></p>     
^cY#v24n1a15.htm##
00420000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016800081002001300249#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#147#143#article#180#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. 	Maffei FHA. Do
en&ccedil;as Vasculares Perif&eacute;ricas. 3.ed. Rio de Janeiro: Medsi, 2002.  
  ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#148#144#article#180# </font></p>     
^cY#v24n1a15.htm##
00601000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034900081002001300430#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#149#145#article#180#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. 	Matoso M. Enve
lhecimento da pele. Dispon&iacute;vel em: &lt;<a href="http://marcellefisioterap
euta.blogspot.com/2008/10/evelhecimentoda-pele.html" target="_blank">http://marc
ellefisioterapeuta.blogspot.com/2008/10/evelhecimentoda-pele.html</a>&gt;. Acess
o em: 10 abr. 2010.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#150#146#article#180# </font></p>     
^cY#v24n1a15.htm##
00680000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042800081002001300509#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#151#147#article#180#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. 	Mondo PKS, Ros
as RF. Efeitos da corrente galv&acirc;nica no tratamento das estrias atr&oacute;
ficas. 2004. Dispon&iacute;vel em: &lt;<a href="http://www.fisio-tb.unisul.br/Tc
cs/04b/patricia/artigopatriciakochsavimondo.pdf" target="_blank">http://www.fisi
o-tb.unisul.br/Tccs/04b/patricia/artigopatriciakochsavimondo.pdf</a>&gt;. Acesso
 em: 22 mar. 2010.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#152#148#article#180# </font></p>     
^cY#v24n1a15.htm##
00420000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016800081002001300249#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#153#149#article#180#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Negrato CA. Obe
sidade, um problema de sa&uacute;de p&uacute;blica. Revista Racine 2003;18-33.  
  ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#154#150#article#180# </font></p>     
^cY#v24n1a15.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031200081002001300393#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#155#151#article#180#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Oliveira AMA, C
erqueira EMM, Oliveira AC. Preval&ecirc;ncia de Sobrepeso e Obesidade Infantil n
a Cidade de Feira de Santana-BA: detec&ccedil;&atilde;o na fam&iacute;lia x diag
n&oacute;stico cl&iacute;nico. J Pediatr. 2003; 79(4):325-328.    ^cY#v24n1a15.h
tm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#156#152#article#180# </font></p>     
^cY#v24n1a15.htm##
00573000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032100081002001300402#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#157#153#article#180#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Pinheiro D. Bra
sil, imp&eacute;rio do bisturi. Veja on line. 2001. Dispon&iacute;vel em: &lt;<a
 href="http://www.veja.abril.com.br/170101/p_084.html" target="_blank">http://ww
w.veja.abril.com.br/170101/p_084.html</a>&gt;. Acesso em: 02 abr. 2010.    ^cY#v
24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#158#154#article#180# </font></p>     
^cY#v24n1a15.htm##
00410000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015800081002001300239#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#159#155#article#180#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Potter PA. Fund
amentos de Enfermagem. 5.ed. Rio de Janeiro: Guanabara Koogan, 2004.    ^cY#v24n
1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#160#156#article#180# </font></p>     
^cY#v24n1a15.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022200081002001300303#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#161#157#article#180#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Ribeiro EM. Obe
sidade severa e cirurgia bari&aacute;trica: o &uacute;ltimo recurso, a solu&cced
il;&atilde;o do problema. Revista Recenf 2003; 1(3).    ^cY#v24n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#162#158#article#180#</font></p>     ^
cY#v24n1a15.htm##
00398000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014600081002001300227#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#163#159#article#180#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35.  Rossi MH. Celu
lite. J Eur Acad Dermatol Venereol. 2001; 14(4):251-255.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#164#160#article#180# </font></p>     
^cY#v24n1a15.htm##
00410000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015800081002001300239#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#165#161#article#180#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Sampaio SAP, Ri
viti EA. Dermatologia. S&atilde;o Paulo: Artes M&eacute;dicas, 2008.    ^cY#v24n
1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#166#162#article#180# </font></p>     
^cY#v24n1a15.htm##
00446000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019400081002001300275#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#167#163#article#180#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Sigulem DM. Cre
scimento P&ocirc;ndero-estatural do Pr&eacute;-escolar. Compacta Nutri&ccedil;&a
tilde;o 2005; 6(1):1-27.    ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#168#164#article#180# </font></p>     
^cY#v24n1a15.htm##
00421000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016900081002001300250#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#169#165#article#180#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Souza RV. Novo 
atlas pr&aacute;tico de dermatologia. Porto Alegre: Artes M&eacute;dicas, 2003. 
   ^cY#v24n1a15.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#170#166#article#180# </font></p>     
^cY#v24n1a15.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024200081002001300323#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#171#167#article#180#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Tamega AA, Aran
ha AMP, Guiotoku MM, Miot LDB, Miot HA. Associa&ccedil;&atilde;o entre acroc&oac
ute;rdons e resist&ecirc;ncia &agrave; insulina. An Bras Dermatol. 2010;    ^cY#
v24n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#172#168#article#180# </font></p>     
 ^cY#v24n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#173#169#article#180#<p>&nbsp;</p>    
 ^cY#v24n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#174#170#article#180#<p>&nbsp;</p>    
 ^cY#v24n1a15.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019800078002001300276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#175#171#article#180#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#n
ote1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ec
irc;ncia:</b>    ^cY#v24n1a15.htm##
00292000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005500078002001300133#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#176#172#article#180#<br> Rosimeri da 
Silva Castanho Mendon&ccedil;a    ^cY#v24n1a15.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010200078002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#177#173#article#180#<br> e-mail: <a h
ref="mailto:geruzabaima@hotmail.com">geruzabaima@hotmail.com</a> </font></p>    
 ^cY#v24n1a15.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012100078002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#178#174#article#180#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atil
de;o: 19/10/2010    ^cY#v24n1a15.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#179#175#article#180#<br> Aceito para 
publica&ccedil;&atilde;o: 25/01/2011    ^cY#v24n1a15.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#180#176#article#180#<br> Fonte de fin
anciamento: n&atilde;o h&aacute;    ^cY#v24n1a15.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007000078002001300148#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#181#177#article#180#<br> Conflito de 
interesses: n&atilde;o h&aacute; </font></p>     ^cY#v24n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#182#178#article#180#<p>&nbsp;</p>    
 ^cY#v24n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#183#179#article#180#<p>&nbsp;</p>    
 ^cY#v24n1a15.htm##
00459000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022200078002001300300#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a15.htm#S#p#184#180#article#180#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Curso de Esp
ecializa&ccedil;&atilde;o em Fisioterapia Dermatofuncional da Faculdade Christus
, Fortaleza, CE, Brasil.</font></p>      ^cY#v24n1a15.htm##
00474000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770180074000950660
01000169062002900179065000900208064000500217865000900222002001300231#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#185#1#article#38#1#^rND^sAraújo^n
AM.#Análise comparativa da efetividade da corrente russa na região glútea^lpt#Fo
rtaleza#Faculdade Integrada do Ceará#20090000#2009#20110300#v24n1a15.htm##
00690000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100020000960100
01600116010001600132010001600148010001800164012011300182030001800295710000200313
06500090031506400050032403100030032903200020033201400080033486500090034200200130
0351#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#186#2#article#38#
2#^rND^sAraújoI^nLBM#^rND^sViveiros^nAMC#^rND^sLopes^nRC#^rND^sViana^nAC#^rND^sF
ukui^nRT#^rND^sUrsich^nMJM#Acanthosis nigricans em mulheres obesas de uma popula
ção miscigenada: um marcador de distúrbios metabólicos.^lpt#An. Bras Dermatol#2#
20020000#2002#77#5#537-543#20110300#v24n1a15.htm##
00438000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160017000770160017000940180
01700111066001500128062001700143065000900160064000500169865000900174002001300183
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#187#3#article#38#3#^r
ND^sAzulay^nRD#^rND^sAzulay^nDR#Dermatologia^lpt#Rio de Janeiro#Guanabara Koogan
#20060000#2006#20110300#v24n1a15.htm##
00537000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770100016001000120
07700116030001500193710000200208065000900210064000500219031000300224032000200227
014000800229865000900237002001300246#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a15.htm#S#c#188#4#article#38#4#^rND^sBatista Filho^nM#^rND^sRissin^nA#A trans
ição nutricional no Brasil: tendências regionais e temporais. Cad^lpt#Saúde Públ
ica,#2#20030000#2003#19#1#181-191#20110300#v24n1a15.htm##
00481000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170010000770180023000870650
00900110064000500119037007100124110000900195109001300204865000900217002001300226
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#189#5#article#38#5#BI
BLIOMED#Acantose nigricans^lpt#20040000#2004#http://boasaude.uol.com.br/realce/e
mailorprint.cfm?id=14814 & type=lib#20100402#02 abr. 2010#20110300#v24n1a15.htm#
#
00479000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170010000770180016000870650
00900103064000500112037007600117110000900193109001300202865000900215002001300224
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#190#6#article#38#6#BI
BLIOMED#Acrocórdons^lpt#20000000#2000#http://www.bibliomed.com.br/bibliomed/bmbo
oks/dermato/livro5/cap/ cap30.htm#20100404#04 abr. 2010#20110300#v24n1a15.htm##
00450000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160017000770180073000940660
01000167062000700177065000900184064000500193865000900198002001300207#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#191#7#article#38#7#^rND^sBorges^n
FS#Dermato funcional: modalidades terapêuticas nas disfunções estéticas^lpt#São 
Paulo#Phorte#20060000#2006#20110300#v24n1a15.htm##
00409000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770180033000950660
00800128062000700136065000900143064000500152865000900157002001300166#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#192#8#article#38#8#^rND^sBouchard
^nC#Atividade física e obesidade^lpt#Barueri#Manole#20030000#2003#20110300#v24n1
a15.htm##
00578000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100014000920100
01700106010001800123010001800141012004600159030001000205710000200215065000900217
064000500226031000300231032000200234014000600236865000900242002001300251#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#193#9#article#38#9#^rND^sBoza
^nJC#^rND^sRech^nL#^rND^sSachett^nL#^rND^sMenegon^nDB#^rND^sCestari^nTF#Manifest
ações dermatológicas da obesidade^lpt#Rev HCPA,#2#20100000#2010#30#1#55-62#20110
300#v24n1a15.htm##
00437000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790180013000960370
06600109110000900175109001300184865000900197002001300206#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a15.htm#S#c#194#10#article#38#10#^rND^sCampos^nS.#Impetig
o^lpt#http://www.drashirleydecampos.com.br/imprimir.php?noticiaid=23566#20100411
#11 abr. 2010#20110300#v24n1a15.htm##
00719000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
02000117010001800137010001600155012008400171030002600255065000900281064000500290
03100030029503200020029801400080030086500090030800200130031703500100033080100530
0340#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#195#11#article#38
#11#^rND^sCarneiro^nJRI#^rND^sKushnir^nMC#^rND^sClemente^nELS#^rND^sBrandão^nMG#
^rND^sGomes^nMB#Obesidade na adolescência: fator de risco para complicações clín
ico-metabólicas^lpt#Arq Bras Endocrinol Metab#20000000#2000#44#5#390-396#2011030
0#v24n1a15.htm#0004-2730#Arquivos Brasileiros de Endocrinologia & Metabologia##
00506000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160018000970180
05900115037005800174110000900232109001300241865000900254002001300263#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#196#12#article#38#12#^rND^sCarrar
a^nAH#^rND^sBrito^nMAP.#O uso do laser de 905 nm na reparação de ferida aberta^l
pt#http://www.fisionet.com.br/monografias/interna.php?cod=17#20100410#10 abr. 20
10#20110300#v24n1a15.htm##
00496000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160020000790180067000990660
00900166062003400175065000900209064000500218051000900223865000900232002001300241
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#197#13#article#38#13#
^rND^sCastro^nAPPL.#Obesidade feminina: um estudo de sua relação com a sexualida
de^lpt#Brasília#Universidade Católica de Brasília#20060000#2006#Mestrado#2011030
0#v24n1a15.htm##
00699000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100017001000100
02000117010001900137012002600156030003400182065000900216064000500225037006700230
110000900297109001300306865000900319002001300328035001000341801003400351#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#198#14#article#38#14#^rND^sCa
valcante^nFH#^rND^sTalhari^nS#^rND^sFerreira^nLCL#^rND^sAndrade^nRV.#Elastose fo
cal linear^lpt#Anais brasileiros de dermatologia#20070000#2007#http://www.anaisd
edermatologia.org.br/artigo_imprimir.php?id=10244#20100402#02 abr. 2010#20110300
#v24n1a15.htm#0365-0596#Anais brasileiros de dermatologia##
00447000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160015000790160016000940180
02700110063000200137066001000139062000800149065000900157064000500166865000900171
002001300180#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#199#15#ar
ticle#38#15#^rND^sCucé^nLC#^rND^sNeto^nCF.#Manual de dermatologia^lpt#2#São Paul
o#Atheneu#20010000#2001#20110300#v24n1a15.htm##
00436000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790180056000960660
01000152062000800162065000900170064000500179865000900184002001300193#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#200#16#article#38#16#^rND^sFisber
g^nM#Atualização em obesidade na infância e adolescência^lpt#São Paulo#Atheneu#2
0050000#2005#20110300#v24n1a15.htm##
00730000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100018001010100
01800119010001700137010001700154010001600171010002500187012007100212030002000283
06500090030306400050031203100030031703200020032001400060032286500090032800200130
0337035001000350801002000360#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.h
tm#S#c#201#17#article#38#17#^rND^sFrancischi^nRPP#^rND^sPereira^nLO#^rND^sFreita
s^nCS#^rND^sKlopfer^nM#^rND^sSantos^nRC#^rND^sVieira^nP#^rND^sLancha Júnior^nAH.
#Obesidade: Atualização Sobre Sua Etiologia, Morbidade e Tratamento^lpt#Revista 
de Nutrição#20000000#2000#13#1#17-28#20110300#v24n1a15.htm#1415-5273#Revista de 
Nutrição##
00463000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160029000790180015001080650
00900123064000500132037004000137110000900177109001300186865000900199002001300208
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#202#18#article#38#18#
^rND^sFrancischelli Neto^nM.#A celulite^lpt#20070000#2007#http://www.naturale.me
d.br/celulite.htm#20100414#14 abr. 2010#20110300#v24n1a15.htm##
00456000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160017000950180
03500112063000200147066001000149062000700159065000900166064000500175865000900180
002001300189#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#203#19#ar
ticle#38#20#^rND^sGuirro^nE#^rND^sGuirro^nR.#Fisioterapia dermato-funcional^lpt#
3#São Paulo#Manole#20040000#2004#20110300#v24n1a15.htm##
00452000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790160018000960180
04300114066001000157062000700167065000900174064000500183865000900188002001300197
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#204#20#article#38#21#
^rND^sGodoy^nJMP#^rND^sGodoy^nMFG.#Celulite, do diagnóstico ao tratamento^lpt#Sã
o Paulo#Riocor#20030000#2003#20110300#v24n1a15.htm##
00712000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
01700115010001500132010001900147010001500166012010600181030001300287065000900300
06400070030903100030031603200020031901400080032186500090032900200130033803500100
0351801001300361#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#205#2
1#article#38#22#^rND^sIsomaa^nB#^rND^sHenricsson^nM#^rND^sAlmgren^nP#^rND^sTuomi
^nT#^rND^sTaskinen^nMR#^rND^sGroop^nL#The metabolic syndrome influences the risk
 of chronic complications in patients with type II diabetes^len#Diabetologia#200
10900#200109#44#9#1148-54#20110300#v24n1a15.htm#0012-186X#Diabetologia##
00577000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01800110010001800128012003500146030000900181065000900190064000700199031000200206
032000400208014001000212865000900222002001300231035001000244801000900254#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#206#22#article#38#23#^rND^sJa
mes^nPT#^rND^sLeach^nR#^rND^sKalamara^nE#^rND^sShayeghi^nM#The worldwide obesity
 epidemic^len#Obes Res#20011100#200111#9#^s4#228S-233S#20110300#v24n1a15.htm#107
1-7323#Obes Res##
00437000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160020000950180
02600115066001000141062000800151065000900159064000500168865000900173002001300182
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#207#23#article#38#24#
^rND^sKede^nMPV#^rND^sSabatovich^nO#Dermatologia Estética^lpt#São Paulo#Atheneu#
20040000#2004#20110300#v24n1a15.htm##
00471000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160015000790160015000940180
06800109066001200177062000400189065000900193064000500202865000900207002001300216
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#208#24#article#38#25#
^rND^sLima^nKS#^rND^sPress^nL#O uso da microgalvanopuntura no tratamento de estr
ias atróficas^lpt#Passo Fundo#UPS#20050000#2005#20110300#v24n1a15.htm##
00581000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160021000950180
08000116065000900196064000500205037007300210110000900283109001300292865000900305
002001300314#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#209#25#ar
ticle#38#26#^rND^sLopes^nSC#^rND^sBroungholi^nK.#A utilização da corrente russa 
no tratamento da flacidez muscular abdominal^lpt#20090000#2009#http://www.fisio-
tb.unisul.br/Tccs/04a/cristiana/artigocristinasouza.pdf#20100525#25 maio 2010#20
110300#v24n1a15.htm##
00434000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790180035000980630
00200133066001500135062000600150065000900156064000500165865000900170002001300179
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#210#26#article#38#27#
^rND^sMaffei^nFHA.#Doenças Vasculares Periféricas^lpt#3#Rio de Janeiro#Medsi#200
20000#2002#20110300#v24n1a15.htm##
00462000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790180027000960370
07700123110000900200109001300209865000900222002001300231#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a15.htm#S#c#211#27#article#38#28#^rND^sMatoso^nM.#Envelhe
cimento da pele^lpt#http://marcellefisioterapeuta.blogspot.com/2008/10/evelhecim
entoda-pele.html#20100410#10 abr. 2010#20110300#v24n1a15.htm##
00575000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790160017000960180
07000113065000900183064000500192037008000197110000900277109001300286865000900299
002001300308#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#212#28#ar
ticle#38#29#^rND^sMondo^nPKS#^rND^sRosas^nRF.#Efeitos da corrente galvânica no t
ratamento das estrias atróficas^lpt#20040000#2004#http://www.fisio-tb.unisul.br/
Tccs/04b/patricia/artigopatriciakochsavimondo.pdf#20100322#22 mar. 2010#20110300
#v24n1a15.htm##
00443000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120044000980300
01500142710000200157065000900159064000500168014000600173865000900179002001300188
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#213#29#article#38#30#
^rND^sNegrato^nCA.#Obesidade, um problema de saúde pública^lpt#Revista Racine#2#
20030000#2003#18-33#20110300#v24n1a15.htm##
00646000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100021000990100
01900120012012600139030001000265065000900275064000500284031000300289032000200292
014000800294865000900302002001300311035001000324801001000334#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a15.htm#S#c#214#30#article#38#31#^rND^sOliveira^nAMA#
^rND^sCerqueira^nEMM#^rND^sOliveira^nAC#Prevalência de Sobrepeso e Obesidade Inf
antil na Cidade de Feira de Santana-BA: detecção na família x diagnóstico clínic
o^lpt#J Pediatr#20030000#2003#79#4#325-328#20110300#v24n1a15.htm#0022-3476#J Ped
iatr##
00515000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120031000980300
01300129710000200142065000900144064000500153037004700158110000900205109001300214
865000900227002001300236#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S
#c#215#31#article#38#32#^rND^sPinheiro^nD.#Brasil, império do bisturi^lpt#Veja o
n line#2#20010000#2001#http://www.veja.abril.com.br/170101/p_084.html#20100402#0
2 abr. 2010#20110300#v24n1a15.htm##
00438000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790180030000960630
00200126066001500128062001700143065000900160064000500169865000900174002001300183
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#216#32#article#38#33#
^rND^sPotter^nPA#Fundamentos de Enfermagem^lpt#5#Rio de Janeiro#Guanabara Koogan
#20040000#2004#20110300#v24n1a15.htm##
00493000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120084000980300
01500182710000200197065000900199064000500208031000200213032000200215865000900217
002001300226#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#217#33#ar
ticle#38#34#^rND^sRibeiro^nEM.#Obesidade severa e cirurgia bariátrica: o último 
recurso, a solução do problema^lpt#Revista Recenf#2#20030000#2003#1#3#20110300#v
24n1a15.htm##
00503000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120013000950300
02900108065000900137064000500146031000300151032000200154014000800156865000900164
002001300173035001000186801002900196#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a15.htm#S#c#218#34#article#38#35#^rND^sRossi^nMH#Celulite^lpt#J Eur Acad Derm
atol Venereol#20010000#2001#14#4#251-255#20110300#v24n1a15.htm#0926-9959#J Eur A
cad Dermatol Venereol##
00434000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790160017000980180
01700115066001000132062001400142065000900156064000500165865000900170002001300179
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#219#35#article#38#36#
^rND^sSampaio^nSAP#^rND^sRiviti^nEA#Dermatologia^lpt#São Paulo#Artes Médicas#200
80000#2008#20110300#v24n1a15.htm##
00477000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120049000970300
01800146710000200164065000900166064000500175031000200180032000200182014000500184
865000900189002001300198#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a15.htm#S
#c#220#36#article#38#37#^rND^sSigulem^nDM#Crescimento Pôndero-estatural do Pré-e
scolar^lpt#Compacta Nutrição#2#20050000#2005#6#1#1-27#20110300#v24n1a15.htm##
00427000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790180039000950660
01300134062001400147065000900161064000500170865000900175002001300184#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a15.htm#S#c#221#37#article#38#38#^rND^sSouza^
nRV#Novo atlas prático de dermatologia^lpt#Porto Alegre#Artes Médicas#20030000#2
003#20110300#v24n1a15.htm##
00593000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01900114010001600133010001600149012005800165030001700223065000900240064000500249
865000900254002001300263035001000276801001700286#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a15.htm#S#c#222#38#article#38#39#^rND^sTamega^nAA#^rND^sAranha^nA
MP#^rND^sGuiotoku^nMM#^rND^sMiot^nLDB#^rND^sMiot^nHA.#Associação entre acrocórdo
ns e resistência à insulina^lpt#An Bras Dermatol#20100000#2010#20110300#v24n1a15
.htm#0365-0596#An Bras Dermatol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#o#1#1#article#1
#20110411#103927#v24n1a16.htm#217##
03038000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002700109
03100030013603200020013906500090014101400090015003500100015901200520016901200510
02210100034002720100035003060100038003410830956003790850010013350850021013450850
02701366085003301393085002101426085002601447083075801473085001002231085002002241
08500270226108500270228808500200231508500250233511700080236007200030236811200090
2371111001102380114000902391113001102400002001302411#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a16.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#16#ABCD070#n
d#ABCD, arq. bras. cir. dig.#24#1#20110300#^f74^l80#0102-6720#Tratamento paliati
vo do adenocarcinoma gástrico^lpt#Palliative treatment of gastric adenocarcinoma
^len#^rND^nFernando de Oliveira^sSouza#^rND^nLuis Carlos Moreira^sAntunes#^rND^n
Luis Humberto Ribas dos^sSantos#^lpt^aINTRODUÇÃO: Embora decrescendo nos países 
do chamado primeiro mundo, o adenocarcinoma gástrico mantém-se como terceiro tum
or mais frequente no sexo masculino mundialmente. Sua mortalidade é muito elevad
a, fruto do diagnóstico tardio em lesões muito avançadas, o que frequentemente t
orna paliativo seu tratamento, motivos pelos quais se justificam estudos no sent
ido de melhorar estes resultados. MÉTODO: Revisão da literatura através do porta
l de periódicos da CAPES indicados por busca no sites da Bireme e PubMed. Além d
isso, foram consultados os sumários do 8º Congresso Internacional de Câncer Gást
rico em 2009. Foi apresentada uma sugestão de algoritmo de atendimento destes pa
cientes. CONCLUSÕES: O surgimento de novas drogas anticancer, mais efetivas, est
á propiciando novas alternativas para a ressecção gástrica como tratamento palia
tivo. Novos protocolos estão surgindo mostrando boas perspectivas para melhorar 
os resultados desta doença.#^ddecs^i1#^tm^lpt^kEstômago^i1#^tm^lpt^kAdenocarcino
ma^i1#^tm^lpt^kTratamento paliativo^i1#^tm^lpt^kCirurgia^i1#^tm^lpt^kQuimioterap
ia^i1#^len^aINTRODUCTION: Although decreasing in the well developed countries, g
astric adenocarcinoma still represents the third most common cancer in males wor
ldwide. Its mortality is very high because of the lateness of its diagnosis over
 advanced lesions, which turns palliative its treatment in the majority of the c
ases. METHOD: Literature review using CAPES, PubMed and Bireme sites as well as 
the abstracts of the 8 º International Gastric Cancer Congress which was held in
 Krakow in 2009. CONCLUSIONS: The release of new anticancer drugs against gastri
c cancer is providing a revival of gastrectomy as an effective palliative treatm
ent of advanced gastric cancer. New protocols are being published, showing bette
r results in the treatment of this disease.#^ddecs^i2#^tm^len^kStomach^i2#^tm^le
n^kAdenocarcinoma^i2#^tm^len^kPaliative care^i2#^tm^len^kSurgery^i2#^tm^len^kDru
g therapy^i2#vancouv#45#20100727#27/07/2010#20110125#25/01/2011#v24n1a16.htm##
03094000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002700109
03100030013603200020013906500090014101400090015003500100015901200590016901200580
02280100034002860100035003200100038003550830977003930850010013700850021013800850
02701401085003301428085002101461085002601482083077901508085001002287085002002297
08500270231708500270234408500200237108500250239111700080241607200030242411200090
2427111001102436114000902447113001102456002001302467#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a16.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#16#ABCD070#n
d#ABCD, arq. bras. cir. dig.#24#1#20110300#^f74^l80#0102-6720#<b>Tratamento pali
ativo do adenocarcinoma gástrico</b>^lpt#<b>Palliative treatment of gastric aden
ocarcinoma</b>^len#^rND^nFernando de Oliveira^sSouza#^rND^nLuis Carlos Moreira^s
Antunes#^rND^nLuis Humberto Ribas dos^sSantos#^lpt^a<b>INTRODUÇÃO:</b> Embora de
crescendo nos países do chamado primeiro mundo, o adenocarcinoma gástrico mantém
-se como terceiro tumor mais frequente no sexo masculino mundialmente. Sua morta
lidade é muito elevada, fruto do diagnóstico tardio em lesões muito avançadas, o
 que frequentemente torna paliativo seu tratamento, motivos pelos quais se justi
ficam estudos no sentido de melhorar estes resultados. <b>MÉTODO: </b>Revisão da
 literatura através do portal de periódicos da CAPES indicados por busca no site
s da Bireme e PubMed. Além disso, foram consultados os sumários do 8º Congresso 
Internacional de Câncer Gástrico em 2009. Foi apresentada uma sugestão de algori
tmo de atendimento destes pacientes. <b>CONCLUSÕES:</b> O surgimento de novas dr
ogas anticancer, mais efetivas, está propiciando novas alternativas para a resse
cção gástrica como tratamento paliativo. Novos protocolos estão surgindo mostran
do boas perspectivas para melhorar os resultados desta doença.#^ddecs^i1#^tm^lpt
^kEstômago^i1#^tm^lpt^kAdenocarcinoma^i1#^tm^lpt^kTratamento paliativo^i1#^tm^lp
t^kCirurgia^i1#^tm^lpt^kQuimioterapia^i1#^len^a<b>INTRODUCTION: </b>Although dec
reasing in the well developed countries, gastric adenocarcinoma still represents
 the third most common cancer in males worldwide. Its mortality is very high bec
ause of the lateness of its diagnosis over advanced lesions, which turns palliat
ive its treatment in the majority of the cases. <b>METHOD: </b>Literature review
 using CAPES, PubMed and Bireme sites as well as the abstracts of the 8 º Intern
ational Gastric Cancer Congress which was held in Krakow in 2009. <b>CONCLUSIONS
: </b>The release of new anticancer drugs against gastric cancer is providing a 
revival of gastrectomy as an effective palliative treatment of advanced gastric 
cancer. New protocols are being published, showing better results in the treatme
nt of this disease.#^ddecs^i2#^tm^len^kStomach^i2#^tm^len^kAdenocarcinoma^i2#^tm
^len^kPaliative care^i2#^tm^len^kSurgery^i2#^tm^len^kDrug therapy^i2#vancouv#45#
20100727#27/07/2010#20110125#25/01/2011#v24n1a16.htm##
03168000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000260012703100030015303200020015606500090015801400090016703500100017601200520
01860120051002380100034002890100035003230100038003580830956003960850010013520850
02101362085002701383085003301410085002101443085002601464083075801490085001002248
08500200225808500270227808500270230508500200233208500250235211700080237707200030
2385112000902388111001102397114000902408113001102417002001302428008008902441#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#l#4#1#article#1#^mjan./mar.
^a2011#oa#pt#br1.1#1#4.0#ilus#16#ABCD070#nd#ABCD, arq. bras. cir. dig#24#1#20110
300#^f74^l80#0102-6720#Tratamento paliativo do adenocarcinoma gástrico^lpt#Palli
ative treatment of gastric adenocarcinoma^len#^rND^nFernando de Oliveira^sSouza#
^rND^nLuis Carlos Moreira^sAntunes#^rND^nLuis Humberto Ribas dos^sSantos#^lpt^aI
NTRODUÇÃO: Embora decrescendo nos países do chamado primeiro mundo, o adenocarci
noma gástrico mantém-se como terceiro tumor mais frequente no sexo masculino mun
dialmente. Sua mortalidade é muito elevada, fruto do diagnóstico tardio em lesõe
s muito avançadas, o que frequentemente torna paliativo seu tratamento, motivos 
pelos quais se justificam estudos no sentido de melhorar estes resultados. MÉTOD
O: Revisão da literatura através do portal de periódicos da CAPES indicados por 
busca no sites da Bireme e PubMed. Além disso, foram consultados os sumários do 
8º Congresso Internacional de Câncer Gástrico em 2009. Foi apresentada uma suges
tão de algoritmo de atendimento destes pacientes. CONCLUSÕES: O surgimento de no
vas drogas anticancer, mais efetivas, está propiciando novas alternativas para a
 ressecção gástrica como tratamento paliativo. Novos protocolos estão surgindo m
ostrando boas perspectivas para melhorar os resultados desta doença.#^ddecs^i1#^
tm^lpt^kEstômago^i1#^tm^lpt^kAdenocarcinoma^i1#^tm^lpt^kTratamento paliativo^i1#
^tm^lpt^kCirurgia^i1#^tm^lpt^kQuimioterapia^i1#^len^aINTRODUCTION: Although decr
easing in the well developed countries, gastric adenocarcinoma still represents 
the third most common cancer in males worldwide. Its mortality is very high beca
use of the lateness of its diagnosis over advanced lesions, which turns palliati
ve its treatment in the majority of the cases. METHOD: Literature review using C
APES, PubMed and Bireme sites as well as the abstracts of the 8 º International 
Gastric Cancer Congress which was held in Krakow in 2009. CONCLUSIONS: The relea
se of new anticancer drugs against gastric cancer is providing a revival of gast
rectomy as an effective palliative treatment of advanced gastric cancer. New pro
tocols are being published, showing better results in the treatment of this dise
ase.#^ddecs^i2#^tm^len^kStomach^i2#^tm^len^kAdenocarcinoma^i2#^tm^len^kPaliative
 care^i2#^tm^len^kSurgery^i2#^tm^len^kDrug therapy^i2#vancouv#45#20100727#27/07/
2010#20110125#25/01/2011#v24n1a16.htm#Internet^ihttp://www.scielo.br/scielo.php?
script=sci_arttext&pid=S0102-67202011000100016##
00363000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704013000074002001300204#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#5#1#article#168#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif" ><b>ARTIGO DE REVIS&Atil
de;O </b></font></p>     ^cY#v24n1a16.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#6#2#article#168#<p>&nbsp;</p>     ^cY
#v24n1a16.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016500074002001300239#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#7#3#article#168#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif" ><a name="note1"></a><b>Tratamento pal
iativo do adenocarcinoma g&aacute;strico</b></font></p>     ^cY#v24n1a16.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#8#4#article#168#<p>&nbsp;</p>     ^cY
#v24n1a16.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#9#5#article#168#<p>&nbsp;</p>     ^cY
#v24n1a16.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017900075002001300254#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#10#6#article#168#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif" ><b>Fernando de Oliveira Souza; Luis 
Carlos Moreira Antunes; Luis Humberto Ribas dos Santos </b></font></p>     ^cY#v
24n1a16.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012500075002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#11#7#article#168#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;nci
a</a></font></p>     ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#12#8#article#168#<p>&nbsp;</p>     ^c
Y#v24n1a16.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704004400075002001300119#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#13#9#article#168#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v24n1a16.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#14#10#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>RESUMO </b></font></p>     ^cY#v
24n1a16.htm##
00773000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053800076002001300614#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#15#11#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>INTRODU&Ccedil;&Atilde;O:</b> Em
bora decrescendo nos pa&iacute;ses do chamado primeiro mundo, o adenocarcinoma g
&aacute;strico mant&eacute;m-se como terceiro tumor mais frequente no sexo mascu
lino mundialmente. Sua mortalidade &eacute; muito elevada, fruto do diagn&oacute
;stico tardio em les&otilde;es muito avan&ccedil;adas, o que frequentemente torn
a paliativo seu tratamento, motivos pelos quais se justificam estudos no sentido
 de melhorar estes resultados.     ^cY#v24n1a16.htm##
00611000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037600076002001300452#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#16#12#article#168#<br><b>M&Eacute;TOD
O: </b> Revis&atilde;o da literatura atrav&eacute;s do portal de peri&oacute;dic
os da CAPES indicados por busca no sites da Bireme e PubMed. Al&eacute;m disso, 
foram consultados os sum&aacute;rios do 8º Congresso Internacional de C&acirc;nc
er G&aacute;strico em 2009. Foi apresentada uma sugest&atilde;o de algoritmo de 
atendimento destes pacientes.    ^cY#v24n1a16.htm##
00578000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034300076002001300419#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#17#13#article#168#<br>  <b>CONCLUS&Ot
ilde;ES:</b>  O surgimento de novas drogas anticancer, mais efetivas, est&aacute
; propiciando novas alternativas para a ressec&ccedil;&atilde;o g&aacute;strica 
como tratamento paliativo. Novos protocolos est&atilde;o surgindo mostrando boas
 perspectivas para melhorar os resultados desta doen&ccedil;a. </font></p>      
^cY#v24n1a16.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020400076002001300280#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#18#14#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>Descritores:</b> Est&ocirc;mago.
 Adenocarcinoma. Tratamento paliativo. Cirurgia. Quimioterapia.</font></p> <hr s
ize="1" noshade>     ^cY#v24n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#19#15#article#168#<p>&nbsp;</p>     ^
cY#v24n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#20#16#article#168#<p>&nbsp;</p>     ^
cY#v24n1a16.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#21#17#article#168#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>INTRODU&Ccedil;&Atilde;O</b></fo
nt></p>     ^cY#v24n1a16.htm##
00840000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060500076002001300681#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#22#18#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Embora decrescendo nos pa&iacute;se
s do chamado primeiro mundo, o adenocarcinoma g&aacute;strico (AG) continua send
o dos mais frequentes no sexo masculino (ocupa a terceira posi&ccedil;&atilde;o 
depois de pr&oacute;stata e pulm&atilde;o), por&eacute;m sua import&acirc;ncia &
eacute; ainda maior em fun&ccedil;&atilde;o de sua alta mortalidade (segunda pos
i&ccedil;&atilde;o depois de pulm&atilde;o). Foram computados mundialmente no an
o de 2008 quase um milh&atilde;o de novos casos e 780 mil &oacute;bitos<sup>11</
sup>. </font></p>     ^cY#v24n1a16.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022600076002001300302#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#23#19#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >No Brasil, esperam-se para 2010, ap
roximadamente 22 000 novos casos considerando-se ambos os sexos, segundo estimat
ivas do INCA<sup>20</sup>. </font></p>     ^cY#v24n1a16.htm##
00670000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043500076002001300511#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#24#20#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Analisando os resultados obtidos no
 tratamento do adenocarcinoma g&aacute;strico no mundo ocidental, pode-se consid
er&aacute;-lo de uma maneira geral como paliativo, visto que as recidivas s&atil
de;o o seguimento mais prov&aacute;vel e a sobrevida em cinco anos atinge em m&e
acute;dia somente 20 %, computando-se todos os est&aacute;gios em conjunto. </fo
nt></p>     ^cY#v24n1a16.htm##
01998000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704176300076002001301839#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#25#21#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Mesmo as ressec&ccedil;&otilde;es d
e residualidade zero (R0), com inten&ccedil;&atilde;o curativa, conforme propost
o por Hermanek<sup>24</sup> em 1994, ou seja, margens cir&uacute;rgicas microsco
picamente negativas assim como o leito tumoral, a recidiva chega a 52%<sup>4</su
p>, a maioria loco-regional, seja linfonodos ou perit&ocirc;nio envolvido. Antec
ipadamente, j&aacute; se pode visualizar a necessidade de estabelecer crit&eacut
e;rios adicionais para a defini&ccedil;&atilde;o de opera&ccedil;&atilde;o com i
nten&ccedil;&atilde;o curativa j&aacute; que, como foi visto, n&atilde;o &eacute
; certo defini-la como tal com um &iacute;ndice t&atilde;o elevado de recorr&eci
rc;ncia da doen&ccedil;a. Mais correto seria definir R0 como "tumor residual n&a
tilde;o detect&aacute;vel pelos m&eacute;todos diagn&oacute;sticos convencionais
". A inten&ccedil;&atilde;o curativa deveria incluir citologia negativa de l&iac
ute;quido peritoneal (5 a 20% dos pacientes submetidos a ressec&ccedil;&otilde;e
s "curativas" apresentam c&eacute;lulas neopl&aacute;sicas no lavado peritoneal 
mesmo na aus&ecirc;ncia de les&otilde;es macrosc&oacute;picas, principalmente em
 tumores T3<sup>43</sup>), assim como pesquisa negativa de c&eacute;lulas isolad
as tumorais no sangue perif&eacute;rico, portal (encontradas em 18 a 24% dos cas
os<sup>39</sup>) e na medula &oacute;ssea dos pacientes (encontradas em 50% dos 
casos no pr&eacute;-operat&oacute;rio<sup>36</sup>. Brennan e Karpeh<sup>12 </su
p>consideram as ressec&ccedil;&otilde;es g&aacute;stricas em pacientes com tumor
es T3 como paliativas pela alta incid&ecirc;ncia de citologia positiva para c&ea
cute;lulas neopl&aacute;sicas nestes casos. </font></p>     ^cY#v24n1a16.htm##
00749000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051400076002001300590#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#26#22#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Discorrer-se-&aacute; a seguir sobr
e o tratamento paliativo do ponto de vista cir&uacute;rgico, quimioter&aacute;pi
co e suas associa&ccedil;&otilde;es, adicionando proposi&ccedil;&atilde;o de um 
algoritmo de atendimento (<a href="/img/revistas/abcd/v24n1/a16tab1.jpg">Figura 
1</a>), proposta esta que quer-se submeter &agrave; aprecia&ccedil;&atilde;o da 
comunidade cient&iacute;fica, sempre tratando de tumores avan&ccedil;ados. </fon
t></p>     ^cY#v24n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#27#23#article#168#<p>&nbsp;</p>     ^
cY#v24n1a16.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#28#24#article#168#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>M&Eacute;TODO</b> </font></p>   
  ^cY#v24n1a16.htm##
00763000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052800076002001300604#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#29#25#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Foram utilizados os descritores "es
t&ocirc;mago" e "adenocarcinoma" para pesquisa no PubMed e Bireme e a seguir sel
ecionadas as publica&ccedil;&otilde;es pertinentes no Portal CAPES com aten&cced
il;&atilde;o especial para metan&aacute;lises e estudos cl&iacute;nicos controla
dos.  Al&eacute;m disto, foi revisado o Abstract Book do 8º Congresso Internacio
nal de C&acirc;ncer G&aacute;strico realizado na Crac&oacute;via, Pol&ocirc;nia 
em 2009. </font></p>     ^cY#v24n1a16.htm##
00363000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012800076002001300204#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#30#26#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>Tratamento cir&uacute;rgico pali
ativo</b></font></p>     ^cY#v24n1a16.htm##
00751000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051600076002001300592#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#31#27#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Do ponto de vista cir&uacute;rgico,
 a ressec&ccedil;&atilde;o sempre que poss&iacute;vel como tratamento paliativo 
deve ser analisada quanto a rela&ccedil;&atilde;o risco/benef&iacute;cio, entend
endo-se como benef&iacute;cio a qualidade e quantidade da sobrevida destes pacie
ntes. Para esta an&aacute;lise h&aacute; que se particularizar cada caso baseand
o-se no grau de comprometimento provocado pela doen&ccedil;a (estadiamento). </f
ont></p>     ^cY#v24n1a16.htm##
01529000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704129400076002001301370#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#32#28#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >A primeira etapa no algoritmo de at
endimento destes pacientes &eacute; a avalia&ccedil;&atilde;o de sua aptid&atild
e;o em receber algum tipo de tratamento, seja cir&uacute;rgico, qu&iacute;mio ou
 radioter&aacute;pico. Para tanto, al&eacute;m dos exames de rotina, se adota es
calas de performance como as de Karnofsky<sup>26</sup> ou ECOG<sup>30</sup>. Os 
considerados n&atilde;o aptos s&atilde;o encaminhados para o melhor tratamento d
e suporte, os aptos para estadiamento cl&iacute;nico que inclui exame f&iacute;s
ico minucioso &agrave; procura de doen&ccedil;a disseminada como, por exemplo, a
 plataforma de Blummer no toque retal, exames de imagem incluindo tomografia com
putadorizada de pelve, abdome (com contraste) e t&oacute;rax, e marcadores tumor
ais no sangue (CEA e CA 19-9). A tomografia abdominal deve buscar evid&ecirc;nci
as de envolvimento linfonodal sat&eacute;lite (linfonodos acima de 1 cm de di&ac
irc;metro), met&aacute;stases  hep&aacute;ticas e sinais de irresecabilidade com
o, por exemplo,  invas&atilde;o difusa do retroperit&ocirc;nio, com comprometime
nto de grandes vasos. O estudo gastrosc&oacute;pico com bi&oacute;psia pr&eacute
;via idealmente deve vir acompanhado de ecoendoscopia. </font></p>     ^cY#v24n1
a16.htm##
01602000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704136700076002001301443#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#33#29#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Ap&oacute;s esta avalia&ccedil;&ati
lde;o inicial, s&atilde;o exclu&iacute;dos aqueles com sangramento tumoral ou ob
stru&ccedil;&atilde;o g&aacute;strica significativos e os demais (principalmente
 os que apresentam tumores g&aacute;stricos envolvendo todo o &oacute;rg&atilde;
o e/ou linfoadenomegalia &gt;1 cm) s&atilde;o encaminhados &agrave; laparoscopia
 com lavado peritoneal. A partir destes resultados, os pacientes com doen&ccedil
;a difusa (far advanced gastric cancer - FAGC), com um fator de incurabilidade, 
s&atilde;o encaminhados para ressec&ccedil;&atilde;o g&aacute;strica de redu&cce
dil;&atilde;o tumoral seguida de tratamento adjuvante. Aqueles com v&aacute;rios
 fatores de incurabilidade v&atilde;o para radioquimioterapia paliativa. Os paci
entes sem evid&ecirc;ncias de doen&ccedil;a difusa (local advanced gastric cance
r - LAGC), s&atilde;o indicados para tratamento quimioter&aacute;pico perioperat
&oacute;rio com tr&ecirc;s ciclos pr&eacute; e tr&ecirc;s p&oacute;s-operat&oacu
te;rios. Estes pacientes devem ser monitorados na fase pr&eacute; quanto &agrave
; resposta &agrave; medica&ccedil;&atilde;o utilizando os crit&eacute;rios recis
t<sup>19</sup>; no caso de n&atilde;o resposta, deve ser antecipado o seu encami
nhamento para um procedimento cir&uacute;rgico. </font></p>     ^cY#v24n1a16.htm
##
01020000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078500076002001300861#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#34#30#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >A opera&ccedil;&atilde;o recomendad
a &eacute; a gastrectomia com linfadenectomia D2 respeitando-se as margens de se
guran&ccedil;a recomendadas para tumores difusos e intestinais e avalia&ccedil;&
atilde;o por congela&ccedil;&atilde;o dos linfonodos para-a&oacute;rticos (grupo
 16). Nos pacientes com tumores considerados irressec&aacute;veis, seja no pr&ea
cute; ou no transoperat&oacute;rio, desde que n&atilde;o haja doen&ccedil;a difu
sa com v&aacute;rios fatores de incurabilidade, &eacute; recomendado tratamento 
neoajuvante na tentativa de redu&ccedil;&atilde;o tumoral e opera&ccedil;&atilde
;o de revis&atilde;o (2<sup>nd</sup> look) (<a href="/img/revistas/abcd/v24n1/a1
6tab1.jpg">Figura 1</a>). </font></p>     ^cY#v24n1a16.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020400076002001300280#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#35#31#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >A ressec&ccedil;&atilde;o multivisc
eral est&aacute; indicada na aus&ecirc;ncia de doen&ccedil;a difusa/sist&ecirc;m
ica. </font></p>     ^cY#v24n1a16.htm##
00469000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023400076002001300310#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#36#32#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Todos estes procedimentos devem ser
 realizados em centros de refer&ecirc;ncia com alto volume de casos no tratament
o do c&acirc;ncer g&aacute;strico. </font></p>     ^cY#v24n1a16.htm##
00780000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054500076002001300621#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#37#33#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Comparando-se com a literatura atua
l, destacam-se como os pontos mais pol&ecirc;micos do algoritmo - no que se refe
re ao tratamento cir&uacute;rgico paliativo do AG -, as gastrectomias de redu&cc
edil;&atilde;o tumoral (reductive gastrectomy) para tratamento adjuvante em paci
entes com um fator de incurabilidade, e as gastrectomias de resgate (salvage gas
trectomy) ap&oacute;s tratamento neoadjuvante em paciente inicialmente considera
dos irressec&aacute;veis. </font></p>     ^cY#v24n1a16.htm##
01178000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094300076002001301019#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#38#34#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Na primeira situa&ccedil;&atilde;o,
 foi ativado em fevereiro de 2008 um estudo randomizado controlado (RCT) entre J
ap&atilde;o (JCOG 0705) e Cor&eacute;ia (KGC01) comparandose dois grupos de paci
entes com AG est&aacute;gio IV com um fator de incurabilidade, seja hep&aacute;t
ico, peritoneal ou linfonodal distante, um deles para tratamento exclusivamente 
quimioter&aacute;pico e o outro encaminhado para gastrectomia de redu&ccedil;&at
ilde;o tumoral seguida do mesmo esquema quimioter&aacute;pico com expectativa de
 10% de incremento de sobrevida em dois anos no grupo cir&uacute;rgico<sup>38</s
up>. Efetivamente, j&aacute; em 2006, Saidi et al<sup>34</sup> relataram aumento
 de sobrevida de 10,4 meses no grupo de pacientes operados concluindo que h&aacu
te; um papel para o que eles chamaram de gastrectomia paliativa nos pacientes co
m AG est&aacute;gio IV. </font></p>     ^cY#v24n1a16.htm##
00695000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046000076002001300536#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#39#35#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Quanto &agrave;s gastrectomias de r
esgate, com a evolu&ccedil;&atilde;o e a elabora&ccedil;&atilde;o de novas droga
s anticancer, foram surgindo trabalhos propondo, nos pacientes com AG disseminad
os ou irressec&aacute;veis, opera&ccedil;&otilde;es de ressec&ccedil;&atilde;o a
p&oacute;s tratamento neoadjuvante com resultados bastante satisfat&oacute;rios 
<sup>14,25,44</sup>. </font></p>     ^cY#v24n1a16.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#40#36#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>Tratamento quimioter&aacute;pico
 paliativo</b></font></p>     ^cY#v24n1a16.htm##
00444000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020900076002001300285#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#41#37#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><i>C&acirc;ncer g&aacute;strico met
ast&aacute;tico: suporte cl&iacute;nico vs tratamento quimioter&aacute;pico comb
inado </i></font></p>     ^cY#v24n1a16.htm##
00735000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050000076002001300576#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#42#38#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Em 1977, Glimelius, et al.<sup>23</
sup> publicaram um estudo randomizado que revelou maior taxa de sobrevida global
 com melhor qualidade de vida para os pacientes que receberam quimioterapia pali
ativa, comparado com tratamento de suporte cl&iacute;nico (69% VS 47%; p&lt;0,05
)<sup>23</sup>. Entretanto, pelo menos tr&ecirc;s estudos da mesma d&eacute;cada
 n&atilde;o confirmaram estes resultados<sup>18,28,33</sup>. </font></p>     ^cY
#v24n1a16.htm##
00751000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051600076002001300592#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#43#39#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Com a evolu&ccedil;&atilde;o tanto 
dos quimioter&aacute;picos quanto dos cuidados de suporte, novos estudos realiza
dos na d&eacute;cada de 90 revelaram claro benef&iacute;cio a favor da quimioter
apia paliativa. Metan&aacute;lise publicada por Wagner, et al.<sup>41</sup> com 
tr&ecirc;s estudos incluindo 184 pacientes, demonstrou HR de 0,39(IC:95%; 0,28ª 
0,52) em rela&ccedil;&atilde;o a sobrevida global, a favor da quimioterapia. </f
ont></p>     ^cY#v24n1a16.htm##
00384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014900076002001300225#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#44#40#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><i>Quimioterapia com agente &uacute
;nico vs regime combinado </i></font></p>     ^cY#v24n1a16.htm##
01108000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087300076002001300949#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#45#41#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Fluorouracil (5FU) foi o mais exten
sivamente agente quimioter&aacute;pico estudado para c&acirc;ncer g&aacute;stric
o metast&aacute;tico, sendo usado como monoterapia em 10 estudos, e em nove regi
mes de quimioterapia combinada, de um total de 11 estudos revisados por Wagner, 
et al.<sup>41</sup>. Com 1472 pacientes comparando quimioterapia com um &uacute;
nico agente vs combina&ccedil;&atilde;o, os autores encontraram HR de 0,83 (IC: 
95%, 0,74 &agrave; 0,93) para sobrevida a favor de regimes de combina&ccedil;&at
ilde;o, correspondendo a ganho de sobrevida de aproximadamente um m&ecirc;s. Sei
s destes estudos, que usaram 5FU como monoterapia, reportaram taxas de morte rel
acionada ao tratamento de 1,7% para o tratamento combinado e 0,8% para 5FU como 
agente &uacute;nico<sup>41</sup>. </font></p>     ^cY#v24n1a16.htm##
00399000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016400076002001300240#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#46#42#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><i>Cisplatina e antrac&iacute;clico
s em regimes combinados de quimioterapia </i></font></p>     ^cY#v24n1a16.htm##
01041000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080600076002001300882#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#47#43#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >A metan&aacute;lise de Wagner, et a
l.<sup>41</sup> avaliou tamb&eacute;m tr&ecirc;s estudos randomizados com 501 pa
cientes, comparando combina&ccedil;&atilde;o de cisplatina/5FU com ou sem antrac
&iacute;clicos, demonstrando beneficio estatisticamente significativo a favor do
 regime com tr&ecirc;s drogas (HR= 0,77; IC 95%, 0,62 -0,91), com ganho de sobre
vida global de aproximadamente dois meses.  Esta revis&atilde;o tamb&eacute;m av
aliou o papel da cisplatina em combina&ccedil;&otilde;es com tr&ecirc;s drogas, 
com sete estudos comparando 5FU/ antrac&iacute;clico/cisplatina vs 5FU/ antrac&i
acute;clico, verificando ganho de sobrevida global de aproximadamente um m&ecirc
;s (HR: 0,83; IC 95%, 0,76-0,91)<sup>41</sup>. </font></p>     ^cY#v24n1a16.htm#
#
00855000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062000076002001300696#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#48#44#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >O regime ECF (epirrubicina, cisplat
ina e 5FU em infus&atilde;o cont&iacute;nua) foi comparado com PELF, uma combina
&ccedil;&atilde;o de quatro drogas (epirrubicina, cisplatina, leucovorin e 5FU e
m bolus) que resultou em taxa de morte relacionada ao tratamento de 3,3% vs 0,6%
 (OR= 5,36 IC 95%, 1,1 a 27,4; p=0,028), sugerindo aumento da toxicidade para o 
PELF. Outros dois estudos analisaram qualidade de vida, demonstrando superiorida
de para o ECF em rela&ccedil;&atilde;o ao 5FU/doxorrubicina/metotrexate e mitomi
cina/cisplatina/5FU. </font></p>     ^cY#v24n1a16.htm##
00394000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015900076002001300235#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#49#45#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><i>Oxaliplatina e capecitabina nos 
regimes combinados de quimioterapia </i></font></p>     ^cY#v24n1a16.htm##
01531000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704129600076002001301372#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#50#46#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Cunningham, et al.<sup>16</sup> apr
esentaram os dados de um estudo fase III (REAL-2) com 1002 pacientes randomizado
s em quatro bra&ccedil;os em formato 2X2, tendo o ECF como bra&ccedil;o de refer
&ecirc;ncia, e avaliando a n&atilde;o inferioridade da substitui&ccedil;&atilde;
o do 5FU pela capecitabina e da cisplatina pela oxaliplatina. A capecitabina n&a
tilde;o foi inferior ao 5FU (HR: 0,86; IC:95%, 0,80-0,99) e a oxaliplatina n&ati
lde;o foi inferior &agrave; cisplatina (HR: 0,92; IC: 95%, 0,80-1,10). O grupo q
ue recebeu o regime EOX (epirrubicina/oxaliplatina/ capecitabina) apresentou mai
or sobrevida em um ano (46,8% vs 37,7%, p=0,02) e sobrevida global (11,2 vs 9,9 
meses, p=0,02) quando comparado ao ECF. Os quatro regimes apresentaram taxas de 
resposta semelhantes, sem diferen&ccedil;a estat&iacute;stica significativa com 
47,9% para EOX , 46,4% para EOF (epirrubicina, oxaliplatina e 5FU), 42,4% para E
CX (epirrubicina, cisplatina e capecitabina) e 40,7% para ECF. Os regimes conten
do oxaliplatina foram bem tolerados, apresentando menor incid&ecirc;ncia de neut
ropenia severa, alop&eacute;cia e nefrotoxicidade, mas com maiores taxas de neur
opatia perif&eacute;rica e diarr&eacute;ia<sup>16</sup>. </font></p>     ^cY#v24
n1a16.htm##
01464000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122900076002001301305#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#51#47#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Outro estudo fase III, com 220 paci
entes, comparou um regime contendo oxaliplatina (FLO: oxaliplatina/ 5FU/leucovor
in) versus um regime com cisplatina (FLP: cisplatina/5FU/leucovorin) em rela&cce
dil;&atilde;o ao sobrevida livre de progress&atilde;o(SLP) com base na an&aacute
;lise de inten&ccedil;&atilde;o de tratar. Foi encontrada uma tend&ecirc;ncia em
 rela&ccedil;&atilde;o ao TLP para o regime FLO, embora sem diferen&ccedil;a est
at&iacute;stica significativa (5,8 versus 3,9 meses; p=0,077), assim como para a
 sobrevida global (10,7 versus 8,8 meses). Entretanto, quando analisados pacient
es acima de 65 anos (n=94), o regime FLO revelou-se significativamente superior 
em rela&ccedil;&atilde;o &agrave; taxa de resposta (41,3 versus 16,7%; p=0,012),
 tempo para falha do tratamento (5,4 versus 2,3 meses; P&lt;0,001), e SLP (6,0 v
ersus 3,1 meses; p=0,029), al&eacute;m de um aumento da sobrevida global (13,9 v
ersus 7,2 meses). Este grupo tamb&eacute;m apresentou menor toxicidade quanto &a
grave; leucopenia grau 1-4, n&aacute;usea, fadiga e nefrotoxicidade, por&eacute;
m maior incid&ecirc;ncia de neuropatia perif&eacute;rica<sup>7</sup>. </font></p
>     ^cY#v24n1a16.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#52#48#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><i>Docetaxel </i></font></p>     ^c
Y#v24n1a16.htm##
01417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704118200076002001301258#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#53#49#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >O uso do docetaxel em primeira linh
a para c&acirc;ncer g&aacute;strico avan&ccedil;ado foi investigado no estudo TA
X 325, cuja fase II comparou os regimes docetaxel/cisplatina (DC) e docetaxel/ci
splatina/5FU (DCF) com o objetivo de identificar o regime mais efetivo. O DCF fo
i superior em efic&aacute;cia (43% vs 26%) e tempo de progress&atilde;o (5,9 vs 
5 meses), sendo escolhido para fase III. Para esta fase, foram randomizados 457 
pacientes em dois grupos para receber primeira linha de DCF ou CF (cisplatina e 
5FU). Novamente o DCF foi superior, com melhores resultados em rela&ccedil;&atil
de;o ao tempo para progress&atilde;o (5,6 vs 3,7 meses, p=0,0004), sobrevida glo
bal (9,2 vs 8,6 meses, p=0,02), sobrevida em dois anos (18% vs 9%), taxa de resp
osta global (37 vs 25%, p=0,01) e an&aacute;lise de qualidade de vida. Entretant
o, a toxicidade foi significativamente superior, com taxas de neutropenia grau I
II e IV de 82,3%, e incid&ecirc;ncia de neutropenia febril de 30% no grupo DCF, 
devendo-se monitorizar cuidadosamente as rea&ccedil;&otilde;es adversas deste re
gime<sup>40,4,5</sup>. </font></p>     ^cY#v24n1a16.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#54#50#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><i>Irinotecano </i></font></p>     
^cY#v24n1a16.htm##
01437000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120200076002001301278#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#55#51#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >O estudo V-306 avaliou o uso de iri
notecano em regime de combina&ccedil;&atilde;o para primeira linha de c&acirc;nc
er g&aacute;strico avan&ccedil;ado em um estudo inicialmente fase II que comparo
u IC (irinotecano e cisplatina) e ILF (irinotecano, leucovorin e fluorouracil), 
definindo a superioridade deste &uacute;ltimo<sup>13</sup>. O estudo fase III do
 V-306, comparou o ILF com CF, e demonstrou tend&ecirc;ncia a maior tempo para p
rogress&atilde;o (5 vs 4,2 meses, p=0,088) e taxa de resposta (31,8% vs 25,8%) a
 favor do IFL, mas sem diferen&ccedil;a estat&iacute;stica significativa. Com te
mpo de sobrevida m&eacute;dia similar nos dois grupos (9 vs 8,7 meses, p= 0,53),
 mas menor toxicidade para o grupo com IFL, este pode ser usado como alternativa
 ao regime CF<sup>17</sup>. Bouche, et al.<sup>10 </sup>publicaram um estudo fas
e II comparando outro regime com irinotecano, combinado a leucovorin, 5FU em bol
us e 5FU em infus&atilde;o continua (FOLFIRI), com LF (leucovorin e 5FU) ou CLF 
(cisplatina, leucovorin e 5FU). As taxas de resposta objetiva, TP e SG foram sup
eriores com o regime FOLFIRI<sup>10</sup>. </font></p>     ^cY#v24n1a16.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009500076002001300171#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#56#52#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><i>S-1 </i></font></p>     ^cY#v24n
1a16.htm##
01633000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704139800076002001301474#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#57#53#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >O uso de uma quarta gera&ccedil;&at
ilde;o de fluoropirimidinas chamada de S-1 e composta por tegafur/ gimeracil/ ot
eracil tem sido investigado principalmente no Jap&atilde;o, onde foi aprovado co
mo quimioterapia paliativa ou tratamento adjuvante para pacientes submetidos &ag
rave; ressec&ccedil;&atilde;o curativa. Outros pa&iacute;ses asi&aacute;ticos ta
mb&eacute;m definiram regimes com S-1 como adjuv&acirc;ncia (Cor&eacute;ia) ou c
omo tratamento padr&atilde;o em c&acirc;ncer g&aacute;strico avan&ccedil;ado (Co
r&eacute;ia, Singapura e China). O SPIRITS, um estudo fase III realizado por Koi
zumi, et al.<sup>29</sup> com 305 pacientes, comparou S-1 sozinho com S-1/cispla
tina, encontrando superioridade para o regime combinado em rela&ccedil;&atilde;o
 &agrave; sobrevida global (p=0,04; HR=0,77, IC:95%, 0,61-0,98) e &agrave; taxa 
de resposta (54% vs 31%). Apesar da maior toxicidade (maior incid&ecirc;ncia de 
neutropenia, anemia, n&aacute;usea e anorexia) do regime combinado, este foi ger
almente bem tolerado<sup>29</sup>. Outro estudo Japon&ecirc;s fase III, publicad
o por Boku et al.<sup>9</sup>, demonstrou sobrevida global similar para o S-1 qu
ando comparado a 5FU ou &agrave; combina&ccedil;&atilde;o irinotecano/cisplatina
 (tempos de sobrevida m&eacute;dia de 11,4 vs 10,8 vs 12,3 meses)<sup>9</sup>. <
/font></p>     ^cY#v24n1a16.htm##
01553000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704131800076002001301394#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#58#54#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Como a taxa de convers&atilde;o met
ab&oacute;lica da pr&oacute;-droga oral, tegafur para o fluorouracil parece ser 
diferente conforme a popula&ccedil;&atilde;o &eacute;tnica, foi conduzido um est
udo fase I para estabelecer a dose m&aacute;xima tolerada de S-1/cisplatina no o
cidente<sup>3</sup>. Ap&oacute;s avaliada a efic&aacute;cia e seguran&ccedil;a d
esta combina&ccedil;&atilde;o, em um estudo multic&ecirc;ntrico fase II, Ajani ,
 et al.<sup>6</sup> publicaram os resultados do estudo FLAGS que incluiu 24 pa&i
acute;ses e 146 centros, com 1053 pacientes estratificados (centro, n&uacute;mer
o de s&iacute;tios metast&aacute;ticos, quimioterapia adjuvante pr&eacute;via e 
extens&atilde;o da doen&ccedil;a) e randomizados para receber S-1/cisplatina ou 
5FU/cisplatina (5FU em infus&atilde;o de 24h). O regime S-1/cisplatina n&atilde;
o apresentou aumento estatisticamente significativo da sobrevida global (8,6 vs 
7,9 meses, com HR: 0,92; IC 95%, 0,80 a 1,05; p=0,20), mas resultou em menor tox
icidade com taxas inferiores de neutropenia grau 3/4 (32,3 % vs 63,6%), neutrope
nia complicada (5% vs 14,4%), estomatite (1,3% vs 13,6%), hipocalemia (3,6% vs 1
0,8%) e morte relacionada ao tratamento (2,5% vs 4,9%; p&lt;0,05)<sup>6</sup>. <
/font></p>     ^cY#v24n1a16.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#59#55#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><i>Anticorpo monoclonal </i></font>
</p>     ^cY#v24n1a16.htm##
01279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104400076002001301120#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#60#56#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Foi aprovado na Europa o uso do tra
stuzumabe combinado a quimioterapia para tratamento de primeira linha em tumores
 g&aacute;stricos avan&ccedil;ados positivos para HER2<sup>37</sup>. O trastuzum
abe &eacute; um anti-corpo monoclonal que bloqueia o receptor HER2, envolvido no
 crescimento celular. Um estudo fase III, multic&ecirc;ntrico, internacional e r
andomizado (ToGA) encontrou redu&ccedil;&atilde;o no risco de morte de 26% para 
os pacientes que receberam esta droga combinada &agrave; quimioterapia (5FU ou c
apecitabina em combina&ccedil;&atilde;o com cisplatina) em compara&ccedil;&atild
e;o &agrave; quimioterapia apenas. A sobrevida global m&eacute;dia encontrada fo
i de 13,8 meses no grupo do trastuzumabe vs 11,1 meses no grupo controle, tornan
do este o primeiro anti-corpo monoclonal a mostrar benef&iacute;cio na sobrevida
 entre as v&aacute;rias outras terapias alvo que est&atilde;o sendo testadas par
a c&acirc;ncer g&aacute;strico<sup>31</sup>. </font></p>     ^cY#v24n1a16.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014600076002001300222#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#61#57#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>C&acirc;ncer g&aacute;strico loc
almente avan&ccedil;ado</b></font></p>     ^cY#v24n1a16.htm##
01245000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101000076002001301086#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#62#58#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >A defini&ccedil;&atilde;o de c&acir
c;ncer g&aacute;strico localmente avan&ccedil;ado possui diferentes interpreta&c
cedil;&otilde;es dependendo do autor e da institui&ccedil;&atilde;o. Pode ser co
nsiderado como o tumor prim&aacute;rio que o cirurgi&atilde;o n&atilde;o espera 
ressecar com margens negativas microscopicamente (sem possibilidade de ressec&cc
edil;&atilde;o curativa conforme explora&ccedil;&atilde;o cir&uacute;rgica ou av
alia&ccedil;&atilde;o pr&eacute;-operatoria com tomografia computadorizada, ultr
assonografia endosc&oacute;pica, laparoscopia, ou outros exames de imagem; recid
ivas locais sem evid&ecirc;ncia de met&aacute;stases). Ou ainda, podese incluir 
doen&ccedil;a completamente ressec&aacute;vel, mas com fatores de alto risco par
a recorr&ecirc;ncia local ou met&aacute;stases &agrave; dist&acirc;ncia (envolvi
mento nodal, extens&atilde;o al&eacute;m da parede g&aacute;strica, ou ambos)<su
p>1</sup>. </font></p>     ^cY#v24n1a16.htm##
01202000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704096700076002001301043#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#63#59#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Pacientes com invas&atilde;o profun
da, localmente volumosos e irressec&aacute;veis devido &agrave; infiltra&ccedil;
&atilde;o de estruturas adjacentes, recebiam apenas tratamento quimioter&aacute;
pico paliativo. Entretanto, com a introdu&ccedil;&atilde;o da quimioterapia peri
-operat&oacute;ria este cen&aacute;rio vem sendo modificado. A quimioterapia neo
-adjuvante pode reduzir o volume tumoral, tornando o paciente oper&aacute;vel; e
vitar o retardo no tratamento de poss&iacute;veis micromet&aacute;stases; melhor
ar a tolerabilidade &agrave; quimioterapia, uma vez que a quimioterapia adjuvant
e pode apresentar maior toxicidade devido ao alto consumo de energia e poss&iacu
te;veis complica&ccedil;&otilde;es p&oacute;s-operat&oacute;rias; e ainda, testa
r a resposta do paciente &agrave; determinada droga, definindo o regime empregad
o no p&oacute;s-operat&oacute;rio<sup>45</sup>. </font></p>     ^cY#v24n1a16.htm
##
01920000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704168500076002001301761#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#64#60#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Schumacher, et al.<sup>35</sup> pub
licaram em 2001 os resultados de cinco anos de seguimento de um estudo fase II c
om 42 pacientes com c&acirc;ncer g&aacute;strico localmente avan&ccedil;ado (est
&aacute;gios IIIA, IIIB e IV). Estes foram inicialmente avaliados com endoscopia
, ultrassonografia endosc&oacute;pica, tomografia computadorizada para excluir i
nfiltra&ccedil;&atilde;o de &oacute;rg&atilde;os adjacentes e detec&ccedil;&atil
de;o de met&aacute;stases &agrave; dist&acirc;ncia, e com laparoscopia para excl
uir carcinomatose peritoneal oculta. Cada paciente recebeu tr&ecirc;s ou quatro 
ciclos de quimioterapia combinada (doxorrubicina/cisplatina/etoposide). Ap&oacut
e;s reavalia&ccedil;&atilde;o, 36 pacientes foram submetidos &agrave; gastrectom
ia total, obtendo ressec&ccedil;&atilde;o patol&oacute;gica completa em 31 (73,8
%). A sobrevida m&eacute;dia global dos 42 pacientes foi de 19,1 meses, sendo qu
e aqueles que n&atilde;o receberam tratamento cir&uacute;rgico, a sobrevida foi 
de apenas 1,5 meses, contra 22,2 meses para os submetidos ao tratamento cir&uacu
te;rgico (7,6 meses com ressec&ccedil;&atilde;o incompleta vs 28,4 meses para re
ssec&ccedil;&atilde;o completa, p=0,0001). Ressalta-se superior taxa de sobrevid
a associada &agrave; maior resposta cl&iacute;nica &agrave; quimioterapia, com s
obrevida m&eacute;dia de 45 meses<sup>35</sup>. V&aacute;rios outros estudos dem
onstraram benef&iacute;cio para quimioterapia neo-adjuvante no c&acirc;ncer g&aa
cute;strico localmente avan&ccedil;ado, com aumento da ressecabilidade (42,4%) e
 da sobrevida <sup>2,21,22,27,32,42,44</sup>. </font></p>     ^cY#v24n1a16.htm##
01297000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704106200076002001301138#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#65#61#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Em 2006, Cunningham, et al.<sup>15<
/sup> publicaram os resultados do estudo MAGIC, onde 503 pacientes oper&aacute;v
eis foram randomizados em um estudo fase III, para receber tr&ecirc;s ciclos de 
ECF antes e ap&oacute;s a opera&ccedil;&atilde;o ou apenas tratamento cir&uacute
;rgico. Os pacientes do grupo de quimioterapia peri-operat&oacute;ria apresentar
am maiores taxas de T1 e T2 (51,7% vs 36,8%) na an&aacute;lise patol&oacute;gica
 p&oacute;s-operat&oacute;ria, e um ganho de 13% na sobrevida em cinco anos (36%
 vs 23%), al&eacute;m de n&atilde;o ter ocorrido diferen&ccedil;a estat&iacute;s
tica significativa na morbidade cir&uacute;rgica entre os dois grupos (45,7% vs 
45,3%). Houve maior n&uacute;mero de opera&ccedil;&otilde;es consideradas curati
vas (79,3% vs 70,3%; p=0,003), aumento da sobrevida livre de progress&atilde;o (
HR=0,66; IC95%: 0,53 &agrave; 0,81) e da sobrevida global (HR=0,75; IC95%: 0,60 
&agrave; 0,93) no bra&ccedil;o com quimioterapia<sup>15</sup>. </font></p>     ^
cY#v24n1a16.htm##
00836000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060100076002001300677#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#66#62#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >Enquanto na doen&ccedil;a metast&aa
cute;tica as doses dos regimes de quimioterapia n&atilde;o devem ser t&atilde;o 
altas - evitando-se toxicidades relevantes com inten&ccedil;&atilde;o de melhora
r a qualidade de vida com maior sobrevida -, por outro lado na doen&ccedil;a loc
almente avan&ccedil;ada a quimioterapia neoadjuvante tem como objetivo aumentar 
as taxas de ressec&ccedil;&atilde;o e eventualmente de cura, devendo-se usar reg
imes combinados com duas ou tr&ecirc;s drogas e com doses menos flex&iacute;veis
. </font></p>     ^cY#v24n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#67#63#article#168#<p>&nbsp;</p>     ^
cY#v24n1a16.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#68#64#article#168#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>CONCLUS&Atilde;O </b></font></p>
     ^cY#v24n1a16.htm##
00608000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037300076002001300449#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#69#65#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >O surgimento de novas drogas antica
ncer, mais efetivas, est&aacute; propiciando novas alternativas para a ressec&cc
edil;&atilde;o g&aacute;strica como tratamento paliativo. Novos protocolos est&a
tilde;o surgindo mostrando boas perspectivas para melhorar os resultados desta d
oen&ccedil;a. </font></p>     ^cY#v24n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#70#66#article#168#<p>&nbsp;</p>     ^
cY#v24n1a16.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#71#67#article#168#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif" ><b>REFER&Ecirc;NCIAS </b></font></p
>     ^cY#v24n1a16.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017000078002001300248#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#72#68#article#168#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >1. Abeloff MD: Clinic
al oncology, 3rd ed. Philadelphia, Pa.: Elsevier/Churchill Livingstone, 2004.   
 ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#73#69#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00588000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033900078002001300417#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#74#70#article#168#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >2. Ajani JA, Mansfiel
d PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, C
urley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patient
s with potentially resectable gastric carcinoma. J Clin Oncol. 1999 Aug;17(8):24
03-11.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#75#71#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028100078002001300359#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#76#72#article#168#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >3. Ajani JA, Faust J,
 Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic 
study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin 
Oncol 2005; 23(28): 6957-65.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#77#73#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00706000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704045700078002001300535#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#78#74#article#168#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >4. Ajani JA, Moiseyen
ko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y,
 Voznyi E, Marabotti C, Van Cutsem E. Clinical benefit with docetaxel plus fluor
ouracil and cisplatin compared with cisplatin and fluorouracil in a phase III tr
ial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Stu
dy Group. J Clin Oncol 2007; 25(22): 3205-9.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#79#75#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00696000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704044700078002001300525#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#80#76#article#168#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >5. Ajani JA, Moiseyen
ko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y,
 Voznyi E, Awad L, Van Cutsem E. Quality of life with docetaxel plus cisplatin a
nd fluorouracil compared with cisplatin and fluorouracil from a phase III trial 
for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. 
J Clin Oncol 2007; 25(22): 3210-6.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#81#77#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00642000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704039300078002001300471#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#82#78#article#168#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >6. Ajani JA, Rodrigue
z W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A,
 Lang I, Falcon S. Multicenter Phase III Comparison of Cisplatin/S-1 With Cispla
tin/ Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcin
oma Study: The FLAGS Trial. J Clin Oncol 2010;28(9):1547-53.    ^cY#v24n1a16.htm
##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#83#79#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00800000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704055100078002001300629#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#84#80#article#168#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >7. Al-Batran SE, Hart
mann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipel
t G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker 
S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, J&auml;ger E. Phase I
II trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucov
orin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft In
ternistische Onkologie. J Clin Oncol 2008; 26(9): 1435-42.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#85#81#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025400078002001300332#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#86#82#article#168#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >8. Allum W, Garofalo 
A, Degiuli M, Schuhmacher C. The first european union network of excellence for 
gastric cancer conference, Rome, Italy, april 2008. Gastric Cancer 2009;12:56-65
.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#87#83#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00607000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704035800078002001300436#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#88#84#article#168#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif" >9. Boku N, Yamamoto S
, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi
 H, Nasu J, Ohtsu A. Fluorouracil versus combination of irinotecan plus cisplati
n versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet On
col 2009; 10(11): 1063-9.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#89#85#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00851000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704060100079002001300680#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#90#86#article#168#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif" >10. Bouch&eacute; O,
 Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Ars&egrave;ne D, Pait
el JF, Gu&eacute;rin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier
 P, Bedenne L, Milan C. Randomized multicenter phase II trial of a biweekly regi
men of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 pl
us irinotecan in patients with previously untreated metastatic gastric cancer: a
 Federation Francophone de Cancerologie Digestive Group Study -FFCD 9803. J Clin
 Oncol 2004; 22(21): 4319-28.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#91#87#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00389000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704013900079002001300218#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#92#88#article#168#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif" > 11. Boyle P, Levin 
B. World cancer report. IARC publications 2008.    ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#93#89#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00418000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704016800079002001300247#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#94#90#article#168#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif" >12. Brennan MF, Karp
eh MS Jr. Surgery for gastric cancer. Seminars in Oncology 1996;23(3):352-9.    
^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#95#91#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704016900079002001300248#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#96#92#article#168#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif" > 13. Bugat R: Irinot
ecan in the treatment of gastric cancer. Ann Oncol 2003; 14 Suppl 2: ii37-40.   
 ^cY#v24n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#97#93#article#168# </font></p>     ^c
Y#v24n1a16.htm##
00642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040700076002001300483#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#98#94#article#168#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif" >14. Cise&#322; B., Lewicka M., Jazi
enicki M., Mielko J., Kurylcio A.,Wierzbicki R., Budny W., Sokoluk M., Polkowski
 W. Results of perioperative chemotherapy and second look operation in patients 
with advanced initially inoperable gastric carcinoma. Poster 275, 8th Internatio
nal Gastric Cancer Congress, Abstract Book:170. </font></p>     ^cY#v24n1a16.htm
##
00618000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704036800079002001300447#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#99#95#article#168#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif" >15. Cunningham D, Al
lum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts
 FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perio
perative chemotherapy versus surgery alone for resectable gastroesophageal cance
r. N Engl J Med 2006; 355(1): 11-20.    ^cY#v24n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#100#96#article#168# </font></p>     ^
cY#v24n1a16.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704028200080002001300362#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#101#97#article#168#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif" >16. Cunningham D, S
tarling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J,
 Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N 
Engl J Med 2008; 358(1): 36-46.    ^cY#v24n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#102#98#article#168# </font></p>     ^
cY#v24n1a16.htm##
00703000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704045200080002001300532#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#103#99#article#168#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif" >17. Dank M, Zaluski
 J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K
, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluor
ouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemothera
py naive patients with advanced adenocarcinoma of the stomach or esophagogastric
 junction. Ann Oncol 2008; 19(8): 1450-7.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#104#100#article#168# </font></p>     
^cY#v24n1a16.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#105#101#article#168#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >18. Dent DM, Werne
r ID, Novis B, Cheverton P, Brice P: Prospective randomized trial of combined on
cological therapy for gastric carcinoma. Cancer 1979; 44(2): 385-91.    ^cY#v24n
1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#106#102#article#168# </font></p>     
^cY#v24n1a16.htm##
00622000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037000081002001300451#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#107#103#article#168#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >19. Eisenhauer EA,
 Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwy
ther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij 
J. New response evaluation criteria in solid tumors: revised Recist guideline(ve
rsion 1.1). Eur J Cancer 2009;45:228-47.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#108#104#article#168# </font></p>     
^cY#v24n1a16.htm##
00394000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014200081002001300223#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#109#105#article#168#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >20. Estimativa. In
cid&ecirc;ncia de C&acirc;ncer no Brasil. INCA 2010.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#110#106#article#168# </font></p>     
^cY#v24n1a16.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033800081002001300419#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#111#107#article#168#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >21. Fink U, Schuhm
acher C, Stein HJ, Busch R, Feussner H, Dittler HJ, Helmberger A, B&ouml;ttcher 
K, Siewert JR. Preoperative chemotherapy for stage III-IV gastric carcinoma: fea
sibility, response and outcome after complete resection. Br J Surg 1995; 82(9): 
1248-52.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#112#108#article#168# </font></p>     
^cY#v24n1a16.htm##
00614000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036200081002001300443#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#113#109#article#168#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >22. Gallardo-Rinco
n D, Onate-Ocana LF, Calderillo-Ruiz G: Neoadjuvant chemotherapy with P-ELF (cis
platin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in 
patients with initially unresectable gastric adenocarcinoma: a phase II study. A
nn Surg Oncol 2000; 7(1): 45-50.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#114#110#article#168# </font></p>     
^cY#v24n1a16.htm##
00629000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037700081002001300458#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#115#111#article#168#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >23. Glimelius B, E
kstr&ouml;m K, Hoffman K, Graf W, Sj&ouml;d&eacute;n PO, Haglund U, Svensson C, 
Enander LK, Linn&eacute; T, Sellstr&ouml;m H, Heuman R. Randomized comparison be
tween chemotherapy plus best supportive care with best supportive care in advanc
ed gastric cancer. Ann Oncol 1997; 8(2): 163-8.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#116#112#article#168# </font></p>     
^cY#v24n1a16.htm##
00444000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019200081002001300273#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#117#113#article#168#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >24. Hermanek P, Wi
ttekind C. The pathologist and the residual tumor(R) classification. Pathol Res 
Pract 1994;190:115-23.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#118#114#article#168# </font></p>     
^cY#v24n1a16.htm##
00598000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034600081002001300427#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#119#115#article#168#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >25. Ishigami S, Na
tsugoe S, Nakajo A, Matsumoto M, Uenosono Y, Arigami T, Setoyama T, Arima H, Uch
ikado A, Kita Y, Sasaki K, Aikou T. Salvage gastrectomy following a combination 
of biweekly paclitaxel and S-1 for stage IV gastric cancer. J Gastrointest Surg 
2008;12:1370-75.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#120#116#article#168# </font></p>     
^cY#v24n1a16.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025900081002001300340#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#121#117#article#168#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >26. Karnofsky DA, 
Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: 
MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press, 194
9 P. 196.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#122#118#article#168# </font></p>     
^cY#v24n1a16.htm##
00660000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704040800081002001300489#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#123#119#article#168#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >27. Kelsen D, Karp
eh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y,
 Saltz L, Quan V, Brennan M. Neoadjuvant therapy of high-risk gastric cancer: a 
phase II trial of preoperative FAMTX and postoperative intraperitoneal fluoroura
cilcisplatin plus intravenous fluorouracil. J Clin Oncol 1996; 14(6): 1818-28.  
  ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#124#120#article#168# </font></p>     
^cY#v24n1a16.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026300081002001300344#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#125#121#article#168#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >28. Kingston RD, E
llis DJ, Powell J, Brookes VS, Waterhouse JA, Hurst MD, Smith JA. The West Midla
nds gastric carcinoma chemotherapy trial: planning and results. Clin Oncol 1978;
 4(1): 55-69.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#126#122#article#168# </font></p>     
^cY#v24n1a16.htm##
00668000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704041600081002001300497#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#127#123#article#168#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >29. Koizumi W, Nar
ahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobaya
shi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Ta
keuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanc
ed gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9(3): 2
15-21.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#128#124#article#168# </font></p>     
^cY#v24n1a16.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022000081002001300301#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#129#125#article#168#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >30. Oken MM, Creec
h RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncol
ogy Group. Am. J. Clin. Oncol. 1982;5 (6): 649-55.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#130#126#article#168# </font></p>     
^cY#v24n1a16.htm##
00718000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704046600081002001300547#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#131#127#article#168#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >31. Petrelli NJ, W
iner EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, 
Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D
, Ganz PA, Kramer B. Clinical Cancer Advances 2009: major research advances in c
ancer treatment, prevention, and screening--a report from the American Society o
f Clinical Oncology. J Clin Oncol 2009; 27(35): 6052-69.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#132#128#article#168# </font></p>     
^cY#v24n1a16.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#133#129#article#168#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >32. Plukker JT, Mu
lder NH, Sleijfer DT, Grond J, Verschueren RC: Chemotherapy and surgery for loca
lly advanced cancer of the cardia and fundus: phase II study with methotrexate a
nd 5-fluorouracil. Br J Surg 1991; 78(8): 955-8.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#134#130#article#168# </font></p>     
^cY#v24n1a16.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#135#131#article#168#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >33. Rake MO, Malli
nson CN, Cocking JB, Cwynarski MT, Fox CA, Wass VJ, Diffey BL, Jackson GA. Chemo
therapy in advanced gastric cancer: a controlled, prospective, randomised multi-
centre study. Gut 1979; 20(9): 797-801.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#136#132#article#168# </font></p>     
^cY#v24n1a16.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023200081002001300313#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#137#133#article#168#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >34. Saidi RF,  ReM
ine SG, Dudrick PS, Hanna NN. Is There a Role for Palliative Gastrectomy in Pati
ents with Stage IV Gastric Cancer? World J Surg 2006;30:21-27.    ^cY#v24n1a16.h
tm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#138#134#article#168# </font></p>     
^cY#v24n1a16.htm##
00596000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034400081002001300425#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#139#135#article#168#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >35. Schuhmacher CP
, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, Siewert JR. Neoadjuvant ther
apy for patients with locally advanced gastric carcinoma with etoposide, doxorub
icin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001; 
91(5): 918-27.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#140#136#article#168# </font></p>     
^cY#v24n1a16.htm##
00582000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033000081002001300411#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#141#137#article#168#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >36. Szczepanik A, 
Kolodziejczyk P, Drabik G, Bucki K, Milanowski W. Cancer cells in bone marrow of
 gastric cancer patients during follow-up after radical resection -preliminary r
eport. Poster 129, 8th International Gastric Cancer Congress, Abstract Book:134.
    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#142#138#article#168# </font></p>     
^cY#v24n1a16.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030700081002001300388#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#143#139#article#168#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >37. Triazinate and
 platinum efficacy in combination with 5-fluorouracil and doxorubicin: results o
f a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tu
mor Study Group. J Natl Cancer Inst 1988; 80(13): 1011-5.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#144#140#article#168# </font></p>     
^cY#v24n1a16.htm##
00683000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704043100081002001300512#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#145#141#article#168#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >38. Tsujinaka T, F
ujitani K, Yang H, Kurokawa Y, Park B, Fukuda H, Noh S, Boku N, Bang Y, Sasako M
, Lee J. A randomized controlled trial comparing gastrectomy plus Chemotherapy w
ith chemotherapy alone in advanced gastric cancer with a single  non-curable fac
tor: JCOG 0705 and KGCA01. Abstract S64, 8th International Gastric Cancer Congre
ss, Abstract Book:32.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#146#142#article#168# </font></p>     
^cY#v24n1a16.htm##
00626000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037400081002001300455#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#147#143#article#168#39#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >39. Uenosono Y., A
rigami T., Kozono T., Yanagita S., Hirata M., Arima H., Ishigami S., Aikou T., N
atsugoe S. Circulating tumor cells in blood detected by CellSearch System are pr
edictive factor of recurrences in gastric cancer. Abstract S57, 8th Internationa
l Gastric Cancer Congress, Abstract Book:30.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#148#144#article#168# </font></p>     
^cY#v24n1a16.htm##
00682000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704043000081002001300511#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#149#145#article#168#40#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >40. Van Cutsem E, 
Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M,
 Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplati
n plus fluorouracil compared with cisplatin and fluorouracil as first-line thera
py for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2
006; 24(31): 4991-7.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#150#146#article#168# </font></p>     
^cY#v24n1a16.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#151#147#article#168#41#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >41. Wagner AD, Gro
the W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastr
ic cancer: a systematic review and meta-analysis based on aggregate data. J Clin
 Oncol 2006; 24(18): 2903-9.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#152#148#article#168# </font></p>     
^cY#v24n1a16.htm##
00604000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035200081002001300433#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#153#149#article#168#42#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >42. Wilke H, Preus
ser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, K
nipp H. Preoperative chemotherapy in locally advanced and nonresectable gastric 
cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Onco
l 1989; 7(9): 1318-26.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#154#150#article#168# </font></p>     
^cY#v24n1a16.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019300081002001300274#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#155#151#article#168#43#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >43. Wittekind C, C
ompton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Can
cer 2002;94(9):2511-16.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#156#152#article#168# </font></p>     
^cY#v24n1a16.htm##
00574000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032200081002001300403#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#157#153#article#168#44#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >44. Yano M, Shioza
ki H Inoue M, Tamura S, Doki Y,Yasuda T, Fujiwara Y, Tsujinaka T, Monden M. Neoa
djuvant Chemotherapy followed by Salvage Surgery: Effect on survival of patients
 with primary noncurative gastric cancer. World J Surg 2002; 26:1155-59.    ^cY#
v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#158#154#article#168# </font></p>     
^cY#v24n1a16.htm##
00434000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018200081002001300263#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#159#155#article#168#45#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif" >45. Xu RH, Teng KY
: Progress in chemotherapy for advanced gastric cancer. Chin J Cancer 2009; 28(1
0): 1108-13.    ^cY#v24n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#160#156#article#168# </font></p>     
^cY#v24n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#161#157#article#168#<p>&nbsp;</p>    
 ^cY#v24n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#162#158#article#168#<p>&nbsp;</p>    
 ^cY#v24n1a16.htm##
00438000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704020100078002001300279#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#163#159#article#168#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif" ><a name="note2"></a><b><a href="#
note1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0" ></a> Correspond&
ecirc;ncia:</b>     ^cY#v24n1a16.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#164#160#article#168#<br>Fernando de O
liveira Souza    ^cY#v24n1a16.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009600078002001300174#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#165#161#article#168#<br> e-mail: <a h
ref="mailto:geruzabaima@hotmail.com">fsouza@via-rs.net </a></font></p>     ^cY#v
24n1a16.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012200078002001300200#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#166#162#article#168#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif" >Recebido para publica&ccedil;&ati
lde;o: 27/07/2010    ^cY#v24n1a16.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#167#163#article#168#<br> Aceito para 
publica&ccedil;&atilde;o: 25/01/2011    ^cY#v24n1a16.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005600078002001300134#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#168#164#article#168#<br>Fonte de fina
nciamento: n&atilde;o h&aacute;    ^cY#v24n1a16.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007000078002001300148#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#169#165#article#168#<br> Conflito de 
interesses: n&atilde;o h&aacute; </font></p>     ^cY#v24n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#170#166#article#168#<p>&nbsp;</p>    
 ^cY#v24n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#171#167#article#168#<p>&nbsp;</p>    
 ^cY#v24n1a16.htm##
00511000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704027400078002001300352#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#p#172#168#article#168#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif" >Trabalho realizado no Departament
o de Cirurgia e Servi&ccedil;o de Oncologia e Radioterapia do Hospital Universit
&aacute;rio da Universidade Federal de Santa Maria, Santa Maria, RS, Brasil. </f
ont></p>     ^cY#v24n1a16.htm##
00457000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770180022000950630
00200117066001700119062000900136062002200145065000900167064000500176865000900181
002001300190#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#173#1#art
icle#45#1#^rND^sAbeloff^nMD#Clinical oncology^len#3#Philadelphia^ePa#Elsevier#Ch
urchill Livingstone#20040000#2004#20110300#v24n1a16.htm##
00858000000000397000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100020000930100
01600113010001800129010001400147010001500161010001600176010001700192010001900209
01000160022801000140024401201150025803000130037306500090038606400070039503100030
0402032000200405014000800407865000900415002001300424035001000437801001300447#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#174#2#article#45#2#^rND^s
Ajani^nJA#^rND^sMansfield^nPF#^rND^sLynch^nPM#^rND^sPisters^nPW#^rND^sFeig^nB#^r
ND^sDumas^nP#^rND^sEvans^nDB#^rND^sRaijman^nI#^rND^sHargraves^nK#^rND^sCurley^nS
#^rND^sOta^nDM#Enhanced staging and all chemotherapy preoperatively in patients 
with potentially resectable gastric carcinoma^len#J Clin Oncol#19990800#199908#1
7#8#2403-11#20110300#v24n1a16.htm#0732-183X#J Clin Oncol##
00747000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01500108010001400123010001400137010001500151010001800166010001500184012010000199
03000130029906500090031206400050032103100030032603200030032901400080033286500090
0340002001300349035001000362801001300372#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a16.htm#S#c#175#3#article#45#3#^rND^sAjani^nJA#^rND^sFaust^nJ#^rND^sIkeda
^nK#^rND^sYao^nJC#^rND^sAnbe^nH#^rND^sCarr^nKL#^rND^sHoughton^nM#^rND^sUrrea^nP#
Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced ga
stric carcinoma^len#J Clin Oncol#20050000#2005#23#28#6957-65#20110300#v24n1a16.h
tm#0732-183X#J Clin Oncol##
00995000000000409000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100021000930100
01900114010001600133010001900149010001400168010001900182010001500201010001400216
01000160023001000190024601000200026501202150028503000130050006500090051306400050
05220310003005270320003005300140007005338650009005400020013005490350010005628010
01300572#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#176#4#article
#45#4#^rND^sAjani^nJA#^rND^sMoiseyenko^nVM#^rND^sTjulandin^nS#^rND^sMajlis^nA#^r
ND^sConstenla^nM#^rND^sBoni^nC#^rND^sRodrigues^nA#^rND^sFodor^nM#^rND^sChao^nY#^
rND^sVoznyi^nE#^rND^sMarabotti^nC#^rND^sVan Cutsem^nE#Clinical benefit with doce
taxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil i
n a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinom
a: the V-325 Study Group^len#J Clin Oncol#20070000#2007#25#22#3205-9#20110300#v2
4n1a16.htm#0732-183X#J Clin Oncol##
00985000000000409000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100021000930100
01900114010001600133010001900149010001400168010001900182010001500201010001400216
01000160023001000140024601000200026001202100028003000130049006500090050306400050
05120310003005170320003005200140007005238650009005300020013005390350010005528010
01300562#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#177#5#article
#45#5#^rND^sAjani^nJA#^rND^sMoiseyenko^nVM#^rND^sTjulandin^nS#^rND^sMajlis^nA#^r
ND^sConstenla^nM#^rND^sBoni^nC#^rND^sRodrigues^nA#^rND^sFodor^nM#^rND^sChao^nY#^
rND^sVoznyi^nE#^rND^sAwad^nL#^rND^sVan Cutsem^nE#Quality of life with docetaxel 
plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a 
phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-3
25 Study Group^len#J Clin Oncol#20070000#2007#25#22#3210-6#20110300#v24n1a16.htm
#0732-183X#J Clin Oncol##
00897000000000385000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01600112010002000128010002100148010001900169010002100188010001500209010001400224
01000160023801201720025403000130042606500090043906400050044803100030045303200020
0456014000800458865000900466002001300475035001000488801001300498#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#178#6#article#45#6#^rND^sAjani^nJA#^r
ND^sRodriguez^nW#^rND^sBodoky^nG#^rND^sMoiseyenko^nV#^rND^sLichinitser^nM#^rND^s
Gorbunova^nV#^rND^sVynnychenko^nI#^rND^sGarin^nA#^rND^sLang^nI#^rND^sFalcon^nS#M
ulticenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/ Infusional Fluo
rouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS
 Trial^len#J Clin Oncol#20100000#2010#28#9#1547-53#20110300#v24n1a16.htm#0732-18
3X#J Clin Oncol##
01228000000000505000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100019000970100
01600116010002200132010002000154010001800174010001900192010001700211010001600228
01000170024401000160026101000220027701000170029901000260031601000190034201000170
03610100016003780100019003940100015004130100015004280120194004430300013006370650
00900650064000500659031000300664032000200667014000800669865000900677002001300686
035001000699801001300709#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S
#c#179#7#article#45#7#^rND^sAl-Batran^nSE#^rND^sHartmann^nJT#^rND^sProbst^nS#^rN
D^sSchmalenberg^nH#^rND^sHollerbach^nS#^rND^sHofheinz^nR#^rND^sRethwisch^nV#^rND
^sSeipelt^nG#^rND^sHomann^nN#^rND^sWilhelm^nG#^rND^sSchuch^nG#^rND^sStoehlmacher
^nJ#^rND^sDerigs^nHG#^rND^sHegewisch-Becker^nS#^rND^sGrossmann^nJ#^rND^sPauligk^
nC#^rND^sAtmaca^nA#^rND^sBokemeyer^nC#^rND^sKnuth^nA#^rND^sJäger^nE#Phase III tr
ial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin 
plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Interni
stische Onkologie^len#J Clin Oncol#20080000#2008#26#9#1435-42#20110300#v24n1a16.
htm#0732-183X#J Clin Oncol##
00606000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100018000920100
01700110010002100127012010600148030001500254710000200269065000900271064000500280
031000300285014000600288865000900294002001300303#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a16.htm#S#c#180#8#article#45#8#^rND^sAllum^nW#^rND^sGarofalo^nA#^
rND^sDegiuli^nM#^rND^sSchuhmacher^nC#The first european union network of excelle
nce for gastric cancer conference, Rome, Italy, april 2008^len#Gastric Cancer#2#
20090000#2009#12#56-65#20110300#v24n1a16.htm##
00863000000000397000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100018000910100
01600109010001600125010001300141010001600154010001700170010001500187010001900202
01000180022101000140023901000150025301201330026803000130040171000020041406500090
0416064000500425031000300430032000300433014000700436865000900443002001300452#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#181#9#article#45#9#^rND^s
Boku^nN#^rND^sYamamoto^nS#^rND^sFukuda^nH#^rND^sShirao^nK#^rND^sDoi^nT#^rND^sSaw
aki^nA#^rND^sKoizumi^nW#^rND^sSaito^nH#^rND^sYamaguchi^nK#^rND^sTakiuchi^nH#^rND
^sNasu^nJ#^rND^sOhtsu^nA#Fluorouracil versus combination of irinotecan plus cisp
latin versus S-1 in metastatic gastric cancer: a randomised phase 3 study^len#La
ncet Oncol#2#20090000#2009#10#11#1063-9#20110300#v24n1a16.htm##
01191000000000457000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01900111010002000130010001800150010001500168010001600183010001700199010002200216
01000150023801000170025301000190027001000160028901000170030501000170032201000150
03390120293003540300013006470650009006600640005006690310003006740320003006770140
00800680865000900688002001300697035001000710801001300720#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a16.htm#S#c#182#10#article#45#10#^rND^sBouché^nO#^rND^sRa
oul^nJL#^rND^sBonnetain^nF#^rND^sGiovannini^nM#^rND^sEtienne^nPL#^rND^sLledo^nG#
^rND^sArsène^nD#^rND^sPaitel^nJF#^rND^sGuérin-Meyer^nV#^rND^sMitry^nE#^rND^sBuec
her^nB#^rND^sKaminsky^nMC#^rND^sSeitz^nJF#^rND^sRougier^nP#^rND^sBedenne^nL#^rND
^sMilan^nC#Randomized multicenter phase II trial of a biweekly regimen of fluoro
uracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan
 in patients with previously untreated metastatic gastric cancer: a Federation F
rancophone de Cancerologie Digestive Group Study -FFCD 9803^len#J Clin Oncol#200
40000#2004#22#21#4319-28#20110300#v24n1a16.htm#0732-183X#J Clin Oncol##
00418000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160015000790160016000940180
02400110062001800134065000900152064000500161865000900166002001300175#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#183#11#article#45#11#^rND^sBoyle^
nP#^rND^sLevin^nB.#World cancer report^len#IARC publications#20080000#2008#20110
300#v24n1a16.htm##
00537000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970120
03100117030002100148065000900169064000500178031000300183032000200186014000600188
865000900194002001300203035001000216801002100226#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a16.htm#S#c#184#12#article#45#12#^rND^sBrennan^nMF#^rND^sKarpeh J
r^nMS#Surgery for gastric cancer^len#Seminars in Oncology#19960000#1996#23#3#352
-9#20110300#v24n1a16.htm#0093-7754#Seminars in oncology##
00503000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120050000940300
01000144065000900154064000500163031000300168032000400171014000800175865000900183
002001300192035001000205801001000215#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a16.htm#S#c#185#13#article#45#13#^rND^sBugat^nR#Irinotecan in the treatment o
f gastric cancer^len#Ann Oncol#20030000#2003#14#^s2#ii37-40#20110300#v24n1a16.ht
m#0923-7534#Ann Oncol##
00779000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160018000950160
02100113016001700134016001900151016002100170016001600191016001800207016002000225
018013300245053004700378062001400425014000400439865000900443002001300452#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#186#14#article#45#14#^rND^sCi
sel^nB.#^rND^sLewicka^nM.#^rND^sJazienicki^nM.#^rND^sMielko^nJ.#^rND^sKurylcio^n
A.#^rND^sWierzbicki^nR.#^rND^sBudny^nW.#^rND^sSokoluk^nM.#^rND^sPolkowski^nW.#Re
sults of perioperative chemotherapy and second look operation in patients with a
dvanced initially inoperable gastric carcinoma^len#International Gastric Cancer 
Congress^n8^i1^i1#Abstract Book#170#20110300#v24n1a16.htm##
00972000000000445000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
01900115010001900134010002400153010001900177010001900196010001700215010001600232
01000180024801000170026601000190028301000160030201000170031801000160033501200910
03510300013004420650009004550640005004640310004004690320002004730140006004758650
00900481002001300490035001000503801001300513#v24n1#V:\SciELO\serial\abcd\v24n1\m
arkup\v24n1a16.htm#S#c#187#15#article#45#15#^rND^sCunningham^nD#^rND^sAllum^nWH#
^rND^sStenning^nSP#^rND^sThompson^nJN#^rND^sVan de Velde^nCJ.#^rND^sNicolson^nM.
#^rND^sScarffe^nJH.#^rND^sLofts^nFJ.#^rND^sFalk^nSJ.#^rND^sIveson^nTJ.#^rND^sSmi
th^nDB.#^rND^sLangley^nRE.#^rND^sVerma^nM.#^rND^sWeeden^nS.#^rND^sChua^nYJ.#Peri
operative chemotherapy versus surgery alone for resectable gastroesophageal canc
er^len#N Engl J Med#20060000#2006#355#1#11-20#20110300#v24n1a16.htm#0028-4793#N 
Engl J Med##
00785000000000385000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
01300117010001600130010001800146010001500164010001900179010001600198010001500214
01000170022901200690024603000130031506500090032806400050033703100040034203200020
0346014000600348865000900354002001300363035001000376801001300386#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#188#16#article#45#16#^rND^sCunningham
^nD#^rND^sStarling^nN#^rND^sRao^nS#^rND^sIveson^nT#^rND^sNicolson^nM#^rND^sCoxon
^nF#^rND^sMiddleton^nG#^rND^sDaniel^nF#^rND^sOates^nJ#^rND^sNorman^nAR#Capecitab
ine and oxaliplatin for advanced esophagogastric cancer^len#N Engl J Med#2008000
0#2008#358#1#36-46#20110300#v24n1a16.htm#0028-4793#N Engl J Med##
00970000000000397000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01600110010001700126010001600143010001700159010001600176010001500192010001500207
01000140022201000150023601202430025103000100049406500090050406400050051303100030
0518032000200521014000700523865000900530002001300539035001000552801001000562#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#189#17#article#45#17#^rND
^sDank^nM#^rND^sZaluski^nJ#^rND^sBarone^nC#^rND^sValvere^nV#^rND^sYalcin^nS#^rND
^sPeschel^nC#^rND^sWenczl^nM#^rND^sGoker^nE#^rND^sCisar^nL#^rND^sWang^nK#^rND^sB
ugat^nR#Randomized phase III study comparing irinotecan combined with 5-fluorour
acil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy 
naive patients with advanced adenocarcinoma of the stomach or esophagogastric ju
nction^len#Ann Oncol#20080000#2008#19#8#1450-7#20110300#v24n1a16.htm#0923-7534#A
nn Oncol##
00645000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01500111010001900126010001500145012008700160030000700247065000900254064000500263
03100030026803200020027101400070027386500090028000200130028903500100030280100070
0312#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#190#18#article#45
#18#^rND^sDent^nDM#^rND^sWerner^nID#^rND^sNovis^nB#^rND^sCheverton^nP#^rND^sBric
e^nP#Prospective randomized trial of combined oncological therapy for gastric ca
rcinoma^len#Cancer#19790000#1979#44#2#385-91#20110300#v24n1a16.htm#0008-543X#Can
cer##
00972000000000445000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100018001000100
01800118010001900136010001700155010001400172010001600186010001600202010001700218
01000160023501000200025101000170027101000140028801000160030201000170031801000170
03350120092003520300013004440650009004570640005004660310003004710140007004748650
00900481002001300490035001000503801001300513#v24n1#V:\SciELO\serial\abcd\v24n1\m
arkup\v24n1a16.htm#S#c#191#19#article#45#19#^rND^sEisenhauer^nEA#^rND^sTherasse^
nP#^rND^sBogaerts^nJ#^rND^sSchwartz^nLH#^rND^sSargent^nD#^rND^sFord^nR#^rND^sDan
cey^nJ#^rND^sArbuck^nS#^rND^sGwyther^nS#^rND^sMooney^nM#^rND^sRubinstein^nL#^rND
^sShankar^nL#^rND^sDodd^nL#^rND^sKaplan^nR#^rND^sLacombe^nD#^rND^sVerweij^nJ#New
 response evaluation criteria in solid tumors: revised Recist guideline(version 
1.1)^len#Eur J Cancer#20090000#2009#45#228-47#20110300#v24n1a16.htm#0014-2964#Eu
r J Cancer##
00373000000000205000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180047000790620005001260650
00900131064000500140865000900145002001300154#v24n1#V:\SciELO\serial\abcd\v24n1\m
arkup\v24n1a16.htm#S#c#192#20#article#45#20#Estimativa: Incidência de Câncer no 
Brasil^lpt#INCA#20100000#2010#20110300#v24n1a16.htm##
00815000000000373000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100021000930100
01600114010001500130010001800145010001800163010002000181010001800201010001800219
01201250023703000100036206500090037206400050038103100030038603200020038901400080
0391865000900399002001300408035001000421801001000431#v24n1#V:\SciELO\serial\abcd
\v24n1\markup\v24n1a16.htm#S#c#193#21#article#45#21#^rND^sFink^nU#^rND^sSchuhmac
her^nC#^rND^sStein^nHJ#^rND^sBusch^nR#^rND^sFeussner^nH#^rND^sDittler^nHJ#^rND^s
Helmberger^nA#^rND^sBöttcher^nK#^rND^sSiewert^nJR#Preoperative chemotherapy for 
stage III-IV gastric carcinoma: feasibility, response and outcome after complete
 resection^len#Br J Surg#19950000#1995#82#9#1248-52#20110300#v24n1a16.htm#0007-1
323#Br J Surg##
00690000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790100022001040100
02500126012015100151030001500302065000900317064000500326031000200331032000200333
014000600335865000900341002001300350035001000363801001500373#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a16.htm#S#c#194#22#article#45#22#^rND^sGallardo-Rinco
n^nD#^rND^sOnate-Ocana^nLF#^rND^sCalderillo-Ruiz^nG#Neoadjuvant chemotherapy wit
h P-ELF followed by radical resection in patients with initially unresectable ga
stric adenocarcinoma: a phase II study^len#Ann Surg Oncol#20000000#2000#7#1#45-5
0#20110300#v24n1a16.htm#1068-9265#Ann Surg Oncol##
00866000000000397000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001400132010001700146010001700163010001800180010001800198010001500216
01000190023101000160025001201260026603000100039206500090040206400050041103100020
0416032000200418014000600420865000900426002001300435035001000448801001000458#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#195#23#article#45#23#^rND
^sGlimelius^nB#^rND^sEkström^nK#^rND^sHoffman^nK#^rND^sGraf^nW#^rND^sSjödén^nPO#
^rND^sHaglund^nU#^rND^sSvensson^nC#^rND^sEnander^nLK#^rND^sLinné^nT#^rND^sSellst
röm^nH#^rND^sHeuman^nR#Randomized comparison between chemotherapy plus best supp
ortive care with best supportive care in advanced gastric cancer^len#Ann Oncol#1
9970000#1997#8#2#163-8#20110300#v24n1a16.htm#0923-7534#Ann Oncol##
00546000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970120
06100116030001700177065000900194064000500203031000400208014000700212865000900219
002001300228035001000241801001700251#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a16.htm#S#c#196#24#article#45#24#^rND^sHermanek^nP#^rND^sWittekind^nC#The pat
hologist and the residual tumor(R) classification^len#Pathol Res Pract#19940000#
1994#190#115-23#20110300#v24n1a16.htm#0344-0338#Pathol Res Pract##
00883000000000397000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01600115010001900131010001800150010001700168010001800185010001500203010001800218
01000140023601000160025001000150026601201070028103000200038806500090040806400050
0417031000300422014000800425865000900433002001300442035001000455801002000465#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#197#25#article#45#25#^rND
^sIshigami^nS#^rND^sNatsugoe^nS#^rND^sNakajo^nA#^rND^sMatsumoto^nM#^rND^sUenoson
o^nY#^rND^sArigami^nT#^rND^sSetoyama^nT#^rND^sArima^nH#^rND^sUchikado^nA#^rND^sK
ita^nY#^rND^sSasaki^nK#^rND^sAikou^nT#Salvage gastrectomy following a combinatio
n of biweekly paclitaxel and S-1 for stage IV gastric cancer^len#J Gastrointest 
Surg#20080000#2008#12#1370-75#20110300#v24n1a16.htm#1091-255X#J Gastrointest Sur
g##
00571000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100021000990120
06500120016001800185018004200203062002000245065000900265064000500274014000400279
865000900283002001300292#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S
#c#198#26#article#45#26#^rND^sKarnofsky^nDA#^rND^sBurchenal^nJH.#The clinical ev
aluation of chemotherapeutic agents in cancer^len#^rED^sMacLeod^nCM#Evaluation o
f Chemotherapeutic Agents^len#Columbia Univ Press#19490000#1949#196#20110300#v24
n1a16.htm##
00947000000000409000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01800111010001600129010001900145010001500164010001600179010001800195010001500213
01000150022801000140024301000170025701201780027403000130045206500090046506400050
04740310003004790320002004820140008004848650009004920020013005010350010005148010
01300524#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#199#27#articl
e#45#27#^rND^sKelsen^nD#^rND^sKarpeh^nM#^rND^sSchwartz^nG#^rND^sGerdes^nH#^rND^s
Lightdale^nC#^rND^sBotet^nJ#^rND^sLauers^nG#^rND^sKlimstra^nD#^rND^sHuang^nY#^rN
D^sSaltz^nL#^rND^sQuan^nV#^rND^sBrennan^nM#Neoadjuvant therapy of high-risk gast
ric cancer: a phase II trial of preoperative FAMTX and postoperative intraperito
neal fluorouracilcisplatin plus intravenous fluorouracil^len#J Clin Oncol#199600
00#1996#14#6#1818-28#20110300#v24n1a16.htm#0732-183X#J Clin Oncol##
00710000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01600114010001800130010002100148010001600169010001600185012008100201030001100282
06500090029306400050030203100020030703200020030901400060031186500090031700200130
0326035001000339801001100349#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.h
tm#S#c#200#28#article#45#28#^rND^sKingston^nRD#^rND^sEllis^nDJ#^rND^sPowell^nJ#^
rND^sBrookes^nVS#^rND^sWaterhouse^nJA#^rND^sHurst^nMD#^rND^sSmith^nJA#The West M
idlands gastric carcinoma chemotherapy trial: planning and results^len#Clin Onco
l#19780000#1978#4#1#55-69#20110300#v24n1a16.htm#0305-7399#Clin Oncol##
01012000000000457000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01400114010001800128010001500146010001600161010001900177010001900196010001900215
01000180023401000130025201000160026501000160028101000180029701000170031501000150
03320100018003470120127003650300013004927100002005050650009005070640005005160310
00200521032000200523014000700525865000900532002001300541#v24n1#V:\SciELO\serial\
abcd\v24n1\markup\v24n1a16.htm#S#c#201#29#article#45#29#^rND^sKoizumi^nW#^rND^sN
arahara^nH#^rND^sHara^nT#^rND^sTakagane^nA#^rND^sAkiya^nT#^rND^sTakagi^nM#^rND^s
Miyashita^nK#^rND^sNishizaki^nT#^rND^sKobayashi^nO#^rND^sTakiyama^nW#^rND^sToh^n
Y#^rND^sNagaie^nT#^rND^sTakagi^nS#^rND^sYamamura^nY#^rND^sYanaoka^nK#^rND^sOrita
^nH#^rND^sTakeuchi^nM#S-1 plus cisplatin versus S-1 alone for first-line treatme
nt of advanced gastric cancer (SPIRITS trial): a phase III trial^len#Lancet Onco
l#2#20080000#2008#9#3#215-21#20110300#v24n1a16.htm##
00562000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01700111012007700128030001800205710000200223065000900225064000500234031000200239
032000200241014000700243865000900250002001300259#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a16.htm#S#c#202#30#article#45#30#^rND^sOken^nMM#^rND^sCreech^nRH#
^rND^sTormey^nDC#Toxicity and response criteria of the Eastern Cooperative Oncol
ogy Group^len#Am. J. Clin Oncol#2#19820000#1982#5#6#649-55#20110300#v24n1a16.htm
##
01114000000000481000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01700114010001500131010001500146010001600161010001700177010001400194010001900208
01000170022701000210024401000170026501000150028201000200029701000160031701000180
03330100015003510100017003660120163003830300013005460650009005590640005005680310
00300573032000300576014000800579865000900587002001300596035001000609801001300619
#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#203#31#article#45#31#
^rND^sPetrelli^nNJ#^rND^sWiner^nEP#^rND^sBrahmer^nJ#^rND^sDubey^nS#^rND^sSmith^n
S#^rND^sThomas^nC#^rND^sVahdat^nLT#^rND^sObel^nJ#^rND^sVogelzang^nN#^rND^sMarkma
n^nM#^rND^sSweetenham^nJW#^rND^sPfister^nD#^rND^sKris^nMG#^rND^sSchuchter^nLM#^r
ND^sSawaya^nR#^rND^sRaghavan^nD#^rND^sGanz^nPA#^rND^sKramer^nB.#Clinical Cancer 
Advances 2009: major research advances in cancer treatment, prevention, and scre
ening--a report from the American Society of Clinical Oncology^len#J Clin Oncol#
20090000#2009#27#35#6052-69#20110300#v24n1a16.htm#0732-183X#J Clin Oncol##
00708000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01900114010001500133010002200148012013500170030001000305065000900315064000500324
03100030032903200020033201400060033486500090034000200130034903500100036280100100
0372#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#204#32#article#45
#32#^rND^sPlukker^nJT#^rND^sMulder^nNH#^rND^sSleijfer^nDT#^rND^sGrond^nJ#^rND^sV
erschueren^nRC#Chemotherapy and surgery for locally advanced cancer of the cardi
a and fundus: phase II study with methotrexate and 5-fluorouracil^len#Br J Surg#
19910000#1991#78#8#955-8#20110300#v24n1a16.htm#0007-1323#Br J Surg##
00747000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
01800114010002000132010001400152010001500166010001700181010001800198012010200216
03000040031806500090032206400050033103100030033603200020033901400080034186500090
0349002001300358035001000371801000400381#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a16.htm#S#c#205#33#article#45#33#^rND^sRake^nMO#^rND^sMallinson^nCN#^rND^
sCocking^nJB#^rND^sCwynarski^nMT#^rND^sFox^nCA#^rND^sWass^nVJ#^rND^sDiffey^nBL#^
rND^sJackson^nGA#Chemotherapy in advanced gastric cancer: a controlled, prospect
ive, randomised multi-centre study^len#Gut#19790000#1979#20#9#797-801#20110300#v
24n1a16.htm#0017-5749#Gut##
00617000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01800112010001600130012008800146030001300234065000900247064000500256031000300261
014000600264865000900270002001300279035001000292801001300302#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a16.htm#S#c#206#34#article#45#34#^rND^sSaidi^nRF#^rND
^sReMine^nSG#^rND^sDudrick^nPS#^rND^sHanna^nNN#Is There a Role for Palliative Ga
strectomy in Patients with Stage IV Gastric Cancer^len#World J Surg#20060000#200
6#30#21-27#20110300#v24n1a16.htm#0364-2313#World J Surg##
00787000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100014001010100
01600115010001500131010001800146010001700164010001800181012016600199030000700365
06500090037206400050038103100030038603200020038901400070039186500090039800200130
0407035001000420801000700430#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.h
tm#S#c#207#35#article#45#35#^rND^sSchuhmacher^nCP#^rND^sFink^nU#^rND^sBecker^nK#
^rND^sBusch^nR#^rND^sDittler^nHJ#^rND^sMueller^nJ#^rND^sSiewert^nJR#Neoadjuvant 
therapy for patients with locally advanced gastric carcinoma with etoposide, dox
orubicin, and cisplatinum: Closing results after 5 years of follow-up^len#Cancer
#20010000#2001#91#5#918-27#20110300#v24n1a16.htm#0008-543X#Cancer##
00647000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160020000790160023000990160
01600122016001500138016002100153018012000174053004700294062001400341014000400355
865000900359002001300368#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S
#c#208#36#article#45#36#^rND^sSzczepanik^nA#^rND^sKolodziejczyk^nP#^rND^sDrabik^
nG#^rND^sBucki^nK#^rND^sMilanowski^nW.#Cancer cells in bone marrow of gastric ca
ncer patients during follow-up after radical resection -preliminary report^len#I
nternational Gastric Cancer Congress^n8^i1^i1#Abstract Book#134#20110300#v24n1a1
6.htm##
00636000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760120194000790300019002730650
00900292064000500301031000300306032000300309014000700312865000900319002001300328
035001000341801001900351#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S
#c#209#37#article#45#37#Triazinate and platinum efficacy in combination with 5-f
luorouracil and doxorubicin: results of a three-arm randomized trial in metastat
ic gastric cancer. Gastrointestinal Tumor Study Group^len#J Natl Cancer Inst#198
80000#1988#80#13#1011-5#20110300#v24n1a16.htm#0027-8874#J Natl Cancer Inst##
00853000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790160018000980160
01400116016001800130016001400148016001600162016001300178016001400191016001400205
01600160021901600140023501801800024905300470042906200140047601400030049086500090
0493002001300502#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#210#3
8#article#45#38#^rND^sTsujinaka^nT#^rND^sFujitani^nK#^rND^sYang^nH#^rND^sKurokaw
a^nY#^rND^sPark^nB#^rND^sFukuda^nH#^rND^sNoh^nS#^rND^sBoku^nN#^rND^sBang^nY#^rND
^sSasako^nM#^rND^sLee^nJ.#A randomized controlled trial comparing gastrectomy pl
us Chemotherapy with chemotherapy alone in advanced gastric cancer with a single
 non-curable factor: JCOG 0705 and KGCA01^len#International Gastric Cancer Congr
ess^n8^i1^i1#Abstract Book#32#20110300#v24n1a16.htm##
00761000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790160018000980160
01700116016001900133016001700152016001600169016001900185016001600204016001900220
018012200239053004700361062001400408014000300422865000900425002001300434#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#211#39#article#45#39#^rND^sUe
nosono^nY.#^rND^sArigami^nT.#^rND^sKozono^nT.#^rND^sYanagita^nS.#^rND^sHirata^nM
.#^rND^sArima^nH.#^rND^sIshigami^nS.#^rND^sAikou^nT.#^rND^sNatsugoe^nS.#Circulat
ing tumor cells in blood detected by CellSearch System are predictive factor of 
recurrences in gastric cancer^len#International Gastric Cancer Congress^n8^i1^i1
#Abstract Book#30#20110300#v24n1a16.htm##
00969000000000409000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100021000990100
01900120010001600139010001900155010001400174010001900188010001500207010001400222
01000160023601000160025201000160026801201900028403000130047406500090048706400050
04960310003005010320003005040140007005078650009005140020013005230350010005368010
01300546#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#212#40#articl
e#45#40#^rND^sVan Cutsem^nE#^rND^sMoiseyenko^nVM#^rND^sTjulandin^nS#^rND^sMajlis
^nA#^rND^sConstenla^nM#^rND^sBoni^nC#^rND^sRodrigues^nA#^rND^sFodor^nM#^rND^sCha
o^nY#^rND^sVoznyi^nE#^rND^sRisse^nML#^rND^sAjani^nJA#Phase III study of docetaxe
l and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as fi
rst-line therapy for advanced gastric cancer: a report of the V325 Study Group^l
en#J Clin Oncol#20060000#2006#24#31#4991-7#20110300#v24n1a16.htm#0732-183X#J Cli
n Oncol##
00709000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01800112010001600130010001700146010001600163012010700179030001300286065000900299
06400050030803100030031303200030031601400070031986500090032600200130033503500100
0348801001300358#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#213#4
1#article#45#41#^rND^sWagner^nAD#^rND^sGrothe^nW#^rND^sHaerting^nJ#^rND^sKleber^
nG#^rND^sGrothey^nA#^rND^sFleig^nWE#Chemotherapy in advanced gastric cancer: a s
ystematic review and meta-analysis based on aggregate data^len#J Clin Oncol#2006
0000#2006#24#18#2903-9#20110300#v24n1a16.htm#0732-183X#J Clin Oncol##
00855000000000385000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01400112010001600126010001600142010001500158010001800173010002000191010001500211
01000150022601201440024103000130038506500090039806400050040703100020041203200020
0414014000800416865000900424002001300433035001000446801001300456#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#214#42#article#45#42#^rND^sWilke^nH#^
rND^sPreusser^nP#^rND^sFink^nU#^rND^sGunzer^nU#^rND^sMeyer^nHJ#^rND^sMeyer^nJ#^r
ND^sSiewert^nJR#^rND^sAchterrath^nW#^rND^sLenaz^nL#^rND^sKnipp^nH#Preoperative c
hemotherapy in locally advanced and nonresectable gastric cancer: a phase II stu
dy with etoposide, doxorubicin, and cisplatin^len#J Clin Oncol#19890000#1989#7#9
#1318-26#20110300#v24n1a16.htm#0732-183X#J Clin Oncol##
00584000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01700116010001600133012004800149030000700197065000900204064000500213031000300218
032000200221014000800223865000900231002001300240035001000253801000700263#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a16.htm#S#c#215#43#article#45#43#^rND^sWi
ttekind^nC#^rND^sCompton^nCC#^rND^sGreene^nFL#^rND^sSobin^nLH#TNM residual tumor
 classification revisited^len#Cancer#20020000#2002#94#9#2511-16#20110300#v24n1a1
6.htm#0008-543X#Cancer##
00806000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100018000930100
01600111010001700127010001500144010001700159010001900176010002000195010001700215
01201290023203000130036106500090037406400050038303100030038801400080039186500090
0399002001300408035001000421801001300431#v24n1#V:\SciELO\serial\abcd\v24n1\marku
p\v24n1a16.htm#S#c#216#44#article#45#44#^rND^sYano^nM#^rND^sShiozaki^nH#^rND^sIn
oue^nM.#^rND^sTamura^nS.#^rND^sDoki^nY.#^rND^sYasuda^nT.#^rND^sFujiwara^nY.#^rND
^sTsujinaka^nT.#^rND^sMonden^nM.#Neoadjuvant Chemotherapy followed by Salvage Su
rgery: Effect on survival of patients with primary noncurative gastric cancer^le
n#World J Surg#20020000#2002#26#1155-59#20110300#v24n1a16.htm#0364-2313#World J 
Surg##
00508000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100015000920120
05700107030001400164710000200178065000900180064000500189031000300194032000300197
014000800200865000900208002001300217#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a16.htm#S#c#217#45#article#45#45#^rND^sXu^nRH#^rND^sTeng^nKY#Progress in chem
otherapy for advanced gastric cancer^len#Chin J Cancer#2#20090000#2009#28#10#110
8-13#20110300#v24n1a16.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#o#1#1#article#1
#20110411#103928#v24n1a17.htm#109##
02927000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002700109
03100030013603200020013906500090014101400090015003500100015901201020016901201090
02710100030003800830782004100850010011920850017012020850017012190850023012360850
03301259083090301292085001002195085001802205085001802223085002202241085003402263
11700080229707200030230511200090230811100110231711400090232811300110233700200130
2348#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#h#2#1#article#1#le#
pt#br1.1#1#4.0#ILUS#17#ABCD050#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f81^
l83#0102-6720#Técnica do aproveitamento da papila íleo-cecal naileostomia defini
tiva e na anastomose íleo-retal^lpt#Technique of preserving the ileum-caecal pap
illa in the definitive ileostomy and ileum-rectal anastomose^len#^rND^nAlcino Lá
zaro da^sSilva#^lpt^aINTRODUÇÃO: Quando se faz ileostomia com a papila, a perda 
líquida é bem menor e a irritação local às vezes é nula, podendo o paciente vive
r sem o uso da bolsa. OBJETIVO: Mostrar uma técnica operatória em que se preserv
a a papila na ileostomia ou na anastomose íleo-retal. Ela consta da preservação 
da vasculatura do ceco e íleo terminal e secção do ceco deixando-se 1 cm de orla
 na papila ileal que é fixada na pele por contra-abertura para ileostomia defini
tiva. Quando se resseca o cólon, a papila é anastomosada ao reto (íleo-papilo-re
tostomia). RESULTADOS: São bons, pois há diminuição do número de evacuações, da 
perda de líquidos nas fezes e da irritação epidérmica. CONCLUSÃO: O procedimento
 é exequível e traz resultados que melhoram a qualidade de vida do paciente.#^dd
ecs^i1#^tm^lpt^kÍleo^i1#^tm^lpt^kCeco^i1#^tm^lpt^kIleostomia^i1#^tm^lpt^kAnastom
ose cirúrgica^i1#^len^aINTRODUCTION: When ileostomy is done with the ileum-caeca
l papilla, the liquid is decreased and happens much less local irritation and it
s possible that the patient can live without the use of the bag. OBJECTIVE: To s
how a surgical technique that preserves the papilla in ileostomy or ileo-rectal 
cancer. METHOD: It is done with the preservation of the vasculature of the cecum
 and terminal ileum; cecum section is made leaving 1 cm border, coronal, on the 
ileal papilla, which is fixed on the skin for a counter-opening for permanent il
eostomy. When a colectomy is needed, the anastomosis can be made with the rectal
 stump (papilla-ileum-retostomy). RESULTS: They are good because there is a decr
ease in the number of bowel movements, loss of fluid in the stool and less epide
rmal irritation. CONCLUSION: The procedure is feasible and brings results that i
mprove the quality of life of patients.#^ddecs^i2#^tm^len^kIleum^i2#^tm^len^kCec
um^i2#^tm^len^kIleostomy^i2#^tm^len^kAnastomosis, surgical^i2#vancouv#10#2010121
7#07/12/2010#20101221#21/12/2010#v24n1a17.htm##
03004000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002700109
03100030013603200020013906500090014101400090015003500100015901201090016901201160
02780100030003940830810004240850010012340850017012440850017012610850023012780850
03301301083093801334085001002272085001802282085001802300085002202318085003402340
11700080237407200030238211200090238511100110239411400090240511300110241400200130
2425#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#f#3#1#article#1#le#
pt#br1.1#1#4.0#ILUS#17#ABCD050#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f81^
l83#0102-6720#<b>Técnica do aproveitamento da papila íleo-cecal naileostomia def
initiva e na anastomose íleo-retal</b>^lpt#<b>Technique of preserving the ileum-
caecal papilla in the definitive ileostomy and ileum-rectal anastomose</b>^len#^
rND^nAlcino Lázaro da^sSilva#^lpt^a<b>INTRODUÇÃO:</b> Quando se faz ileostomia c
om a papila, a perda líquida é bem menor e a irritação local às vezes é nula, po
dendo o paciente viver sem o uso da bolsa. <b>OBJETIVO:</b> Mostrar uma técnica 
operatória em que se preserva a papila na ileostomia ou na anastomose íleo-retal
. Ela consta da preservação da vasculatura do ceco e íleo terminal e secção do c
eco deixando-se 1 cm de orla na papila ileal que é fixada na pele por contra-abe
rtura para ileostomia definitiva. Quando se resseca o cólon, a papila é anastomo
sada ao reto (íleo-papilo-retostomia). <b>RESULTADOS:</b> São bons, pois há dimi
nuição do número de evacuações, da perda de líquidos nas fezes e da irritação ep
idérmica. <b>CONCLUSÃO:</b> O procedimento é exequível e traz resultados que mel
horam a qualidade de vida do paciente.#^ddecs^i1#^tm^lpt^kÍleo^i1#^tm^lpt^kCeco^
i1#^tm^lpt^kIleostomia^i1#^tm^lpt^kAnastomose cirúrgica^i1#^len^a<b>INTRODUCTION
: </b>When ileostomy is done with the ileum-caecal papilla, the liquid is decrea
sed and happens much less local irritation and its possible that the patient can
 live without the use of the bag. <b>OBJECTIVE:</b> To show a surgical technique
 that preserves the papilla in ileostomy or ileo-rectal cancer. <b>METHOD:</b> I
t is done with the preservation of the vasculature of the cecum and terminal ile
um; cecum section is made leaving 1 cm border, coronal, on the ileal papilla, wh
ich is fixed on the skin for a counter-opening for permanent ileostomy. When a c
olectomy is needed, the anastomosis can be made with the rectal stump (papilla-i
leum-retostomy). <b>RESULTS:</b> They are good because there is a decrease in th
e number of bowel movements, loss of fluid in the stool and less epidermal irrit
ation. <b>CONCLUSION: </b>The procedure is feasible and brings results that impr
ove the quality of life of patients.#^ddecs^i2#^tm^len^kIleum^i2#^tm^len^kCecum^
i2#^tm^len^kIleostomy^i2#^tm^len^kAnastomosis, surgical^i2#vancouv#10#20101217#0
7/12/2010#20101221#21/12/2010#v24n1a17.htm##
03057000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000260012703100030015303200020015606500090015801400090016703500100017601201020
01860120109002880100030003970830782004270850010012090850017012190850017012360850
02301253085003301276083090301309085001002212085001802222085001802240085002202258
08500340228011700080231407200030232211200090232511100110233411400090234511300110
2354002001302365008008902378#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.h
tm#S#l#4#1#article#1#^mjan./mar.^a2011#le#pt#br1.1#1#4.0#ilus#17#ABCD050#nd#ABCD
, arq. bras. cir. dig#24#1#20110300#^f81^l83#0102-6720#Técnica do aproveitamento
 da papila íleo-cecal naileostomia definitiva e na anastomose íleo-retal^lpt#Tec
hnique of preserving the ileum-caecal papilla in the definitive ileostomy and il
eum-rectal anastomose^len#^rND^nAlcino Lázaro da^sSilva#^lpt^aINTRODUÇÃO: Quando
 se faz ileostomia com a papila, a perda líquida é bem menor e a irritação local
 às vezes é nula, podendo o paciente viver sem o uso da bolsa. OBJETIVO: Mostrar
 uma técnica operatória em que se preserva a papila na ileostomia ou na anastomo
se íleo-retal. Ela consta da preservação da vasculatura do ceco e íleo terminal 
e secção do ceco deixando-se 1 cm de orla na papila ileal que é fixada na pele p
or contra-abertura para ileostomia definitiva. Quando se resseca o cólon, a papi
la é anastomosada ao reto (íleo-papilo-retostomia). RESULTADOS: São bons, pois h
á diminuição do número de evacuações, da perda de líquidos nas fezes e da irrita
ção epidérmica. CONCLUSÃO: O procedimento é exequível e traz resultados que melh
oram a qualidade de vida do paciente.#^ddecs^i1#^tm^lpt^kÍleo^i1#^tm^lpt^kCeco^i
1#^tm^lpt^kIleostomia^i1#^tm^lpt^kAnastomose cirúrgica^i1#^len^aINTRODUCTION: Wh
en ileostomy is done with the ileum-caecal papilla, the liquid is decreased and 
happens much less local irritation and its possible that the patient can live wi
thout the use of the bag. OBJECTIVE: To show a surgical technique that preserves
 the papilla in ileostomy or ileo-rectal cancer. METHOD: It is done with the pre
servation of the vasculature of the cecum and terminal ileum; cecum section is m
ade leaving 1 cm border, coronal, on the ileal papilla, which is fixed on the sk
in for a counter-opening for permanent ileostomy. When a colectomy is needed, th
e anastomosis can be made with the rectal stump (papilla-ileum-retostomy). RESUL
TS: They are good because there is a decrease in the number of bowel movements, 
loss of fluid in the stool and less epidermal irritation. CONCLUSION: The proced
ure is feasible and brings results that improve the quality of life of patients.
#^ddecs^i2#^tm^len^kIleum^i2#^tm^len^kCecum^i2#^tm^len^kIleostomy^i2#^tm^len^kAn
astomosis, surgical^i2#vancouv#10#20101217#07/12/2010#20101221#21/12/2010#v24n1a
17.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67
202011000100017##
00351000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704011900073002001300192#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#5#1#article#95#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>T&Eacute;CNICA </b></f
ont></p>     ^cY#v24n1a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#6#2#article#95#<p>&nbsp;</p>     ^cY#
v24n1a17.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704022900073002001300302#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#7#3#article#95#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>T&eacute;cnica d
o aproveitamento da papila &iacute;leo-cecal naileostomia definitiva e na anasto
mose &iacute;leo-retal </b></font></p>     ^cY#v24n1a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#8#4#article#95#<p>&nbsp;</p>     ^cY#
v24n1a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#9#5#article#95#<p>&nbsp;</p>     ^cY#
v24n1a17.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704012000074002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#10#6#article#95#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Alcino L&aacute;zaro da Silva </b><
/font></p>     ^cY#v24n1a17.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704012500074002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#11#7#article#95#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;ncia
</a></font></p>     ^cY#v24n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704002200074002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#12#8#article#95#<p>&nbsp;</p>     ^cY
#v24n1a17.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704004400074002001300118#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#13#9#article#95#<p>&nbsp;</p> <hr siz
e="1" noshade>     ^cY#v24n1a17.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009600075002001300171#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#14#10#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v24n
1a17.htm##
00529000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704029500075002001300370#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#15#11#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O:</b>  Qua
ndo se faz ileostomia com a papila, a perda l&iacute;quida &eacute; bem menor e 
a irrita&ccedil;&atilde;o local &agrave;s vezes &eacute; nula, podendo o pacient
e viver sem o uso da bolsa.    ^cY#v24n1a17.htm##
00727000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704049300075002001300568#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#16#12#article#95#<br>  <b>OBJETIVO:</
b> Mostrar uma t&eacute;cnica operat&oacute;ria em que se preserva a papila na i
leostomia ou na anastomose &iacute;leo-retal. Ela consta da preserva&ccedil;&ati
lde;o da vasculatura do ceco e &iacute;leo terminal e sec&ccedil;&atilde;o do ce
co deixando-se 1 cm de orla na papila ileal que &eacute; fixada na pele por cont
ra-abertura para ileostomia definitiva. Quando se resseca o c&oacute;lon, a papi
la &eacute; anastomosada ao reto (&iacute;leo-papilo-retostomia).    ^cY#v24n1a1
7.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704022100075002001300296#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#17#13#article#95#<br> <b>RESULTADOS:<
/b>  S&atilde;o bons, pois h&aacute; diminui&ccedil;&atilde;o do n&uacute;mero d
e evacua&ccedil;&otilde;es, da perda de l&iacute;quidos nas fezes e da irrita&cc
edil;&atilde;o epid&eacute;rmica.    ^cY#v24n1a17.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704015600075002001300231#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#18#14#article#95#<br>  <b>CONCLUS&Ati
lde;O:</b> O procedimento &eacute; exequ&iacute;vel e traz resultados que melhor
am a qualidade de vida do paciente. </font></p>     ^cY#v24n1a17.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018500075002001300260#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#19#15#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Descritores: </b>&Iacute;leo. Ceco
. Ileostomia. Anastomose cir&uacute;rgica. </font></p> <hr size="1" noshade>    
 ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#20#16#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#21#17#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011400075002001300189#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#22#18#article#95#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v24n1a17.htm##
00850000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704061600075002001300691#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#23#19#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os estudos da papila ileal (v&aacute;
lvula &iacute;leo-cecal) v&ecirc;m de muitos anos, liderada por Schiler<sup>10</
sup> e DiDio<sup>1</sup>. Dos conceitos fisiol&oacute;gicos por eles emitidos e 
ap&oacute;s tentativas experimentais, passou-se a aproveitar a papila na ileosto
mia definitiva, ap&oacute;s proctocolectomia total e na anastomose &iacute;leo-r
etal ap&oacute;s a colectomia total. A evolu&ccedil;&atilde;o cl&iacute;nica &ea
cute; satisfat&oacute;ria e d&aacute; ao paciente condi&ccedil;&atilde;o de vida
 menos sofrida. </font></p>     ^cY#v24n1a17.htm##
00399000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704016500075002001300240#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#24#20#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo deste trabalho &eacute; re
latar a t&eacute;cnica desses procedimentos. </font></p>     ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#25#21#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010300075002001300178#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#26#22#article#95#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODO</b></font></p>     ^
cY#v24n1a17.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704013200075002001300207#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#27#23#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Mobiliza&ccedil;&atilde;o do c&oac
ute;lon </b></font></p>     ^cY#v24n1a17.htm##
00840000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704060600075002001300681#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#28#24#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s laparotomia, &eacute; fei
ta a ligadura dos ped&iacute;culos vasculares col&ocirc;nicos, preservando-se as
 arcadas do ceco e do &iacute;leo. Uma delas ser&aacute; mantida ao final. Nos o
besos, em geral, n&atilde;o se consegue aproveitar a arcada vascular do &iacute;
leo terminal, por isto cuidado especial &eacute; destinado &agrave; arcada do ce
co (ramo inferior da c&oacute;lica direita ou o final da art&eacute;ria mesent&e
acute;rica superior, chamada art&eacute;ria &iacute;leo-ceco-apendiculoc&oacute;
lica).</font></p>     ^cY#v24n1a17.htm##
00650000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704041600075002001300491#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#29#25#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Isola-se a cavidade abdominal com com
pressas. A seguir &eacute; realizada sec&ccedil;&atilde;o no ceco em torno da pa
pila ileal. H&aacute; sangramento abundante. Faz-se a ligadura &agrave; medida q
ue se vai seccionando. Completa-se o contorno da papila de forma a deixar no m&a
acute;ximo um cent&iacute;metro de ceco, em torno dela. </font></p>     ^cY#v24n
1a17.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704015600075002001300231#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#30#26#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Aproveitamento da papila ileal (v&
aacute;lvula &iacute;leo-cecal) </b></font></p>     ^cY#v24n1a17.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704019000075002001300265#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#31#27#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Se o reto &eacute; conservado faz-se 
o seu preparo e exposi&ccedil;&atilde;o para anastomose com a papila. </font></p
>     ^cY#v24n1a17.htm##
00594000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704036000075002001300435#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#32#28#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O &iacute;leo &eacute; transferido pa
ra a pelve e anastomosado ao reto, em pontos separados, com fio de baixa absor&c
cedil;&atilde;o ou inabsorv&iacute;vel. Revis&atilde;o da cavidade e fechamento 
dos mesos para n&atilde;o haver h&eacute;rnias internas &eacute; o tempo final. 
</font></p>     ^cY#v24n1a17.htm##
00602000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704036800075002001300443#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#33#29#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quando o reto &eacute; ressecado, rea
liza-se a ileostomia terminal fixando-se o &iacute;leo na parede abdominal, &agr
ave; direita. Ap&oacute;s sua exterioriza&ccedil;&atilde;o, &eacute; feita sutur
a da orla cecal &agrave; pele, expondo-se somente a papila (Figuras 1 a 9)<sup>9
</sup>. </font></p>     ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#34#30#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#35#31#article#95#<p align="center"><i
mg src="/img/revistas/abcd/v24n1/a17fig1.jpg"></p>     ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#36#32#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#37#33#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#38#34#article#95#<p align="center"><i
mg src="/img/revistas/abcd/v24n1/a17fig2.jpg"></p>     ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#39#35#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#40#36#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#41#37#article#95#<p align="center"><i
mg src="/img/revistas/abcd/v24n1/a17fig3.jpg"></p>     ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#42#38#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#43#39#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#44#40#article#95#<p align="center"><i
mg src="/img/revistas/abcd/v24n1/a17fig4.jpg"></p>     ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#45#41#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#46#42#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#47#43#article#95#<p align="center"><i
mg src="/img/revistas/abcd/v24n1/a17fig5.jpg"></p>     ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#48#44#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#49#45#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#50#46#article#95#<p align="center"><i
mg src="/img/revistas/abcd/v24n1/a17fig6.jpg"></p>     ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#51#47#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010000075002001300175#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#52#48#article#95#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v24n1a17.htm##
00774000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704054000075002001300615#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#53#49#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">T&ecirc;m sido satisfat&oacute;rios c
om rela&ccedil;&atilde;o a dois aspectos. No primeiro, ou seja, na ileostomia co
m a papila, o esvaziamento ileal, incontinente, cai &agrave; metade de sua produ
&ccedil;&atilde;o e, mais precocemente, o conte&uacute;do ileal tornase menos l&
iacute;quido. No segundo, a irrita&ccedil;&atilde;o inc&ocirc;moda e doentia da 
pele, perileost&ocirc;mica, &eacute; bem menor do que a da ileostomia cl&aacute;
ssica sem a papila. </font></p>     ^cY#v24n1a17.htm##
00566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704033200075002001300407#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#54#50#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quando a anastomose se faz com o reto
, o n&uacute;mero de evacua&ccedil;&otilde;es di&aacute;rias cai &agrave; metade
 em poucos dias. A irrita&ccedil;&atilde;o perineal &eacute; bem menor ou nula d
o que na anastomose &iacute;leo-retal sem a papila. </font></p>     ^cY#v24n1a17
.htm##
00491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704025700075002001300332#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#55#51#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Se o doente &eacute; bem orientado, e
m menor tempo, consegue-se fazer melhor controle do n&uacute;mero de evacua&cced
il;&otilde;es di&aacute;rias, em ambos os procedimentos. </font></p>     ^cY#v24
n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#56#52#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#57#53#article#95#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O </b></font></p>  
   ^cY#v24n1a17.htm##
00999000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704076500075002001300840#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#58#54#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com a experi&ecirc;ncia obtida, sem p
ossibilidade de controle casualizado (randomizado) pode-se aceitar que o m&eacut
e;todo, preservando-se a papila ileal, &eacute; leg&iacute;timo e superior ao tr
adicional, sem a papila. Esta dedu&ccedil;&atilde;o resulta de que na ileostomia
 cl&aacute;ssica o volume l&iacute;quido perdido, especialmente no p&oacute;s-op
erat&oacute;rio imediato, &eacute; muito grande a ponto de levar o paciente &agr
ave; desidrata&ccedil;&atilde;o. Sobre isto, h&aacute; irrita&ccedil;&atilde;o d
a pele levando, em alguns pacientes, a &uacute;lceras rasas, dolorosas e inc&oci
rc;modas e que n&atilde;o permitem boa fixa&ccedil;&atilde;o da bolsa de ileosto
mia. </font></p>     ^cY#v24n1a17.htm##
00730000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704049600075002001300571#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#59#55#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quando se faz a ileostomia com a papi
la, a perda l&iacute;quida &eacute; bem menor e a irrita&ccedil;&atilde;o, &agra
ve;s vezes, &eacute; nula. H&aacute; observa&ccedil;&atilde;o em uma paciente qu
e consegue viver sem o uso de bolsa com controle relativo do esvaziamento ileal 
e, ap&oacute;s a higiene, ela usa uma faixa, comprimindo e ocluindo o orif&iacut
e;cio por algumas horas, sem vazamentos<sup>2, 3</sup>. </font></p>     ^cY#v24n
1a17.htm##
00598000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704036400075002001300439#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#60#56#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O segredo t&eacute;cnico &eacute; mob
ilizar o conjunto &iacute;leocecal sem que a vasculariza&ccedil;&atilde;o seja c
omprometida. Ap&oacute;s toda escultura e exposi&ccedil;&atilde;o do conjunto &e
acute; que se preservar&aacute; a vasculariza&ccedil;&atilde;o ceco-ileal ou ile
al. </font></p>     ^cY#v24n1a17.htm##
00475000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704024100075002001300316#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#61#57#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Acredita-se n&atilde;o haver d&uacute
;vida quanto ao procedimento, que deve ser o de escolha, quando se vai fazer ile
ostomia ou anastomose &iacute;leo-retal. </font></p>     ^cY#v24n1a17.htm##
00821000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704058700075002001300662#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#62#58#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O desafio a se enfrentar &eacute; ten
tar a mobiliza&ccedil;&atilde;o eficaz e bem vascularizada do &iacute;leo com a 
papila e anastomos&aacute;la no &acirc;nus. Em n&iacute;vel experimental &eacute
; poss&iacute;vel. No homem a dificuldade &eacute; o alongamento do ped&iacute;c
ulo ileal para se atingir o n&iacute;vel do &acirc;nus. Para obter isto, talvez,
 tem-se que fazer a opera&ccedil;&atilde;o em dois tempos, ou seja, alongamento 
do ped&iacute;culo e depois o abaixamento<sup>4, 5, 6, 7, 8</sup>. </font></p>  
   ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#63#59#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#64#60#article#95#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O </b></font></p>  
   ^cY#v24n1a17.htm##
00422000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018800075002001300263#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#65#61#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O procedimento &eacute; exequ&iacute;
vel e traz resultados que melhoram a qualidade de vida do paciente. </font></p> 
    ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#66#62#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010800075002001300183#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#67#63#article#95#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS </b></font></p> 
    ^cY#v24n1a17.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704030600077002001300383#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#68#64#article#95#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Didio LJA e Carril 
CF. Observa&ccedil;&otilde;es sobre o mecanismo do piloro &iacute;leo-ceco-c&oac
ute;lico em indiv&iacute;duo vivo com papila &iacute;leo-ceco-c&oacute;lica exte
riorizada. Rev. Bras. Gastroenterol, 1954; 6: 67-69.    ^cY#v24n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#69#65#article#95# </font></p>     ^cY
#v24n1a17.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704021500077002001300292#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#70#66#article#95#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Formiga GJS, Barreto
 Neto PF, Nossa FLC e Silva JH. Ileostomia Continente-Relato de Quatro Casos. Re
v. Bras. Coloproctol, 1998; 18(1): 34-36.    ^cY#v24n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#71#67#article#95# </font></p>     ^cY
#v24n1a17.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704015500077002001300232#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#72#68#article#95#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Glassman JA. Artific
ial Ileocecal Valve. Surg. Gynecol. Obstet., 74: 92-98, 1942.    ^cY#v24n1a17.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#73#69#article#95# </font></p>     ^cY
#v24n1a17.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023800077002001300315#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#74#70#article#95#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 4. Kalil M. Colectomia
 Total e Telescopagem ileorretal preservando-se a papila ileocecal com ou sem mu
cosectomia retal. Tese Mestrado. Belo Horizonte, FM, UFMG, 1990.    ^cY#v24n1a17
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#75#71#article#95# </font></p>     ^cY
#v24n1a17.htm##
00437000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704018900077002001300266#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#76#72#article#95#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 5. L&aacute;zaro da Si
lva A. Ileostomia, Alternativas T&eacute;cnicas. Rev. Assoc. M&eacute;d., MG., 1
978; 29: 28-29.    ^cY#v24n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#77#73#article#95# </font></p>     ^cY
#v24n1a17.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704017100077002001300248#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#78#74#article#95#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6 L&aacute;zaro da Silv
a A. Ileal Papilla and Ileal Pylorus. Arq. Bras. Cir. Dig.,1993; 8(2): 48-49.   
 ^cY#v24n1a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#79#75#article#95#</font></p>     ^cY#
v24n1a17.htm##
00415000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704016700077002001300244#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#80#76#article#95#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 7 L&aacute;zaro da Sil
va A. Ileostomia Continente. Rev. Bras. Colo-proctol, 1991; 11(1): 33-35.    ^cY
#v24n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#81#77#article#95# </font></p>     ^cY
#v24n1a17.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704024100077002001300318#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#82#78#article#95#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Mattos 	MP e L&aacut
e;zaro da Silva A. Study of ileostomy in dogs. Functional aspects, optic and sca
nning electronic microscopy. Arq. Gastroenterol, 1986; 23: 159-168.    ^cY#v24n1
a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#83#79#article#95# </font></p>     ^cY
#v24n1a17.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704020800077002001300285#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#84#80#article#95#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif"> 9. Ogilviie, WH. The p
reservation of the ileocaecal sphincter in resection of the right half of the co
lon. Br. J. Surg., 1931; 19: 8-16.    ^cY#v24n1a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#85#81#article#95#</font></p>     ^cY#
v24n1a17.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704023600078002001300314#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#86#82#article#95#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 10. Schiller WR, Didi
o LJA and Anderson MC. Production of Artificial Sphincters. Ablation of the Long
itudinal Layer of the Intestine. Arch. Surg., 1967; 95: 436-42.    ^cY#v24n1a17.
htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002100075002001300096#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#87#83#article#95# </font></p>     ^cY
#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#88#84#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002400075002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#89#85#article#95#<p>&nbsp;</p>       
^cY#v24n1a17.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704019900075002001300274#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#90#86#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#note
1"><img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ecirc
;ncia: </b>    ^cY#v24n1a17.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004200075002001300117#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#91#87#article#95#<br> Alcino L&aacute
;zaro da Silva    ^cY#v24n1a17.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011900075002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#92#88#article#95#<br>  e-mail: <a hre
f="mailto:franciscoalberto@superig.com.br">franciscoalberto@superig.com.br</a> <
/font></p>     ^cY#v24n1a17.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704012300075002001300198#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#93#89#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> Recebido para publica&ccedil;&atilde
;o: 07/12/2010     ^cY#v24n1a17.htm##
00295000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006100075002001300136#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#94#90#article#95#<br> Aceito para pub
lica&ccedil;&atilde;o: 21/12/2010    ^cY#v24n1a17.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005700075002001300132#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#95#91#article#95#<br> Fonte de financ
iamento: n&atilde;o h&aacute;    ^cY#v24n1a17.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007100075002001300146#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#96#92#article#95#<br> Conflito de int
eresses: n&atilde;o h&aacute; </font></p>      ^cY#v24n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#97#93#article#95#<p>&nbsp;</p>     ^c
Y#v24n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002300075002001300098#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#98#94#article#95#<p>&nbsp;</p>      ^
cY#v24n1a17.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704019900075002001300274#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a17.htm#S#p#99#95#article#95#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Departamento de
 Cirurgia da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil. <
/font></p>     ^cY#v24n1a17.htm##
00570000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940120
13200111030001500243710000200258065000900260064000500269031000200274014000600276
865000900282002001300291#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S
#c#100#1#article#10#1#^rND^sDidio^nLJA#^rND^sCarril^nCF#Observações sobre o meca
nismo do piloro íleo-ceco-cólico em indivíduo vivo com papila íleo-ceco-cólica e
xteriorizada: Rev. Bras^lpt#Gastroenterol,#2#19540000#1954#6#67-69#20110300#v24n
1a17.htm##
00574000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100023000960100
01700119010001600136012004900152030002200201710000200223065000900225064000500234
031000300239032000200242014000600244865000900250002001300259#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a17.htm#S#c#101#2#article#10#2#^rND^sFormiga^nGJS#^rN
D^sBarreto Neto^nPF#^rND^sNossa^nFLC#^rND^sSilva^nJH#Ileostomia Continente-Relat
o de Quatro Casos^lpt#Rev. Bras Coloproctol#2#19980000#1998#18#1#34-36#20110300#
v24n1a17.htm##
00450000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120031000960300
02200127710000200149031000300151014000600154065000900160064000500169865000900174
002001300183#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#c#102#3#art
icle#10#3#^rND^sGlassman^nJA#Artificial Ileocecal Valve^len#Surg. Gynecol. Obste
t#2#74#92-98#19420000#1942#20110300#v24n1a17.htm##
00507000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160015000770180125000920660
01500217062000900232065000900241064000500250865000900255002001300264#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#c#103#4#article#10#4#^rND^sKalil^nM
#Colectomia Total e Telescopagem ileorretal preservando-se a papila ileocecal co
m ou sem mucosectomia retal.Tese Mestrado^lpt#Belo Horizonte#FM, UFMG#19900000#1
990#20110300#v24n1a17.htm##
00461000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100025000770120038001020300
02000140710000200160065000900162064000500171031000300176014000600179865000900185
002001300194#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#c#104#5#art
icle#10#5#^rND^nLázaro da Silva^sA#Ileostomia, Alternativas Técnicas^lpt#Rev. As
soc Méd., MG#2#19780000#1978#29#28-29#20110300#v24n1a17.htm##
00472000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100025000770120036001020300
02000138710000200158065000900160064000500169031000200174032000200176014000600178
865000900184002001300193#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S
#c#105#6#article#10#6#^rND^nLázaro da Silva^sA#Ileal Papilla and Ileal Pylorus^l
en#Arq. Bras. Cir. Dig#2#19930000#1993#8#2#48-49#20110300#v24n1a17.htm##
00511000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100025000770120026001020300
02400128065000900152064000500161031000300166032000200169014000600171865000900177
002001300186035001000199801002400209#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a17.htm#S#c#106#7#article#10#7#^rND^nLázaro da Silva^sA#Ileostomia Continente
^lpt#Rev. Bras. Colo-proctol#19910000#1991#11#1#33-35#20110300#v24n1a17.htm#0101
-9880#Rev. bras. colo-proctol##
00583000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100025000940120
09300119030001800212065000900230064000500239031000300244014000800247865000900255
002001300264035001000277801001800287#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a17.htm#S#c#107#8#article#10#8#^rND^sMattos^nMP#^rND^nLázaro da Silva^sA#Stud
y of ileostomy in dogs: Functional aspects, optic and scanning electronic micros
copy^len#Arq Gastroenterol#19860000#1986#23#159-168#20110300#v24n1a17.htm#0004-2
803#Arq Gastroenterol##
00500000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120093000960300
01100189710000200200065000900202064000500211031000300216014000500219865000900224
002001300233#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a17.htm#S#c#108#9#art
icle#10#9#^rND^sOgilviie^nWH#The preservation of the ileocaecal sphincter in res
ection of the right half of the colon^len#Br J. Surg#2#19310000#1931#19#8-16#201
10300#v24n1a17.htm##
00593000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01900115012009300134030001000227065000900237064000500246031000300251014000700254
865000900261002001300270035001000283801001000293#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a17.htm#S#c#109#10#article#10#10#^rND^sSchiller^nWR#^rND^sDidio^n
LJA#^rND^nAnderson^sMC#Production of Artificial Sphincters: Ablation of the Long
itudinal Layer of the Intestine^len#Arch Surg#19670000#1967#95#436-42#20110300#v
24n1a17.htm#0004-0010#Arch Surg##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#o#1#1#text#1#20
110411#103930#v24n1a18.htm#86##
00812000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002700106
03100030013303200020013606500090013801400090014703500100015612300020016601200460
01680120041002140100028002550100031002830100030003140100022003441170008003660720
00300374002001300377#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#h#2
#1#text#1#le#pt#br1.1#1#4.0#ILUS#18#ABCD100#nd#ABCD, arq. bras. cir. dig.#24#1#2
0110300#^f84^l85#0102-6720#1#Cisto mesentérico quiloso: relato de caso^lpt#Chylo
us mesenteric cyst: case report^len#^rND^nLuiz Ronaldo^sAlberti#^rND^nLeandro Ti
búrcio^sRegina#^rND^nGustavo Mariani^sBolina#^rND^nAndy^sPetroianu#vancouv#13#v2
4n1a18.htm##
00840000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002700106
03100030013303200020013606500090013801400090014703500100015612300020016601200600
01680120055002280100028002830100031003110100030003420100022003721170008003940720
00300402002001300405#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#f#3
#1#text#1#le#pt#br1.1#1#4.0#ILUS#18#ABCD100#nd#ABCD, arq. bras. cir. dig.#24#1#2
0110300#^f84^l85#0102-6720#1#<b>Cisto mesentérico quiloso</b>: <b>relato de caso
</b>^lpt#<b>Chylous mesenteric cyst</b>: <b>case report</b>^len#^rND^nLuiz Ronal
do^sAlberti#^rND^nLeandro Tibúrcio^sRegina#^rND^nGustavo Mariani^sBolina#^rND^nA
ndy^sPetroianu#vancouv#13#v24n1a18.htm##
00942000000000445000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101038000500105121000300110049000800113158000300121
03000260012403100030015003200020015306500090015501400090016403500100017312300020
01830120046001850120041002310100028002720100031003000100030003310100022003611170
00800383072000300391002001300394008008900407#v24n1#V:\SciELO\serial\abcd\v24n1\m
arkup\v24n1a18.htm#S#l#4#1#text#1#^mjan./mar.^a2011#le#pt#br1.1#1#4.0#ilus#18#AB
CD100#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f84^l85#0102-6720#1#Cisto mese
ntérico quiloso: relato de caso^lpt#Chylous mesenteric cyst: case report^len#^rN
D^nLuiz Ronaldo^sAlberti#^rND^nLeandro Tibúrcio^sRegina#^rND^nGustavo Mariani^sB
olina#^rND^nAndy^sPetroianu#vancouv#13#v24n1a18.htm#Internet^ihttp://www.scielo.
br/scielo.php?script=sci_arttext&pid=S0102-67202011000100018##
00349000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012000070002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#5#1#text#69#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CARTA AO EDITOR</b></font
></p>      ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#6#2#text#69#<p>&nbsp;</p>     ^cY#v24
n1a18.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704015800070002001300228#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#7#3#text#69#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Cisto mesent&eacute
;rico quiloso: relato de caso</b></font></p>     ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#8#4#text#69#<p>&nbsp;</p>     ^cY#v24
n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#9#5#text#69#<p>&nbsp;</p>     ^cY#v24
n1a18.htm##
00412000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704018200071002001300253#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#10#6#text#69#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Luiz Ronaldo Alberti; Leandro Tib&uacu
te;rcio Regina; Gustavo Mariani Bolina; Andy Petroianu</b></font></p>     ^cY#v2
4n1a18.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012800071002001300199#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#11#7#text#69#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspond&ecirc;ncia</a
></font></p>        ^cY#v24n1a18.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#12#8#text#69#<p>&nbsp;</p>     ^cY#v2
4n1a18.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#13#9#text#69#<p>&nbsp;</p>     ^cY#v2
4n1a18.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011400072002001300186#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#14#10#text#69#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font></
p>     ^cY#v24n1a18.htm##
00912000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704068100072002001300753#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#15#11#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Os cistos de mesent&eacute;rio s&atilde;
o tumores abdominais raros, que podem acometer indiv&iacute;duos de qualquer fai
xa et&aacute;ria. H&aacute; predom&iacute;nio do sexo feminino, na quarta d&eacu
te;cada de vida e geralmente n&atilde;o causam sintomas, sendo diagnosticados oc
asionalmente. S&atilde;o classificados em linfangiomas ou cistos mesoteliais e p
odem originar-se de tecidos linf&aacute;ticos, vascular, nervoso e conjuntivo. O
 tratamento consiste em sua retirada ou abertura ampla. Em alguns casos, pode se
r necess&aacute;ria enterectomia segmentar. O progn&oacute;stico &eacute; bom.</
font></p>     ^cY#v24n1a18.htm##
00480000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704024900072002001300321#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#16#12#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O objetivo deste trabalho &eacute; apres
entar o caso de uma paciente portadora de um cisto quiloso volumoso, no mesojeju
no, ressecado atrav&eacute;s de laparotomia.</font></p>       ^cY#v24n1a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#17#13#text#69#<p>&nbsp;</p>     ^cY#v
24n1a18.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010400072002001300176#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#18#14#text#69#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>RELATO DO CASO</b></font></p>     ^cY
#v24n1a18.htm##
00991000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704076000072002001300832#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#19#15#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Paciente do sexo feminino, 40 anos de id
ade, obesa, hipertensa e diab&eacute;tica, deu entrada no Servi&ccedil;o de Ciru
rgia Geral da Santa Casa de Belo Horizonte com hist&oacute;ria de dor abdominal 
cont&iacute;nua e de pouca intensidade, no hipoc&ocirc;ndrio esquerdo e epig&aac
ute;strio, sem irradia&ccedil;&otilde;es, durante cerca de tr&ecirc;s meses. A d
or melhorava com analg&eacute;sicos comuns, associava-se a epis&oacute;dios de n
&aacute;useas, v&ocirc;mitos e plenitude p&oacute;s-prandial. Ap&oacute;s um m&e
circ;s do in&iacute;cio dos sintomas ela percebeu massa em andar superior do abd
ome. N&atilde;o houve trauma na regi&atilde;o, febre, melena ou hematoquezia.</f
ont></p>     ^cY#v24n1a18.htm##
01496000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704126500072002001301337#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#20#16#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A massa era palp&aacute;vel desde o epig
&aacute;strio at&eacute; o flanco esquerdo, de consist&ecirc;ncia endurecida, po
uco m&oacute;vel, superf&iacute;cie regular e dolorosa. A tomografia computadori
zada de abdome evidenciou forma&ccedil;&atilde;o c&iacute;stica de paredes finas
 e lisas, medindo 12,9 x 11,6 x 9,9 cm, situada em flanco esquerdo, em regi&atil
de;o mesent&eacute;rica, deslocando estruturas adjacentes, sugestiva de cisto me
sent&eacute;rico <a href="#fig1a">(Figura 1A</a>). &Agrave; laparotomia evidenci
ouse uma massa c&iacute;stica, com aproximadamente 10 cm de di&acirc;metro, de p
arede fina e lisa, cor amarelada, com vasos tortuosos na superf&iacute;cie, sem 
ader&ecirc;ncia a estruturas adjacentes, localizada no mesojejuno a cerca de 50 
cm da flexura duodenojejunal (<a href="#fig1b">Figura 1B</a>). O cisto foi compl
etamente retirado e seu conte&uacute;do era l&iacute;quido brancacento e inodor,
 sugestivo de quilo. O exame anatomopatol&oacute;gico revelou cisto mesotelial b
enigno mesent&eacute;rico (<a href="#fig1c">Figura 1C</a>). A paciente evoluiu s
atisfatoriamente, recebendo alta no segundo dia do p&oacute;s-operat&oacute;rio,
 assintom&aacute;tica.</font></p>     ^cY#v24n1a18.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003600072002001300108#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#21#17#text#69#<p><a name="fig1a"></a>
</p>     ^cY#v24n1a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#22#18#text#69#<p>&nbsp;</p>     ^cY#v
24n1a18.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007500072002001300147#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#23#19#text#69#<p align="center"><img 
src="/img/revistas/abcd/v24n1/a18fig1a.jpg">    ^cY#v24n1a18.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008500072002001300157#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#24#20#text#69#<br>   <a name="fig1b">
</a><img src="/img/revistas/abcd/v24n1/a18fig1b.jpg" >    ^cY#v24n1a18.htm##
00318000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008700072002001300159#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#25#21#text#69#<br> <a name="fig1c"></
a><img src="/img/revistas/abcd/v24n1/a18fig1c.jpg"></p>     ^cY#v24n1a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#26#22#text#69#<p>&nbsp;</p>     ^cY#v
24n1a18.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010600072002001300178#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#27#23#text#69#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>     ^
cY#v24n1a18.htm##
00884000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704065300072002001300725#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#28#24#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Os cistos mesent&eacute;ricos s&atilde;o
 tumores abdominais raros. H&aacute; cerca de 820 casos publicados na literatura
 desde sua primeira descri&ccedil;&atilde;o em 1507, por Benevieni, anatomista i
taliano, em necr&oacute;psia de uma menina de oito anos de idade<sup>3,6,7,9,10<
/sup>. A primeira descri&ccedil;&atilde;o de cisto mesent&eacute;rico quiloso da
ta de 1842, por Rokitanski<sup>11</sup>. A primeira ressec&ccedil;&atilde;o com 
sucesso de um cisto mesent&eacute;rico e a primeira descapsula&ccedil;&atilde;o,
 ou seja retirada parcial do cisto<sup>7,11</sup>.</font></p>     ^cY#v24n1a18.h
tm##
00729000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704049800072002001300570#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#29#25#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A incid&ecirc;ncia de tratamento desses 
cistos &eacute; de um caso para cada 100.000 a 250.000 interna&ccedil;&otilde;es
 hospitalares<sup>5,9,10,11,12</sup>. Eles se manifestam em qualquer faixa et&aa
cute;ria, por&eacute;m, dois ter&ccedil;os dos casos s&atilde;o diagnosticados e
m maiores de 10 anos de idade, com predomin&acirc;ncia  do sexo feminino, na ter
ceira e quarta d&eacute;cadas de vida<sup>6,7,11</sup>.</font></p>     ^cY#v24n1
a18.htm##
00851000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704062000072002001300692#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#30#26#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Os cistos podem ocorrer em qualquer part
e do intestino desde o duodeno at&eacute; o reto, contudo a maior parte acomete 
o &iacute;leo seguido pelo c&oacute;lon ascendente, sendo os cistos quilosos mai
s frequentes no intestino delgado e os serosos no c&oacute;lon <sup>6,7,10,12</s
up>. Sua causa ainda n&atilde;o est&aacute; esclarecida, mas acredita-se que pos
sam derivar de malforma&ccedil;&otilde;es de ductos linf&aacute;ticos abdominais
 em fundo cego ou serem sequelas de trauma, infec&ccedil;&otilde;es ou neoplasia
s<sup>5,10</sup>.</font></p>     ^cY#v24n1a18.htm##
01246000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704101500072002001301087#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#31#27#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A maior parte dos casos &eacute; assinto
m&aacute;tica sendo descoberta incidentalmente durante proped&ecirc;utica para o
utras afec&ccedil;&otilde;es; todavia podem apresentar-se com quadro de dor abdo
minal aguda ou cr&ocirc;nica, obstru&ccedil;&atilde;o intestinal, n&aacute;useas
 e v&ocirc;mitos ou at&eacute; mesmo como quadro de abdome agudo e choque devido
 &agrave; ruptura, infec&ccedil;&atilde;o ou tor&ccedil;&atilde;o<sup>5,6,9,10</
sup>. O diagn&oacute;stico &eacute; suspeitado no exame do abdome, com o aux&iac
ute;lio do sinal de Tillaux - mobiliza&ccedil;&atilde;o do cisto como um todo &a
grave; palpa&ccedil;&atilde;o abdominal profunda<sup>4</sup>. A confirma&ccedil;
&atilde;o ocorre com ultrassonografia e tomografia computadorizadaque auxiliam n
a diferencia&ccedil;&atilde;o entre massas c&iacute;sticas e s&oacute;lidas e na
 avalia&ccedil;&atilde;o de comprometimento de estruturas adjacentes<sup>5,8,10,
11,13</sup>.</font></p>     ^cY#v24n1a18.htm##
00554000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704032300072002001300395#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#32#28#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Testes laboratoriais n&atilde;o s&atilde
;o &uacute;teis nesses casos. O diagn&oacute;stico diferencial &eacute; feito co
m linfangiomas e mesoteliomas. Sua degenera&ccedil;&atilde;o mal&iacute;gna &eac
ute; rara, 3 a 4% dos casos<sup>9</sup>.</font></p>     ^cY#v24n1a18.htm##
00866000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704063500072002001300707#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#33#29#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O tratamento consiste basicamente na ret
irada do cisto ou sua descapsula&ccedil;&atilde;o, acompanhada de bi&oacute;psia
 da c&aacute;psula, que pode ser realizado de prefer&ecirc;ncia por via laparosc
&oacute;pica<sup>2,12</sup>. A recorr&ecirc;ncia chega a 13,6%, estando relacion
ada com a t&eacute;cnica operat&oacute;ria. O seguimento p&oacute;s-operat&oacut
e;rio &eacute; realizado por meio de exames ultrassonogr&aacute;ficos peri&oacut
e;dicos<sup>5,9</sup>. O progn&oacute;stico &eacute; bom, com remiss&atilde;o to
tal dos sintomas<sup>10</sup>.</font></p>       ^cY#v24n1a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#34#30#text#69#<p>&nbsp;</p>     ^cY#v
24n1a18.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#35#31#text#69#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>     
^cY#v24n1a18.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026400074002001300338#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#36#32#text#69#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Adams JT. Parede Abdomi
nal, Omento, Mesent&eacute;rio e Retroperit&ocirc;nio. In Scwarts SI. et al. Pri
nc&iacute;pios de Cirurgia. 5ª Ed, Rio de Janeiro: Guanabara Koogan;1991. p .126
4-1266.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#37#33#text#69#</font></p>     ^cY#v24
n1a18.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704020700074002001300281#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#38#34#text#69#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Al-Haifi MB, Abdulsmad 
AM, Juma TH. Laparoscapic Excision of Mesenteric Cyst: Case Report. Kuwait Medic
al Journal 2007;39(2):167-169.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#39#35#text#69#</font></p>     ^cY#v24
n1a18.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704015800074002001300232#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#40#36#text#69#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Block FB. Chylous mesen
teric cyst: Case report. Annals of Surgery 1948; 128:158-160.    ^cY#v24n1a18.ht
m##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#41#37#text#69#</font></p>     ^cY#v24
n1a18.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026900074002001300343#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#42#38#text#69#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. C&ocirc;nsolo FS, Cardo
so AAP, Monge M, Santos P, Hernandez PM. Forma&ccedil;&atilde;o C&iacute;stica d
e T&uacute;nica Serosa de C&oacute;lon Ascendente - Relato de caso. RAMB 2005;55
(1/2),36-39.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#43#39#text#69#</font></p>     ^cY#v24
n1a18.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704020400074002001300278#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#44#40#text#69#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Duldulao MP, Thiruchitr
ambalam A, Kaul A. Mesenteric cyst: A rare cause of lower abdominal pain. Surg R
ounds 2008; 31(3): 123-127.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#45#41#text#69#</font></p>     ^cY#v24
n1a18.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026500074002001300339#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#46#42#text#69#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Filho FAC, Landim FM, P
erdig&atilde;o FB. Linfangioma C&iacute;stico do Mesent&eacute;rio: Uma Rara Apr
esenta&ccedil;&atilde;o de Abd&ocirc;men Agudo. Rev. Col. Bras. Cir. 1999;27(2):
139-140.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#47#43#text#69#</font></p>     ^cY#v24
n1a18.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704021600074002001300290#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#48#44#text#69#7#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Fraga MR, Cavalcante AF
S, Ben&iacute;cio IB, Pereira AA, Leite CAC, Dias RP. Cisto Mesent&eacute;rico. 
Rev. Ped. Cear&aacute; 2004;5(1):34-37.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#49#45#text#69#</font></p>     ^cY#v24
n1a18.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704019600074002001300270#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#50#46#text#69#8#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Fujita N, Noda Y, Kobay
ashi G ET AL. Chylous cyst of the mesentery: US and CT diagnosis. Abdom. Imaging
1995;20(3):259-261.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#51#47#text#69#</font></p>     ^cY#v24
n1a18.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704021100074002001300285#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#52#48#text#69#9#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Garcia RP, L&oacute;pez
 ET, Ovalle JLR. Quiste mesent&eacute;rico: Descripci&oacute;n de um caso. Cirur
jano General 2001; 23(2): 109-112.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#53#49#text#69#</font></p>     ^cY#v24
n1a18.htm##
00475000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704022900075002001300304#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#54#50#text#69#10#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Miliaras S, Trygonis 
S, Papandoniou A, Trygonis C, Kiskinis D. Mesenteric Cyst of the Descending Colo
n: Report of a Case. Actachir belg 2006;106: 714-716.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#55#51#text#69#</font></p>     ^cY#v24
n1a18.htm##
00425000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704017900075002001300254#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#56#52#text#69#11#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Miljikovic D, Gmijovi
c D, Radojkovic G, Radovanovic Z. Mesenteric cyst. Arch Oncol 2007; 15(3-4): 91-
93.    ^cY#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#57#53#text#69#</font></p>     ^cY#v24
n1a18.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704025000075002001300325#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#58#54#text#69#12#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Sahin DA, Akbulut G, 
Saykol V, San O, Tokyol C, Dilek ON. Laparoscopic Enucleation of Mesenteric Cyst
: A Case Report. The Mount Sinai Journal of Medicine 2006;73(7);1019-1020.    ^c
Y#v24n1a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#59#55#text#69#</font></p>     ^cY#v24
n1a18.htm##
00407000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704016100075002001300236#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#60#56#text#69#13#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Simeone DM, Pranikoff
 T, Mesenteric Cyst. Images in Clinical Medicine 1999;341(9):659.    ^cY#v24n1a1
8.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#61#57#text#69#</font></p>     ^cY#v24
n1a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#62#58#text#69#<p>&nbsp;</p>     ^cY#v
24n1a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#63#59#text#69#<p>&nbsp;</p>     ^cY#v
24n1a18.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019900072002001300271#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#64#60#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#note1">
<img src="/img/revistas/abcd/v24n1/seta.jpg" border="0" ></a> Correspond&ecirc;n
cia:</b>    ^cY#v24n1a18.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002700072002001300099#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#65#61#text#69#<br> Andy Petroianu    
^cY#v24n1a18.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010500072002001300177#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#66#62#text#69#<br> e-mail: <a href="m
ailto:petroian@medicina.ufmg.br">petroian@medicina.ufmg.br</a></font></p>     ^c
Y#v24n1a18.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012100072002001300193#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#67#63#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Recebido para publica&ccedil;&atilde;o: 
14/07/2009    ^cY#v24n1a18.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006200072002001300134#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#68#64#text#69#<br>  Aceito para publi
ca&ccedil;&atilde;o: 25/01/2011    ^cY#v24n1a18.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005700072002001300129#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#69#65#text#69#<br> Fonte de financiam
ento: n&atilde;o h&aacute;    ^cY#v24n1a18.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007000072002001300142#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#70#66#text#69#<br> Conflito de intere
sses: n&atilde;o h&aacute;</font></p>      ^cY#v24n1a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#71#67#text#69#<p>&nbsp;</p>     ^cY#v
24n1a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#72#68#text#69#<p>&nbsp;</p>     ^cY#v
24n1a18.htm##
00500000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704026900072002001300341#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a18.htm#S#p#73#69#text#69#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Servi&ccedil;o de 
Cirurgia Geral e P&oacute;s-Gradua&ccedil;&atilde;o em Ci&ecirc;ncias da Sa&uacu
te;de da Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brasil.</font></p>   
  ^cY#v24n1a18.htm##
00568000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730120058000890160
01800147810000600165018002700171063000200198066001500200062001700215065000900232
064000500241014001000246865000900256002001300265#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a18.htm#S#c#74#1#text#13#1#^rND^sAdams^nJT#Parede Abdominal, Omen
to, Mesentério e Retroperitônio^lpt#^rND^sScwarts^nSI#et al#Princípios de Cirurg
ia^lpt#5#Rio de Janeiro#Guanabara Koogan#19910000#1991#1264-1266#20110300#v24n1a
18.htm##
00549000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100019000730100020000920100
01500112012005800127030002300185710000200208065000900210064000500219031000300224
032000200227014000800229865000900237002001300246#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a18.htm#S#c#75#2#text#13#2#^rND^sAl-Haifi^nMB#^rND^sAbdulsmad^nAM
#^rND^sJuma^nTH#Laparoscapic Excision of Mesenteric Cyst: Case Report^len#Kuwait
 Medical Journal#2#20070000#2007#39#2#167-169#20110300#v24n1a18.htm##
00490000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730120041000890300
01800130065000900148064000500157031000400162014000800166865000900174002001300183
035001000196801001800206#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S
#c#76#3#text#13#3#^rND^sBlock^nFB#Chylous mesenteric cyst: Case report^len#Annal
s of Surgery#19480000#1948#128#158-160#20110300#v24n1a18.htm#0003-4932#Annals of
 Surgery##
00605000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100019000910100
01500110010001600125010002000141012007400161030000500235710000200240065000900242
064000500251031000300256032000400259014000600263865000900269002001300278#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#c#77#4#text#13#4#^rND^sCônsolo^
nFS#^rND^sCardoso^nAAP#^rND^sMonge^nM#^rND^sSantos^nP#^rND^sHernandez^nPM#Formaç
ão Cística de Túnica Serosa de Cólon Ascendente: Relato de caso^lpt#RAMB#2#20050
000#2005#55#1/2#36-39#20110300#v24n1a18.htm##
00576000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100019000730100027000920100
01400119012005800133030001200191065000900203064000500212031000300217032000200220
014000800222865000900230002001300239035001000252801001200262#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a18.htm#S#c#78#5#text#13#5#^rND^sDuldulao^nMP#^rND^sT
hiruchitrambalam^nA#^rND^sKaul^nA#Mesenteric cyst: A rare cause of lower abdomin
al pain^len#Surg Rounds#20080000#2008#31#3#123-127#20110300#v24n1a18.htm#0161-13
72#Surg Rounds##
00564000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100017000900100
01900107012007800126030001900204710000200223065000900225064000500234031000300239
032000200242014000800244865000900252002001300261#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a18.htm#S#c#79#6#text#13#6#^rND^sFilho^nFAC#^rND^sLandim^nFM#^rND
^sPerdigão^nFB#Linfangioma Cístico do Mesentério: Uma Rara Apresentação de Abdôm
en Agudo^lpt#Rev. Col. Bras Cir#2#19990000#1999#27#2#139-140#20110300#v24n1a18.h
tm##
00590000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100022000890100
01800111010001800129010001700147010001500164012002200179030001500201710000200216
06500090021806400050022703100020023203200020023401400060023686500090024200200130
0251#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#c#80#7#text#13#7#^r
ND^sFraga^nMR#^rND^sCavalcante^nAFS#^rND^sBenício^nIB#^rND^sPereira^nAA#^rND^sLe
ite^nCAC#^rND^sDias^nRP#Cisto Mesentérico^lpt#Rev. Ped Ceará#2#20040000#2004#5#1
#34-37#20110300#v24n1a18.htm##
00586000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100014000890100
01900103810000600122012005500128030001500183065000900198064000500207031000300212
032000200215014000800217865000900225002001300234035001000247801001500257#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#c#81#8#text#13#8#^rND^sFujita^n
N#^rND^sNoda^nY#^rND^sKobayashi^nG#ET AL#Chylous cyst of the mesentery: US and C
T diagnosis^len#Abdom. Imaging#19950000#1995#20#3#259-261#20110300#v24n1a18.htm#
0942-8925#Abdom. imaging##
00530000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100016000900100
01800106012004700124030001800171710000200189065000900191064000500200031000300205
032000200208014000800210865000900218002001300227#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a18.htm#S#c#82#9#text#13#9#^rND^sGarcia^nRP#^rND^sLópez^nET#^rND^
sOvalle^nJLR#Quiste mesentérico: Descripción de um caso^lpt#Cirurjano General#2#
20010000#2001#23#2#109-112#20110300#v24n1a18.htm##
00596000000000301000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100018000750100018000930100
02100111010001800132010001800150012006200168030001400230710000200244065000900246
064000500255031000400260014000800264865000900272002001300281#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a18.htm#S#c#83#10#text#13#10#^rND^sMiliaras^nS#^rND^s
Trygonis^nS#^rND^sPapandoniou^nA#^rND^sTrygonis^nC#^rND^sKiskinis^nD#Mesenteric 
Cyst of the Descending Colon: Report of a Case^len#Actachir belg#2#20060000#2006
#106#714-716#20110300#v24n1a18.htm##
00538000000000301000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100020000750100018000950100
02000113010002100133012002000154030001100174710000200185065000900187064000500196
031000300201032000400204014000600208865000900214002001300223#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a18.htm#S#c#84#11#text#13#11#^rND^sMiljikovic^nD#^rND
^sGmijovic^nD#^rND^sRadojkovic^nG#^rND^sRadovanovic^nZ#Mesenteric cyst^len#Arch 
Oncol#2#20070000#2007#15#3-4#91-93#20110300#v24n1a18.htm##
00647000000000325000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100017000910100
01600108010001300124010001600137010001600153012006300169030003600232710000200268
06500090027006400050027903100030028403200020028701400100028986500090029900200130
0308#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a18.htm#S#c#85#12#text#13#12#
^rND^sSahin^nDA#^rND^sAkbulut^nG#^rND^sSaykol^nV#^rND^sSan^nO#^rND^sTokyol^nC#^r
ND^sDilek^nON#Laparoscopic Enucleation of Mesenteric Cyst: A Case Report^len#The
 Mount Sinai Journal of Medicine#2#20060000#2006#73#7#1019-1020#20110300#v24n1a1
8.htm##
00486000000000277000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100018000750100019000930120
02000112030002800132710000200160065000900162064000500171031000400176032000200180
014000400182865000900186002001300195#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a18.htm#S#c#86#13#text#13#13#^rND^sSimeone^nDM#^rND^sPranikoff^nT#Mesenteric 
Cyst^len#Images in Clinical Medicine#2#19990000#1999#341#9#659#20110300#v24n1a18
.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#o#1#1#text#1#20
110411#103931#v24n1a19.htm#79##
00757000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002700106
03100030013303200020013606500090013801400090014703500100015612300020016601200520
0168012004600220010004300266010002600309117000800335072000300343002001300346#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#h#2#1#text#1#le#pt#br1.1#1#
4.0#ILUS#19#ABCD100#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f86^l88#0102-67
20#1#Má rotação intestinal em adulto: relato de caso^lpt#Adult intestinal malrot
ation: case report^len#^rND^nUbirajara Rutilio M. e F. de^sAraújo#^rND^nImad Iza
t El^sTawil#vancouv#10#v24n1a19.htm##
00785000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002700106
03100030013303200020013606500090013801400090014703500100015612300020016601200660
0168012006000234010004300294010002600337117000800363072000300371002001300374#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#f#3#1#text#1#le#pt#br1.1#1#
4.0#ILUS#19#ABCD100#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f86^l88#0102-67
20#1#<b>Má rotação intestinal em adulto</b>: <b>relato de caso</b>^lpt#<b>Adult 
intestinal malrotation</b>: <b>case report</b>^len#^rND^nUbirajara Rutilio M. e 
F. de^sAraújo#^rND^nImad Izat El^sTawil#vancouv#10#v24n1a19.htm##
00887000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101038000500105121000300110049000800113158000300121
03000260012403100030015003200020015306500090015501400090016403500100017312300020
01830120052001850120046002370100043002830100026003261170008003520720003003600020
01300363008008900376#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#l#4
#1#text#1#^mjan./mar.^a2011#le#pt#br1.1#1#4.0#ilus#19#ABCD100#nd#ABCD, arq. bras
. cir. dig#24#1#20110300#^f86^l88#0102-6720#1#Má rotação intestinal em adulto: r
elato de caso^lpt#Adult intestinal malrotation: case report^len#^rND^nUbirajara 
Rutilio M. e F. de^sAraújo#^rND^nImad Izat El^sTawil#vancouv#10#v24n1a19.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-672020110001
00019##
00349000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012000070002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#5#1#text#65#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CARTA AO EDITOR </b></fon
t></p>     ^cY#v24n1a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#6#2#text#65#<p>&nbsp;</p>     ^cY#v24
n1a19.htm##
00408000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704017900070002001300249#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#7#3#text#65#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>M&aacute; rota&cced
il;&atilde;o intestinal em adulto: relato de caso </b></font></p>     ^cY#v24n1a
19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#8#4#text#65#<p>&nbsp;</p>     ^cY#v24
n1a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#9#5#text#65#<p>&nbsp;</p>     ^cY#v24
n1a19.htm##
00384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015400071002001300225#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#10#6#text#65#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Ubirajara Rutilio M. e  F. de Ara&uacu
te;jo; Imad Izat El Tawil</b> </font></p>     ^cY#v24n1a19.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012700071002001300198#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#11#7#text#65#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"> <a href="#note2">Correspond&ecirc;ncia</
a></font></p>      ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#12#8#text#65#<p>&nbsp;</p>     ^cY#v2
4n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#13#9#text#65#<p>&nbsp;</p>     ^cY#v2
4n1a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011500072002001300187#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#14#10#text#65#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b> </font><
/p>     ^cY#v24n1a19.htm##
01684000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704145300072002001301525#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#15#11#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"></b>A m&aacute; rota&ccedil;&atilde;o in
testinal &eacute; anomalia cong&ecirc;nita causada por rota&ccedil;&atilde;o inc
ompleta ou n&atilde;o rota&ccedil;&atilde;o do intestino no eixo da art&eacute;r
ia mesent&eacute;rica superior durante o desenvolvimento embriol&oacute;gico<sup
>2</sup>. Apresenta-se tipicamente nos primeiros meses de vida, mas &agrave;s ve
zes pode se apresentar tardiamente causando dificuldade e erro no diagn&oacute;s
tico<sup>9</sup>. Sabe-se que 64% dos casos tornam</b>se evidentes clinicamente 
nos primeiros meses de vida e 82% at&eacute; o primeiro ano<sup>9</sup>, por&eac
ute;m, alguns autores afirmam que at&eacute; 90% dos casos s&atilde;o diagnostic
ados ao  se completar um ano<sup>4</sup>. A real incid&ecirc;ncia desta malforma
&ccedil;&atilde;o n&atilde;o &eacute; conhecida, com estimativas variando de 1:2
00 a 1:6000 nascidos vivos<sup>4</sup>. Em adultos, a incid&ecirc;ncia &eacute; 
de 0,2%<sup>5</sup>, sendo que cerca de 15% de todos os pacientes com diagn&oacu
te;stico firmado de m&aacute; rota&ccedil;&atilde;o intestinal permanecem assint
om&aacute;ticos por toda vida<sup>6</sup>. Por estes motivos, o diagn&oacute;sti
co desta doen&ccedil;a faz parte do dia-a-dia do cirurgi&atilde;o pedi&aacute;tr
ico, mas esta hip&oacute;tese diagn&oacute;stica frequentemente fica esquecida n
os casos de dor abdominal em adultos<sup>1</sup>. </font></p>     ^cY#v24n1a19.h
tm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#16#12#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010500072002001300177#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#17#13#text#65#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>RELATO DO CASO</b> </font></p>     ^c
Y#v24n1a19.htm##
00843000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704061200072002001300684#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#18#14#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Mulher de 21 anos, telefonista, deu entr
ada no hospital com quadro de intensa dor abdominal com tr&ecirc;s dias de evolu
&ccedil;&atilde;o e piora progressiva nas &uacute;ltimas 24 horas. Referia ser a
 dor abdominal do tipo difusa, em c&oacute;lica, por&eacute;m mais intensa em re
gi&atilde;o epig&aacute;strica e com irradia&ccedil;&atilde;o para dorso. Ela ap
resentava piora importante ap&oacute;s as refei&ccedil;&otilde;es, quando era ac
ompanhada de n&aacute;useas e v&ocirc;mitos. Negava quaisquer outras queixas ass
ociadas. </font></p>     ^cY#v24n1a19.htm##
00610000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704037900072002001300451#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#19#15#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">N&atilde;o apresentava nenhuma comorbida
de, mas referia na hist&oacute;ria m&oacute;rbida pregressa epis&oacute;dio seme
lhante h&aacute; tr&ecirc;s anos, por&eacute;m de car&aacute;ter fugaz e com mel
hora espont&acirc;nea com repouso intestinal e medica&ccedil;&atilde;o anti-espa
sm&oacute;dica. </font></p>     ^cY#v24n1a19.htm##
00699000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704046800072002001300540#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#20#16#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Ao exame f&iacute;sico apresentava-se em
 bom estado geral, levemente desidratada, normocorada, afebril e com dados vitai
s est&aacute;veis (PA=110x60 mmHg e FC=80 bpm). O abd&ocirc;men estava plano, fl
&aacute;cido, ru&iacute;dos hidroa&eacute;reos presentes, levemente doloroso &ag
rave; palpa&ccedil;&atilde;o de epig&aacute;strio, mas sem sinais de irrita&cced
il;&atilde;o peritoneal. </font></p>     ^cY#v24n1a19.htm##
01204000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704097300072002001301045#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#21#17#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Foram solicitados exames laboratoriais (
hemograma, eletr&oacute;litos, avalia&ccedil;&atilde;o da fun&ccedil;&atilde;o h
ep&aacute;tica e pancre&aacute;tica) que encontravam-se dentro dos limites da no
rmalidade, bem como ultrassonografia abdominal total que evidenciou somente dist
ens&atilde;o de al&ccedil;as intestinais. Iniciaram-se medica&ccedil;&otilde;es 
analg&eacute;sicas e bloqueador de bomba de pr&oacute;tons e solicitouse endosco
pia digestiva alta, a qual demonstrou apenas pequena h&eacute;rnia hiatal. No se
gundo dia de internamento o quadro cl&iacute;nico permanecia inalterado, mas com
 maior intoler&acirc;ncia alimentar; ent&atilde;o, foi solicitada tomografia de 
abd&ocirc;men que concluiu tratarse de m&aacute; rota&ccedil;&atilde;o intestina
l ao longo do eixo da art&eacute;ria mesent&eacute;rica superior, com sinais de 
sub-oclus&atilde;o do trato gastrintestinal alto. </font></p>     ^cY#v24n1a19.h
tm##
01435000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704120400072002001301276#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#22#18#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Optou-se por conduta cir&uacute;rgica at
rav&eacute;s da via laparot&ocirc;mica. No intra-operat&oacute;rio observou-se t
odo o intestino delgado disposto para o lado direito do abd&ocirc;men e o c&oacu
te;lon para o lado esquerdo. Al&eacute;m disto, o jejuno proximal encontrava-se 
isqu&ecirc;mico e fazendo volvo de 270º sobre o eixo dos vasos mesent&eacute;ric
os superiores; j&aacute; o c&oacute;lon direito estava disposto por tr&aacute;s 
destes vasos, mas com a sua arcada vascular disposta acima deles. Para a corre&c
cedil;&atilde;o da anomalia fez-se uma enterotomia do jejuno proximal, a cerca d
e 10 cm do &acirc;ngulo duodenojejunal, e desfez-se o volvo, o que cursou com me
lhora progressiva da isquemia intestinal, permitindo que se fizesse uma enteroan
astomose. O c&oacute;lon direito comprimia os vasos mesent&eacute;ricos superior
es atrav&eacute;s da arcada vascular da c&oacute;lica direita, fazendo ingurgita
mento vascular. A seguir, realizou-se ligadura do ped&iacute;culo da art&eacute;
ria c&oacute;lica m&eacute;dia em sua origem e colectomia direita seguida de ile
otransversostomia l&aacute;tero-lateral. </font></p>     ^cY#v24n1a19.htm##
00523000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704029200072002001300364#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#23#19#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A paciente evoluiu bem, tendo alta hospi
talar no 5º dia do p&oacute;s-operat&oacute;rio e manteve-se assintom&aacute;tic
a at&eacute; o &uacute;ltimo seguimento, dois anos ap&oacute;s a opera&ccedil;&a
tilde;o. </font></p>     ^cY#v24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#24#20#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#25#21#text#65#<p align="center"><img 
src="/img/revistas/abcd/v24n1/a19fig1.jpg"></p>     ^cY#v24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#26#22#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#27#23#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#28#24#text#65#<p align="center"><img 
src="/img/revistas/abcd/v24n1/a19fig2.jpg"></p>     ^cY#v24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#29#25#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#30#26#text#65#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O </b></font></p>     
^cY#v24n1a19.htm##
02383000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704215200072002001302224#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#31#27#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Segundo alguns autores a grande maioria 
dos casos de m&aacute; rota&ccedil;&atilde;o intestinal em adultos &eacute; assi
ntom&aacute;tica<sup>4,5,9</sup>; dentre aqueles que desenvolver&atilde;o algum 
sintoma, a evolu&ccedil;&atilde;o pode ocorrer de forma aguda ou cr&ocirc;nica. 
A aguda, cursa com quadro de v&ocirc;mitos e dor abdominal sem distens&atilde;o 
(por se tratar de obstru&ccedil;&atilde;o alta) que pode evoluir para isquemia e
 necrose intestinal com peritonite<sup>1</sup>. Isto pode ser causado por obstru
&ccedil;&atilde;o intestinal por volvo ou h&eacute;rnia interna, com ou sem isqu
emia intestinal<sup>2,5)</sup>. Em geral, com boa anamnese descobre-se hist&oacu
te;ria pr&eacute;via de sintomas intermitentes, mas leves<sup>1</sup>. No presen
te caso, a evolu&ccedil;&atilde;o ocorreu de forma aguda, tendo sido causada por
 volvo do jejuno com consequente obstru&ccedil;&atilde;o intestinal. J&aacute; n
os casos de evolu&ccedil;&atilde;o cr&ocirc;nica, os sintomas s&atilde;o inespec
&iacute;ficos, como dor abdominal tipo c&oacute;lica de car&aacute;ter intermite
nte e v&ocirc;mitos recorrentes<sup>1,6</sup>. A causa dessa anomalia &eacute; a
 incorreta fixa&ccedil;&atilde;o do intestino delgado, causando estreitamento no
 ped&iacute;culo dos vasos mesent&eacute;ricos superiores, o que predisp&otilde;
e o intestino ao volvo<sup>5,6</sup>. Al&eacute;m disto, formam-se feixes de per
it&ocirc;nio para tentar fixar compensatoriamente o ceco (que est&aacute; locali
zado no quadrante superior direito) na parede abdominal; estes feixes cruzam o d
uodeno mal posicionado e podem causar obstru&ccedil;&atilde;o ou criar espa&cced
il;os para forma&ccedil;&atilde;o de h&eacute;rnias internas<sup>5,6</sup>. Este
s sintomas vagos tornam o diagn&oacute;stico obscuro, retardando-o, e n&atilde;o
 raro o paciente &eacute; atendido por v&aacute;rios m&eacute;dicos, que atribue
m as causas das queixas a problemas da motilidade intestinal ou a desordens de o
rigem psiqui&aacute;trica antes de esclarecer o correto e definitivo diagn&oacut
e;stico<sup>2,3,4,5,6</sup>. </font></p>     ^cY#v24n1a19.htm##
01950000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704171900072002001301791#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#32#28#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Quanto ao relatado, o diagn&oacute;stico
 foi elucidado atrav&eacute;s de tomografia contrastada de abd&ocirc;men. Este e
xame vem sendo cada vez mais solicitado e demonstra altera&ccedil;&otilde;es de 
par&acirc;metros anat&ocirc;micos caracter&iacute;sticos, tais como: rela&ccedil
;&atilde;o inversa entre os vasos mesent&eacute;ricos superiores (veia est&aacut
e; situada &agrave; esquerda da art&eacute;ria)<sup>1,4,10</sup>, aus&ecirc;ncia
 ou hipoplasia do processo uncinado do p&acirc;ncreas<sup>4,10 </sup>e altera&cc
edil;&otilde;es na disposi&ccedil;&atilde;o das al&ccedil;as intestinais<sup>4</
sup>. Por&eacute;m, o diagn&oacute;stico poderia ter sido feito atrav&eacute;s d
e estudo radiogr&aacute;fico contrastado do trato gastrintestinal alto, o qual s
egundo muitos autores, &eacute; o exame padr&atilde;o-ouro para o diagn&oacute;s
tico de m&aacute; rota&ccedil;&atilde;o intestinal<sup>1,4</sup>, tendo acur&aac
ute;cia superior a 80%<sup>2,6 </sup>e em alguns estudos atingindo 100%<sup>5</s
up>. O achado mais importante a ser observado &eacute; a jun&ccedil;&atilde;o du
odenojejunal, a qual n&atilde;o cruza a linha m&eacute;dia e fica localizada &ag
rave; direita da coluna vertebral<sup>1,4,6</sup>. Al&eacute;m destes, h&aacute;
 outros exames para o diagn&oacute;stico tais como: ultrassonografia de abd&ocir
c;men (tamb&eacute;m avaliando a rela&ccedil;&atilde;o inversa entre os vasos me
sent&eacute;ricos)<sup>3,6,9,10</sup>, angiografia<sup>3,6 </sup>e a videolaparo
scopia<sup>7</sup>. Nos casos agudos, no entanto, o diagn&oacute;stico na maiori
a das vezes continua a ser feito atrav&eacute;s da laparotomia<sup>3</sup>. </fo
nt></p>     ^cY#v24n1a19.htm##
01981000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704175000072002001301822#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#33#29#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Finalmente, no que diz respeito ao trata
mento, n&atilde;o existe padroniza&ccedil;&atilde;o para adultos, sendo que vai 
depender dos achados intra-operat&oacute;rios e do tipo de malforma&ccedil;&atil
de;o associada<sup>4</sup>. Por&eacute;m, em geral deve-se fazer uma s&eacute;ri
e de manobras chamadas de procedimento de Ladd, que consiste na libera&ccedil;&a
tilde;o das ader&ecirc;ncias existentes, mobiliza&ccedil;&atilde;o do duodeno e 
do c&oacute;lon direito, libera&ccedil;&atilde;o e alargamento do ped&iacute;cul
o dos vasos mesent&eacute;ricos superiores e realiza&ccedil;&atilde;o de apendic
ectomia profil&aacute;tica<sup>1,2,4,5,8</sup>. N&atilde;o h&aacute; consenso qu
anto &agrave; preven&ccedil;&atilde;o de complica&ccedil;&otilde;es peri e p&oac
ute;s-operat&oacute;rias atrav&eacute;s da cecopexia<sup>4</sup>. Atualmente, te
m-se sugerido a realiza&ccedil;&atilde;o do procedimento de Ladd por videolaparo
scopia, por ter bons resultados e pouca morbidade<sup>4,7,8</sup>. Segundo algun
s estudos, a videolaparoscopia, quando comparada ao procedimento convencional, t
em significativamente menor tempo de internamento p&oacute;soperat&oacute;rio e 
menor necessidade de analgesia p&oacute;soperat&oacute;ria<sup>5</sup>. Com rela
&ccedil;&atilde;o aos casos assintom&aacute;ticos, n&atilde;o h&aacute; consenso
 quanto &agrave; conduta a ser tomada<sup>4</sup>; h&aacute; autores que afirmam
 que n&atilde;o se deve operar o paciente<sup>1</sup>, mas h&aacute; outros, em 
contrapartida, que alegam que o tratamento cir&uacute;rgico deve ser institu&iac
ute;do para prevenir complica&ccedil;&otilde;es causadas por volvo ou h&eacute;r
nia interna<sup>5,6</sup>. </font></p>     ^cY#v24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#34#30#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#35#31#text#65#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O </b></font></p>     
^cY#v24n1a19.htm##
00817000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704058600072002001300658#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#36#32#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A m&aacute; rota&ccedil;&atilde;o intest
inal em adultos &eacute; doen&ccedil;a de dif&iacute;cil diagn&oacute;stico prim
&aacute;rio devido a n&atilde;o constar entre as hip&oacute;teses diagn&oacute;s
ticas iniciais do cirurgi&atilde;o geral. A sua lembran&ccedil;a &eacute; fundam
ental nos quadros arrastados de dor abdominal sem explica&ccedil;&atilde;o plaus
&iacute;vel, pois evita complica&ccedil;&otilde;es e a rotula&ccedil;&atilde;o d
o paciente como tendo uma dor de origem psicossom&aacute;tica. </font></p>     ^
cY#v24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#37#33#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010800072002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#38#34#text#65#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS </b></font></p>    
 ^cY#v24n1a19.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704025700074002001300331#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#39#35#text#65#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Dietz DW, Walsh RM, Gru
dfest-Broniatowski S, Lavery IC, et al. Intestinal malrotation: a rare but impor
tant cause of bowel obstruction in adults. Dis Colon Rectum 2002, 45(10):1381-6.
    ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#40#36#text#65# </font></p>     ^cY#v2
4n1a19.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704021900074002001300293#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#41#37#text#65#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Gamblin TC, Stephens J
r RE, Jhonson RK, Rothwell M. Adult malrotation: a case report and review of the
 literature. Curr Surg 2003, 60(5):517-20.    ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#42#38#text#65# </font></p>     ^cY#v2
4n1a19.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704020900074002001300283#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#43#39#text#65#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Jayathillake A, Shields
 MA. Malrotation with volvus: a rare cause of acute bowel obstruction in na adul
t. ANZ J Surg 2005, 75(9):831-3.    ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#44#40#text#65# </font></p>     ^cY#v2
4n1a19.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704020700074002001300281#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#45#41#text#65#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Krapfer SA, Rappold JF.
 Intestinal malrotation - not just the pedriatric surgeon&acute;s problem. J Am 
Coll Surg 2004, 199(4):628-35.    ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#46#42#text#65# </font></p>     ^cY#v2
4n1a19.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026800074002001300342#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#47#43#text#65#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Matzke GM, Dozois EJ, L
arson DW, Moir CR. Surgical management of intestinal malrotation in adults: comp
arative results for open and laparoscopic Ladd procedures. Surg Endosc 2005, 19(
10):1416-9.    ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#48#44#text#65# </font></p>     ^cY#v2
4n1a19.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704021300074002001300287#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#49#45#text#65#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 6. Maxson RT, Franklin PA
, Wagner CW. Malrotation in the older child; surgical management, treatment, and
 outcome. Am Surg 1995, 61(2):135-8.    ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#50#46#text#65# </font></p>     ^cY#v2
4n1a19.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022500074002001300299#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#51#47#text#65#7#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 7. Mazziotti MV, Strasber
g SM, Langer JC. Intestinal rotation abnormalities without volvulus: the role of
 laparoscopy. J Am Coll Surg 1997, 185(2):172-6.    ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#52#48#text#65# </font></p>     ^cY#v2
4n1a19.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704019600074002001300270#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#53#49#text#65#8#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Seymour NE, Andersen DK
 . Laparoscopic treatment of intestinal malrotation in adults. JSLS 2005, 9(3):2
98-301 </font></p>     ^cY#v24n1a19.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704021500074002001300289#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#54#50#text#65#9#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Vukie Z. Presentation o
f intestinal malrotation syndromes in older children and adults: report of three
 cases. Croat Med J 1998, 39(4):455-7.    ^cY#v24n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#55#51#text#65# </font></p>     ^cY#v2
4n1a19.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704022000075002001300295#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#56#52#text#65#10#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Zissin R, Rathaus V, 
Oscadchy A, Kots E, et al. Intestinal malrotation as na incidental finding on CT
 in adults. Abdom Imaging 1999, 24(6):550-5.    ^cY#v24n1a19.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002300072002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#57#53#text#65# </font></p>       ^cY#
v24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#58#54#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#59#55#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019900072002001300271#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#60#56#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#note1">
<img src="/img/revistas/abcd/v24n1/seta.jpg" border="0" ></a> Correspond&ecirc;n
cia:</b>    ^cY#v24n1a19.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003800072002001300110#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#61#57#text#65#<br>   Ubirajara Ara&ua
cute;jo    ^cY#v24n1a19.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009500072002001300167#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#62#58#text#65#<br>e-mail: <a href="ma
ilto:biraraujo@bol.com.br">biraraujo@bol.com.br</a> </font></p>     ^cY#v24n1a19
.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012300072002001300195#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#63#59#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Recebido para publica&ccedil;&atilde;o:
 10/08/2009     ^cY#v24n1a19.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006000072002001300132#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#64#60#text#65#<br>Aceito para publica
&ccedil;&atilde;o: 25/01/2011    ^cY#v24n1a19.htm##
00289000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005800072002001300130#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#65#61#text#65#<br> Fonte de financiam
ento: n&atilde;o h&aacute;     ^cY#v24n1a19.htm##
00300000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006900072002001300141#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#66#62#text#65#<br>Conflito de interes
ses: n&atilde;o h&aacute; </font></p>     ^cY#v24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#67#63#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#68#64#text#65#<p>&nbsp;</p>     ^cY#v
24n1a19.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704016100072002001300233#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a19.htm#S#p#69#65#text#65#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"></b>Trabalho realizado no &Ocirc;nix Cen
tro Hospitalar, Curitiba, PR, Brasil. </font></p>     ^cY#v24n1a19.htm##
00664000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100016000890100
03100105010001700136810000600153012008600159030001700245065000900262064000500271
03100030027603200030027901400070028286500090028900200130029803500100031180100170
0321#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#c#70#1#text#10#1#^r
ND^sDietz^nDW#^rND^sWalsh^nRM#^rND^sGrudfest-Broniatowski^nS#^rND^sLavery^nIC#et
 al#Intestinal malrotation: a rare but important cause of bowel obstruction in a
dults^len#Dis Colon Rectum#20020000#2002#45#10#1381-6#20110300#v24n1a19.htm#0012
-3706#Dis Colon Rectum##
00607000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100022000910100
01800113010001800131012006600149030001000215065000900225064000500234031000300239
032000200242014000700244865000900251002001300260035001000273801001000283#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#c#71#2#text#10#2#^rND^sGamblin^
nTC#^rND^sStephens Jr^nRE#^rND^sJhonson^nRK#^rND^sRothwell^nM#Adult malrotation:
 a case report and review of the literature^len#Curr Surg#20030000#2003#60#5#517
-20#20110300#v24n1a19.htm#0149-7944#Curr Surg##
00530000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100022000730100018000950120
07900113030001100192710000200203065000900205064000500214031000300219032000200222
014000600224865000900230002001300239#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a19.htm#S#c#72#3#text#10#3#^rND^sJayathillake^nA#^rND^sShields^nMA#Malrotatio
n with volvus: rare cause of acute bowel obstruction in na adult^len#ANZ J Surg#
2#20050000#2005#75#9#831-3#20110300#v24n1a19.htm##
00558000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100018000910120
07000109030001500179065000900194064000500203031000400208032000200212014000700214
865000900221002001300230035001000243801001500253#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a19.htm#S#c#73#4#text#10#4#^rND^sKrapfer^nSA#^rND^sRappold^nJF#In
testinal malrotation: not just the pedriatric surgeon´s problem^len#J Am Coll Su
rg#20040000#2004#199#4#628-35#20110300#v24n1a19.htm#1072-7515#J Am Coll Surg##
00659000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100017000900100
01700107010001500124012012300139030001200262065000900274064000500283031000300288
032000300291014000700294865000900301002001300310035001000323801001200333#v24n1#V
:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#c#74#5#text#10#5#^rND^sMatzke^n
GM#^rND^sDozois^nEJ#^rND^sLarson^nDW#^rND^sMoir^nCR#Surgical management of intes
tinal malrotation in adults: comparative results for open and laparoscopic Ladd 
procedures^len#Surg Endosc#20050000#2005#19#10#1416-9#20110300#v24n1a19.htm#0930
-2794#Surg Endosc##
00581000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100019000900100
01700109012008000126030000800206065000900214064000500223031000300228032000200231
014000600233865000900239002001300248035001000261801000800271#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a19.htm#S#c#75#6#text#10#6#^rND^sMaxson^nRT#^rND^sFra
nklin^nPA#^rND^sWagner^nCW#Malrotation in the older child; surgical management, 
treatment, and outcome^len#Am Surg#19950000#1995#61#2#135-8#20110300#v24n1a19.ht
m#0003-1348#Am Surg##
00600000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100020000730100020000930100
01700113012008000130030001500210065000900225064000500234031000400239032000200243
014000600245865000900251002001300260035001000273801001500283#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a19.htm#S#c#76#7#text#10#7#^rND^sMazziotti^nMV#^rND^s
Strasberg^nSM#^rND^sLanger^nJC#Intestinal rotation abnormalities without volvulu
s: the role of laparoscopy^len#J Am Coll Surg#19970000#1997#185#2#172-6#20110300
#v24n1a19.htm#1072-7515#J Am Coll Surg##
00506000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100019000910120
06300110030000500173710000200178065000900180064000500189031000200194032000200196
014000800198865000900206002001300215#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a19.htm#S#c#77#8#text#10#8#^rND^sSeymour^nNE#^rND^sAndersen^nDK#Laparoscopic 
treatment of intestinal malrotation in adults^len#JSLS#2#20050000#2005#9#3#298-3
01#20110300#v24n1a19.htm##
00552000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100015000730120105000880300
01200193065000900205064000500214031000300219032000200222014000600224865000900230
002001300239035001000252801001200262#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v2
4n1a19.htm#S#c#78#9#text#10#9#^rND^sVukie^nZ#Presentation of intestinal malrotat
ion syndromes in older children and adults: report of three cases^len#Croat Med 
J#19980000#1998#39#4#455-7#20110300#v24n1a19.htm#0353-9504#Croat Med J##
00625000000000325000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100017000910100
01800108010001400126810000600140012006800146030001400214065000900228064000500237
03100030024203200020024501400060024786500090025300200130026203500100027580100140
0285#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a19.htm#S#c#79#10#text#10#10#
^rND^sZissin^nR#^rND^sRathaus^nV#^rND^sOscadchy^nA#^rND^sKots^nE#et al#Intestina
l malrotation as na incidental finding on CT in adults^len#Abdom Imaging#1999000
0#1999#24#6#550-5#20110300#v24n1a19.htm#0942-8925#Abdom Imaging##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#o#1#1#text#1#20
110411#103932#v24n1a20.htm#76##
00957000000000445000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002700106
03100030013303200020013606500090013801400090014703500100015612300020016601200780
01680120065002460100027003110100032003380100031003700100032004010100035004330100
02000468117000800488072000200496002001300498#v24n1#V:\SciELO\serial\abcd\v24n1\m
arkup\v24n1a20.htm#S#h#2#1#text#1#le#pt#br1.1#1#4.0#ILUS#20#ABCD100#nd#ABCD, arq
. bras. cir. dig.#24#1#20110300#^f89^l91#0102-6720#1#Procedimento de ladd para m
á rotação intestinal no adulto: relato de caso^lpt#Ladd procedure for adult inte
stinal malrotation: case report^len#^rND^nPaulo Gustavo^sKotze#^rND^nJuliana Fer
reira^sMartins#^rND^nJuliana Gonçalves^sRocha#^rND^nCristiano Denoni^sFreitas#^r
ND^nJuliana Stradiotto^sSteckert#^rND^nErika^sFugita#vancouv#6#v24n1a20.htm##
00985000000000445000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002700106
03100030013303200020013606500090013801400090014703500100015612300020016601200920
01680120079002600100027003390100032003660100031003980100032004290100035004610100
02000496117000800516072000200524002001300526#v24n1#V:\SciELO\serial\abcd\v24n1\m
arkup\v24n1a20.htm#S#f#3#1#text#1#le#pt#br1.1#1#4.0#ILUS#20#ABCD100#nd#ABCD, arq
. bras. cir. dig.#24#1#20110300#^f89^l91#0102-6720#1#<b>Procedimento de ladd par
a má rotação intestinal no adulto</b>: <b>relato de caso</b>^lpt#<b>Ladd procedu
re for adult intestinal malrotation</b>: <b>case report</b>^len#^rND^nPaulo Gust
avo^sKotze#^rND^nJuliana Ferreira^sMartins#^rND^nJuliana Gonçalves^sRocha#^rND^n
Cristiano Denoni^sFreitas#^rND^nJuliana Stradiotto^sSteckert#^rND^nErika^sFugita
#vancouv#6#v24n1a20.htm##
01087000000000469000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101038000500105121000300110049000800113158000300121
03000260012403100030015003200020015306500090015501400090016403500100017312300020
01830120078001850120065002630100027003280100032003550100031003870100032004180100
03500450010002000485117000800505072000200513002001300515008008900528#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#l#4#1#text#1#^mjan./mar.^a2011#le#p
t#br1.1#1#4.0#ilus#20#ABCD100#nd#ABCD, arq. bras. cir. dig#24#1#20110300#^f89^l9
1#0102-6720#1#Procedimento de ladd para má rotação intestinal no adulto: relato 
de caso^lpt#Ladd procedure for adult intestinal malrotation: case report^len#^rN
D^nPaulo Gustavo^sKotze#^rND^nJuliana Ferreira^sMartins#^rND^nJuliana Gonçalves^
sRocha#^rND^nCristiano Denoni^sFreitas#^rND^nJuliana Stradiotto^sSteckert#^rND^n
Erika^sFugita#vancouv#6#v24n1a20.htm#Internet^ihttp://www.scielo.br/scielo.php?s
cript=sci_arttext&pid=S0102-67202011000100020##
00349000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012000070002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#5#1#text#66#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CARTA AO EDITOR </b></fon
t></p>     ^cY#v24n1a20.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#6#2#text#66#<p>&nbsp;</p>     ^cY#v24
n1a20.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704020400070002001300274#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#7#3#text#66#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="note1"></a><b>Procedimento de lad
d para m&aacute; rota&ccedil;&atilde;o intestinal no adulto: relato de caso</b><
/font></p>     ^cY#v24n1a20.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#8#4#text#66#<p>&nbsp;</p>     ^cY#v24
n1a20.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#9#5#text#66#<p>&nbsp;</p>     ^cY#v24
n1a20.htm##
00467000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704023700071002001300308#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#10#6#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Paulo Gustavo Kotze; Juliana Ferreira 
Martins; Juliana Gon&ccedil;alves Rocha; Cristiano Denoni Freitas; Juliana Strad
iotto Steckert; Erika Fugita</b> </font></p>     ^cY#v24n1a20.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011900071002001300190#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#11#7#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#note2">Correspondência</a></fon
t></p>     ^cY#v24n1a20.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#12#8#text#66#<p>&nbsp;</p>     ^cY#v2
4n1a20.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#13#9#text#66#<p>&nbsp;</p>     ^cY#v2
4n1a20.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011500072002001300187#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#14#10#text#66#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O </b></font><
/p>     ^cY#v24n1a20.htm##
00981000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704075000072002001300822#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#15#11#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">M&aacute; rota&ccedil;&atilde;o intestin
al &eacute; condi&ccedil;&atilde;o rara cong&ecirc;nita causada pela aus&ecirc;n
cia ou rota&ccedil;&atilde;o incompleta do intestino delgado durante o per&iacut
e;odo embrion&aacute;rio<sup>1</sup>. a incid&ecirc;ncia na popula&ccedil;&atild
e;o geral &eacute; de um para cada 200 a 500 rec&eacute;mnascidos. Os casos sint
om&aacute;ticos s&atilde;o raros, ocorrendo em um para 6.000 rec&eacute;m-nascid
os<sup>1</sup>. O diagn&oacute;stico &eacute; feito principalmente durante o per
&iacute;odo neonatal, antes do primeiro m&ecirc;s de vida. Os sintomas s&atilde;
o geralmente obstru&ccedil;&atilde;o do intestino devido ao volvo. </font></p>  
   ^cY#v24n1a20.htm##
00745000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704051400072002001300586#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#16#12#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A apresenta&ccedil;&atilde;o da m&aacute
; rota&ccedil;&atilde;o intestinal em adultos &eacute; rara e ocorre em aproxima
damente 0,2%<sup>5</sup>. Em geral, a maioria dos adultos afetados &eacute; assi
ntom&aacute;tica. A dor abdominal cr&ocirc;nica e constipa&ccedil;&atilde;o pode
m ocorrer em alguns casos. Em revis&atilde;o de literatura, detectou-se apenas 4
0 casos descritos em adultos entre os anos de 1923 e 1992<sup>5</sup>. </font></
p>     ^cY#v24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#17#13#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010500072002001300177#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#18#14#text#66#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>RELATO DO CASO </b></font></p>     ^c
Y#v24n1a20.htm##
01021000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704079000072002001300862#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#19#15#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Mulher branca 23 anos de idade, apresent
ou c&oacute;licas e dor abdominal difusa de in&iacute;cio durante a inf&acirc;nc
ia e piora durante os &uacute;ltimos tr&ecirc;s meses. ela relatou constipa&cced
il;&atilde;o cr&ocirc;nica e tinha utilizado laxantes nos &uacute;ltimos anos. A
s evacua&ccedil;&otilde;es foram pouco frequentes, ocorrendo a cada tr&ecirc;s d
ias, com grande esfor&ccedil;o para defecar. Durante os &uacute;ltimos tr&ecirc;
s meses, queixou-se de distens&atilde;o abdominal, v&ocirc;mitos frequentes e ag
ravamento da dor e da constipa&ccedil;&atilde;o. N&atilde;o houve sangramento re
tal, gravidez ou  opera&ccedil;&otilde;es abdominais. N&atilde;o havia consumo d
e &aacute;lcool ou tabaco. </font></p>     ^cY#v24n1a20.htm##
00574000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704034300072002001300415#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#20#16#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O exame f&iacute;sico revelou perfil jov
em e magro, com sinais vitais est&aacute;veis. O exame do abdome revelou distens
&atilde;o abdominal moderada, com dor difusa significativa, sem irrita&ccedil;&a
tilde;o peritoneal. O exame f&iacute;sico geral foi normal. </font></p>     ^cY#
v24n1a20.htm##
01039000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704080800072002001300880#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#21#17#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Estudo ultrassonogr&aacute;fico abdomina
l e colonoscopia total foram normaia. Tr&acirc;nsito de delgado revelou defeito 
de rota&ccedil;&atilde;o do duodeno, intestino delgado, com o todo jejuno e &iac
ute;leo no lado direito da linha m&eacute;dia do duodeno e duodeno verticalizado
 sem &acirc;ngulo duodenojejunal (<a href="#fig1">Figuras 1</a> e <a href="#fig2
">2</a>). Apesar das altera&ccedil;&otilde;es de rota&ccedil;&atilde;o descritas
, o b&aacute;rio era normalmente processados atrav&eacute;s do c&oacute;lon dire
ito, localizado em frente da coluna lombar, ao lado do l&oacute;bulo esquerdo do
 f&iacute;gado. Resson&acirc;ncia magn&eacute;tica mostrou o posicionamento norm
al dos vasos mesent&eacute;ricos superiores. </font></p>     ^cY#v24n1a20.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#22#18#text#66#<p><a name="fig1"></a><
/p>     ^cY#v24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#23#19#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#24#20#text#66#<p align="center"><img 
src="/img/revistas/abcd/v24n1/a20fig1.jpg"></p>     ^cY#v24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#25#21#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#26#22#text#66#<p><a name="fig2"></a><
/p>     ^cY#v24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#27#23#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008000072002001300152#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#28#24#text#66#<p align="center"><img 
src="/img/revistas/abcd/v24n1/a20fig2.jpg" ></p>     ^cY#v24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#29#25#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
01156000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704092500072002001300997#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#30#26#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Com o diagn&oacute;stico de m&aacute; ro
ta&ccedil;&atilde;o intestinal sintom&aacute;tica, ela foi submetida &agrave; la
parotomia com o procedimento de ladd. Ap&oacute;s inspe&ccedil;&atilde;o da cavi
dade abdominal, o achado mais importante foi a falta do &acirc;ngulo duodenojeju
nal e as 3ª. e 4ª. Por&ccedil;&otilde;es duodenais dirigidas para a fossa il&iac
ute;aca direita. O intestino delgado inteiro foi localizado no lado direito do a
bd&ocirc;men e o c&oacute;lon foi fixado nos quadrantes da esquerda. Houve v&aac
ute;rias ader&ecirc;ncias desde o duodeno at&eacute; o perit&ocirc;nio do quadra
nte superior direito (ader&ecirc;ncias ladd), que foram ressecadas. O intestino 
delgado foi libertado e colocado na posi&ccedil;&atilde;o anat&ocirc;mica normal
, sem qualquer fixa&ccedil;&atilde;o. Apendicectomia tamb&eacute;m foi realizada
. </font></p>     ^cY#v24n1a20.htm##
00567000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704033600072002001300408#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#31#27#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A paciente respondeu bem durante o per&i
acute;odo p&oacute;s-operat&oacute;rio. Ela n&atilde;o tinha c&oacute;licas e pr
is&atilde;o de ventre diminuiu significativamente. Ela permanece assintom&aacute
;tica dois anos ap&oacute;s a opera&ccedil;&atilde;o.</font></p>     ^cY#v24n1a2
0.htm##
00507000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704027600072002001300348#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#32#28#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Este relat&oacute;rio foi aprovado pelo 
Conselho de &Eacute;tica do Hospital Universit&aacute;rio Cajuru. A paciente ass
inou o termo de consentimento autorizando esta publica&ccedil;&atilde;o. </font>
</p>     ^cY#v24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#33#29#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#34#30#text#66#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O </b></font></p>     
^cY#v24n1a20.htm##
00781000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055000072002001300622#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#35#31#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Anomalias cong&ecirc;nitas da rota&ccedi
l;&atilde;o intestinal s&atilde;o raramente encontradas em adultos<sup>1</sup>. 
A maioria dos casos &eacute; diagnosticada durante o per&iacute;odo neonatal. El
a pode levar a sintomas inespec&iacute;ficos cr&ocirc;nicos em adultos jovens, e
 s&atilde;o dif&iacute;ceis de diagnosticar. O conhecimento da embriologia intes
tinal &eacute; essencial para a compreens&atilde;o do mecanismo de sua forma&cce
dil;&atilde;o<sup>2</sup>. </font></p>     ^cY#v24n1a20.htm##
00910000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704067900072002001300751#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#36#32#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A aus&ecirc;ncia de rota&ccedil;&atilde;
o completa do intestino, durante o per&iacute;odo embrion&aacute;rio, &eacute; a
 chave para a fisiopatologia. O duodeno n&atilde;o assume sua posi&ccedil;&atild
e;o normal, posterior &agrave; art&eacute;ria mesent&eacute;rica superior. Por c
onseguinte, n&atilde;o h&aacute; fixa&ccedil;&atilde;o do mesent&eacute;rio na p
arede abdominal posterior. Isso faz com que tor&ccedil;&atilde;o intestinal atra
v&eacute;s da art&eacute;ria mesent&eacute;rica superior, uma das complica&ccedi
l;&otilde;es mais comuns de anomalias de rota&ccedil;&atilde;o<sup>2</sup>. </fo
nt></p>     ^cY#v24n1a20.htm##
00697000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704046600072002001300538#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#37#33#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Estas anomalias podem ser classificadas 
de acordo com o est&aacute;gio de ocorr&ecirc;ncia. A fase 1 &eacute; principalm
ente a onfalocele; a fase 2 inclui m&aacute; rota&ccedil;&atilde;o, n&atilde;o r
ota&ccedil;&atilde;o e rota&ccedil;&atilde;o inversa do intestino; a fase 3 incl
ui ceco m&oacute;vel, duodeno m&oacute;vel e mesent&eacute;rio livre do intestin
o delgado<sup>1</sup>. </font></p>     ^cY#v24n1a20.htm##
01351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704112000072002001301192#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#38#34#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A apresenta&ccedil;&atilde;o cl&iacute;n
ica pode ser inespec&iacute;fica. Dietzet al.<sup>2</sup>, em 2002, descreveu na
 Cleveland Clinic s&eacute;rie de 10 adultos com este tipo de anomalia intestina
l. Eles descreveram dois grupos diferentes de pacientes, de acordo com seus sint
omas. O primeiro, apresentou sintomas de obstru&ccedil;&atilde;o intestinal cr&o
circ;nica caracterizada por hist&oacute;ria de epis&oacute;dios recorrentes de n
&aacute;useas, v&ocirc;mitos biliosos, e c&oacute;licas abdominais e dor; disten
s&atilde;o abdominal normalmente n&atilde;o &eacute; uma caracter&iacute;stica p
ois estas obstru&ccedil;&otilde;es s&atilde;o proximais; pris&atilde;o de ventre
 pode ser sintoma comum nesses casos. O segundo grupo apresentou sintomas relaci
onados com o in&iacute;cio agudo de obstru&ccedil;&atilde;o, principalmente devi
do &agrave;s ader&ecirc;ncias e volvo. Neste caso, a paciente teve pris&atilde;o
 de ventre e dor abdominal intermitentes leves, e pode ser inclu&iacute;da no pr
imeiro grupo descrito anteriormente. </font></p>     ^cY#v24n1a20.htm##
01066000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704083500072002001300907#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#39#35#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A maioria dos pacientes apresenta sinais
 de obstru&ccedil;&atilde;o durante o per&iacute;odo neonatal, e esta condi&cced
il;&atilde;o deve ser considerada em todos os rec&eacute;mnascidos com v&ocirc;m
itos biliosos e dor abdominal<sup>1</sup>. As crian&ccedil;as mais velhas e adul
tos com mais frequ&ecirc;ncia apresentam recorr&ecirc;ncia de sintomas leves, co
mo se fez nesta paciente. aproximadamente 30% apresentam v&ocirc;mitos e 20% t&e
circ;m dor abdominal inespec&iacute;fica recorrente<sup>1</sup>. O diagn&oacute;
stico diferencial inclui outras causas de v&ocirc;mitos e dor, incluindo &uacute
;lceras p&eacute;pticas, dist&uacute;rbios funcionais, s&iacute;ndrome do intest
ino irrit&aacute;vel ou transtornos psiqui&aacute;tricos<sup>1,5</sup>. </font><
/p>     ^cY#v24n1a20.htm##
01386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704115500072002001301227#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#40#36#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O diagn&oacute;stico de m&aacute; rota&c
cedil;&atilde;o intestinal pode ser confirmado estudo radiol&oacute;gico com con
traste<sup>3,4 </sup>que pode revelar duodeno verticalizado, e a aus&ecirc;ncia 
do &acirc;ngulo duodenojejunal. Estes resultados s&atilde;o encontrados em quase
 80% dos pacientes<sup>4</sup>. No entanto, por vezes, este estudo pode ser norm
al. enema opaco com duplo contraste pode mostrar a localiza&ccedil;&atilde;o ano
rmal do ceco, logo abaixo do f&iacute;gado, pr&oacute;ximo &agrave; linha m&eacu
te;dia, e todo o c&oacute;lon localizado lateralmente &agrave; coluna do lado es
querdo<sup>3</sup>. Tomografia computadorizada tamb&eacute;m pode identificar es
sas posi&ccedil;&otilde;es anormais do intestino delgado e do c&oacute;lon e do 
posicionamento contr&aacute;rio da veia mesent&eacute;rica superior, situado no 
lado esquerdo da art&eacute;ria. Tamb&eacute;m pode ser &uacute;til na identific
a&ccedil;&atilde;o de obstru&ccedil;&atilde;o aguda<sup>3,4</sup>. No caso relat
ado, o diagn&oacute;stico foi confirmado com tr&acirc;nsito de delgado. </font><
/p>     ^cY#v24n1a20.htm##
01060000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704082900072002001300901#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#41#37#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O procedimento de Ladd, descrito inicial
mente em 1936, &Eacute; o tratamento cir&uacute;rgico cl&aacute;ssico para m&aac
ute; rota&ccedil;&atilde;o intestinal<sup>1</sup>. &Eacute; descrito como uma as
socia&ccedil;&atilde;o de mobiliza&ccedil;&atilde;o do duodeno e do c&oacute;lon
 direito, sec&ccedil;&atilde;o de ader&ecirc;ncias at&eacute; pr&oacute;ximo da 
mesent&eacute;rica superior e apendicectomia. O objetivo deste procedimento redu
zir o risco de volvo agudo, localizando o intestino delgado em uma posi&ccedil;&
atilde;o n&atilde;o-rotativa e alargando a base do mesent&eacute;rio. A apendice
ctomia &eacute; feita devido &agrave; eventual dificuldade no diagn&oacute;stico
 de apendicite futuro, distante da posi&ccedil;&atilde;o correta. </font></p>   
  ^cY#v24n1a20.htm##
00892000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704066100072002001300733#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#42#38#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O procedimento de ladd pode ser seguro q
uando realizado por laparoscopia. Embora a maioria dos relat&oacute;rios descrev
em laparotomia como abordagem cl&aacute;ssica, mais recentes estudos apontam par
a a efic&aacute;cia e viabilidade de laparoscopia<sup>5,6</sup>. Mazziotti, et a
l.<sup>6 </sup>descreveram que h&aacute; possibilidade de procedimento laparosc&
oacute;pico de ladd quando a dist&acirc;ncia entre a jun&ccedil;&atilde;o duoden
ojejunal e a v&aacute;lvula ileocecal &eacute; inferior &agrave; metade do di&ac
irc;metro transversal da cavidade peritoneal<sup>6</sup>. </font></p>     ^cY#v2
4n1a20.htm##
00811000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704058000072002001300652#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#43#39#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A Cl&iacute;nica Mayo descreveu uma s&ea
cute;rie de 21 adultos com ma rota&ccedil;&atilde;o intestinal, tratados com o p
rocedimento de Ladd. Onze deles foram submetidos &agrave; cirurgia laparosc&oacu
te;pica, e comparados com 10 operados por laparotomia. eles conclu&iacute;ram qu
e a laparoscopia &eacute; t&atilde;o segura, vi&aacute;vel e eficiente quanto a 
laparotomia, com todas as vantagens deste m&eacute;todo relacionado com a alta p
recoce e r&aacute;pida ingest&atilde;o oral<sup>5</sup>. </font></p>     ^cY#v24
n1a20.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022900072002001300301#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#44#40#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">No presente caso, a laparotomia foi real
izada devido &agrave; falta de experi&ecirc;ncia dos autores no manejo desta con
di&ccedil;&atilde;o rara. </font></p>     ^cY#v24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#45#41#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010800072002001300180#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#46#42#text#66#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS </b></font></p>    
 ^cY#v24n1a20.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026900074002001300343#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#47#43#text#66#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Brandt ML. Intestinal M
alrotation. In: Intestinal Malrotation 2006.   Available via DIALOG. <a href="ht
tp://www.uptodate.com." target="_blank">http://www.uptodate.com.</a> Accessed 22
   Sep 2007.    ^cY#v24n1a20.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#48#44#text#66#</font></p>     ^cY#v24
n1a20.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704027700074002001300351#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#49#45#text#66#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Dietz DW, Walsh RM, Gr
undfest-Broniatowski S, Lavery IC, Fazio   VW, Vogt DP. Intestinal malrotation: 
a rare but important cause   of bowel obstruction in adults. Dis Colon Rectum 20
02; 45:   1381-1386.    ^cY#v24n1a20.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#50#46#text#66#</font></p>     ^cY#v24
n1a20.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704024000074002001300314#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#51#47#text#66#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 3. Dilley AV, Pereira J, 
Shi EC, Adams S, Kern IB, Currie B, Henry GM.   The radiologist says malrotation
: does the surgeon operate?   Pediatr Surg Int 2000; 16: 45-49.    ^cY#v24n1a20.
htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#52#48#text#66#</font></p>     ^cY#v24
n1a20.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022200074002001300296#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#53#49#text#66#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 4. Gamblin TC, Stephens R
E Jr, Johnson RK, Rothwell M. Adult   malrotation: a case report and review of t
he literature. Curr Surg   2003; 60: 517-520.    ^cY#v24n1a20.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#54#50#text#66#</font></p>     ^cY#v24
n1a20.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704027500074002001300349#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#55#51#text#66#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 5. Matzke GM, Dozois EJ, 
Larson DW, Moir CR. Surgical   management of intestinal malrotation in adults: c
omparative   results for open and laparoscopic Ladd procedures. Surg Endosc   20
05; 19: 1416-1419.    ^cY#v24n1a20.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#56#52#text#66#</font></p>     ^cY#v24
n1a20.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022800074002001300302#v24
n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#57#53#text#66#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 6. Mazzioti MV, Strasberg
 SM, Langer JC. Intestinal rotation   abnormalities without volvulus: the role o
f laparoscopy. J Am   Coll Surg 1997; 185: 183-187.    ^cY#v24n1a20.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#58#54#text#66#</font></p>     ^cY#v24
n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#59#55#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002300072002001300095#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#60#56#text#66#<p>&nbsp;</p>      ^cY#
v24n1a20.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019800072002001300270#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#61#57#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="note2"></a><b><a href="#note1">
<img src="/img/revistas/abcd/v24n1/seta.jpg" border="0"></a> Correspond&ecirc;nc
ia:</b>    ^cY#v24n1a20.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003300072002001300105#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#62#58#text#66#<br> Paulo Gustavo Kotz
e     ^cY#v24n1a20.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009400072002001300166#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#63#59#text#66#<br> e-mail: <a href="m
ailto:pgkotze@hotmail.com">pgkotze@hotmail.com</a> </font></p>     ^cY#v24n1a20.
htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012200072002001300194#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#64#60#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Recebido para Publica&ccedil;&atilde;o: 
18/03/2010     ^cY#v24n1a20.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006200072002001300134#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#65#61#text#66#<br> Aceito para public
a&ccedil;&atilde;o: 25/01/2011     ^cY#v24n1a20.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005600072002001300128#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#66#62#text#66#<br>Fonte de Financiame
nto: n&atilde;o h&aacute;    ^cY#v24n1a20.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007100072002001300143#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#67#63#text#66#<br> Conflito de Intere
sses: n&atilde;o h&aacute; </font></p>      ^cY#v24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#68#64#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#69#65#text#66#<p>&nbsp;</p>     ^cY#v
24n1a20.htm##
00467000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704023600072002001300308#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a20.htm#S#p#70#66#text#66#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Trabalho realizado no Hospital Universit
ário Cajuru da Pontifícia Universidade Católica do Paraná, Unidade de Cirurgia C
olorretal, Curitiba, PR, Brasil. </font></p>     ^cY#v24n1a20.htm##
00446000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720120027000890180
03200116037002500148110000900173109001200182865000900194002001300203#v24n1#V:\Sc
iELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#c#71#1#text#6#1#^rND^sBrandt^nML#In
testinal Malrotation^len#Intestinal Malrotation 2006^len#http://www.uptodate.com
.#20070922#22 Sep 2007#20110300#v24n1a20.htm##
00689000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100016000720100016000880100
03200104010001700136010001600153010001500169012008600184030001700270065000900287
06400050029603100030030101400100030486500090031400200130032303500100033680100170
0346#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#c#72#2#text#6#2#^rN
D^sDietz^nDW#^rND^sWalsh^nRM#^rND^sGrundfest-Broniatowski^nS#^rND^sLavery^nIC#^r
ND^sFazio^nVW#^rND^sVogt^nDP#Intestinal malrotation: a rare but important cause 
of bowel obstruction in adults^len#Dis Colon Rectum#20020000#2002#45#1381-1386#2
0110300#v24n1a20.htm#0012-3706#Dis Colon Rectum##
00673000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100017000890100
01400106010001500120010001500135010001600150010001600166012006400182030001700246
06500090026306400050027203100030027701400060028086500090028600200130029503500100
0308801001700318#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a20.htm#S#c#73#3#
text#6#3#^rND^sDilley^nAV#^rND^sPereira^nJ#^rND^sShi^nEC#^rND^sAdams^nS#^rND^sKe
rn^nIB#^rND^sCurrie^nB#^rND^sHenry^nGM#The radiologist says malrotation: does th
e surgeon operate?^len#Pediatr Surg Int#20000000#2000#16#45-49#20110300#v24n1a20
.htm#0179-0358#Pediatr Surg Int##
00593000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100018000720100022000900100
01800112010001800130012006600148030001000214065000900224064000500233031000300238
014000800241865000900249002001300258035001000271801001000281#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a20.htm#S#c#74#4#text#6#4#^rND^sGamblin^nTC#^rND^sSte
phens Jr^nRE#^rND^sJohnson^nRK#^rND^sRothwell^nM#Adult malrotation: a case repor
t and review of the literature^len#Curr Surg#20030000#2003#60#517-520#20110300#v
24n1a20.htm#0149-7944#Curr Surg##
00646000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100017000890100
01700106010001500123012012300138030001200261065000900273064000500282031000300287
014001000290865000900300002001300309035001000322801001200332#v24n1#V:\SciELO\ser
ial\abcd\v24n1\markup\v24n1a20.htm#S#c#75#5#text#6#5#^rND^sMatzke^nGM#^rND^sDozo
is^nEJ#^rND^sLarson^nDW#^rND^sMoir^nCR#Surgical management of intestinal malrota
tion in adults: comparative results for open and laparoscopic Ladd procedures^le
n#Surg Endosc#20050000#2005#19#1416-1419#20110300#v24n1a20.htm#0930-2794#Surg En
dosc##
00586000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100019000720100020000910100
01700111012008000128030001500208065000900223064000500232031000400237014000800241
865000900249002001300258035001000271801001500281#v24n1#V:\SciELO\serial\abcd\v24
n1\markup\v24n1a20.htm#S#c#76#6#text#6#6#^rND^sMazzioti^nMV#^rND^sStrasberg^nSM#
^rND^sLanger^nJC#Intestinal rotation abnormalities without volvulus: the role of
 laparoscopy^len#J Am Coll Surg#19970000#1997#185#183-187#20110300#v24n1a20.htm#
1072-7515#J Am Coll Surg##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a21.htm#S#o#1#1#text#1#20
110411#103933#v24n1a21.htm#10##
00523000000000337000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000300093158000300096030002700099
03100030012603200020012906500090013101400090014003500100014912300020015901200110
0161002001300172#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a21.htm#S#h#2#1#t
ext#1#tr#pt#br1.1#1#4.0#ND#21#nd#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f9
1^l91#0102-6720#1#Errata^lpt#v24n1a21.htm##
00530000000000337000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000300093158000300096030002700099
03100030012603200020012906500090013101400090014003500100014912300020015901200180
0161002001300179#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a21.htm#S#f#3#1#t
ext#1#tr#pt#br1.1#1#4.0#ND#21#nd#nd#ABCD, arq. bras. cir. dig.#24#1#20110300#^f9
1^l91#0102-6720#1#<b>Errata</b>^lpt#v24n1a21.htm##
00638000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000300108158000300111030002600114
03100030014003200020014306500090014501400090015403500100016312300020017301200110
0175002001300186008008900199#v24n1#V:\SciELO\serial\abcd\v24n1\markup\v24n1a21.h
tm#S#l#4#1#text#1#^mjan./mar.^a2011#tr#pt#br1.1#1#4.0#21#nd#nd#ABCD, arq. bras. 
cir. dig#24#1#20110300#^f91^l91#0102-6720#1#Errata^lpt#v24n1a21.htm#Internet^iht
tp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202011000100021##
00328000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000200067704010000069002001300169#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a21.htm#S#p#5#1#text#6#<p ><font size="4" face="V
erdana, Arial, Helvetica, sans-serif" > <b>Errata </b></font></p>     ^cY#v24n1a
21.htm##
00250000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000200067704002200069002001300091#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a21.htm#S#p#6#2#text#6#<p>&nbsp;</p>     ^cY#v24n
1a21.htm##
00250000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000200067704002200069002001300091#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a21.htm#S#p#7#3#text#6#<p>&nbsp;</p>     ^cY#v24n
1a21.htm##
00484000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000200067704025600069002001300325#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a21.htm#S#p#8#4#text#6#<p><font size="2" face="Ve
rdana, Arial, Helvetica, sans-serif" >Na edi&ccedil;&atilde;o do volume 22(1):61
 houve erro de editora&ccedil;&atilde;o no resumo do artigo. O ABCD pede desculp
as aos autores e efetua a corre&ccedil;&atilde;o. </font></p>     ^cY#v24n1a21.h
tm##
01421000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000200067704119300069002001301262#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a21.htm#S#p#9#5#text#6#<p><font size="2" face="Ve
rdana, Arial, Helvetica, sans-serif" ><b>ABSTRACT</b></font> - <font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif" ><b><i>Background</i> - </b>The diffe
rential diagnosis of the unconscious patient must always include hyperosmolar hy
perglycemic non-ketotic hypothesis     <b><i>Case report</i> - </b> A 22 year-ol
d woman, ABO - O+ with history of fatigability and jaundice. Physical examinatio
n revealed a markedly jaundice patient. Fulminant hepatic failure was the diagno
stic. Liver transplant was performed from a brain- dead cadaver donor with succe
ss. Arterial hepatic thrombosis was considered one week after liver transplant a
nd confirmed with Doppler-US. The hepatic retransplant occurred without problems
. After two days of liver transplant the serum glucose was 600 mg/dl and unconsc
iousness. Hyperosmolar coma was controlled and treated with succes for 48 h. The
 patient left the hospital after 30 days of liver transplantation without diabet
es. <b><i>Conclusion</i> - </b> Hyperosmolar coma is an rare event after liver t
ransplant. The early recognition and treatment of this disorder should result in
 improvement of evolution. </font></p>     ^cY#v24n1a21.htm##
00384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000200068704015500070002001300225#v24n1#V:\SciELO
\serial\abcd\v24n1\markup\v24n1a21.htm#S#p#10#6#text#6#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif" ><b>HEADINGS</b> - Liver transplantation. 
Hyperosmolar. Hyperglycemic. </font></p>      ^cY#v24n1a21.htm##
